CA2451465A1 - Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer - Google Patents

Abstract

Described herein are genes whose expression are up-regulated or down-regulat ed in ovarian cancer. Related methods and compositions that can be used for diagnosis and treatment of ovarian cancer are disclosed. Also described here in are methods that can be used to identify modulators of ovarian cancer.</SDOA B>

Description

DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

METHODS OF DIAGNOSIS OF OVARIAN CANCER, COMPOSITIONS AND
METHODS OF SCREENING FOR MODULATORS OF OVARIAN CANCER
CROSS-REFERENCES TO RELATED APPLICATIONS.
This application is related to USSN 60/299,234, filed June 18, 2001; USSN
60/315,287, filed August 27, 2001; USSN 60/317,544, filed September 5, 2001;
USSN
60/350,666, filed November 13, 2001; and USSN 60/372,246, filed April 12, 2002, each of which is incorporated herein by reference for all purposes.
FIELD OF THE INVENTION
The invention relates to the identification of nucleic acid and protein expression profiles and nucleic acids, products, and antibodies thereto that are involved in ovarian cancer; and to the use of such expression profiles and compositions in the diagnosis, prognosis, and therapy of ovarian cancer. The invention further relates to methods for identifying and using agents and/or targets that inhibit ovarian cancer.
BACKGROUND OF THE INVENTION
Ovarian cancer is the sixth most common cancer in women, accounting for 6% of all female cancers. It ranks fifth as the cause of cancer death in women. The American Cancer Society predicts that there will be about 23,100 new cases of ovarian cancer in this country in the year 2000 and about 14,000 women will die of the disease. Because many ovarian cancers cannot be detected early in their development, they account for a disproportionate number of fatal cancers, being responsible for almost half the deaths from cancer of the female genital tract; more deaths than any other reproductive organ cancer.
Most patients with epithelial ovarian cancer, the predominant form, are asymptomatic in early-stage disease and usually present with stage III or IV disease. Their five-year survival is less than 25%, with lower survival among African-American women.
The minority of patients discovered with early-stage disease have a five-year survival rate of 80%-90%. See, Parker, et. al.. (1997) "Cancer Statistics, 1997" CA Cancer J.
Clin. 47:5-27.
In the absence of a family history of ovarian cancer, lifetime risk of ovarian cancer is 1170. Risk factors include familial cancer syndromes (risk of up to 82% by age 70 in women with hereditary breast/ovarian syndrome); family history (1.4% lifetime risk with no affected relatives, 5% with orie affected relative, 7% with two affected relatives;
Kerlikowske, et.al.
(1992) Obstet. G~necol. 80:700-707); nulliparity; advancing age; obesity;
personal history of breast, endometrial, or colorectal cancer; fewer pregnancies; or older age (>35 years) at first pregnancy. However, 95% of all ovarian cancers occur in women without risk factors. Use of hormonal contraceptives, oophorectomy, and tubal sterilization reduce risk of ovarian cancer (Kerlikowske, et. al. (1992) Obstet. Gynecol. 80:700-707; Grimes (1992) Am J.
Obstet. Gynecol. 166:1950-1954; Hankinson, et. al. (1993) JAMA 270:2813-2818);
however, even bilateral oophorectomy may not be completely effective in preventing ovarian cancer.
Treatment of ovarian cancer consists largely of surgical oophorectomy, anti-hormone therapy, and/or chemotherapy. Although many ovarian cancer patients are effectively treated, the current therapies can all induce serious side effects which diminish quality of life.
Deciding on a particular course of treatment is typically based on a variety of prognostic parameters and markers (Fitzgibbons, et al. (2000) Arch. Pathol. Lab. Med.
124:966-978;
Hamilton and Piccart (2000) Ann. Oncol. 11:647-663), including genetic predisposition markers BRCA-1 and BRCA-2 (Robson (2000) J. Clin. Oncol. 18:113sup-118sup).
The identification of novel therapeutic targets and diagnostic markers is essential for improving the current treatment of ovarian cancer patients. Recent advances in molecular medicine have increased the interest in tumor-specific cell surface antigens that could serve as targets for various immunotherapeutic or small molecule strategies.
Antigens suitable for immunotherapeutic strategies should be highly expressed in cancer tissues and ideally not expressed in normal adult tissues. Expression in tissues that are dispensable for life, however, may be tolerated. Examples of such antigens include Her2/neu and the B-cell antigen CD20. Humanized monoclonal antibodies directed to Her2lneu (Herceptin~/trastuzumab) are currently in use for the treatment of metastatic breast cancer.
Ross and Fletcher (1998) Stem Cells 16:413-428. Similarly, anti-CD20 monoclonal antibodies (Rituxin~/rituximab) are used to effectively treat non-Hodgkin's lymphoma.
Maloney, et al. (1997) Blood 90:2188-2195; Leget and Czuczman (1998) Curr.
Opin. Oncol.
10:548-551.
Potential immunotherapeutic targets have been identified for ovarian cancer.
One such target is polymorphic epithelial mucin (MLJC1). MUC1 is a transmembrane protein, present at the apical surface of glandular epithelial cells. It is often overexpressed in ovarian cancer, and typically exhibits an altered glycosylation pattern, resulting in an antigenically distinct molecule, and is in early clinical trials as a vaccine target.
Gilewski, et al. (2000) Clin. Cancer Res. 6:1693-1701; Scholl, et al. (2000) J. Immunother. 23:570-580. The tumor-expressed protein is often cleaved into the circulation, where it is detectable as the tumor marker, CA 15-3. See, e.g., Bon, et al. (1997) Clin. Chem. 43:585-593.
However, many patients have tumors that express neither HER2 nor MUC-1; therefore, it is clear that other targets need to be identified to manage localized and metastatic disease.
Mutations in both BRCAl and BRCA2 are associated with increased susceptibility to ovarian cancer. Mutations in BRCA1 occur in approximately 5 percent (95 percent confidence interval, 3 to 8 percent) of women in whom ovarian cancer is diagnosed before the age of 70 years. See Stratton, et al. (1997) N.E.J. Med. 336:1125-1130.
And, in BRCA1 gene Garners, the risk for developing ovarian cancer is .63. See Easton (1995) Am. J. Hum.
Genet. 56:267-xxx; and Elit (2001) Can. Fam. Physician 47:778-84.
Other biochemical markers such as CA125 have been reported to be associated with ovarian cancer, but they are not absolute indicators of disease. Although roughly 85% of women with clinically apparent ovarian cancer have increased levels of CA125, CA125 is also increased during the first trimester of pregnancy, during menstruation, in the presence of non-cancerous illnesses, and in cancers of other sites.
While industry and academia have identified novel gene sequences, there has not been an equal effort exerted to identify the function of these novel sequences. The elucidation of a role for novel proteins and compounds in disease states for identification of therapeutic targets and diagnostic markers is essential for improving the current treatment of ovarian cancer patients. Accordingly, provided herein are molecular targets for therapeutic intervention in ovarian and other cancers. Additionally, provided herein are methods that can be used in diagnosis and prognosis of ovarian cancer. Further provided are methods that can be used to screen candidate bioactive agents for the ability to modulate ovarian cancer.

SUMMARY OF THE INVENTION
The present invention therefore provides nucleotide sequences of genes that are up-and down-regulated in ovarian cancer cells. Such genes are useful for diagnostic purposes, and also as targets for screening for therapeutic compounds that modulate ovarian cancer, such as hormones or antibodies. The methods of detecting nucleic acids of the invention or their encoded proteins can be used for many purposes, e.g., early detection of ovarian cancers, monitoring and early detection of relapse following treatment, monitoring response to therapy, selecting patients for postoperative chemotherapy or radiation therapy, selecting therapy, determining tumor prognosis, treatment, or response to treatment (of primary or metastatic tumors), and early detection of pre-cancerous lesions. Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.
In one aspect, the present invention provides a method of detecting an ovarian cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26.
In one embodiment, the present invention provides a method of determining the level of an ovarian cancer associated transcript in a cell from a patient.
In one embodiment, the present invention provides a method of detecting an ovarian cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26.
In one embodiment, the polynucleotide selectively hybridizes to a sequence at least 95% identical to a sequence as shown in Tables 1-26.
In one embodiment, the biological sample is a tissue sample. In another embodiment, the biological sample comprises isolated nucleic acids, e.g., mRNA.
In one embodiment, the polynucleotide is labeled, e.g., with a fluorescent label.
In one embodiment, the polynucleotide is immobilized on a solid surface.
In one embodiment, the patient is undergoing a therapeutic regimen to treat ovarian cancer. In another embodiment, the patient is suspected of having metastatic ovarian cancer.
In one embodiment, the patient is a human.
In one embodiment, the ovarian cancer associated transcript is mRNA.
In one embodiment, the method further comprises the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.
In another aspect, the present invention provides a method of monitoring the efficacy of a therapeutic treatment of ovarian cancer, the method comprising the steps of (i) providing a biological sample from a patient undergoing the therapeutic treatment; and (ii) determining the level of an ovarian cancer-associated transcript in the biological sample by contacting the biological sample with a polynucleotide that selectively hybridizes to a sequence at least 80%
identical to a sequence as shown in Tables 1-26, thereby monitoring the efficacy of the therapy. In a further embodiment, the patient has metastatic ovarian cancer.
In a further embodiment, the patient has a drug resistant form of ovarian cancer.
In one embodiment, the method further comprises the step of (iii) comparing the level of the ovarian cancer-associated transcript to a level of the ovarian cancer-associated transcript in a biological sample from the patient prior to, or earlier in, the therapeutic treatment.
Additionally, provided herein is a method of evaluating the effect of a candidate ovarian cancer drug comprising administering the drug to a patient and removing a cell sample from the patient. The expression profile of the cell is then determined. This method may further comprise comparing the expression profile to an expression profile of a healthy individual. In a preferred embodiment, said expression profile includes a gene of Tables 1-26.
In one aspect, the present invention provides an isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-26.
In one embodiment, an expression vector or cell comprises the isolated nucleic acid.
In one aspect, the present invention provides an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-26.
In another aspect, the present invention provides an antibody that specifically binds to an isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-26.
In one embodiment, the antibody is conjugated to an effector component, e.g., a fluorescent label, a radioisotope or a cytotoxic chemical.
In one embodiment, the antibody is an antibody fragment. In another embodiment, the antibody is humanized.
In one aspect, the present invention provides a method of detecting an ovarian cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody as described herein.
In another aspect, the present invention provides a method of detecting antibodies specific to ovarian cancer in a patient, the method comprising contacting a biological sample from the patient with a polypeptide encoded by a nucleic acid comprising a sequence from Tables 1-26.
In another aspect, the present invention provides a method for identifying a compound that modulates an ovarian cancer-associated polypeptide, the method comprising the steps of (i) contacting the compound with an ovarian cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26; and (ii) determining the functional effect of the compound upon the polypeptide.
In one embodiment, the functional effect is a physical effect, an enzymatic effect, or a chemical effect.
In one embodiment, the polypeptide is expressed in a eukaryotic host cell or cell membrane. In another embodiment, the polypeptide is recombinant.
In one embodiment, the functional effect is determined by measuring ligand binding to the polypeptide.
In another aspect, the present invention provides a method of inhibiting proliferation of an ovarian cancer-associated cell to treat ovarian cancer in a patient, the method comprising the step of administering to the subject a therapeutically effective amount of a compound identified as described herein.
In one embodiment, the compound is an antibody.
In another aspect, the present invention provides a drug screening assay comprising the steps of: (i) administering a test compound to a mammal having ovarian cancer or to a cell sample isolated from; (ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell sample or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of ovarian cancer.
In one embodiment, the control is a mammal with ovarian cancer or a cell sample that has not been treated with the test compound. In another embodiment, the control is a normal cell or mammal, or is non-malignant tissue.
In one embodiment, the test compound is administered in varying amounts or concentrations. In another embodiment, the test compound is administered for varying time periods. In another embodiment, the comparison can occur after addition or removal of the drug candidate.
In one embodiment, the levels of a plurality of polynucleotides that selectively hybridize to a sequence at least 80% identical to a sequence as shown in Tables 1-26 are individually compared to their respective levels in a control cell sample or mammal. In a preferred embodiment the plurality of polynucleotides is from three to ten.
In another aspect, the present invention provides a method for treating a mammal having ovarian cancer comprising administering a compound identified by the assay described herein.
In another aspect, the present invention provides a pharmaceutical composition for treating a mammal having ovarian cancer, the composition comprising a compound identified by the assay described herein and a physiologically acceptable excipient.
In one aspect, the present invention provides a method of screening drug candidates by providing a cell expressing a gene that is up- and down-regulated as in an ovarian cancer.
In one embodiment, a gene is selected from Tables 1-26. The method further includes adding a drug candidate to the cell and determining the effect of the drug candidate on the expression of the expression profile gene.
In one embodiment, the method of screening drug candidates includes comparing the level of expression in the absence of the drug candidate to the level of expression in the presence of the drug candidate, wherein the concentration of the drug candidate can vary when present, and wherein the comparison can occur after addition or removal of the drug candidate. In a preferred embodiment, the cell expresses at least two expression profile genes. The profile genes may show an increase or decrease.
Also provided is a method of evaluating the effect of a candidate ovarian cancer drug comprising administering the drug to a transgenic animal expressing or over-expressing the ovarian cancer modulatory~protein, or an animal lacking the ovarian cancer modulatory protein, for example as a result of a gene knockout.
Moreover, provided herein is a biochip comprising one or more nucleic acid segments of Tables 1-26, wherein the biochip comprises fewer than 1000 nucleic acid probes.
Preferably, at least two nucleic acid segments are included. More preferably, at least three nucleic acid segments are included.
Furthermore, a method of diagnosing a disorder associated with ovarian cancer is provided. The method comprises determining the expression of a gene of Tables 1-26 in a first tissue type of a first individual, and comparing the distribution to the expression of the gene from a second normal tissue type from the first individual or a second unaffected individual. A difference in the expression indicates that the first individual has a disorder associated with ovarian cancer.
In a further embodiment, the biochip also includes a polynucleotide sequence of a gene that is not up- and down-regulated in ovarian cancer.
In one embodiment a method for screening for a bioactive agent capable of interfering with the binding of an ovarian cancer modulating protein (ovarian cancer modulatory protein) or a fragment thereof and an antibody which binds to said ovarian cancer modulatory protein or fragment thereof. In a preferred embodiment, the method comprises combining an ovarian cancer modulatory protein or fragment thereof, a candidate bioactive agent and an antibody which binds to said ovarian cancer modulatory protein or fragment thereof. The method further includes determining the binding of said ovarian cancer modulatory protein or fragment thereof and said antibody. Wherein there is a change in binding, an agent is identified as an interfering agent. The interfering agent can be an agonist or an antagonist.
Preferably, the agent.inhibits ovarian cancer.
Also provided herein are methods of eliciting an immune response in an individual.
In one embodiment a method provided herein comprises administering to an individual a composition comprising an ovarian cancer modulating protein, or a fragment thereof. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-26.
Further provided herein are compositions capable of eliciting an immune response in an individual. W one embodiment, a composition provided herein comprises an ovarian cancer modulating protein, preferably encoded by a nucleic acid of Table 1-26 or a fragment thereof, and a pharmaceutically acceptable carrier. In another embodiment, said composition comprises a nucleic acid comprising a sequence encoding an ovarian cancer modulating protein, preferably selected from the nucleic acids of Tables 1-26, and a pharmaceutically acceptable carrier.
Also provided are methods of neutralizing the effect of an ovarian cancer protein, or a fragment thereof, comprising contacting an agent specific for said protein with said protein in an amount sufficient to effect neutralization. In another embodiment, the protein is encoded by a nucleic acid selected from those of Tables 1-26.

In another aspect of the invention, a method of treating an individual for ovarian cancer is provided. In one embodiment, the method comprises administering to said individual an inhibitor of an ovarian cancer modulating protein. In another embodiment, the method comprises administering to a patient having ovarian cancer an antibody to an ovarian cancer modulating protein conjugated to a therapeutic moiety. Such a therapeutic moiety can be a cytotoxic agent or a radioisotope.

DETAILED DESCRIPTION OF THE INVENTION
In accordance with the objects outlined above, the present invention provides novel methods for diagnosis and prognosis evaluation for ovarian cancer (OC), including metastatic ovarian cancer, as well as methods for screening for compositions which modulate ovarian cancer. Also provided are methods for treating ovarian cancer and related conditions, e.g., ovarian carcinoma (e.g., epithelial (including malignant serous tumors, malignant mucinous tumors, and malignant endometrioid tumors), germ cell (including teratomas, choriocarcinomas, polyembryomas, embryonal carcinoma, endodermal sinus tumor, dysgerminoma, and gonadoblastoma), and stromal carcinomas (e.g., granulosal stromal cell tumors)), fallopian tube carcinoma, and peritoneal carcinoma.
Tables 1-26 provide unigene cluster identification numbers for the nucleotide sequence of genes that exhibit increased or decreased expression in ovarian cancer samples.
Tables 1-26 also provide an exemplar accession number that provides a nucleotide sequence that is part of the unigene cluster.
Definitions The term "ovarian cancer protein" or "ovarian cancer polynucleotide" or "ovarian cancer-associated transcript" refers to nucleic acid and polypeptide polymorphic variants, alleles, mutants, and interspecies homologues that: (1) have a nucleotide sequence that has greater than about 60% nucleotide sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or greater nucleotide sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more nucleotides, to a nucleotide sequence of or associated with a gene of Tables 1-26; (2) bind to antibodies, e.g., polyclonal antibodies, raised against an immunogen comprising an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-26, and conservatively modified variants thereof; (3) specifically hybridize under stringent hybridization conditions to a nucleic acid sequence, or the complement thereof of Tables 1-26 and conservatively modified variants thereof; or (4) have an amino acid sequence that has greater than about 60% amino acid sequence identity, 65%, 70%, 75%, 80%, 85%, 90%, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% or greater amino sequence identity, preferably over a region of over a region of at least about 25, 50, 100, 200, 500, 1000, or more amino acid, to an amino acid sequence encoded by a nucleotide sequence of or associated with a gene of Tables 1-26. A polynucleotide or polypeptide sequence is typically from a mammal including, but not limited to, primate, e.g., human;
rodent, e.g., rat, mouse, hamster; cow, pig, horse, sheep, or other mammal. An "ovarian cancer polypeptide" and an "ovarian cancer polynucleotide," include both naturally occurring or recombinant forms.
A "full length" ovarian cancer protein or nucleic acid refers to an ovarian cancer polypeptide or polynucleotide sequence, or a variant thereof, that contains all of the elements normally contained in one or more naturally occurnng, wild type ovarian cancer polynucleotide or polypeptide sequences. The "full length" may be prior to, or after, various stages of post-translation processing or splicing, including alternative splicing.
"Biological sample" as used herein is a sample of biological tissue or fluid that contains nucleic acids or polypeptides, e.g., of an ovarian cancer protein, polynucleotide or transcript. Such samples include, but are not limited to, tissue isolated from primates, e.g., humans, or rodents, e.g., mice, and rats. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, etc. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A
biological sample is typically obtained from a eukaryotic organism, most preferably a mammal such as a primate e.g., chimpanzee or human; cow; dog; cat; a rodent, e.g., guinea pig, rat, mouse; rabbit; or a bird; reptile; or fish. Livestock and domestic animals are of particular interest.
"Providing a biological sample" means to obtain a biological sample for use in methods described in this invention. Most often, this will be done by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention in vivo. Archival tissues, having treatment or outcome history, will be particularly useful.
The terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (e.g., about 60% identity, preferably 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters described below, or by manual alignment and visual inspection (see, e.g., NCBI
web site http://www.ncbi.nlm.nih.gov/BLAST/ or the like). Such sequences are then said to be "substantially identical." This definition also refers to, or may be applied to, the compliment of a test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions, as well as naturally occurring, e.g., polymorphic or allelic variants, and man-made variants. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region that is at least about 25 amino acids or nucleotides in length, or more preferably over a region that is 50-100 amino acids or nucleotides in length.
For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated.
Preferably, default program parameters can be used, or alternative parameters can be designated.
The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.
A "comparison window", as used herein, includes reference to a segment of one of the number of contiguous positions selected from the group consisting typically of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith and Waterman (1981) Adv. Appl.
Math.
2;482-489, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol.
Biol. 48:443-453, by the search for similarity method of Pearson and Lipman (1988) Proc.
Nat'l. Acad. Sci. USA 85:2444-2448, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Ausubel, et al. (eds. 1995 and supplements) Current Protocols in Molecular Biolo~y Lippincott.
Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity include the BLAST and BLAST 2.0 algorithms, which are described in Altschul, et al. (1977) Nuc. Acids Res. 25:3389-3402 and Altschul, et al. (1990) J. Mol. Biol. 215:403-410. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http://www.ncbi.nhn.nih.gov~.
This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, e.g., for nucleotide sequences, the parameters M (reward score for a pair of matching residues;
always > 0) and N (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score.
Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X
determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Nat'1 Acad. Sci. USA 89:10915-919) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.
The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'1 Acad. Sci.
USA 90:5873-5887). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001. Log values may be large negative numbers, e.g., 5, 10, 20, 30, 40, 40, 70, 90, 110, 150, 170, etc.

An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions, as described below.
Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequences.
A "host cell" is a naturally occurring cell or a transformed cell that contains an expression vector and supports the replication or expression of the expression vector. Host cells may be cultured cells, explants, cells in vivo, and the like. Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells, such as CHO, HeLa, and the like (see, e.g., the American Type Culture Collection catalog or Web site, www.atcc.org).
The terms "isolated," "purified," or "biologically pure" refer to material that is substantially or essentially free from components that normally accompany it as found in its native state. Purity and homogeneity are typically determined using analytical chemistry techniques such as polyacrylamide gel electrophoresis or high performance liquid chromatography. A protein or nucleic acid that is the predominant species present in a preparation is substantially purified. In particular, an isolated nucleic acid is separated from some open reading frames that naturally flank the gene and encode proteins other than protein encoded by the gene. The term "purified" in some embodiments denotes that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel.
Preferably, it means that the nucleic acid or protein is at least ~5% pure, more preferably at least 95% pure, and most preferably at least 99% pure. "Purify" or "purification" in other embodiments means removing at least one contaminant from the composition to be purified. In this sense, purification does not require that the purified compound be homogenous, e.g., 100% pure.
The terms "polypeptide," "peptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurnng amino acid, as well as to naturally occurnng amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymers.

The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, y-S carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the ICTPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
"Conservatively modified variants" applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e:g., naturally contiguous, sequences.
Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. In certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, a silent variation of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not necessarily with respect to actual probe sequences.

As to amino acid sequences, one of skill will recognize that individual substitutions, deletions, or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds, or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant" where the alteration results in the substitution of an amino acid with a chemically similar amino acid.
Conservative substitution tables providing functionally similar amino acids are well known in the art.
Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention. Typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (I~, Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton (1984) Proteins Freeman).
Macromolecular structures such as polypeptide structures can be described in terms of various levels of organization. For a general discussion of this organization, see, e.g., Alberts, et al. (2001) Molecular Biology of the Cell (4th ed.) Garland Pub.;
and Cantor and Schimmel (1980) Biophysical Chemistry Part I: The Conformation of Biological Macromolecules Freeman. "Primary structure" refers to the amino acid sequence of a particular peptide. "Secondary structure" refers to locally ordered, three dimensional structures within a polypeptide. These structures are commonly known as domains.
Domains are portions of a polypeptide that often form a compact unit of the polypeptide and are typically 25 to approximately 500 amino acids long. Typical domains are made up of sections of lesser organization such as stretches of (3-sheet and a-helices.
"Tertiary structure"
refers to the complete three dimensional structure of a polypeptide monomer.
"Quaternary structure" refers to the three dimensional structure formed, usually by the non-covalent association of independent tertiary units. Anisotropic terms are also known as energy terms.
"Nucleic acid" or "oligonucleotide" or "polynucleotide" or grammatical equivalents used herein means at least two nucleotides covalently linked together.
Oligonucleotides are typically from about 5, 6, 7, 8, 9, 10, 12, 15, 25, 30, 40, 50, or more nucleotides in length, up to about 100 nucleotides in length. Nucleic acids and polynucleotides are a polymers of any length, including longer lengths, e.g., 200, 300, 500, 1000, 2000, 3000, 5000, 7000, 10,000, etc. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs are included that may have at least on,e different linkage, e.g., phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphosphoroamidite linkages (see Eckstein (1992) Oli~onucleotides and Analogues: A
Practical Approach Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones;
non-ionic backbones, and non-ribose backbones, including those described in U.S. Patent Nos.
5,235,033 and 5,034,506, and Chapters 6 and 7 of Sanghvi and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ASC Symposium Series 580.
Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids. Modifications of the ribose-phosphate backbone may be done for a variety of reasons, e.g., to increase the stability and half life of such molecules in physiological environments or as probes on a biochip. Mixtures of naturally occurring nucleic acids and analogs can be made; alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made.
A variety of references disclose such nucleic acid analogs, including, e.g., phosphoramidate (Beaucage, et al. (1993) Tetrahedron 49:1925-1963 and references therein;
Letsinger (1970) J. Org. Chem. 35:3800-3803; Sprinzl, et al. (1977) Eur. J.
Biochem. 81:579-589; Letsinger, et al. (1986) Nucl. Acids Res. 14:3487-499; Sawai, et al.
(1984) Chem. Lett.
805, Letsinger, et al. (1988) J. Am. Chem. Soc. 110:4470-4471; and Pauwels, et al. (1986), Chemica Scri~ta 26:141-149), phosphorothioate (Mag, et a1. (1991) Nucl. Acids Res.
19:1437-441; and U.S. Patent No. 5,644,048), phosphorodithioate (Brill, et al.
(1989) J. Am.
Chem. Soc. 111:2321-2322), O-methylphophoroamidite linkages (see Eckstein (1992) Oligonucleotides and Analogues: A Practical Approach Oxford Univ. Press), and peptide nucleic acid backbones and linkages (see Egholm (1992) J. Am. Chem. Soc.
114:1895-897;
Meier, et al. (1992) Angew. Chem. Int. Ed. En~l. 31:1008-1010; Nielsen (1993) Nature, 365:566-568; Carlsson, et al. (1996) Nature 380:207, each of which is incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy, et al.
(1995) Proc. Nat'1 Acad. Sci. USA 92:6097-101; non-ionic backbones (U.S.
Patent Nos.
5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi, et al.
(1991) Angew.
Chem. Intl. Ed. En 1g ish 30:423-426; Letsinger, et al. (1988) J. Am. Chem.
Soc. 110:4470-4471; Jung, et al. (1994) Nucleoside and Nucleotide 13:1597; Chapters 2 and 3, in Sanghvi and Cook (eds. 1994) Carbohydrate Modifications in Antisense Research ASC
Symposium Series SM; Mesmaeker, et al. (1994) Bioorganic and Medicinal Chem. Lett. 4:395-398; Jeffs, et al. (1994) J. Biomolecular NMR 34:17-xx; Horn, et al. (1996) Tetrahedron Lett. 37:743-xxx) and non-ribose backbones, including those described in U.S. Patent Nos.
5,235,033 and 5,034,506, and Chapters 6 and 7, in Sanghvi and Cook (eds. 1994) Carbohydrate Modifications 'in Antisense Research ASC Symposium Series 580. Nucleic acids containing one or more carbocyclic sugars are also included within one definition of nucleic acids (see Jenkins, et al. (1995) Chem. Soc. Rev. pp 169-176). Several nucleic acid analogs are described in Rawls (p. 35 June 2, 1997) C&E News. Each of these references is hereby expressly incorporated by reference.
Particularly preferred are peptide nucleic acids (PNA) which includes peptide nucleic acid analogs. These backbones are substantially non-ionic under neutral conditions, in contrast to the highly charged phosphodiester backbone of naturally occurring nucleic acids.
This results in two advantages. First, the PNA backbone exhibits improved hybridization kinetics. PNAs have larger changes in the melting temperature (Tm) for mismatched versus perfectly matched base pairs. DNA and RNA typically exhibit a 2-4° C
drop in Tm for an internal mismatch. With the non-ionic PNA backbone, the drop is closer to 7-9° C.
Similarly, due to their non-ionic nature, hybridization of the bases attached to these backbones is relatively insensitive to salt concentration. In addition, PNAs are not degraded by cellular enzymes, and thus can be more stable.
The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence.
The nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc. "Transcript" typically refers to a naturally occurring RNA, e.g., a pre-mRNA, hnRNA, or mRNA. As used herein, the term "nucleoside" includes nucleotides and nucleoside and nucleotide analogs, and modified nucleosides such as amino modified nucleosides. In addition, "nucleoside"
includes non-naturally occurnng analog structures. Thus, e.g., the individual units of a peptide nucleic acid, each containing a base, are referred to herein as a nucleoside.
A "label" or a "detectable moiety" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into the peptide or used to S detect antibodies specifically reactive with the peptide. The labels may be incorporated into the ovarian cancer nucleic acids, proteins and antibodies at aaiy position.
Any method known in the art for conjugating the antibody to the label may be employed, including those methods described by Hunter, et al. (1962) Nature 144:945-xxx; David, et al. (1974) Biochemistry 13:1014-1021; Pain, et al. (1981) J. Immunol. Meth. 40:219-230; and Nygren (1982) J.
Histochem. and C. ochem. 30_:407-412.
An "effector" or "effector moiety" or "effector component" is a molecule that is bound (or linked, or conjugated), either covalently, through a linker or a chemical bond, or non-covalently, through ionic, van der Waals, electrostatic, or hydrogen bonds, to an antibody. The "effector" can be a variety of molecules including, e.g., detection moieties including radioactive compounds, fluorescent compounds, an enzyme or substrate, tags such as epitope tags, a toxin; activatable moieties, a chemotherapeutic agent; a lipase; an antibiotic; or a radioisotope emitting "hard" e.g., beta radiation.
A "labeled nucleic acid probe or oligonucleotide" is one that is bound, either covalently, through a linker or a chemical bond, or non-covalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the probe may be detected by detecting the presence of the label bound to the probe.
Alternatively, method using high affinity interactions may achieve the same results where one of a pair of binding partners binds to the other, e.g., biotin, streptavidin.
As used herein a "nucleic acid probe or oligonucleotide" is a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. As used herein, a probe may include natural (e.g., A, G, C, or T) or modified bases (7-deazaguanosine, inosine, etc.). In addition, the bases in a probe may be joined by a linkage other than a phosphodiester bond, so long as it does not functionally interfere with hybridization. Thus, e.g., probes may be peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages. Probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. The probes are preferably directly labeled, e.g., with isotopes, chromophores, lumiphores, chromogens, or indirectly labeled such as with biotin to which a streptavidin complex may later bind. By assaying for the presence or absence of the probe, one can detect the presence or absence of the select sequence or subsequence. Diagnosis or prognosis may be based at the genomic level, or at the level of RNA or protein expression.
The term "recombinant" when used with reference, e.g., to a cell, or nucleic acid, protein, or vector, indicates that the cell, nucleic acid, protein or vector, has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, e.g., recombinant cells express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed in vitro, in general, by the manipulation of nucleic acid, e.g., using polymerases and endonucleases, in a form not normally found in nature. In this manner, operably linkage of different sequences is achieved. Thus an isolated nucleic acid, in a linear form, or an expression vector formed in vitro by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, e.g., using the in vivo cellular machinery of the host cell rather than in vitro manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention. Similarly, a "recombinant protein" is a protein made using recombinant techniques, e.g., through the expression of a recombinant nucleic acid as depicted above.
The term "heterologous" when used with reference to portions of a nucleic acid indicates that the nucleic acid comprises two or more subsequences that are not normally found in the same relationship to each other in nature. For instance, the nucleic acid is typically recombinantly produced, having two or more sequences, e.g., from unrelated genes arranged to make a new functional nucleic acid, e.g., a promoter from one source and a coding region from another source. Similarly, a heterologous protein will often refer to two or more subsequences that are not found in the same relationship to each other in nature (e.g., a fusion protein).

A "promoter" is defined as an array of nucleic acid control sequences that direct transcription of a nucleic acid. As used herein, a promoter includes necessary nucleic acid sequences near the start site of transcription, such as, in the case of a polymerise II type promoter, a TATA element. A promoter also optionally includes distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A "constitutive" promoter is a promoter that is active under most environmental and developmental conditions. An "inducible" promoter is a promoter that is active under environmental or developmental regulation. The term "operably linked" refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, or array of transcription factor binding sites) and a second nucleic acid sequence, e.g., wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.
An "expression vector" is a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a host cell. The expression vector can be part of a plasmid, virus, or nucleic acid fragment. Typically, the expression vector includes a nucleic acid to be transcribed operably linked to a promoter.
The phrase "selectively (or specifically) hybridizes to" refers to the binding, duplexing, or hybridizing of a molecule only to a particular nucleotide sequence under stringent hybridization conditions when that sequence is present in a complex mixture (e.g., total cellular or library DNA or RNA).
The phrase "stringent hybridization conditions" refers to conditions under which a probe will hybridize to its target subsequence, typically in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in "Overview of principles of hybridization and the strategy of nucleic acid assays" in Tijssen (1993) Hybridization with Nucleic Probes (Laboratory Techniques in Biochemistr~and Molecular Biolo (vol. 24) Elsevier. Generally, stringent conditions are selected to be about 5-10° C
lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm is the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, SO% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C for S short probes (e.g., 10 to 50 nucleotides) and at least about 60° C
for long probes (e.g., greater than SO nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal is typically at least two times background, preferably 10 times background hybridization. Exemplary stringent hybridization conditions can be as following: 50%
formamide, Sx SSC, and 1% SDS, incubating at 42° C, or, Sx SSC, 1% SDS, incubating at 65° C, with wash in 0.2x SSC, and 0.1% SDS at 65° C. For PCR, a temperature of about 36°
C is typical for low stringency amplification, although annealing temperatures may vary between about 32-48° C depending on primer length. For high stringency PCR amplification, a temperature of about 62° C is typical, although high stringency annealing temperatures can range from about SO° C to about 65° C, depending on the primer length and specificity.
Typical cycle conditions for both high and low stringency amplifications include a denaturation phase of 90-95° C for 30-120 sec, an annealing phase lasting 30-120 sec, and an extension phase of about 72° C for 1-2 min. Protocols and guidelines for low and high stringency amplification reactions are available, e.g., in Innis, et al.
(1990) PCR Protocols: A
Guide to Methods and Applications Academic Press, N.Y.
Nucleic acids that do not hybridize to each other under stringent conditions are still substantially identical if the polypeptides which they encode are substantially identical. This occurs, e.g., when a copy of a nucleic acid is created using the maximum codon degeneracy permitted by the genetic code. In such cases, the nucleic acids typically hybridize under moderately stringent hybridization conditions. Exemplary "moderately stringent hybridization conditions" include a hybridization in a buffer of 40%
formamide, 1 M NaCI, 1% SDS at 37° C, and a wash in 1X SSC at 45° C. A positive hybridization is at least twice background. Alternative hybridization and wash conditions can be utilized to provide conditions of similar stringency. Additional guidelines for determining hybridization parameters are provided, e.g., Ausubel, et al. (ed. 1991 and supplements) Current Protocols in Molecular Biolo~y Lippincott.
The phrase "functional effects" in the context of assays for testing compounds that modulate activity of an ovarian cancer protein includes the determination of a parameter that is indirectly or directly under the influence of the ovarian cancer protein or nucleic acid, e.g., a functional, physical, physiological, or chemical effect, such as the ability to decrease ovarian cancer. It includes ligand binding activity; cell growth on soft agax;
anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation;
cellular transformation; growth factor or serum dependence; tumor specific marker levels;
invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of ovarian cancer cells.
"Functional effects" include in vitro, in vivo, and ex vivo activities.
By "determining the functional effect" is meant assaying for a compound that increases or decreases a parameter that is indirectly or directly under the influence of an ovarian cancer protein sequence, e.g., functional, enzymatic, physical, physiological, and chemical effects. Such functional effects can be measured by any means known to those skilled in the art, e.g., changes in spectroscopic characteristics (e.g., fluorescence, absorbance, refractive index), hydrodynamic (e.g., shape), chromatographic, or solubility properties for the protein, measuring inducible markers or transcriptional activation of the ovarian cancer protein; measuring binding activity or binding assays, e.g., binding to antibodies or other ligands, and measuring cellular proliferation.
Determination of the functional effect of a compound on ovarian cancer can also be performed using ovarian cancer assays known to those of skill in the art such as an in vitro assays, e.g., cell growth on soft agar; anchorage dependence; contact inhibition and density limitation of growth; cellular proliferation; cellular transformation; growth factor or serum dependence;
tumor specific marker levels; invasiveness into Matrigel; tumor growth and metastasis in vivo; mRNA and protein expression in cells undergoing metastasis, and other characteristics of ovarian cancer cells. The functional effects can be evaluated by means known to those skilled in the art, e.g., microscopy for quantitative or qualitative measures of alterations in morphological features, measurement of changes in RNA or protein levels for ovarian cancer-associated sequences, measurement of RNA stability, or identification of downstream or reporter gene expression (CAT, luciferase, (3-gal, GFP, and the like), e.g., via chemiluminescence, fluorescence, colorimetric reactions, antibody binding, inducible markers, and ligand binding assays.
"Inhibitors", "activators", and "modulators" of ovarian cancer polynucleotide and polypeptide sequences are used to refer to activating, inhibitory, or modulating molecules or compounds identified using in vitro and in vivo assays of ovarian cancer polynucleotide and polypeptide sequences. Inhibitors are compounds that, e.g., bind to, partially or totally block activity, decrease, prevent, delay activation, inactivate, desensitize, or down regulate the activity or expression of ovarian cancer proteins, e.g., antagonists.
Antisense or inhibitory nucleic acids may inhibit expression and subsequent function of the protein.
"Activators" are compounds that increase, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate ovarian cancer protein activity. Inhibitors, activators, or modulators also include genetically modified versions of ovarian cancer proteins, e.g., versions with altered activity, as well as naturally occurring and synthetic ligands, antagonists, agonists, antibodies, small chemical molecules, and the like. Assays for inhibitors and activators include, e.g., expressing the ovarian cancer,protein in vitro, in cells, or cell membranes, applying putative modulator compounds, and then determining the functional effects on activity, as described above. Activators and inhibitors of ovarian cancer can also be identified by incubating ovarian cancer cells with the test compound and determining increases or decreases in the expression of one or more ovarian cancer proteins, e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, S0, or more ovarian cancer proteins, such as ovarian cancer proteins encoded by the sequences set out in Tables 1-26.
Samples or assays comprising ovarian cancer proteins that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of inhibition. Control samples (untreated with inhibitors) are assigned a relative protein activity value of 100%. Inhibition of a polypeptide is achieved when the activity value relative to the control is about 80%, preferably SO%, more preferably 25% or less. Activation of an ovarian cancer polypeptide is achieved when the activity value relative to the control (untreated with activators) is 110%, more preferably 1.50%, more preferably 200-500% (e.g., 2-5 fold higher relative to the control), more preferably 1000-3000% higher.
The phrase "changes in cell growth" refers to a change in cell growth and proliferation characteristics in vitro or in vivo, e.g., cell viability, formation of foci, anchorage independence, semi-solid or soft agar growth, change in contact inhibition or density limitation of growth, loss of growth factor or serum requirements, change in cell morphology, gain or loss of immortalization, gain or loss of tumor specific markers, ability to form or suppress tumors when injected into suitable animal hosts, and/or immortalization of the cell. See, e.g., pp. 231-241 in Freshney (1994) Culture of Animal Cells: A
Manual of Basic Technique (3d ed.) Wiley-Liss.

"Tumor cell" refers to pre-cancerous, cancerous, and normal cells in a tumor.
"Cancer cells," "transformed" cells or "transformation" in tissue culture, refers to spontaneous or induced phenotypic changes that do not necessarily involve the uptake of new genetic material. Although transformation can arise from infection with a transforming virus and incorporation of new genomic DNA, or uptake of exogenous DNA, it can also arise spontaneously or following exposure to a carcinogen, thereby mutating an endogenous gene.
Transformation is typically associated with phenotypic changes, such as immortalization of cells, aberrant growth control, non-morphological changes, and/or malignancy.
See, Freshney (1994) Culture of Animal Cells.
"Antibody" refers to a,polypeptide comprising a framework region from an immunoglobulin gene or fragments thereof that specifically binds and recognizes an antigen.
The recognized immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon, and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD, and IgE, respectively. Typically, the antigen-binding region of an antibody or its functional equivalent will be most critical in specificity and affinity of binding. See, e.g., Paul (ed. 1999) Fundamental Immunolo~y (4th ed.) Raven.
An exemplary immunoglobulin (antibody) structural unit comprises a tetramer.
Each tetramer is composed of two identical pairs of polypeptide chains, each pair having one "light" (about 25 kD) and one "heavy" chain (about 50-70 kD). The N-terminus of each chain defines a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The terms variable light chain (VL) and variable heavy chain (VH) refer to these light and heavy chains respectively.
Antibodies exist, e.g., as intact immunoglobulins or as a number of well-characterized fragments produced by digestion with various peptidases. Thus, e.g., pepsin digests an antibody below the disulfide linkages in the hinge region to produce F(ab)'2, a dimer of Fab which itself is a light chain joined to Vg-CH1 by a disulfide bond. The F(ab)'2 may b.e reduced under mild conditions to break the disulfide linkage in the hinge region, thereby converting the F(ab)'2 dimer into an Fab' monomer. The Fab' monomer is essentially Fab with part of the hinge region. See Paul (ed. 1999) Fundamental Immunolo~y (4th ed.) Raven.
While variouseantibody fragments are defined in ternls of the digestion of an intact antibody, one of skill will appreciate that such fragments may be synthesized de novo either chemically or by using recombinant DNA methodology. Thus, the term antibody, as used herein, also includes antibody fragments either produced by the modification of whole antibodies, or those synthesized de novo using recombinant DNA methodologies (e.g., single chain Fv) or those identified using phage display libraries. See, e.g., McCafferty, et al.
(1990) Nature 348:552-554. ' For preparation of antibodies, e.g., recombinant, monoclonal, or polyclonal antibodies, many techniques known in the art can be used (see, e.g., Kohler and Milstein (1975) Nature 256:495-497; Kozbor, et al. (1983) Immunolo~y TodaX 4:72; Cole, et al., pp.
77-96 in Reisfeld and Sell (1985) Monoclonal Antibodies and Cancer Therapy Liss; Coligan (1991) Current Protocols in Immunolo~y Lippincott; Harlow and Lane (1988) Antibodies: A
Laboratory Manual CSH Press; and Goding (1986) Monoclonal Antibodies:
Principles and Practice (2d ed.) Academic Press. Techniques for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce antibodies to polypeptides of this invention. Transgenic mice, or other organisms, e.g., other mammals, may be used to express humanized antibodies. Alternatively, phage display technology can be used to identify antibodies and heteromeric Fab fragments that specifically bind to selected antigens. See, e.g., McCafferty, et al. (1990) Nature 348:552-554; and Marks, et al. (1992) Biotechnolo~y 10:779-783.
A "chimeric antibody" is an antibody molecule in which (a) the constant region, or a portion thereof, is altered, replaced or exchanged so that the antigen binding site (variable region) is linked to a constant region of a different or altered class, effector function and/or species, or an entirely different molecule which confers new properties to the chimeric antibody, e.g., an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region, or a portion thereof, is altered, replaced or exchanged with a variable region having a different or altered antigen specificity.
Identification of ovarian cancer-associated sequences In one aspect, the expression levels of genes are determined in different patient samples for which diagnosis information is desired, to provide expression profiles. An expression profile of a particular sample is essentially a "fingerprint" of the state of the sample; while two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is characteristic of the state of the cell. That is, normal tissue (e.g., normal ovarian or other tissue) may be distinguished from cancerous or metastatic cancerous tissue of the ovarian, or ovarian cancer tissue or metastatic ovarian cancerous tissue can be compared with tissue samples of ovarian and other tissues from surviving cancer patients. By comparing S expression profiles of tissue in known different ovarian cancer states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Molecular profiling may distinguish subtypes of a currently collective disease designation, e.g., different forms of a cancer.
The identification of sequences that are differentially expressed in ovarian cancer versus non-ovarian cancer tissue allows the use of this information in a number of ways. For example, a particular treatment regime may be evaluated: does a chemotherapeutic drug act to down-regulate ovarian cancer, and thus tumor growth or recurrence, in a particular patient.
Alternatively, does existing treatment induce expression of a target.
Similarly, diagnosis and treatment outcomes may be done or confirmed by comparing patient samples with the known expression profiles. Metastatic tissue can also be analyzed to determine the stage of ovarian cancer in the tissue or origin of the primary tumor. Furthermore, these gene expression profiles (or individual genes) allow screening of drug candidates with an eye to mimicking or altering a particular expression profile; e.g., screening can be done for drugs that suppress the ovarian cancer expression profile. This may be done by making biochips comprising sets of the important ovarian cancer genes, which can then be used in these screens.
These methods can also be based on evaluating protein expression; that is, protein expression levels of the ovarian cancer proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the ovarian cancer nucleic acid sequences can be administered for gene therapy purposes, including the administration of antisense or RNAi nucleic acids, or the ovarian cancer proteins (including antibodies and other modulators thereof) administered as therapeutic drugs.
Thus the present invention provides nucleic acid and protein sequences that are differentially expressed in ovarian cancer relative to normal tissues and/or non-malignant tissues, herein termed "ovarian cancer sequences." As outlined below, ovarian cancer sequences include those that are up-regulated (e.g., expressed at a higher level) in ovarian cancer, as well as those that are down-regulated (e.g., expressed at a lower level). In a preferred embodiment, the ovarian cancer sequences are from humans; however, as will be appreciated by those in the art, ovarian cancer sequences from other organisms may be useful in animal models of disease and drug evaluation; thus, other ovarian cancer sequences are provided, from vertebrates, including mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm animals (including sheep, goats, pigs, cows, horses, etc.) and pets (e.g., dogs, cats, etc.). Ovarian cancer sequences, e.g., counterpart genes, from other organisms may be obtained using the techniques outlined below.
Ovarian cancer sequences can include both nucleic acid and amino acid sequences.
Ovarian cancer nucleic acid sequences are useful in a variety of applications, including diagnostic applications, which will detect naturally occurring nucleic acids.
Screening applications; e.g., biochips comprising nucleic acid probes or PCR microtiter plates with selected probes to the ovarian cancer sequences, are also provided.
An ovarian cancer sequence can be initially identified by substantial nucleic acid and/or amino acid sequence homology to the ovarian cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization 1 S conditions.
For identifying ovarian cancer-associated sequences, the ovarian cancer screen typically includes comparing genes identified in different tissues, e.g., normal and cancerous tissues, or tumor tissue samples from patients who have metastatic disease vs.
non metastatic tissue. Other suitable tissue comparisons include comparing ovarian cancer samples with metastatic cancer samples from other cancers, such as lung, ovarian, gastrointestinal cancers, etc. Samples of different stages of ovarian cancer, e.g., survivor tissue, drug resistant states, and tissue undergoing metastasis, are applied to biochips comprising nucleic acid probes.
The samples are first microdissected, if applicable, and treated for the preparation of mRNA.
Suitable biochips are commercially available, e.g., from Affymetrix. Gene expression profiles as described herein are generated and the data analyzed.
In one embodiment, the genes showing changes in expression as between normal and disease states are compared to genes expressed in other normal tissues, preferably normal ovarian, but also including, and not limited to, lung, heart, brain, liver, ovarian, kidney, muscle, colon, small intestine, large intestine, spleen, bone, and/or placenta. In a preferred embodiment, those genes identified during the ovarian cancer screen that are expressed in any significant amount in other tissues are removed from the profile, although in some embodiments, expression in non-essential tissues may be tolerated. That is, when screening for drugs, it is usually.preferable that the target be disease specific, to minimize possible side effects by interaction with target present in other organs.
In a preferred embodiment, ovarian cancer sequences are those that are up-regulated in ovarian cancer; that is, the expression of these genes is higher in the ovarian cancer tissue as compared to non-cancerous tissue. "Up-regulation" as used herein often means at least about a two-fold change, preferably at least about a three fold change, with at least about five-fold or higher being preferred. Other embodiments are directed to sequences up regulated in non-malignant conditions relative to normal.
Unigene cluster identification numbers and accession numbers herein refer to the GenBank sequence database and the sequences of the accession numbers are hereby expressly incorporated by reference. GenBank is known in the art, see, e.g., Benson, et al.
(1998) Nucl. Acids Res. 26:1-7; and http:/lwww.ncbi.nlm.nih.govl. Sequences are also available in other databases, e.g., European Molecular Biology Laboratory (EMBL) and DNA Database of Japan (DDBJ). In some situations, the sequences may be derived from assembly of available sequences or be predicted from genomic DNA using exon prediction algorithms, e.g., FGENESH. See Salamov and Solovyev (2000) Genome Res. 10:516-522.
In other situations, sequences have been derived from cloning and sequencing of isolated nucleic acids.
In another preferred embodiment, ovarian cancer sequences are those that are down-regulated in ovarian cancer; that is, the expression of these genes is lower in ovarian cancer tissue as compared to non-cancerous tissue. "Down-regulation" as used herein often means at least about a two-fold change, preferably at least about a three-fold change, with at least about five-fold or higher being preferred.
Informatics The ability to identify genes that are over or under expressed in ovarian cancer can additionally provide high-resolution, high-sensitivity datasets which can be used in the areas of diagnostics, therapeutics, drug development, pharmacogenetics, protein structure, biosensor development, and other related areas. Expression profiles can be used in diagnostic or prognostic evaluation of patients with ovarian cancer. Subcellular toxicological information can be generated to better direct drug structure and activity correlation (see Anderson (June 11-12, 1998) Pharmaceutical Proteomics: Targets, Mechanism, and Function, paper presented at the IBC Proteomics conference, Coronado, CA) or in a biological sensor device to predict the likely toxicological effect of chemical exposures and likely tolerable exposure thresholds (see U.S. Patent No. 5,811,231). Similar advantages accrue from datasets relevant to other biomolecules and bioactive agents (e.g., nucleic acids, saccharides, lipids, drugs, and the like).
Thus, in another embodiment, the present invention provides a database that includes at least one set of assay data. The data contained in the database is acquired, e.g., using array analysis either singly or in a library format. The database can be in a form in which data can be maintained and transmitted, but is preferably an electronic database, and can be maintained on any electronic device allowing for the storage of and access to the database, such as a personal computer, but is preferably distributed on a wide area network, such as the World Wide Web.
The focus of the present section on databases that include peptide sequence data is for clarity of illustration only. It will be apparent to those of skill in the art that similar databases can be assembled for any assay data acquired using an assay of the invention.
The compositions and methods for identifying and/or quantitating the relative and/or 1 S absolute abundance of a variety of molecular and macromolecular species from a biological sample undergoing ovarian cancer, e.g., the identification of ovarian cancer-associated sequences described herein, provide an abundance of information which can be correlated with pathological conditions, predisposition to disease, drug testing, therapeutic monitoring, gene-disease causal linkages, identification of correlates of immunity and physiological status, and outcome data, among others. Although data generated from the assays of the invention is suited for manual review and analysis, in a preferred embodiment, data processing using high-speed computers is utilized.
An array of methods for indexing and retrieving biomolecular information is known in the art. For example, U.S. Patents 6,023,659 and 5,966,712 disclose a relational database system for storing biomolecular sequence information in a manner that allows sequences to be catalogued and searched according to one or more protein function hierarchies. U.S.
Patent 5,953,727 discloses a relational database having sequence records containing information in a format that allows a collection of partial-length DNA
sequences to be catalogued and searched according to association with one or more sequencing projects for obtaining full-length sequences from the collection of partial length sequences. U.S. Patent 5,706,498 discloses a gene database retrieval system for making a retrieval of a gene sequence similar to a sequence data item in a gene database based on the degree of similarity between a key sequence and a target sequence. U.S. Patent 5,538,897 discloses a method using mass spectroscopy fragmentation patterns of peptides to identify amino acid sequences in computer databases by comparison of predicted mass spectra with experimentally-derived mass spectra using a closeness-of fit measure. U.S. Patent 5,926,818 discloses a multi-dimensional database comprising a functionality for mufti-dimensional data analysis described as on-line analytical processing (OLAP), which entails the consolidation of projected and actual data according to more than one consolidation path or dimension. U.S.
Patent 5,295,261 reports a hybrid database structure in which the fields of each database record are divided into two classes, navigational and informational data, with navigational fields stored in a hierarchical topological map which can be viewed as a tree structure or as the merger of two or more such tree structures.
Fundamentals of bioinformatics are provided, e.g., in Mount, et al. (2001) Bioinformatics: Sequence and Genome Analysis CSH Press, NY; Durbin, et al.
(eds. 1999) Biological Sequence Analysis: Probabilistic Models of Proteins and Nucleic Acids Cambridge Univ. Press; Baxevanis and Oeullette (eds. 1998) Bioinformatics: A
Practical Guide to the Analysis of Genes and Proteins (2d ed.) Wiley-Liss; Rashidi and Buehler (1999) Bioinformatics: Basic Applications in Biological Science and Medicine CRC
Press; Setubal, et al. (eds 1997) Introduction to Computational Molecular Biolo~y Brooks/Cole;
Misener and Krawetz (eds. 2000) Bioinformatics: Methods and Protocols Humana Press;
Higgins and Taylor (eds. 2000) Bioinformatics: Sequence, Structure, and Databanks: A
Practical Approach Oxford Univ. Press; Brown (2001) Bioinformatics: A Biologist's Guide to Biocomputin~ and the Internet Eaton Pub.; Han and Kamber (2000) Data Mining:
Concepts and Techniques Kaufinann Pub.; and Waterman (1995) Introduction to Computational Biolog.~ps, Sequences, and Genomes Chap and Hall.
The present invention provides a computer database comprising a computer and software for storing in computer-retrievable form assay data records cross-tabulated, e.g., with data specifying the source of the target-containing sample from which each sequence specificity record was obtained.
In an exemplary embodiment, at least one of the sources of target-containing sample is from a control tissue sample known to be free of pathological disorders. In a variation, at least one of the sources is a known pathological tissue specimen, e.g., a neoplastic lesion or another tissue specimen to be analyzed for ovarian cancer. In another variation, assay records cross-tabulate one or more of the following parameters for a target species in a sample: (1) a unique identification code, which can include, e.g., a target molecular structure and/or characteristic separation coordinate (e.g., electrophoretic or genomic position coordinates);
(2) sample source; and (3) absolute andlor relative quantity of target species present in the sample.
The invention also provides for the storage and retrieval of a collection of target data in a computer data storage apparatus, which can include magnetic disks, optical disks, magneto-optical disks, DRAM, SRAM, SGR.AM, SDRAM, RDRAM, DDR RAM, magnetic bubble memory devices, and other data storage devices, including CPU registers and on-CPU
data storage arrays. Typically, the target data records are stored as a bit pattern in an array of magnetic domains on a magnetizable medium or as an array of charge states or transistor gate states, such as an array of cells in a DRAM device (e.g., each cell comprised of a transistor and a charge storage area, which may be on the transistor). In one embodiment, the invention provides such storage devices, and computer systems built therewith, comprising a bit pattern encoding a protein expression fingerprint record comprising unique identifiers fox at least 10 target data records cross-tabulated with target source.
When the target is a peptide or nucleic acid, the invention preferably provides a method for identifying related peptide or nucleic acid sequences, comprising performing a computerized comparison between a peptide or nucleic acid sequence assay record stored in or retrieved from a computer storage device or database and at least one other sequence. The comparison can include a sequence analysis or comparison algorithm or computer program embodiment thereof (e.g., FASTA, TFASTA, GAP, BESTFIT) and/or the comparison may be of the relative amount of a peptide or nucleic acid sequence in a pool of sequences determined from a polypeptide or nucleic acid sample of a specimen.
The invention also preferably provides a magnetic disk, such as an IBM-compatible (DOS, Windows, Windows95/98/2000, Windows NT, OS/2) or other format (e.g., Linux, SunOS, Solaris, AIX, SCO Unix, VMS, MV, Macintosh, etc.) floppy diskette or hard (fixed, Winchester) disk drive, comprising a bit pattern encoding data from an assay of the invention in a file format suitable for retrieval and processing in a computerized sequence analysis, comparison, or relative quantitation method.
The invention also provides a network, comprising a plurality of computing devices linked via a data link, such as an Ethernet cable (coax or lOBaseT), telephone line, ISDN
line, wireless network, optical fiber, or other suitable signal transmission medium, whereby at least one network device (e.g., computer, disk array, etc.) comprises a pattern of magnetic domains (e.g., magnetic disk) andlor charge domains (e.g., an array of DRAM
cells) composing a bit pattern encoding data acquired from an assay of the invention.
The invention also provides a method for transmitting assay data that includes generating an electronic signal on an electronic communications device, such as a modem, ISDN terminal adapter, DSL, cable modem, ATM switch, or the like, wherein the signal includes (in native or encrypted format) a bit pattern encoding data from an assay or a database comprising a plurality of assay results obtained by the method of the invention.
In a preferred embodiment, the invention provides a computer system for comparing a query target to a database containing an array of data structures, such as an assay result obtained by the method of the invention, and ranking database targets based on the degree of identity and gap weight to the,target data. A central processor is preferably initialized to load and execute the computer program for alignment and/or comparison of the assay results.
Data for a query target is entered into the central processor via an I/O
device. Execution of the computer program results in the central processor retrieving the assay data from the data file, which comprises a binary description of an assay result.
The target data or record and the computer program can be transferred to secondary memory, which is typically random access memory (e.g., DRAM, SRAM, SGRAM, or SDRAM). Targets are ranked according to the degree of correspondence between a selected assay characteristic (e.g., binding to a selected affinity moiety) and the same characteristic of the query target and results are output via an I/O device. For example, a central processor can be a conventional computer (e.g., Intel Pentium, PowerPC, Alpha, PA-8000, SPARC, MIl'S 4400, MIPS 10000, VAX, etc.); a program can be a commercial or public domain molecular biology software package (e.g., UWGCG Sequence Analysis Software, Darwin); a data file can be an optical or magnetic disk, a data server, a memory device (e.g., DRAM, SRAM, SGRAM, SDRAM, EPROM, bubble memory, flash memory, etc.); an I/O device can be a terminal comprising a video display and a keyboard, a modem, an ISDN
terminal adapter, an Ethernet port, a punched card reader, a magnetic strip reader, or other suitable I/O
device.
The invention also preferably provides the use of a computer system, e.g., which typically comprises one or more of (1) a computer; (2) a stored bit pattern encoding a collection of peptide sequence specificity records obtained by methods of the inventions, which may be stored in the computer; (3) a comparison target, such as a query target; and (4) a program for alignment and comparison, typically with rank-ordering of comparison results on the basis of computed similarity values.

Characteristics of ovarian cancer-associated proteins Ovarian cancer proteins of the present invention may be categorized as secreted proteins, transmembrane proteins, or intracellular proteins. In one embodiment, the ovarian S cancer protein is an intracellular protein. Intracellular proteins may be found in the cytoplasm and/or in the nucleus. Intracellular proteins are involved in all aspects of cellular function and replication (including, e.g., signaling pathways); aberrant expression of such proteins often results in unregulated or disregulated cellular processes. See, e.g., Alberts, et al. (eds. 1994) Molecular Biology of the Cell (3d ed.) Garland. For example, many intracellular proteins have enzymatic activity such as protein kinase activity, protein phosphatase activity, protease activity, nucleotide cyclase activity, polymerase activity, and the like. Intracellular proteins can also serve as docking proteins that are involved in organizing complexes of proteins, or targeting proteins to various subcellular localizations, and are often involved in maintaining the structural integrity of organelles.
An increasingly appreciated concept in characterizing proteins is the presence in the proteins of one or more structural motifs for which defined functions have been attributed.
In addition to the highly conserved sequences found in the enzymatic domain of proteins, highly conserved sequences have been identified in proteins that are involved in protein-protein interaction. For example, Src-homology-2 (SH2) domains bind tyrosine-phosphorylated targets in a sequence dependent manner. PTB domains, which are distinct from SH2 domains, also bind tyrosine phosphorylated targets. SH3 domains bind to proline-rich targets. In addition, PH domains, tetratricopeptide repeats and WD
domains to name only a few, have been shown to mediate protein-protein interactions. Some of these may also be involved in binding to phospholipids or other second messengers. As will be appreciated by one of ordinary skill in the art, these motifs can be identified on the basis of amino acid sequence; thus, an analysis of the sequence of proteins may provide insight into both the enzymatic potential of the molecule andlor molecules with which the protein may associate.
One useful database is Pfam (protein families), which is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains.
Versions are available via the Internet from Washington University in St.
Louis, the Sanger Center in England, and the I~arolinska Institute in Sweden. See, e.g., Bateman, et al. (2000) Nuc. Acids Res. 28:263-266; Sonnhammer, et al. (1997) Proteins 28:405-420;
Bateman, et al.
(1999) Nuc. Acids Res. 27:260-262; and Sonnhammer, et al. (1998) Nuc. Acids Res. 26:320-322.
In another preferred embodiment, the ovarian cancer sequences are transmembrane proteins. Transmembrane proteins are molecules that span a phospholipid bilayer of a cell.
They may have an intracellular domain, an extracellular domain, or both. The intracellular domains of such proteins may have a number of functions including those already described for intracellular proteins. For example, the intracellular domain may have enzymatic activity and/or may serve as a binding site for additional proteins. Frequently the intracellular domain of transmembrane proteins serves both roles. For example certain receptor tyrosine kinases have both protein kinase activity and SH2 domains. In addition, autophosphorylation of tyrosines on the receptor molecule itself, creates binding sites for additional SH2 domain containing proteins.
Transmembrane proteins may contain from one to many transmembrane domains.
For example, receptor tyrosine kinases, certain cytokine receptors, receptor guanylyl cyclases and receptor serine/threonine protein kinases contain a single transmembrane domain.
However, various other proteins including channels and adenylyl cyclases contain numerous transmembrane domains. Many important cell surface receptors such as G protein coupled receptors (GPCRs) are classified as "seven transmembrane domain" proteins, as they contain 7 membrane spanning regions. Characteristics of transmembrane domains include approximately 17 consecutive hydrophobic amino acids that may be followed by charged amino acids. Therefore, upon analysis of the amino acid sequence of a particular protein, the localization and number of transmembrane domains within the protein may be predicted (see, e.g., PSORT web site http://psort.nibb.ac.jp/). Important transmembrane protein receptors include, but are not limited to the insulin receptor, insulin-like growth factor receptor, human growth hormone receptor, glucose transporters, transferrin receptor, epidermal growth factor receptor, low density lipoprotein receptor, epidermal growth factor receptor, leptin receptor, interleukin receptors, e.g., IL-1 receptor, IL-2 receptor, etc.
The extracellular domains of transmembrane proteins are diverse; however, conserved motifs are found repeatedly among various extracellular domains. Conserved structure and/or functions have been ascribed to different extracellular motifs. Many extracellular 30. domains are involved in binding to other molecules. In one aspect, extracellular domains are found on receptors. Factors that bind the receptor domain include circulating ligands, which may be peptides, proteins, or small molecules such as adenosine and the like.
For example, growth factors such as, EGF, FGF, and PDGF are circulating growth factors that bind to their cognate receptors to initiate a variety of cellular responses. Other factors include cytokines, mitogenuc factors, neurotrophic factors and the like. Extracellular domains also bind to cell-associated molecules, or may be processed or shed to the blood stream. In this respect, they can mediate cell-cell interactions. Cell-associated ligands can be tethered to the cell, e.g., via a glycosylphosphatidylinositol (GPl~ anchor, or may themselves be transmembrane proteins.
Extracellular domains also associate with the extracellular matrix and contribute to the maintenance of the cell structure.
Ovarian cancer proteins that are transmembrane are particularly preferred in the present invention as they are readily accessible targets for immunotherapeutics, as are described herein. In addition, as outlined below, transmembrane proteins can be also useful in imaging modalities. Antibodies may be used to label such readily accessible proteins in situ. Alternatively, antibodies can also label intracellular proteins, in which case samples are typically permeablized to provide access to intracellular proteins. In addition, some membrane proteins can be processed to release a soluble protein, or to expose a residual fragment. Released soluble proteins may be useful diagnostic markers, processed residual protein fragments may be useful ovarian markers of disease.
It will also be appreciated by those in the art that a transmembrane protein can be made soluble by removing transmembrane sequences, e.g., through recombinant methods.
Furthermore, transmembrane proteins that have been made soluble can be made to be secreted through recombinant means by adding an appropriate signal sequence.
In another embodiment, the ovarian cancer proteins are secreted proteins; the secretion of which can'be either constitutive or regulated. These proteins may have a signal peptide or signal sequence that targets the molecule to the secretory pathway.
Secreted proteins are involved in numerous physiological events; e.g., if circulating, they often serve to transmit signals to various other cell types. The secreted protein may function in an autocrine manner (acting on the cell that secreted the factor), a paracrine manner (acting on cells in close proximity to the cell that secreted the factor), an endocrine manner (acting on cells at a distance, e.g., secretion into the blood stream), or exocrine (secretion, e.g., through a duct or to an adjacent epithelial surface as sweat glands, sebaceous glands, pancreatic ducts, lacrimal glands, mammary glands, wax producing glands of the ear, etc.). Thus, secreted molecules often find use in modulating or altering numerous aspects of physiology. Ovarian cancer proteins that are secreted proteins are particularly preferred as good diagnostic markers, e.g., for blood, plasma, serum, or stool tests. Those which are enzymes may be antibody or small molecule therapeutic targets. Others may be useful as vaccine targets, e.g., via CTL mechanisms, as protein or DNA vaccines.
Use of ovarian cancer nucleic acids As described above, ovarian cancer sequence is initially identified by substantial nucleic acid and/or amino acid sequence homology or linkage to the ovarian cancer sequences outlined herein. Such homology can be based upon the overall nucleic acid or amino acid sequence, and is generally determined as outlined below, using either homology programs or hybridization conditions. Typically, linked sequences on a mRNA
are found on the same molecule.
The ovarian cancer nucleic acid sequences of the invention, e.g., in Table 1-26, can be fragments of larger genes, e.g., they are nucleic acid segments. "Genes" in this context includes coding regions, non-coding regions, and mixtures of coding and non-coding regions.
Accordingly, as will be appreciated by those in the art, using the sequences provided herein, extended sequences, in either direction, of the ovarian cancer genes can be obtained, using techniques well known in the art for cloning either longer sequences or the full length sequences; see Ausubel, et al., supra. Much can be done by informatics and many sequences can be clustered to include multiple sequences corresponding to a single gene, e.g., systems such as UniGene (see, http://www.ncbi.nlm.nih.gov/IJniGene~.
Once the ovarian cancer nucleic acid is identified, it can be cloned and, if necessary, its constituent parts recombined to form the entire ovarian cancer nucleic acid coding regions or the entire mRNA sequence. Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised as a linear nucleic acid segment, the recombinant ovarian cancer nucleic acid can be further-used as a probe to identify and isolate other ovarian cancer nucleic acids, e.g., extended coding regions. It can also be used as a "precursor" nucleic acid to make modified or variant ovarian cancer nucleic acids and proteins.
The ovarian cancer nucleic acids of the present invention are useful in several ways.
In a first embodiment, nucleic acid probes to the ovarian cancer nucleic acids are made and attached to biochips to be used in screening and diagnostic methods, as outlined below, or for administration, e.g., for gene therapy, vaccine, RNAi, and/or antisense applications.
Alternatively, the ovarian cancer nucleic acids that include coding regions of ovarian cancer proteins can be put into expression vectors for the expression of ovarian cancer proteins, again for screening puxposes or for administration to a patient.

In a preferred embodiment, nucleic acid probes to ovarian cancer nucleic acids (both the nucleic acid sequences outlined in the figures andlor the complements thereof are made.
The nucleic acid probes attached to the biochip are designed to be substantially complementary to the ovarian cancer nucleic acids, e.g., the target sequence (either the target sequence of the sample or to other probe sequences, e.g., in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.
1 S A nucleic acid probe is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. That is, generally whole genes are not used. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases.
In a preferred embodiment, more than one probe per sequence is used, with either overlapping probes or probes to different sections of the target being used.
That is, two, three, four or more probes, with three being preferred, are used to build in a redundancy for a particular target. The probes can be overlapping (e.g., have some sequence in common), or separate. In some cases, PCR primers may be used to amplify signal for higher sensitivity.
As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can typically be covalent or non-covalent. By "non covalent binding" and grammatical equivalents herein is meant one or more of electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds.
Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.
In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.
The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant a material that can be modified to contain 1 S discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably fluoresce. See, e.g., W00055627 Reusable Low Fluorescent Plastic Biochip.
Generally the substrate is planar, although as will be appreciated by those in the art, other configurations of substrates may be used as well. For example, the probes may be placed on the inside surface of a tube, fox flow-through sample analysis to minimize sample volume. Similarly, the substrate may be flexible, such as a flexible foam, including closed cell foams made of particular plastics.
In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, e.g., the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxyl groups, oxo groups and thiol groups, with amino groups being particularly preferred. . Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, e.g., using linkers as are known in the art; e.g., homo-or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.
In this embodiment, oligonucleotides are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.
In another embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces covalently coated with streptavidin, resulting in attachment.
Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO
95125116; WO 95!35505; U.S. Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affymetrix GeneChipTM technology.
Often, amplification-based assays are performed to measure the expression level of ovarian cancer-associated sequences. These assays are typically performed in conjunction with reverse transcription. In such assays, an ovarian cancer-associated nucleic acid sequence acts as a template in an amplification reaction (e.g., Polymerase Chain Reaction, or PCR). In a quantitative amplification, the amount of amplification product will be proportional to the amount of template in the original sample. Comparison to appropriate controls provides a measure of the amount of ovarian cancer-associated RNA.
Methods of quantitative amplification are well known to those of skill in the art.
Detailed protocols for quantitative PCR are available. See, e.g., Innis, et a!.(1990) PCR Protocols:
A Guide to Methods and Applications Academic Press.
In some embodiments, a TaqMan based assay is used to measure expression.
TaqMan based assays use a fluorogenic oligonucleotide probe that contains a 5' fluorescent dye and a 3' quenching agent. The probe hybridizes to a PCR product, but cannot itself be extended due to a blocking agent at the 3' end. When the PCR product is amplified in subsequent cycles, the 5' nuclease activity of the polymerase, e.g., AmpliTaq, results in the cleavage of the TaqMan probe. This cleavage separates the 5' fluorescent dye and the 3' quenching agent, thereby resulting in an increase in fluorescence as a function of amplification (see, e.g., literature provided by Perkin-Elmer, e.g., www2.perkin-elmer.com).
Other suitable amplification methods include, but are not limited to, ligase chain reaction (LCR; see Wu and Wallace (1989) Genomics 4:560-569; Landegren, et al.
(1988) Science 241:1077-1980; and Barringer, et al. (1990) Gene 89:117-122), transcription amplification (Kwoh, et al. (1989) Proc. Naf1 Acad. Sci. USA 86:1173-1177), self sustained sequence replication (Guatelli, et al. (1990) Proc. Nat'1 Acad. Sci. USA
87:1874-1878), dot PCR, linker adapter PCR, etc.
Expression of ovarian cancer proteins from nucleic acids In a preferred embodiment, ovarian cancer nucleic acids, e.g., encoding ovarian cancer proteins are used to make a variety of expression vectors to express ovarian cancer proteins which can then be used in screening assays, as described below.
Expression vectors and recombinant DNA technology are well known and are used to express proteins. See, e.g., Ausubel, supra; and Fernandez and Hoeffler (eds. 1999) Gene Expression Systems Academic Press. The expression vectors may be either self replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the ovarian cancer protein. The term "control sequences" refers to DNA sequences used for the expression of an operably linked coding sequence in a particular host organism.
Control sequences that are suitable for prokaryotes, e.g., include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a pre-sequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the.polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation; and two sequences may be operably linked when they are physically part of the same polymer.
Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is typically accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. Transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the ovarian cancer protein.
Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.
In general, transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.
Promoter sequences typically encode constitutive or inducible promoters. The promoters may be naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.
In addition, an expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, e.g., in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are available.
See, e.g., Fernandez and Hoeffler, supra.
In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.
The ovarian cancer proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding an ovarian cancer protein, under the appropriate conditions to induce or cause expression of the ovarian cancer protein. Conditions appropriate for ovarian cancer protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation or optimization. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculovirus systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.
Appropriate host cells include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are Saccharomyces cerevisiae and other yeasts, E. coli, Bacillus subtilis, Sf~ cells, C129 cells, 293 cells, Neurospora, BHI~, CHO, COS, HeLa cells, HCTVEC (human umbilical vein endothelial cells), THP1 cells (a macrophage cell line) and various other human cells and cell lines.
In a preferred embodiment, the ovarian cancer proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral and adenoviral systems. One expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter. See, e.g., Fernandez and Hoeffler, supra. Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. Examples of transcription terminator and polyadenylation signals include those derived form SV40.
The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used.
Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the 30. polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.
In a preferred embodiment, ovarian cancer proteins are expressed in bacterial systems.
Bacterial expression systems are well known in the art. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; e.g., the tac promoter is a hybrid of the trp and lac promoter sequences.
Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable.
The expression vector may also include a signal peptide sequence that provides for secretion of the ovarian cancer protein in bacteria. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin, and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways. These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for Bacillus subtilis, E. coli, Streptococcus cremoris, and Streptococcus lividans, among others. See Fernandez and Hoeffler, supra. The bacterial expression vectors are transformed into bacterial host cells using techniques well known ~in the art, such as calcium chloride treatment, electroporation, and others.
In one embodiment, ovarian cancer proteins are produced in insect cells.
Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.
In a preferred embodiment, an ovarian cancer protein is produced in yeast cells.
Yeast expression systems are well known in the art, and include expression vectors for Saccharomyces cerevisiae, Candida albicans and C. maltosa, Hansenula polymorpha, Kluyveromyces fragilis and K. lactis, Pichia guillerimondii and P. pastoris, Schizosaccharomyces pombe, and Yarrowia lipolytica.
The ovarian cancer protein may also be made as a fusion protein, using techniques well known in the art. Thus, e.g., for the creation of monoclonal antibodies, if the desired epitope is small, the ovarian cancer protein may be fused to a carrier protein to form an immunogen. Alternatively, the ovarian cancer protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the ovarian cancer protein is an ovarian cancer peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes.

In a preferred embodiment, the ovarian cancer protein is purified or isolated after expression. Ovarian cancer proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample.
Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the ovarian cancer protein may be purified using a standard anti-ovarian cancer protein antibody column.
Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes (192) Protein Purification Springer-Verlag.,, The degree of purification necessary will vary depending on the use of the ovarian cancer protein. In some instances no purification will be necessary.
Once expressed and purified if necessary, the ovarian cancer proteins and nucleic acids are useful in a number of applications. They may be used as immunoselection reagents, as vaccine reagents, as screening agents, etc.
Variants of ovarian cancer proteins In one embodiment, the ovarian cancer proteins are derivative or variant ovarian cancer proteins as compared to the wild-type sequence. That is, as outlined more :fully below, the derivative ovarian cancer peptide will often contain at least one amino acid substitution, deletion or insertion, with amino acid substitutions being particularly preferred. The amino acid substitution, insertion, or deletion may occur at most any residue within the ovarian cancer peptide.
Also included within one embodiment of ovarian cancer proteins of the present invention are amino acid sequence variants. These variants typically fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the ovarian cancer protein, using cassette or PCR mutagenesis or other techniques.well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant ovarian cancer protein fragments having up to about 100-150 residues may be prepared by in vitro synthesis using established techniques.
Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the ovarian cancer protein. amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurnng analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.
While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed ovarian cancer variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, e.g., M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of ovarian cancer protein activities.
Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.
Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the ovarian cancer protein are desired, substitutions are generally made in accordance with the amino acid substitution relationships provided in the definition section.
The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analog, although variants also are selected to modify the characteristics of the ovarian cancer proteins as needed. Alternatively, the variant may be designed such that the biological activity of the ovarian cancer protein is altered. For example, glycosylation sites may be altered or removed. ' Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those described above. For example, substitutions may be made which more significantly affect: the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure;
the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain.
The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g., serine or threonine is substituted for (or by) a hydrophobic residue, e.g., leucine, isoleucine, phenylalanine, valine, or alanine; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g., lysine, arginine, or histidine, is substituted for (or by) an electronegative residue, e.g., glutamic or aspartic acid; (d) a residue having a bulky side chain, e.g., phenylalanine, is substituted for (or by) one not having a side chain, e.g., glycine; or (e) a proline residue is incorporated or substituted, which changes the degree of rotational freedom of the peptidyl bond.
Covalent modifications of ovarian cancer polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of an ovarian cancer polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of an ovarian cancer polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking ovarian cancer polypeptides to a water-insoluble support matrix or surface for use in the method for purifying anti-ovarian cancer polypeptide antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, e.g., esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-((p-azidophenyl)dithio)propioimidate.
Other modifications include deamidation of glutamine and asparagine residues to the corresponding glutamic and aspartic acid residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of serine, threonine, or tyrosine residues, methylation of the amino groups of the lysine, arginine, and histidine side chains (e.g., pp.
79-86, Creighton (1983) Proteins: Structure and Molecular Pro ep rties Freeman), acetylation o.f the N-terminal amine, and amidation of a C-terminal carboxyl group.
Another type of covalent modification of the ovarian cancer polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence ovarian cancer polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence ovarian cancer polypeptide. Glycosylation patterns can be altered in many ways.
For example the use of different cell types to express ovarian cancer-associated sequences can result in different glycosylation patterns.
Addition of glycosylation sites to ovarian cancer polypeptides may also be accomplished by altering the amino acid sequence thereof. The alteration may be made, e.g., by the addition of, or substitution by, one or more serine or threonine residues to the native sequence ovarian cancer polypeptide (for O-linked glycosylation sites). The ovarian cancer amino acid sequence may optionally be altered through changes at the DNA
level, particularly by mutating the DNA encoding the ovarian cancer polypeptide at pre-selected bases such that colons are generated that will translate into the desired amino acids.
Another means of increasing the number of carbohydrate moieties on the ovarian cancer polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide.
See, e.g., WO 87105330, and pp. 259-306 in Aplin and Wriston (1981) CRC Crit.
Rev.
Biochem. CRC Press.
Removal of carbohydrate moieties present on the ovarian cancer polypeptide may be accomplished chemically or enzymatically or by mutational substitution of colons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are applicable. See, e.g., Sojar and Bahl (1987) Arch. Biochem.
Biophys. 259:52-IS 57; and Edge, et al. (1981) Anal. Biochem. 118:131-137. Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases. See, e.g., Thotakura, et al. (1987) Meth. Enzymol., 138:350-359.
Another type of covalent modification of ovarian cancer comprises linking the ovarian cancer polypeptide to one of a variety of non-proteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylene. See, e.g., U.S.
Patent Nos.
4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192; or 4,179,337.
Ovarian cancer polypeptides of the present invention may also be modified in a way to form chimeric molecules, e.g., comprising an ovarian cancer polypeptide fused to another heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of an ovarian cancer polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino-or carboxyl-terminus of the ovarian cancer polypeptide. The presence of such epitope-tagged forms of an ovarian cancer polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the ovarian cancer polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of an ovarian cancer polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG
molecule.
Various tag polypeptides and their respective antibodies are well known in the art.
Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; His6 and metal chelation tags, the flu HA tag polypeptide and its antibody 12CA5 (Field, et al.
(1988) Mol. Cell. Biol. 8:2159-2165); the c-myc tag and the 8F9, 3C7, 6E10, G4, B7, and 9E10 antibodies thereto (Evan, et al. (1985) Mol. Cell. Biol. 5:3610-3616);
and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody (Paborsky, et al.
(1990) Protein Engineering 3:547-553). Other tag polypeptides include, e.g., the Flag-peptide (Hopp, et al.
(1988) BioTechnolo~y 6:1204-1210); the KT3 epitope peptide (Martin, et al.
(1992) Science 255:192-194); tubulin epitope peptide (Skinner, et al. (1991) J. Biol. Chem.
266:15163-15166); and the T7 gene 10 protein peptide tag (Lutz-Freyermuth et al. (1990) Proc. Nat'1 Acad. Sci. USA 87:6393-6397).
Also included are other ovarian cancer proteins of the ovarian cancer family, and ovarian cancer proteins from other organisms, which are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related ovarian cancer proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR
primer sequences include the unique areas of the ovarian cancer nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed.
The conditions for the PCR reaction are well known in the art (e.g., Innis, PCR
Protocols, supra).
Antibodies to ovarian cancer proteins In a preferred embodiment, when the ovarian cancer protein is to be used to generate antibodies, e.g., for immunotherapy or immunodiagnosis, the ovarian cancer protein should share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is typically meant a portion of a protein which will generate and/or bind an antibody or T-cell receptor in the context of MHC. Thus, in most instances, antibodies made to a smaller ovarian cancer protein will be able to bind to the full-length protein, particularly linear epitopes. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity.
Methods of preparing polyclonal antibodies are known to the skilled artisan (e.g., Coligan, supra; and Harlow and Lane, supra). Polyclonal antibodies can be raised in a mammal, e.g., by one or more injections of an immunizing agent and, if desired, an adjuvant.
Typically, the immunizing agent andlor adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include a protein encoded by a nucleic acid of the figures or fragment thereof or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.
The antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler and Milstein (1975) Nature 256:495-497. In a hybridoma method, a mouse, hamster, or other appropriate 16 host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro. The immunizing agent will typically include a polypeptide encoded by a nucleic acid of Tables 1-26 or fragment thereof, or a fusion protein thereof. Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (e.g., pp. 59-103 in Goding (1986) Monoclonal Antibodies:
Principles and Practice Academic Press). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT
medium"), which substances prevent the growth of HGPRT-deficient cells.
In one embodiment, the antibodies are bispecific antibodies. Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens ar that have binding specificities for two epitopes on the same antigen. In one embodiment, one of the binding specificities is for a protein encoded~by a nucleic acid Table 1-26 or a fragment thereof, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit, preferably one that is tumor specific. Alternatively, tetramer-type technology may create multivalent reagents.
In a preferred embodiment, the antibodies to ovarian cancer protein are capable of reducing or eliminating a biological function of an ovarian cancer protein, as is described below. That is, the addition of anti-ovarian cancer protein antibodies (either polyclonal or preferably monoclonal) to ovarian cancer tissue (or cells containing ovarian cancer) may reduce or eliminate the ovarian cancer. Generally, at least a 25% decrease in activity, growth, size or the like is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.
In a preferred embodiment the antibodies to the ovarian cancer proteins are humanized antibodies (e.g., Xenerex Biosciences; Medarex, Inc.; Abgenix, Inc.;
Protein Design Labs, Inc.) Humanized forms of non-human (e.g., murine) antibodies are chimeric molecules of immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR
of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Humanization can be essentially performed following the method of Winter and co-workers, e.g., by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. See, e.g., Jones, et al. (1986) Nature 321:522-525; Riechmann, et al. (1988) Nature 332:323-329; Presta (1992) Curr. Op.
Struct. Biol.
2:593-596; and Verhoeyen, et al. (1988) Science 239:1534-1536). Accordingly, such humanized antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species.
Human antibodies can also be produced using various techniques known in the art, including phage display libraries (see, e.g., Hoogenboom and Winter (1991) J.
Mol. Biol.
227:381-388; and Marks, et al. (1991) J. Mol. Biol. 222:581-597) or human monoclonal antibodies (see, e.g., p. 77, Cole, et al. in Reisfeld and Sell (1985) Monoclonal Antibodies and Cancer Therany Liss; and Boerner, et al. (1991) J. Immunol. 147:86-95).
Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. See, e.g., U.S. Patent Nos. 5,545,807;
5,545,806;
5,569,825; 5,625,126; 5,633,425; 5,661,016; Marks, et al. (1992) Bio/Technolo~y 10:779-783; Lonberg, et al. (1994) Nature 368:856-859; Mornson (1994) Nature 368:812-13;
Neuberger (1996) Nature Biotechnolo~y 14:826 commenting on Fishwild, et al.
(1996) Nature Biotechnolo~y 14:845-51; and Lonberg and Huszar (1995) Intern. Rev.
Immunol.
13:65-93.
By immunotherapy is meant treatment of ovarian cancer, e.g., with an antibody raised against ovarian cancer proteins. As used herein, immunotherapy can be passive or active.
Passive immunotherapy as defined herein is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response is the result of providing the recipient with an antigen to which antibodies are raised. The antigen may be provided by inj ecting a polypeptide against which antibodies are desired to be raised into a recipient, or contacting the recipient with a nucleic acid capable of expressing the antigen and under conditions for expression of the antigen, leading to an immune response.
In a preferred embodiment the ovarian cancer proteins against which antibodies are raised are secreted proteins as described above. Without being bound by theory, antibodies used for treatment, bind and prevent the secreted protein from binding to its receptor, thereby inactivating the secreted ovarian cancer protein.
In another preferred embodiment, the ovarian cancer protein to which antibodies are raised is a transmembrane protein. Without being bound by theory, antibodies used for treatment, bind the extracellular domain of the ovarian cancer protein and prevent it from binding to other proteins, such as circulating ligands or cell-associated molecules. The antibody may cause down-regulation of the transmembrane ovarian cancer protein. As will be appreciated by one of ordinary skill in the art, the antibody may be a competitive, non-competitive or uncompetitive inhibitor of protein binding to the extracellular domain of the ovarian cancer protein. The antibody is also an antagonist of the ovarian cancer protein.
Further, the antibody prevents activation of the transmembrane ovarian cancer protein. In one aspect, when the antibody prevents the binding of other molecules to the ovarian cancer protein, the antibody prevents growth of the cell. The antibody may also be used to target or sensitize the cell to cytotoxic agents, including, but not limited to TNF-a, TNF-(3, IL-1, INF
y, and IL-2, or chemotherapeutic agents including SFU, vinblastine, actinomycin D, cisplatin, 1 S methotrexate, and the like. In some instances the antibody belongs to a sub-type that activates serum complement when complexed with the transmembrane protein thereby mediating cytotoxicity or antigen-dependent cytotoxicity (ADCC). Thus, ovarian cancer is treated by administering to a patient antibodies directed against the transmembrane ovarian cancer protein. Antibody-labeling may activate a co-toxin, localize a toxin payload, or otherwise provide means to locally ablate cells.
In another preferred embodiment, the antibody is conjugated to an effector moiety.
The effector moiety can be any number of molecules, including labeling moieties such as radioactive labels or fluorescent labels, or can be a therapeutic moiety. In one aspect the therapeutic moiety is a small molecule that modulates the activity of the ovarian cancer protein. In another aspect the therapeutic moiety modulates the activity of molecules associated with or in close proximity to the ovarian cancer protein. The therapeutic moiety may inhibit enzymatic activity such as protease or collagenase or protein kinase activity associated with ovarian cancer.
In a preferred embodiment, the therapeutic moiety can also be a cytotoxic agent. In this method, targeting the cytotoxic agent to ovarian cancer tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with ovarian cancer. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A
chain, abrin A
chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against ovarian cancer proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody. Targeting the therapeutic moiety to transmembrane ovarian cancer proteins not only serves to increase the local concentration of therapeutic moiety in the ovarian cancer afflicted area, but also serves to reduce deleterious side effects that may be associated with the untargeted therapeutic moiety.
Tn another preferred embodiment, the ovarian cancer protein against which the antibodies are raised is an intracellular protein. In this case, the antibody may be conjugated to a protein which facilitates entry into the cell. In one case, the antibody enters the cell by endocytosis. In another embodiment, a nucleic acid encoding the antibody is administered to the individual or cell. Moreover, wherein the ovarian cancer protein can be targeted within a cell, e.g., the nucleus, an antibody thereto contains a signal for that target localization, e.g., a nuclear localization signal.
The ovarian cancer antibodies of the invention specifically bind to ovarian cancer proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a I~ of at least about 0.1 mM, more usually at least about 1 pM, preferably at least about 0.1 p,M or better, and most preferably, 0.01 p.M or better. Selectivity of binding is also important.
Detection of ovarian cancer sequence for diagnostic and therapeutic applications In one aspect, the RNA expression levels of genes are determined for different cellular states in the ovarian cancer phenotype. Expression levels of genes in normal tissue (e.g., not undergoing ovarian cancer) and in ovarian cancer tissue (and in some cases, for varying seventies of ovarian cancer that relate to prognosis, as outlined below, or in non-malignant disease are evaluated to provide expression profiles. An expression profile of a particular cell state or point of development is essentially a "fingerprint"
of the state of the cell. While two states may have any particular gene similarly expressed, the evaluation of a number of genes simultaneously allows the generation of a gene expression profile that is reflective of the state of the cell. By comparing expression profiles of cells in different states, information regarding which genes are important (including both up- and down-regulation of genes) in each of these states is obtained. Then, diagnosis may be performed or confirmed to determine whether a tissue sample has the gene expression profile of normal or cancerous tissue. This will provide for molecular diagnosis of related conditions.
"Differential expression," or grammatical equivalents as used herein, refers to qualitative or quantitative differences in the temporal and/or cellular gene expression patterns within and among cells and tissue. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, e.g., normal versus ovarian cancer tissue. Genes may be turned on or turned off in a particular state, relative to another state thus permitting comparison of two or more states. A
qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques. Some genes will be expressed in one state or cell type; but not in both. Alternatively, the difference in expression may be quantitative, e.g., in that expression is modulated, either up-regulated, resulting in an increased amount of transcript, or down-regulated, resulting in a decreased amount of transcript.
The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChipTM
expression arrays.
See, e.g., Lockhart (1996) Nature Biotechnolo~y 14:1675-1680. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, northern analysis, and RNase protection. As outlined above, preferably the change in expression (e.g., up-regulation or down-regulation) is at least about SO%, more preferably at least about 100%, more preferably at least about 150%, more preferably at least about 200%, with from 300 to at least 1000%
being especially preferred.
Evaluation may be at the gene transcript, or the protein level. The amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA
equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, e.g., with antibodies to the ovarian cancer protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc. Proteins corresponding to ovarian cancer genes, e.g., those identified as being important in an ovarian cancer or disease phenotype, can be evaluated in an ovarian disease diagnostic test. In a preferred embodiment, gene expression monitoring is performed simultaneously on a number of genes.
Multiple protein expression monitoring can be performed, or on an individual basis.

In this embodiment, the ovarian cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of ovarian cancer sequences in a particular sample. The assays are further described below in the example. PCR
techniques can be used to provide greater sensitivity.
In a preferred embodiment nucleic acids encoding the ovarian cancer protein are detected. Although DNA or RNA encoding the ovarian cancer protein may be detected, of particular interest are methods wherein an mRNA encoding an ovarian cancer protein is detected. Probes to detect mRNA can be a nucleotideldeoxynucleotide probe that is complementary to and hybridizes with the mRNA and includes, but is not limited to, oligonucleotides, cDNA or RNA. Probes also should contain a detectable label, as defined herein. In one method the mRNA is detected after immobilizing the nucleic acid to be examined on a solid support such as nylon membranes and hybridizing the probe with the sample. Following washing to remove the non-specifically bound probe, the label is detected. In another method detection of the mRNA is performed in situ. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxygenin labeled riboprobe (RNA probe) that is complementary to the mRNA
encoding an ovarian cancer protein is detected by binding the digoxygenin with an anti-digoxygenin secondary antibody and developed with vitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate.
In a preferred embodiment, various proteins from the three classes of proteins as described herein (secreted, transmembrane or intracellular proteins) are used in diagnostic assays. The ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing ovarian cancer sequences are used in diagnostic assays. This can be performed on an individual gene or corresponding polypeptide level. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes and/or corresponding polypeptides.
As described and defined herein, ovarian cancer proteins, including intracellular, transmembrane, or secreted proteins, find use as prognostic or diagnostic markers of ovarian disease. Detection of these proteins in putative ovarian cancer tissue allows for detection, diagnosis, or prognosis of ovarian disease, and for selection of therapeutic strategy. In one embodiment, antibodies are used to detect ovarian cancer proteins. A preferred method separates proteins from a sample by electrophoresis on a gel (typically a denaturing and reducing protein gel, but may be another type of gel, including isoelectric focusing gels and the like). Following separation of proteins, the ovarian cancer protein is detected, e.g., by immunoblotting with antibodies raised against the ovarian cancer protein.
Methods of immunoblotting are well known to those of ordinary skill in the art.
In another preferred method, antibodies to the ovarian cancer protein find use in in situ imaging techniques, e.g., in histology. See, e.g., Asai (ed. 1993) Methods in Cell Biology: Antibodies in Cell Biolo~y (vol. 37) Academic Press. Cells are contacted with from one to many antibodies to the ovarian cancer protein(s). Following washing to remove non-specific antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the ovarian cancer proteins) contains a detectable label, e.g., an enzyme marker that can act on a substrate. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of ovarian cancer proteins. As will be appreciated by one of ordinary skill in the art, many other histological imaging techniques are also provided by the invention.
In a preferred embodiment the label is detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in the method.
In another preferred embodiment, antibodies find use in diagnosing ovarian cancer from blood, serum, plasma, stool, and other samples. Such samples, therefore, are useful as samples to be probed or tested for the presence of ovarian cancer proteins.
Antibodies can be used to detect an ovarian cancer protein by previously described immunoassay techniques including ELISA, immunoblotting (western blotting), immunoprecipitation, BIACORE
technology, and the like. Conversely, the presence of antibodies may indicate an immune response against an endogenous ovarian cancer protein.
In a preferred embodiment, in situ hybridization of labeled ovarian cancer nucleic acid probes to tissue arrays is done. For example, arrays of tissue samples, including ovarian cancer tissue and/or normal tissue, are made. In situ hybridization (see, e.g., Ausubel, supra) is then performed. When comparing the fingerprints between an individual and a standard, the skilled artisan can make a diagnosis, a prognosis, or a prediction based on the findings. It is further understood that the genes which indicate the diagnosis may differ from those which indicate the prognosis and molecular profiling of the condition of the cells may lead to distinctions between responsive or refractory conditions or may be predictive of outcomes.
In a preferred embodiment, the ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing ovarian cancer sequences are used in prognosis assays.
As above, gene expression profiles can be generated that correlate to ovarian cancer, clinical, pathological, or other information, in terms of long term prognosis. Again, this may be done on either a protein or gene level, with the use of a plurality of genes being preferred. As above, ovarian cancer probes may be attached to biochips for the detection and quantification of ovarian cancer sequences in a tissue or patient. The assays proceed as outlined above. for diagnosis. PCR method may provide more sensitive and accurate quantification.
Assays for therapeutic compounds In a preferred embodiment members of the proteins, nucleic acids, and antibodies as described herein are used in drug screening assays. The ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing ovarian cancer sequences are used in drug screening assays or by evaluating the effect of drug candidates on a "gene expression profile" or expression profile of polypeptides. In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent. See, e.g., Zlokarnik, et al. (1998) Science 279:84-88; and Heid (1996) Genome Res.
6:986-994.
In a preferred embodiment, the ovarian cancer proteins, antibodies, nucleic acids, modified proteins and cells containing the native or modified ovarian cancer proteins are used in screening assays. That is, the present invention provides novel methods for screening for compositions which modulate the ovarian cancer phenotype or an identified physiological function of an ovarian cancer protein. As above, this can be done on an individual gene level or by evaluating the effect of drug candidates on a "gene expression profile".
In a preferred embodiment, the expression profiles are used, preferably in conjunction with high throughput screening techniques to allow monitoring for expression profile genes after treatment with a candidate agent. See, e.g., Zlokarnik, supra.
Having identified the differentially expressed genes herein, a variety of assays may be executed. In a preferred embodiment, assays may be run on an individual gene or protein level. That is, having identified a particular gene as up regulated in ovarian cancer, test compounds can be screened for the ability to modulate gene expression or for binding to the ovarian cancer protein. "Modulation" thus includes both an increase and a decrease in gene expression. The preferred amount of modulation will depend on the original change of the gene expression in normal versus tissue undergoing ovarian cancer, with changes of at least 10%, preferably 50%, more preferably 100-300%, and in some embodiments 300-1000% or greater. Thus, if a gene exhibits a 4-fold increase in ovarian cancer tissue compared to normal tissue, a decrease of about four-fold is often desired; similarly, a 10-fold decrease in ovarian cancer tissue compared to normal tissue often provides a target value of a 10-fold increase in expression to be induced by the test compound.
The amount of gene expression may be monitored using nucleic acid probes and the quantification of gene expression levels, or, alternatively, the gene product itself can be monitored, e.g., through the use of antibodies to the ovarian cancer protein and standard immunoassays. Proteomics and separation techniques may also allow quantification of expression.
In a preferred embodiment, gene expression or protein monitoring of a number of entities, e.g., an expression profile, is monitored simultaneously. Such profiles will typically involve a plurality of those entities described herein.
In this embodiment, the ovarian cancer nucleic acid probes are attached to biochips as outlined herein for the detection and quantification of ovarian cancer sequences in a particular cell. Alternatively, PCR may be used. Thus, a series, e.g., of microtiter plate, may be used with dispensed primers in desired wells. A PCR reaction can then be performed and analyzed for each well.
Expression monitoring can be performed to identify compounds that modify the expression of one or more ovarian cancer-associated sequences, e.g., a polynucleotide sequence set out inTables 1-26. Generally, in a preferred embodiment, a test modulator is added to the cells prior to analysis. Moreover, screens are also provided to identify agents that modulate ovarian cancer, modulate ovarian cancer proteins, bind to an ovarian cancer protein, or interfere with the binding of an ovarian cancer protein and an antibody or other binding partner.
The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., to be tested for the capacity to directly or indirectly alter the ovarian cancer phenotype or the expression of an ovarian cancer sequence, e.g., a nucleic acid or protein sequence. In preferred embodiments, modulators alter expression profiles, or expression profile nucleic acids or proteins provided herein. In one embodiment, the modulator suppresses an ovarian cancer phenotype, e.g., to a normal or non-malignant tissue fingerprint. In another embodiment, a modulator induced an ovarian cancer phenotype. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, e.g., at zero concentration or below the level of detection.
Drug candidates encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Preferred small molecules are less than 2000, or less than 1500 or less than 1000 or less than 500 D. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.
In one aspect, a modulator will neutralize the effect of an ovarian cancer protein. By "neutralize" is meant that activity of a protein is inhibited or blocked and the consequent effect on the cell.
In certain embodiments, combinatorial libraries of potential modulators will be screened for an ability to bind to an ovarian cancer polypeptide or to modulate activity.
Conventionally, new chemical entities with useful properties are generated by identifying a chemical compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.
In one preferred embodiment, high throughput screening methods involve providing a library containing a large number of potential therapeutic compounds (candidate compounds). Such "combinatorial chemical libraries" are then screened in one or more assays to identify those library members (particular chemical species or subclasses) that display a desired characteristic activity. The compounds thus identified can serve as conventional "lead compounds" or can themselves be used as potential or actual therapeutics.
A combinatorial chemical library is a collection of diverse chemical compounds generated by either chemical synthesis or biological synthesis by combining a number of chemical "building blocks" such as reagents. For example, a linear combinatorial chemical library, such as a polypeptide (e.g., mutein) library, is formed by combining a set of chemical building blocks called amino acids in every possible way for a given compound length (e.g., the number of amino acids in a polypeptide compound). Millions of chemical compounds can be synthesized through such combinatorial mixing of chemical building blocks. See, e.g., Gallop, et al. (1994) J. Med. Chem. 37:1233-1251.
Preparation and screening of combinatorial chemical libraries is well known to those of skill in the art. Such combinatorial chemical libraries include, but are not limited to, peptide libraries (see, e.g., U.S. Patent No. 5,010,175; Furka (1991) Pept.
Prot. Res. 37:487-493; and Houghton, et al. (1991) Nature 354:84-88), peptoids (PCT Publication No WO
91/19735), encoded peptides (PCT Publication WO 93/20242), random bio-oligomers (PCT
Publication WO 92/00091), benzodiazepines (U.5. Pat. No. 5,288,514), diversomers such as hydantoins, benzodiazepines and dipeptides (Hobbs, et al. (1993) Proc. Nat'1 Acad. Sci. USA
90:6909-913), vinylogous polypeptides (Hagihara, et al. (1992) J. Amer. Chem.
Soc.
114:6568-570), non-peptidal peptidomimetics with a Beta-D-Glucose scaffolding (Hirschmann, et al. (1992) J. Amer. Chem. Soc. 114:9217-218), analogous organic syntheses of small compound libraries (Chen, et al. (1994) J. Amer. Chem. Soc. 116:2661-662), oligocarbamates (Cho, et al. (1993) Science 261:1303-305), and/or peptidyl phosphonates (Campbell, et a1.(1994) J. Org'Chem. 59:658-xxx). See, generally, Gordon, et al. (1994) J.
Med. Chem. 37:1385-401, nucleic acid libraries (see, e.g., Stratagene, Corp.), peptide nucleic acid libraries (see, e.g., U.S. Patent 5,539,083), antibody libraries (see, e.g., Vaughn, et a1.(1996) Nature Biotechnolo~y 14:309-314; and PCTlLTS96/14287), carbohydrate libraries (see, e.g., Liang, et al. (1996) Science 274:1520-1522; and U.S. Patent No.
5,593,853), and small organic molecule libraries (see, e.g., benzodiazepines, page 33, Baum (Jan. 18, 1993) C&E News; isoprenoids, U.S. Patent No. 5,569,588; thiazolidinones and metathiazanones, U.S. Patent No. 5,549,974; pyrrolidines, U.S. Patent Nos. 5,525,735 and 5,519,134;
morpholino compounds, U.S. Patent No. 5,506,337; benzodiazepines, U.S. Patent No.
5,288,514; and the like).
Devices for the preparation of combinatorial libraries are commercially available.

See, e.g., 357 MPS, 390 MPS, Advanced Chem Tech, Louisville KY; Symphony, Rainin, Woburn, MA; 433A Applied Biosystems, Foster City, CA; 9050 Plus, Millipore, Bedford, MA.
A number of well known robotic systems have also been developed for solution phase chemistries. These systems include automated workstations like the automated synthesis apparatus developed by Takeda Chemical Industries, LTD. (Osaka, Japan) and many robotic systems utilizing robotic arms (Zymate II, Zymark Corporation, Hopkinton, MA;
Orca, Hewlett-Packard, Palo Alto, CA), which mimic the manual synthetic operations performed by a chemist. Any of the above devices are suitable for use with the present invention. The nature and implementation of modifications to these devices (if any) so that they can operate as discussed herein will be apparent to persons skilled in the relevant art.
In addition, numerous combinatorial libraries are themselves commercially available (see, e.g., ComGenex, Princeton, N.J.; Asinex, Moscow, RU; Tripos, Inc., St. Louis, MO;
ChemStar, Ltd, Moscow, RU; 3D Pharmaceuticals, Exton, PA; Martek Biosciences, Columbia, MD;
1 S etc.).
. The assays to identify modulators are amenable to high throughput screening.
Preferred assays thus detect enhancement or inhibition of ovarian cancer gene transcription, inhibition or enhancement of polypeptide expression, and inhibition or enhancement of polypeptide activity.
High throughput assays for the presence, absence, quantification, or other properties of particular nucleic acids or protein products are well known to those of skill in the art.
Similarly, binding assays and reporter gene assays are similarly well known.
Thus, e.g., U.S.
Patent No. 5,559,410 discloses high throughput screening methods for proteins, U.S. Patent No. 5,585,639 discloses high throughput screening methods for nucleic acid binding (e.g., in arrays), while U.S. Patent Nos. 5,576,220 and 5,541,061 disclose high throughput methods of screening for ligand/antibody binding.
In addition, high throughput screening systems are commercially available (see, e.g., Zymark Corp., Hopkinton, MA; Air Technical Industries, Mentor, OH; Beckman Instruments, Inc. Fullerton, CA; Precision Systems, Inc., Natick, MA, etc.).
These systems typically automate entire procedures, including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detectors) appropriate for the assay. These configurable systems provide high throughput and rapid start up as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for various high throughput systems. Thus, e.g., Zymark Corp. provides technical bulletins describing screening systems for detecting the modulation of gene transcription, ligand binding, and the like.
In one embodiment, modulators are proteins, often naturally occurring proteins or fragments of naturally occurring proteins. Thus, e.g., cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of proteins may be made for screening in the methods of the invention. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred. Particularly useful test compound will be directed to the class of proteins to which the target belongs, e.g., substrates for enzymes or ligands and receptors.
In a preferred embodiment, modulators are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides.
By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively.
Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.
In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased.
That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, e.g., of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of nucleic acid binding domains, the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.
Modulators of ovarian cancer can also be nucleic acids, as defined above.
As described above generally for proteins, nucleic acid modulating agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids.

For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.
In a preferred embodiment, the candidate compounds are organic chemical moieties, a wide variety of which are available in the literature.
After the candidate agent has been added and the cells allowed to incubate for some period of time, the sample containing a target sequence to be analyzed is added to the biochip. If required, the target sequence is prepared using known techniques.
.For example, the sample may be treated to lyse the cells, using known lysis buffers, electroporation, etc., with purification and/or amplification such as PCR performed as appropriate.
For example, an in vitro transcription with labels covalently attached to the nucleotides is performed.
Generally, the nucleic acids are labeled with biotin-FITC or PE, or with cy3 or cy5.
In a preferred embodiment, the target sequence is labeled with, e.g., a fluorescent, a . chemiluminescent, a chemical, or a radioactive signal, to provide a means of detecting the target sequence's specific binding to a probe. The label also can be an enzyme, such as, alkaline phosphatase or horseradish peroxidase, which when provided with an appropriate substrate produces a product that can be detected. Alternatively, the label can be a labeled compound or small molecule, such as an enzyme inhibitor, that binds but is not catalyzed or altered by the enzyme. The label also can be a moiety or compound, such as, an epitope tag or biotin which specifically binds to streptavidin. For the example of biotin, the streptavidin is labeled as described above, thereby, providing a detectable signal for the bound target sequence. Unbound labeled streptavidin is typically removed prior to analysis.
As will be appreciated by those in the art, these assays can be direct hybridization assays or can comprise "sandwich assays", which include the use of multiple probes, as is generally outlined in U.S. Patent Nos. 5,681,702; 5,597,909; 5,545,730;
5,594,117;
5,591,584; 5,571,670; 5,580,731; 5,571,670; 5,591,584; 5,624,802; 5,635,352;
5,594,118;
5,359,100; 5,124,246; and 5,681,697, each of which is hereby incorporated by reference. In this embodiment, in general, the target nucleic acid is prepared as outlined above, and then added to the biochip comprising a plurality of nucleic acid probes, under conditions that allow the formation of a hybridization complex.
A variety of hybridization conditions may be used in the present invention, including high, moderate and low stringency conditions as outlined above. The assays are generally run under stringency conditions which allows formation of the label probe hybridization complex only in the presence of target. Stringency can be controlled by altering a step parameter that is a thermodynamic variable, including, but not limited to, temperature, formamide concentration, salt concentration, chaotropic salt concentration pH, organic solvent concentration, etc.
These parameters may also be used to control non-specific binding, as is generally outlined in U.S. Patent No. 5,681,697. Thus it may be desirable to perform certain steps at higher stringency conditions to reduce non-specific binding.
The reactions outlined herein may be accomplished in a variety of ways.
Components of the reaction may be added simultaneously, or sequentially, in different orders, with preferred embodiments outlined below. In addition, the reaction may include a variety of other reagents. These include salts, buffers, neutral proteins, e.g., albumin, detergents, etc.
which may be used to facilitate optimal hybridization and detection, and/or reduce non-specific or background interactions. Reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may also be used as appropriate, depending on the sample preparation methods and purity of the target.
The assay data are analyzed to determine the expression levels, and changes in expression levels as between states, of individual genes, forming a gene expression profile.
Screens are performed to identify modulators of the ovarian cancer phenotype.
In one embodiment, screening is performed to identify modulators that can induce or suppress a particular expression profile, thus preferably generating the associated phenotype. In another embodiment, e.g., for diagnostic applications, having identified differentially expressed genes important in a particular state, screens can be performed to identify modulators that alter expression of individual genes. In an another embodiment, screening is performed to identify modulators that alter a biological function of the expression product of a differentially expressed gene. Again, having identified the importance of a gene in a particular state, screens are performed to identify agents that bind and/or modulate the biological activity of the gene product.
In addition screens can be done for genes that are induced in response to a candidate agent. After identifying a modulator based upon its ability to suppress an ovarian cancer expression pattern leading to a normal expression pattern, or to modulate a single ovarian cancer gene expression profile so as to mimic the expression of the gene from normal tissue, a screen as described above can be performed to identify genes that are specifically modulated in response to the agent. Comparing expression profiles between normal tissue and agent treated ovarian cancer tissue reveals genes that are not expressed in normal tissue or ovarian cancer tissue, but are expressed in agent treated tissue. These agent-specific sequences can be identified and used by methods described herein for ovarian cancer genes or proteins. In particular these sequences and the proteins they encode find use in marking or identifying agent treated cells. In addition, antibodies can be raised against the agent induced proteins and used to target novel therapeutics to the treated ovarian cancer tissue sample.
Thus, in one embodiment, a test compound is administered to a population of ovarian cancer cells, that have an associated ovarian cancer expression profile. By "administration"
or "contacting" herein is meant that the candidate agent is added to the cells in such a manner as to allow the agent to act upon the cell, whether by uptake and intracellular action, or by action at the cell surface. In some embodiments, nucleic acid encoding a proteinaceous candidate agent (e.g., a peptide) may be put into a viral construct such as an adenoviral or retroviral construct, and added to the cell, such that expression of the peptide agent is accomplished, e.g., PCT US97101019. Regulatable gene therapy systems can also be used.
Once the test compound has been administered to the cells, the cells can be washed if desired and are allowed to incubate under preferably physiological conditions for some period of time. The cells are then harvested and a new gene expression profile is generated, as outlined herein.
Thus, e.g., ovarian cancer or non-malignant tissue may be screened for agents that modulate, e.g., induce or suppress the ovarian cancer phenotype. A change in at least one gene, preferably many, of the expression profile indicates that the agent has an effect on ovarian cancer activity. By defining such a signature for the ovarian cancer phenotype, screens for new drugs that alter the phenotype can be devised. With this approach, the drug target need not be known and need not be represented in the original expression screening platform, nor does the level of transcript for the target protein need to change.
In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of either the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "ovarian cancer proteins"
or a "ovarian cancer modulatory protein". The ovarian cancer modulatory protein may be a fragment, or alternatively, be the full length protein to the fragment encoded by the nucleic acids of the Tables. Preferably, the ovarian cancer modulatory protein is a fragment. In a preferred embodiment, the ovarian cancer amino acid sequence which is used to determine sequence identity or similarity is encoded by a nucleic acid of the Tables. In another embodiment, the sequences are naturally occurring allelic variants of a protein encoded by a nucleic acid of the Tables. In another embodiment, the sequences are sequence variants as further described herein.
Preferably, the ovarian cancer modulatory protein is a fragment of approximately 14 to 24 amino acids long. More preferably the fragment is a soluble fragment.
Preferably, the fragment includes a non-transmembrane region. In a preferred embodiment, the fragment has an N-terminal Cys to aid in solubility. In another embodiment, the C-terminus of the fragment is kept as a free acid and the N-terminus is a free amine to aid in coupling, e.g., to cysteine. Or, the ovarian cancer proteins are conjugated to an immunogenic agent, e.g., to BSA.
Measurements of ovarian cancer polypeptide activity, or of ovarian cancer or the ovarian cancer phenotype can be performed using a variety of assays. For example, the effects of the test compounds upon the function of the ovarian cancer polypeptides can be measured by examining parameters described above. A suitable physiological change that affects activity can be used to assess the influence of a test compound on the polypeptides of this invention. When the functional consequences are determined using intact cells or animals, one can also measure a variety of effects such as, in the case of ovarian cancer associated with tumors, tumor growth, tumor metastasis, neovascularization, hormone release, transcriptional changes to both known and uncharacterized genetic markers (e.g., northern blots), changes in cell metabolism such as cell growth or pH changes, and changes in intracellular second messengers such as cGMP. In the assays of the invention, mammalian ovarian cancer polypeptide is typically used, e.g., mouse, preferably human.
Assays to identify compounds with modulating activity can be performed in vitro.
For example, an ovarian cancer polypeptide is first contacted with a potential modulator and incubated for a suitable amount of time, e.g., from 0.5 to 4g hours. In one embodiment, the ovarian cancer polypeptide levels are determined in vitro by measuring the level of protein or mRNA. The level of protein is measured using immunoassays such as western blotting, ELISA and the like with an antibody that selectively binds to the ovarian cancer polypeptide or a fragment thereof. For measurement of mRNA, amplification, e.g., using PCR, LCR, or hybridization assays, e.g., northern hybridization, RNAse protection, dot blotting, are preferred. The level of protein or mRNA is detected using directly or indirectly labeled detection agents, e.g., fluorescently or radioactively labeled nucleic acids, radioactively or enzymatically labeled antibodies, and the like, as described herein.
Alternatively, a reporter gene system can be devised using the ovarian cancer protein promoter operably linked to a reporter gene such as luciferase, green fluorescent protein, CAT, or (3-gal. The reporter construct is typically transfected into a cell.
After treatment with a potential modulator, the amount of reporter gene transcription, translation, or activity is measured according to standard techniques known to those of skill in the art.
In a preferred embodiment, as outlined above, screens may be done on individual genes and gene products (proteins). That is, having identified a particular differentially expressed gene as important in a particular state, screening of modulators of the expression of the gene or the gene product itself can be done. The gene products of differentially expressed genes are sometimes referred to herein as "ovarian cancer proteins." The ovarian cancer protein may be a fragment, or alternatively, be the full length protein to a fragment shown herein.
In one embodiment, screening for modulators of expression of specific genes is 1 S performed. Typically, the expression of only one or a few genes are evaluated. In another embodiment, screens are designed to first find compounds that bind to differentially expressed proteins. These compounds are then evaluated for the ability to modulate differentially expressed activity. Moreover, once initial candidate compounds are identified, variants can be further screened to better evaluate structure activity relationships.
In a preferred embodiment, binding assays are done. In general, purified or isolated gene product is used; that is, the gene products of one or more differentially expressed nucleic acids are made. For example, antibodies are generated to the protein gene products, and standard immunoassays are run to determine the amount of protein present.
Alternatively, cells comprising the ovarian cancer proteins can be used in the assays.
Thus, in a preferred embodiment, the methods comprise combining an ovarian cancer protein and a candidate compound, and determining the binding of the compound to the ovarian cancer protein. Preferred embodiments utilize the human ovarian cancer protein, although other mammalian proteins, e.g., counterparts, may also be used, e.g., for the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative ovarian cancer proteins may be used.
Generally, in a preferred embodiment of the methods herein, the ovarian cancer protein or the candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g., a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening: The surface of such supports may be solid or porous and of any convenient shape.
Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflonTM, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples.
The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is non-diffusible. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety.
In a preferred embodiment, the ovarian cancer protein is bound to the support, and a test compound is added to the assay. Alternatively, the candidate agent is bound to the support and the ovarian cancer protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.
The determination of the binding of the test modulating compound to the ovarian cancer protein may be done in a number of ways. In a preferred embodiment, the compound is labeled, and binding determined directly, e.g., by attaching all or a portion of the ovarian cancer protein to a solid support, adding a labeled candidate agent (e.g., a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support.
Various blocking and washing steps may be utilized as appropriate.
In some embodiments, only one of the components is labeled, e.g., the proteins (or proteinaceous candidate compounds) can be labeled. Alternatively, more than one component can be labeled with different labels, e.g., 125I for the proteins and a fluorophor for the compound. Proximity reagents, e.g., quenching or energy transfer reagents are also useful.
In one embodiment, the binding of the test compound is determined by competitive S binding assay. The competitor is a binding moiety known to bind to the target molecule (e.g., an ovarian cancer protein), such as an antibody, peptide, binding partner, ligand, etc. Under certain circumstances, there may be competitive binding between the compound and the binding moiety, with the binding moiety displacing the compound. In one embodiment, the test compound is labeled. Either the compound, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at a temperature which facilitates optimal activity, typically 4-40° C.
Incubation periods are typically optimized, e.g., to facilitate rapid high throughput screening.
Typically between 0.1 and 1 hr will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.
In a preferred embodiment, the competitor is added first, followed by the test compound. Displacement of the competitor is an indication that the test compound is binding to the ovarian cancer protein and thus is capable of binding to, and potentially modulating, the activity of the ovarian cancer protein. In this embodiment, either component can be labeled. Thus, e.g., if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the test compound is labeled, the presence of the label on the support indicates displacement.
In an alternative embodiment, the test compound is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the test compound is bound to the ovarian cancer protein with a higher affinity. Thus, if the test compound is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate~that the test compound is capable of binding to the ovarian cancer protein.
In a preferred embodiment, the methods comprise differential screening to identity agents that are capable of modulating the activity of the ovarian cancer proteins. In this embodiment, the methods comprise combining an ovarian cancer protein and a competitor in a first sample. A second sample comprises a test compound, an ovarian cancer protein, and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the ovarian cancer protein and potentially modulating its activity.
That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the ovarian cancer protein.
Alternatively, differential screening is used to identify drug candidates that bind to the native ovarian cancer protein, but cannot bind to modified ovarian cancer proteins. The structure of the ovarian cancer protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect the activity of an ovarian cancer protein are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.
Positive controls and negative controls may be used in the assays. Preferably control and test samples are performed in at least triplicate to obtain statistically significant results.
Incubation of all samples is for a time sufficient for the binding of the agent to the protein.
Following incubation, samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.
A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g., albumin, detergents, etc. which may be used to facilitate optimal protein-protein binding and/or reduce~non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in an order that provides for the requisite binding.
In a preferred embodiment, the invention provides methods for screening for a compound capable of modulating the activity of an ovarian cancer protein. The methods comprise adding a test compound, as defined above, to a cell comprising ovarian cancer proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes an ovarian cancer protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.
In one aspect, the assays are evaluated in the presence or absence or previous or subsequent exposure of physiological signals, e.g., hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including chemotherapeutics, radiation, carcinogenics, or other cells (e.g., cell-cell contacts). In another example, the determinations are determined at different stages of the cell cycle process.
In this way, compounds that modulate ovarian cancer agents are identified.
Compounds with pharmacological activity are able to enhance or interfere with the activity of the ovarian cancer protein. Once identified, similar structures are evaluated to identify critical structural feature of the compound.
In one embodiment, a method of inhibiting ovarian cancer cell division is provided.
The method comprises administration of an ovarian cancer inhibitor. 1n another embodiment, a method of inhibiting ovarian cancer is provided. The method comprises administration of an ovarian cancer inhibitor. In a further embodiment, methods of treating cells or individuals with ovarian cancer are provided. The method comprises administration of an ovarian cancer inhibitor.
In one embodiment, an ovarian cancer inhibitor is an antibody as discussed above. In 1 S another embodiment, the ovarian cancer inhibitor is an antisense or RNAi molecule.
A variety of cell viability, growth, proliferation, and metastasis assays are known to those of skill in the art, as described below.
Soft agar growth or colony formation in suspension Normal cells require a solid substrate to attach and grow. When the cells are transformed, they lose this phenotype and grow detached from the substrate.
For example, transformed cells can grow in stirred suspension culture or suspended in semi-solid media, such as semi-solid or soft agar. The transformed cells, when transfected With tumor suppressor genes, regenerate normal phenotype and require a solid substrate to attach and grow. Soft agar growth or colony formation in suspension assays can be used to identify modulators of ovarian cancer sequences, which when expressed in host cells, inhibit abnormal cellular proliferation and transformation. A therapeutic compound would reduce or eliminate the host cells' ability to grow in stirred suspension culture or suspended in semi=
solid media, such as semi-solid or soft.
Techniques for soft agar growth or colony formation in suspension assays are described in Freshney (1994) Culture of Animal Cells: A Manual of Basic Technique (3d ed.) Wiley-Liss, herein incorporated by reference. See also, the methods section of Garkavtsev, et al. (1996), supra, herein incorporated by reference.

Contact inhibition and density limitation of growth Normal cells typically grow in a flat and organized pattern in a petri dish until they touch other cells. When the cells touch one another, they are contact inhibited and stop growing. When cells are transformed, however, the cells are not contact inhibited and continue to grow to high densities in disorganized foci. Thus, the transformed cells grow to a higher saturation density than normal cells. This can be detected morphologically by the formation of a disoriented monolayer of cells or rounded cells in foci within the regular pattern of normal surrounding cells. Alternatively, labeling index with (3H)-thymidine at saturation density can be used,to measure density limitation of growth. See, e.g., Freshney (1994), supra. The transformed cells, when transfected with tumor suppressor genes, regenerate a normal phenotype and become contact inhibited and would grow to a lower density.
In this assay, labeling index with (3H)-thymidine at saturation density is a preferred method of measuring density limitation of growth. Transformed host cells are transfected with an ovarian cancer-associated sequence and are grown for 24 hr at saturation density in non-limiting medium conditions. The percentage of cells labeling with (3H)-thymidine is determined autoradiographically. See, e.g., Freshney (1994), supra.
Growth factor or serum dependence Transformed cells typically have a lower serum dependence than their normal counterparts. See, e.g., Temin (1966) J. Nat'1 Cancer Inst. 37:167-175; Eagle, et al. (1970) J.
Exp. Med. 131:836-879; and Freshney, supra. This is in part due to release of various growth factors by the transformed cells. Growth factor or serum dependence of transformed host cells can be compared with that of control.
Tumor specific markers levels Tumor cells release an increased amount of certain factors (hereinafter "tumor specific maxkers") than their normal counterparts. For example, plasminogen activator (PA) is released from human glioma at a higher level than from normal brain cells (see, e.g., Gullino, pp. 178-184 "Angiogenesis, tumor vascularization, and potential interference with tumor growth" in Mihich (ed. 1985) Biological Responses in Cancer Plenum.
Similarly, tumor angiogenesis factor (TAF) is released at a higher level in tumor cells than their normal counterparts. See, e.g., Folkman (1992) Sem Cancer Biol. 3:89-96.
Various techniques which measure the release of these factors are described in Freshney (1994), supra. Also, see, Unkeless, et al. (1974) J. Biol. Chem.
249:4295-4305;
Strickland and Beers (1976) J. Biol. Chem. 251:5694-5702; Whur, et al. (1980) Br. J. Cancer 42:305-312; Gullino, pp. 178-184 "Angiogenesis, tumor vascularization, and potential interference with tumor growth" in Mihich (ed. 1985) Biological Responses in Cancer Plenum; and Freshney (1985) Anticancer Res. 5:111-130.
Invasiveness into Matrigel , The degree of invasiveness into Matrigel or some other extracellular matrix constituent can be used as an assay to identify compounds that modulate ovarian cancer-associated sequences. Tumor cells exhibit a good correlation between malignancy and invasiveness of cells into Matrigel or some other extracellular matrix constituent. In this assay, tumorigenic cells are typically used as host cells. Expression of a tumor suppressor gene in these host cells would decrease invasiveness of the host cells.
Alternatively, the level of invasion of host cells can be measured by using filters coated with Matrigel or some other extracellular matrix constituent.
Penetration into the gel, or through to the distal side of the filter, is rated as invasiveness, and rated histologically by number of cells and distance moved, or by pre-labeling the cells with 1251 and counting the radioactivity on the distal side of the filter or bottom of the dish. See, e.g., Freshney (1984), supra.
Tumor growth in vivo Effects of ovarian cancer-associated sequences on cell growth can be tested in transgenic or immune-suppressed mice. Knock-out transgenic mice can be made, in which the ovarian cancer gene is disrupted or in which an ovarian cancer gene is inserted. Knock-out transgenic mice can be made by insertion of a marker gene or other heterologous gene into the endogenous ovarian cancer gene site in the mouse genome via homologous recombination. Such mice can also be made by substituting the endogenous ovarian cancer gene with a mutated version of the ovarian cancer gene, or by mutating the endogenous ovarian cancer gene, e.g., by exposure to carcinogens.

A DNA construct is introduced into the nuclei of embryonic stem cells. Cells containing the newly engineered genetic lesion are injected into a host mouse embryo, which is re-implanted into a recipient female. Some of these embryos develop into chimeric mice that possess germ cells partially derived from the mutant cell line. By breeding the chimeric mice it is possible to obtain a new line of mice containing the introduced genetic lesion. See, e.g., Capecchi, et al. (1989) Science 244:1288-1292. Chimeric targeted mice can be derived according to Hogan, et al. (1988) Manipulating the Mouse Embryo: A Laboratory Manual CSH Press; and Robertson (ed. 1987) Teratocarcinomas and Embryonic Stem Cells:
A
Practical Approach IRL Press, Washington, D.C.
Alternatively, various~immune-suppressed or immune-deficient host animals can be used. For example, genetically athymic "nude" mouse (see, e.g., Giovanella, et al. (1974) J.
Nat'1 Cancer Inst. 52:921-930), a SCID mouse, a thymectomized mouse, or an irradiated mouse (see, e.g., Bradley, et al. (1978) Br. J. Cancer 38:263-272; Selby, et al. (1980) Br. J.
Cancer 41:52-61) can be used as a host. Transplantable tumor cells (typically about 106 cells) injected into isogenic hosts will produce invasive tumors in a high proportions of cases, while normal cells of similar origin will not. In hosts which developed invasive tumors, cells expressing an ovarian cancer-associated sequences are injected subcutaneously.
After a suitable length of time, preferably 4-8 weeks, tumor growth is measured (e.g., by volume or by its two largest dimensions) and compared to the control. Tumors that have statistically significant reduction (using, e.g., Student's T test) are said to have inhibited growth.
Polynucleotide modulators of ovarian cancer Antisense and RNAi Polynucleotides In certain embodiments, the activity of an ovarian cancer-associated protein is down-regulated, or entirely inhibited, by the use of antisense polynucleotide, e.g., a nucleic acid complementary to, and which can preferably hybridize specifically to, a coding mRNA
nucleic acid sequence, e.g., an ovarian cancer protein mRNA, or a subsequence thereof.
Binding of the antisense polynucleotide to the mRNA reduces the translation andlor stability of the mRNA.
In the context of this invention, antisense polynucleotides can comprise naturally-occurring nucleotides, or synthetic species formed from naturally-occurring subunits or their close homologs. Antisense polynucleotides may also have altered sugar moieties or inter-sugar linkages. Exemplary among these are the phosphorothioate and other sulfur containing species which are known for use in the art. Analogs are comprehended by this invention so long as they function effectively to hybridize with the ovarian cancer protein mRNA. See, e.g., Isis Pharmaceuticals, Carlsbad, CA; Sequitor, Inc., Natick, MA.
Such antisense polynucleotides can readily be synthesized using recombinant means, or can be synthesized in vitro. Equipment for such synthesis is sold by several vendors, including Applied Biosystems. The preparation of other oligonucleotides such as phosphorothioates and alkylated derivatives is also well known to those of skill in the art.
Antisense molecules as used herein include antisense or sense oligonucleotides.
Sense oligonucleotides can, e;g., be employed to block transcription by binding to the anti-sense strand. The antisense and sense oligonucleotide comprise a single-stranded nucleic acid sequence (either RNA or DNA) capable of binding to target mRNA (sense) or DNA
(antisense) sequences for ovarian cancer molecules. A preferred antisense molecule is for an ovarian cancer sequences in Tables 1-26, or for a ligand or activator thereof.
Antisense or sense oligonucleotides, according to the present invention, comprise a fragment generally at least about 14 nucleotides, preferably from about 14 to 30 nucleotides. An antisense or a sense oligonucleotide can be developed based upon a cDNA sequence encoding a given protein. See, e.g., Stein and Cohen (1988) Cancer Res. 48:2659-2668; and van der Krol, et al. (1988) BioTechniques 6:958-976.
RNA interference is a mechanism to suppress gene expression in a sequence specific manner. See, e.g., Brumelkamp, et al. (2002) Sciencexpress (2lMarch2002);
Sharp (1999) Genes Dev. 13:139-141; and Cathew (2001) Curr. Op. Cell Biol. 13:244-248. In mammalian cells, short, e.g., 21 nt, double stranded small interfering RNAs (siRNA) have been shown to be effective at inducing an RNAi response. See, e.g., Elbashir, et al. (2001) Nature 411:494-498. The mechanism may be used to down-regulate expression levels of identified genes, e.g., treatment of or validation of relevance to disease.
Ribozymes In addition to antisense polynucleotides, ribozymes can be used to target and inhibit transcription of ovarian cancer-associated nucleotide sequences. A ribozyme is an RNA
molecule that catalytically cleaves other RNA molecules. Different kinds of ribozymes have been described, including group I ribozymes, hammerhead ribozymes, hairpin ribozymes, RNase P, and axhead ribozymes (see, e.g., Castanotto, et al. (1994) Adv.
Pharmacol. 25: 289-317 for a general review of the properties of different ribozymes).
The general features of hairpin ribozymes are described, e.g., in Hampel, et al. (1990) Nucl. Acids Res. 18:299-304; European Patent Publication No. 0 360 257; U.S.
Patent No.
5,254,678. Methods of preparing them are well known to those of skill in the art. See, e.g., WO 94/26877; Ojwang, et al. (1993) Proc. Nat'1 Acad. Sci. USA 90:6340-6344;
Yamada, et al. (1994) Hum. Gene Ther. 1:39-45; Leavitt, et al. (1995) Proc. Nat'1 Acad.
~Sci. USA
92:699-703; Leavitt, et al. (1994) Hum. Gene Ther. 5:1151-120; and Yamada, et al. (1994) Virolo~y 205:121-126.
Polynucleotide modulators of ovarian cancer may be introduced into a cell containing the target nucleotide sequence by formation of a conjugate with a ligand binding molecule, as described in WO 91/04753. Suitable ligand binding molecules include, but are not limited to, cell surface receptors, growth factors, other cytokines, or other ligands that bind to cell surface receptors. Preferably, conjugation of the ligand binding molecule does not substantially interfere with the ability of the ligand binding molecule to bind to its corresponding molecule or receptor, or block entry of the sense or antisense oligonucleotide or its conjugated version into the cell. Alternatively, a polynucleotide modulator of ovarian cancer may be introduced into a cell containing the target nucleic acid sequence, e.g., by formation of an polynucleotide-lipid complex, as described in WO 90/10448. It is understood that the use of antisense molecules or knock out and knock in models may also be used in screening assays as discussed above, in addition to methods of treatment.
Thus, in one embodiment, methods of modulating ovarian cancer in cells or organisms are provided. Ix~ one embodiment, the methods comprise administering to a cell an anti-ovarian cancer antibody that reduces or eliminates the biological activity of an endogenous ovarian cancer protein. Alternatively, the methods comprise administering to a cell or organism a recombinant nucleic acid encoding an ovarian cancer protein. This may be accomplished in any number of ways. In a preferred embodiment, e.g., when the ovarian cancer sequence is down-regulated in ovarian cancer, such state may be reversed by increasing the amount of ovarian cancer gene product in the cell. This can be accomplished, e.g., by over-expressing the endogenous ovarian cancer gene or administering a gene encoding the ovarian cancer sequence, using known gene-therapy techniques, e.g.. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), e.g., as described in PCT/IJS93/03868, hereby incorporated by reference in its entirety.
Alternatively, e.g., when the ovarian cancer sequence is up-regulated in ovarian cancer, the activity of the endogenous ovarian cancer gene is decreased, e.g., by the administration of an ovarian cancer antisense or RNAi nucleic acid.
In one embodiment, the ovarian cancer proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to ovarian cancer proteins.
Similarly, the ovarian cancer proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify ovarian cancer antibodies useful for production, diagnostic, or therapeutic purposes. In a preferred embodiment, the antibodies are generated to epitopes unique to an ovarian cancer protein;
that is, the antibodies show little or no cross-reactivity to other proteins.
The ovarian cancer antibodies may be coupled to standard affinity chromatography columns and used to purify ovarian cancer proteins. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the ovarian cancer protein.
Methods of identifying variant ovarian cancer-associated sequences Without being bound by theory, expression of various ovarian cancer sequences is correlated with ovarian cancer. Accordingly, disorders based on mutant or variant ovarian cancer genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant ovarian cancer genes, e.g., determining all or part of the sequence of at least one endogenous ovarian cancer genes in a cell. This may be accomplished using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the ovarian cancer genotype of an individual, e.g., determining all or part of the sequence of at least one ovarian cancer gene of the individual.
This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced ovarian cancer gene to a known ovarian cancer gene, e.g., a wild-type gene.
The sequence of all or part of the ovarian cancer gene can then be compared to the sequence of a known ovarian cancer gene to determine if any differences exist.
This can be done using any number of known homology programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the ovarian cancer gene of the patient and the known ovarian cancer gene correlates with a disease state or a propensity for a disease state, as outlined herein.

In a preferred embodiment, the ovarian cancer genes are used as probes to determine the number of copies of the ovarian cancer gene in the genome.
In another preferred embodiment, the ovarian cancer genes are used as probes to determine the chromosomal localization of the ovarian cancer genes.
Information such as chromosomal localization finds use in providing a diagnosis or prognosis in particular when chromosomal abnormalities such as translocations, and the like are identified in the ovarian cancer gene locus.
Administration of pharmaceutical and vaccine compositions In one embodiment, a therapeutically effective dose of an ovarian cancer protein or modulator thereof, is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. See, e.g., Ansel, et al. (1999) Pharmaceutical Dosage Forms and Drug Deliver~ystems Lippincott; Lieberman (1992) Pharmaceutical Dosage Fornis (vols. 1-3) Dekker, ISBN 0824770846, 082476918X, 0824712692, 0824716981; Lloyd (1999) The Art, Science and Technology of Pharmaceutical Cornpoundin~ Amer. Pharmaceutical Assn.; and Pickar (1999) Dosage Calculations Thomson. Adjustments for ovarian cancer degradation, systemic versus localized delivery, and rate of new protease synthesis, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction, and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art. U.S. Patent Application No.
09/687,576, further discloses the use of compositions and methods of diagnosis and treatment in ovarian cancer is hereby expressly incorporated by reference.
A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, preferably a primate, and in the most preferred embodiment the patient is human.
The administration of the ovarian cancer proteins and modulators thereof of the present invention can be done in a variety of ways as discussed above, including, but not limited to, orally, subcutaneously, intravenously, infra-nasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, e.g., in the treatment of wounds and inflammation, the ovarian cancer proteins and modulators may be directly applied as a solution or spray.
The pharmaceutical compositions of the present invention comprise an ovarian cancer protein in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as S pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malefic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
"Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurnng substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine.
The pharmaceutical compositions may also include one or more of the following:
Garner proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents;
coloring agents; and polyethylene glycol.
The pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration. For example, unit dosage forms suitable for oral administration include, but are not limited to, powder, tablets, pills, capsules, and lozenges. It is recognized that ovarian cancer protein modulators (e.g., antibodies, antisense constructs, ribozymes, small organic molecules, etc.) when administered orally, should be protected from digestion. This is typically accomplished either by complexing the molecules) with a composition to render it resistant to acidic and enzymatic hydrolysis, or by packaging the molecules) in an appropriately resistant Garner, such as a liposome or a protection burner. Means of protecting agents from digestion are well known in the art.

The compositions for administration will commonly comprise an ovarian cancer protein modulator dissolved in a pharmaceutically acceptable carrier, preferably ari aqueous carrier. A variety of aqueous Garners can be used, e.g., buffered saline and the like. These solutions are sterile and generally free of undesirable matter. These compositions may be sterilized by conventional, well known sterilization techniques. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the.like, e.g., sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. The concentration of active agent in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight, and the like in accordance with the particular mode of administration selected and the patient's needs. See, e.g., Remington's Pharmaceutical Science (15th ed., 1980) and Hardman and Limbird (eds. 2001) Goodman and Gillman: The Phannacolo~ical Basis of Therapeutics (10th ed.) McGraw-Hill. Thus, a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the drug is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. Substantially higher dosages are possible in topical administration.
Actual methods for preparing parenterally administrable compositions are readily available.
The compositions containing modulators of ovarian cancer proteins can be administered for therapeutic or prophylactic treatments. In therapeutic applications, compositions are administered to a patient suffering from a disease (e.g., a cancer) in an amount sufficient to cure or at least partially arrest the disease and/or its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose." Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the agents of this invention to effectively treat the patient. An amount of modulator that is capable of preventing or slowing the development of cancer in a mammal is referred to as a "prophylactically effective dose."
The particular dose required for a prophylactic treatment will depend upon the medical condition and history of the mammal, the particular cancer being prevented, as well as other factors such as age, weight, gender, administration route, efficiency, etc.
Such prophylactic treatments may be used, e.g., in a mammal who has previously had cancer to prevent a recurrence of the cancer, or in a mammal who is suspected of having a significant likelihood of developing cancer based, e.g., in part, upon gene expression profiles.
Vaccine strategies may be used, in either a DNA vaccine form, or protein vaccine.
It will be appreciated that the present ovarian cancer protein-modulating compounds can be administered alone or in combination with additional ovarian cancer modulating compounds or with other therapeutic agent, e.g., other anti-cancer agents or treatments.
In numerous embodiments, one or more nucleic acids, e.g., polynucleotides comprising nucleic acid sequences set forth in Tables 1-26, such as RNAi, antisense polynucleotides or ribozymes, will be introduced into cells, in vitro or in vivo. The present invention provides methods, reagents, vectors, and cells useful for expression of ovarian cancer-associated polypeptides and nucleic acids using in vitro (cell-free), ex vivo or in vivo (cell or organism-based) recombinant expression systems.
The particular procedure used to introduce the nucleic acids into a host cell for expression of a protein or nucleic acid is application specific. Many procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, spheroplasts, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic material into a host cell. See, e.g., Berger and Kimmel (1987) Guide to Molecular Cloning Techniques from Methods in Enzymolo~y (vol. 152) Academic Press; Ausubel, et al. (eds. 1999 and supplements) Current Protocols Lippincott; and Sambrook, et al. (2001) Molecular Cloning: A
Laboratory Manual (3d ed., Vol. 1-3) CSH Press.
In a preferred embodiment, ovarian cancer proteins and modulators are administered as therapeutic agents, and can be formulated as outlined above. Similarly, ovarian cancer genes (including both the full.-length sequence, partial sequences, or regulatory sequences of the ovarian cancer coding regions) can be administered in a gene therapy application. These ovarian cancer genes can include antisense applications, either as gene therapy (e.g., for incorporation into the genome) or as antisense compositions, as will be appreciated by those in the art.
Ovarian cancer polypeptides and polynucleotides can also be administered as vaccine compositions to stimulate HTL, CTL, and antibody responses.. Such vaccine compositions can include, e.g., lipidated peptides (see, e.g., Vitiello, et al. (1995) J.
Clin. Invest. 95:341-349), peptide compositions encapsulated in poly(D,L-lactide-co-glycolide, "PLG") microspheres (see, e.g., Eldridge, et al. (1991) Molec. Immunol. 28:287-294;
Alonso, et al.
(1994) Vaccine 12:299-306; Jones, et al. (1995) Vaccine 13:675-681), peptide compositions contained in immune stimulating complexes (ISCOMS; see, e.g., Takahashi, et al. (1990) Nature 344:873-875; Hu, et al. (1998) Clin. Exp. Immunol. 113:235-243), multiple antigen .
peptide systems (MAPS; see, e.g., Tam (1988) Proc. Nat'1 Acad. Sci. USA
85:5409-5413;
Tam (1996) J. Immunol. Methods 196:17-32), peptides formulated as multivalent peptides;
peptides for use in ballistic delivery systems, typically crystallized peptides, viral delivery vectors (Perkus, et al., p. 379, in Kaufmann (ed. 1996) Concepts in Vaccine Development de Gruyter; Chakrabarti, et al. (1986) Nature 320:535-537; Hu, et al. (1986) Nature 320:537-540; Kieny, et al. (1986) AIDS Bio/Technolo~y 4:790-795; Top, et al. (1971) J.
Infect. Dis.
124:148-154; Chanda, et al. (1990) Virolo~y 175:535-547), particles of viral or synthetic origin (see, e.g., Kofler, et al. (1996) J. hmnunol. Methods 192:25-35;
Eldridge, et al. (1993) Sem. Hematol. 30:16-24; Falo, et al. (1995) Nature Med. 7:649-653), adjuvants (Warren, et a1. (1986) Ann. Rev. Immunol. 4:369-388; Gupta, et al. (1993) Vaccine 11:293-306), liposomes (Reddy, et a1.(1992) J. Immunol. 148:1585-1589; Rock (1996) Immunol.
Today 17:131-137), or, naked or particle absorbed cDNA (Ulmer, et al. (1993) Science 259:1745-1749; Robinson, et al. (1993) Vaccine 11:957-960; Shiver, et al., p. 423, in Kaufmann (ed.
1996) Concepts in Vaccine Development de Gruyter; Cease and Berzofsky (1994) Ann. Rev.
Immunol. 12:923-989; and Eldridge, et al. (1993) Sem. Hematol. 30:16-24).
Toxin-targeted delivery technologies, also known as receptor mediated targeting, such as those of Avant Immunotherapeutics, Inc. (Needham, Massachusetts) may also be used.
Vaccine compositions often include adjuvants. Many adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a stimulator of immune responses, such as lipid A, Bortadella pertussis, or Mycobacterium tuberculosis derived proteins. Certain adjuvants are commercially available as, e.g., Freund's Incomplete Adjuvant and Complete Adjuvant (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKline Beecham, Philadelphia, PA); aluminum salts such as aluminum hydroxide gel (alum) or aluminum phosphate; salts of calcium, iron or zinc; an insoluble suspension of acylated tyrosine; acylated sugars; cationically or anionically derivatized polysaccharides;
polyphosphazenes; biodegradable microspheres; monophosphoryl lipid A and quil A.
Cytokines, such as GM-CSF, interleukin-2, -7, -12, and other like growth factors, may also be used as adjuvants.
Vaccines can be administered as nucleic acid compositions wherein DNA or RNA
encoding one or more of the polypeptides, or a fragment thereof, is administered to a patient.
See, e.g., Wolff et. al. (1990) Science 247:1465-1468; U.S. Patent Nos.
5,580,859; 5,589,466;
5,804,566; 5,739,118; 5,736,524; 5,679,647; and WO 98/04720. Examples of DNA-based delivery technologies include "naked DNA", facilitated (bupivicaine, polymers, peptide-mediated) delivery, cationic lipid complexes, and particle-mediated ("gene gun") or pressure-mediated delivery (see, e.g., U.S. Patent No. 5,922,687).
For therapeutic or prophylactic immunization purposes, the peptides of the invention can be expressed by viral or bacterial vectors. Examples of expression vectors include attenuated viral hosts, such as vaccinia or fowlpox. This approach involves the use of vaccinia virus, e.g., as a vector to express nucleotide sequences that encode ovarian cancer polypeptides or polypeptide fragments. Upon introduction into a host, the recombinant vaccinia virus expresses the immunogenic peptide, and thereby elicits an immune response.
Vaccinia vectors and methods useful in immunization protocols are described in, e.g., U.S.
Patent No. 4,722,848. Another vector is BCG (Bacille Calmette Guerin). BCG
vectors are described in Stover, et al. (1991) Nature 351:456-460. A wide variety of other vectors useful for therapeutic administration or immunization e.g., adeno and adeno-associated virus vectors, retroviral vectors, Salmonella typhi vectors, detoxified anthrax toxin vectors, and the like, will be apparent. See, e.g., Shata, et al. (2000) Mol. Med. Today 6:66-71; Shedlock, et al. (2000) J. Leukoc. Biol. 68:793-806; and Hipp, et al. (2000) In Vivo 14:571-85.
Methods for the use of genes as DNA vaccines are well known, and include placing an ovarian cancer gene or portion of an ovarian cancer gene under the control of a regulatable promoter or a tissue-specific promoter for expression in an ovarian cancer patient. The ovarian cancer gene used for DNA vaccines can encode full-length ovarian cancer proteins, but more preferably encodes portions of the ovarian cancer proteins including peptides derived from the ovarian cancer protein. In one embodiment, a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from an ovarian cancer gene. For example, ovarian cancer-associated genes or sequence encoding subfragments of an ovarian cancer protein are introduced into expression vectors and tested for their immunogenicity in the context of Class I MHC and an ability to generate cytotoxic T cell responses. This procedure provides for production of cytotoxic T cell responses against cells which present antigen, including intracellular epitopes.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the ovarian cancer polypeptide encoded by the DNA
vaccine.
Additional or alternative adjuvants are available.
In another preferred embodiment ovarian cancer genes find use in generating animal models of ovarian cancer. When the ovarian cancer gene identified is repressed or diminished in cancer tissue, gene therapy technology, e.g., wherein antisense RNA directed to the ovarian cancer gene will also diminish or repress expression of the gene. Animal models of ovarian cancer find use in screening for modulators of an ovarian cancer-associated sequence or modulators of ovarian cancer. Similarly, transgenic animal technology including gene knockout technology, e.g., as a result of homologous recombination with an appropriate gene targeting vector, will result in the absence or increased expression of the ovarian cancer protein. When desired, tissue-specific expression or knockout of the ovarian cancer protein may be necessary.
It is also possible that the ovarian cancer protein is overexpressed in ovarian cancer.
As such, transgenic animals can be generated that overexpress the ovarian cancer protein.
Depending on the desired expression level, promoters of various strengths can be employed to express the transgene. Also, the number of copies of the integrated transgene can be determined and compared for a determination of the expression level of the transgene.
Animals generated by such methods find use as animal models of ovarian cancer and are additionally useful in screening for modulators to treat ovarian cancer.
Kits for Use in Diagnostic andlor Prognostic Applications For use in diagnostic, research, and therapeutic applications suggested above, kits are also provided by the invention. In the diagnostic and research applications such kits may include any or all of the following: assay reagents, buffers, ovarian cancer-specific nucleic acids or antibodies, hybridization probes and/or primers, siRNA or antisense polynucleotides, ribozymes, dominant negative ovarian cancer polypeptides or polynucleotides, small molecules inhibitors of ovarian cancer-associated sequences etc. A therapeutic product may include sterile saline or another pharmaceutically acceptable emulsion and suspension base.
In addition, the kits may include instructional materials containing directions (e.g., protocols) for the practice of the methods of this invention. While the instructional materials typically comprise written or printed materials they are not limited to such.
Any medium ~5 capable of storing such instructions and communicating them to an end user is contemplated by this invention. Such media include, but are not limited to electronic storage media (e.g., magnetic discs, tapes, cartridges, chips), optical media (e.g., CD ROM), and the like. Such media may include addresses to Internet sites that provide such instructional materials.
The present invention also provides for kits for screening for modulators of ovarian cancer-associated sequences. Such kits can be prepared from readily available materials and reagents. For example, such kits can comprise one or more of the following materials: an ovarian cancer-associated polypeptide or polynucleotide, reaction tubes, and instructions for testing ovarian cancer-associated activity. Optionally, the kit contains biologically active ovarian cancer protein. A wide variety of kits and components can be prepared according to the present invention, depending upon the intended user of the kit and the particular needs of the user. Diagnosis would typically involve evaluation of a plurality of genes or products.
The genes will be selected based on correlations with important parameters in disease which may be identified in historical or outcome data.

EXAMPLES
Example 1: Gene Chip Analysis Molecular profiles of various normal and cancerous tissues were determined and analyzed using gene chips. RNA was isolated and gene chip analysis was performed as described (Glynne, et al. (2000) Nature 403:672-676; Zhao, et al. (2000) Genes Dev. 14:981-993).
TABLE 1A lists about 1119 genes up-regulated in ovarian cancer compared to normal adult tissues. These were selected from 59000 probesets on the AffymetrixlEos Hu03 GeneChip array such that the ratio of "average" ovarian cancer to "average' normal adult tissues was greater Than or equal to 5Ø The "average" ovarian cancer level was set to the 80th percentile value amongst various ovarian cancers. The "average"
normal adult tissue level was set to the 85th percenUle amongst various non-malignant tissues.
3O TABLE tA: ABOUT 1119 UP-REGULATED OVARIAN CANCER GENES
Pkey: Primekey Ex. Accn:
Exemplar Accession UGID: UniGeneID

rUe: UniGenetitle ratio: ratio tumor vs normal Ussues Pkey Ex. UG Title ratio Accn ID

423634 AW959908Hs.1690heparin-binding growth 65.7 factor binding protein 423017 AWt78761Hs.227948'serine (or cysfeine) 63.6 proteinase inhibitor, Glade B(ovalbumi 432938 T27013Hs.3132steroidogenic acute 58.3 regulatory protein 445810 AW265700Hs.155660ESTs 35.9 431938 AA938471Hs.115242developmentally regulated32.0 GTP-binding protein 407112 AA070801Hs.51615"ESTs, Weakly similar 31.3 to ALU7-HUMAN ALU SUBFAM

425650 NM-001944Hs.1925desmoglein 3 (pemphigus30.0 vulgaris antigen) 402075 predicted exon 27.9 400301 X03635Hs.1657estrogenreceptorl 26.4 402639 predicted exon 25.3 421948L42583Hs.111758kerafin 6A 24.7 414540BE379050 "gb:601236655F1 NIH 24.6 MGC_44 Homo Sapiens cDNA clon 418994AA296520Hs.89546selecfin E (endothelial24.5 adhesion molecule 1) 401575 predicted exon 23.6 457024AA397546Hs.119151ESTs 23.2 440684A1253123Hs.127356"ESTs, Highly similar 23.1 to NEST-HUMAN NESTI
[H.sapien 459006AW298631Hs.27721hypothetical protein 22.8 400964 predicted exon 22.5 1 402421 predicted exon 20.9 ~

437329AA811977Hs.291761ESTs 20.8 414605BE390440 "g6:60128360iF1 N1H 20.7 MGC 44 Homo sapiens cDNA clon 411004AW813242 'gb:MR3-ST0191-020200-207-g10ST019120.4 Homosapiens 401283 predicted exon 20.3 1 440633AI140686Hs.263320ESTs 19.9 445603H08345Hs.106234ESTs 19.7 403786 predicted exon 19.7 436508AW6D4381Hs.121121ESTs 19.6 459390BE385725 "gb:601276347F1 NIH_MGC-2019.2 Homo Sapiens cDNA clon 421823N40B50Hs.28625ESTs 19.0 417366BE185289Hs.1076small proline-rich protein18.9 18 (comifin) 422525AA758797Hs.192807ESTs 18.5 458121S42416Hs.74647Human T-cell receptor 18.3 acfive alpha-chain mRNA from JM c 430520NM_016190Hs.242057chromosome 1 open reading18.1 frame 10 25 450192AA263143Hs.24596RAD51-interacting protein18.0' 416839H94900Hs.17882ESTs 17.9 440788A1806594Hs.128577ESTs 17.9 451072AA013451Hs.117929ESTs 17.7 402203 predicted exon 17.3 417611AW993983 "gb:RC1-BN0035-130400-013-a0417.3 BN0035 Homo Sapiens 438658AI222068Hs.123571ESTs 17.3 403747 predicted exon 17.2 444958AW292643Hs.167047ESTs 17.2 404097 predicted exon 17.1 35 459375BE251770 "gb:601112470FiNIH MGC_l6HomosapienscDNAclon16.9 443198A1039813 gb:ox49dD6.x1 Soares 16.9 total-fetus Nb2HF8 9w Homo sapi 441557AW452647Hs.270482ESTs 16.9 433871W02410Hs.205555ESTs 16.8 429163AA884766 gb:am20a10.s1 Soares_NFL_T16.7 GBC S1 Homo Sapiens cD

443406A1056238Hs.143316ESTs ' 16.7 400613 predicted exon 16.6 448372AWd45166Hs.170802ESTs 16.5 410929H47233Hs.30643ESTs 16.5 445687A1263105Hs.145597ESTs 16.1 45 422036AA302647Hs.271891ESTs 16.0 404767 predicted exon 15.9 420831AA280824Hs.190035ESTs 15.8 405196 predicted exon 15.8 452947AW130413 "gb:xf50104.x1 NCI-CGAP_Gas415.8 Homo sapiens cDNA clo 429538BE182592Hs.139322small proline-rich protein15.8 d35313AI769400Hs.189729ESTs 15.7 449635AI989942Hs.232150ESTs 15.6 424098AF077374Hs.139322small praline-rich protein15.4 411660AW855718 "gb:RCt-CT0279-070100-021-a0615.4 CT0279 Homo Sapiens c 55 442653BE269247Hs.170226Homo Sapiens clone 2357915.4 mRNA sequence 443534A1076123 gb:oy92e04.x1 Soares 15.4 ' fetal-liver_spleen_1NFLS_S1 Homo 458012At424899Hs.188211ESTs 15.3 441018A1809587Hs.148782ESTs 15.1 425972BE391563Hs.165433"ESTs, Highly similar 15.1 to T17342 hypothefical protein DKFZ

60 418092845154Hs.106604ESTs 15.1 410909AW898161Hs.53112"ESTs, Weakly similar 15.1 to ALUB-HUMAN ALU SUBFAM

458234BE551408Hs.127196ESTs 15.0 4342D8T92641Hs.127648hypotheficalprotein 15.0 d03177 predicted exon 15.0 6 423725AJ4D3108Hs.132127hypotheficalprotein 14.9 425090AA350552 "gb:EST57886 Infant 14.7 brain Homo Sapiens cDNA 5' end, m8 409723AW885757Hs.257862ESTs 1d.6 423735AA330259 "gb:EST33963 Embryo,12 14.6 week II Homo Sapiens cDNA 5' 444266AI424984Hs.125465ESTs 14.5 443341AW631480Hs.8688ESTs 14.4 457336AW969657Hs.291029ESTs 14.4 440500AA972165Hs.150308ESTs 14.4 446292AF081497Hs.279682Rh type C glycoprotein 14.3 438086AA336519Hs.301167"Homo Sapiens cDNA: 14.3 FLJ21545 fir, clone COL06195"

75 434715BE005346Hs.116410ESTs 14.2 409387AW384900Hs.123526ESTs 14.2 409272A8014569Hs.52526KIAA0669 gene product 14.2 454913AW841462 "gb:RC6-CN0014-080300-012-80914.0 CN0014 Homo Sapiens 439846T63959Hs.228320'Homo Sapiens cDNA: 14.0 FLJ23537 fir, clone LNG07690"

409695AA296961 "gb:EST112514 Adrenal i3.9 gland tumor Homo Sapiens cDNA

422897AA679784Hs.4290ESTs 13.9 d04664 predicted exon 13.9 458829AI557388 "gb:PT2.1 6 G03.r tumor213.8 Homo Sapiens cDNA 3', mRNA

407327AA487182Hs.269414ESTs 13.8 g7 455435AW939445 'gb:OV1-DT0072-310100-056-b0713.7 OT0072 Homo Sapiens 449327AI638743Hs.224672ESTs 13.7 411693AW857271 "gb:CMO-CT0307-210100-158-g0913.7 CT0307 Homo Sapiens 407463AJ272034 gb:Homo Sapiens mRNA 13.6 for putative capacitative calcium c 446767AI380107Hs.158954ESTs 13.6 433040H70423Hs.300511ESTs 13.5 435209AW027809Hs.187698'ESTs, Highly similar 13.5 to cytomegaloviros partial fusion race 441459AI919142Hs.214233ESTs 13.5 401269 predicted axon 13.4 1 438663AI199575Hs.153070ESTs 13.4 ~

426698AA394104Hs.97489ESTs 13.4 423637AL137279Hs.130187Homo Sapiens mRNA; cDNA 13.2 DKFZp43401214 (from clon 448543AW897741Hs.21380Homo Sapiens mRNA; cDNA 13.2 DKFZp586P1124 (from clon 456714AW897265 'gb:CMO-NN0057-150400-335-a0413.2 NN0057 Homo Sapiens 1 458356A1024855Hs.131575ESTs 13.2 .

431822AA516049 "gb:ng65d01.s1 NCI CGAP_Lip213.1 Homo Sapiens cDNA clo 454822AW833793 'gb:OV4-TT0008-130100-O80-a0613.1 TT0008 Homo Sapiens c 453358AI990738Hs.240066ESTs 13.1 435542AA687376Hs.269533ESTs 13.1 421286AA806584Hs.187895ESTs 13.0 452799AI948829Hs.213786ESTs 13.0 444355BE383686Hs.191621ESTs 13.0 444271AW452569Hs.149804ESTs 12.9 443860AW866632 'gb:OV4-SN0024-210400-181-g0412.9 SN0024 Homo Sapiens 428719AA358193Hs.193128hypothetical prgtein 12.9 418282AA215535Hs.98i33ESTs 12.8 437308AA749417Hs.292353ESTs 12.7 400584 predicted axon 12.7 426306AA447310Hs.164059'Homo Sapiens cDNA FLJi333812.7 fis, clone OVARC100188 448466AI522109Hs.171066ESTs 12.7 402738 predicted axon 12.7 451531AA018311Hs.114762ESTs 12.6 435243AW292886Hs.261373adenosine A2b receptor 12.6 pseudogene 431725X65724Hs.2839Norrie disease (pseudoglioma)12.6 35425108A1000489Hs.96967ESTs 12.5 422330D30783Hs.i15263epiregulin 12.5 432949AA570749Hs.298866ESTs 12.5 417009AA19i719Hs.171872DEADIH (Asp-Glu-Ala-AspIHis)12.4 box polypeptide 8 (RNA

456378AA843387Hs.87279ESTs 12.4 40432966AA650114 "gb:ns92h09.s1 NCI-CGAP_Pr312.4 Homo Sapiens cDNA clon 440571AA904461Hs.130798ESTs 12.3 411178AW820852 'gb:RC2-ST0301-120200-011-f1212.3 ST0301 Homo Sapiens c 445934AF131737Hs.13475hypothetical protein 12.3 433917AI809325Hs.i Human DNA sequence from 12.2 22814clone RP5-1028Di5 on chrom 4S402018 predicted axon 12.2 424101AA335394 "gb:EST39787 Epididymus 12.2 Homo Sapiens cDNA 5' end, mR

448533AL119710Hs.21365nucleosome assembly protein12.1 1-like 3 458154AW816379 "gb:OV4-ST0234-181199-035-g0112.1 ST0234 Homo sapiens c 440919AW291274Hs.262826ESTs 12.0 415747AA381209 "gb:EST94257 Activated 12.0 T-cells I Homo Sapiens cDNA 5' a 411748AW859920 "gb:OV1-CT03o4-260100-052-g0512.0 CT0364 Homo sapieos 452975M85521Hs.69469dendritic cell protein 12.0 427276AA400269Hs.49598ESTs 12.0 454315AW373564Hs.251928nuclear pore complex 12.0 interacting protein 5 450786H86632Hs.33654ESTs 12.0 J

402578 predicted axon 11.9 459591AL037185 gb:DKFZp564Ai 169 r1 11.9 564 (synonym: hibr2) Homo sapie 433449AW772282 'gb:hn71b05.x1NCl_CGAP_KidilHomosapienscDNAc11.9 429108AA890521Hs.126035ESTs 11:8 454556AW807073 'gb:MR4-ST0062-031199-018-40611.7 ST0062 Homo Sapiens 443613A1079356 gb:oz39b09.s1 Soares 11.7 NhHMPu-St HomosapienscDNAc 400385NM Hs.283104putative capacitative 11.6 020389 calcium channel 411725AW858396 "gb:CMO-CT0341-181299-130-c0611.5 CT0341 Homo Sapiens 455174A1694575Hs.147801ESTs 11.5 65412402AW984788 "gb:RC1-HN0015-120400-021-c0711.5 HN0015 Homo Sapiens 434205AF119861Hs.283032hypothetical protein 11.5 450496AW449251Hs.257131ESTs 11.5 411149N68715Hs.269128ESTs 11.5 414210HE383592 'gb:601297871F1 NIH MGC-1911.4 Homo sapiens cDNAclon 409994D86864Hs.57735acetyl LDL receptor; 11.3 SREC

453845AL157568 gb:DKFZp761F0816_r1761 11.3 (synonym: hamy2) Homo sapi 404849 predicted axon 11.3 442824BE178065Hs.144081ESTs 11.3 428548AA430058Hs.98649EST 11.3 75434804AA649530 'gb:ns44f05.s1 NCI CGAP-Alvt11.3 Homo Sapiens cDNA clo 430486BE062109Hs.241551'chloride channel, calcium11.3 activated, family member 2"

400174 predicted axon 11.2 424324AA346316 'gb:EST52440 Greater 11.2 omentum tumor Homo Sapiens cDN

447724AW298375Hs.24477ESTs 11.2 457028AW449838Hs.97562ESTs 11.2 429900AA460421Hs.30875ESTs 11.2 452240AI591147Hs.61232ESTs 11.2 458067AA393603Hs.36752"Homo Sapiens cDNA: FLJ2283411.1 fis, clone KAIA4314' 402222 predicted axon 11.1 446745AW118189Hs.156400ESTs 11.1 453060AW29d092Hs.21594ESTs 11.1 443482AW188093Hs.250385ESTs 11.1 436843M824588 "gb:oc83d02.s1 NCI_CGAP_GCB111.0 Homo Sapiens cDNA c 416320H47867Hs.34024ESTs 11.0 435772AA700019Hs.132992"ATP-binding cassette, 11.0 sub-family G (WHITE), member 5 ( 451542AA018365Hs.32713ESTs 11.0 408522AI541214Hs.46320"Small proline-rich protein11.0 SPRK [human, odontogenic kera 414712N88858.compHs.77039ribosomal protein S3A 10.9 1 411940AW876686 "gb:CM4-PT0031-180200-507-e0510.9 ~ PT0031 Homo Sapiens c 408733AW264812Hs.254290ESTs 10.9 452030AL137578Hs.27607Homo Sapiens mRNA; cDNA 10.9 DKFZp56dN2464 (from clon 458175AW296024Hs.150434ESTs . 10.9 400612 predicted exon 10.9 1 440159AI637599Hs.126127ESTs 10.8 429443A8028967Hs.202687"potassium voltage-gated10.8 channel, Shal-related subfamily, m 416319AI815601Hs.79197"CD83 anflgen (activated10.8 B lymphocytes, immunoglobulin s 405783 predicted exon 10.7 405708 predicted exon 10.7 433266AI863224Hs.288677"Homo sapiens cDNA FLJ1387210.6 fis, clone THYR0100132 456900AA355442Hs.i69054ESTs 10.6 432408N39127Hs.76391"myxovirus (influenza) 10.6 resistance 1, homolog of murine (int 451702AW665452Hs.246503ESTs 10.6 418179X51630Hs.1145Wilms tumor 1 10.6 25 408987H85615 gb:yt03f11.r1 Soares 10.6 reflna N2b5HR Homo sapiens cDNA

405285 predicted exori 10.5 419276BE165909Hs.134682"Homo Sapiens cDNA: FLJ2316110.5 fls, clone LNG09730"

407287AI678812Hs.201658"ESTs, Weakly similar 10.5 to ALU4_HUMAN ALU SUBFAM

403065 predicted exon 10.5 414195BE263293 "gb:601144881 F2 NIH 10.4 MGC 19 Homo Sapiens cDNA clan 454258AI457286Hs.i43979"ESTs, Weakly similar 10.4 to KIAA1276 protein [H.sapiens]"

412951BE018611Hs.251946"Homo Sapiens cDNA: FLJ2310710.4 fis, clone LNG07738"

428888AA437010Hs.266584ESTs 10.4 440834AA907027Hs.128606ESTs 10.4 437096AA744d06 "gb:ny51h02.s1 NCI_CGAP_Prl810.4 Homo Sapiens cDNA clo 400135 predicted exon 10.4 447849AI538147Hs.164277ESTs 10.3 400593 predicted exon 10.3 427469AA403084Hs.269347ESTs 10.3 402794 predicted exon 10.2 452743AW965082Hs.61455ESTs 10.2 448983AI611654Hs.224908ESTs 10.2 422696AF242524Hs.26323hypothetical nuclear 10.2 factor 588122 428949AA442153Hs.104744"ESTs, Weakly similar 10.2 io AF2088551 BM-013 [H.sapiens]

45 409191AW818390 "gb:RCt-ST0278-160200-014-41010.2 5T0278 Homo Sapiens c 428493AK001745Hs.184628hypotheflcai protein 10.2 406076AL390179Hs.137011Homo Sapiens mRNA; cDNA 10.2 DKFZp547P134 (from clone 410626BE407727 "gb:60i299771F1 NIH_MGC_2110.1 HomosapienscDNAclon 445835AW290999Hs.145534chromosome 21 open reading10.1 frame 23 452507AI904646 "gb:OV-BT065-020399-103 10.1 BT065 Homo Sapiens cDNA, m 433297AV658581Hs.282633ESTs 10.1 426724AA383623Hs.293616ESTs 10.0 436659AI217900Hs.144464ESTs 10.0 405675 predicted exon 10.0 S 413466BE141737Hs.254105"enolase 1, (alpha)" 10.0 447198D61523Hs.283435ESTs 10.0 403306NM Hs.74368"transmembrane protein 10.0 006825 (63kD), endoplasmic reticulumlGo 413544BE147225 "gb:PM2-HT0225-031299-003-f119.9 HT0225 Homo Sapiens 437094AW103746Hs.136907ESTs 9.9 401497 predicted exon 9.9 416203H27794Hs.269055ESTs 9.9 426882AA393108Hs.97365ESTs 9.9 454874AW836407 "gb:PM3-LT0031-301299-002-b099.9 LT0031 Homo Sapiens 406702220656Hs.278432"myosin, heavy polypeptide9.9 6, cardiac muscle, alpha (cardio 65 404952 predicted exon 9.9 430691C14187Hs.103538ESTs 9.9 444518A1160278Hs.146884ESTs 9.8 416665H72974 gb:yu28a10.s1 Soaresfetal9.8 liver spleen iNFLS Homosapie 438691AA906288Hs.212184ESTs 9.8 405636 predicted exon 9.8 437242AA747538Hs.187942ESTs 9.8 425627AF019612Hs.297007ESTs 9.8 452226AA024898Hs.296002ESTs 9.8 418986A1i23555Hs.81796ESTs 9.8 75 441139AW449009Hs.126647ESTs 9.7 427244AA402400Hs.178045ESTs 9.7 423756AA828125 "gb:od71a09.s1 NCI CGAP-Ov2HomosapienscDNAclo9.7 457940AL360159Hs.30445Homo Sapiens mRNA full 9.6 length insert cDNA clone EURO

443526AW792804Hs.134002ESTs~ 9.6 440576AW449775Hs.126008ESTs 9.6 419088AI538323Hs.77496small nuclear ribonucleoprotein9.6 polypepflde G

454707AW814989 "gb:MR1-ST0206-170400-024-g059.6 ST020fi Homo Sapiens 446252A1283125Hs.150009ESTs 9.6 434374AA631439 "gb:np86d02.s1 NCI-CGAP 9.6 Thy1 Homo Sapiens cDNA
c7 403093 predicted exon 9.6 454633AW811380 "gbaL3-ST0143-290999-019-D059.6 ST0143 Homo Sapiens c 407291AA001464 gb:ze45b01.r1 Soares 9.5 refina N2b4HR Homo Sapiens cDNA

455203AW865450 'gb:PM4-SN0020-010400-00&b099.5 SN0020 Homo sapiens 403647 predicted exon 9.5 401530 predicted exon 9.5 414281BE269751Hs.288995hypothefical protein 9.5 411057AW815098 'gb:OV4-ST0212-091199-023-f109.5 ST0212 Homo sapiens c 415953H14425Hs.27947ESTs 9.5 1 450174T82121Hs.177285ESTs 9.5 422949AA319435 "gb:EST21657 Adrenal 9.5 gland tumor Nomo Sapiens cONA 5 402112856624Hs.2186eukaryotic translation 9.5 elongation factor 1 gamma 457886AA742279Hs.293346ESTs 9.4 458145At239457Hs.130794ESTs ~ 9.4 15 452332AW014859Hs.101657ESTs 9.4 ~

434950AW974892 "gb:EST386997 MAGE resequences,9.3 MAGN Homo sapien 409601AF237621Hs.80828keratin 1 (epidermolytic9.3 hyperkeratosis) 419968X04430Hs.93913'iniedeukin 6 (interferon,9.3 beta 2)"

436211AIf001581Hs.80961"polymerase (DNA directed),9.3 gamma' 2,0428412AA4282d0Hs.126083ESTs 9.3 449441AI656040Hs.196532ESTs 9.3 458771AW295151Hs.163612ESTs 9.3 458543AA213403Hs.257542ESTs 9.3 414257A1828600Hs.21124"ESTs, Weakly similar 9.3 to ALUS_HUMAN ALU SUBFAM

442826A1018777Hs.131241ESTs ' 9.3 446740A1611635Hs.192605ESTs ' 9.2 408938AA059013Hs.22607ESTs 9.2 434157A1538316Hs.158451ESTs 9.2 408774AW270899Hs.254569ESTs 9.2 424268AA397653Hs.144339Human DNA sequence from9.2 clone 495010 on chromosome 415715F30364 "gb:HSPD20786 HM3 Homo 9.1 Sapiens cDNA clone s400009 405277 predicted exan 9.1 412167AW897230 "gb;CMO-NN0057-150400-335-al9.1 l NN0057 Homo Sapiens 442771AWd09808Hs.101550ESTs 9.1 35 404898 predictedexon 9.1 401230 predicted exon 9.1 400623 predicted exan 9.1 418808AI821836Hs.10359ESTs 9.1 436396AI683487Hs.299112'Homo Sapiens cDNA FLJ 9.1 11441 fis, clone HEMBA100132 40 440466AA885871Hs.i35727ESTs 9.0 437568A1954795Hs.156135ESTs 9.0 405382 predicted exon 9.0 435673AF202961Hs.284200"Homo Sapiens uncharacterized9.0 gastric protein ZG12P
mRN

405848 predicted exon 9.0 45 437229AW976005 'gb:EST388114 MAGE resequences,9.0 MAGN Homo sapien 417728AW138437Hs.24790ICIAA1573 protein 9.0 454597AW809648 ~gb:MR4-5T0124-261099-015-d0i9.0 ST0124 Homo Sapiens 427093AA398118Hs.97579ESTs 9.0 408000L11690Hs.620bullous pemphigoid antigen9.0 1 (2301240kD) 50 440556AW206958Hs.125968ESTs 9.0 predicted exon .9 420120AL049610Hs.95243transcripfion elongation8.9 factorA (SII)-like 417549AA203651 gb:zx58fi0.r1 Soares 8.9 fetal liver-spleen_1NFLS
S1 Homo 406163 predicted exon 8.9 55 437918AI761449Hs.121629ESTs 8.9 449419834910Hs.119172ESTs 8.9 434683AW298724Hs.202639ESTs 8.9 418432M14156Hs.85112insulin-like growth 8.9 factor 1 (somatomedia C) 454590AW809762Hs.222056"Homo Sapiens cDNA FLJ115728.8 fis, clone HEMBA100337 60 454574AW809109 ~gb:MR4-ST0117-070100-027-a048.8 ST0117 Homo Sapiens c 441433AA933809Hs.42746ESTs 8.8 416858AW979294Hs.85634ESTs 8.8 421978AJ243662Hs.110196NICE-1 protein 8.8 451528AA018297Hs.35493ESTs 8.8 408751N91553Hs.258343ESTs 8.7 401862 predicted exon 8.7 417344AW997313 "gb:RC2-BN0048-250400-018-f128.7 BN0048 Homo sapiens 454455AW752710 'gb:IL3-CT0219-281099-024-A038.7 CT0219 Homo Sapiens c 455592BE008002 "gb:QVO-BN0147-290400-214-h048.7 BN0147 Homo Sapiens 70 417650T05870Hs.100640ESTs 8.7 456309AA225A23 ~gb:nc24a12.r1 NCI_CGAP_Prt8.7 Homo Sapiens cDNA clon 432030AI908400Hs.143789ESTs 8.7 421492BE176990Hs.104916hypothetical protein 8.7 402576 predicted exon 8.7 75 426874N67325Hs.247132ESTs 8.7 403334 predicted exon 8.7 408562AI436323Hs.31141"Homo sapiens mRNA for 8.7 IfIAA1568 protein, partial cds"

439443AF086261Hs.127892ESTs 8.7 428600AW863261Hs.15036"ESTs, Highly similar 8.7 to AFi613581 HSPC095 [H.sapiens 414539BE379046 'gb:601236646F1 NIH_MGC-448.6 Homo Sapiens cDNA clon 432527AW975028Hs.102754ESTs 8.6 403273 predicted exon 8.6 452077BE144949 "gb:RC2-HT0187-041099-011-4128.6 HT0187 Homo Sapiens 444598A1288830Hs.149924ESTs 8.6 434066AF116649Hs.283944"Homo Sapiens PR00566 8.6 mRNA, complete cds"

429643AA455889Hs.187548ESTs 8.6 432340AA534222 gb:nj21d02.s1 NCI-CGAP-AA18.6 Homo Sapiens cDNA clon 446142AI754693Hs.145968ESTs 8.6 417412X16896Hs.82112'intedeukin 1 receptor, 8.6 type I"

416913AW934714 "gb:RC1-DT0001-031299-011-all8.5 DT0001 Homo Sapiens 451318AA029888Hs.95071ESTs 8.5 405547 predicted exon 8.5 423843AA332652 'gb:EST36627 Embryo, 8.5 8 week I Homo Sapiens cDNA 5' en 1 454145AA046872Hs.62798ESTs 8.4 ~

401200 predicted exon 8.4 404166 predicted exon 8.4 412761AW995092 "gb:OVO-BN0041-030300-145-a108.4 BN0041 Homo Sapiens 412333AW937485 'gb:OV3-DT0044-221299-045b098.4 DT0044 Homo Sapiens 15 455092BE152428 "gb:CMO-HT0323-151299-126-b048.4 HT0323 Homo Sapiens 419281N96452Hs.42189ESTs 8.4 446171A1374927 gbaa66c04.x1 Scares total-fetus8.3 Nb2HF8_9w Homo sapie 437362AL359561Hs.i6493,hypotheficalprotein DKFZp762N23168.3 402631 predicted exon 8.3 458573AV653838Hs.295131ESTs 8.3 439185AF087976Hs.233343ESTs 8.3 445881A1263029Hs.210689ESTs 8.3 449737A1668581Hs.246316ESTs 8.3 401830AJ004832Hs.5038neuropathytargetesterase8.3 25 421991NN[_014918Hs.110488KIAA0990 protein 8.3 416996W91892Hs.59609ESTs ' 8.2 443626A1540644Hs.138479"ESTs, Moderately similar8.2 to ALU7_HUMAN ALU SURF

407471D55644 gb:Human spleen PABL 8.2 (pseudoautosomal boundary-like se 402664 predicted exon 8.2 417682W69561 gb:zd47a08.r1 Soares-fetal_heart_NbHHI9W8.2 Homo sapien 424983A1742434Hs.169911ESTs 8.2 434353AA630863Hs.131375"ESTs, Weakly similar 8.2 to ALUB-HUMAN !!!! ALU
CLAS

453448AL036710Hs.209527ESTs 8.2 455121BE156459 "gb:QVO-HT0368-040100-082-f068.2 HT0368 Homo Sapiens 35 404270 predicted exon 8.1 438297AW515196Hs.258238"ESTs, Moderately similar8.1 to ALU1 HUMAN ALU SUBF

418122842778Hs.22217ESTs 8.1 419929U90268Hs.93810cerebral cavernous malformations8.1 400925 predicted exon 8.1 40 403350 predicted exan 8.1 426116AA868729Hs.144694ESTs 8.1 441518AW161697Hs.294150ESTs 8.1 421888AA299780Hs.121036ESTs 8.1 402745 predicted exon 8.1 45 402071 prodicted exon 8.1 444781NM Hs.11950GPI-anchored metastasis-associated8.0 014400 protein homolog 430372AI206173Hs.211375ESTs 8.0 449867A1672379Hs.73919"clathrin, light polypepfide8.0 (Lcb)"

422174AL049325Hs.112493Nomo Sapiens mRNA; cDNA 8.0 DKFZp564D036 (from clone 413382BE090689 "gb:RCt-BT0720-280300-011-f088.0 BT0720 Homo Sapiens c 456502A1798611Hs.157277ESTs 8,0 405336 predicted exon 8.0 405917 predicted exon 8.0 436007AI247716Hs.232168ESTs 8.0 S 439192AW970536Hs.105413ESTs 8.0 437724AW444828Hs.184323ESTs 8.0 452755AW138937Hs.213436ESTs 8.0 401781 predicted exon 7.9 406057 prodicted exon 7.9 406289AW068311Hs.82582"integrin, beta-like 7.9 1 (with EGF-like repeat domains)"

421459AI821539Hs.97249ESTs 7.9 4482518E280486Hs.84045"Homo Sapiens cDNA FLJi 7.9 1979 fis, clone HEM88100128 429125AA446854Hs.271004ESTs 7.9 440154BE077129Hs.126119"Homo Sapiens cDNA FLJ132737.9 fis, clone OVARC100i01 65 413233AW578713Hs.47534"ESTs, Weakly similar 7.9 to ORF YKL201c [S.cerevisiae]"

438268AA782163Hs.293502ESTs 7.9 452466N84635Hs.29664Human DNA sequence from 7.9 clone 682J15 on chromosome 441194BE274581 "gb:601120870F1 NIH_MGC 7.9 20 Homo sapiens cDNA
clon 425292NM-005624Hs.15554537 kDa leucine-dch repeat7.9 (L88) protein 445090AW205208Hs.147293ESTs 7.9 431292AA370141Hs.251453Human DNA sequence from 7.9 clone 967N21 on chromosome 414266BE267834 "gb:601124428F1 NIH_MGC_87.8 Homo Sapiens cDNA clone 407839AA045144Hs.161566ESTs 7.8 456101AA159478 gb:zo74dO6.s1 Stralagene7.8 pancreas (937208) Homo Sapiens 75 455853BE147225 'gb:PM2-HT0225-031299-003-f117.8 HT0225 Homo sapiens 414995C18200 gb:C18200 Human placenta7.8 cDNA (TFujiwara) Homo sapie 447247AW369351Hs.287955"Homo Sapiens cDNA FLJ130907.8 fis, clone NT2RP3002142 416151T26661 "gb:A865C7R Infant brain,7.8 LLNL array of Dr. M.
Soares 1 446435AW206737Hs.253582ESTs 7.8 403698 prodicted exon 7.8 424914AA348410Hs.119065ESTs 7.8 409731AA125985Hs.56145'thymosin, beta, idenfified7.8 in neuroblastoma cells' 401604 predicted exon 7.8 413025AA805265Hs.291646ESTs 7.8 405896 predicted exon 7.8 454505AW801365 "gb:IL5-UM0067-240300-050-a017.7 UM0067 Homo Sapiens 448283AI340462Hs.182979ritwsomal protein L12 7.7 434098AA625499 'gb:af69g08.r1 Soares_NhHMPu_Si7.7 Homo Sapiens cDNA

431673AW971302Hs.293233ESTs 7.7 421029AW057782Hs.293053ESTs 7.7 408391AW859276 'gb:MR1-CT0352-240200-105-d027.7 CT0352 Homo Sapiens 422529AW015128Hs.256703ESTs 7.7 454389AW752571 "gb:IL3-CT0213-170100-055-F027.7 CT0213 Homo Sapiens c 1 427821AA470158Hs.98202ESTs 7.7 ~

434657AA641876Hs.191840ESTs 7.7 445628A13d4166Hs.155743ESTs 7.7 424872AA347923 "gb:EST54302 Fetal heart7.7 II Homo sapiens cDNA
5' end, m 439232Nd8590Hs.46693ESTs 7.7 1 441417AI733297Hs.144474ESTs 7.7 453596AA441838Hs.62905ESTs 7.7 430440X52599Hs.2561'nerve growth factor, 7.7 beta polypepGde"

413306AW303544Hs.118654ESTs 7.7 400968 predicted exon 7.7 446726AW300144Hs.209209'Homo Sapiens cDNA FLJ116297.7 fis, clone HEMBA100424 427504AA776743Hs.191589ESTs 7.7 405621 predicted exon 7.6 414127AI431863Hs.135270ESTs 7.6 409866AW502152 gb:Ul-HF-BROp-ajr-f 11-0-ULr17.6 NIN-MGC 52 Homo sap 446232AI281848Hs.165547ESTs 7.6 403568 predicted exon 7.6 451458A1797558Hs.270820ESTs 7.6 439157AA912737Hs.20160ESTs 7.6 401793 predicted exon 7.6 429839AI190291Hs.112143ESTs 7.6 445672A1907438Hs.282862ESTs 7.6 449444AW818436Hs.23590"salute carrier family 7.6 16 (monocarboxylic acid transporters) 447499AW262580Hs.147674KIAA1621 protein 7.6 421773W69233Hs.112457ESTs 7.6 3 439706AW872527Hs.59761ESTs 7.5 432189AA527941 "gb:nh30c04.s1 NCI-CGAP-Pr37.5 Homo Sapiens cDNA clon 402050 predicted exon 7.5 429687AI675749Hs.211608nucleoporin 153kD 7.5 423193807299Hs.254837"Homo Sapiens cDNA FLJ135027.5 fis, clone PLACE1004836 40 416548H62953 gb:yr47f06.r1 Soares 7.5 fetal liver spleen iNFLS
Homo sapien 443236A1079496Hs.134169ESTs 7.5 436053A1057224Hs.15443ESTs 7.4 437191NM-006846Hs.5476"swine protease inhibitor,7.4 Kazal type, 5"

451829AW964081Hs.247377ESTs 7.4 45 443151AI827193Hs.132714ESTs 7.4 452055A1377431Hs.293772ESTs 7.4 445265A1218295Hs.144942ESTs 7.d 401032 predicted exon 7.4 448184BE541249Hs.109697ESTs 7.4 J~~414808795945 gb:ye42e02.r1SoaresfetalliverspleeniNFLSHomosapien7.4 418540AI821597Hs.90877"ESTs, Weakly similar 7.4 to ALU1 HUMAN ALU SUBFAM

410449AW748954Hs.18192SerIArg-related nuclear 7.4 matrix protein (plenty of prolines 1 435568AA688048Hs.294080ESTs 7.4 459160A1904723 'gb:CM-BTO66-120299-092 7.4 BTO66 Homo sapiens cDNA, J~ 419753N42531 gb:yy11c12.r1 Soares 7.4 5 melanocyte 2NbHM Homo Sapiens cD

432383AK000144Hs.274449"Homo Sapiens cDNA FW201377.4 fis, clone COL07137"

404893 predicted exon 7.4' 425349AA425234Hs.79886ribose 5-phosphate isomerase7.4 A (ribose 5-phosphate epimer 413864BE175582 "gb:RC5-HT0580-100500-022-C017.3 HT0580 Homo Sapiens 426871AA393041Hs.216493ESTs 7.3 415613820233 gb:yg18h11.r1 Soares 7.3 infant brain 1N18 Homo Sapiens cDN

427025AA397589Hs.97523ESTs 7.3 444683A1375101Hs.158721"ESTs, Weakly similar 7.3 to ALU1 HUMAN ALU SUBFAM

447700AI420183Hs.171077"ESTs, Weakly similar 7.3 to similar to sednelthreonine kinase 412740AW993984 "gb:RC1-BN0035-130400-013-a057.3 8N0035 Homo Sapiens 416642796118Hs.226313"ESTs, Weakly similar 7.3 to ALU1 FIUMAN ALU SUBFAM

416506H59879Hs.237306ESTs 7.3 426130AA853282 gb:NHTBCae04f07r1 Normal7.3 Human Trabecular Bone Cell 407392A8032369 "gb:Homo Sapiens MIST 7.3 mRNA, partial cds."

432365AK001106Hs.274419hypothetical protein 7.3 451221A1949701Hs.210589ESTs 7.3 443161A1038316 gb:ox48c08.x1 Soares 7.3 total fetus Nb2HF8 9w Homo sapi 418186BE541042Hs.23240"Homo Sapiens cDNA FLJ134967.3 fis, clone PLACE1004471 439152H65014 gb:yu66f10.r1 Weizmann 7.2 Olfactory Epithelium Homo sapie 75 459534BE386808Hs.147905ESTs 7.2 443326BE156494Hs.188478ESTs 7.2 417351790278Hs.15049ESTs 7.2 454182AW177335 "gb:CMi-CT0129-180899-006-b087.2 CT0129 Homo Sapiens 402298 predicted exon 7.2 458562N34128Hs.145268ESTs 7.2 407021052077 "gb:Human madnerl Uansposase7.2 gene,complete consensus 449276AW241510Hs.252713ESTs 7.2 418251AA832123Hs.177723ESTs 7.2 420788AA937957Hs.193367ESTs 7.2 401881 ~ predicted exon 7.2 456436AA251079Hs.158386ESTs 7.2 413425F20956 "gb:HSPD05390 HM3 Homo 7.2 Sapiens cDNA clone 448966AW372914Hs.287462"Homo Sapiens cDNA FLJ118757.2 fis, clone HEMBA100707 429340N35938Hs.199429Homo sapiens mRNA; cDNA7.2 DKFZp434M2216 (from clon 406053 predicted exon 7.2 405851 predicted exon 7.2 431009BE149762Hs.248213"gap juncfion protein, 7.2 beta 6 (connexin 30)"

426662AA879474Hs.122710ESTs 7.2 1~ 408536AW38i532Hs.135188ESTs 7.1.

455013BE073250 "gb:MRO-BT0551-060300-102-e057.1 BT0551 Homo Sapiens 428910W03667Hs.193792ESTs 7.1 424634NM Hs.151407"cartilage intermediate7.1 003613 layer protein, nucleotide pyrophosph 449794AW444502Hs.256982"ESTs, Highly similar 7.1 to AF1168651 hedgehog-interacting I 423410AF058989Hs.128231"G antigen, family B,1 7.1 S (prostate associated)"

445460AI797473Hs.209468ESTs 7.1 447285A1371849Hs.200696"ATPase, Class Vl,iype 7.1 11C"

419750AL079741Hs.183114"Homo Sapiens cDNA FLJ142367.1 fis, clone NT2RP4000515 438986AF085888Hs.269307ESTs 7.1 420757X78592Hs.99915androgen receptor (dihydrotestosterone7.1 receptor, testicular 432479AL042844Hs.275675katanin p80 (WD40-containing)7.1 subunit B 1 449733874546Hs.29438"Homo Sapiens cDNA FLJ120947.1 fis, clone HEMB8100260 437846AA773866Hs.244569ESTs 7.1 454934AW846080 "gb:MR3-CT0176-081099-D02-b097.1 CT0176 Homo Sapiens 421929AA300543Hs.247360ESTs 7.1 401780 predicted exon 7.0 448106AI800470Hs.171941ESTs 7.0 448835BE277929Hs.11081"ESTs, Weakly similar 7.0 to S57447 HPBRII-7 protein [H.sap 400842 predicted exon 7.0 3 429364AA451797Hs.201202"ESTs, Moderately similar7.0 ~ to Pro-Pol-dUTPase polyprotein 454963AW847647 "gb:IL3-CT0213-280100-056-A067.0 CT0213 Homo sapiens c 423891AK002042Hs.134795"Homo Sapiens cDNA FLJ111807.0 fis, clone PLACE1007452 407506071600 "gb:Human zinc finger 7.0 protein zfp31 (zf31) mRNA, partial 413802AW964490Hs.32241ESTs 7.0 35 440051BE559980 "gb:601345293F1 NIH_MGC-87.0 Homo Sapiens cDNA clone 446283AI948801Hs.171073ESTs 7.0 419236AA330447Hs.135159"Homo Sapiens cDNA FLJ114817.0 fis, clone HEMBA100180 405472 predicted exan 7.0 435024AI863518Hs.127743"ESTs, Weakly similar 7.0 to V-ATPase G-subunit like protein ~

453969AW090783Hs.301731"Homo Sapiens cDNA FLJ117387.0 fis, clone HEMBA100547 404992 predicted exon 7.0 428129AI244311Hs.26912ESTs 7.0 414315224878 "gb:HSB65D052 STRATAGENE7.0 Human skeletal muscle cD

400491H25530Hs.50868"solute carrier family 6.9 22 (organic ca6on fransporter), memb 45 459275AI808913Hs.118321ESTs 6.9 450853AA479629Hs.44243ESTs 6.9 457460A1143312Hs.164004ESTs 6.9 434168AI204525Hs.i ESTs 6.9 445153AI214671 "gb:qm32d02.x1 NCI_CGAP-Lu56.9 Homo Sapiens cDNA clo 450028AI912012Hs.200737ESTs 6.9 414954D81402 gb:HUM162A03B Human 6.9 fetal brain (TFujiwara) Homo sa 459478AW195566Hs.253182ESTs 6.9 426269H153D2Hs.168950Homo Sapiens mRNA; cDNA6.9 DKFZp566A1D4fi (from clon 401050 predicted exon 6.9 447588AI394154Hs.279659"ESTs, Weakly similar 6.9 S to unknown protein [H.sapiensJ"

449002AI620018Hs.117461ESTs 6.9 452759AW590773Hs.258996ESTs 6.9 443220885304Hs.132032"Homo Sapiens cDNA FLJ116836.9 fis, clone HEMBA100490 400749 predicted exon 6.8 406277 predicted exan 6.8 433785BE044593Hs.112704ESTs 6.8 434129A1807757Hs.221041ESTs 6.8 453369BE551550Hs.232630ESTs 6.8 411722AW875942 "gb:CM1-PT0013-131299-067-b106.8 PT0013 Homo sapiens 65 .455152AW858621 "gb:CMO-CT0342-021299-115-f046.8 CT0342 Homo Sapiens 412670AA115456 gb:zk89b05.r1 Soares~regnant_uterus6.8 NbHPU Homo sapi 419054N40340Hs.191510"ESTs, Weakly similar 6.8 to ORF2 [M.muscutusJ"

421316AA287203Hs.251397SMA5 6.8 432363AA534489 gb:nf76g11.s1 NCI_CGAP_Co36.8 Homo Sapiens cDNA clone 458603AW103046Hs.6162KIAA0771 protein 6.8 439527AW298119Hs.202536ESTs 6.8 408920AL120071Hs.48998fibronecfin leucine 6.8 rich fransmembrane protein 2 439127AW978465Hs.292368ESTs 6.8 434890AF161345Hs.283930"Homo sapiens HSPC082 6.8 mRNA, parfial cds"

75 429413NM_014058Hs.201877DESC1 protein 6.7 407788BE514982Hs.38991S100 calcium-binding 6.7 protein A2 447252890916 gb:ynOte10.r1 Soares 6.7 adult brain N2b4HB55Y
Homo sapien 455851BE146879 "gb:OV4-HT0222-261099-014-c116.7 HT0222 Homo Sapiens 439509AF086332Hs.58314ESTs 6.7 418858AW961605Hs.21145"Homo Sapiens cDNA: 6.7 FLJ22489 fis, clone HRC10951"

419323A1092379Hs.135275ESTs 6.7 415317243388Hs.5570hypothetical protein 6.7 418654AA226334Hs.154291ESTs 6.7 407413AF067801 'gb:Homo sapiens HDCGC21P6.7 mRNA, complete cds."

439694AA843915Hs.54707ESTs 6.7 451191N67900Hs.118446ESTs 6.7 454006U12775Hs.37006agouti (mouse)-signaling6.7 protein 443657814973 gb:yf42f10.s1 Soares 6.7 fetal liver spleen 1NFLS
Homo sapien 455879BE153275 "gb:PMO-HT0335-180400-008-ei6.7 t HT0335 Homo Sapiens 451368BE242152Hs.288417protein serine ihreonine6.7 kinase CIk4 453509AL040021 gb:DKFZp434N1812-r1434 6.7 (synonym: htes3) Homo sapie 420892AW975076Hs.172589nuclear phosphoprotein 6.7 similar to 5. cerevisiae 423372AI246375Hs.154458ESTs 6.7 1 450316W84446Hs.17850ESTs 6.7 ~

447795AW295151Hs.163612ESTs 6.7 413252BE074910 "gb:RC5-BT0580-170300-021-F126.7 BT0580 Homo Sapiens 405771 predicted exon 6.6 411483AW848115 "gb:IL3-CT0214-301299-048-C096.6 CT021d Homo Sapiens c 15 420271AI954365Hs.42892ESTs 6.6 431948AA917706Hs.194616ESTs 6.6 409629AW449589Hs.279724ESTs 6.6 458841W28965 gb:5dd10 Human retina 6.6 cDNA randomly primed sublibrary 416565AW000960Hs.44970ESTs 6.6 2~ 409097AA677927Hs.1d4269ESTs 6.6 441832A1018249Hs.128062ESTs 6.6 457285A1038858Hs.228780"ESTs, Highly similar 6.6 to AF1995971 A-type potassium cha 406504 predicted exon 6.6 414606BE387771 "gb:601283251 Fi NIH_MGC-446.6 Homo Sapiens cDNA clon 452956AW003578Hs.231872ESTs 6.6 410743AA089d74Hs.272153ESTs ' 6.6 404599 predicted exon 6.6 423575C18863Hs.163443"Homo sapiens cDNA FLJ115766.6 fis, clone HEMBA100354 443027A1027847Hs.253550ESTs 6.6 30 458663AV658d44Hs.280776"Homo Sapiens cDNA FLJ136846.6 fis, clone PLACE2000021 431277AA501806Hs.249965ESTs 6.6 445232BE294357 "gb:601172878F1 N1H_MGC-176.6 Homo Sapiens cDNA clon 459170AI905518 "gb:RGBT091-210199-098 6.6 BT091 Homo Sapiens cDNA, m 437876AA770151Hs.126424ESTs fi,6 35 406752A1285598Hs.217493annexinA2 6.6 401245 predicted exon 6.6 446102AW768067Hs.252956ESTs 6.5 446989AK001898Hs.16740hypothetical protein 6.5 421160AL080215Hs.102301Homo Sapiens mRNA; cDNA 6.5 DKFZp586J0323 (from clone 4~ 458831H71739Hs.200227ESTs 6.5 408914AW450309 gb:Ul-H-B13-akz-g-08-0-ULs16.5 NCI-CGAP-Subs Homo sa 411018AW813428 "gb:MR3-ST0192-010200-210-c056.5 ST0192 Homo sapiens c 436562H71937Hs.169756"complement component 6.5 1, s subcomponent"

457620AA602711 "gb:np03h06.s1 NCI_CGAP_Pr26.5 Homo Sapiens cDNA clon 45 438647AA813118Hs.163230ESTs 6.5 439570T79925Hs.269165ESTs 6.5 419273BE271180Hs.293490ESTs 6.5 443745A8039610Hs.9728ALEX1 protein 6.5 431029BE392725Hs.248571Homo Sapiens PAC clone 6.5 RP5-1163J12 from 7q21.2-q31.1 458695AV660159Hs.282284ESTs 6.5 410966AW812088 "gb:RC4-ST0173-191099-032-a076.4 ST0173 Homo Sapiens c 417135AA422067Hs.50547ESTs 6.4 416441BE407197 "gb:601301552F1 NIH_MGC-216.4 Homo Sapiens cDNA clon 413702BE170313 "gb:QV4-HT0536-040500-193-g026.4 HT0536 Homo Sapiens 55 452563AI907552 "gb:RGBT147-120499-044 6.4 BT147 Homo Sapiens cDNA, m 408956AK001868Hs.295306"ESTs, Highly similar 6.4 to unnamed protein product [H.sapien 406349 predicted exon 6.4 425420BE536911Hs.234545"ESTs, Weakly similar 6.4 to AF1551351 novel retinal pigmen 459430AW662886 gb:hi82h11.x1 Soares 6.4 NFLLT_GBC-S1 Homo Sapiens cDN

425733F13287Hs.159388Homo Sapiens clone 235786.4 mRNA sequence 458678AI306162Hs.170938"ESTs, Weakly similar 6.4 to KIAA0705 protein [H.sapiens]"

429695AA835714Hs.293556ESTs 6.4 426872AA410446Hs.112011"ESTs, Weakly similar 6.4 to unknown [H.sapiens]"

437152AL050027 gb:Homo Sapiens mRNA; 6.4 cDNA DKFZp566C0324 (from c 65 440517AW139632Hs.132246ESTs 6.4 450877A1799608Hs.29178ESTs 6.4 410664NM_006033Hs.65370"lipase, endothelial" 6.4 405793 predicted exan 6.4 418709AA227394 gb:zr17c10.r1 Stratagene6.4 NT2 neuronal precursor 428684AA431792Hs.44784ESTs 6.4 448516AW898595 "gb:RCi-NN0073-260400-011-g096.4 NN0073 Homo Sapiens 400983 predicted exon 6.3 422365AF035537Hs.115521"REV3 (yeast homology-like,6.3 catalytic subunit of DNA poly 425612BE004257 "gb:CMO-BN0103-180300-296-c046.3 BN0103 Homo Sapiens 75 401521 predicted exon 6.3 430290AI734110Hs.136355ESTs 6.3 414931AK000342Hs.77646Homo Sapiens mRNA; cDNA 6.3 DKFZp761 M0223 (from clon 437939AW298600Hs.141840"ESTs, Weakly similar 6.3 to S59501 interferon receptor JFNA

451842AI820539Hs.267087"ESTs, Moderately similar6.3 to ALU4_HUMAN ALU SURF

g0 405810 predicted exan 6.3 443747AV646352 "gb:AV646352 GLC Homc 6.3 Sapiens cDNA clone GLCAME

427287NM Hs.174188KIAA0938 protein 6.3 413521BE145814 "gb:MRO-HT0208-101299-202-a046.3 HT0208 Homosapiens 429090AW820278Hs.99066ESTs 6.3 451488H22999Hs.208846ESTs 6.3 455713BE069891 "gb:QV4-BT0401-201299-064-b016.3 BT0401 Homo Sapiens 452161843077Hs.221747ESTs 6.3 428647AA830050Hs.124344ESTs 6.3 445063A1246275Hs.149196ESTs 6.3 456671ABOi1i42Hs.114293KIAA0570 gene product 6.3 401508 predicted exon 6.3 412677AW029608Hs.17384ESTs 6.3 441720AI346487Hs.28739ESTs 6.3 1 418051AW192535Hs.19479ESTs 6.3 438014N71183Hs.121806"Homo Sapiens cDNA FLJ119716.3 fis, clone HEMBB100120 432101A1918950Hs.11092"Homo Sapiens cDNA FLJ142906.3 fis, clone PLACE1006795 421032AW293133Hs.101340ESTs 6.3 436532AA721522 "gb:nv54h12.r1 NCI_CGAP-Ew16.3 Homo sapiens cDNA clo 1 431318AA502700Hs.293147ESTs 6.3 413470N20934 gb:yx54c1 1.s1 Soares 6.3 metanocyte 2NbHM Homo Sapiens c 402425 predicted exon 6.3 455993BE179085 "gb:RCO-HT0613-140300-021-4066.3 HT0613 Homo Sapiens 400160 predicted exon 6.3 20 413795AL040178Hs.142003ESTs 6.2 405071 predicted exon 6.2 403741 predicted exon 6.2 432489AI804855Hs.207530ESTs 6.2 402296 predicted exan 6.2 446091AW022192Hs.200197ESTs 6.2 444788A1871122Hs.202821ESTs ' 6.2 404972 predicted exan 6.2 400227 predicted exon 8.2 433804AI936561Hs.112740ESTs 6.2 448807A1571940Hs.7549ESTs 6.2 404340 predicted exon 6.2 424632AB014523Hs.151406KIAA0623 gene product 6.2 449547H93543Hs.117963ESTs 6.2 406945KOi383Hs.203967metallothioneinlA(iunctional)6.2 3 433663AF083131Hs.229535CATX-15 protein 6.2 407809AW082279Hs.244106ESTs 6.2 418342BE002723Hs.293504"ESTs, Moderately similar6.2 to ALU1 HUMAN ALU SURF

438007AA133008Hs.158675ribosomal protein L14 6.2 410536N39533 gb:yv27d04.s1 Soares 6.2 fetal liver spleen 1 NFLS Homo sapie 448005AW207437Hs.170378ESTs . 6.2 414083AL121282Hs.257786ESTs 6.2 405362 predicted exon 6.2 410102AW248508Hs.279727"Homo Sapiens cDNA FLJ140356.2 fis, clone HEMBA100463 457868AW975133 "gb:EST387239 MAGE resequences,6.2 MAGN Homo sapien 45 407395AF005082 "gb:Homo sapiens skin-specific6.2 protein (xp33) mRNA, part 443603BE502601Hs.134289"ESTs, Weakly similar 6.2 to KIAA1063 protein (H.sapiens]"

430051AA464611Hs.52515transducin (beta)-like 6.1 434569AI311295Hs.58609ESTs 6.1 430481AA479678Hs.203269"ESTs, Moderately similar6.1 to ALUB_HUMAN ALU SUBF

402859 predicted exon 6.1 401260 predicted exon 6.1 406544 predicted exon 6.1 428446A1024600Hs.98612ESTs 6.1 .

412246A1160873Hs.69233"ESTs, Weakly similar 6.1 to KIAA1064 protein [H.sapiens]"

55 400420AJ277247Hs.287369intedeukin 22 6.1 455662BE065387 "gb:RC1-BT0314-030500-016-4036.1 BT0314 Homo Sapiens 428613AB037749Hs.186928KIAA1328 protein 6.1 443267AW450630Hs.133851ESTs 6.1 433405AW157566Hs.156892ESTs 6.1 416795AI497778Hs.168053"ESTs, Highly similar 6.1 to AF2279481 HBV pX
associated p 435706W31254Hs.7045GL004 protein 6.1 450769AA057418Hs.33654ESTs 6.1 427174AA398848Hs.97541ESTs 6.1 425389AW974499Hs.192183ESTs 6.1 65 416675H73802Hs.35381ESTs 6.1 432749NM-014438Hs.278909lntedeukin-1 Superfamilye6.1 401809 predicted exon 6.1 403041 predicted exon 6.0 408523AW833259 "gb:RC2-TT0007-131099-011-c016.0 TT0007 Homo sapiens c 70 416515N91716Hs.194140ESTs 6.0 452591BE173164Hs.1516insulin-like growth 6.0 factor-binding protein 437146AA730977 "gb:nw55f05.s1 NCI-CGAP_Ew16.0 Homo Sapiens cDNA clo 450094AI174947Hs.295789Homo Sapiens mRNA; cDNA6.0 DKFZp564D1164 (from clon 402529 predicted exon 6.0 75 430706NM Hs.247816"H4 histone family, 6.0 003540 member C"

459186AI908287 "gb:RGBT168-020499-035 6.0 BT168 Homo Sapiens cDNA, m 452158AI699120Hs.61198ESTs 6.0 411237AW833676 "gb:OV4-TTOOOB-181199-038-h04TT00086.0 Homosapiens 400441M15530Hs.99879B-cell growth factor 6.0 1 (l2kD) 439398AA284267Hs.221504ESTs .

6.0 440662H39048Hs.127432ESTs 6.0 415451H19415Hs.268720"ESTs, Moderately similar6.0 to ALUt HUMAN ALU SUBF

459587AA031956 gb:zk15e04.s1 Soares,~regnant-uterus-NbHPU6.0 Homo sapi 456072H54381 gb:yq89a03.s1 Soares 6.0 fetal liver spleen 1NFLS Homo sapie 409954AW512770Hs.266457ESTs 6.0 443488A1073495Hs.i "ESTs, Weakly similar 6.0 33912to methyl-CpG binding domain-coot 430825A1734186Hs.185105ESTs 6.0 454466AA984138Hs.279895"Homo Sapiens mRNA for 6.0 KIAA1578 protein, partial cds' 456506AA278277Hs.194212ESTs 6.0 449228AJ403107Hs.148590"ESTs, Weakly similar 6.0 to AF2088461 BM-004 (H.sapiens]

457727AW974687 "gb:EST386776 MAGE resequences,6.0 MAGM Homo sapien 442440BE464435Hs.146180"ESTs, Weakly similar 5.9 to non-receptor protein tyrosine kina 455110BE154505 "gb:PMO-HT0343-281299-003-e065.9 HT0343 Homo Sapiens 1 402790 predicted exon 5.9 ~

409982BE005839 "gb:RC2-BN0120-250400.012-f035.9 BN0120 Homo Sapiens 427635BE397988Hs.179982tumor protein p5&binding5.9 protein 408948AW296713Hs.221441ESTs 5.9 402046 predicted exon 5.9 1 416438889238Hs.34262ESTs 5.9 S

403083 predicted exon 5.9 402481 predicted exon 5.9 409867AW502161 gb:Ul-HF-BROp-ajr-g-12-0-ULr15.9 NIH_MGC-52 Homo sap 420362079734Hs.97206huntingtin interacting 5.9 protein 1 421375AA489200Hs.100595"ESTs, Moderately similar5.9 to ALU1 HUMAN ALU SUBF

437630AI252782Hs.153029ESTs 5.9 443500AV646388Hs.137071ESTs 5.9 448995A1613276Hs.5662"guanine nucleotide binding5.9 protein (G protein), beta polyp 438214H06076Hs.26320TRABID protein 5.9 428046AW812795Hs.155381"ESTs, Moderately similar5.9 to 138022 hypothetical protein [H

431941AK000106Ns.272227"Homo sapien's cDNA FLJ200995.9 tis, clone COL04544"

403356 predicted exon 5.9 439031AF075079 gb:Homo sapiens full 5.9 length insert cDNA YQ80A08 430032AW936136Hs.99610ESTs 5.9 423457FOB208Hs.155606paired mesoderm homeo 5.9 box 1 422158L10343Hs.112341"protease inhibitor 3, 5.9 skin-derived (SKALP)"

406592 predicted exon 5.9 418636AW749855 "gb:OV4-BT0534-281299-053-c055.8 BT0534 Homo Sapiens 429399AA452244Hs.16727ESTs 5.8 35 408590AW238162Hs.253873ESTs 5.8 422168AA586894Hs.112408S100 calcium-binding 5.8 protein A7 (psoriasin 1) 417421AL138201Hs.82120"nuclear receptor subfamily5.8 4, group A, member 2"

401129 predicted exon 5.8 434745AW974445Hs.185155"ESTs, Weakly similar 5.8 to HuEMAP [H.sapiens)"

402600 predicted exon 5.8 436185AW753380Hs.49753"Homo Sapiens mRNA for 5.8 KIAA1561 protein, partial cds"

419519AI198719Hs.176376ESTs 5.8 452542AW812256 "gb:RCO-ST0174-191099-031-a075.8 ST0174 Homo Sapiens c 427166AA431576Hs.155658ESTs 5.8 45 416168H23687 gb:yn72d12.r1 Soares 5.8 adult brain N2b5HB55Y
Homo sapie 431467N71831Hs.256398Homo Sapiens mRNA; cDNA 5.8 DKFZp434E0528 (from clon 421558AB011125Hs.105749KIAA0553 protein 5.8 458055AW979121Hs.131375"ESTs, Weakly similar 5.8 to ALUB HUMAN !!!! ALU
CLAS

418345AJ001696Hs.241407'serine (orcysteine) 5.8 proteinase inhibitor, Glade 8 (ovalbumi 426544AA492325 gb:ng81b11.siNCI-CGAP_Pr6HomosapienscDNAclone5.8 433544AI793211Hs.i65372'ESTs, Moderately similar5.8 to ALUt HUMAN ALU SUBF

442007AA301116Ns.142838"Homo Sapiens cDNA: FLJ234445.8 tis, clone HSI01343"

443422810288Hs.301529ESTs 5.8 434311BE543469Hs.266263"Homo Sapiens cDNA FLJ141155.8 tis, clone MAMMA10017 55 424966AU077312Hs.153985"solute carrier family 5.8 7 (cationic amino acid transporter, y+

441744AA960922Hs.200938ESTs 5.8 413101BE065215 "gb:RCt-BT0314-310300-015-f015.7 BT0314 Homo Sapiens c 445687W80382Hs.149297ESTs 5.7 441369AA931535 gb:oo56a04.s1 NCl_CGAP_Lu55.7 Homo Sapiens cDNA clon 414428BE296906Hs.182625VAMP (vesicle-associated5.7 membrane protein)-associated pr 43.1211M86849Hs.5566"gap junction protein, 5.7 beta 2, 26kD (connexin 26)"

411541W03940 gb:za62b02.r1 Soares 5.7 fetal liver spleen 1 NFLS Homo sapien 448612AI696363Hs.171285ESTs 5.7 419118AA234223Hs.139204ESTs 5.7 65 406322 predictedexon 5.7 454690AW854639 "gb:MR1-CT0258-140100-203-4105.7 CT0258 Homo Sapiens 450313A1038989Ns.24809hypotheticalprotein FLJ108265.7 ' 416292AA179233Hs.42390nasopharyngeal carcinoma5.7 susceptibility protein 449309AW589823Hs.224189ESTs 5.7 408418AW963897Hs.44743KIAA1435 protein 5.7 416100H18700Hs.268799ESTs 5.7 437845AA769578Hs.90488ESTs 5.7 443345A1052508Hs.164482"ESTs, Weakly similar 5.7 to contains similarity to TPR domain 418407AL044818Hs.84928"nuclear Uanscription 5.7 factor Y, beta' 75 434557AW855466Hs.271866"ESTs, Weakly similar 5.7 to ALU1 HUMAN ALU SUBFAM

431688AA513906 "gb:ng67c08.s1 NCI-CGAP-Up2HomosapienscDNAclo5.7 437641AA811452Hs.291911ESTs 5.7 409319AW752736Hs.33565ESTs 5.7 403967AF030107Hs.17165regulator of G-protein 5.7 signalling 13 445189AI936450Hs.147482ESTs 5.7 414418H62943Hs.154188ESTs 5.7 446563BE326588Hs.141454ESTs 5.7 446075AWd51457Hs.279179ESTs 5.7 428068AW016437Hs.233462ESTs 5.7 438425AW292922Hs.293170ESTs 5.7 415532814780Hs.12826ESTs 5.7 441442AL043282Hs.131824ESTs 5.7 443380A1792478Hs.135377ESTs 5.7 445527W39694Hs.83286ESTs 5.7 4143768E393856Hs.669i5'ESTs, Weakly similar 5.7 to 16.7Kd protein [H.sapiens]"

457960AA771881Hs.298149ESTs 5.6 453293AA382267Hs.10653ESTs 5.6 452503AB000509Hs.29736TNF receptor-associated5.6 factor 5 1 405227 predicted exon 5.6 ~

442257AW503831 gb:Ul-HF-BNO-alb-b-05-0-Ut.r15.6 NtH MGC-50 Homo sap 403403 predicted exon 5.6 454377AA076811 gb:7B03C12 Chromosome 5.6 7 Fetal Brain cDNA
Library Hom 438656H85310Hs.209456"ESTs, Weakly similar -to NG22 [H.sapiens]" 5.6 1 419936AI792788 "gb:o191d05.y5 NCI_CGAP_KidS5.6 S Homo Sapiens cDNA clo 437267AW511443Hs.258110ESTs 5.6 430563AA481269Hs.178381ESTs 5.6 444835A1198994Hs.158479ESTs 5.6 444902AJ132099Hs.12114vanin 1 5.6 451800AW977435Hs.31890ESTs 5.6 405465 predicted exon 5.6 403891 predicted exan 5.6 425557AI694300Hs.46730ESTs 5.6 432162AA584062Hs.272798hypothetical protein 5.6 450152AI138635Hs.22968ESTs 5.6 410053AW579707Ns.59332ESTs ' 5.6 d21285NM Hs.1363"cytochrome P450, subfamily5.6 000102 XVII (steroid 17-alpha-hydro 425264AA353953Hs.20369"ESTs, Weakly similar 5.6 to gonadotropin inducible transcript 418844M62982Hs.1200arachidonate 12-lipoxygenase5.6 30 429616AI982722Hs.120845ESTs 5.6 423528AB011137Hs.129740KIAA0565 gene product 5.6 403089 predicted exon 5.6 414373AW162907Hs.75969praline-rich protein 5.6 with nuclear largeGng signal 403687 predicted exon 5.6 35 417079U65590Hs.81134interleukin 1 receptor 5.5 antagonist 432501BE546532Hs.287329Fas binding protein 5.5 403691 predicted exon 5.5 409545BE296182 "gb:601177324F1 NIN-MGC_175.5 Homo Sapiens cDNA clon 435990A1015862Hs.131793ESTs 5.5 444409A1792140Hs.49265ESTs 5.5 435478AA682622 gb:zj20f09.s1 Soares 5.5 fetal liver_spleen 1NFLS S1 Homo 439981AI348408Hs.124675"ESTs, Weakly similar 5.5 to unnamed protein product [H.sapie 433644AW342028Hs.256112ESTs 5.5 441541AA938663Hs.199828ESTs 5.5 45 400709 predicted exon 5.5 407615AW753085 'gb:PM1-CT0247-151299-005-a035.5 CT0247 Homo Sapiens 424153AA451737Hs.141496MAGE-like 2 5.5 452465AA610211Hs.342d4ESTs 5.5 406030 predicted exan 5.5 431071AA491379 'gb:aa65f05.r1 NCI_CGAP5.5 GCB1 Homo Sapiens cDNA
c1 418086AA211791Hs.269666"Homo sapiens cDNA FLJ134155.5 fis, clone PLACE1001799 453034BE246010Hs.184109ribosomal protein L37a 5.5 412953245794Hs.238809ESTs 5.5 425351A1206234Hs.155924cAMP responsive element5.5 modulator 55 406149 predictedexon 5.5 416533BE244053Hs.79362retinoblastoma-like 5.5 2 (p130) 458378A1040535Hs.150524ESTs 5.5 401213 predicted exon 5.5 405904 predicted exon 5.5 60 445132244811 gb:HSC29G031 normalized' infant brain cDNA Homo 5.5 sapie 405138 predicted exon 5.5 442238AW135374Hs.270949ESTs 5.5 416852AF283776Hs.80285Homo Sapiens mRNA; cDNA5.5 DKFZp586C1723 (from clon 448691AA481119Ns.283558hypothetical protein 5.5 65 452242850956Hs.59503"ESTs, Weakly similar 5.5 to AF1573181 AD-017 protein (H.s 456994AA383623Hs.293616ESTs 5.5 440913A1267491Hs.160593ESTs 5.5 435380AA679001Hs.192221ESTs 5.5 450375AA009647Hs.8850a disinlegrin and metalloproteinase5.5 domain 12 (meltrin alph 414035Y00630Hs.75716"serine (orcysteine) 5.4 proteinase inhibitor, Glade B (ovalbumi 459084H01699Hs.27289CGI-125 protein 5.4 405867 predicted exon 5.4 414093BE544867 "gb:601078872F1 NIH_MGC-125.4 Homo Sapiens cDNA clon 447306Ai373163Hs.170333ESTs 5.4 75 413083BE064528 'gb:RC4-BT0311-250200-014-hD65.4 BT0311 Homo sapiens 404828 predicted exon 5.4 402543 predicted exan 5.4 421988AW450481Hs.161333ESTs 5.4 413404BE503463Hs.297431ESTs 5.4 459043A1806444Hs.208113"ESTs, Weakly similar 5.4 to N-WASP [H.sapiens]' 404410 predicted exon 5.4 430264AA470519 'gb:nc71f10.s1 NCI_CGAP_Pr15.4 Homo Sapiens cDNA clon 431499NM-001514Hs.258561general transcription 5.4 factor 118 412566AW962574 'gb:EST374647 MAGE resequences,5.d MAGG Homo sapien 454239BE176420Hs.8177ESTs 5.4 458163AA884304Hs.131163ESTs 5.4 446205AW172662Hs.149479ESTs 5.4 455275AW977806 "gb:EST389810 MAGE resequences,5.4 MAGO Homo sapien 415579AA165232Hs.222069ESTs 5.4 423200AA323073Hs.289083ESTs 5.4 440052A1633744Hs.1956d8ESTs 5.4 424717H03754Hs.152213"wingless-type MMTV 5.d integration site family, member 5A"

420111AA255652 gb:zs21h11.r1 NCI CGAP 5.4 GCBt Homo Sapiens cDNA
clo 1 432140Alf000404Hs.272688hypothetical protein 5.4 ~ FLJ20397 414904AA157881Hs.143056ESTs 5.4 409479BE163800Hs.1369i2ESTs 5.4 404727 predicted exon 5.4 446011AI623778Hs.145809ESTs 5.4 15 456083046922Hs.77252fragile hislidine toad 5.4 gene 424834AVf001432Hs.153408"Homo Sapiens cDNA FLJ105705.4 fis, clone NT2RP2003117 425071NM Hs.154424"deiodinase, iodothyronine,5.4 013989 type II"

426065N32049 gb:yw96g08.s1 Soares-placenta-8to9weeks-2NbHP8to9W5.4 d15602F12920Hs.165575ESTs 5.4 432839AA579465Hs.287332ESTs 5.4 416879H98899Hs.42599ESTs 5.4 456088BE177320Hs.156148"Homo Sapiens cDNA: 5.4 FLJ23082 fis, clone LNG06451"

423175W27595Hs.18653ESTs 5.4 424585AA464840 gb:zx43h11.r1 Soares 5.3 total-fetus Nb2HF8-9w Homo sapie 452281T93500Hs.28792"Homo sapie0s cDNA FLJ110415.3 fis, clone PLACE1004405 424323AA338791 Hs.146763nascent-polypepGde-associated5.3 complex alpha polypepfide 426701AI968103Hs.209461"Homo Sapiens cDNA FLJ128365.3 fis, clone NT2RP2003206 447645AW897321Hs.159699ESTs 5.3 402974 predicted exon 5.3 436607AW661783Hs.211061ESTs 5.3 428873AI701609Hs.98908ESTs 5.3 405454 predicted exon 5.3 431867AA523660Hs.191727ESTs 5.3 442768AL048534Hs.48458"ESTs, Weakly similar 5.3 to ALUB HUMAN ALU SUBFAM

35 424085NM-002914Hs.139226replication factor C 5.3 (activator 1) 2 (40kD) 435098AF174394Hs.177461"Homo Sapiens apoptotic-related5.3 protein PCAR mRNA, par 421284062435Hs.103128"cholinergic receptor, 5.3 nicofinic, alpha polypeptide 6"

435711AF226667Hs.58553CTP synthase II 5.3 405292 predicted exon ~ 5.3 410123T16981Hs.21963ESTs 5.3 435435T89473Hs.192328ESTs 5.3 417071N58820Hs.275133ESTs 5.3 d38958H50167Hs.33113ESTs 5.3 457405AA504860 gb:ab03a10.s15tratagene5.3 fetal retina 937202 Homo Sapiens 45 413642BE154837 "gb:PMi-HT0345-121199-001-c0B5.3 HT0345 Homo Sapiens 433868AA612960 gb:nq38gO6.s1 NCI_CGAP_CoIO5.3 Homo sapiens cDNA clo 444461853734Hs.25978ESTs 5.3 427088AA398085Hs.142390ESTs 5.3 451307AW293207Hs.211516ESTs 5.3 403831 predicted exon 5.3 402892 predicted exon 5.3 433420AI674093Hs.293961ESTs 5.3 455759BE080469 "gb:OVt-BT0630-280200-086-d065.3 BT0630 Homo Sapiens 411379A1816344Hs.12554"ESTs, Weakly similar 5.3 to Nucleosome Assembly Protein 1-55 428483AI908539Hs.184592ICIAA0344 gene product 5.3 429208AA447990Hs.190478ESTs 5.3 447572A1631546Hs.159732ESTs 5.3 434896AW022054Hs.136591ESTs 5.3 417616807728Hs.268668ESTs 5.3 411805AW864183 "gb:PMO-SN0014-260400-002-d025.3 SN0014 Homo Sapiens 419000T79855Hs.268592ESTs 5.3 413488BE144017Hs.184693"Uanscdption elongation5.3 factor B (SIII), polypeptide 1 (15k 400975 predicted exan 5.3 407453AJ132087 gb:Homo Sapiens mRNA 5.3 for axonemal dynein heavy chain ( 65 430757AI458623 "gbak04g09.x1 NCI CGAP_Lu245.3 Homo Sapiens cDNA clo 417793AW405434Hs.82575small nuclear ribonucleoprotein5.2 polypeptide B"

401877A8011094Hs.129892ItIAA0522 protein 5.2 457122A1026157Hs.33728"ESTs, Weakly similar 5.2 , to ALUi HUMAN ALU SUBFAM

410706A1732404Hs.68846ESTs 5.2 435807A1033299Hs.113614ESTs 5.2 d28398AI249368Hs.98558ESTs 5.2 401088 predicted exon 5.2 414501N43991Hs.171984ESTs 5.2 419083AI479560Hs.98613"Homo Sapiens cDNA FLJ122925.2 fis, clone MAMMA10018 75 421107AA283822Hs.55606"ESTs, Weakly similar 5.2 to ZN91 HUMAN ZINC
FINGER P

411489AW848346 "gb:IL3-CT0214-150200-076-F035.2 CT0214 Homo Sapiens c 419249X14767Hs.89768"gamma-aminobutyric 5.2 acid (GABA) A receptor, beta 1"

430082AW514083Hs.190135ESTs 5.2 425698NM Hs.159241polycysGc kidney disease5.2 016112 2-like 1 8~ 451686AA059246Hs.110293ESTs 5.2 453867AI929383Hs.108196HSPC037 protein 5.2 419985H66373Hs.15973"ESTs, Highly similar 5.2 to bA393J16.3 [H.sapiens]"

426650AA382814 "gb:EST96097 Tests I 5.2 Homo Sapiens cDNA 5' end, mRNA

424115AA335497Hs.293965ESTs 5.2 405576 predicted exon 5.2 409584AA076010 gb:zm89f12.s1 SUatagene5.2 ovarian cancer (937219) Homo so 454423AW603985Hs.179662nucleosome assembly 5.2 protein 1-like 1 417173061397Hs.81424ubiquifin-like 1 (sentrin)5.2 439155H81076Hs.269001ESTs 5.2 432267AK000872Hs.274227"Homo Sapiens cDNA FLJ100105.2 fis, clone HEMBA100030 459024AA020799Hs.179825RAN binding protein 5.2 2-like 1 404088 predicted exon 5.2 403525 predicted exon 5.2 l 445882AI948717Hs.225155"ESTs, Weakly similar 5.2 0 to PSF_HUMAN PTB-ASSOCIATE

448257AW772070Hs.253146ESTs 5.2 410500809442 gb:yf26c09.r1 Snares 5.2 fetal liver spleen 1 NFLS Homo sapien 456084AAi55859Hs.79708ESTs 5.2 410523BE143839 "gb:MRO-HT0164-151299-012-d035.2 HT0164 Homo Sapiens I 434623A8023163Hs.4014KIAA0946 protein; Hunfingtin5.2 S interacfing protein H

454484AW795196Hs.215857ring finger protein 5.2 1d 402131 predicted exon 5.2 438913AI380429Hs.172445ESTs 5.2 402628 predicted exon 5.1 415973824707Hs.260201ESTs 5.1 455640BE064059 "gb:qV3-BT0296-010300-111-e045.1 BT0296 Homo Sapiens 442750A1016803Hs.131096ESTs 5.1 404638 predicted exon 5.1 431117AF003522Hs.250500delta (Drosophila)-like5.1 428619ALi35623Hs.193914KIAA0575 gene product 5.1 439519AA837118Hs.118366ESTs 5.1 427335AA448542Hs.251677G antigen 7B 5.1 416450AA180467Hs.142556ESTs 5.1 440676AW613524Hs.279570ESTs 5.1 414584BE409585 "gb:601301836F1 NIH 5.1 MGC_2l Homo Sapiens cDNA clon 443175N57863 gb:yv60c02.s1 Snares 5.1 fetal liver spleen 1 NFLS Homo sapie 408968AI652236Hs.49376hypotheficalprotein 5.1 415654AW968363 "gb:EST380439 MAGE resequences,5.1 MAGJ Homo Sapiens 440559AW629054Hs.125976"ESTs, Weakly similar 5.1 to metalloproteaseldisintegrinicystei 35 421236AI287622Hs.15i956ESTs 5.1 416258N45661Hs.275131ESTs 5.1 405982 predicted exon 5.1 406589 predicted exon 5.1 412458AW953229Hs.169142ESTs 5.1 435693A1033134Hs.119887ESTs 5.1 449182AW292381Hs.224i50ESTs 5.1 403963 predicted exon 5.1 440630AI733112Hs.176101ESTs 5.1 415412F08049Hs.52132ESTs 5.1 45 442832AW206560Hs.253569ESTs 5.1 445359A1808725Hs.147783ESTs 5.1 412088A1689496Hs.108932ESTs 5.1 428785AIOi5953Hs.i25265ESTs 5.1 430163X66610Hs.234748"enolase alpha, lung-specific"5.1 455441AW945964 "gb:OVO-ET0001-050500-228-e095.1 ET0001 Homo Sapiens c 400304AF005082Hs.113261"Homo Sapiens skin-specific5.1 protein (xp33) mRNA, partial 403944 predicted exon 5.1 457069BE159191Hs.i "ESTs, Weakly similar 5.1 14318 to ORF1 [H.sapiens]"

414125BE253197 "g6:601116804F1 NIN_MGC_165.1 Homo Sapiens cDNA clon SS 448566AW291319Hs.i94574ESTs 5.1 457948A1498640Hs.159354ESTs 5.1 438240N92638Hs.124004ESTs 5.1 404070 predicted exon 5.1 402709 predicted exon 5.1 416425BE077308 "gb:RC1-BTO606-060200-012-h125.0 BTO606 Homo Sapiens 40.7173T64349 gb:yc10d08.s1 Stratagene5.0 lung (937210) Homo sapiens cDN

452502AI904296 "gb:PM-BT046-220199-2865.0 1 BT046 Homo Sapiens cDNA

446657AI335191Hs.260702"ESTs, Moderately similar5.0 to ALU7-HUMAN ALU SUBF

459124AW301478Hs.299178ESTs 5.0 65 409940BE548143 "gb:601073109F1 NIH 5.0 MGC_12 Homo Sapiens cONA clon 443547AW271273Hs.23767"Homo Sapiens cDNA FLJ126665.0 fis, clone NT2RM400225 447452BE618258Hs.102480ESTs 5.0 414327SE408145Hs.185254"ESTs, Moderately similar5.0 to NAG1 protein [R.norvegicus]

416155AI807264Hs.205442"ESTs, Weakly similar 5.0 to AF1176101 inner centromere pro 408081AW451597Hs.167409ESTs 5.0 426834A1091533Hs.135167ESTs 5.0 433368AW877277 "gb:MR4-PT0051-150200-001-d035.0 PT0051 Homo Sapiens 433098AW190593Hs.151143ESTs 5.0 439721W92142Hs.271963"ESTs, Weakly similar 5.0 to ALU5_HUMAN ALU SUBFAM

75 441818AI630451Hs.7976KIAA0332 protein 5.0 458804AL157625 gb:DKFZp761L2016-r1 5.0 761 (synonym: hamy2) Homo sapi 411905BE265067 "gb:601193893F1 NIH_MGC_75.0 Homo Sapiens cDNA clone 434248AA628151Hs.187783ESTs 5.0 423967AW296756Hs.11641"Homo Sapiens cDNA: 5.0 FLJ21432 fis, clone COL04219"

g0 456212N51636 gb:yy87bOt.s1 Snares-mulfiple-sclerosis-2NbHMSPHomo5.0 442914AW188551Hs.99519"Homo Sapiens cDNA Fl,l140075.0 fis, clone Y79AA1002407 436084AK000185 "gb:Homo Sapiens cDNA 5.0 FLJ20178 fis, clone COL09990"

449252AW594482Hs.253315ESTs 5.0 454653AW812227 'gb:RC2-ST0173-201099-011-g095.0 ST0173 Homo Sapiens c 414699AI815523Hs.76930"synuclein, alpha (non A4 component of amyloid precursor) 5.0 443335T89697Hs.16645ESTs 5.0 448419AL080072Hs.2iHomo Sapiens mRNA; cDNA
195 DVfFZp564M0616 (from clop 5.0 425574AA359663 "gb:EST68717 Fetai lung II Homo Sapiens cDNA 5' end, m8 5.0 d35174AA687378Hs.194624ESTs 5.0 429548AW138872Ns.135288ESTs 5.0 450613A1702055 "gbaq20g10.x1 NCI_CGAP-Ut1 Homo sapiens cDNA clop 5.0 400432AX01580Hs.287767Sequence 8 from Patent W09950285 5.0 421751AW813731Hs.i59153ESTs 5.0 10405800 predicted exon 5.0 429430AI381837Hs.155335ESTs 5.0 439518W76326 gb:zd60d04.r1 Soares fetal hear~NbHHI9W Homo sapien 5.0 430884AF053748Hs.248114glial cell derived neurotrophic factor 5.0 452741BE392914Hs.30503"Homo Sapiens cDNA FLJ11344 fis, clone PLACE1010870 5.0 I 441001AW137017Hs.126373Human DNA sequence from S clone RP5-1184F4 on chromos 5.0 438490AW593272Hs.26261ESTs 5.0 408170AW204516Hs.31835ESTs 5.0 449104808702 gb:yf24cO6.r1 Soares fetal liver spleen 1NFLS Homo sapien 5.0 ZO TABLE 1B:
Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Accession Number 4083911055687_1AW859276 AW85927d AW 190959 T91463 d085231063925AW833259 AW833273 AW206846 3 408987109306' H85615 H86300 H86263 H86282 AA059278 H86304 40 410523_ BE143839 AW752787 AW752795 BE143584 N71805 4105361207322_1N39533 AW753094 AW753093 4106261212621_-iBE407727 4110571230493AW8f5098 BE154843 BE154831 4111781234752_1AW820852 AW820773 AW821088 5 4117221254914_1AW875942 AW858234 AW875938 AW875941 AW858235 AW875958 4117251255047_1AW858396 AW858505 AW858476 AW861971 AW858556 AW86190B

4118051259273AW864183AW864181AW864135AW864i98 60 411905_ BE265067 BE264978 AW875420 65 _ AW984789 AW984823 AW948021 AW984802 AW984800 AW984799 75 413425136885F20956 AA12937d AA133740 AW819878 4135211374612_1BE145814 BE145830 BE145884 BE145823 BE145905 BE145883 $0 4137021383899BE170313 BE158339 BE158290 4141951424854-8E263293.

414540_ BE379050 415654154135_1AW968363 AA465492 834539 AA165411 4166651607797_1H72974 W28967 417344166827_1AW997313 AA195805 418709178363_1AA227394 AA641866 AW750732 3 419936_ A1792788 BE142230 AA252019 422949223184AA319435 N56456 AA319377 AW961532 Td8452 AA894424 424324238127_1AA346316 BE160193 AA338802 AW954536 4266502702831AA382814AA4024i1AA412355 430757322947AId58623 AA639708 AA485409 822065 AA485570 431688336609_1AA513906 AA847734 AI35704d 434374384889_1AA631439 A1086355 A1082577 434804393481AA649530 AA659316 Hfi4973 70 _ AI239729 AI251752 AA485791 BE568425 AW962958 437229434947_1AW976005 AW419264 AA747275 AA810377 443534572957_1A1076123 A1244834 A1695239 443860 583216_1 AW866632 A1089351 D61942 _ 446171 664826_1 A1374927 A1278380 A1301383 1 ~ 449104 798149-1 808702 809864 AI630313 450613 840016_1 A1702055 889204 886260 1 ~ 452542 921410_1 AW812256 AW812257 A1906423 A1906422 452947 939810_1 AW130413 A1932362 454377 114761 1 AA0768i1 AW814764 454389 115682_1 AW752571 AW847602 AA077979 25 454556 1223878_1 AW807073 AW807055 AW807067 AW807276 AW807030 AW807363 454597 1226059_1 AW809648 AW809704 AW809643 AW809653 AW809709 AW809949 454633 1227504_1 AW811380 AW811385 454707 1230250_1 AW814989 AW814852 AW814808 454934 1245577_1 AW846080 AW846074 AW846118 AW846130 455013 1248899_1 BE073250 BE073378 BE073379 AW850533 AW850529 455110 1253955 1 BE154505 BE154462 BEi54454 BE154460 BE154489 BE154496 AW856909 BEi54497 BE154565 BE154572 BE154500 BE154472 455121 1254339-i BE156459 BE156469 BE156468 AW857d47 455441 1291505_1 AW945964 AW946020 AW946034 AW946027 AW946041 AW946044 455592 1335196_1 BE008002 BE007997 BE007998 BE008000 455713 1352512_1 BE069891 BE158893 BE069898 BE158900 455879 1380017_1 BE153275 BE153189 BE153329 BE153022 BE153030 BE152974 456101 151654_1 AA159478 AW901089 AA160437 AW593155 456309 177026_1 AA225423 AA225369 BE144153 AW801549 456714 221500_1 AW897265 AW897274 AL119504 AW897275 AW897270 AW897312 AW897318 457405 333127_1 AA504860 AA504911 457727 393566_1 AW974687 AA649656 AA652145 457868 426095 1 AW975133 AA7299d3 AA805813 458154 491768_1 AW816379 AA888282 AA879046 AA879195 ,75 459186 922888-1 AI906287 BE064074 BE068820 BE068823 BE068822 BE068826 TABLE 1C: ' Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22" Dunham, et al. (1999) Nature 402:489-095 $o SUand: Indicates DNA strand from which exons were predicted Nt_position: Indicates nucleotide positions of predicted exons Pkey Ref StrandN~posi6on 4005849887612Minus18398-18573 4005939887642Minus25013-25127 -4006129929646Minus151513-151662 4006139664507Plus 92278-92472 4006237228177Plus 74195-74335,74653-74827 4007097249204Plus 153075-154680 4007497331445Minus9162-9293 4008421927148Plus 90462-90673 1 4009257651921Plus 38183-38391,43900-44086 4009647139719Minus155282-155403 4009687923967Plus 19938-20043 4009757139779Minus108473-108847 4009838081198Plus 107903-108832 15 4010328117525Minus68451-68555 4010508117628Minus78449-79425 4010888492704Plus 194659-195179 4011298699792Minus62022-62242,62326-62451,62543-62710,63072-63167 4012009743387Minus111586-111806 114791-114916,115419-115583,116351-116446,116847-116907,122653-123067,124982-125407 4012139858408Plus 96243-98380,98489-98619 4012309929527Minus33835-34006,34539-34592,36461-36745,48925-09098,52604-52758 4012454827300Minus59373-59531 4012608076883Minus86008-86355 4012698954206Plus 2259-2591 4012639800093Minus47256-47456., 4014977381770Plus 92607-92813 4015087534110Minus110779-110983 4015217705251Plus 9127-9234 4015307770649Plus 41468-42406 3 4015757229804Minus76253-76364 4016047689963Minus119835-120185 4017807249190Minus28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573 4017817249190Minus83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814 4017937263888Minus102945-103083 3 4018097342191Minus107548-108298 S

4018627770606Minus55839-55993,59145-59293 4018818122429Minus148470-148651,153418-153618,154282-154438 4020187528100Plus 168728-168659 4020468072415Plus 166394-166556,168167-168395 40 4020508076908Minus130105-130227 4020718117361Plus 85924-86039 4020758117407Plus 121907-122035,122804-122921,124019-124161,124455-124610,125672-126076 4021317704961Minus33114-33209,33496-33678 4022038576119Minus8124-8285 45 4022229958106Plus 3261-3834,3939-4269 4022966598824Plus 22587-23723 4022986598824Plus 36758-37953 4024219796341Minus46609-46662,46758-46811,86293-86346,89776-89829,9004&90101,102817-102924 4024259796347Minus50224-50395 4024819797406Plus 87891-88991 4025297630937Minus165-917 4025439838066Minus89684-90893 4025767230225Minus1867-2247 4025789684928Plus 66350-66496 5 4026289931216Plus 31753-31966 4026319931231Minus115658-116580 4026399958129Minus20167-22383 4026648077024Plus 70318-70846 4027098901246Minus56847-57055 60 4027387331557Minus8725-8859 4027459212200Minus76516-76690 4027904835258Minus147744-147861 4027946136940Minus131034-131794 4028006010175Plus 43921-44049,46181-46273 4028599588237Minus69821-75323 4028928086844Minus194384-194645 4029749663349Plus 124035-124321 4030413171152Plus 70527-71019 4030658954197Minus71615-71773,73930-74144 70 4030838954241Plus 163070-163351 4030898954241Plus 171964-172239 4030938954241Plus 177083-177373,177464-177751 4031779838213Minus142560-142726 4032738018055Plus 133809-134099 4033348568877.Minus137205-137350 4033508569775Minus135374-135523 4033568569930Plus 92839-93036 4034039436460Plus 21240-21399 4035257960440Plus 152431-153243 g 4035688101145Minus85509-85658 4036478699843Minus35849-36204 4036877367384Plus 9009-9534 4036917387384Minus88280-88463 4036984263532Plus 10464-10907 4037417630932Minus2833-3468 4037477658395Minus20493-20621 4037868083636Minus73028-73217 4038317249249Minus61468-61575 4038917331467Minus191508-193220 4039447711864Minus129213-129415 4039638568150Plus149466-149665 4040702996642Plus7210-7414,1004&10195 4040889958257Plus184131-184295 1 4040977770701Plus55512-55781 4041667596822Plus86147-86509 4042709828129Minus3649-3750,4161-4306,5962-6049,6849-6965 4043407630856Plus10898-11506 4044107342122Plus49052-49176,56177-56273,59384-59488 15 4045998705107Plus110443-110733 4046389796751Minus99433-99528,100035-100161 4046649797142Minus104257-105215 4047278081050Plus115534-115747 4047677882827Minus23244-23759 20 4048286580415Minus26291-27253 4048497706886Plus144843-144964,149846-150121 4048936850447Plus65083-65223 4048987331420Minus177015-177328 4049527382669Minus136326-136618 4049723213020Plus48711-49524,, 4049924662677Minus106104-106199,111659-111781 4050717708797Minus11115-11552 4051388576241Plus90303-90516 4051967230083Minus135716-135851 3 4052276731245Minus22550-22802 40527739110473Plus23471-23572 4052856139075Minus55744-55903,57080-57170,61478-61560 4052923845420Plus33227-33442 4053366094635Plus33267-33563 3 4053622337862Minus105008-105142,105980-106091,140445-140556,142519-142641 4053826552767Plus31923-32311 4054547656675Plus133807-134053 4054657767904Plus8935-9073,12242-12367,13364-13506,14965-15493 4054728439781Plus106297-106447,108462-108596 40 4055471054740Plus124361-124520,124914-125050 4055764003382Plus84000-85009 4056215523811Plus59362-59607 4056365123990Plus56384-56587 4056754557087Plus70304-70630 45 4057084156182Plus55030-55604 4057717018349Plus91191-91254,91510-91589 4057835738434Minus27238-27865 4057931405887Minus89197-89453 4058002791346Plus19271-19813 5 4058104938307Minus64543-64966 4058487651809Minus28135-28244 4058516164995Minus26407-27151 4058676758731Minus74553-75173 4058966758795Plus57311-57874 .5 40590477051111Minus16375-16584 4059177712162Minus106829-107213 4059828247790Minus36028-36408 4060308312328Minus~ 96123-96547 4060536758997Plus30921-31532 60 4060576691254Minus20830-21222 4061497144791Minus44464-45164 4061637158901Plus66690-66835 4062775686030Minus4759-5490 4063229212102Minus130230-130418 65 4063499256007Minus21251-21526 4065047711360Minus107068-107277 4065447711508Plus46576-46757 4065898224211Plus38806-38989 4065924567182I~lus352560-352963 TABLE 2A lists about 187 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to be exlracellular or cell-surface proteins. These were selected as for Table 1A, except that the ratio was greater than or equal to 2.5, and the predicted protein contained a PFAM domain that is indicative of extracellular localizafion (e.g., 1g, ,7$ fi3, egf, 71m domains).
TABLE 2A: ABOUT 187 UP-REGULATED OVARIAN CANCER GENES ENCODING
EXTRACELLULARICELL SURFACE PROTEINS
Pkey: Primekey Ex.Accn: ExempIarAccession UG ID: UniGene ID
g0 Title: UnigeneTiBe PFAM domains , ratio: tumor vs. normal tissues Pkey Ex. UG Tifle PFAM domain ratio Accn ID
No.

423017AW178761Hs.227948serine (or cysteine)serpin 63.6 proteinase inhibito 431938AA938471Hs.115242developmentally SCP 32.0 regulated GTP-bindi 425650NM Hs.1925desmoglein 3 (pemphiguscadherin 30.0 001944 vulgarts ant 418994AA296520Hs.89546selecfln E (endothelialEGF;IecGn c;sushi24.5 adhesion molec 452947AW130413 gb:xf50f04.x1 alpha-amylase 15.8 NCI-CGAP_Gas4 Hom 418092845154Hs.106604ESTs pkinase;Acflvin 15.1 recp 431725X65724Hs.2839Norrie disease Cys-knot 12.6 (pseudoglioma) 422330D30783Hs.115263epiregulin EGF 12.5 1~ 446745AW1i8189Hs.156400ESTs vwa 11.1 416319AI815601Hs.79197CD83 anflgen (activatedig 10.8 B lymphocyt 432408N39127Hs.76391myxovirus (influenza)ion trans;K tetra10.6 resistance 1, ho 405285 predicted exon A2M;A2M-N 10.5 405636 predicted exon EGF;IdI_recep~a;ldl-recepLb9.8 I 403093 predicted exon fn3 9.6 S

446740AI611635Hs.192605ESTs RYDR ITPR 9.2 405547 predicted exon ABC-tran;ABC_membrane8.5 412333AW937485 gb:OV3-DTOOd4-221299-045-b0971m 1 8.4 DT

404270 predicted exon SCP 8.1 402745 predicted exon EGF;IdI_recept-b;thyroglobulin-18.1 452755AW138937Hs.213436ESTs cystafln 8.0 421459A1821539Hs.97249ESTs , 7.9 disintegrin;Repralysin 416151T26661 gb:AB65C7R Infantlaminin-G;EGF 7.8 brain, LLNL area 446232AI281848Hs.165547ESTs 71m 7.6 431009BE149762Hs.248213gap junctionprotein_ 7.2 beta 6 (connexin connexin 424634NM Hs.151407cartilage intermediateig;tsp-1 7.1 003613 layer protein, n 400749 predicted exon fn3;ldl_recept_a;ldl_recept_b6.8 419054N40340Hs.191510ESTs, Weakly similarioig;SPRY 6.8 ORF2 [M.m 459170AI905518 gb:RGBT091-210199-098ABC tran;ABC_membrane6.6 BT091 Ho 416441BE407197 gb:601301552F1 SDF 6.4 NIH_MGC_21 Hom 410664NM-006033Hs.65370lipase, endothelialRibosomal-L22 6.4 402425 predicted exon ion traps 6.3 415451H19415Hs.268720ESTs, Moderately Ephrin 6.0 similar to ALUt H

403083 predicted exon fn3 5.9 35 448995AI613276Hs.5662guanine nucleofldeSDF 5.9 binding protein (G

418345AJ001696Hs.241407serine (or cysteine)serpin 5.8 proteinase inhibilo 424966AU077312Hs.153985solute carrter aa~ermeases 5.8 family 7 (cationic amino 431211M86849Hs.5566gap juncflon protein,connexin 5.7 beta 2, 26kD
(co 430563AA481269Hs.1783B1ESTs ABC tran;ABC_membrane5.6 40 450152AI138635Hs.22968ESTs ig;pkinase 5.6 418844M62982Hs.1200arachidonate 12-lipoxygenaseIipoxygenase;PLAT5.6 403089 predicted exon fn3 5.6 d03687 predicted exon isp-i;Reprolysin5.6 403691 predicted exon isp-l;Reproiysin5.5 45 414035Y00630Hs.75716sedne (or cysteine)serpin 5.4 proteinase inhibilo 421284U62435Hs.103128cholinergic receptor,neur-chap 5.3 nicotinic, alpha p 435435T89473Hs.192328ESTs Iipase;PLAT 5.3 457122A1026157Hs.33728ESTs, Weakly similarIipoxygenase;PLAT5.2 to ALU1 HUM

419249X14767Hs.89768gamma-aminobutyricneur-chap 5.2 acid (GAGA) A

425698NM Hs.159241polycysflc kidneyion inns 5.2 016112 disease 2-like 431117AF003522Hs.250500delta (Drosophila)-likeEGF;DSL 5.1 457948AI498640Hs.159354ESTs G-alpha;arf 5.1 435174AA687378Hs.194624ESTs SPRY 5.0 408170AW204516Hs.31835ESTs arf;ras 5.0 434351AW974991Hs.191852ESTs,WeaklysimilartoALUiarf;ras 4.9 HUM

430708U78308Hs.278485olfactory receptor,7trr~1 4.8 family 1, subfamily d22597BE245909Hs.118634ATP-binding cassette,ABC tran;ABC-membrane4.8 sub-family B
(M

405545 predicted exon ABC-tran;ABC_membrane4.8 426471M22440Hs.170009transforming growthEGF 4.7 factor, alpha 409632W74001Hs.55279sertne (orcysteine)serpin 4.7 proteinase inhibito 420206M91463Hs.95958solute carrter sugar_tr 4.6 family 2 (facilitated gluc 415138C18356Hs.78045tissue factor Kunitz-BPTI;G-gamma4.6 pathway inhibitor 424402M63108Hs.1769luteinizing hormonelchodogonadotrop7tm 1 4.5 436480AJ271643Hs.87469putaflve acid-sensingASC 4.5 ion channel 65 430226BE245562Hs.2551adrenergic, beta-2-,7tm_1 4.4 receptor, surface 436126AW449757Hs.163036ESTs SNF 4.4 406812AF000575Hs.67846leukocyte immunoglobulin-likeig 4.4 recep 409385AA071267 gb:zm61g01.r1 TIMP 4.3 Stratagene fibroblast ( 449184AW296295Hs.196491ESTs TNFR 4.3 c6 410555U92649Hs.64311a disintegrtn - 4.3 and metalloproteinasedisinlegrin;Reprolysin do 422389AF240635Hs.115897protocadhertn cadhedn 4.3 12 .

405281 predicted exon A2M;A2M-N 4.3 413548BE147555Hs.288541Homo sapiens mRNAEGF;IdI-recept 4.3 for KIAA1558 a;ldl_recept-b 449535W15267Hs.23672low density lipoproteinIdl recept_a;EGF;IdI_recepf_b4.3 receptor-relate 425864U56420Hs.159903olfactory receptor,7trr~1 4.3 family 5, subfamily 410611AW954134Hs.20924KIAA1628 protein Peptidase-S9 4.2 430686NM Hs.2633desmoglein 1 cadherin;Cadherin-C4.1 001942 term 418693At750878Hs.87409thrombospondin vwc;TSPN 4.0 445924AI264671Hs.164166ESTs sugar-tr 3.9 g0 457148AF091035Hs.184627KIAA0118 protein arf;ras 3.9 428568AC004755Hs.184922one cut domain, E1-E2 ATPase 3.9 family member 412170D16532Hs.73729very low density EGF;IdI recept_a;ldl_recept3.8 lipoprotein receptorb 442566837337Hs.12111ESTs ' ank;death;RHD;TIG3.8 403763 predicted exon 7tm-1 3.8 403074 predicted exon fn3 3.8 413605BE152644 gb:CMi-HT0329-250200-128-f09alpha-amylase 3.8 HT

442295AI827248Hs.224398Homo Sapiens cDNACollagen;COLFI 3.7 FLJ11469 fis, c 403661 predicted exon 7tm_3;ANF_receptor3.7 407305AA715284 gb:nv35f03.r1 pkinase;Sema;Plexin_repeat;TIG3.7 NCI CGAP_Br5 Hom 457353X65633Hs.248144melanocortin 2 7tm_1 3.7 receptor (adrenocortic 431176A1026984Hs.293662ESTs laminin_EGF;laminin_B3.6 436233AI742878Hs.124116ESTs 1g 3.6 431808M30703Hs.270833amphiregulin (schwannoma-derivedEGF 3.6 g 445798NM Hs.13321rearranged L-myc zf C2H2 3.6 012421 fusion sequence 400380NM Hs.283079G protein-coupled7tm_1 3.6 018485 receptor C5L2 453893NM Hs.36451glutamate receptor,lig chap 3.5 000835 ionotropic, N-met 409402AF208234Hs.695cystafin B (stefincystafin 3.5 B) 421166AA305407Hs.102308potassium inwardly-rectifyingIRK 3.5 channe 1 445575225368Hs.172004fifin fn3 3.5 428957NM_003881Hs.194679WNT1 inducible tsp_l;vwc;IGFBP 3.5 signaling pathway p 403909NM_016255Hs.95260Homo Sapiens mRNA;Na H Exchanger 3.5 cDNA DKFZp 403077 predicted exon fn3 3.5 455612BE042896Hs.274848ESTs ABC Van;ABC_membrane3.5 424091AF235097Hs.139263calcium channel, ion traps 3.5 voltage-dependent, a 403956W28077Hs.79389net (chicken)-likecadherin;Cadherin_C3.4 2 ierm 457470A8040973Hs.272385G protein-coupled7tm_1 3.4 receptor 72 401522N47812Hs.81360CGI-35 protein disintegrin;Reprolysin3.4 404886 predicted exon ion traps 3.4 437692AA176959Hs,172004fifin fi3 3.4 407944834008Hs.239727desmocollin 2 cadherin 3.d 407393AB038237 gb:Homo Sapiens 71m 1 3.3 mRNA for G protei 436936AL134451Hs.i97478ESTs EGF;laminin_G 3.3 423309BE006775Hs.126782sushi-repeat proteinsushi;HYR 3.3 402172 predicted exon 1g 3.3 447420AI378628 gbac72g07.x1 Soares_NhHMPu_S1ank;pkinase;death3.3 H

438901AF085834Hs.29036ESTs sushi 3.3 424362AL137646Hs.146001Homo Sapiens mRNA;trypsin;sushi;CUB3.3 cDNA DKFZp 430453BE387060Hs.3903Cdc42 effector fn3 3.3 protein 4; binder of Rh 416631H69466 gb:yr88f07.r1 Idl recept-a;MACPF3.3 Soaresfetalliverspleen 453174AI633529Hs.135238ESTs 77m_1 3.3 433848AF095719Hs.93764car6oxypepfidase Zn carbOpept;Propep_M143.2 408546W49512Hs.46348bradykinin receptor77m 1 3.2 423573AA328504 gb:EST31993 Embryo,1271m 1 ' 3.2 week I Hom 458662AI823410Hs.i69149karyopherin alpha7Un_3;ANF receptor3.2 1 (imporlin alpha 433430AI863735Hs.186755ESTs thyroglobulin_1;IGFBP3.2 438850833727Hs.24688EST ank;pkinase;death3.2 420783A1659838Hs.99923lecfin, galactoside-binding,Gal-bind tecfin 3.2 soluble, 7 409968056102Hs.57699adhesion glycoprotein1g 3.1 430630AW269920Hs.2621cystatin A (stefin, 3.1 A) 7tm_3;ANF receptor 420737L08096Hs.99B99tumornecrosisfactor(ligand)superfaTNF 3.1 422279H69644Hs.114231Gtype leclin-likelectin c 3.1 receptor-2 400289X07820Hs.2258matrix metalloproteinasehemopexin;Pepiidase_M103.1 10 (stromely 412597AU077051Hs.74561alpha-2-macroglobulinA2M;A2M N 3.1 5 453420AJ003459. gb:AJ003459 SelectedIRK 3.1 0 chromosome 2 404243 predicted exon zf-C3HC4;SPRY;zf-B3.1 box 449987AW079749Hs.184719ESTs, Weakly similarABC han;ABC_membrane3.1 to AF116721 1 422471AA311027Hs.271894ESTs 1g 3.0 400464 predicted exon Peptidase_S9 3.0 SS 458713BE044496Hs.282707ESTs EGF 3.0 421340F07783Hs.1369decay accelerafingsushi 3.0 factor for complem 449523NM_000579Hs.54443chemokine (GC 71m_1 3.0 motif) receptor 400704 predicted exon lig chan;ANF 3.0 receptor 416239AL03B450Hs.48948ESTs E1-E2 ATPase;Hydrolase3.0 60 433664AW292176Hs.245834ESTs Ricin_B lecfin 3.0 423994X01057Hs.1724interleukin 2 rtm 2.9 receptor, alpha 447726AL137638Hs.19368Homo Sapiens mRNA;vwa 2.9 cDNA DKFZp 425483AF231022Hs.301273Homo Sapiens protocadherinEGF;cadhedn;laminin2.9 Fat 2 (FA G

423513AF035960Hs.129719transglutaminase Transglut_core;Transglutamin_N2.9 65 d01537 predicted exon ig;pkinase;LRRNT;LRRCT2.9 405790 predicted exon Sema;Plexin repeat;TIG2.9 422669H12402Hs.119122ribosomal proteinarf;ras;Ribosomal_S172.9 Ll3a d30793M83181Hs.2479405-hydroxytryptamine71rr~1 2.9 (serotonin) recep 403411 predicted exon ABC Uan;ABC membrane2.8 70 428188M98447Hs.22transglutaminase Transglutamin_N;Transglut_core2.8 1 (K polypepfide ep 414482S57498Hs.76252 7trr~1 2.8 endothelin receptor type A

427223BE208189Hs.174031cytochrome c oxidaseCOX6B 2.8 subunit Vlb 404187 predicted exon 1g 2.8 443537D13305Hs.203cholecystokinin 7trn-1 2.8 B receptor 75 428701NM_013276Hs.190207carbohydrate kinase-likevwa;integrin_A;P2X_receptor2.7 411213AA676939Hs.69285neuropilin 1 CUB;MAM;FS F8 2.7 type C

453999BE328153Hs.240087ESTs kazal 2.7 401244 predicted exon vwa;vwd;TIL 2.7 458930NM Hs.24640sema domain, immunoglobulinSema 2.7 003612 domai g0 434411AA632649Hs.201372ESTs . sushi 2.7 400421AF263537Hs.287370fibroblastgrowthfactor23FGF 2.7 448999AF179274Hs.22791transmembrane kazal 2.7 protein with EGF-like 417350050928Hs.82001polycysfic kidneyion traps 2.6 disease 2 (autosoma 419452033635Hs.90572, PTK7 protein pkinase;ig 2.6 tyrosine kinase 401657 prodicted exon 71m 1 2.6 456711AA033699Hs.83938 ESTs, Moderatelysushi;trypsin;CUB2.6 similar to MASP-2 432042AW971345Hs.292715 ESTs sugar-U 2.6 433138AB029496Hs.59729 semaphodn sem2 ig;Sema 2.6 452530AI905518gb:RGBT091-210199-098 ABC Uan;ABC-membrane2.6 BT091 Ho 426418M90464Hs.169825 collagen, typeCollagen;C4 2.6 IV, alpha 5 (Alport syn 403796 predicted exon cadherin 2.6 431728NM Hs.268107 multimedn EGF;CIq 2.6 441595AW206035Hs.192123 ESTs sugar-U 2.6 1 445537AJ245671Hs.12844 EGF-like-domain,EGF;MAM 2.6 ~ multiple 6 447197836075gb:yh88b01.s1 Soaves SDF 2.5 placenta Nb2H

428765X54150Hs.i93122 FcfragmentoflgA,receptorfor1g 2.5 450245AA007536Hs.271767 ESTs, Moderately1g 2.5 similar to ALU1 N

416429H54658Hs.268942 ESTs E1-E2 ATPase;Hydrolase2.5 I 417067AJ001417Hs.81086 solute comer sugar-U 2.5 S family 22 (extraneurona 433182A8039920Hs.127821 BWRT protein ion traps 2.5 403092 predicted exon fi3 2.5 406850AI624300Hs.172928 collagen, typevwc;Collagen;COLFI2.5 I, alpha 1 438698AW297855Hs.125815 ESTs Iipoxygenase;PLAT2.5 d56815NM-013348Hs.144011 potassium inwardly-rectifyingIRK 2.5 channe 28:

Pkey:ue identifier number Uniq Eos probeset CAT number number:
Gene cluster Accession:Genbank accession numbers s Pkey CAT Accession Number d09385112523AA071267 T65940 T64515 4136051379792_1BE152644 BE152712 BE752668BE152816 BE152656BE152715 BE152707 BE152815 BE152678BE152682 BEi52778BE152762 45 _ TABLE
2C:

Pkey:
Unique number corresponding to an Eos probeset Ref: . "Dunham ublicationDNA sequence Sequence 1. et aL" entitledof source. refers to "The The the p digit numbers in this column are Genbank Identifier (GI) numbers hum an 22" Dunham, et al. (1999) chromosomeNature 402:489-095 SUand: nd from which exons were Indicates predicted DNA
stra Nt~osition: Indicates nucleotide positions of predicted exons Pkey Ref Strand Nt_position 4004649929670Plus 22074-22214 4007048118864Minus 63110-63241 4007497331445Minus 9162-9293 4012444827300Minus 55359-56376 4015377960358Minus 186786-187029,190607-190779,198218-198348 4016579100664Minus 7312-8163 4021728575911Minus 143378-143671 4024259796347Minus 50224-50395 4027459212200Minus 76516-76690 4030748954241Plus 143375-143561 4030778954241Plus 146923-147222,147326-147628 65 4030838954241Plus 163070-163351 4030898954241Plus 171964-172239 4030928954241Plus 174720-175016,175104-175406,175508-175813 4030938954241Plus 177083-177373,177464-177751 4034119438635Minus 104247-104420 70 4036618705027Minus 30268-30482 4036877387384Plus 9009-9534 4036917387384Minus 88280-88463 4037637229888Minus 43575-43887 4037968099896Minus 75073-77664 75 4041874481839Plus 7644-7991 4042435672609Plus 74695-75123 4042709828129Minus 3649-3750,4161-4306,5962-6049,6849-6965 d048864884062Plus 30058-30596 4052816139075Minus 34202-34351,35194-35336,45412-45475,d5731-05958,47296-47457,49549-09658,49790-49904,50231-50342, 53583-53667,54111-4052856139075Minus 55744-55903,57080-57170,61478-61560 4055451054740Plus 118677-118807,119091-119296,121626-121823 4055471054740Plus 124361-124520,124914-125050 4056365123990Plus 56384-56587 1~7 405790 1203968 Plus 136364-136509,136579-136699,136805-136941 TABLE 3A lists about 1643 genes up-regulated in ovarian cancer compared to normal ovaries. These were selected as for Table 1A, except that the ratio was greater than or equal to 15, and the denominator was the arithmefic mean value for various non-malignant ovary specimens obtained.
TABLE 3A: ABOUT 1643 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL OVARY
Pkey:
Primekey Ex.Accn:ExempIarAccession UG niGene ID: ID
U

Title:
Unigene Title PFAMmains do rafio:
tumor vs.
normal tissues PkeyEx. 0G Title rafio Accn ID
No.

420859AW468397Hs.1000005100 calcium-binding 219.9 protein A8 (calgranulin A) 422166W72424Hs.112405S100 calcium-binding 180.2 protein A9 (calgranulin B) 422158L10343Hs.112341protease inhibitor 165.0 3, skin-derived (SKALP) 424799BE550723Hs.153179fatty acid binding 161.5 protein 5 (psoriasis-associated) 442402NM_000954Hs.8272prosiagiandin D2 synthase150.2 (21kD, brain) 408522AI541214Hs.46320Small praline-rich 149.5 protein SPRK [human, odontogenic k 431369BE184455Hs.251754secretory leukocyte 144.9 protease inhibitor (aniileukoprotein 430520NM-016190Hs.242057chromosome 1 open reading.
frame 10 136.6 428471X57348Hs.184510strafifin 129.5 421978AJ243662Hs.110196NICE-1 protei0 108.7 437191NM_006846Hs.5476serine protease inhibitor,106.2 Kazal type, 5 407788BE514982Hs.38991S100 calcium-binding 105.5 protein A2 441565AW953575Ns.169902solute carrier family 103.6 2 (facilitated glucose transporter), 431211M86849Hs.5566gap junction protein, 102.1 beta 2, 26kD (connexin 26) 419329AY007220Hs.288998S100-Type calcium binding95.3 protein A14 430572033114Hs.245188tissue inhibitor of 87.0 metalloproteinase 3 (Sorsby fundus d 417079065590Hs.81134interleukin 1 receptor86.1 antagonist 412636NM_004415Hs.74316desmoplakin (DPI, DPII)85.0 417515L24203Hs.82237ataxia-telangiectasia 84.8 group D-associated protein 426295AW367283Hs.75839zinc fingerprotein6(CMPX1)84.5 452669AA216363Hs.262958ESTs, Weakly similar 84.4 to allemafively spliced product a 406711N25514Hs.77385myosin, light polypepfide83.8 6, alkali, smooth muscle and n 406712M31212Hs.77385myosin, light polypeptide81.0 6, alkali, smooth muscle and n 432680T47364Hs.278613interferon, alpha-inducible81.0 protein 27 416889AW250318Hs.80395mat, T-cell differenfialion77.8 protein 409453AI885516Hs.95612ESTs 75.3 424670W61215Hs.116651epithelial V-like anfigen67.5 417130AW276858Hs.81256S100 calcium-binding 67.0 protein A4 (calcium protein, calv 423634AW959908Hs.1690heparin-binding growth65.7 factor binding protein 442379NM_004613Hs.8265transglutaminase 2 64.7 (C polypeptide, protein-glutamine-g 456898NM Hs.155597Dcomponentofcomplement(adipsin)64.6 423017AW178761Hs.227948sedne (or cysteine) 63.6 proteinase inhibitor, Glade B (ovalbu 447990BE048821Hs.20144small inducible cytokine60.7 subfamily A (Cys-Cys), memb 424362AL137646Hs.146001Homo sapiens mRNA; 60.3 cDNA DKFZp586F0824 (from 414438AI879277Hs.76136thioredoxin 59.9 420136AW801090Hs.195851acfin, alpha 2, smooth58.9 muscle, aorta 433336AF017986Hs.31386ESTs, Highly similar 58.8 to JE0174 friuled protein-2 [H.sa 403741 predicted exon 57.0 430637BE160081Hs.256290S100 calcium-binding 56.1 protein A11 (calgiuarin) 424098AF077374Hs.139322small proline-rich 55.8 protein 3 441591AF055992Hs.183Duffy blood group 55.6 426521AF161445Hs.170219hypothetical protein 55.5 406713002629Hs.77385myosin, IigM pclypepfide55.3 6, alkali, smooth muscle and n 406725D51245Hs.288061actin, beta 54.1 422168AA586894Hs.1124085100 calcium-binding 54.1 protein A7 (psoriasin 1 ) 406755N80129Hs.94360metalloihionein 1L 54.0 425593AA278921Hs.1908proteoglycan 1, secretory53.3 granule 442257AW503831 gb:Ul-HF-BNO-alb-b-OS-0-ULr153.1 N!H-MGC-50 Homo 421957AW068637Hs.109857hypoihefical protein 52.3 DKFZp434H0820 447526AL048753Hs.340small inducible cytokine51.2 A2 (monocyte chemotacfic pro 406722H27498Hs.283305Homo sapiens SNC73 51.0 protein (SNC73) mRNA, comple 427223BE208189Hs.174031cytochrome c oxidase 51.0 subunit Vlb 414420AA043424Hs.76095immediate early response50.9 417259AW903838Hs.81800chondroifin sulfate 50.3 proteoglycan 2 (versican) 414191AW250089Hs.75807PDZ and LIM domain 49.5 1 (elfin) 436906H95990Hs.181244major histocompatibility49.0 complex, class I, A

408000L11690Hs.620bullous pemphigoid 49.0 antigen 1 (2301240kD) 414035Y00630Hs.75716serine (or cysteine) 48.8 proteinase inhibitor, Glade B (ovalbu 432706NM Hs.286124CD24 anfigen (small 48.8 013230 cell lung caroinoma cluster 4 antig 421948L42583Hs.111758kerafin 6A 48.7 414662AL036058Hs.76807major histocompatibilily48.5 complex, class II, DR alpha 425071NM-013989Hs.154424deiodinase, iodothyronine,48.5 type II

404767 predicted exon 48.4 418327070370Hs.84136paired-like homeodomain48.2 transcripfion factor 436729BE621807Hs.3337transmembrane 4 superfamily47.7 member 1 414183AW957446Hs.30i711ESTs 47.2 400163 predicted exon 47.0 433423BE407127Hs.8997heat shock 70kD protein46.9 423457F08208Hs.155606paired mesoderm homeo 46.6 box 1 414085AA114016Hs.75746aldehyde dehydrogenase46.0 423189M59371 Hs.171596EphA2 45.6 438240N92638 Hs.124004ESTs 45.5 417366BE185289Hs.1076small praline-rich 45.3 protein 1B (comifin) 412774AA120B65Hs.23136ESTs 45.1 407242M18728 gb:Human nonspecific 44.8 crossreacting antigen mRNA, ca 431292AA370141Hs.251453Human DNA sequence 44.8 from clone 967N21 on chromos 403695 predicted exon 43.5 417365D506B3 Hs.82028Uansforming growth 43.4 factor, beta receptor II (70-80kD) 1 432331W37862 Hs.274368Homo Sapiens mRNA; 43.4 ~ cDNA DKFZp58611524 (from c 424479AF064238Hs.149098smoothelin 43.3 444726NM-006147Hs.11801interferon regulatory 43.2 factor 6 432314AA533447Hs.285173ESTs 43.2 429500X78565 Hs.289114hexabrachion (tenascin43.1 C,cytotacfin) 1 441406245957 Hs.7837Homo Sapiens cDNA FLJ 42.7 S 10457 fis, clone NT2RP1001 412969AI373162Hs.75103tyrosine 3-monooxygenaselUyptophan42.6 5-monooxygenas 423720AL044191Hs.23388Homo Sapiens cDNA: 42.5 FLJ21310 fis, clone 400111 predicted exon 42.4 407207T03651 Hs.179661tubulin, beta polypepfide42.4 417164AA338283Hs.81361heterogeneous nuclear 42.2 ribonucleoprotein AIB

424971AA479005Hs.154036tumor suppressing subtransferable41.9 candidate 3 439394AA149250Hs.56105ESTs, Weakly similar 41.9 to WDNM RAT WDNM1 PROT

406657AI678644Hs.277477major histocompatibility41.8 complex, class I, C

451092AI207256Hs.13766Homo Sapiens mRNA for 41.6 FLJ00074 protein, partial cds 25 412596AA161219Hs.799diphtheria toxin receptor41.6 (heparin-binding epidermal gro 422103AA984330Hs.111676protein kinase H11; 41.5 small stress protein-like protein HS

428785A1015953Hs.125265ESTs 41.3 450988BE618571Hs.429ATP synthase, H+transporting,41.0 mitochondria) FO camp 414622AI752666Hs.76669nicofinamide N-methylUansferase40.8 405022 predicted exon 40.8 408221AA912183Hs.47447ESTs 40.8 446500078093 Hs.15154sushi-repeat-containing40.7 protein, X chromosome 421416BE302950Hs.104125adenylyl cyclase-associated40.6 protein 412247AF022375Hs.73793vascular endothelial 40.5 growth factor 35 410541AA065003Hs.64179hypothetical protein 40.5 406658AI920965Hs.77961major histocompafibility40.0 complex, class I, B

420225AW243046Hs.94789ESTs 40.0 406825A1982529Hs.84298CD74 antigen (invariant39.4 polypeptide of major histocom 443623AA345519Hs.9641complement component 39.4 1, q subcomponent, alpha poly 40 404201AF059566Hs.103983solute cartier family 39.3 5 (sodium iodide symporter), mem 405138 predicted exon 39.1 408733AW264812Hs.254290ESTs 39.0 414044BE614194Hs.75721profilin 1 38.9 430152A8001325Hs.234642aquaporin 3 38.8 45 428121AB006622Hs.182536Homo Sapiens cDNA: 38.8 FLJ21370 fis, clone 434311BE543469Hs.266263Homo Sapiens cDNA FLJ1411538.7 fis, clone MAMMA10 406140 predicted exon 38.5 432918AF077200Hs.279813hypotheficalprolein 38.4 420107AL043980Hs.7886pellino (Drosophila) 38.4 homolog 1 5~ 427693BE546832Hs.180370cofilin 1 (non-muscle)38.1 448835BE277929Hs.11081ESTs, Weakly similar 38.1 to S57447 HPBRII-7 protein [H.

432374W68815 Hs.301885Homo Sapiens cDNA FLJ1134637.9 fis, clone PLACE1010 428383BE616599Hs.184029hypothefical protein 37.7 DKFZp761A052 436258AW867491Hs.107125ESTs, Weakly similar 37.7 to S57447 HPBRII-7 protein [H.

55 420798W93774 Hs.99936keratin 10 (epidertnolyfic37.7 hypedceratosis; keralosis palm 400327M18679 Hs.247942Human variant 5S rRNA-like37.6 gene and ORF, complete 401781 predicted exon 37.6 448257AW772070Hs.253146ESTs 37.3 428415AA337211Hs.184222Down syndrome crifical37.2 region gene 1 424206NM-003734Hs.198241amine oxidase, copper 37.2 , containing 3 (vascular adhesion p 406812AF000575Hs.67846leukocyte immunoglobulin-like37.2 receptor, subfamily 8 ( 425882083115 Hs.161002absentin melanoma 1 37.2 432501BE546532Hs.287329Fas binding protein 37.1 421786AI188653Hs.2i351ESTs 37.1 65 427981BE275986Hs.181311asparaginyl-tRNA synthetase37.0 410143AA188169Hs.288819Homo Sapiens cDNA: 36.8 FLJ21022 fis, clone 451328AW853606Hs.109012ESTs 36.7 414135NM 004419Hs.2128dual specificity phosphatase36.7 414602AW630088Hs.76550Homo sapiens mRNA; 36.7 cDNA DKFZp564B1264 (from 401785 predicted exon 36.5 411469T09997 Hs.70327cysteine-rich protein 36.2 419693AA133749Hs.92323FXYD domain-containing36.1 ion Uansport regulator 417039AA302180Hs.80986ATP synthase, H+Uansporfing,36.1 mitochonddal FO comp 406718AA505525Hs.169476glyceraldehyde-3-phosphate36.0 dehydrogenase 75 402543 predicted exon 36.0 408669AI493591Hs.78146plateleUendothelial 35.9 cell adhesion molecule (CD31 anfig 414987AA524394Hs.165544ESTs 35.9 445810AW265700Hs.155660ESTs ' 35.9 406653AA574074Hs.77961major histocompafibility35.7 complex, class I, B

g0 407498028131 gb:Human HMGI-C chimedc35.6 transcript mRNA, parfial 412524AA417813Hs.11177ESTs 35.5 401521 predicted exon 35.4 408948AW296713Hs.221441ESTs 35.1 406728AI986345Hs.183704ubiquitin C 34.9 440669AI206964 gb:qr30g06.x1 NCI CGAP34.8 GC6 Homo Sapiens cDNA

422658AF231981Hs.250175homolog of yeast long 34.8 chain polyunsaturated fatty acid 452924AW5B0939Hs.97199complement component 34.7 C1q receptor 428600AW863261Hs.15036ESTs, Highly similario34.7 [H.sapi 409828AW501137 gb:Ul-HF-BPOp-ait-e-12-0-ULr134.5 NIH MGC 51 Homo 459390BE385725 gb:601276347F1 NIH 34.5 MGC_20 Homo Sapiens cDNA

445055BE512856Hs.109051glycoprotein, synaptic34.3 411789AF245505Hs.72157Homo Sapiens adlican 34.3 mRNA, complete cds 410626BE407727 gb:601299771F1 NIH_MGC-2134.2 Homo Sapiens cDNA

1 410706A1732404Hs.68846ESTs 34.2 419273BE271180Hs.293490ESTs 34.2 d07839AA045144Hs.161566ESTs 34.0 444286A1625304Hs.190312ESTs 34.0 449226AB002365Hs.23311KIAA0367 protein 34.0 1 414290A1568801Hs.71721ESTs 33.9 401245 predicted exon 33.9 425222M85430Hs.155191villin 2 (ezrin) 33.8 409950842678Hs.301669KIAA0564 protein 33.8 437201F29279Hs.177486amyloid beta (A4) precursor33.7 protein (protease nexin-II, 406566AF088886Hs.11590cathepsin F 33.7 405071 predicted axon 33.7 455426AW937792 gb:OV3-DT0045-140200-082-b0733.6 DT0045 Homo sapi 415160T82802 gb:yd38a04.r1 Soares 33.5 fetal liver spleen 1NFLS Homo s 424995245023 gb:HSC2FA041 normalized33.5 infant brain cDNA
Homo s 453870AW385001Hs.8042Homo Sapiens cDNA: 33.5 FLJ23173 fis, clone 433470AW960564Hs.3337transmembrane 4 superfamily33.4 member 1 428188M98447Hs.22 iransglutaminase 1 33.3 (K polypepfide epidermal type I, pro 417409BE272506Hs.82109syndecan 1 33.3 425389AW974499Hs.192183ESTs 33.3 30 434658AI624436Hs.194488ESTs 33.2 456562AA306049Hs.102669DKFZP4340125 protein 33.1 447111A1017574Hs.17409cysteine-rich protein 33.0 1 (intestinal) 432360BE045243Hs.274416NADH dehydrogenase 32.9 (ubiquinone) 1 alpha subcomple 424125M31669Hs.1735inhibin, beta B (activin32.7 AB beta polypeptide) 3 419968X04430Hs.93913interleukin 6 (interferon,32.7 5 beta 2) 429415NM Hs.202097procollagen Gendopeptidase32.6 002593 enhancer 451541BE279383Hs.26557plakophilin 3 32.6 424499N90344Hs.149436kinesin family member 32.4 ~ 58 402144 predicted axon 32.4 40 422511AU076442Hs.117938collagen, type XVII, 32.4 alpha 1 400231 predicted axon 32.3 437712X04588Hs.85844neurotrophic tyrosine 32.3 kinase, receptor, type 1 417433BE270266Hs.82i285T4 oncofetal trophoblast32.2 glycoprotein 419659A8023206Hs.92186Lemon coiled-coil protein32.0 45 428582BE336699Hs.185055GENE protein 32.0 421401AW410478Hs.104019Uansforming, acidic 32.0 coiled-coil containing protein 3 414064BE245289Hs.16165expressed in activated32.0 TILAK lymphocytes 431938AA938471Hs.115242developmentally regulated32.0 GTP-binding protein 411930F06485 gb:HSC19G051 normalized31.9 infant brain cDNA
Homo s 428150AW950547Hs.182684cytochrome c oxidase ~
subunit Vlla polypeptide31.8 2 (liver) 401887 predicted axon 31.8 412570AA033517Hs.74047electron-Uansfer-fiavoprotein,31.7 beta polypeptide 422738X80915Hs.1573growth differentiation31.6 factor 5 (cartilage-derived morph 453092X64838Hs.31638restin (Reed-Steinberg31.5 cell-expressed intermediate filam 5 413924AL119964Hs.75616KIAA0018 gene product 31.4 S

420231806866Hs.19813ESTs 31.3 434715BE005346Hs.116410ESTs 31.3 422831802504 gb:yeB6fO6.r1 Soares 31.2 fetal liver spleen 1 NFLS Homo so 416854H40164Hs.80296Purkinje cell protein 31.2 422976AU076657Hs.1600sec61 homolog 31.1 4263568E536836 gb:601064837F1 NIH_MGC_1031.0 Homo Sapiens cDNA

433935AF112208Hs.44163l3kDadifferenfiation-associated30.8 protein 430040AW503115Hs.227823pM5 protein 30.8 406340AA299679Hs.180370cofilin 1 (non-muscle)30.8 65 426050AF017307Hs.166096E74-like factor 3 (ets30.7 domain Uanscription factor, epith 425105BE280066Hs.24956hypothetical protein 30.7 402066 predicted axon 30.7 429538BE182592Hs.139322small proline-rich 30.6 protein 3 418371M13560Hs.84298CD74 antigen (invariant30.4 polypeptide of major histocom 70 421251228913Hs.102948enigma (LIM domain 30.3 protein) 456084AA155B59Hs.79708ESTs 30.3 402023 predicted axon . 30.3 404356 predicted axon 30.2 415973824707Hs.260201ESTs 30.2 75 445983A1269107Hs.132219ESTs 30.1 450440A8024334Hs.25001tyrosine 3-monooxygenaseltryptophan30.1 5-monooxygenas 458789AL157468Hs.20157Homo Sapiens cDNA FLJ2084830.1 fis, clone ADKA01732 400842 predicted axon 30.1 406828AA419202Hs.84298CD74 antigen (invariant30.0 polypeptide of major histocom g0 423267AL137416Hs.126177Homo Sapiens mRNA; 30.0 cDNA DKFZp4340192 (from c 451383AW239364Hs.20242hypothetical protein 30.0 437042AK000702Hs.5420hypothetical protein 30.0 459399BE407712 gb:601299745F1 NIH 30.0 MGC_21 Homo Sapiens cDNA

425650NM-001944Hs.1925desmoglein 3 (pemphigus30.0 vulgads antigen) 416511NM-006762Hs.79356Lysosomal-associated 29.9 multispanning membrane protein 431009BE149762Hs.248213gap junction protein, 29.7 beta 6 (connexin 30) 436651BE045962Hs.275998ESTs 29.6 419766BE243101Hs.22391chromosome 20open reading29.5 frame 3 420747BE294407Hs.99910phosphofructokinase, 29.5 platelet 436895AF037335Hs.5338carbonic anhydrase 29.5 XII

412765AK000620Hs.74571ADP-ribosyialion factor29.4 419223X60111Hs.1244CD9 antigen(p24) 29.4 413796AW408094Hs.75545intedeukin 4 receptor 29.4 1~ 447795AW295151Hs.163612ESTs 29.4 431 M57399Hs.44 pleiofrophin (heparin 29.4 1 binding growth factor 03 8, neurite g 415314N88802Hs.5422glycoprotein M68 29.3 428411AW291464Hs.10338ESTs 29.3 430580AA806105Hs.140immunoglobulin heavy 29.3 constant gamma 3 (Gm marker) 15 430451AA836472Hs.249982cathepsin B 29.2 453949AU077146Hs.36927heatshock105kD 29.2 413859AW992356Hs.8364pymvate dehydrogenase 29.2 kinase, isoenzyme 407845AL036518Hs.118598ESTs 29.1 453500A1478427Hs.43125ESTs 29.1 456054BE313241 gb:601151545F1 NIN-MGC_1929.0 Homo Sapiens cDNA

453467AI535997Hs.30089ESTs 29.0 411794AL118577Hs.75658phosphorylase, glycogen;28.9 brain 421773W69233Hs.112457ESTs 28.9 423621BE002904 gb:OV4-BN0090-070400-163-c0728.8 BN0090 Hamo sapi 25 408935BE539706Hs.285363ESTs 28.8 450847NM Hs.25590stanniocalcin 1 28.8 431243U46455Hs.252189syndecan 4 (amphiglycan,28.7 ryudocan) 423225AA852604Hs.125359Thy-1 cell surface 28.7 antigen 433469F12741 gb:HSC3DG061 normalized28.7 infant brain cDNA
Homo 30 405783 predicted exon 28.7 417308H60720Hs.81892KIAA0i01 gene product 28.7 400749 predicted exon 28.7 413442BE140643 gb:RCO-HT0015-310599-01628.6 HT0015 Homo Sapiens c 404828 predicted exon 28.6 3 407453AJ132087 gb:Homo Sapiens mRNA 28.6 for axonemal dynein heavy ch 418529AW005695Hs.250897TRK-fused gene (NOTE: 28.6 non-standard symbol and nam 413787Ai352558Hs.75544tyrosine 3-monooxygenaseltryptophan28.5 5-monooxygenas 450690AA296696Hs.25334FXYD domain-containing28.5 ion fransport regulator 402430 predicted exon 28.4 40 413929BE501689Hs.75617collagen, type IV, 28.2 alpha 2 423803NM_005709Hs.132945PDZ-73 protein 28.2 406086 predicted exon 28.2 416585X54162Hs.79386leiomodin 1 (smooth 28.2 muscle) 417055N39489Hs.7258Homo sapiens cDNA: 28.1 FL,122021 fis, clone 45 449184AW296295Hs.196491ESTs 28.1 446542NM-004281Hs.15259BCL2-associated athanogene28.1 412793AW997986 gb:RC1-BN0056-230200-021-e1128.0 BN0056 Homo sapie 452818W21909Hs.8372ubiquinol-cytochrome 28.0 c reductase (6.4kD) subunit 402869 predicted exon 27.9 4361310AA353044Hs.5321ARP3 (actin-related 27.9 protein 3, yeast) homolog 402075 predicted exon 27.9 410480897457Hs.63984cadhedn 13, H-cadherin27.8 (heart) 406690M29540Hs.220529carcinoembryonic antigen-related27.8 cell adhesion molecul 439766AB033492Hs.301241Homo sapiens mRNA; 27.7 cDNA DKFZp586A0424 (from 55 424482BE268621Hs.149155voltage-dependent anion27.6 channel 1 420737L08096Hs.99899tumor necrosis factor 27.6 (ligand) superfamily, member 7 414663BE396326 gb:601289258F1 NIH 27.6 MGC_8 Homo Sapiens cDNA c 409703NM-006187Hs.560092'-5'oligoadenylate 27.6 synthetase 3 446108AL036596Hs.102773ESTs 27.5 60 428144BE269243Hs.182625VAMP (vesicle-associated27.5 membrane protein)-associate 445688AI248205'Hs.153244ESTs 27.5 405411 predicted exon 27.5 410275U85658Hs.61796franscription factor 27.5 AP-2 gamma (activating enhancer-b 424675NM Hs.151641glycoprotein A repetitions27.3 005512 predominant 65 450455AL117424Hs.25035chloddeintracellularchannel427.3 414855AA156986Hs.104640HIV-1 inducer of short27.2 franscripts binding protein 433578BE336886Hs.3416adipose differentiation-related27.2 protein 401994 predicted exon 27.2 445033AV652402Hs.155145ESTs 27.2 7~ 402277 predicted exon 27.1 428106BE620016Hs.182470PTDO10 protein 27.1 448625AW970786Hs.178470Homo Sapiens cDNA: 27.1 FLJ22662 fis, clone 422587AI879352Hs.118625hexokinase 1 27.0 457204BE264152Hs.221994ESTs 27.0 75 444094A1695764Hs.202394ESTs 27.0 414053BE391635Hs.75725fransgelin 2 26.9 430511BE018156Hs.2575calpain 1, (mull) large26.9 subunit 434039L32977Hs.3712ubiquinot-cytochrome 26.9 c reductase, Rieske iron-sulfur po 424939AK000059Hs.153881Homo Sapiens NY-REN-6226.9 antigen mRNA, partial cds 414539BE379046 gb:601236646F1 NIH_MGC-4426.9 Homo Sapiens cDNA

404675 predicted exon 26.8 401597AA172106Hs.110950Rag C protein 26.8 401405 predicted exon 26.8 411541W03940 gb:za62b02.r1 Soares 26.8 fetal liver spleen 1 NFLS Homo sa 412025AI827451Hs.24143ESTs 26.7 414276BE297862 gb:601174780F1 NIH 26.7 MGC_17 Homo sapiens cDNA

444065AW449415Hs.10260Homo Sapiens cDNA FLJ7134126.7 fis, clone PLACE1010 447981853772Hs.8929hypothetical protein 26.7 410677NM Hs.65424tetranecfin (plasminogen-binding26.5 003278 protein) 400982 predicted exon 26.5 452933AW391423Hs.288555Homo Sapiens cDNA: 26.5 FLJ22425 fis, clone 407233X16354Hs.50964carcinoembryonic anfigen-related26.4 cell adhesion molecul 430127AA219498Hs.233952proteasome (prosome, 26.3 macropain) subunit, alpha type 7 1 448218A1188489 gb:qd09b12.x1 Soares~lacenta26.3 ~ 8to9weeks_2NbHP8to 413511A1627178Hs.75412Arginine-rich protein 26.2 459511AI142379 gb:qg6dc01.r1 Soares 26.2 tesfis-NHT Homo Sapiens cDNA

4106688E379794Hs.65403hypothetical protein 26.2 458662AI823410Hs.169149karyopherin alpha 1 26.2 (imporiin alpha 5) 15 451219AA054209Hs.167904ESTs 26.2 448939BE267795Hs.22595hypotheficalprotein 26.2 400800Y10262Hs.46925eyes absent (Drosophila)26.2 homolog 3 446342BE298665Hs.14846Homo Sapiens mRNA; 26.2 cDNA DKFZp564D016 (from c 421177AW070211Hs.102415Homo Sapiens mRNA; 26.1 cDNA DKFZp586N0121 (from 433848AF095719Hs.93764carboxypepfidase A3 26.1 448497BE613269Hs.21893ESTs, Weakly similar 26.1 to glycerol 3-phosphate pertnease 415279F04237Hs.1447glial fibdllary acidic26.0 protein 419323A1092379Hs.135275ESTs 26.0 430265L36033Hs.237356stromal cell-derived 25.9 factor 1 25 437679NM Hs.5753inositol(myo):~(or4)-monophosphatase225.9 425535AB007937Hs.158287KIAA0468 gene product 25.8 412923AA179922Hs.75056adaptor-related protein25.8 complex 3, delta 1 subunit 447980AI703397Hs.202355ESTs 25.8 , 419118AA234223Hs.139204ESTs 25.8 421224AW402154Hs.125812ESTs 25.8 414890BE281095Hs.77573uridine phosphorylase 25.8 447330BE279949Hs.18141ladinin 1 25.7 405610 predicted exon 25.7 447604AW089933Hs.293674ESTs 25.7 3 445677H96577Hs.6838ras homolog gene family,25.7 member E

456088BE177320Hs.156148Homo Sapiens cDNA: 25.7 FLJ23082 fis, clone 417120N79687Hs.46616ESTs 25.6 405194 predicted exon 25.6 410687U24389Hs.65436lysyl oxidase-like 25.6 421888AA299780Hs.121036ESTs 25.6 420459AF016045Hs.97905ovo (Drosophila) homolog-like25.5 416323N72630Hs.33981Homo sapiens genomic 25.5 . DNA, chromosome 21q, section 446292AF081497Hs.279682Rh type G glycoprotein25.5 416274AW160404Hs.79126guanine nucteofide 25.5 binding protein 10 45 430028BE564110Hs.227750NADH dehydrogenase 25.5 (ubiquinone) 1 beta subcomplex 438450A1050866Hs.65853nodal, mouse, homolog 25.5 400215 predicted exon 25.4 430014H59354Hs.182485acfinin, alpha 4 25.4 453582AW854339Hs.33476hypothefical protein 25.4 FLJi1937 405867 predicted exon 25.4 459170AI905518 gb;RGBT091-210199-098 25.4 8T091 Homo Sapiens cDNA

407944834008Hs.239727desmocollin 2 25.4 415748090086Hs.979pyruvate dehydrogenase25.3 (lipoamide)beta 423287H38340 gb:yp70h07.r1 Soares 25.3 adult brain N2b4HB55Y
Homo s 55 450944AA554989Hs.209061sudD (suppressor of 25.3 bimD6, Aspergillus nidulans) homo 432906BE265489Hs.3123lethal giant larvae 25.3 (Drosophila) homolog 400104 predicted exon 25.3 449019AI949095Hs.67776ESTs, Weakly similar 25.3 to ALU7-HUMAN ALU
SUBFA

406897M57417 gb:Homo Sapiens mucin 25.3 (mucin) mRNA, partial cds.

402639 predicted exon 25.3 447147AA910353Hs.292815ESTs 25.3 453379AA035261Hs.61753ESTs 25.3 414217AI309298Hs.279898Homo Sapiens cDNA: 25.3 FLJ23165 fis, clone 430223NM Hs.235935nephroblastoma overexpressed25.3 002514 gene 65 406685M18728 gb:Human nonspecific 25.3 crossreacting antigen mRNA, co 444747AW450407Hs.257291ESTs, Weakly similar 25.2 to PSSS_HUMAN PROSTASIN

417883822519Hs.23398ESTs 25.2 430235BE268048Hs.236494RAB10, member RAS oncogene25.2 family d59001AI761313Hs.204605ESTs 25.2 434368AW519020Hs.212640Homo Sapiens cDNA FLJ1326525.2 fis, clone OVARC1000 415917143912 gb:HSCIOAi 1 t normalized25.2 infant brain cDNA
Homo 444409AI792140Hs.49265ESTs 25.2 428578BE391797Hs.82148hypothetical protein 25.1 433417AA587773Hs.136494ESTs 25.1 75 426372BE304680Hs.169531DEADIH (Asp-Glu-Ala-AspIHis)25.1 box polypepfide 21 402131 predicted exon 25.1 450545AW135582Hs.201767ESTs 25.0 434162A1221214Hs.116136ESTs 25.0 406571 predicted exon 24.9 427600AW630918Hs.179774proteasome (prosome, 24.9 macropain) activator subunit 2 (P

409402AF208234Hs.695cystatin B (stefin 24.9 B) 400135 predicted exon 24.9 426403AI393048Hs.239894leucine rich repeat 24.9 (in FLII) interacting protein 1 403223 predicted exon 24.8 435236T03890Hs.157208ESTs,HighlysimilartoArxhomeoprotein[M.musculu24.8 457439AW410408Hs.271167L-pipecolic acid oxidase24.8 448667278394Hs.d896Homo Sapiens cDNA: 24.8 FLJ22046 fis, clone 440605240094Hs.185698ESTs 24.8 426724AA383623Hs.293616ESTs 24.8 predicted exon 4.7 442826AIOi8777Hs.131241ESTs 24.7 411503AW190338Hs.28029purinergic receptor 24.6 P2X, ligand-gated ion channel, 4 414540BE379050 gb:601236655F1 NIH 24.6 MGC 44 Homo Sapiens cDNA

1 421595AB014520Hs.105958Homo Sapiens cDNA: 24.5 ~ FLJ22735 fis, clone 438802AA825976Hs.136954ESTs 24.5 400491H25530Hs.50868solute carrier family 24.5 22 (organic cotton transporter), me 418994AA296520Hs.89546selectin E (endothelial24.5 adhesion molecule 1) 426383BE537380 gb:601064570F1 NIH-MGC_1024.4 Homo Sapiens cDNA

1 418408AA219321Hs.173294ESTs 24.4 416186W87575Hs.269177ESTs 24.4 416908AA333990Hs.80424coagulafion factor 24.4 XII1, A1 polypepfide 453857AL080235Hs.35861DKFZP586E1621 protein 24.4 439706AW872527Hs.5976tESTs 24.4 441619NM-014056Hs.7917DKFZP564K247 protein 24.4 417198F11533Hs.81634ATP synthase, H+Uansporiing,24.3 mitochondrial FO comp 433662W07162Hs.150826CATX-8 protein 24.3 453986M13232Hs.36989coagulafion factor 24.3 VII (serum prothrombin conversion a 457123AA770021Hs.16332ESTs 24.3 25 433864AA931550Hs.192785ESTs 24.3 409865AW502208 gb:Ul-HF-BROp-aju-e-09-0-ULr124.3 NIH MGC 52Hom 448175BE296174Hs.225160Homo Sapiens cDNA FLJ1310224.3 fis, clone NT2RP3002 406277 predicted exon 24.3 451957AI796320Hs.10299Homo Sapiens cDNA FLJ1354524.3 fis, clone PLACE1006 3 408802AL048269Hs.288544Homo Sapiens cDNA: 24.2 ~ FLJ20882 fis, clone 401757 predicted exon 24.2 444751AI207d06Hs.11866hypotheficalprotein 24.2 408647AW245831 gb:2822937.5prime NIH 24.2 MGC 7 Homo Sapiens cDNA

418870AF147204Hs.89d14chemokine (GX-C motif),24.2 receptor 4 (fusin) 35 436913AA789074Hs.187478ESTs 24.2 434745AW974445Hs.185155ESTs, Weakly similar 24.2 to HuEMAP [H.sapiens]

451743AW074266Hs.23071ESTs 24.2 421853AL117472Hs.108924DKFZP586P1422 protein 24.2 407926AW956382Hs.59771ESTs 24.1 413973BE279858Hs.128417Homo Sapiens cDNA FLJ1400924.1 fis, clone Y79AA1002 439078AF085936 gb:Homo Sapiens full 24.1 length insert cDNA
clone YR58F

401913 predicted exon 24.1 435138BE314734 gb:601152976F1 NIH_MGC_1924.1 Homo Sapiens cDNA

405311 predicted exon 24.0 4$ 413127BE066529Hs.83484SRY (sex determining 24.0 region Y)-box 4 430793M83181Hs.2479d05-hydroxytryptamine 24.0 (serotonin) receptor 434445AI349306Hs.11782ESTs 24.0 418166AI754416Hs.260024Cdc42 effector protein24.0 431971BE274907Hs.77385myosin, light polypeptide23.9 6, alkali, smooth muscle and n 401167 predicted exon 23.9 454163AW175997 gb:QVO-BT0078-190899-005-E0223.9 BT0078 Homo sapi 403306NM Hs.74368Uansmembrane protein 23.9 006825 (63kD), endoplasmic reticuluml 410627AA181339Hs.929myosin, heavy polypeptide23.9 7, cardiac muscle, beta 450796NM Hs.25482envoplakin 23.8 55 442199BE277633Hs.286027etoposide-induced mRNA23.8 402699 predicted exon 23.8 426143BE379836Hs.167106proteasome (prosome, 23.8 macropain) subunit, alpha type, 3 437592NM Hs.5710cellular repressor 23.8 003851- ofEtA-sfimulatedgenes 433598AI762836Hs.271433ESTs, Moderately similar23.8 to ALU2-HUMAN ALU
SU

401088 predicted exon 23.8 445924AI264671Hs.164166ESTs 23.8 420902AA742277 gb:ny28e09.s1 NCI CGAP_GCBi23.8 Homo Sapiens cDN

426369AF134157Hs.169487Kreisler (mouse) maf 23.8 related leucine zipper homolog 458698AW452189Hs.257528ESTs 23.7 65 422048NM Hs.288126spondin 2, extracellular23.7 012445 matrix protein 413460Rfi1610Hs.21527ESTs, Weakly similar 23.6 to KIAA0918 protein [H.sapiens 401575 predicted exon 23.6 431822AA516049 gb:ng65d01.s1 NCI-CLAP-Lip223.6 Homo sapiens cDNA

427276AA400269Hs.49598ESTs 23.6 417069AA442192Hs.81097cytochrome c oxidase 23.5 subunit Vlll 400161 predicted exon 23.5 417190NM Hs.815482,4-dienoyl CoA reductase23.5 001359 1, mitochondrial 443667AI129066Hs.135457ESTs 23.5 413544BE147225 gb:PM2-HT0225-031299-003-f1123.5 HT0225 Homo sapie 75 400685 predicted exon 23.5 422090W05345Hs.293884ESTs 23.4 432517AF275816Hs.283096PR domain containing 23.4 predicted exon 23.4 416328H48389Hs.268886ESTs 23.4 go 427174AA398848Hs.97541ESTs 23.4 426148AI751071Hs.i67135Homo Sapiens cDNA FLJ1072823.3 fis, clone NT2RP3001 452544AW851888 gb:OVO-CT0225-131099-034-40523.3 CT0225 Homo sapie 404890 predicted exon 23.3 408725AA131539Hs.15669ESTs 23.3 428362AA426555Hs.169333ESTs 23.3 425349AA425234Hs.79886ribose 5-phosphate 23.3 isomerase A (ribose 5-phosphate ep 422440NM Hs.116724aldo-keto reductase 23.3 004812 family 1, member 811 (aldose redu 410962BE273749Hs.752FK506-binding protein 23.2 1A (l2kD) 411796AA807197Hs.6918ESTs 23.2 458954AW379075Hs.141742Homo Sapiens cDNA FLJ1221123.2 fis, clone MAMMA10 408896AI6104d7Hs.48778niban protein 23.2 457024AA397546Hs.119151ESTs 23.2 414591A1888490Hs.55902ESTs 23.2 1 437846AA773866Hs.244569ESTs 23.2 ~

401220 predicted exon 23.1 421747AI816224Hs.107747DKFZP566C243 protein 23.1 452950AA428123Hs.7745l7kD fetal brain protein23.1 414327BE408145Hs.185254ESTs, Moderately similar23.1 to NAG1 protein [R.norvegic 1 405256 predicted exon 23.1 452416AA026115Hs.114777ESTs 23.1 440684A1253123Hs.127356ESTs, Highly similar 23.1 to NEST_HUMAN NESTI
[H.sap 445603H08345Hs.106234ESTs 23.1 436306AA805939Hs.117927ESTs 23.1 20 434867AF159442Hs.103382phospholipid scramblase23.0 404727 predicted exon 23.0 407317AI20d033Hs.271461ESTs, Weakly similar 23.0 to ALUS_HUMAN ALU
SUBFA

405580 predicted exon 23.0 437898W81260Hs.43410ESTs 22.9 25 448781AW243419Hs.254048ESTs , 22.9 457297AW968188Hs.290999ESTs 22.9 405545 predicted exon 22.9 431562A1884334Hs.11637ESTs 22.9 440703AL137663Hs.7378Homo sapiens mRNA; 22.9 cDNA DKFZp434G227 (from c 30 439848AW979249 gb:EST391359 MAGE resequences,22.9 MAGP Homo sap 418149AA811473Hs.291877ESTs 22.9 439332AW842747Hs.293314ESTs, Highly similar 22.8 to unnamed protein product [H.sa 401566 predicted exon 22.8 425078NM Hs.154437phosphodiesterase 2A, 22.8 002599 cGMP-stimulated 35 406684X16354Hs.50964caroinoembryonic antigen-related22.8 cell adhesion molecul 421651AW860612Hs.283586ESTs 22.8 421064A1245432Hs.101382tumor necrosis factor,22.8 alpha-induced protein 441249AA971585Hs.166250ESTs 22.8 457624AA809159Hs.287581Homo Sapiens cDNA FLJ1354422.8 fis, clone PLACE1006 4~ 407395AF005082 gb:Homo Sapiens skin-specific22.8 protein (xp33) mRNA, p 459006AW298631Hs.2772thypothetical protein 22.8 436827H72187Hs.5322guanine nucleotide 22.7 binding protein (G
protein), gamma 418174120688Hs.83656Rho GDP dissociation 22.7 inhibitor (GDI) beta 418307U70867Hs.83974solute carrier family 22.7 21 (prostaglandin transporter), mem 45 456035N54956Hs.271726ESTs 22.7 457867AA045767Hs.5300bladdercancerassociated22.7 protein 440401A1126341Hs.143887ESTs 22.7 400126 predicted exon 22.7 414931AK000342Hs.77646Homo Sapiens mRNA; 22.7 cDNA DKFZp761 M0223 (from 406719A1832962Hs.169476glyceraldehyde-3-phosphate22.6 dehydrogenase 439675W95357Hs.138860Rho GTPase activating 22.6 protein 1 456058N94587Hs.55063ESTs 22.6 441926A1015051Hs.130953ESTs 22.6 428423AU076517Hs.184276solute carrier family 22.6 9 (sodiumlhydrogen exchanger), is 55 438516BE561958Hs.285823immunoglobulin heavy 22.6 constant mu 420674NM Hs.1327butyrylcholinesterase 22.6 422160AW582898 gb:ia07e04.y1 Human 22.5 Pancreatic Islets Homo Sapiens c 412408D51103Hs.73851ATP synthase, H+transporting,22.5 mitochondria) FO camp 400964 predicted exon 22.5 434360AW015415Hs.127780ESTs 22.5 427977AW630727Hs.181307H3 histone, family 22.4 450339A1693281Hs.54547ESTs 22.4 424059AW451266Hs.107418ESTs 22.4 414626BE410589 gb:601303308F1 NIH_MGC-2122.4 Homo sapiens cDNA

65 401991 predicted exon 22.4 419741NM Hs.93002ubiqui6n comer protein22.3 457952U25750Hs.210783Human chromosome 17q2122.3 mRNA clone 1046:1-1 422597BE245909Hs.118634ATP-binding cassette, 22.3 sub-family 8 (MDR1TAP), mem 429504X99133Hs.204238lipocalin 2 (oncogene 22.3 24p3) 447306AI373163Hs.170333ESTs 22.3 424966AU077312Hs.t solute comer family 22.3 539857 (cationic amino acid transporter, 422739H20106Hs.119591adaptor-related protein22.2 complex 2, sigma 1 subunit 432504AL121015Hs.277704oxygen regulated protein(150kD)22.2 423804AW403448Hs.1706interferon-stimulated 22.2 transcripUon factor 3, gamma (48k 75 404683AI924294Hs.173259uncharacterized bone 22.2 marrow protein BM033 441624AF220191Hs.179666uncharacterized hypothalamus22.2 protein HSMNP1 425751T19239Hs.1940crystallin, alpha B 22.2 452976844214Hs.101189ESTs 22.2 414642AA150350 gb:z103h01.r1 Soares~regnant-uterus22.2 NbHPU Homo 437452AL390127Hs.7104Homo Sapiens mRNA; 22.2 cDNA DKFZp761 P06121 (from 417426NM_002291Hs.82124laminin, beta 1 22.2 414774X02419Hs.77274plasminogen activator,22.1 urokinase 424631AA688021Hs.179808ESTs 22.1 413967AW204431Hs.117853ESTs 22.1 400174 predicted exon 22.1 431837T79326Hs.298262ESTs, Weakly similar 22.1 to dJ88J8.1 (H.sapiensJ

401628 predicted exon 22.1 418374AJ011916Hs.84359hypotheficalprotein 22.0 429297X82494Hs.198862fibulin 2 22.0 403508 predicted exon 22.0 432638A1017717Hs.126525chromosome 21 open 22.0 reading frame 15 407382AA503620 gb:ne49bOB.s1 NCI CGAP22.0 Co3 Homo Sapiens cDNA

411492T46848Hs.70337immunoglobulin superfamily,22.0 member 4 1 420185AL044056Hs.158047ESTs 22.0 409545BE296182 gb:601177324F1 NIH_MGC_1722.0 Homo Sapiens cDNA

426662AA879474Hs.122710ESTs 22.0 424247X14008Hs.234734lysozyme (renal amyloidosis)22.0 443062N77999Hs.8963Homo Sapiens mRNA full21.9 length insert cDNA
clone EU

1 422447AA310711Hs.12d340ESTs 21.9 421574AJ000152Hs.105924defensin,beta 2 21.9 435302A1076259Hs.190337ESTs 21.9 414527BE241739Hs.76359catalase 21.9 441436AW137772Hs.185980ESTs 21.9 454178AW177274 gb:CM2-CT0128-230899-005-a0221.8 CT0128 Homo sapie 448838BE614761 gb:601281335F1 NIH 21.8 MGC_39 Homo sapiens cDNA

427889AI400968Hs.181046dual specificity phosphatase21.8 3 (vaccinia virus phosphat 441114AA917466Hs.126600ESTs 21.8 451831NM_00167dHs.460aclivafing iranscripfion21.8 factor 3 ~

405600 predicted exon 21.8 446981AI6527d3Hs.197497ESTs 21.8 432839AA579465Hs.287332ESTs 21.8 405208 predicted exon 21.8 435025T08990Hs.4742anchor attachment protein21.7 1 (Gaa1 p, yeast) homolog 413976BE295452Hs.75655procollagen-proline, 21.7 2-oxoglutarate 4-dioxygenase (pro 423515AA327017Hs.162204ESTs 21.7 452329N36626Hs.29106mitogen-activated protein21.7 kinase phosphatase x 423050AA320946 gb:EST23529 Adipose 21.7 tissue, brown Homo Sapiens cD

413679BE156765 gb:RC1-HT0370-120100-012~c0921.7 HT0370 Homo sapie 35 442166AW845280Hs.204723ESTs 21.6 445585AI243836Hs.1d7066ESTs 21.6 406160 predicted exon 21.6 433025AA374743Hs.279920tyrosine 3-monooxygenase/tryptophan21.6 ' 5-monooxygenas 446598AW250546 gb:2821774.5prime NIH_MGC21.6 7 Homo Sapiens cDNA

434493AA635305Hs.121574ESTs 21.6 429582A1569068Hs.22247ESTs 21.6 403796 predicted exon 21.6 405028 predicted exon 21.6 426597AA382250Hs.145601ESTs 21.6 45 437308AA749417Hs.292353ESTs 21.6 447384AI377221Hs.40528ESTs 21.6 429060AW139155Hs.194995hypothefical protein 21.6 DKFZp43400320 437068AA743643Hs.291427ESTs 21.6 418509A8028624Hs.85539ATP synthase, H+transporfing,21.5 mitochondria) FO comp 432999BE29d029Hs.279903Ras homolog enriched 21.5 in brain 2 407663NM_016429Hs.37482C0PZ2 for nonclathrin 21.5 coat protein zeta-COP

446627AI973016Hs.15725hypothefical protein 21.5 413605BE152644 gb:CM1-HT0329-250200-128-f0921.5 HT0329 Homo sapie 427286AW732802Hs.2132epidermal growth factor21.5 receptor pathway substrate 55 405226 predicted exon 21.4 402570 predicted exon 21.4 457960AA771881Hs.298149ESTs 21.4 400684 predicted exon 21.4 425943H46986Hs.31861ESTs 21.4 60 434240AF119912Hs.25B119hypothefical protein 21.4 448376AI494332Hs.196963ESTs 21.4 408089H59799Hs.42644thioredoxin-like 21.4 400304AF005082Hs.113261Homo Sapiens skin-specific21.4 protein (xp33) mRNA, part 412652AI801777Hs.6774ESTs 21.4 65 428373A1751656Hs.183986poliovirus receptor-related21.3 2 (herpesvirus entry mediato 416138C18946Hs.79026myeloidleukemiafactor221.3 425184BE278288Hs.155048Lutheran blood group 21.3 (Auberger b antigen included) 411028AW813703 gb:RC3-ST0197-130100-014-h0921.3 ST0197 Homo sapien 417438243989Hs.821d1Human clone 23612 mRNA21.3 sequence 70 417534NM Hs.82251myosin IC 21.3 427767AI879283Hs.180714cytochrome c oxidase 21.2 subunit Vla polypepiide 433300AA582307 gb:nn49d09.s1 NCI-CGAP-Kid621.2 Homo Sapiens cDNA

452061A1074259Hs.469succinate dehydrogenase21.2 complex, subunit A, flavoprot 411939AI365585Hs.i46246ESTs 21.2 75 435060A1422719Hs.233349ESTs, Weakly similar 21.2 to fork head like protein [H.sapie 432412AI470549Hs.162201ESTs 21.2 407491S82769 gb:GABAA receptor gamma21.2 3 subunit [human, fetal bra 418960NM Hs.89525hepatoma-derfved growth21.1 004494 factor (high-mobility group p 426254BE018103Hs.168541Homo Sapiens mRNA full21.1 length insert cDNA
clone EU

458188AW297226Hs.137840ESTs, Moderately similar21.1 to SIXt HUMAN HOMEOB

406215 predicted exon 21.1 425461AK000602Hs.157938hypotheficalprotein 21.1 448296BE622756Hs.10949Homo Sapiens cDNA FLJ1416221.1 fis, clone NT2RM4002 409415A4579258Hs.6083Homo sapiens cDNA: 21.1 FLJ21028 fis, clone 408546W49512Hs.46348bradykinin receptor 21.1 Bt 450008H52970Hs.36688WAP four-disulfide core21.1 domain 1 430998AFi28847Hs.204038indolelhylamine N-methyltransferase21.1 438901AF085834Hs.29036ESTs 21.1 440500AA972165Hs.150308ESTs 21.1 413101BE065215 gb:RC1-BT0314-310300-015-f0121.1 BT0314 Homo sapie 447452BE618258Hs.102480ESTs 21.1 412446AI7680i5Hs.92127ESTs 21.1 418975T75496Hs.296980ESTs 21.0 1 454961AW847807 gb:IL3-CT0213-190200-040-E1221.0 ~ CT0213 Homo sapien 401072 predicted exon 21.0 401204 predicted exon 21.0 433626AF078859Hs.86347hypothetical protein 21.0 418047837633Hs.4847ESTs 21.0 1 443380AI792478Hs.135377ESTs 21.0 427424AA402453Hs.113011ESTs 21.0 433412AV653729Hs.8185CGI-44 protein; sulfide21.0 dehydrogenase like (yeast) 422599BE387202Hs.118638non-metaslatic cells 20.9 1, protein (NM23A) expressed in 435656893409Hs.120759ESTs 20.9 413745AW247252Hs.75514nucleoside phosphorylase20.9 418874T60872 gb:yb72h11.s1 Stratagene20.9 ovary (937217) Homo sapien 452574AF127481Hs.35093lymphoid blast crisis 20.9 oncogene ' 400332S66407Hs.248032FLT4 20.9 402421 predicted exon 20.9 25 427138N77624Hs.173717phosphatidic acid phosphatase20.9 type 2B

432038AA524746Hs.162110ESTs 20.8 423711AF059194Hs.131953v-maf musculoaponeurofic20.8 fibrosarcoma (avian) oncoge 402297 predicted exon 20.8 405133 predicted exon 20.8 436661AI125270Hs.128069ESTs, Weakly similar 20.8 to similar to collagen [C.elegans]

437836BE269291Hs.292458ESTs 20.8 437329AA811977Hs.291761ESTs 20.8 445830H10451Hs.42656Homo Sapiens cDNA FLJ1266720.8 fis, clone NT2RM4002 406824AW515961Hs.84298CD74 antigen (invariant20.7 polypeptide of major histocom 35 421271AW170057Hs.133179ESTs 20.7 predicted exon 0.7 414028AA782576Hs.4944Homo Sapiens cDNA FLJ1278320.7 fis, clone NT2RP2001 456728AL120077Hs.122967ketch (Drosophila)-like20.7 2 (Mayven) 417707AL035786Hs.82425actin related protein 20.7 213 complex, subunit 5 (16 kD) 438713H16902Hs.6749ESTs 20.7 450306ALO80080Hs.24766DKFZP564E1962 protein 20.7 438898AI819863Hs.106243ESTs 20.7 403273 predicted exon 20.7 414605BE390440 gb:601283601F1 NIH_MGC-4420.7 Homo Sapiens cDNA

45 401283 predicted exon 20.7 403703 predicted exon 20.6 416969A1815443Hs.283404organic cation transporter20.6 442400AW381148Hs.3593ESTs 20.6 4475638E536115Hs.160983ESTs 20.5 419754H52299Hs.75243bromodomain-containing 20.5 408204AA454501Hs.43666protein tyrosine phosphatase20.5 type IVA, member 3 450507AW295603Hs.250891ESTs 20.5 429612AF062649Hs.252587pituitary tumor-transforming20.5 413758BEi62391 gb:PM2-HT0451-090100-002-f0420.5 HT0451 Homo sapie 55 432140AK000404Hs.272688hypothetical protein 20.5 400642 predicted exon 20.4 431582F07136Hs.261828G protein-coupled receptor20.4 kinase 7 442724AA355525Hs.159604cysteinyl-iRNA synthetase20.4 417861AA334551Hs.82767sperm specific antigen 20.4 402948 predicted exon 20.4 411004AW813242 gb:MR3-ST0191-020200-207-g1020.4 ST0191 Homo sapie 435478AA682622 gb:zj20t09.s1 Soares 20.4 fetal liver_spleen 1NFLS Si Ho 447955BE544271Hs.288390Homo Sapiens cDNA: FLJ2279520.3 fis, clone KAIA2543 433592NM Hs.3436deleted in oral cancer 20.3 004642 (mouse, homology 1 420865N73241Hs.100001solute cartier family 20.3 17 (sodium phosphate), memt~er 1 449482AI784266Hs.28774ESTs 20.3 400807 predicted exon 20.3 419942025138Hs.93841potassium large conductance20.3 calcium-activated channel 420783AI659838Hs.99923lecfin, galactoside-binding,20.3 soluble, 7 (galectin 7) 402986BE244588Hs.6456chaperonin containing 20.3 TCP1, subunit 2 (beta) 451375. A1792066Hs.283902Homo Sapiens 8AC clone 20.3 RP11-d81J13 from 2 453586AA248089Hs.50841ESTs, Weakly similar 20.3 to tuftelin [M.musculus]

433090AI720050Hs.145362immortalization-upregulated20.3 protein 425053AF046024Hs.154320ubiquifin-acfivafing 20.3 enzyme E1 C (homologous to yeast 75 412802041518Hs.74602aquapodn 1 (channel-forming20.3 integral protein, 28kD) 409738BE222975Hs.56205insulin induced gene 20.3 428245AF151048Hs.183180hypothefical protein 20.2 412582BE270631Hs.74077proteasome (prosome, 20.2 macropain) subunit, alpha type, 6 406207 predicted exon 20.2 400931 predicted exon 20.2 410709AL122109Hs.65735Homo Sapiens mRNA; cDNA20.2 DKFZp434M1827 (from 428436NM-001955Hs.2271endothelin 1 20.2 446918AL135125Hs.13913KIAA1577 protein 20.2 417821BE245149Hs.82643protein tyrosine kinase20.2 429113D28235Hs.196384prostaglandin-endoperoxide20.2 synthase 2 (prostaglandin G

414511AAi48725Hs.12969hypothetical protein 20.2 451546AF051782Hs.26584Homo Sapiens clone 20.1 CDABP0038 mRNA sequence 441899AI372588Hs.8022TU3A protein 20.1 425811AL039104Hs.159557karyophedn alpha 2 20.1 (RAG cohort 1, importin alpha 1) 411014AW816072 gb:MR3-ST0220-070100-021-h0720.1 ST0220 Homo sapie 451400BE160479 gb:QV1-HT0413-210200-081-g0520.1 HT0413 Homo sapi 459247N46243Hs.110373ESTs 20.1 441633AW958544Hs.112242ESTs 20.1 1 427466AA523543Hs.7678cellular retinoic acid-binding20.0 ~ protein 1 406893M22406 gb:Human intestinal 20.0 mucin mRNA, partial cds, clone SM

406268 predicted exon 20.0 403348 predicted exon 20.0 400970 predicted exon 20.0 15 414045NM-002951Hs.75722ribophorin II 20.0 427169AA398823Hs.97549EST 20.0 405586 predicted exon 20.0 445834AI913290Hs.145532ESTs, Weakly similar 20.0 to Gag polyprotein [M.musculus 422525AA75B797Hs.192807ESTs 20.0 425383D83407Hs.156007Down syndrome critical20.0 region gene 1-like 454590AW809762Hs.222056Homo sapiens cDNA FLJ1157220.0 fis, clone HEMBA100 411529AA430348Hs.288837Homo Sapiens cDNA FLJ1292720.0 fis, clone NT2RP2004 425397J04088Hs.i56346topoisomerase (DNA) 20.0 II alpha (170kD) 403234 predicted exoh 19.9 427267At201185Hs.119164ESTs 19.9 400203 predicted exon 19.9 449296AL137257Hs.23458Homo Sapiens mRNA; 19.9 cDNA DKFZp43401613 (from 406704M21665Hs.929myosin, heavy polypepfide19.9 7, cardiac muscle, beta 423083AA321774Hs.10941ESTs, Weakly similar 19.9 to IPP1 HUMAN PROTEIN
PH

422112BE540240Hs.111783Lsm1 protein 19.9 413282BE078159 gb:CMO-BT0615-140200-175-e0619.9 BT0615 Homo sapie 453702AA037637Hs.42128ESTs 19.9 403065 predicted exon 19.9 440633AI140686Hs.263320ESTs 19.9 35 456994AA383623Hs.293616ESTs 19.9 458260841782Hs.22279ESTs 19.9 452388BE019696Hs.29287retinoblastoma-binding19.9 protein 8 422278AF072873Hs.114218fiizzled (Drosophila) 19.9 homolog 6 441989AA306207Hs.286241Homo Sapiens cDNA: 19.9 FLJ22698 fis, clone HSIi 2044 418758AW959311Hs.87019ESTs 19.9 406646M33600Hs.180255major histocompatibility19.8 complex, class II, DR beta 1 d33053BE301909Hs.279952glutathione S-transferase19.8 subunit 13 homolog 414194BE175494Hs.75811N-acylsphingosine amidohydrolase19.8 (acid ceramidase) 452321AW844498Hs.289052Homo Sapiens LENG8 19.8 mRNA, variant C, partial sequen 45 449713AW027025Hs.239262ESTs 19.8 458827AW970786Hs.178470Homo Sapiens cDNA: 19.8 FLJ22662 fis, clone 414092214244Hs.75752cytochromecoxidasesubunitVllb19.8 441730AI243276Hs.149017ESTs 19.8 420701N42919Hs.88630ESTs, Weakly similar 19.8 to AC0072281 831665 2 [H.sap 403642 predicted exon 19.8 d08987H85615 gb:yt03f11.r1 Soares 19.8 retina N2b5HR Homo sapiens cD

446712AW204789Hs.209828ESTs 19.8 403286 predicted exon 19.8 434439A1022360Hs.190583ESTs 19.8 55 404067 predicted exon 19.7 455694BE067300 gb:PM2-BT0349-161299-001-h1019.7 BT0349 Homo sapie 403287 predicted exon 19.7 434633AI189587Hs.120915ESTs 19.7 408199AA132637Hs.15396ESTs 19.7 420080M94065Hs.94925dihydroorotate dehydrogenase19.7 408852AW291435Hs.254961ESTs 19.7 403786 predicted exon 19.7 416839H94900Hs.17882ESTs 19.7 434385AA631946Hs.259580ESTs 19.7 65 446645A1343645Hs.156108ESTs 19.7 425612BE004257 gb:CMO-BN0103-180300-296-c0419.7 8N0103 Homo sapi 402520 predicted exon 19.6 436098820597Hs.9739ESTs 19.6 438974AF089816Hs.6454chromosome 19 open 19.6 reading frame 3 7~ 447751AA339541Hs.24956hypothetical protein 19.6 451310AW250651Hs.26213ESTs, Moderately similar19.6 to dJ447F3.3 [H.sapiens]

435961BE293127Hs.283722GTTt protein 19.6 452937BE410390Hs.288940five-span transmembrane19.6 protein M83 404850 prodicted exon 19.6 75 438360H74149Hs.288193hypothetical protein 19.6 436508AW604381Hs.121121ESTs 19.6 4304868E062109Hs.241551chloride channel, calcium19.6 acfivated, family member 2 407824AA147884Hs.9812ESTs 19.6 406388 predicted exon 19.6 $0 430204AA618335Hs.146137ESTs, Weakly similar 19.5 to putative [C.elegans]

457560AI801934Hs.163909ESTs 19.5 429521BE048708Hs.50949ESTs 19.5 429758AW137722Hs.246804ESTs 19.5 441473AA934995Hs.184846ESTs, Weakly similar 19.5 to 8288301 [H.sapiens]
.

411724AA770559Hs.71618polymerase (RNA) II 19.5 (DNA directed) polypeptide L (7.

450453AA009883Hs.50186ESTs 19.5 419687A1638859Hs.227699ESTs, Weakly similar 19.5 to Yhr217cp [S.cerevisiae]

442162AW294966Hs.150849ESTs 19.5 435056AW023337Hs.5422glycoprotein M6B 19.5 417412X16896Hs.82112intedeukin 1 receptor,19.5 type I

413825BE299181Hs.75564CD151 antigen 19.4 422687AW068823Hs.119206insulin-like growth 19.4 factor binding protein 435551AF212365Hs.5470IL-178 receptor 19.4 1 440069BE617892Hs.6895acfin related protein 19.4 ~ 213 complex, subunit 3 (21 kD) 432277AI669790Hs.161825ESTs 19.4 428044AA093322Hs.182225RNA binding motif protein19.4 456064AA256213Hs.72010ESTs 19.4 424897D63216Hs.153684fizzled-related protein19.4 15 424673AA345051Hs.294092ESTs 19.4 403852 predicted exon 19.3 405699 predicted exon 19.3 433096AU076803Hs,282975carboxylesterase 2 19.3 (intestine, liver) 400344NM-012368Hs.258574olfactory receptor, 19.3 . family 2, subfamily C, member 1 20 417501AL041219Hs.82222sema domain, immunoglobulin19.3 domain (1g), short basic 400449 predicted exon 19.3 453801ALi34751Hs.23450mRNAforFLJ00023 protein19.3 435849BE305242Hs.112442ESTs, Weakly similar 19.3 to CLDE HUMAN CLAUDIN-454181AW177377 gb:CM4-CT0129-190899-007-e0919.3 CT0129 Homo sapie 25 414807AI738616Hs.77348hydroxyprostaglandin 19.3 dehydrogenase 15-(NAD) 406326 predicted exon 19.3 421921H83363Hs.109571translocase of inner 19.3 mitochondrial membrane 10 (yeast) 416700AW498958Hs.79572cathepsin D (lysosomal19.2 aspartyl protease) 458857AI627342Hs.224601ESTs 19.2 405501 predicted exon 19.2 416601808652Hs.20205hemoglobin, beta pseudogene19.2 426600NM Hs.171014VGF nerve growth factor19.2 003378 inducible 425590AI954686Hs.158321beaded filament structural19.2 protein 2, phakinin 428151AA422028 gb:zv26g06.r1 Soares-NhNMPu-S119.2 Homo sapiens cDN

35 426420BE383808Hs.169829KIAA1180 protein 19.2 414428BE296906Hs.182625VAMP (vesicle.associaled19.2 membrane protein)-associate 404601 predicted exon 19.2 403861 predicted exon _ 19.2 448363BE174595Hs.3666-pyruvoyltetrahydropterin19.2 synthase 40 406655M21533Hs.181244ma]or hislocompatibility19.1 complex, class I, A

435372AA809591Hs.106486ESTs, Highly similar 19.1 to CIKG HUMAN VOLTAGE-G

413154BE067870 gb:RCO-BT0362-021299-031-b0619.1 BT0362 Homo sapie 443021AA368546Hs.8904Ig superfamily protein19.1 412975T70956Hs.75106clusterin (complement 19.1 lysis inhibitor, 5P-40,40, sulfated 45 412633AF001691Hs.74304pedplakin 19.1 402071 predicted exon 19.1 410387AI277367Hs.47094ESTs 19.1 423961D13666Hs.136348osteoblast specific 19.1 factor 2 (fasciclin I-like) 407032U73799 gb:Human dynactin mRNA,19.0 partial cds.

404034 predicted exon 19.0 456534X91195Hs.100623phospholipase C,beta 19.0 3,neighborpseudogene 446599297832Hs.15476differentially expressed19.0 in FDCP (mouse homology 426410BE298446Hs.180372BCL2-like 1 19.0 419618AA528295 gb:nh26e06.s1 NCI_CGAP_Pr319.0 Homo Sapiens cDNA
c 457632AW292151Hs.112689ESTs 19.0 S

417138AA193646Hs.65771Homo Sapiens chromosome19.0 19, BAC CIT-HSPC_204F

417933X02308Hs.82962thymidylate synthetase19.0 458808AW134832Hs.246295ESTs 19.0 415860D56051Hs.78888diazepam binding inhibitor18.9 (GABA receptor modulator 440919AW291274Hs.262826ESTs 18.9 423725AJ403108Hs.132127hypotheficalprotein 18.9 401747 predicted exon 18.9 454209AW179083 gb:MR4-ST0065-270899-006-A0718.8 ST0065 Homo sapi 417661T84155Hs.15464Homo Sapiens cDNA: 18.8 FLJ21351 fis, clone 65 426499C14937Hs.11169Gene 331Mig-6 18.8 404240 predicted exon 18.8 439718AA307634Hs.6650vacuolar protein sorting18.8 458 (yeast homology 401789 predicted exon 18.8 456952AW445081Hs.301469ESTs 18.8 439739A1199391Hs.124464ESTs 18.8 437974T74445Hs.5957Homo sapiens clone 18.8 24416 mRNA sequence 427490295152Hs.178695mitogen-acfivated protein18.8 kinase 13 443482AW188093Hs.250385ESTs 18.8 411420BE390652 gb:601286820F1 NIH 18.8 MGC-44 Homo Sapiens cDNA

75 435196F35675Hs.188128ESTs, Moderately similar18.8 1o ALUB HUMAN !!!!
ALU

417022NM-014737Hs.80905Ras associafion (RaIGDSIAF-6)18.8 domain family 2 413531AL036958Hs.75416DAZ associated protein18.7 428981BE313077Hs.93135ESTs 18.7 421598AW630942Hs.106061RD RNA-binding protein18.7 443907AU076484Hs.9963TYRO protein tyrosine 18.7 kinase binding protein 406754AA477223Hs.75922brain protein 13 18.7 400661 predicted exon ~ 18.7 442638A1088742Hs.134713ESTs 18.7 434169AA883752Hs.179724ESTs 18.7 llg 424126AA335635Hs.96917ESTs 18.7 408473BE259039Hs.129953Ewing sarcoma breakpoint18.7 region 1 401962 predicted exon 18.7 447326AW002252Hs.201395ESTs 18.7 459053AI807052Hs.210361ESTs 18.7 403362 predicted exon 18.7 427697T18997Hs.180372BCL2-like 1 18.7 402061H83363Hs.109571Uanslocase of inner 18.7 mitochondrial membrane 10 (yeast) 433785BE044593Hs.112704ESTs 18.7 1 405423 predicted exon 18.6 ~

429259AA420450Hs.292911ESTs 18.6 444071A1627808Hs.110524ESTs 18.6 410512AA085603Hs.250570ESTs 18.6 440376A1024452Hs.236816ESTs 18.6 15 457353X65633Hs.24814dmelanocortin 2 receptor18.6 (adrenocorticotropic hormone) 432749NM-014438Hs.278909Interleukin-1 Superfamily18.6 a .

415602F12920Hs.165575ESTs 18.6 407891AA486620Hs.41135endomucin-2 18.6 455910243712 gb:HSC1JA121 normalized18.6 infant brain cDNA
Homo s 426716NM Hs.171921sema domain, immunoglobulin18.6 006379 domain (1g), short basic 444246H93281Hs.10710hypotheflcalprotein 18.6 428125AA393071Hs.182579leucine aminopeptidase18.6 406457 predicted exon 18.5 446625AI333070Hs.156141ESTs 18.5 423334AK000906Hs.127273hypotheUcalprotein 18.5 423103AA322029 gb:EST24685'Cerebellum18.5 II Homo Sapiens cDNA
5' en 443549T89608Hs.16601ESTs 18.5 419299A1311085Hs.62406Homo Sapiens cDNA: 18.5 FLJ22573 fls, clone 411942AW877015 gb:QV2-PT0010-250300-096-f1218.5 PT0010 Homo sapien 3 442440BE464435Hs.146180ESTs, Weakly similar 18.5 0 to non-receptor protein tyrosine k 454574AW809109 gb:MR4-ST0117-070100-027-a0418.5 ST0117 Homo sapie 454377AA076811 gb:7B03C12 Chromosome 18.5 7 Feiai Brain cDNA
Library 422365AF035537Hs.i REV3 (yeast homology-like,18.5 15521 catalytic subunit of DNA p 421733AL119671Hs.1420fibroblast growth factor18.5 receptor 3 (achondroplasia, tha 35 420603A8042636Hs.4775junctophilin 3 18.4 401373 predicted exon 18.4 402292 predicted exon 18.4 444118AA458542Hs.10326coatomer protein complex,18.4 subunit epsilon 408310AW179023 gb:PM3-ST0036-170899-001-e0818.4 ST0036 Homo sapie 411236AW833752 gb:QVd-TT0008-130100-077-b0718.4 TT0008 Homo sapie 431405AI470895Hs.252574ritwsomal protein LlOa18.4 441408AI733249Hs.i26897ESTs 18.4 453994BE180964Hs.165590ribosomal protein S13 18.4 444518AI160278Hs.146884ESTs 18.4 45 402407 predicted exon 18.4 404270 predicted exon 18.4 409103AF251237Hs.112208RAGE-1 protein 18.4 415198AW009480Hs.943natural killer cell 18.3 Uanscript 4 430771BE387244Hs.2664flavin containing monooxygenase18.3 S 432636AA340864Hs.278562claudin 7 18.3 o 433504NM Hs.3363KIAA0214 gene product 18.3 415606W70022 gb:zd51e10.r1 Soares 18.3 fetal heart-NbHH19W
Homo so 401401BE047878Hs.99093Homo Sapiens chromosome18.3 19, cosmid 828379 420758AW297536Hs.33053ESTs 18.3 55 457520AA553495Hs.162264ESTs 18.3 432323AK001409Hs.274356hypotheGcalprotein 18.3 404750 predicted exon 18.3 450645AL117441Hs.25264DKFZP434N126 protein 18.3 .

445160AI299144Hs.150797ESTs 18.3 418461BE242781Hs.288037Homo Sapiens cDNA FLJ1299918.3 fis, clone NT2RP3000 40.1809 predicted exon 18.3 458121S42416Hs.74647Human T-cell receptor 18.3 active alpha~chain mRNA from 435106AA100847Hs.193380ESTs, Highly similar 18.3 to AF1746001 F-box protein Fbx 448398AW444655Hs.170838ESTs 18.3 65 428145BE243327Hs.182626chromosome 22 open 18.2 reading frame 5 445302AK001537Hs.12488hypotheflcal protein 18.2 407352H47860 gb:yp76h12.r1 Soares 18.2 fetal liver spleen 1 NFLS Homo s 413190AA151802Hs.40368adaplor-related protein18.2 complex 1, sigma 2 subunit 436371AI821912Hs.113912ESTs 18.2 400965 predicted exon 18.2 433427AI816449Hs.171889cholinephosphotransferase18.2 427504AA776743Hs.191589ESTs 18.2 426759A1590401Hs.21213ESTs 18.2 423792AW135866Hs.245854ESTs 18.2 75 406826AW516005Hs.84298CD74 anflgen (invariant18.1 polypeptide of major histocom 406659AA663985Hs.277477major histocompatibility18.1 complex, class I, C

437453AI761350Hs.181391hypothetical protein 18.1 DKFZp761G2113 ~

409276AW372097Hs.278429hepatocellular carcinoma-associated18.1 antigen 59 449628AI697676Hs.197713ESTs 18.1 421043BE379455Hs.89072ESTs 18.1 442344A1022925Hs.301212ESTs 18.1 448744AL135424Hs.9469phosphoinositol 3-phosphate18.1 binding protein-1 416062AA724811Hs.74427p53-induced protein 18.1 414500W24087Hs.76285DKFZP5648167 protein 18.1 427272NM Hs.17d140ATP citrate lyase 18.1 403964 predicted exon 18.1 433217AB040914Hs.278628KIAA1481 protein 18.1 427902AI809202Hs.208343ESTs, Weakly similar 18.1 to cerebroside sulfoUansferase [H

449586AI863918Hs.195078ESTs 18.1 430826U10061Hs.248019POU domain, class 4, 18.1 Uanscription factor 414195BE263293 gb:601144881F2 NIH 18.1 MGC_19 Homo Sapiens cDNA

416305AU076628Hs.79187coxsackie virus and 18.1 adenovirus receptor 411088BE247593Hs.145053ESTs 18.1 419407AW410377Hs.41502Homo Sapiens cDNA: 16.1 FLJ21276 fis, clone 407938AA905097Hs.85050phospholamban 18.1 449360AI640623Hs.252720ESTs 18.1 d17286AA122237Hs.81874microsomal glutathione18.0 S-Uansferase 2 405515 predicted exon 18.0 439319AW016401Hs.233476ESTs 18.0 419387BE379356Hs.90107cell membrane glycoprotein,110000M(r)18.0 (surface antig 414015AA34098Hs.756937 18.0 prolylcarboxypeptidase (angiotensinase C) 447778BE620592Hs.71190ESTs 18.0 435523T62849Hs.11090high affinity immunoglobulin18.0 epsilon receptor beta sub 429230AF088991Hs.198274NADH dehydrogenase 18.0 (ubiquinone) 1 beta sutxomplex 457822AA970001Hs.150319ESTs 18.0 442424AI342715Hs.129569ESTs, Moderately similar18.0 to 834087 hypothetical prote 418394AF132818Hs.84728Kroppel-like factor 18.0 5 (intestinal) 413477AI815825Hs.48756ESTs, Moderately similar18.0 to neuronal-STOP protein [M

405277 predicted exon 18.0 450192AA263143Hs.24596RAD51-interaEting protein18.0 442191W95186Hs.8136endothelial PAS domain18.0 protein 1 429490AI971131Hs.293684ESTs, Weakly similar 18.0 to alternatively spliced product a 406744AA554082Hs.279860hypothetical protein 17.9 425205NM_005854Hs.155106receptor (calcitonin) 17.9 activity modifying protein 2 414387AL043148Hs.186257ESTs 17.9 411811AW864370 gb:PM4-SN0016-100500-004-h0917.9 SN0016 Homo sapie 433882U90441Hs.3622procollagen-proline, 17.9 2-oxoglutarate 4-dioxygenase (pro 414333BE274897 gb:601122959F1 NIH_MGC_2017.9 Homo Sapiens cDNA

403747 predicted exon 17.9 435542AA687376Hs.269533ESTs 17.9 403093 predicted exon 17.9 412088AI689496Hs.108932ESTs 17.9 450506NM Hs.418fibroblast activation 17.9 004460 protein, alpha 404763 predicted exon 17.9 454633AW811380 gb:IL3-5T0143-290999-019-D0517.9 ST0143 Homo sapien 440788AI806594Hs.128577ESTs 17.9 411800N39342Hs.5184TH1 drosophila homolog17.9 441361BE263308Hs.7797TERFi (TRFt)-interacting17.8 nuclearfactor2 422033AW245805Hs.110903claudin 5 (Uansmembrane17.8 protein deleted in velocardiof d05333 predicted exon 17.8 408297817710Hs.113314ESTs 17.8 403036 predicted exon 17.8 417924AU077231Hs.82932cyclin Di (PRAD1: parathyroid17.8 adenomatosis 1) 417091AA193283Hs.291990ESTs 17.8 440789AB007857Hs.7416KIAA0397 gene product 17.8 438397AA806478Hs.123206ESTs 17.8 435948AA702675Hs.114135ESTs 17.8 450273AW296454Hs.24743hypothetical protein 17.8 435969W85773Hs.191386ESTs 17.8 427031AA397601Hs.125147ESTs 17.8 454505AW801365 gb:IL5-UM0067-240300-050-a0117.8 UM0067 Homo sapi 403447 predicted exon 17.8 433297AV658581Hs.282633ESTs 17.8 443326BE156494Hs.188478ESTs t7.8 448283AI340462Hs.182979ribosomal protein L12 17.8 458067AA393603Hs.36752Homo Sapiens cDNA: 17.8 FLJ22834 fis, clone 452359BE167229Hs.29206Homo Sapiens clone 17.8 24659 mRNA sequence 434098AA625499 gb:af69g08.r1 Soares_NhHMPu_S117.8 Homo Sapiens cDN

450911AA011586Hs.272097ESTs 17.7 410342831350Hs.743Fc fragment of IgE, 17.7 high affinity I, receptor far; gamma 407082247055 gb:Human partial cDNA 17.7 sequence, famesyl pyrophosph 415271X94232Hs.78335microtubule-associated17.7 protein, RP/EB family, member 417413AA197072Hs.86092Human DNA sequence 17.7 from clone RP11-243Ji 6 on chr 408937AA210734Hs.291386ESTs 17.7 433459AA593498 gb:nn27b05.s1 NCI_CGAP-Gas117.7 Homo Sapiens cDNA

459536AI254723Hs.145496ESTs 17.7 428500AI815395Hs.184641delta-6 fatty acid 17.7 desaturase 433463841963Hs.4197ESTs 17.7 406537 predicted exon 17.7 410003AA079487 gb:zm97f08.s1 SUatagene17.7 colon HT29 (937221) Homo 440857AA907808Hs.135556ESTs 17.7 451072AA013451Hs.117929ESTs 17.7 418693AI750878Hs.87409ihrombospondin 1 17.7 443624BE616129Hs.9651related RAS viral (r-ras)17.6 oncogene homolog 422626AA344932Hs.118786metallothionein 2A 17.6 410756AB037820Hs.66159KIAA1399 protein 17.6 436621AI266254Hs.132929ESTs 17.6 453317NM-002277Hs.41696keratin, hair, acidic,l17.6 456828AFt56889Hs.1d8427LIM homeobox protein 17.6 421486AWd08800Hs.104859hypothetical protein 17.6 DKFZp762E1312 428834AW899713Hs.10338ESTs 17.6 451419836309Hs.174369EST 17.6 448413A1745379Hs.42911ESTs 17.6 424323AA338791Hs.146763nascent-polypepflde-associated17.6 complex alpha polypept 423943AF163570Hs.135756polymerase (DNA-directed)17.6 kappa 439423BE536678Hs.147099ESTs 17.6 434025AFt Hs.216381Homo Sapiens clone 17.6 14264 HH409 unknown mRNA

1 408246N55669Hs.43946L13 protein 17.6 441579AW468847Hs.12719dESTs 17.5 420667NM_0i4183Hs.104002HSPC162protein 17.5 453680AL079647Hs.14485ESTs 17.5 400202 prodicted exon 17.5 15410768AF038185Hs.66187Homo Sapiens clone 17.5 23700 mRNA sequence 409932AI376750Hs.57600adaptor-related protein17.5 complex 1, sigma 1 subunit 425563AF084199Hs.299837ESTs 17.5 440475A1807671Hs.128343ESTs 17.5 452767AW014195Hs.61472ESTs, Weakly similar 17.5 to unknown [S.cerevisiae]

20410570AI133096Hs.64593ATP synthase, H+transporflng,17.4 mitochonddai F1F0, su 419600AA448958Hs.91481NEU1 protein 17.4 419588AI347205Hs.91375Human clone 23614 mRNA17.4 sequence 428975NM Hs.194694mitogen-acflvated protein17.4 004672 kinase kinase kinase 448928AI350260Hs.5384Homo Sapiens cDNA FLJ1174317.4 fis, clone HEMBA100 403924 predicted exon 17.4 419889AA251600 gb:zs10d12.r1~NCl CGAP-GCBs17.4 HomosapienscDNA

405023AW408800Hs.104859hypothetical protein 17.4 DKFZp762E1312 426065N32049 gb:yw96g08.s1 Soares-placenta17.4 8to9weeks 2NbHP8to 453199A1336266Hs.301854Homo Sapiens PR00412 17.4 mRNA, complete cds 455132AW857955 gb:PMO-CT0325-151299-002-A1217.4 CT0325 Homo sapi 442932AA457211Hs.8858bromodomainadjacenttozincfingerdomain,lA17.4 432065AA401039Hs.2903protein phosphatase 17.3 4 (formerly X), catalyflc subunit 444652BE513613Hs.11538acfln related protein 17.3 213 complex, subunit 1A (41 kD) 417935853697Hs.170044_ 17.3 ESTs 35430050AA430993Hs.227913AP15-like 1 17.3 446272BE268912Hs.14601hematopoieflc cell-specific17.3 Lyn substrate 1 425996W67330Hs.81256S100 calcium-binding 17.3 protein A4 (calcium protein, calv 416964D87467Hs.80620guanine nucleotide 17.3 exchange factor for Rapl; M-Ras-re 437418AI478954Hs.59459ESTs 17.3 447255A1884908Hs.158607ESTs 17.3 402203 predicted exon 17.3 417611AW993983 gb:RC1-BN0035-130400-013-a0417.3 BN0035 Homo sapie 426560AA381661Hs.119878ESTs 17.3 446163AA026880Hs.25252Homo Sapiens cDNA FLJ 17.3 13603 fis, clone PLACE1010 45445017AI205493Hs.176860ESTs 17.3 438658A1222068Hs.123571ESTs ' 17.3 442238AW135374Hs.270949ESTs 17.3 443195BE148235Hs.193063Homo Sapiens cDNA FLJ1420117.3 fis, clone NT2RP3002 442609AL020996Hs.8518selenoprolein N 17.2 50416591AA091976Hs.79387proleasome (prosome, 17.2 macropain) 26S subunit, ATPase 403674 predicted exon 17.2 430514AA318501Hs.241587megakaryocyte-enhanced17.2 gene transcript 1 protein 411696AW857404 gb:CM3-CT0313-291199-046-c1117.2 CT0313 Homo sapie 434560813052Hs.3964Homo Sapiens clone 17.2 ' 24877 mRNA sequence S 422627BE336857Hs.118787transforming growth 17.2 factor, beta-induced, 68kD

414364D38521Hs.75935KIAA0077 protein 17.2 409119AA531133Hs.4253G protein-coupled receptor17.2 425640034051Hs.299204ESTs, Highly similar 17.2 to CDSS_HUMAN CYCLIN-DE

436044BE247571Hs.15627Nit protein 2 17.2 401657 predicted exon 17.2 449763A1822t12Hs.118241ESTs 17.2 409601AF237621Hs.80828kera8n t (epidermolytic17.2 hyperkeralosis) 449636AI656608Hs.281328ESTs 17.2 444958AW292643Hs.167047ESTs 17.2 65429978AA249027Hs.24t507ribosomal protein S6 17.2 453043AW136440Hs.224277ESTs 17.2 458640AI284935 gb:qk55g09.x1 NCI CGAP-Co817.1 Homo Sapiens cDNA

456329T41418 gb:phlh3-1911TV Outward17.1 Alu-primed hncDNA
librar 414839X63692Hs.77462DNA (cytosine-5-)-methyltransferase17.1 403662 predicted exan 17.1 411651AW855392 gb:CM3-CT0275-191099-024-e1217.1 CT0275 Homo sapie 404097 predicted exon 17.1 447252890916 gb:yn01e10.r1 Soares 17.1 adult brain N2b4HB55Y
Homo s 430024AI808780Hs.227730integrin, alpha 6 17.1 75412828AL133396Hs.74621prion protein (p27-30)17.1 (Creutzfeld-Jakob disease, Gerst 444558AW18t975Hs.165892ESTs 17.1 420869X58964Hs.123638regulatory factorX,1(influencesHLAclassllexpressi17.1 448812H30775Hs.22140BM88 anflgen 17.0 431777AA570296Hs.105470found in inflammatory 17.0 zone 1 422007AI739435Hs.39168ESTs 17.0 403051 predicted exon 17.0 402427 predicted exon 17.0 417408F17211Hs.86092.Human DNA sequence 17.0 from clone RP11-243J16 on chr 450598AF151076Hs.25199hypotheflcalprotein 17.0 421121AA459028Hs.86228TRIAD3 protein 17.0 458488AL040565Hs.209544ESTs 17.0 417158AW965223Hs.110062ESTs, Weakly similar 17.0 to ACR3_HUMAN 30 KD
ADIP

439318AW837046Hs.6527G protein-coupled receptor17.0 428758AA433988Hs.98502Homo Sapiens cDNA FLJ1430317.0 fis, clone PLACE2000 447572AI631546Hs.159732ESTs 17.0 434434AA633516Hs.157201ESTs 17.0 409994D86B64Hs.57735acetyl LDL receptor, 17.0 SREC

408927AW295650Hs.255453ESTs 17.0 1 439093AA534163Hs.5476serine protease inhibitor,17.0 ~ Kazal type, 5 454-066AA984138Hs.279895Homo Sapiens mRNA for 17.0 KIAA1578 protein, partial cd 426996AW968934Hs.173108Homo Sapiens cDNA: 17.0 FLJ21897 fis, clone HEP03447, 436659AI217900Hs.144464ESTs 17.0 422731AL138411 gb:DKFZp434A1229 r143417.0 (synonym: htes3) Homo s 1 429294AA095971Hs.198793KIAA0750 gene product 17.0 432847BE266941Hs.279554proteasome (prosome, 16.9 macropain) 26S subunit, non-AT

416977AW130242Hs.293476ESTs 16.9 406827AA971409Hs.84298CD74 anfigen (invariant16.9 polypepfide of major histocom 453758083527 gb:HSU83527 Human fetal16.9 brain (M.Lovetl) Homo sap 431314AI732204Hs.105423ESTs 16.9 423185BE299590Hs.125078omithine decarboxylase16.9 antizyme 1 435086AW975243Hs.122596ESTs 16.9 447383N24231 gb:yx22a11.ri Soares 16.9 melanocyte 2NbHM Homo sapie 456251813326Hs.21303ESTs 16.9 456327H68741Hs.38774ESTs 16.9 450594N31036 gb:yx51g04.r1~Soares 16.9 melanocyte 2NbHM Homo sapie 428177AA423967Hs.178113ESTs, Moderately similar16.9 to kinesin like protein 9 [M.m 453250AI346520Hs.121619chromosome 11 open 16.9 reading Frame 15 418294AF061739Hs.83954protein associated 16.9 with PRK1 446546BE167687Hs.156628ESTs 16.9 421100AW351839Hs.124660Homo Sapiens cDNA: 16.9 FLJ21763 fis, clone 455993BE179085 gb:RCO-HT0613-140300-021-40616.9 HT0613 Homo sapie 459375BE251770 gb:601112470F1 NIH 16.9 MGC_16 Homo Sapiens cDNA

454803AW860148 gb:RCO-CT0379-290100-032-b1016.9 CT0379 Homo sapie 35 445474AI240014Hs.259558ESTs 16.9 443198A1039B13 gb:ox49dO6.x1 Soares 16.9 total-fetus-Nb2HF8-9w Homo 441557AW452647Hs.270482ESTs 16.9 420206M91463Hs.95958solute carrier family 16.9 2 (facilitated glucose transporter), 442202BE272862Hs.106534Homo sapiens cDNA: 16.9 FLJ22625 fis, clone 416913AW934714 gb:RCt-DT0001-031299-011-al16.9 l DT0001 Homo sapie 419355AA428520Hs.90061progesterone binding 16.9 protein 452975M85521Hs.69469dendritic cell protein16.9 432525AI796096Hs.109414ESTs 16.8 453718AL119317Hs.120360phospholipase A2, group16.8 VI (cytosolic, calcium-indepe 45 437270818087Hs.11282ESTs, Weakly similar 16.8 to cleft lip and palate transmemb 408007AW135965Hs.246783ESTs 16.8 450954A1904740Hs.25691receptor (calcitonin) 16.8 activity modifying protein 3 402958 predicted exon 16.8 445656W22050Hs.21299ESTs, Weakly similar 16.8 to AFi 518401 CGI-82 protein [H

410684AA088500Hs.170298ESTs 16.8 437669A1358105Hs.123164ESTs, Weakly similar 16.8 to match to ESTs AA667999 [H.

447869AW139113Hs.164307ESTs 16.8 458025AI275406 gb:q163c10.x1 Soares_NhHMPu_S116.8 Homo Sapiens cDN

445614AV660763Hs.110675apolipoprotein GIV 16.8 55 454610AW8i0224 gb:MR4-ST0125-021199-017-e07ST012516.8 Homosapie 449303AK001495Hs.23467hypothetical protein 16.8 422105AI929700Hs.111680endosulfine alpha 16.8 444788AI871122Hs.202821ESTs 16.8 414057AI815559Hs.75730signal recognition 16.8 particle receptor ('docking protein') 408822AW500715Hs.57079Homo Sapiens cDNA FLJ1326716.8 fis, clone OVARC1000 433379AA586368Hs.190232ESTs 16.8 441552AA937975 gb:oc08ei2.s1 NCI-CGAP-GCB116.8 HomosapienscDN

403582 predicted exon 16.8 433871W02410Hs.205555ESTs 16.8 65 439509AF086332Hs.58314ESTs 16.8 431639AK000680Hs.266175phosphoprotein associated16.8 with GEMS

430129BE301708Hs.233955hypotheficalprotein 16.8 401465 predicted exon 16.8 448913AA194d22Hs.22564myosin VI 16.8 70 410261AF145713Hs.61490schwannomin interacting16.8 protein 1 421199BE244219Hs.102497paxillin 16.7 450489AI697990Hs.224375ESTs 16.7 410186AW602528 gb:RC5-BT0562-260100-011-A0216.7 BT0562 Homo sapi 447224BE617125 gb:601441664F1 NIH_MGC_6516.7 Homo Sapiens cDNA

75 403010 predicted exon 16.7 404881 predicted exon 16.7 445572AI243445Hs.189654ESTs 16.7 419440A8020689Hs.90419KIAA0882 protein 16.7 443406A1056238Hs.143316ESTs 16.7 457901AW207023Hs.250497ESTs, Highly similar 16.7 to dJ745C22.1 [H.sapiensj 448364T08958Hs.16561HSPC141 protein 16.6 407239AA076350Hs.67846leukocyte immunoglobulin-like16.6 receptor, subfamily B ( 401847 predicted exon 16.6 429523AK000788Hs.205280Homo Sapiens cDNA FLJ2078116.6 fis, clone COLOd235 432845AI989751Hs.150378ESTs 16.6 400246 predicted exon 16.6 404971 predicted exon 16.6 422954AW998605Hs.32399ESTs, Weakly similar 16.6 to Similar to Ena-VASP
like prat 415042NM Hs.77837UDP-glucose pyrophosphorylase16.6 432201AI5386i3Hs.135657ESTs 16.6 456993AL134577Hs.200302ESTs 16.6 456525AW468397Hs.100000S100 calcium-binding 16.6 protein A8 (calgranulin A) 444060AA340277Hs.10248Homo Sapiens cDNA FLJ2016716.6 fis, clone COL09512 1 428928BE409838Hs.194657cadhe~n 1, type 1, E-cadherin16.6 ~ (epithelial) 448199AI953278Hs.170557ESTs 16.6 443422810288Hs.301529ESTs 16.6 401117 predicted exon 16.6 400613 predicted exon 16.6 15 431214AA294921Hs.250811v-rat simian leukemia 16.6 viral oncogene homolog B (ras re 431649AL133077Hs.266746Homo Sapiens cDNA: FLJ2261516.5 fis, clone HSI05118 421335X99977Hs.103505ARS component B 16.5 427154AL137262Hs.288991Homo sapiens cDNA: FLJ2252316.5 fis, clone HRC12507 401010 predicted exon 16.5 436678BE512828Hs.5273NADH dehydrogenase (ubiquinone)16.5 Fe-S protein 3 (30k 401589 predicted exon 16.5 402538 predicted exon 16.5 430478NM Hs.241535TNF-inducible protein 16.5 437623D63880Hs.5719chromosome condensation-related16.5 SMGassociated pro 25 401244 predicted exon 16.5 415167AA160784Hs.26410ESTs ' 16.5 438291BE514605Hs.289092Homo Sapiens cDNA: FLJ2238016.5 fis, clone HRC07453, 405183 predicted exon 16.5 436480AJ271643Hs.87469putative acid-sensing 16.5 ion channel 30 456691A1023428Hs.205696ESTs 16.5 418332834976Hs.78293ESTs 16.5 446052AA358760 gb:EST67699 Fetal lung 16.5 II Homo Sapiens cDNA
5' end 444859AW449137Hs.157487ESTs 16.5 437192AW975786Hs.75355ubiquitin-conjugating 16.5 enzyme E2N (homclogous to yea 35 400891 predicted exon 16.5 448372AW445166Hs.170802ESTs 16.5 425798AA364002 gb:EST74529 Pineal gland16.5 II Homo Sapiens cDNA
5' en 459253AL157476Hs.32913Homo Sapiens mRNA; cDNA16.5 DKFZp761 C082 (from c 420746AWi95932Hs.197488ESTs 16.4 414717BE271039Hs.77060proteasome (prosome, 16.4 macropain) subunit, beta type, 6 400727 predicted exon 16.4 422691NM_003365Hs.119251ubiquinol-cytochrome 16.4 c reductase core protein I

405639 predicted exon 16.4 414444BE298594 gb:601119754F1 NIH MGC_1716.4 Homo Sapiens cDNA

45 456146AL034349Hs.79005protein tyrosine phosphatase,16.4 receptor type, K

414610BE388044 gb:601283747Fi NIH MGC_4416.4 Homo Sapiens cDNA

414267AL078459Hs.289109dimethylarginine dimethylaminohydrolase16.4 401268 predicted exon 16.4 403613 predicted exon 16.4 50 4142038E262170 gb:601150419F1 NIH MGC 16.4 19 Homo Sapiens cDNA

454315AW373564Hs.251928nuclear pore complex 16.4 interacfing protein 452114N22687Hs.8236ESTs 16.4 404638. predicted exon 16.4 404600 predicted exon 16.3 55 448855AF070574Hs.22316Homo Sapiens clone 2481916.3 mRNA sequence 406629AW277078Hs.181165eukaryotic translation 16.3 elongation factor 1 alpha 1 450957BE515202Hs.21497Homo Sapiens mRNA for 16.3 FLJ00042 protein, partial cds 449966H60542Hs.37848ESTs 16.3 402585 predicted exon 16.3 436008A1078428Hs.58785ESTs 16.3 40.1492 predicted exan 16.3 412288NM_003005Hs.73800selecfin P (granule 16.3 membrane protein 140kD, antigen C

405088 predicted exon 16.3 ' 437345BE259522Hs.5556NADH dehydrogenase (ubiquinone)16.3 1, alphalbeta subco 65 4322808E440142Hs.2943signal recognifion particle16.3 l9kD

419596BE379320Hs.91448MKP-1 like protein tyrosine16.3 phosphatase 428801AW277121Hs.254881ESTs 16.3 431394AK000692Hs.252351HERV-H LTR-associating 16.3 452998BE019681Hs.6019Homo Sapiens cDNA: FLJ2128816.3 fis, clone COL01927 439938AI147392Hs.124607ESTs 16.3 418844M62982Hs.1200arachidonate 12-lipoxygenase16.3 .446081AA972412Hs.13755f-box and WD-40 domain 16.3 protein 2 443534A1076123 gb:oy92e04.x1 Soares-fetal16.3 liver-spleen 1NFLS
Si H

459510AA076706 gb:7B01802 Chromosome 16.3 7 Fetal Brain cDNA
Library 75 450517AI523755Hs.59236ESTs, Weakly similar 16.3 to 835049 ankyrin 1, erythrocyte 451936AI354355Hs.16697down-regulator of transcripfion16.3 1, TBP-binding (negativ 454478AW805749 gb:OVi-UM0105-180400-162-f1016.2 UM0105 Homo sap 407214AA412048Hs.279574CGI-39 protein; cell 16.2 death-regulatory protein 406580 predicted exon 16.2 409452BE336714Hs.289271cytochrome c-1 16.2 416841N33878Hs.249495heterogeneous nuclearribonucleoprotein16.2 458710AV660856 gb:AV660856 GLC Homo 16.2 Sapiens cDNA clone GLCG

450657AK001579Hs.25277hypotheficalprotein 16.2 - , predicted exon 16.2 439471W69839Hs.58033ESTs 16.2 400848 predicted exon 16.2 428797AA496205Hs.193700Homo Sapiens mRNA; 16.2 cDNA DKFZp58610324 (from c 416272AA178882 gb:zp38b09.r1 Stratagene16.2 muscle 937209 Homo Sapiens 444465AI206592Hs.143843ESTs 16.2 431257AF039597 gb:Homo Sapiens Ku86 16.2 autoanfigen related protein 1 (K

447775BE179318 gb:RCt-HT0615-290300-021-g0516.2 HT0615 Homo sapie 403833 predicted exon 16.2 444140AV648089Hs.282383ESTs 16.2 l0 446102AW168067Hs.252956ESTs 16.2 416475T70298 gb:yd26g02.siSoaresfetalliverspleenlNFLSHomos16.2 d30783AW971248Hs.291289ESTs, Weakly similar 16.2 to ALU1 FIUMAN ALU
SUBFA

414070AW963783 gb:EST375856 MAGE resequences,16.2 MAGH Homo sap 444283AI138971Hs.154636ESTs 16.2 1 405599X92715Hs.3057zincfingerprotein 74(Cos52)16.2 409427AW389668 gb:RC2-ST0168-071299-013-f0616.2 ST0168 Homo sapien 409417AA156247Hs.295908ESTs, Weakly similar 16.2 to ALU7-HUMAN ALU
SUBFA

435380AAfi79001Hs.192221ESTs 16.2 406752A1285598Hs.217493annexin A2 16.2 2~ 406096F12200Hs.5811chromosome 21 open 16.2 reading frame 59 417551AI816291Hs.82273hypotheticalprotein 16.2 441252AW360901Hs.183047ESTs, Weakly similar 16.2 to unnamed protein product [H.s 419608AL037237Hs.91586transmembrane 9 supeAamily16.1 member 1 438894AI630819Hs.300431ESTs ~ 16.1 25 451287AK002158Hs.26194hypothefical protein 16.1 412499AW956916Hs.11238KIAA0622 protein; Drosophila16.1 mulfiple asters' (Mast 433355AI808235 gb:wf44e01.x1 Soares 16.1 NFL-T-GBC S1 Homo sapien 416818AI986408Hs.204766ESTs, Weakly similar 16.1 to 848013 proline-rich proleogly 438765A1031888Hs.132594ESTs 16.1 424470BE244261Hs.5615nuclear RNA exportfactorl16.1 416194H27114Hs.301212ESTs 16.1 446702844518Hs.143496ESTs 16.1 414222AL135173Hs.878sorbitoldehydrogenase 16.1 443122A1806656Hs.209022ESTs, Weakly similar 1fi.1 to Pro-Pol-dUTPase polyprotein 35 448648BE614345Hs.159089ESTs 16.1 456394W28506 gb:48f1 Human retina 16.1 cDNA randomly primed sublibra 445887AI263105Hs.145597ESTs 16.1 412332AW937661Hs.288324Homo Sapiens cDNA FLJ1328316.1 fis, clone OVARC1001 403912 predicted exon 16.1 4~ 441446866269Hs.28714ESTs 16.1 403153 predicted exan 16.0 444907AW772596Hs.148586ESTs 16.0 421946899629Hs.109773hypotheticalprotein 16.0 437513AW410681Hs.5648proteasome (prosome, 16.D
macropain) 26S subunit, non-AT

45 407752AA573581Hs.13328ESTs 16.0 447953A1804218Hs.209614Homo Sapiens cDNA: 16.0 FLJ22343 fis, clone 425708AK001342Hs.14570Homo sapiens cDNA: 16.0 FLJ22530 fis, clone 421449AA713491Hs.291501ESTs 16.0 418323NM Hs.1162major histocompatibility16.0 002118 complex, class II, DM beta 447787BE620108 gb:601483015F1 NIH_MGC_6916.0 Homo Sapiens cDNA

422716AI702835Hs.124475ESTs 16.0 443958BE241880Hs.10029cathepsin C 16.0 417908AA207221 gb:zq55h04.s1 Stratagene16.0 neuroepithelium (937231) Ho 438542AA810131Hs.123317ESTs 16.0 55 400288X06256Hs.149609integrin, alpha 5 (fibronecfin16.0 receptor, alpha polypeptid 456825H67220Hs.146406ni~ilase 1 16.0 431360NM Hs.251680loricrin 16.0 414266BE267834 gb:601124428F1 NIH-MGC-816.0 Homo Sapiens cDNA
c 440571AA904461Hs.130798ESTs 16.0 426075AW513691Hs.270149ESTs 16.0 413488BE144017Hs.i84693transcdpficn elongafion16.0 factor B (SIII), polypeptide 1 (1 446767AI380107Hs.158954ESTs 16.0 418008W56044Hs.211556Homo Sapiens cDNA: 16.0 FLJ23378 fis, clone 404239 predicted exon 16.0 65 458401AW236939Hs.172154ESTs 16.D

412955BE241849Hs.75082ras homolog gene family,15.9 member G (rho G) 423072AI792946Hs.123116solute comer family 15.9 12 (sodiumlpotassiumlchloride iron 444954AW247076Hs.12163eukaryotic translation15.9 initiation factor 2, subunit 2 (beta 449023AI623261Hs.248875ESTs 15.9 435729BE048886Hs.275017EST 15.9 438575BE304709Hs.146550myosin, heavy polypepfide15.9 9, non-muscle 413047H02209 gb:yj38c09.r1 5oares 15.9 placenta Nb2HP Homo Sapiens cD

425997AK000086Hs.165948hypotheGcalprotein 15.9 446663AW614370Hs.254620ESTs 15.9 75 448564AL044962Hs.21453Homo Sapiens mRNA for 15.9 inositol 1,4,5-trisphosphate 455640BE064059 gb:OV3-BT0296-010300-111-e0415.9 BT0296 Homo sapie 404345AA730407Hs.159156protocadherin 11 15.9 418512AWd98974Hs.89981diacylglycerol kinase,15.9 zeta (104kD) 411551AW851309 gb:IL3-CT0220-170200-067-C1115.9 CT0220 Homo sapien g 446726AW300144Hs.209209Homo Sapiens cDNA FLJ 15.9 0 11629 fis, clone HEMBA100 410748BE383816Hs.136005ESTs, Highly similar 15.9 to bG115G20.2 [H.sapiens]

449618A1076459Hs.i4366Homo sapiens cDNA FLJ1281915.9 fis, clone NT2RP2002 429697AW296451Hs.24605ESTs 15.9 424012AW368377Hs.137569tumor protein 63 kDa 15.9 with strong homology to p53 403151 predicted exon 15.8 452363AI582743Hs.94953ESTs, Highly similar 15.8 to C10C_HUMAN COMPLEME

425971AF135024Hs.165296kallikrein 13 15.8 432626X75363Hs.250770kallikrein 15 15.8 431972AI805145Hs.191711ESTs 15.8 400269 predicted exon 15.8 404703AI904493Hs.99890polymerase (DNA directed),15.8 delta 1, catalytic subunit (1 449335AW150717Hs.296176STAT induced STAT inhibitor15.8 4i NM Hs.85146v-els avian erythroblastosis15.8 8443005239 virus E26 oncogene homolo 1 445773H73456Hs.13299Homo Sapiens mRNA; 15.8 ~ cDNA DKFZp761 M0111 (from 433782AF090945 gb:Homo Sapiens clone 15.8 406473 predicted exon 15.8 420831AA280824Hs.190035ESTs 15.8 402939 predicted exon 15.8 I 405196 predicted exon 15.8 S

452947AW130413 gb:xf50f04.x1 NCI CGAP_Gas415.8 Homo Sapiens cDNA

414170AA335996Hs.3743matrix metalloproteinase15.8 24 (membrane-inserted) 437133A8018319Hs.5460KIAA0776 protein 15.8 458356A1024855Hs.131575ESTs 15.8 407857A1928445Hs.92254hypothetical protein 15.8 405687 predicted exon 15.8 415189L34657Hs.78146plateletlendothelial 15.8 cell adhesion molecule (C031 antig 408662AW247699Hs.105897ESTs 15.7 448338AI492857 gbah72hO8.x1 Soares_NhHMPu_St15.7 HomosapienscDN

25 402694 predicted exon 15.7 430224AW675175 hypothetical protein 15.7 Hs.235975DKFZp434D0412 458792N56666 gb:yw75e02.r1 Soares-placenta-Sto9weeks_2NbHP8to15.7 402944 predicted exon 15.7 422675BE018517Hs.119140eukaryotic franslation15.7 initiation factor 3 408661AW247625 gb:2820094.5prime NIH_MGC-715.7 0 Homo sapiens cDNA

423238AA323569Hs.280482ESTs 15.7 421517AB018352Hs.105399KIAA0809 protein 15.7 429865AB023217Hs.225968KIAA1000 protein 15.7 440815AW071945Hs.7436putative acyltransferase15.7 35 400634 predictedexon 15.7 451034AL050341Hs.25846zinc metalloproteinase,15.7 STE24 (yeast, homology 457571AI375726Hs.279918hypotheticalprotein 15.7 450105BE281124Hs.288013similar to yeast BETS 15.7 (S. cerevisiae) 407464AJ276396 gb:Homo Sapiens mRNA 15.7 for mafrix exfracellular phosp 4o 439465AF086285 gb:Homo Sapiens full 15.7 length insert cDNA
clone ZD47B

451837T92157Hs.16970ESTs 15.7 435313AI769400Hs.189729ESTs 15.7 402738 predicted exon 15.7 432966AA650114 gb:ns92h09.s1 NCI_CGAP_Pr315.7 Homo Sapiens cDNA
c 45 457666AWd70302Hs.129663ESTs 15.7 401269 predicted exon 15.7 427509M62505Hs.2161complement component 15.7 5 receptor 1 (C5a ligand) 418846AI821602Hs.115127ESTs 15.6 448891AI587332Hs.209115ESTs 15.6 445930AF055009Hs.13456Homo Sapiens clone 15.6 24747 mRNA sequence 421254AK001724Hs.102950coat protein gamma-cop15.6 447073AW204821Hs.157726ESTs 15.6 445438AB014578Hs.12707KIAA0678 protein 15.6 432126AA865239Hs.55144ESTs 15.6 55 424091AF235097Hs.139263calcium channel, voltage-dependent,15.6 alpha lFsubunit 440832A1057548Hs.128224ESTs 15.6 449228AJ403107Hs.148590ESTs, Weakly similar 15.6 to AF2088461 BM-004 [H.sapie 434253AI393345Hs.116215ESTs 15.6 459270AL039604 gb:DKFZp434E2211 r1 15.6 434 (synonym: htes3) Homo s 454425AW300927Hs.27192hypothetical protein 15.6 4J1057820.2 412055AA099907Hs.271806ESTs 15.6 400837 predicted exon 15.6 458866BE616694Hs.288042Homo Sapiens cDNA FLJ1429915.6 fis, clone PLACE1010 417124BE122762Hs.25338ESTs 15.6 65 414376BE393856Hs.66915ESTs, Weakly similar 15.6 to 16.7K4 protein [H.sapiens]

418636AW749855 gb:OV4-BT0534-281299-053~c0515.6 BT0534 Homo sapie 454128AL031259Hs.41639programmed cell death 15.6 441074AW500001Hs.4783Homo Sapiens cDNA: 15.6 FLJ22035 fis, clone 451742T77609Hs.117970ankyrin 2, neuronal 15.6 403687 predicted exon 15.6 431838A1097229Hs.217484ESTs 15.6 402855 predicted exon 15.6 449635AI989942Hs.232150ESTs 15.6 434392AW983709Hs.268051ESTs 15.6 75 444301AK000136Hs.10760hypothetical protein 15.6 414973C19089 gb:C19089 Human placenta15.5 cDNA (TFujiwara) Homo 428374AW405156Hs.183994protein phosphatase 15.5 1, catalytic subunit, alpha isoform ' 415745AI301107Hs.150790ESTs 15.5 432532AW058459Hs.162246ESTs 15.5 417112AA193439 gb:zr41609.s1 Soares 15.5 NhHMPu-S1 HomosapienscDN

418101AL047476Hs.98485gap junction protein, 15.5 beta 4 (connexin 30.3) 453110AW384928Hs.225160Homo Sapiens cDNA FLJ1310215.5 fis, clone NT2RP3002 458606AJ239397 gb:AJ239397 Uni-ZAP 15.5 XR retinal pigment epithelium H

436989AA741028Hs.256155ESTs 15.5 407396AF011757 gb:Homo Sapiens RAGE 15.5 binding protein (P12) mRNA, 449684AI659166Hs.207144ESTs 15.5 454666AW812994 gb:RC3-ST0186-230300-019-g0215.5 ST0186 Homo sapien 430492015197Hs.300803Human histo-blood group15.5 ABO protein mRNA, partial 439460AA836220Hs.13774ESTs 15.5 449231BE410360 gb:601302340F1 NIH_MGC_2115.5 Homo Sapiens cDNA

453060AW294092Hs.21594ESTs 15.5 416961BE391476Hs.80617ribosomal protein S16 15.5 439988AA860119Hs.255976ESTs 15.5 1 400917 predicted exon 15.5 ~

424585AA464840 gb:zx43h11.r1 Snares 15.5 total_fetus_Nb2HF8 9w Homo 431029BE392725Hs.248571Homo Sapiens PAC clone15.5 RP5-1163J12 from 7q21.2-q3 441680AW444598Hs.7940RAP1, GTP-GDP dissociation15.5 stimulator 1 437830AB020658Hs.5867KIAA0851 protein 15.5 15 409479BE163800Hs.136912ESTs 15.5 409885AW503068 gb:Ul-HF-BPOp-aje-g-10-0-Ul.rt15.4 NIH MGC_51 Homo 459090AA443323Hs.107812ESTs, Weakly similar 15.4 to SPOP [H.sapiens]

429324AA488101Hs.199245inactivation escape 15.4 403766 predicted exon 15.4 20 413970059309Hs.75653fumarate hydratase 15.4 4566748E266120Hs.269358ESTs 15.4 417931W95642Hs.82961trefoil factor 3 (intestinal)15.4 430125046418Hs.233950serine protease inhibitor,15.4 Kunitz type 1 452154AW953265Hs.271277hypothetical protein 15.4 from EUROIMAGE 363668 422984W28614Hs.75984chorionic somatomammotropin15.4 hormone 2 408649BE242232Hs.26045' 15.4 protein tyrosine phosphatase, receptor type, A

417497AW402482Hs.82212CD53 antigen 15.4 404666 predicted exon 15.4 456847AI360456Hs.37776ESTs 15.4 30 426995AA400646Hs.221988ESTs 15.4 445350AF052112Hs.12540lysophospholipase I 15.4 450214BE439763Hs.227571regulator of G-protein15.4 signalling 4 449733874546Hs.29438Homo Sapiens cDNA FLJ1209415.4 fis, clone HEMB8100 411660AW855718 gb:RCi-CT0279-070100-021-a0615.4 CT0279 Homo sapie 3 442653BE269247Hs.170226Homo sapiens clone 15.4 23579 mRNA sequence 447552AI394i25Hs.160413ESTs 15.4 448712W01046Hs.181634Homo Sapiens cDNA: 15.4 FLJ23602 fis, clone 420180A1004035Hs.25191ESTs 15.4 440099AL080058Hs.6909DKFZP564G202 protein 15.4 427550BE24281Hs.179606nuclear RNA helicase, 15.4 B DECD variant of DEAD
box fam 432894AW167668Hs.279772brain specific protein15.3 412113AW161274Hs.74427p53-induced protein 15.3 431614A1189827 gb:qd19d07.x1 Snares_placenta_8to9weeks_2NbHP8to15.3 445870AW410053Hs.13406syntaxin 18 15.3 45 424347AA723883Hs.145513Homo Sapiens mRNA; 15.3 cDNA DKFZp434L0435 (from 425132AW250114 gb:2821134.5prime NIH 15.3 MGC-7 Homo Sapiens cDNA

439756AL359651Hs.283852Homo Sapiens mRNA full15.3 length insert cDNA
clone EU

432946060899Hs.279854mannosidase, alpha, 15.3 class 28, member 1 406130 predicted exon 15.3 5 453359AA448787Hs.24872ESTs, Weakly similar 15.3 0 to aortic carboxypeptidase-like p 405491 predicted exon 15.3 436481AA379597Hs.5199HSPC150 protein similar15.3 to ubiquilin-conjugating enzy 446826AK000626Hs.16230hypothetical protein 15.3 441211AW946155Hs.7750hypothetical protein 15.3 55 418711AW247977Hs.87595translocase of inner 15.3 mitochondria) membrane 22 (yeast) 457301AA469146 gb:nc67e03.s1 NCI CGAP_Pr115.3 Homo Sapiens cDNA
c 449999AI679421Hs.231098ESTs, Highly similar 15.3 to ALU4_HUMAN ALU
SUBFA

439090H65724Hs.271663ESTs 15.3 416586D44643Hs.14144secreted modular calcium-binding15.3 protein 1 411940AW876686 gb:CM4-PT0031-180200-507-e0515.3 PT0031 Homo sapie 407639AW205369Hs.252936ESTs 15.3 458012A1424899Hs.18B211ESTs 15.3 426490NM_001621Hs.170087arylhydrocarbon receptor15.3 408741M73720Hs.646carboxypeptidase A3 15.3 (mast cell) 6S 437371AK000868Hs.5570hypothelicalprotein 15.3 437134AA349944Hs.42915ARP2 (actin-related 15.3 protein 2, yeast) homolog 441890AI809547Hs.128075ESTs 15.3 409442AA3i0162Hs.169248cytochromec 15.3 407078226256 gb:H.sapiens isoform 15.2 t gene for L-type calcium channe 70 436553AW407157Hs.181125immunoglobulin lambda 15.2 locus 443177BE268461Hs.202benzodiazapine receptor15.2 (peripheral) 448771BE315511Hs.296244SNARE protein 15.2 436837A1968248Hs.187869ESTs 15.2 423623AB011117Hs.129943KIAA0545 protein 15.2 75 422651NM_015670Hs.118926DKFZP586K0919 protein 15.2 403221AL134878Hs.119500karyophedn alpha 4 15.2 (importin alpha 3) 431620AA126109Hs.2649812'-5'oligoadenylale 15.2 symthetase 2 404794NM_000078Hs.89538cholesteryl ester transfer15.2 protein, plasma 412944AA384110Hs.197143ESTs 15.2 450817N71597Hs.29698ESTs 15.2 418666AF001434Hs.155119EH domain containing 15.2 451636AW173270Hs.140444ESTs 15.2 426302AA459085Hs.275163non-metastatic cells 15.2 2, protein (NM23B) expressed in 454485AW795322 gb:PMO-UM0018-120400.002-h0115.2 UM0018 Homo sap 440617AA894880Hs.181181ESTs 15.2 449718AA459480Hs.23956hypotheficalprotein 15.2 405227 predicted exon 15.2 431006BE152871 gb:CM1-HT0333-101299-064-d1215.2 HT0333 Homo sapi 443476AW068594Hs.133878ESTs, Weakly similar 15.2 toAF1518891 CGI-131 protein 438828AL134275Hs.6434hypotheficalprotein 15.2 DKFZp761F2014 407634AW016569Hs.301280ESTs, Highly similar 15.2 to AF241831 1 intracellular hyalu 436857AA732647 gb:nz89d01.s1 NCI 15.2 CGAP-GCB1 HomosapienscDN

431526Y10129Hs.258742myosin-binding protein15.1 C, cardiac 1 447386NM_006289Hs.18420KIAA1027 protein 15.1 ~

436573AA723297Hs.127138ESTs 15.1 432858BE618609Hs.279591Homo sapiens clone 15.1 25056 mRNA sequence 437352AL353957Hs.284181hypothetical protein 15.1 DKFZp434P0531 413209AW083791Hs.21263Homo Sapiens cDNA 15.1 FLJ13152 fis, clone I 407376AA993138Hs.1422fi7ESTs, Weakiy similar 15.1 S to ALUF_HUMAN !!!!
ALU CL

430475BE387420Hs.241531pefiin 15.1 446764AW291276Hs.285532ESTs 15.1 425868. A8017548Hs.160100Homo Sapiens gene 15.1 for Sepiapterin Reductase, parfial c 453464AI884911Hs.32989receptor (calcitonin)15.1 activity modifying protein 1 447246AW449032Hs.170257ESTs 15.1 401780 predicted exon 15.1 434063AA018893Hs.3727unr-interacting protein15.1 416114AI695549Hs.183868glucuronidase,beta 15.1 441018A18095B7Hs.148782ESTs 15.1 25 425972BE391563Hs.165433ESTs, Highly s]milar 15.1 to T17342 hypothefical protein D

426062N57014Hs.44013ESTs 15.1 451234AI914901Hs.24052ESTs 15.1 429565A8020719Hs.207802KIAA0912 protein 15.1 418092845154Hs.106604ESTs 15.1 30 424550A1650541Hs.115298ESTs 15.1 425023AW956889Hs.154210endothelial differentiation,15.1 sphingolipid G-protein-coup 445213AW204314Hs.170784ESTs . 15.1 418102858958Hs.26608ESTs 15.0 450082AI908894Hs.245B93ESTs 15.0 3 446749NM_016069Hs.16089CGI-136 protein 15.0 S

406124 predicted exon 15.0 457408AL137507Hs.255348Homo Sapiens mRNA; 15.0 cDNA DKFZp761 P211 (from c 410051025773Hs.218182ESTs, Weakly similar 15.0 to dJ1042K10.2 [H.sapiens]

440965AI523646Hs.i69859ESTs . 15.0 440190AW752597 gb:IL3-CT0214-161299-045-BO615.0 CT0214 Homo sapien 417437052682Hs.82132interferon regulatory15.0 factor 4 454249AW249008 gb:2821048.5prime 15.0 NIH MGC-7 Homo Sapiens cDNA

432276AF163302Hs.274255somatostafin receptor-interacting15.0 protein 401116 predicted exon 15.0 45 423960AA164516Hs.136309CGI-61 protein 15.0 451661AB020650Hs.26777KIAA0843 protein 15.0 450983AA305384Hs.25740ER01 (S. cerevisiae)-like15.0 446187AK001241Hs.14229hypotheficalprotein 15.0 404122 predicted exon 15.0 50 411299BE409857Hs.69499hypothefical protein 15.0 403077 predicted exon 15.0 438000A1825880Hs.5985non-kinase Cdc42 effector15.0 protein SPEC2 447118A8014599Hs.17411KIAA0699 protein 15.0 417878090916Hs.82845Human clone 23815 15.0 mRNA sequence 55 444079H09048Hs.23606ESTs 15.0 458234BE551408Hs.127196ESTs 15.0 434208T92641Hs.127648hypothefical protein 15.0 423136AW375506Hs.124147ESTs 15.0 403177 predicted exon 15.0 448699A1857269Hs.227351ESTs 15.0 425248AW957442Hs.252766ESTs 15.0 429430AI381837Hs.155335ESTs 15.0 TABLE 38:
65 Pkey: Unique Eos probeset idenfifier number CAT number: Gene cluster number Accession: Genbank accession numbers PkeyCAT Accession Number g 4101861182096_1AW602528 BE073859 238412 4110041228975AW813242 8E14fi089 AW813195 AW813173 AW813206 BE145953 t BE146212 AW813196 AW8545B2 AW813241 BE061582 1~7 d115511249196AW851309 AW850888 AW851419 AW851d12 1 4119401266262_1AW876686 AW876717 AW877215 AW876691 ~ AW876722 AW877218 AW876694 AW876725 1 4131541351077_1BE067870 BE067866 BE165133 BE165334 4132821358147_1BE078159 BE078276 BE078163 BE078277 4134421370508_1BE140643 BE140645 BE140644 BE140657 _ BE152669 BE152661 BE152672 BE152653 BE152714 BE152708 8E152813 BE15266d BE152676 BE152681 8E152808 BE152711 BEt52781 BE152774 BE152763 BE152769 _ BE156789 BE156833 BE156844 BE156831 BE156793 BE156852 3 4142661430984_1BE267834 BE514180 BE514096 4146101466027_1BE388044 8E391117 BE391530 4146261467232_1BE410589 BE390949 BE408297 BE389529 416913163001AW934714 BE161007 BE162500 AW749902 65 BE161006 BE162d99 417908170764_1AA207221 BE538271 d19618186533AA528295 AW971284 AA247945 422160212412_1AW582898 AA305114 422731220507_1AL138411 AL138412 AA315B60 422831221879_1802504 AA317715 AW961465 AF121172 65 425132247059-1AW250114 243124 AA431 d21 A1879054 433355364004A1808235 A102d295 AA584528 43378237414_1AF090945 AW996754 A1064870 434098380006_1AA625499 AA625269 AA625184 435138401159_1BE314734 AA666393 435478406683_1AA682622 BEid1696 12~

440190_ AW752597 AW848781 AW849062 AW848490 AW752699 AW752604 488021_1AW752700 44225753699_1AW503831 AW503317 BE565665 ~ 1 44605265988_1AA358760 AA158850 AW062737 AW062738 AV656291 44659868463_1AW250546 BE257108 BE251006 BE255957 BE250926 BE513012 44821875525_1A1188d89 BE622201 451400868459BE160479 BE160478 BE0692i1 AW861059 A1793147 25 452947_ AW130413 AI932362 939810_1 1 AW177394 AW177396 AW177383 AW177333 AWi77384 AWi77382 _ . .AW177360 AW177356 4544781214744AW805749 AW805872 AW79d466 AW798102 AW796921 AW794538 3 454485_ AW795322 AW795308 AW795311 AW795310 AW795314 AW795321 4551321254686_1AW857955 AW861636 AW857967 AW857958 AW8579d3 AW857945 45 4554261289303_1AW937792 BE072250 BE072251 BE072264 5 456054_ BE313241 BE3831d8 458640670076A1284935 AWd09822 BE408182 45871069727_1AV660856 BE167375 TABLE
3C:

Pkey: ue Uniq number corresponding to an Eos probeset Ref: The 7 digit numbers in this column aro Genbank Identifier Sequence (GI) numbers. "Dunham I. et al." refers to the publication source. entitled "The DNA sequence of human chromosome 22"
Dunham, et al.
(1999) Nature 402:489-495 , Strand:
Indicates DNA
strand from which exons were predicted Nt_position:
Indicates nucleotide positions of predicted exons Pkey Ref Strand Nt position 4004499887692_ Minus 50889-51188 4006139864507Plus 92278-92472 4006348567750Minus 101102-101223,101886-102018 4006428117693Plus 10475-10845 4006618118474Plus 84912-85187 75 4006848118768Plus 58189-58323 4006858118768Minus 72969-73050,73713-73800 4007276705887Plus 106175-107016 4007497331445Minus 9162-9293 4008078567878Plus 69375-70295 4008379188531Plus 144778-144838,145582-145670,146656-146751,147255-147419,147682-147807 4008421927148Plus 90462-90673 4008481927148Plus 107149-107339,110873-111171 4008919958279Minus 140073-140427 4009177283186Minus 173258-173631 4009317651921Minus142145-142353,144311-144721 4009647139719Minus155282-155403 4009657770576Minus173043-173564 4009707960452Minus92744-92895 4009828078794Minus119245-119471 4010108117391Minus83967-84180 4010723687273Plus 64370-64524 4010888492704Plus 194659-195179 4011169966559Plus 123579-124447 1 4011178570083Minus28948-29204 4011679438381Plus 18944-19176 4012049743388Minus33694-33872 4012209929324Minus48079-48279 4012444827300Minus55359-56376 1 4012454827300Minus59373-59531 4012689797154Plus 152272-152483,157312-157418,156025-158205,158838-156974,160716-160952 4012698954206Plus 2259-2591 4012839800093Minus47256-47456 4013737248205Minus84211-84336 4014057768126Minus69276-69452,69548-69958 4014656682292Plus 25676-25800 4014927341778Plus 171020-171282,171858-172241 4015217705251Plus 9127-9234 4015668469090Minus96277-96420;96979-97160 ~

25 4015757229804Minus76253-76364 4015899966292Plus 135969-136263 4016288575954Minus210617-210796 -4016579100664Minus7312-8163 4017479789672Minus118596-118816,119119-119244,119609-119761,120422-120990,130161-130381,130468-130593,131097-131258,131866-3 131932,132451-132575,133580-134011 4017577239630Plus 88641-86751 4017807249190Minus28397-28617,28920-29045,29135-29296,29411-29567,29705-29787,30224-30573 4017817249190Minus83215-83435,83531-83656,83740-83901,84237-84393,84955-85037,86290-86814 4017857249190Minus165776-165996,166189-166314,166408-166569,167112-167268,167387-167469,168634-168942 4017897249213Minus70399-70629,70941-71055 4018097342191Minus107548-108298 4018477139731Plus 85447-85593 4018877229981Plus 93973-94120 4019139369520Minus33753-33904 40 4019623176728Minus71433-71648,76711-76833,78677-78845,79585-79763,82349-4019914156128Plus 2398-2513 4019944153858Minus42904-43124,43211-43336,44607-44763,45199-05281,46337-46732 4020237528158Minus132872-133040 4020666649269Plus 135543-136031 45 4020718117361Plus 85924-86039 4020758117407Plus 121907-122035,122804-122921,124019-124161,124455-124610,125672-126076 4021317704961Minus33114-33209,33496-33678 4021447242326Plus 115425-115977 4022038576119Minus8124-8285 50 4022772894631Plus 16980-17152,17933-16018,18170-18306 4022922447220Plus 33880-34029,34176-34336,34953-35103 4022976598824Plus 35279-35405,35573-35659 4024073962498Minus115812-116187 4024219796341Minus46609-46662,46758-46811,86293-86346,89776-89829,90048-90101,102817-102924 5 4024279796372Plus 16266-16431 4024309796372Minus62382-62552 4025207596899Minus171761-171996 4025389801137Minus96314-96539 4025439838066Minus89684-90893 60 4025709884747Minus12649-12866 4025859908890Minus174893-175050,183210-183435 4026399958129Minus20167-22383 4026948569867Plus 2218-2440 4026998570304Minus182773-182883,184551-184732 65 4027387331557Minus8725-8859 4028559662953Minus59763-59909 4028696434643Minus138639-139335 4029399187334Minus18329-18535 4029449368423Plus 110411-110716,111173-111640 70 4029489368458Minus143456-143626,143808-143935 4029589368493Plus 13324-13507 4030103132346Plus 78365-79052 4030363132360Plus 66545-66712 4030514827080Minus5269-5411 7S 4030658954197Minus71615-71773,73930-74144 4030778954241Plus 146923-147222,147326-147628 4030938954241Plus 177083-177373,177464-177751 4031517407965Minus14055-14264 4031539799871Minus42232-43389 g 4031779838213Minus142560-142726 4032237630969Plus 81529-81692 4032347637801Plus 180641-180822 4032738018055Plus 133809-134099 4032868080320Plus 118369-118872 4032878080320Minus126097-126411 4033487239527Plus 13809-13968 4033598570207Minus108939-109229 4033628571772Plus 64099-64260 4034479837821Minus159072-159387 4035087630896Plus 5570-5719 4035828101186Plus 18308-18458 4036138493504Plus 81290-81465 4036428699671Plus 7062-7311 1 4036625823349Plus 58627-59062,59222-59548 ~

4036747321642Plus 104988-105623,107394-107590 403687738738dPlus 9009-9534 4036953046276Plus 168272-168514 4037034966380Plus 83681-84042 1 4037417630932Minus2833-3468 4037477658395Minus20493-20621 4037667229888Plus 136283-136830 4037868083636Minus73028-73217 4037968099896Minus75073-77664 403833887461Plus 13522-13664 d038527708872Minus124007-124202 4038617708966Plus 58363-58649 4039127710730Minus72000-72290,72431-72700,72929-73199 4039247711688Minus89369-89592 25 4039647596976Plus 178174-178300 -4040348567760Minus44635-47010 ' 4040673282162Plus 1415-2071 4040977770701Plus 55512-55781 4041229796270Plus 90540-92977 4042307981448Minus92934-93093 4042395002624Plus 94841-95095 4042405002624Minus116132-116407,116653-116922 4042709626129Minus3649-3750,4161-4306,5962-6049,6849-6965 4043567630858Minus126433-126623 3 4046008705107Plus 118354-118444,118649-118792 4046018705107Plus 128449-128693,129085-129249,130525-130733 4046389796751Minus99433-99528,100035-100161 4046667272179Minus18677-18993 4046759797204Minus48532-48645,49808-49975,51088-51369,54944-55063 40 4047278081050Plus 115534-115747 4047507596836Plus 181879-182198 4047637882612Plus 50981-51392 4047677882827Minus23244-23759 4048286580415Minus26291-27253 45 4048505420148Minus35145-35413,40635-41062 4048815931510Minus36360-36608 4048907329390Plus 101280-101408 4049713212939Minus74585-75532 4050227330304Plus 217163-217439 5 4050287533974Minus110588-110847,110933-111115 4050717708797Minus11115-11552 4050888072518Minus115690-117621 4051338516055Minus28127-28288 4051388576241Plus 90303-90516 5 4051837209940Plus 12335-12653 4051947230072Plus 190465-190645,193346-193610 4051967230083Minus135716-135851 4052087230142Plus 8068-8214 4052267248966Plus 53547-54128 4052276731245Minus22550-22802 4052567329310Plus 26070-26309 4052773980473Plus 23471-23572 4053073638954Plus 39195-39429 4053113638954Plus 46313-46496 65 4053333165399Plus 149905-150215 4054113451356Minus17503-17778,18021-18290 4054234753276Plus 6162-6983 4054915801645Plus 81857-82045 4055019211311Minus49085-49400,49565-49679,50117-50262 4055159454624Plus 37329-37469 4055451054740Plus 118677-118807,119091-119296,121626-121823 4055804512267Plus 169232-169647 4055865002511Plus 38810-39017 4056005923640Plus 26662-27225 7 4056105757553Minus71907-72080 4056395091650Plus 211184-211350 4056876249668Minus54787-54891,55844-55917 4056994165331Plus 100727-100859 4057835138434Minus27238-27885 4058676758731Minus74553-75173 4060867107817Plus 9418-9573 4061249149714Minus1331-1774 4061309161404Minus32394-32498 4061409168231Minus49887-50219 406160 7144945Plus55498-56268 406207 5923650Minus162607-162800 406215 7342161Plus310-432 406268 6682695Minus6605-7072 406277 5686030Minus4759-5490 406326 9212385Plus84508-84655 406388 9256205Plus85153-85277 406457 9755793Plus44966-45406 406473 9795566Minus109669-109931 4065377711478Plus32904-33017 d06571 7711622Minus65634-65912,66116-66596 406580 7711838Minus96654-97640 TABLE 4A lists about 131 genes up-regulated in ovarian cancer compared to normal ovaries that are likely to be extracellular or cell-surface proteins.
These were selected as for Table 3A, except that the ratio was greater than or equal to 10, and the predicted protein contained a PFAM domain that is indicitive of extracellular localization.
TABLE
4A:

UP-REGULATED
GENES
ENCODING
EXTRACELLULARICELL
SURFACE
PROTEINS, OVARIAN
CANCER
VERSUS
NORMAL
OVARY

Pkey:
Primekey Ex. Exemplar Accn:Accession UG
ID:
UniGene ID

Title:
Unigene Title PFAM
domains ratio:
tumor vs.
normal ovary j Pkey Ex. UG Title PFAM ratio Accn ID

403077 predicted exon fn3 15.0 426535AU077012Hs.288582ESTs, Weakly similarKunitz_BPTI 14.9 to ubiquitous TP

403089 predicted exon fi3 14.9 3~ 457148AF091035Hs.184627KIAA0118protein arf;ras 14.8 431176A1026984Hs.293662ESTs laminin EGF;laminin14.8 B;

434293NM Hs.3796Eph86 fn3;pkinase;EPH_Ibd14.8 408482NM Hs.45743adenosine A2b receptor7tm_1 14.6 428695AI355647Hs.189999purinergic receptor7tm 1 14.5 (family A group 5) 35 426125X87241Hs.166994FAT tumor suppressorEGF 14.4 (Drosophila) ho 423732AF058056Hs.132183solute carver familysugar-tr;MCT 14.3 16 (monocarboxy 422125NM-003459Hs.111967solute carver familyCation efflux 14.2 30 (zinc transporfe~

407483NM_012368 (NONE) 7tm 1 14.2 ' 446689AW594695Hs.167046ESTs 7tm 1 14.1 410184AW503667Hs.59545ring finger proteinzf-C3HC4;SPRY;zf-B14.0 15 box 423217NM Hs.1640collagen, type fn3;vwa 14.0 000094 VII, alpha 1 (epidermoly 405448A10i5709Hs.172089Homo sapiens mRNA;trypsin;sushi;CUB14.0 cDNA DKFZpS

450684AA872605Hs.25333intedeukin 1 receptor,1g 14.0 type II

406692L36607 gb:Homo sapiens 1g 13.9 (clone 22) pregnancy 45 425549U64863Hs.158297programmed cell 1g 13.8 death 1 452755AW138937Hs.213436ESTs cystatin 13.8 427637AK000816Hs.179986flotillin 1 Band 7 13.7 424591855704Hs.150968hypocretin (orexin)7tm 1 13.7 receptor 1 405024 predicted exon TGF-beta;TGFb_propeptide13.7 405285 predicted exon A2M;A2M-N 13.7 412116AW402i66Hs.784Epstein-Barrvims 7tm_i 13.7 induced gene 2 (lym 420256U84722Hs.76206cadherin 5, type cadherin;Cadherin_C13.6 2, VE-cadherin Term (vascu 420511AF052692Hs.98485gapjunc6on protein,connexin 13.5 beta 4 (connexin 448638817122Hs.21639nuclear protein, 1g 13.4 marker far differon6at 55 431117AF003522Hs.250500delta (Drosophila)-likeEGF;DSL 13.4 439285AL133916Hs.298998ESTs ig;pkinase;LRRNT;LRRGT13.4 424283AA338246Hs.301678ESTs E1-E2_ATPase;Hydrolase13.3 436233Ah42878Hs.124116ESTs 1g 13.3 443859NM Hs.9914follista6n kazal 13.2 410016AA297977Hs.57907small inducible IL8 13.2 cytokine subfamily A,( 414020NM-002984Hs.75703small inducible IL8 13.2 cytokine A4 (homologo 400242 predicted exon Ephrin 13.0 429057AF156557Hs.194816stomatin-like proteinBand 7;SCP2 12.9 438294AI693753Hs.143004ESTs E1-E2_ATPase;Hydrclase12.9 65 458493AV649408Hs.282418ESTs RYDR_ITPR 12.8 444181A8033063Hs.10491KIAA1237 protein fi3;ig;PH;RhoGEF12.8 422357AF016272Hs.115418cadherin 16, KSP-cadherincadherin 12.7 409632W74001Hs.55279sedne (or cysteine)serpin 12.7 proteinase inhibitor 407000U12139 gb:Human alphat(XI)TSPN;CoIlagen;COLFI12.6 collagen (COL1 70 417064W02903Hs.15440ESTs lectin c 12.6 439389AA318940Hs.56004ESTs hemopexin;Peptidase-M1012.6 407786AA687538Hs.38972tetraspan 1 transmembrane4 12.5 410498AA355749 gb:EST64459 Jurkataa~ermeases 12.5 T-cells VI Homo 422487AJ010901Hs.198267mucin 4, tracheobronchialvwd 12.5 75 422330D30783Hs.115263epiregulin EGF 12.5 402425 predicted exon ion_trans 12.4 414875H42679Hs.77522major histocompatibilily1g 12.2 complex, clas 424239M67439Hs.143526dopamine receptor 7tm 1 12.2 442622NM-000435Hs.8546Notch (Drosophila)EGF;ank;notch 12.2 homolog 3 405368 predicted exon 7tm 1 12.2 402406 predicted exon Gal-bind IecGn 12.1 426514BE616633Hs.301122bone morphogeneticTGF-beta;TGFb_propepGde12.1 protein 7 (osteoge 406811U82979Hs.67846leukocyte immunoglobulin-like1g 12.0 recepto 416441BE407197 gb:601301552F1 SDF 12.0 NIH_MGC-21 Homo 433221AB040917Hs.97860KIAAi484protein fi3;ig;LRRCT 11.9 442915AA852875Hs.8850a disintegrin and disintegrin;Reprolysin;11.9 metalloproleinase dom 423613AF036035Hs.129910hyaluronoglucosaminidaseig;Sema;AcetylUansf11.9 411213AA676939Hs.69285neuropilin 1 CUB;MAM;F5 F8_type11.9 C

S 425483AF231022Hs.301273Homo sapiens protocadherin_ 11.8 Fat2 (FA EGF;cadherin;laminin-G

421258AA286731 gb:zs53dO8.r1 NCI 7trrL3 11.8 CGAP-GCB1 Hom 423795AW849759 gb:IL3-CT021fi-240200-077-C04arf;ras 11.7 CTO

422424AI186431Hs.116577prostate differentiationTGF-beta 11.7 factor 443296AI765286 gb:wi73b05.x1 NCI 1g 11.7 CGAP_Kidl2 Ho 1 448999AF179274Hs.22791transmembrane proteinkazal 11.7 ~ with EGF-like 414878AA341040Hs.77541ADP-ribosylalion arf;ras 11:5 factor 5 429344894036Hs.199538inhibin, beta C TGF-beta 11.5 402114 predicted exon laminin-EGF;laminin-G11.5 419216AU076718Hs.164021small inducible IL8 11.5 cytokine subfamily B ( ~

1 430263D12614Hs.36lyphotoxin alpha TNF 11.4 S (TNF superfamily, m 400464 predicted exon Peptidase-S9 11.4 456841AA875863Hs.152345poliovirus receptor-related1g 11.4 1 (herpesvir 409420215008Hs.54451laminin, gamma laminin-EGF;laminin-B11.4 2 (nicein (100kD), kal 418043AW377752Hs.83341H.sapiens mRNA fn3;ig;pkinase 11.3 for tyrosine kinase re 426523S68616Hs.170222solute carver familyNa H Exchanger 11.3 9 (sodiumlhydrog 446051BE048061Hs.153315ESTs Reprolysin;disintegrin11.3 439710AF086543 gb:Homo sapiens Xlink 11.3 full length insert cDN

416602NM Hs.79389net (chicken)-likevwc;TSPN 11.3 418299AA279530Hs.83968inlegrin, beta integrin-B 11.3 2 (anfigen CD18 (p95), 1y ZS 425721AC002115Hs.159309uroplakin 1A, Uansmembrane4;COX6B;Ets11.2 409757NM Hs.123114cystatin SN cystatin 11.2 430630AW269920Hs.2621cystatin A (stefin7tm-3;ANF receptor11.2 A) 429630M85289Hs.211573heparan sulfate laminin-EGF,ig;ldf_recept-a11.1 proteoglycan 2 (perleca 427289A1097346Hs.174203solute cartierfamilySDF 11.1 1 (glutamatelneutr 3~ 401248AB028989Hs.88500mitogen-activated vwa;vwd;TIL 11.1 protein kinase 8 tote 412627BE391959Hs.74276chloride intracellularchannellG-patch;ig;MutS11.1 C

420104U09825Hs.1287zinc fingerprotein173zf-C3HC4;SPRY;zf-B11.1 box 405275AB028989Hs.88500mitogen-activated vwa;vwd;TIL 11.1 protein kinase 8 tote 425864U56420Hs.159903olfactory receptor,7tm 1 11.1 family 5, subfamily 3S 446745AW118189Hs.156400ESTs vwa 11.1 441834AL138034Hs.7979KIAA0736 gene productsugar_tr 11.0 450986BE241845Hs.25744Novel human gene PH;RhoGAP;GaI-bind11.0 mapping to chomos lectin 416118N52773Hs.167721ESTs hemopexin;Peptidase_M1011.0 443071AL080021Hs.8986complement componentClq;Collagen 10.9 1, q subcompo 431247AL021578Hs.278489matrilin 4 EGF;vwa 10.9 431449M55994Hs.256278tumor necrosis TNFF~c6 10.9 factor receptor superfam 457044S73899Hs.2i31arginine vasopressin7tm_1 10.9 receptor 1A

416319AI815601Hs.79197CD83 antigen (activatedtg 10.8 B lymphocyte 402172 predicted exon 1g 10.7 4S 424218AF031824Hs.143212cystatin F (leukocystafin)cystatin 10.6 409208Y00093Hs.51077integrin, alpha vwa 10.6 X (antigen CD11 C (p15 426330M77235Hs.169331sodium channel, ion lrans;l4 10.6 voltage-gated, type V, 439758AA845235Hs.124470ESTs transmembrane4 10.6 412429AV650262Hs.75765GR02oncogene IL8 10.6 S~ 449987AW079749Hs.184719ESTs,WeaklysimilartoAF11672111ABC-tran;ABC_membrane10.6 432408N39127Hs.76391myxovirus (influenza)ion trans;K-tetra10.6 resistance 1, hom 406672M26041Hs.198253major histocompafibilityig;MHC_II_alpha10.5 complex, clas 419749X73608Hs.93029sparclosteonectin,kazal;thyroglobulirLl10:5 cwcv and kazal-like 419086NM Hs.89591Kallmann syndrome fn3;wap 10.5 000216 t sequence S 425009X58288Hs.154151protein tyrosine fi3;ig;Y~hosphalase;MAM10.5 S phosphatase, receptor t 423869BE409301Hs.134012C1q-related factorGTP_EFTU;EFG_C 10.4 430209AF177941Hs.235368Pro-(alpha)3(u) Collagen;COLFI;TSPN10.4 collagen 400834 predicted exon IRK 10.4 442941AU076728Hs.8867cysteine-~ch, angiogenicCys knot;tsp_l;vwc;IGFBP10.4 inducer, 61 403691 predicted exon tsp-l;Reprolysin;10.4 430776AJOt Hs.247905potassium voltage~gatedion traps 10.3 1021 channel, subfa 432342AL036128Hs.274404plasminogen activator,EGF;fnl;kringle;irypsin10.3 tissue 413731BE243845Hs.75511connecfive tissue Cys knot;lsp-l;vwc10.3 growth factor 423309BE006775Hs.126782sushi-repeat proteinsushi;HYR 10.3 6S 431728NM-007351Hs.268107mulfimerin EGF;CIq 10.3 450245AA007536Hs.271767ESTs, Moderately 1g 10.2 similar to ALU1 HU

446983AA157484Hs.97199complement componentClqreceptorEGF;XIink 10.2 414320U13616Hs.75893ankyrin 3, node death;ank;ZU5 10.1 of Ranvier (ankyrin G) 400253 predicted exon 7tm-1 10.0 406694M94891Hs.225932pregnancy specific1g 10.0 beta-1-glycoprolein 418793AW382987Hs.88474prostaglandin-endoperoxideEGF 10.0 synthase 1 410664NM Hs.65370lipase, endothelialRibosomal_L22 10.0 427274NM_005211Hs.174142colony sfimulatingpkinase;ig 10.0 factor t receptor, fo 7S TABLE 4B:
Pkey: Unique Eos probeset idenfifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 416441 159480 1 BE407197 AA182474 AAi 80369 BE275628 BE276131 423795 232093_1 AW849759 AW849758 T89549 AA331069 TABLE 4C:

Pkey: Uniquecorresponding to an Eos probeset number Ref: Sequence. The 7 digit numbers in this column are Genbank Identifier source (GI) numbers. Dunham I. et al." refers to the publication entitled "The DNA sequence of human chromosome 22" Ounham, et al.
(1999) Nature 402:489-495 Strand:
Indicates DNA strand from which exons were predicted Nt_position:nucleotide positions of predicted exons Indicates l Pkey Ref Strand Nt_position d00464 Plus 22074-22214 400834 Plus 121963-122288 402114 Plus 71578-71715 1 402172 Minus 143378-143671 402406 Plus 10872-11123,12932-13048 402425 Minus 50224-50395 403077 Plus 146923-147222,147326-147628 403089 Plus 171964-172239 403691 Minus 88280-88463 405024 Plus 88500-88697 405285 Minus 55744-55903,57080-57170,61478-61560 405368 Plus 46055-47188 TABLE 5A lists gbout 685 genes down-regulated in ovarian cancer compared to normal ovaries. These were selected as for Table 3A, except that the numerator and denominator were switched, and the ratio was greater than or equal to 3.0 (1.e. 3-fold down-regulated in tumor vs. normal ovary).
TABLE
5A:

DOWN-REGULATED
GENES, OVARIAN
CANCER
VERSUS
NORMAL
OVARY

Pkey:
Primekey Ex. Exemplar Accn:Accession UG
ID:
UniGene ID

Title:
UniGene Title ratio:
ration normal ovary vs tumor PkeyEx. UG Title ratio Accn ID

421013M62397Hs.1345mutated in colorectal 14.8 cancers 439360AA448488Hs.55346ESTs, Weakly similar 12.8 to Zi41 HUMAN ZINC FINGE

407644D168i5Hs.37288nuclear receptor subfamily12.6 1, group D, member 2 40 424851AA676441Hs.119059ESTs 11.6 455056AW853057 gb:RC1-CT0249-170200-025-h0411.5 CT0249 Homo sapie 420727H75701Hs.99886complement component 11.3 4-binding protein, beta 451617C01056Hs.168000ESTs 10.0 ' 401308 predicted exon 9.9 45 440987AA911705Hs.130229ESTs 9.7 409725T40760Hs.90459EST 9.7 415752BE314524Hs.78776putative transmembrane 9.7 protein 437690AA804362Hs.180544ESTs 9.6 437787A1908263Hs.29i625ESTs 9.5 459054AW798466Hs.823962',5'-oligoadenylate 9.2 synthetase 1 435330816769Hs.185689ESTs 9.2 436642AA724430Hs.127960ESTs 9.1 453752AL120800 gb:DKFZp762E152-rt 762 9.1 (synonym: hmel2) Homo so 451683AI808964Hs.207673ESTs 9.1 5 d01464AF039241Hs.9028histone deacetylase 5 9.0 436812AW298067 gb:Ul-H-BWO-ajp-g-09-0-Ul.si8.7 NCI CGAP_Sub6 Hom 410758BE535988 gb:601062418F1 NIH-MGC-108.7 Homo sapiens cDNA

412637AA115097Hs.261313ESTs 8.4 419166AA234638Hs.293584ESTs 8.3 423739AA398155Hs.97600ESTs 8.1 413813M96956Hs.75561teratocarcinoma-delved 8.1 growth factor 1 416211814625 gb:yg45c03.r1 Soares 8.0 infant brain 1 NIB Homo Sapiens 443131A1033833Hs.132689ESTs 7.9 415Bfi6T10115Hs.92423KIAA1566 protein 7.9 65 410130AI912097Hs.163208ESTs 7.9 439426A113i502Hs.f43135ESTs, Weaktysimilarto 7.8 FAFY-HUMAN PROBABLE

408141069205Hs.45152ESTs, Moderately similar7.7 to neurogenic basic-helix-loop 419015T79262Hs.14463ESTs 7.6 441573BE563966Hs.6529ESTs 7.5 419386AA236867Hs.143868ESTs 7.5 430562D78260Hs.285097ESTs 7.5 434738AA836265 gb:od17e02.s1 NCI_CGAP_GCB17.4 Homosapiens cDNA

403283 predicted exon 7.4 415861Zd3123Hs.144513ESTs 7.4 75 412732AW993300 gb:RC2-BN0033-180200-015-g067.4 BN0033 Homo sapie 441247AW118681Hs.128051ESTs 7.4 442865N57659Hs.114541ESTs, Weakly similario 7.3 neuronal thread protein 409699BE154650 gb:PM3-HT0344-071299-003c087.3 HT0344 Homo sapie 420352BE258835 gb:601117374F1 NIH MGC_167.3 Homo Sapiens cDNA

421418AA806639' gb:ob88g05.s1 NCI-CGAP_GCB17.2 Homo Sapiens cDN

413597AW302885Hs.117183ESTs 7.2 454102AW752363 gb:RCO-CT0201-270999-011-f037.1 CT0201 Homo sapien 445487AI806287Hs.201217ESTs 7.1 457604A1004397Hs.130558ESTs, Weakly similar 7.1 to similar to 0-sialoglycoprotein 400942 predicted exon 6.9 407596886913 gb:yq30f05.r1 Soares 6.9 fetal liver spleen 1NFLS
Homo so 422046AI638562 gbas50at0.x1 NCI-CGAF-Ut16.9 Homo Sapiens cDNA c 441284AA927676Hs.196542ESTs 6.9 446224AW450551Hs.13308ESTs 6.9 424943AU077260Hs.153924death-associated protein6.9 kinase 1 453967AW009077Hs.232947ESTs 6.9 448683AA167642Hs.14632ESTs 6.8 431877AA521204Hs.105507ESTs 6.8 1 411337AW837349 gb:QV2-LT0038-270300-108-4126.8 0 LT0038 Homo sapie 410596AA374186 gb:EST86290 HSC172 cells6.8 I Homo Sapiens cDNA
5' a 417762AA205976 gb:zq48a10.r1 Stratagene6.7 hNT neuron (937233) Homo 406364 predicted exon 6.7 452238F01811Hs.187931ESTs, Moderately similar6.7 to S22703 voltage-gated pota 15 415288815794Hs.141027ESTs, Weakly similar 6.7 to ALUi HUMAN ALU SUBFA

407437AF220264 gb:Homo Sapiens MOST-1 6.7 mRNA, complete cds.

439126AF085984 gb:Homo Sapiens full 6.6 length insert cDNA clone 452453AI9D2519 gb:OV-BT009-101198-051 6.6 BT009 Homo Sapiens cDNA

431800AW452768Hs.162045ESTs 6.5 426380AI291267Hs.149990ESTs, Weakly similar 6.5 to unnamed protein product [H.sa 449529AI990559Hs.232033ESTs 6.4 437755AW204256Hs.291887ESTs 6.4 448307AI480289Hs.211026ESTs 6.4 439586AA922936Hs.110039ESTs 6.4 420051N35696Hs.44745ESTs 6.4 425806AI522299Hs.173369ESTs ~ 6.4 433923A1823453Hs.146625ESTs 6.4 408159H63977Hs.118526ESTs 6.3 434844AF157116Hs.301355hypothetical protein 6.3 3 430197AA468888Hs.187697ESTs, Weakly similar 6.3 ~ to ALU5_HUMAN ALU SUBFA

440332AI218517Hs.188051ESTs 6.3 450061A1797034Hs.201115ESTs 6.3 454994AW850176 gb:IL3-CT0219-271099-022-H046.3 CT0219 Homo sapien 402105 predicted exon 6.3 3 409090W56067Hs.103105ESTs 6.2 405752 predicted exon 6.2 408074820723Hs.124764ESTs 6.2 459200Y09306Hs.30148homeodomain-interacting 6.1 protein kinase 3 416310T81421Hs.221396ESTs 6.1 421976AL138443Hs.23450mRNA for FLJ00023 protein6.1 429755NM_001364Hs.215839discs, large (Drosophila)6.0 homolog 2 (chapsyn-110) 448732BE614063 gb:601503993F1 NIN-MGC-716.0 Homo sapiens cDNA

453909AW004045Hs.203365ESTs 6.0 431178AA493884Hs.218008Homo Sapiens cDNA: FLJ214406.0 tis, clone COL04389 45 449671AW959755Hs.288896Homo sapiens cDNA FLJ129776.0 fis, clone NT2RP20062 421349W01715Hs.102958ESTs, Weakly similar 6.0 to Lpg6p [S.cerevisiae) 453282AK000043Hs.32922hypothetical protein 5.9 420618AA278781Hs.280698ESTs 5.9 412480~E142364 gb:CMO-HT0143-270999-062-4125.9 HT0143 Homo sapi 449858AW205979Hs.196065ESTs 5.9 429884AL049925Hs.225984DKFZP547G0910 protein 5.9 416453H56968Hs.114593ESTs 5.9 459497AA825742Hs.87517ESTs 5.9 433773AA759293Hs.112692ESTs 5.9 55 458942AA009647Hs.8850a disintegrin and metalloproteinase5.9 domain 12 (meltrin a 436054A1076262Hs.119813ESTs 5.9 410495N95428 gb:zb80d09.s1 Soares 5.8 senescent fibroblasts_NbHSF
H

403277 predicted exon 5.8 444302AI140115Hs.225130ESTs 5.8 439834A1754576Hs.124523ESTs 5.8 404020 predicted exon 5.8 454338AW381251Hs.1050pleckstdn homology, Sec75.7 and coiledlcoil domains 1(cy 430922AW373747Hs.183337ESTs 5.7 420269N55394Hs.963988-oxoguanine DNA glycosylase5.7 65 428498AA429575Hs.243032ESTs 5.7 445597H65649 gb:yr72d10.r1 Soares 5.7 fetal liver spleen 1NFLS
Homo so 411543AW85i248 gb:IL3-CT0220-160200-066-F015.7 CT0220 Homo sapien 408354A1382803Hs.159235ESTs 5.7 444431AW513324Hs.42280ESTs 5.7 406605 predicted exon 5.7 405541AF039241Hs.9028histone deacetylase 5 5.6 458090A1282149Hs.56213ESTs, Highly similar 5.6 to FXD3_HUMAN FORKHEAD

454529245439Hs.270425ESTs 5.6 445632A1261545 gb:qz30a07.x1 NCI-CGAP-Kidt5.6 1 Homo sapiens cDNA

75 441223AI475067Hs.132499ESTs 5.6 432552A1537170Hs.173725ESTs, Weakly similar 5.6 to ALUB-HUMAN ALU SUBFA

443650AI698330Hs.151444ESTs 5.6 403714 predicted exon 5.6 444165AL137443Hs.10441hypotheticalprotein FLJ112365.6 458914BE327696Hs.280922ESTs 5.6 420620AA278807Hs.173343ESTs 5.5 458228AA934995Hs.184846ESTs,WeaklysimilartoR288301[H.sapiens[5.5 448067868568Hs.183373src homology 3 domain-containing5.5 protein HIP-55 427000AI187420Hs.145221ESTs 5.5 452351AA025647 gb:ze85d01.r1 Soares 5.5 fetal heart_NbHHI9W
Homo sa 459359N99545 gb:za40a05.r1 Soares 5.5 fetal liver spleen 1 NFLS Homo sa 408385AF055634Hs.44553unc5(C.elegans homolog)c5.5 450938AW753734Hs.277215ESTs 5.5 431888H99557Hs.2864early endosome antigen 5.4 1, 162kD

459418W96550Hs.26418ESTs 5.4 416718883017Hs.204828ESTs 5.4 413236H16442Hs.127376KIAA0266 gene product 5.4 439063AF085922Hs.113968ESTs 5.4 1 446361A1291234Hs.282241ESTs 5.4 ~

458253AW296952Hs.196802ESTs ' 5.4 433682AA642418Hs.17381ESTs 5.4 455790BE090690 gb:RC1-BT0720-280300-011-g025.4 BT0720 Homo sapie 445755AW294870Hs.223672ESTs 5.3 1 436513AJ278110Hs.125507DEAD-box protein 5.3 416671N94087Hs.26073ESTs, Moderately similar5.3 to HG14-HUMAN NONHIS

440231AW015420Hs.163323ESTs 5.3 429866AA460104Hs.99540ESTs 5.3 437779AA345232Hs.21227ESTs 5.3 2~ 424029AB014594Hs.i37579KIAA0694 gene product 5.3 425614A1334963Hs.156256ESTs 5.3 430653AW902062Hs.30280ESTs 5.2 d08855T83061Hs.279604desmin 5.2 410454AW749041 gb:RC3-BT0319-100100-012-c055.2 BT0319 Homo sapie 438116AI904105Hs.122016ESTs 5.2 409138W73159Hs.58290ESTs ' 5.2 423047NM Hs.123064H1 histone family, member5.2 005323 T (testis-specific) 440212AW300959Hs.126216ESTs, Weakly similar 5.2 to good similarity to E. coli hypo 404108 predicted exon 5.2 3 456253T12198 gb:A588F Heart Homo Sapiens5.2 0 cDNA clone A588, mRN

409365AA702376Hs.226440Homo Sapiens clone 248815.1 mRNA sequence 444013T08531Hs.44404hypothetical protein 5.1 454071A1041793Hs.42502ESTs 5.1 419761M17373Hs.93177interferon,beta l,fibroblast5.1 35 451250AA491275Hs.236940Homo Sapiens cDNA FLJ125425.1 fis, clone NT2RM4000 405290 predicted exon 5.1 454487AW796342. gb:PM2-UM0027-230200-002-h025.1 UM0027 Homo sap 444131AI80660UHs.207119EST, Weakly similar to 5.1 intrinsic factor-B12 receptor pr 441679BE502267Hs.65996ESTs 5.1 450077AA523752Hs.120855ESTs 5.1 421209AJ010230Hs.102576retfinger protein-like 5.1 1 anGsense 445140AI650599Hs.i97913ESTs 5.1 421126M74587Hs.102122insulin-like growth factor5.1 binding protein 1 447037AI357568Hs.157612ESTs 5.f 45 407168845175 gb:yg40f01.si Soares 5.0 infant brain 1 NIB Homo Sapiens 436196AK001084 gb:Homo sapiens cDNA 5.0 FLJ10222 fis, clone HEMBBi 442772AW503680Hs.300513ESTs, Weakly similar 5.0 to T15B7.2 (C.elegansj 444138AI701572Hs.151153ESTs 5.0 458589AV654623Hs.288141Homo Sapiens cDNA FLJ130165.0 fis, clone NT2RP30006 S 451640AA195601Hs.26771Human DNA sequence from 5.0 o clone 747H23 on chromos 441318A1078234Hs.176130ESTs 5.0 407490S79281 gb:pancreaGc ribonuclease4.9 [human, mRNA Recombinan 438224AA933999 gb:on91f04.s1 Soares 4.9 NFL-T-GBC_S1 Homo Sapiens 451638AW798466Hs.823962',5'-oligoadenylate 4.9 synthetase 1 5 457356AA489621Hs.191670ESTs 4.9 430679844428Hs.22801ESTs 4.9 445747A1820863Hs.145328ESTs, Weakly similar 4.9 to ALU1 HUMAN ALU SUBFA

409036T88693Hs.226410ESTs 4.9 433382T64293Hs.291453ESTs 4.9 401287 predicted exon 4.9 424188AW954552Hs.142634zinc finger protein 4.9 404868 predicted exon 4.9 410152AW593104Hs.23681ESTs 4.9 444997A1204451Hs.146196ESTs 4.9 65 4310758E267477 gb:601189542F2 NIH MGC-74.8 Homo Sapiens cDNA c1 429033NM-007374Hs.194756sine oculis homeobox 4.8 (Drosophila) homolog 414337BE386606 gb:601273980F1 NIH MGC d.8 20 Homo Sapiens cDNA

410336BE391510Hs.18498Homo sapiens cDNA FLJ122774.8 fis, clone MAMMA10 445283AW515763Hs.246872ESTs 4.8 434792AA649253Hs.132458ESTs 4.8 433403AF040247 gb:Homo Sapiens erythroid4.8 differentiation-related factor 454940AW846202 gb:OVO-CT0179-011299-061-f104.8 CT0179 Homo sapie 455534AW991925 gb:PM3-BN0011-130100-002-b074.8 BN0011 Homo sapi 416437N48990Hs.37204ESTs 4.8 7S 433767AA609245 gb:af13a11.s1 Soares 4.8 tests NHT Homo Sapiens cDNA

434977AI734233Hs.226142ESTs, Weakly similar 4.8 to ALU7-HUMAN ALU SUBFA

416192NM Hs.998peroxisome proliferative4.8 005036 activated receptor, alpha 459218AA812633Ns.10845ESTs 4.8 402109 predicted exon 4.8 0 444490Ai151080Hs.146830ESTs 4.8 432632AW973801Hs.134656ESTs 4.8 438683AA813982Hs.291842ESTs 4.8 404044 predicted exon 4.8 449862AI672277Hs.199475ESTs 4.8 419002T78625Hs.268594ESTs 4.7 425582AL157686Hs.293737ESTs 4.7 416086H18252Hs.227263ESTs 4.7 441133AA918191Hs.194457ESTs 4.7 446323A1288274Hs.149868ESTs .
4.7 440347A1125590Hs.142864ESTs 4.7 439481AF086294Hs.125844ESTs 4.6 456388W28557 gb:48d8 Human refina 4.6 cDNA randomly primed sublibra 441864834177Hs.181315ESTs, Moderately similar4.6 to ALU4-HUMAN ALU SU

1 445910893483Hs.260273ESTs 4.6 ~

403531 predicted exon 4.6 429773AI332482Hs.218791proteoglycan 4, (megakaryocyte4.6 sfimulating factor, arfic 422563BE299342Hs.19348Homo sapiens cDNA FLJ131194.6 fis, clone NT2RP30026 422890243784Hs.78713solu(e comer family 25 4.6 (mitochonddal carrfer;
phospha 1 453663AL048807Hs.180714cytochrome c oxidase 4.6 S subunit Vla polypeptide 447839N72050Hs.164144ESTs 4.5 415612F12893Hs.13301ESTs 4.5 433371T25451 gb:PTH1188 HTGDL1 Homo 4.5 Sapiens cDNA 5'13' simila 410667AW936099 gb:OVO-DT0020-210100-095-d044.5 DT0020 Homo sapie 410890AW809575 gb:MR4-ST0121-060200-002-a124.5 ST0121 Homo sapie 404451 predicted exon 4.5 441705A1087052Hs.55993ESTs 4.5 439597W79579Hs.58552ESTs 4.5 407825NM Hs.d0202lymphoid-restricted membrane4.5 006152 protein 25 423073BE252922Hs.123119MAD (mothers against 4.5 decapentaplegic, Drosophila) ho 456278BE300369Hs.42643ESTs, Weakly similar 4.5 to KIAA1016 protein [H.sapiens 424719H90452 gb:yv01c03.r1 Soares 4.5 fetal liver spleen 1 NFLS Homo so 439542AW297571Hs.17646ESTs 4.5 444433AV649844Hs.282436ESTs 4.5 3~ 438831BE263273Hs.301128ESTs 4.5 410065AW812744 gb:RC3-ST0186-181099-012-c094.5 ST0186 Homo sapien 453895AA039843Hs.61948ESTs 4.5 458250AI807339Hs.152174ESTs, Weakly similar 4.5 to 2140 HUMAN ZINC FINGE

423403AA325483 gb:EST28475 Cerebellum 4.5 II Homo sapiens cDNA
5' en 3 454679AW813110 gb:CM4-5T0189-051099-021-f054.5 ST0189 Homo sapien 445368AI221631Hs.166788ESTs 4.5 401004 predicted exon 4.5 425837AF007567Hs.159609insulin receptor substrate4.5 420497AW206285Hs.253548ESTs 4.5 449438AA927317Hs.176719ESTs 4.5 429409AI694817Hs.155980ESTs 4.5 447959A1452784Hs.270270ESTs 4.4 407340AA810168Hs.232119ESTs d.4 424326NM Hs.145296disintegrin protease 4.4 45 443479AF027219Hs.9443zinc finger protein 202 4.4 443246T75157Hs.285516ESTs, Weakly similar 4.4 to hypothetical protein [H.sapien 414475BE302955Hs.119598ribosomal protein L3 4.4 432075AW972934 gb:EST385030 MAGE resequences,4.4 MAGM Homo sap 417906824769Hs.23725ESTs 4.4 406518W28077Hs.79389nel (chicken)-like 2 4.4 441460AI962478Hs.226804ESTs, Moderately similar4.4 to ALUC_HUMAN !!!! ALU

450549T49427Hs.181244major hisiocompatibility4.4 complex, class I, A

426528AA380828 gb:EST93827 Activated 4.4 T-cells VII Homo Sapiens cDN

430535AW968485 gb:EST380561 MAGE resequences,4.4 MAGJ Homo sapi 55 408479BE047329Hs.144483ESTs 4.3 448636AI557139Hs.129179Homo Sapiens cDNA FLJ135814.3 fis, clone PLACE10090 411280N50617 gb:yy89h02.r1 Soares-multiple-sclerosis-2NbHMSP4.3 H

440790AW593050Hs.128580ESTs 4.3 458301AF003834 gb:AF003834 Clontech 4.3 HI1149x Homo sapiens cDNA

6~ 442277AW448914Hs.202391ESTs 4.3 449463AI657038Hs.196109ESTs 4.3 433426H69125Hs.133525ESTs 4.3 410782AW504860Hs.288836Homo Sapiens cDNA FW 4.3 12673 fis, clone NT2RM4002 423040AA320749Hs.209464KIAA1604 protein 4.3 65 432430AW079984Hs.262480ESTs 4.3 432072N62937Hs.269109ESTs 4.3 452213AL110237Hs.28425Homo Sapiens mRNA; cDNA 4.3 DKFZp566D224 (from c 403635 predicted exon 4.3 441919AI553802Hs.128121ESTs 4.3 416717H79559Hs.297726ESTs 4.3 430995NM_005092Hs.248197tumor necros!s factor 4.2 (ligand) superfamily, member 18 429269AA449013Hs.99203ESTs 4.2 415840815955Hs.21758ESTs 4.2 451300AA017066Hs.237686EST 4.2 75 445366A1221511Hs.298662ESTs 4.2 424194BE245833Hs.169854hypolheficalprotein SP1924.2 459105NM Hs.28423upstream binding protein4.2 014517 1 (LBP-ia) 455387BE069037 gb:OV3-BT0379-161299-040-e124.2 BT0379 Homo sapie 410507AA355288Hs.271408ESTs d.2 go 453823AL137967 gb:DKFZp761D2315_r1 761 4.2 (synonym:hamy2) Homo 450966AA017245Hs.32794ESTs 4.2 432694AW991585Hs.276755ESTs, Weakly similar 4.2 to F53B1.2 (C.elegans]

455108AW856866 gb:RCO-CT0299-291199-031-G024.2 CT0299 Homo sapie 443609AV650231Hs.282941ESTs 4.2 427469AA403084Hs.269347ESTs 4.2 417178N51636 gb:yy87bOt.s1 Soares multiple4.2 sclerosis 2NbHMSP H

439751AA196090Hs.50794Homo Sapiens mRNA full 4.2 length insert cDNA clone EU

431982AW419296Hs.105754ESTs 4.1 442641AI890955Hs.262983ESTs 4.1 422128AW881145 gb:QVO-OT0033-010400-182-a074.1 OT0033 Homo sapie 449156AF103907Hs.171353prostate cancer anfigen 4.1 419668A1033098Hs.132777ESTs 4.1 418236AW994005Hs.172572hypothefical protein FLJ200934.1 1 432663AI984317Hs.122589ESTs 4.1 ~

448313BE622486Hs.121688Homo Sapiens cDNA FLJ134634.1 fis, clone PLACE10034 411279AW884776 gb:QV4-OT0067-010300-121-d014.1 OT0067 Homo sapie 440652AI216751Hs.143977ESTs 4.1 416608811499Hs.189716ESTs 4.1 15 420405AA743396Hs.189023ESTs 4.1 405717 predicted exon 4.1 435267N23797Hs.110114ESTs ' 4.1 412228AW503785Hs.73792complement component (3d/Epstein4.1 Bamviros) recepto 403560AI929721Hs.5120dynein, cytoplasmic, light4.1 polypepfide 2o d49162AI632740Hs.10476ESTs 4.1 459157AI904385 gb:CM-BT054-080399-054 4.1 BT054 Homo sapiens cDN

432474AA584042 gb:nn65e09.s1 NCI CGAP_Lar14.1 Homo Sapiens cDNA

455388AW936234 gb:QVO-DT0020-090200-106-g054.0 DT0020 Homo sapie 426456AA580748Hs.130658ESTs 4.0 438597AA811662Hs.171497ESTs 4.0 437934AW880871Hs.77496small nuclear ribonucleoprotein4.0 polypeptide G

459385BE380047 gb:601159362F2 NIH MGC_534.0 Homo Sapiens cDNA

436404AW968556Hs.137240Homo Sapiens mRNA for 4.0 partial 3'UTR, sequence 457740AW500458 gb:Ul-HF-BNO-akb-d-07-0-ULr14.0 NIH_MGC_50 Homo 3 437385AA757055Hs.164060ESTs , 4.0 ~

444530AV650124Hs.282435ESTs d.0 408066AA046914 gb:zf47h10.r1 Soares retina4.0 N2b4HR Homo Sapiens cD

411256AW834039 gb:QVO-TT0010-091199-053-e094.0 TT0010 Homo sapie 433582BE548749Hs.148016ESTs 4.0 3 438637BE500941Hs.126730ESTs, Weakly similar to 4.0 KIAA1214 protein [H.sapiens 414571BE410746Hs.22868protein tyrosine phosphatase,4.0 non-receptor type 11 446190AI279299Hs.256564ESTs 4.0 443542AI927065Ns.146040ESTs d.0 430444AW296421Hs.121035ESTs 4.0 454573BE146471 gb:QVO-HT0216-011199-043-c094.0 HT0216 Homo sapie 409846AW501748 gb:Ul-HF-BROp-ajm-b-12-0-ULr14.0 NIH MGC 52 Hom . AI751357Hs.288741Homo Sapiens cDNA: FLJ222564.0 456141 fis, clone HRC02860 456140AA169515Hs.6006ESTs 4.0 441685A1459261Hs.144481ESTs 4.0 45 416677T83470 gb:yd46g06.r1 Soares fetal4.0 liver spleen 1 NFLS Homo s 401740 predicted exon 4.0 420122AA255714Hs.284153Fanconi anemia, complementation4.0 group A

442594AW272467Hs.254655Unfified 3.9 426294AA374185 gb:EST86289 HSC172 cells 3.9 1 Homo Sapiens cDNA 5' a 411922AW876260 gb:PM4-PT0019-131299-006-E043.9 PT0019 Homo sapie 452320AA042873Hs.160412ESTs 3.9 431644AW972822Hs.169248cytochrome c 3.9 409892AW956113 gb:EST368183 MAGE resequences,3.9 MAGD Homo sap 418132T92670Hs.117421ESTs 3.9 55 414372AA143654 gb:zo65a02.r1 Stratagene 3.9 pancreas (937208) Homo sap 400196 predicted exon 3.9 416900M59964Hs.1048KIT ligand 3.9 445444AA380876Hs.270pleckstrin homology, Sec73.9 and coiledlcoil domains, bind 435957N39015Hs.190368ESTs 3.9 60 442299AW467791Hs.155561ESTs 3.9 419499AA808136Hs.177698ESTs 3.9 438403AA806607Hs.292206ESTs 3.9 449386AA001308Hs.193213ESTs 3.9 443283BE568610 gb:601342622F1 NIH-MGC 3.9 53 Homo Sapiens cDNA

65 406481 predicted exon 3.9 453530AW021633 gb:df26c02.y1 Morton Fetal3.9 Cochlea Homo Sapiens cDN

415558AA885143Hs.125719ESTs 3.9 41687dH98752Hs.42568ESTs 3.9 454885AW836922 gb:OV1-LT0036-150200-074-h063.9 LT0036 Homo sapie 419896299362 gb:HSZ99362 DKFZphamyl 3.9 Homo Sapiens cDNA clon 440962AI989961Hs.233477ESTs, Moderately similar 3.9 to A Chain A, Secypa Compl 419401AW804663 gb:OV4-UM0094-160300-135-d063.9 UM0094 Homo sap 406562 predicted exon 3.8 405690BE409855Hs.808heterogeneous nuclear 3.8 ribonucleoprotein F

75 435282AA677428Hs.189731ESTs 3.8 402451 predicted exon 3.8 d51577N69101Hs.32703ESTs 3.8 457141AA521410Hs.41371ESTs 3.8 407817H92553Hs.40400ESTs 3.8 8~ 412613AA653507Hs.285711Homo sapiens cDNA FLJ130893.8 fis, clone NT2RP30021 418355L42563Hs.1165ATPase, N+IK+transporfing,3.8 nongastric, alpha polypep 446357AW161533Hs.300866ESTs 3.8 407448AJ001865 gb:Homo Sapiens mRNA, 3.8 parfial cDNA sequence for h 456383AI148037 gb:qg61e01.r1 Soares-tesfis-NHT3.8 Nomo Sapiens cDNA

444651W58469Hs.103120ESTs 3.8 455067AW854538 gb:RC3-CT0255-200100-024-b023.8 CT0255 Homo sapie 442657BE502631Hs.130645ESTs 3.8 429142AA835639Ns.104972ESTs 3.8 429274A1379772Hs.99206ESTs 3.8 437774AW978199Hs.291648ESTs 3.8 427737AA435988Hs.178066ESTs, Weakly similar 3.8 to AF068289 5 HDCME31 P [H.s 405671 prodicted exan 3.8 413627BE182082Hs.246973ESTs 3.8 1 438658837529Hs.269924ESTs 3.8 ~

416612H70565 gb:yr97c04.r1 Soares 3.8 fetal liver spleen 1 NFLS Homo so 423045AW967472Hs.301511ESTs, Highly similar 3.8 to KPT2-HUMAN SERINEITHR

453361AA035197Hs.107375ESTs 3.7 437243AA747549Hs.259122ESTs 3.7 15 437987AW450202Hs.122963ESTs 3.7 408781BE148621Hs.254602ESTs 3.7 455895BE154837 gb:PMi-HT0345-121199-001-c083.7 HT0345 Homo sapie 431492AW612343 gb:hg97c10.x1 NCI-CGAP-Kidl13.7 Homo Sapiens cDN

413247AW963969 gb:EST376042 MAGE resequences,3.7 MAGH Homc sap 422866NM Hs.121502mannosyl (alpha-1,6-)-glycoprotein3.7 002410 beta-1,&N-acetyl-g d31828AA572994 gb:nm33f12.s1 NCI-CGAP-Lip23.7 Homo Sapiens cDNA

438872864197Hs.23589ESTs 3.7 438673A1824717Hs.123443ESTs 3.7 416624H69044 gb:yr77h05.s1SoaresfetalliverspleenlNFLSHomosa3.7 401963 predicted exon 3.7 402867 predicted exon 3.7 408315AW179148 gb:MR4-ST0067-200899-002-B073.7 ST0067 Homo sapie 418320D86981Hs.84084amyloid beta precursor 3.7 protein (cytoplasmic tail)-bindin 447199AI939421Hs.160900ESTs ~ 3.7 422590AA312758Hs.193945Homo Sapiens cDNA FLJ139623.7 fis, clone Y79AA10012 451996AW514021Hs.245510ESTs 3.7 412463AW953444Hs.78672iaminin, alpha 4 3.7 440928AL046575Hs.130198ESTs 3.7 441951W31002Hs.128195ESTs 3.7 35 440705AA904244Hs.153205ESTs 3.7 434231AF119901Hs.250568hypothetical protein 3.7 411039AL135674Hs.163348ESTs 3.7 413137BE066915 gb:PMO-BT0340-231199-001-b073.7 BT0340 Homo sapie 417970AA309234Hs.57760Homo Sapiens cDNA: FLJ231193.7 tis, clone LNG07978 439786AV652707Hs.33756Homo Sapiens mRNA full 3.7 length insert cDNA clone EU

459595AL040421 gb:DKFZp43480714_r1434 3.7 (synonym: htes3) Hamo s 443601A1078554Hs.15682ESTs 3.7 404041 predicted exon 3.6 406122 predicted exon 3.6 45 404582 predicted exon 3.6 455786BE090077 gb:RC6-BT0710-300300.021-F023.6 BT0710 Homo sapie 411899AA370573 gb:EST82238 Prostate 3.6 gland I Homo Sapiens cDNA 5' a 426758AL036430Hs.197772ESTs 3.6 421776AW301994Hs.108183candidate tumor suppressor3.6 p33 ING1 homolog 50 430169AA468531Hs.189047ESTs 3.6 407695AI808007Hs.66450ESTs 3.6 454564AW807573 gb:MR1-ST0088-021299-004-g013.6 ST0088 Homo sapie 425902X52509Hs.161640tyrosine aminotransferase3,6 439328W07411Hs.118212ESTs, Moderately similar3.6 to ALU3_HUMAN ALU SU

55 429066AA868555Hs.178222ESTs 3.6 428690AI948490Hs.98765ESTs 3.6 437302AA837146Hs.180275ESTs 3.6 443973A1580083Hs.176154ESTs 3.6 453993AW615224Hs.252839ESTs 3.6 413623AA825721Hs.246973ESTs 3.6 409196NM_001874Hs.169765carboxypeptidase M 3.6 424916AW867440Hs.23096ESTs 3.6 424769H06469Hs.142653ret finger protein 3.6 400080 predicted exan 3.6 65 421521AI638760Hs.161795ESTs 3.6 405549 predicted exon 3.6 446114A1275715Hs.145926ESTs 3.6 441392AW451831Hs.222119ESTs, Weakly similar 3.6 to K1 CGLHUMAN KERATIN, T

424025A1701852Hs.301296ESTs 3.5 448527A1525606 gb:PTl.3-03 G05.r tumort3.5 Homo Sapiens cDNA 5', m8 437063AA351109Hs.5437Tax1 (human T-cell leukemia3.5 virus type I) binding prot 449880AI673006Hs.231948ESTs, Weakly similar 3.5 to ALUB-HUMAN !!!! ALU
CL

449311A1657014 gbat49a12.x1 NCI_CGAP-GC63.5 Homo Sapiens cDNA c 442999AW662889Hs.132395ESTs 3.5 75 416238W90448 gb:zh78cO8.s1 Soaros 3.5 fetal liver-spleen 1NFLS

423209BE278528Hs.106823H.sapiens gene from PAC 3.5 42616, similar to syntaxin 409854AW501833 gb:Ul-HF-BROp-ajo-d-01-0-ULr13.5 NIH_MGC_52 Hom 414941C14865Hs.182159ESTs 3.5 456337AW751661Hs.65919ESTs 3.5 415296F05086 gb:HSC01A011 normalized 3.5 infant brain cDNA Homo s 423338AB007961Hs.127338KIAA0492 protein 3.5 415618F12954 gb:HSC3GG091 normalized 3.5 infant brain cDNA Homo s 405583 predicted exon 3.5 435601AF217509Hs.283077centrosomal P4.1-associated3.5 protein; uncharacterized bo 450867AA011454Hs.245122ESTs 3.5 431339AA506294Hs.257266ESTs 3.5 441969A1733386Hs.129194ESTs, Weakly similar 3.5 to ALU1 HUMAN ALU SUBFA

431343AW970603Hs.300941Homo Sapiens cDNA FLJ116613.5 fis, clone HEMBA100 434317AI674095Hs.116323ESTs 3.5 414741851321Hs.25780Homo Sapiens cDNA FLJ122523.5 fis, clone MAMMA10 439707AW297702Hs.102915ESTs 3.5 443178AI631241Hs.47312ESTs 3.5 400397AJ270770Hs.154485transcription factor 3.5 7-like 2 (T-cell specific, HMG-box) 455887BE154173 gb:PMi-HT0340-201299-004-f123.5 HT0340 Homo sapie 434362W27081Hs.295446ESTs 3.5 409211AA078835 gb:zm94h04.s1 Stratagene3.5 colon HT29 (937221) Homo 414390BE281040 gb:601156234F1 NIH_MGC_213.5 Homo sapiens cDNA

457142AI924353Hs.290969EST 3.5 423006U29700Hs.123014anG-Mullerian hormone 3.5 receptor, type II

453363AI989776Hs.232623ESTs 3.5 418913BE046745 gb:hn39bO6.x1 NCI_CGAP-RDF23.4 Homo Sapiens cDN

440016AW118114Hs.137057ESTs 3.4 405096 predicted exon 3.4 435072AW592176Hs.116932ESTs 3.4 436535L09078 gb:Homo Sapiens mRNA 3.4 fragment 424001W67883Hs.137476KIAA1051 protein 3.4 428361NM_015905Hs.183858transcripfional intermediary3.4 factor 1 410587AA370706Hs.11252ESTs, Weakly similar 3.4 to Weak similarity with the Ysy6 454543AW806895 gb:QV4-5T0923-160400-172-c063.4 ST0023 Homo sapien 419515S81944Hs.90791gamma-aminobutyric acid 3.4 (GAGA) A receptor, alpha 410280AA083558Hs.261286ESTs 3.4 425714AW963278 gb:EST375351 MAGE resequences,3.4 MAGH Homo sap 416895AW961600 gb:EST373672 MAGE resequences,3.4 MAGG Homo sap 427935AW503687Hs.119424ESTs, Weakly similar 3.4 to unnamed protein product [H.sa 4116738E064863 gb:RC1-BT0313-110300-015-f063.4 BT0313 Homo sapien 453339AW992599Hs.252797ESTs 3.4 424696BE439547Hs.151903Homo Sapiens clone 247063.4 mRNA sequence 436242AK002187 gb:Homo Sapiens cDNA 3.4 FLJ11325 fis, clone 35 442837A1022082Hs.50492ESTs 3.4 452807AA028933Hs.i62434ESTs 3.4 418110843523Hs.217754Homo Sapiens cDNA: FLJ222023.4 fis, clone HRC01333 433936AI208072Hs.123459ESTs 3.4 458177A1744995Hs.267072ESTs, Moderately similar3.4 to ALU4_HUMAN ALU SU

40 401896 predicted exon 3.4 406237 predicted exan 3.4 457688AL110157Hs.3843Homo Sapiens mRNA; cDNA 3.4 DKFZp586F2224 (from 45691AAW363582Hs.75323prohibitin 3.4 421916834441Hs.101007Homo sapiens cDNA: FLJ235463.4 fis, clone LNG08361 45 419321Nd8146Hs.269069ESTs 3.4 447876AV654978Hs.19904cystathionase (cystathionine3.4 gamma-lyase) 406197 predicted exan 3.4 443005A1027184Hs.200918ESTs 3.4 450078A1681743 gbax38g10.xi NCI-CGAP_Lu243.4 Homo Sapiens cDNA

50 431301AA502384Hs.151529ESTs 3.4 430202T85775 gb:yd60g02.r1 Soares 3.4 fetal liver spleen 1 NFLS Homo s 428559H24338Hs.27041ESTs 3.4 455731BE072188 gb:OV4-BT0536-211299-055-b093.4 BT0536 Homo sapie 420735AW297440Hs.88653ESTs 3.4 55 430881NM_000809Hs.248112gamma-aminobutyric acid 3.3 (GAGA) A receptor, alpha 405836 predicted exon 3.3 449178AI633748Hs.197597ESTs 3.3 453265U61232Hs.32675tubulin-specific chaperone3.3 a 430700AA768902Hs.247812H2A histone family, member3.3 K, pseudogene 60 424496AI733451Hs.129212ESTs 3.3 446963A1862668Hs.176333ESTs 3.3 422879AI241409Hs.188092ESTs 3.3 419831AW448930Hs.5415ESTs 3.3 449570AA001793 gb:zh86cO6.r1 Soares 3.3 fetal liver-spleen_1NFLS_S1 H

65 406255 predicted exon 3.3 41231qAW936903 gb:RC1-DT0029-030200-012-d023.3 DT0029 Homo sapie 401350 predicted exon 3.3 '' 439098AF085955 gb:Homo Sapiens full 3.3 length insert cDNA clone 450589AI701505Hs.202526ESTs 3.3 70 430749AJ242956Hs.25960v-myc avian myelocytomatosis3.3 viral related oncogene, n 430689AI695595Hs.293219ESTs 3.3 454753AW819212 gb:CM1-ST0283-071299-061-c073.3 ST0283 Homo sapie 444479AA194980Hs.30818Homo Sapiens cDNA FLJ13fi813.3 fis, clone PLACE20000 413516BE145907 gb:MRO-HT0208-221299-204-e123.3 HT0208 Homo sapie 75 425541AA359119 gb:EST68172 Fetal lung 3.3 II Homo Sapiens cDNA
5' end, 457107AA418246Hs.185796ESTs, Weakly similar 3.3 to b3418.1 [H.sapiens]

421480NM-016158Hs.104671erythrocyte transmembrane3.3 protein 444289BE267060Hs.7fi391myxovirus (influenza) 3.3 resistance 1, homolog of murine 417725825257Hs.21503ESTs 3.3 453631AL046418 gb:DKFZp434N247_r1434 3.3 (synonym: htes3) Homo so 450692H50603Hs.94037hypolheficalprotein FLJ230533.3 413357W47611 gb:zc35e06.r1 Soares 3.3 senescent_fibroblasts_NbHSF
H

415327H22769Hs.1861membrane protein, palmitoylated3.3 1 (55kD) 457569AW970021Hs.291120. ESTs, Weakly similar ~
to ALUB-HUMAN ALU SUBFA 3.3 448601861666Hs.293690ESTs 3.3 436526AW993633Hs.287681Homo Sapiens cDNA: FLJ216853.3 fis, clone COL09372 440589BE397763Hs.194478Homo Sapiens mRNA; cDNA 3.3 DKFZp43401572 (from 418768T39310Hs.1139cold shock domain protein3.3 A

426768AW303337Hs.270411ESTs 3.3 400394AF040257Hs.283818Nomo Sapiens TNF receptor3.3 homolog mRNA, parfial cd 433565AA599763Hs.112520ESTs 3.3 424093AA335025 gb:EST39621 Epididymus 3.3 Homo sapiens cDNA 5' end, .
449552AA001742Hs.83722ESTs 3.3 1 431892A4521315Hs.194424ESTs 3.3 ~

d05512 predicted exon 3.3 446990AI354717Hs.223908ESTs 3.3 457729A1821863Hs.293467ESTs, Weakly similar 3.2 to ALU7-HUMAN ALU SUBFA

417333AL157545Hs.42179bromodomain and PHD finger3.2 conta!ning, 3 1 456420AW401361Hs.91773protein phosphatase 2 3.2 S (formerly 2A), catalyfic subunit, 403497 predicted exon 3.2 427145852635Hs.25935ESTs 3.2 406454 predicted exon 3.2 441033BE562555 gb:601335867F1 NIH-MGC-443.2 Homo Sapiens cDNA

408444AW661839Hs.253204ESTs 3.2 434739AA804487Hs.144130ESTs 3.2 437060AA745591Hs.292063ESTs 3.2 423092BE274837Hs.123637putative homeodomain 3.2 transcripfion factor 424695U58331Hs.151899sarcoglyca~, delta (35kD3.2 dysUophin-associated glycopr 443362A1053464Hs.166505ESTs 3.2 437500AL390150 gb:Homo Sapiens mRNA; 3.2 cDNA DKFZp547L156 (from 425458H89317Hs.182889ESTs 3.2 439171AA831133Hs.294128ESTs 3.2 407647AW860158 gb:RCO-CT0379-290100-032-b043.2 CT0379 Homo sapie 435608AW183971Hs.250896ESTs 3.2 426743AA383833Hs.245022ESTs 3.2 457525AW973800 gb:EST385901 MAGE resequences,3.2 MAGM Homo sap 413800AI129238Hs.192235ESTs 3.2 414193BE260069 gb:601150964F1 NIH MGC 3.2 19 Homo Sapiens cDNA

3 455565BE000537 gb:RC3-BN0072-240200-011-d073.2 BN0072 Homo sapie 410061T91029Hs.15069ESTs 3.2 450666T99968Hs.18799ESTs 3.2 458529AV652120Hs.213232ESTs 3.2 424751AA769482Hs.296320ESTs 3.2 4~ 442225A1306597Hs.129192ESTs 3.2 410990AW812929 gb:RC3-ST0186-250200-018-c053.2 ST0186 Homo sapien 435644AA700867Hs.269659ESTs 3.2 405347 predicted exon 3.2 441202AI632143Hs.135853ESTs 3.2 45 446694AV659942Hs.258132ESTs 3.2 454652AW812088 gb:RC4-ST0173-191099-032-a073.2 ST0173 Homo sapien 418985A1042330Hs.87128ESTs, Weakly similar 3.2 to similar to YBS4 YEAST
[C.el 430118AI377255Hs.183287ESTs 3.2 430691C14187Hs.103538ESTs 3.2 416313H47206Hs.194109ESTs, Weakly similar 3.2 to ALUB-HUMAN !!!! ALU
CL

446122AI362790Hs.181801ESTs 3.2 453725W28543 gb:48c5 Human retina 3.2 cDNA randomly primed sublibra 453954AW118336Hs.75251DEADIH (Asp-Glu-Ala-AspIHis)3.2 box binding protein 428166AA423849Hs.79530M5-14 protein 3.2 55 447506878778Hs.29808Homo Sapiens cDNA: FLJ211223.2 fis, clone CAS059i7 401871 predicted exon 3.2 442160AI337127Hs.156325ESTs 3.2 404708 predicted exon 3.1 412588AW993055Hs.44024ESTs 3.1 431976AA719001Hs.291065ESTs 3.1 408884AW891024Hs.281172ESTs 3.1 433811AW975015Hs.123138ESTs 3.1 431691AI208511Hs.292510ESTs 3.1 418719AW975590Hs.161707ESTs 3.1 65 431740N75450Hs.183412ESTs, Moderately similar3.1 to AF11672167 PR01777 (H

435699AI911488Hs.213724ESTs 3.1 459344AW499533Hs.257976ESTs 3.1 431729AW004714Hs.162033ESTs 3.i 436771AW975687Hs.292979ESTs 3.1 434480AW956268Hs.59395Homo Sapiens clone IMAGE:1125743.1 mRNA sequence 459547AI400579Hs.225186EST 3.1 427962AA946582Hs.133546Homo Sapiens cDNA: FLJ211203.1 fis, clone CAS05691 403743 predicted exon 3.1 4135608E148411 gb:MRO-HT0241-131299-002-f043.1 HT0241 Homo sapie 75 454372H96643Hs.283565FOS-like anfigen-1 3.1 450018AA4216d2Hs.24309hypotheticalprotein FLJ111063.1 428839A1767756Hs.82302ESTs 3.1 407110AA018042Hs.95078ESTs 3.1 436133T77531Hs.191124ESTs 3.1 g0 418872894785Hs.270263ESTs 3.1 404418 predicted exon 3.1 446877AI559472Hs.270720ESTs 3.1 429053AA443967Hs.194114ESTs 3.1 425189H16622 gb:ym26c07.r1 Soares 3.1 infant brain 1NIB Homo Sapiens 404134 predicted exon 3.1 441404AI638880Hs.126895 ESTs 3.1 40007fi predicted exon 3.1 411876AW961336Hs.69705 ESTs, Weakly similar3.1 1o KIAA0443 [H.sapiens) 451048AA013349Hs.60602 ESTs 3.1 447021A1356564Hs.161406 ESTs 3.1 404083 predicted exan 3.0 415833H05175Hs.107510 ESTs 3.0 402142 predicted exon 3.0 1 415820853720Hs.189745 ESTs 3.0 ~

441140AW016534Hs.226994 ESTs 3.0 449376AA001278Hs.59905 ESTs 3.0 457593A1738815Hs.117323 ESTs 3.0 411542AW850767gb:IL3-CT0220-031199-025-A053.0 CT0220 Homo sapien 1 403375 predicted exon 3.0 S

449561A1022240Hs.17924 ESTs 3.0 406241 predicted exon 3.0 d20306AA258318Hs.219226 ESTs 3.0 413161BE068130gb:CM2-BT0368-171299-056-a013.0 BT0368 Homo sapie 2~ 448221BE622615gb:601440775T1 NIH MGC-72 3.0 Homo Sapiens cDNA

415920245684gb:HSCZRDi 21 normalized 3.0 infant brain cDNA Homo 459135AI902802gb:RG8T015-31129&026 8T015 3.0 Homo Sapiens cDNA

425357AA355842. gb:EST64303 Jurkat T-cells3.0 VI Homo Sapiens cDNA 5' 454724AA091228gb:cchn2152.seq.F Human 3.0 fetal heart, Lambda ZAP
Ex 25 429395AK002071Hs.201624 hypotheticalprotein3.0 427607AA406119Hs.270479 ESTs 3.0 443598AW499970Hs.14822 ESTs 3.0 437948AA772920gb:ae73c09.s1 Stratagene 3.0 schizo brain 811 Homo sapien 418105AW937488Hs.178000 ESTs 3.0 426763AL042262Hs.172101 Numan DNA sequence3.0 from clone RP1-202121 on chro 403473 predicted exon 3.0 427501AI369280Hs.131743 ESTs 3.0 453246NM Hs.32539 KIAA1264 protein 3.0 404587M99587Hs.104134 homeo box (H6 3.0 family) 1 35 433964AW241987Hs.197025 ESTs 3.0 453472AL037925gb:DKFZp564M037 r1564 (synonym:3.0 hfbr2) Homo sa 433183AF231338Hs.222024 transcription 3.0 factor BMAL2 435899W89093Hs.189914 ESTs 3.0 425626A1537536Hs.173519 ESTs 3.0 4~ 428931AA994979Hs.98967 ATPase, H(+)-transporting,3.0 lysosomal, noncatalytic acc 426593AW958560gb:EST370630 MAGE resequences,3.0 MAGE Homo sapi 431899AA521381Hs.18772fi ESTs 3.0 d22406AF025441Hs.116206 Opa-interacting 3.0 protein 5 448178AI479482Hs.170789 ESTs 3.0 45 404227 predicted exon 3.0 440575AA889870Hs.126006 ESTs 3.0 431198AL047634Hs.231913 ESTs 3.0 434221AF119885Hs.283040 hypothetical protein3.0 459459AA460445gb:zx66h11.r1 Soares total_fetus-Nb2HF83.0 9w Homo TABLE
58:

Pkey:
Unique Eos probeset identifier number CAT
number:
Gene cluster number Accession:Genbank accession numbers Pkey CAT Accession Number 1 AW86238fi AW862341 AW821869 409211_ AA078835 AA079319 AA078816 41006511742581AW812744AW581974AW8i2725 4107581219899_1BE535988 AW801777 1 AW936551 AW93fi552 AW936530 411673_ BE064863 BE153698 AW856751 1253737_1BE153820 BE064737 BE153fi74 411899126497_1AA370573 BE160501 BE160500 N72424 AA09fi462 413247135544_1AW963969 AW963971 AA127651 AA376726 4133571364165_1W47611 BE087851 4141931424706=BE260069 ~ 1 414372143909_1AA143654 AW753140 AA213770 AW970865 AA569075 AA492132 4152961533528_1F05086 F05091 817158 4162111578993_1814625 817952 H29120 814650 4166241604694_1H69044T47567 H75691 T50292 421418202288_1AA806639 AA291008 AA836274 AW978806 3 422128211994AW881145 AA4907i8 M85637 AA304575 T06067 AA331991 ~ 1 425189247825_1H16622 817322 AA351959 45 431828_ AA572994 AA516249 AA702595 432474348197_1AA5B4042 AW973273 AA548798 434738392562_1AA836265 AA648266 AW974440 43619641562_1AK001084 AA078092 AA829049 43624241641_1AK002187 866351 438224452656_1AA933999 AA781181 60 43912646887_1AF085984 H95905 H95906 .44103350807 BE562555 44328356492_-1BE568610 449311804513_1A1657014 AW594035 A1657036 A1638390 452453918300_1A1902519 A1902518 A1902516 453725978760_1W28543 AL119531 4545731225624_1BE146471 AW833743 AW833609 AW821469 AW821488 AW821541 454753 1233576_1 AW819212 AW819170 BE158474 AW819172 AW819213 AW819200 454885 1238874 1 AW836922 AW876719 AW876688 AW8369i9 AW836997 AW836908 454940 1245640_1 AW846202 AW846i74 AW846532 AW846181 AW846458 AW846206 1 ~ 454994 1248637-1 AW850176 AW850513 AW850412 AW850451 455108 1253916_1 AW856866 AW856858 AW8568S6 15 455388 1287904_1 AW936234 AW936074 AW936181 AW936179 AW936217 AW936077 455534 1322942_1 AW99i925AW991919 455565 1329591 1 BE000537 BEt80584 BE180540 BE180542 BE180546 455731 1353872_1 BE072188 BE072299 BE072269 BE072317 BE072238 455895 1381386 1 BE154837 8E154879 BE154850 BE154877 BE154835 BEi54849 BEi54902 BE154905 BE154867 BE154901 BE154904 BE154899 457525 351732_1 AW973800 AA557589 AA559886 457740 39528_1 AW500458 AW160900 AF161362 AF150327 AW578393 AW360921 AW360920 TABLE 5C:
Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to fhe publication entitled "The DNA sequence of 35 human chromosome 22" Dunham, et al. X1999) Nature 402:489-495 Strand: Indicates DNA strand from which exons were predicted Nt_position: Indicates nucleotide positions of predicted exons Pkey Ref Strand Nt-position 4o d00942 7656749 Minus 91593-91757,92720-92843,93962-94079,94824-94997 401004 7229982 Plus 62580-62772 401287 9801612 Minus 42287-42431 d01308 9212516 Plus 169019-169649 401350 9931226 Plus 14471-14623 45 401740 2982169 Plus 148357-148484,148591-148690 401871 8079355 Minus 58158-59585 401896 8569194 Plus 115129-115294 401963 3126783 Plus 51382-51521 402105 8131588 Minus 22856-24055 402109 8131678 Minus 171722-171859,173197-173303 402142 7704985 Minus 29932-30698 402451 9796677 Minus 48137-48343 402867 5596716 Plus 52806-53106,53500-53818 403277 8072597 Minus 27494-27642 5 403283 8076905 Minus 71124-71996 403375 9255944 Minus 92554-92795 403473 9945095 Minus 54241-54437 403497 6067111 Plus 7221-7441 403531 8076842 Minus 75903-76134 403635 6862664 Minus 157028-157145,161725-161900 403714 7210030 Minus 145556-145873 403743 7652003 Minus 136463-136646 404020 8655966 Minus 174449-174663 404041 8886967 Minus 1334-1503,2483-2565,5230-5337,19656-19804 65 404044 9558573 Minus 225757-225939 404083 9944029 Minus 16650-17082 404108 8247074 Minus 63603-64942 404134 6981900 Minus 40633-40911 404227 7838233 Minus 93110-93259 404418 7382420 Minus 153339-153481,155099-155294 404451 7638438 Minus 105191-105622 404582 9739220 Plus 53230-53424 404708 9800828 Plus 77522-77658 404868 9454593 Plus 39954-40430 75 405096 8072599 Plus 140844-140897,148510-148581 405290 3900849 Minus 79582-79765 405347 2979602 Minus 977-1116 405512 9454624 Plus 17802-17966,18573-18697 405549 1552494 Plus 10878-11048 405583 4512287 Plus 56211-56353 405671 2565031 Plus 25805-26923 405717 9588573 Plus 11275-11973 405752 9212305 Plus 91392-91528 405836 5686282 Minus 5031-5217 406122 9144087Minus30940-31386 406197 7289992Minus47520-47961 406237 7417725Plus 30032-30501 406241 7417725Minus34951-35752 406255 7417729Plus 2959-3200 406364 9256114Minus50715-50833 406454 9588380Minus91746-91958 406481 9864741Minus91439-91579 406562 7711584Plus 37316-37426 1 ~ 4066058272666Minus23275-23493,23723-23903 TABLE 6A lists about 68 genes highly down-regulated in ovarian cancer compared to normal ovaries. These were selected as for Table 5A, except the 'average"
ovarian cancer level was set to the maximum value amongst various ovarian cancers and the "average" normal ovary level was set to the minimum value from various non-malignant ovary 15 specimens, and the ratio was greater than or equal to 2.5 (i.e. 2.5-fold down-regulated in the highest tumor vs. the lowest normal ovary). This has the overall effect of increasing stringency, and reducing the number of false-positives.
TABLE
6A:
ABOUT

HIGHLY
DOWN-REGULATED
GENES, OVARIAN
CANCER
VERSUS
NORMAL
OVARY

Pkey:
Primekey Ex.Accn:
ExempIarAccession UG
1D:
UniGene tD

Titre:
UniGene Titre ratio: vs.
ration tumor of normal ovary 25 Pkey Ex. UG Title , ratio Accn ID

424851AA676441Hs.119059ESTs 7.9 437690AA804362Hs.180544ESTs 4.7 433682AA642418Hs.17381ESTs 4.1 407437AF220264 gb:Homo sapiens MOST-1 mRNA,4.1 complete cds.

30 437787AI908263Hs.291625ESTs 4.0 453262AK000043Hs.32922hypothetical protein FLJ200364.0 440987AA911705Hs.130229ESTs 3.8 443131A1033833Hs.132689ESTs 3.8 431075BE267477 gb:601189542F2 NIH_MGC 7 3.6 Homo Sapiens cDNA clo 3 412637AA115097Hs.261313ESTs 3.6 408141U69205Hs.45152ESTs, Moderately similar 3.5 to neurogenic basic-helix-loop 420122AA255714Hs.284153Fanconi anemia, complementation3.5 group A

430653AW902062Hs.30280ESTs 3.4 401308 predicted exon 3.4 4~ 410758BE535988 gb:601062418F1 NIH MGC 10 3.4 Homo Sapiens cDNA c 421418AA806639 gb:ob88g05.s1 NCI-CGAP-GCB13.4 Homo Sapiens cDNA

450061AI797034Hs.201115ESTs 3.3 409725T40760Hs.90459EST 3.3 434738AA836265 gb:od17e02.s1 NCI_CGAP_GCBt3.3 Homo Sapiens cDNA

45 431644AW972822Hs.169248cytochrome c 3.3 450938AW753734Hs.277215ESTs 3.2 420497AW206285Hs.253548ESTs 3.2 439426A1131502Hs.143135ESTs, Weakly similar to 3.2 FAFY-HUMAN PROBABLE C

407596886913 gb:yq30t05.r1 Soares fetal 3.2 liver spleen iNFLS Homo sap 448683AA167642Hs.14632ESTs 3.2 431982AW419296Hs.105754ESTs 3.1 452320AA042873Hs.160412ESTs 3.1 419401AW804663 gb:OV4-UM009d-160300-135-d063.1 UM0094 Homo sapim 402105 predicted exon 3.1 5 444997AI204451Hs.146196ESTs 3.1 403283 predicted exon 3.0 455388AW936234 gb:OVO-DT0020-090200-106-g053.0 DT0020 Homo sapie 428559H24338Hs.27041ESTs 2.9 419002T78625Hs.268594ESTs 2.9 404868 predicted exon 2.9 ~

409090W56067Hs.103105ESTs 2.9 406605 predicted exon 2.9 441202AI632143Hs.135853ESTs 2.8 422046A1638562 gb:ls50at0.x1 NCI CGAP-Ut1 2.8 Homo Sapiens cDNA c7 65 442865N57659Hs.114541ESTs, Weakly similar to 2.8 neuronal thread protein AD7c-N

444431AW513324Hs.42280ESTs 2.8 426294AA374185 gb:EST86289.HSC172 cells 2.8 ~ I Homo Sapiens cDNA 5' en 412480BE142364 gb:CMO-HT0143-270999-062-d122.8 HT0143 Homo sapie 449858AW205979Hs.196065ESTs 2.8 401464AF039241Hs.9028histone deacetylase 5 2.7 439126AF085984 gb:Homo Sapiens full length2.7 insert cDNA clone YT99F0 403277 predicted exon 2.7 450078AI681743 gbax38g10.x1 NCI GGAP-Lu24 2.7 Homo Sapiens cDNA

458090AI282149Hs.56213ESTs, Highly similar to 2.7 FXD3_HUMAN FORKHEAD D

75 420620AA278807Hs.173343ESTs 2.7 459054AW79B466Hs.823962',5'-oligoadenylate synthetase2.6 421379Y15221Hs.103982small inducible cytokine 2.6 subfamily B (Cys-X-Cys), mem 454338AW381251Hs.1050pleckstrin homology, Sec7 2.6 and coiledicoil domains 1 (cyt 454529245439Hs.270425ESTs 2.6 446877A1559472Hs.270720ESTs 2.6 412588AW993055Hs.44024ESTs 2.6 449862A1672277Hs.199475ESTs 2.6 446694AV659942Hs.258132ESTs " 2.6 424029A8014594Hs.137579KIAA0694 gene product 2.6 .

454102AW752363gb:RCO-CT0201-270999-011-f03 CT0201 Homosapien 2.6 430922AW373747Hs.183337 ESTs 2.6 420289N55394Hs.96398 8-oxoguanine DNA glycosylase 2.6 410495N95428gb:zbBOd09.s1 Soares senescent fibroblasts-NbHSF
Ho 2.5 412319AW936903gb:RCi-DT0029-030200-012-d02 DT0029 Homo sapien 2.5 409699BE154650gb:PM3-HT0344-071299-003-c08 HT0344 Homo sapien 2.5 445832AI261545gb:qz30a07.x1 NCI CGAP_Kidl1 Homo sapiens cDNA 2.5 429755NM Hs.215839 discs, large (Drosophila) 001364homolog 2 (chapsyn-110) 2.5 445755AW294870Hs.223672 ESTs 2.5 O

TABLE
6B:

Pkey: ue Uniq Eos probeset idenfifier number CAT
number:
Gene cluster number Accession:Genbank accession numbers s Pkey CAT Accession Number 422046_ AI638562 T16929 H13401 F07773 855836 210744_1 d26294263994-1AA374185 AW956180 H38344 439126d6887 AF085984 H95905 H95906 4553881287904_1AW936234 AW936074 AW936181 AW936179 3S TABLE6C:
Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA

sequence of human chromosome 22" Dunham, et al. (1999) Nature 402:489-495 Strand: Indicates DNA strand from which exons were predicted 4o Nt-position: Indicates nucleofide positions of predicted exons 401308 9212516 Plus 169019-169649 d02105 8131588 Minus 22856-24055 403277 8072597 Minus 27494-27642 45 403283 8076905 Minus 71124-71996 d04868 9454593 Plus 39954-40430 406605 8272666 Minus 23275-23493,23723-23903 Table 7A lists about 770 genes up-regulated in ovarian cancer compared to normal adult tissues. These were selected from 35403 probesets on the AffymetrixlEos-Hu01 GeneChip array such that the ratio of "average' ovarian cancer to "average' normal adult tissues was greater than or equal to 2.5. The "average"
ovarian cancer level was set to the 2nd highest amongst various ovarian cancers. The 'average" normal adult fissue level was set to the 7th highest amongst various non-malignant tissues.
In order to remove gene-specific background levels of non-specific hybridization, the 15th peroentile value amongst the non-malignant tissues was subtracted from both the numerator and the denominator before the ratio was evaluated.

TABLE 7A: ABOUT 770 UP-REGULATED GENES,ISSUES
OVARIAN CANCER VERSUS NORMAL ADULT
T

Pkey: Primekey Ex.Accn: ExempIarAccession UG ID: UniGene ID

60 Title: UniGene Tifie ra8o: ration tumor vs. normal tissues Pkey Ex. Accn UG ID Title ratio 109680 F09255 Hs.4993 ESTs 23.2 65 119743 W70242 Hs.58086 ESTs 22.0 132528 AA283006 Hs.50758 chromosome-associated22.0 polypeptide C

129571 X51630 Hs.1145 Wilmstumorl 20.0 102151 017280 Hs.3132 sleroidogenic 19.6 acute regulatory protein 130941 D49394 Hs.2142 5-hydroxytrypiamine17.5 (serotonin) receptor 3A

132624 AA164819 Hs.53631 ESTs 15.9 102610 065011 Hs.30743 preferenfially15.4 expressed anfigenin melanoma 101249 L33881 Hs.1904 protein kinase 14.5 C; iota 122802 AA460530 Hs.256579 ESTs 14.5 135242 M74093 Hs.9700 cyclin E1 13.8 75 101804 M86699 Hs.169840 TTK protein 12.2 kinase 123005 AA479726 Hs.105577 ESTs 12.0 114965 AA250737 Hs.72472 ESTs 11.5 115536 AA347193 Hs.62i80 ESTs 11.4 132191 AA449431 Hs.158688 KIAA0741 10.9 gene product g0 121853 AA425887 Hs.98502 ESTs 10.9 115881 AA435577 Hs.184942 G protein-ccupled10.8 receptor 64 119780 W72967 Hs.191381 ESTs; Weakly 10.5 similar to hypothetical protein 104301 D45332 Hs.6783 ESTs 10.3 132632 N59764 Hs.5398 guanine-monophosphale10.1 synthetase 105298AA233459Hs.26369ESTs 9.7 108857AA133250Hs.62180ESTs 9.1 113168T53592Hs.161586EST . 9.0 115892AA435946Hs.50831ESTs 8.9 125666AA199856Hs.118811ESTs 8.9 102200021551Hs.157205branched chain aminotransferase8.8 1; cytosolic 108055AA043562Hs.62637ESTs 8.6 132572AA448297Hs.237825signal recognifion 8.6 parficle 72kD

115909AA436666Hs.59761ESTs 8.5 1 109166AA179845Hs.73625RAB6 interacfing; kinesin-like8.3 ~ (rabkinesin6) 121779AA422036Hs.98367ESTs 8.3 102915X07820Hs.2258matrix metalloproteinase8.0 10 (stromelysin 2) 105317AA233926Hs.23635ESTs 7.8 125250W87465Hs.222926ESTs; Weakly similar 7.8 to D2092.2 [C.elegans]

1 126960AA317900Hs.161756ESTs 7.8 122969AA478539Hs.104336ESTs 7.7 130376840873Hs.155174KIAA0432 gene product 7.7 123339AA504253Hs.101515ESTs 7.7 134972M19720Hs.169252Human L-myc protein 7.6 gene; complete cds 111234N69287Hs.21943ESTs; Weakly similar 7.5 to ORF YGL221c [S.cerevi 123689AA609556Hs.256562ESTs 7.5 123494AA599786Hs.112110ESTs 7.4 131985AA434329Hs.36563ESTs 7.4 106738AA470145Hs.25130ESTs 7.4 25 108768AA127741Hs.61345ESTs 7.3 106474AA450212Hs.42484Homo sapiens mRNA; 7.2 cDNA DKFZp564C053 (from cI

123308AA496211Hs.103538ESTs 7.2 106124AA423987Hs.7567ESTs 7.2 111345N89820Hs.14559ESTs 7.1 105200AA195399Hs.24641ESTs 7.1 116416AA609219Hs.39982ESTs 7.1 118846N80567Hs.50895ESTs 7.1 133434AA278852Hs.250786ESTs 7.1 120472AA251875Hs.104472ESTs; Weakly similar 6.9 to Gag-Pol polyprotein [

3 115291AA279943Hs.122579ESTs 6.9 J

111185N67551Hs.12844EGF-like-domain; multiple6.9 108778AA128548Hs.90847general transcripfion 6.9 factor IIIC; polypeptid 132939076189Hs.61152exostoses (multiple)-like6.9 134520N21407Hs.257325ESTs 6.9 40 114724AA131701Hs.256287ESTs; Highly similar 6.8 to SPERM SURFACE PROTEIN

116296AA489033Hs.62601Homo sapiens mRNA; 6.8 cDNA DKFZp586K1318 (from c 102136015552Hs.85769acidic 82 kDa protein fi.7 mRNA

132725L41887Hs.184167splicing factor; argininelserine-rich6.5 7 (35kD

109648F04600Hs.7154ESTs 6.4 45 116401AA599963Hs.59698ESTs 6.4 127563A1367707Hs.150587ESTs 6.4 104252AF002246Hs.210863cell adhesion molecule6.4 with homology to L1CAM

120438AA243441Hs.99488ESTs; Weakly similar 6.2 to ORF YKR074w [S.cerevi 131978D80008Hs.36232KIAA0186 gene product 6.2 134621L02547Hs.172865cleavage sfimulation 6.2 factor, 3' pre-RNA;
subu 120571AA280738Hs.128679ESTs 6.2 102627066561Hs.158174zinc finger protein 6.1 184 (Kruppel-like) 100661HG2874-HT3018 Ribosomal Protein L39 6.1 Homolog 118204N59859Hs.48443ESTs 6.0 55 131386AA096412Hs.173135dual-specificity tyrosine-(Y)-phosphorylafion6.0 129097S50223 HKR-T7=Kruppel-like 5.9 zinc finger protein [puma 131228AA279157Hs.2d485chondroitin sulfate 5.9 proteoglycan 6 (bamacan) 106369AA443828Hs.25324ESTs 5.9 108255AA063157Hs.172608ESTs 5.8 125370AA256743Hs.151791KIAA0092 gene product 5.8 130010N52966Hs.142838ESTs 5.8 131945M87339Hs.35120replicafion factor 5.7 C (acfivator 1) 4 (37kD) 116238AA479362Hs.47144DKFZP586N0819 protein 5.7 102221024576 LIM domain only 4 5.6 65 130757800641Hs.18925ESTs; Weakly similar 5.6 to cDNA EST yk339a7.5 co 131278081523Hs.25195endometrial bleeding 5.6 associated factor (left-101383M14113Hs.79345coagulationfactorVlllc;procoagulantcompon5.5 131836AA610086Hs.32990DKFZP566F084 protein 5.5 129628026727Hs.1174cyclin-dependent kinase5.5 inhibitor 2A (melanom 70 106523AA453441Hs.31511ESTs 5.5 111772828287Hs.237146ESTs 5.5 101255L34600Hs.149894mitochondrial iranslational5.5 inifiation factor 106895AA489665Hs.25245ESTs 5.5 104943AA065217Hs.169674ESTs 5.5 7S 129229AA211941Hs.109643polyadenylate binding 5.4 protein-interacting pro 102305033286Hs.90073chromosome segregation5.4 1 (yeast homology-like 106553AA454967Hs.5887ESTs; Highly similar 5.4 to RNA binding motif pro 112305854822Hs.26244ESTs 5.3 123972C14782Hs.70337immunoglobulin superfamily;5.3 member 4 102676072514Hs.12045putafive protein 5.3 106459AA449741Hs.4029glioma-amplified sequence-415.2 107865AA025104Hs.61252ESTs 5.2 121121AA399371Hs.189095ESTs; Weakly similar 5.2 to zinc finger protein S

127162N76398Hs.21187ESTs 5.2 131646AA171895Hs.30057Homo Sapiens clone 5.2 24749 and 24750 mRNA
segue 121770AA421714Hs.11469KIAA0896 protein 5.2 122512AA4493t1Hs.98658budding uninhibited 5.1 by benzimidazcles t (yeas 105870AA399623Hs.23505ESTs 5.1 100341D63506Hs.8813syntaxin binding protein5.1 116848H65187Hs.39001ESTs 5.1 120821AA347419Hs.96870Homo Sapiens mRNA full5.1 length insert cDNA
clo 130690AA084286Hs.139033paternally expressed 5.1 gene 3 122661AA454936Hs.245541ESTs 5.1 1 123169AA488892Hs.104472ESTs; Weakly similar 5.1 ~ to Gag-Pol pclyprotetn [

108810AA130596Hs.71331ESTs; Weakly similar 5.0 to POTENT HEAT-STABLE
PR

110799N26101Hs.7838Human ring zinc-finger5.0 protein (ZNF127-Xp) ge 120619AA284372Hs.111471ESTs 5.0 122792AA460225Hs.99519ESTs 5.0 15 129912AA047344Hs.107213ESTs; Highly similar 5.0 tc NY-REN-6 antigen [H.s 102823090914Hs.5057carboxypepfidase D 4.9 129890M13699Hs.i ceruloplasmin (ferroxidase)4.9 101084L05425 Homo sapiens autoanfigen4.9 mRNA; complete cds 134859D87716Hs.90315KIAA0007 protein 4.9 115955AA446121Hs.44198Homo sapiens BAC clone4.9 RG054D04 from 7q31 105516AA257971Hs.21214ESTs 4.9 114932AA242751Hs.16218KIAA0903 protein 4.9 106672AA461300Hs.30643ESTs 4.8 106126AA424006Hs.22972ESTs; Moderately similar4.8 to H5AR [M.musculusj 110695H93463Hs.124777ESTs 4.8 102025003911Hs.78934mutS (E. coli) homolog4.8 2 (colon cancer; nonpo 133282052960Hs.250855SRB7 (suppressor of 4.8 RNA polymerase B;
yeast) 119708W67810Hs.57904mago-nashi (Drosophila)4.7 homolog; proliferafio 120695AA291468 ESTs 4.7 30 128651AA446990Hs.103135ESTs 4.7 103152X66533Hs.77890guanylate cyclase 1; 4.7 soluble; beta 3 108699AA12i514Hs.70832ESTs 4.7 115094AA255921Hs.88095ESTs 4.7 121429AA406293Hs.193498ESTs 4.7 35 123203AA489671Hs.89709glutamate-cysteine 4.7 ligase (gamma-glutamylcyst 126802AA947601Hs.97056ESTs 4.7 130527C17384Hs.184227F-box protein 21 4.7 134470X54942Hs.83758CDC28 protein kinase 4.7 100449D87470Hs.75400KIAA0280 protein 4.7 4~ 110970N51374Hs.96870Homo Sapiens mRNA full4.7 length insert cDNA
clo 115901AA436403Hs.86909ESTs; Moderately similar4.7 to Frizzled-6 [H.sap 109799F10770Hs.180378Homo Sapiens clone 4.6 669 unknown mRNA;
complete 116195AA465148Hs.72402ESTs 4.6 132122065092Hs.40403CbpIp300-interacting 4.6 transacfivator; with Glu 45 108990AA152296Hs.72045ESTs 4.6 109055AA160529Hs.48524ESTs 4.6 115937AA443269Hs.30991KIAA0957 protein 4.6 133520X74331Hs.745t9primase; polypepfide 4.6 2A (58kD) 131200AA609427Hs.210706ESTs; Moderately similar4.6 to !!1l ALU SUBFAMIL

121369AA405657Hs.128791Human DNA sequence 4.5 from clone 967N21 on chrom 132880AAd44369Hs.177537ESTs 4.5 127386A1457411Hs.106728ESTs 4.5 120067W93592Hs.47343ESTs 4.5 122986AA479063Hs.102947ESTs 4.5 55 135286AA401269Hs.97849ESTs 4.5 130155L33404Hs.151254kallikrein 7 (chymotrypfic;4.5 stratum comeum) 106103AA421104Hs.12094ESTs 4.5 102654068494Hs.24385Human hbc647 mRNA sequence4.4 107876AA025315Hs.61184Novel human gene mapping4.4 to chomosome X

109454AA232255Hs.46912ESTs 4.4 125960D63307Hs.145968ESTs 4.4 126892AIt60190Hs.76127hect (homologous to 4.4 the E6-AP (UBE3A) carboxy 100269D38550Hs.1189E2F Uanscripfion factor4.4 134161097188Hs.79440IGF-II mRNA-binding 4.3 protein 3 65 100502HG1491i-HT1496 Adrenal-Specific Protein4.3 Pg2 105542AA261858Hs.8241ESTs; Weakly similar 4.3 to heat shack protein hs 109787F10610Hs.34853inhibitor of DNA binding4.3 4; dominant negative 110759N21671Hs.19025ESTs 4.3 129970AA478975Hs.200434ESTs 4.3 134666AA482319Hs.8752putafive type II membrane4.3 protein 117693N40939Hs.44162ESTs; Weakly similar 4.3 to cDNA EST yk342h12.5 c 111008N53388Hs.7222ESTs 4.3 120977AA398155Hs.97600ESTs 4.2 105808AA393808Hs.21490KIAA0438 gene product 4.2 75 121381AA405747Hs.97865ESTs; Weakly similar 4.2 to WASP-family protein [

100893HG4557-HT4962 Small Nuclear tZbonucleoprotein4.2 U1, tsnrp 107176AA621762Hs.7576ESTs 4.2 118976N93629Hs.93391ESTs 4.2 130703N63295Hs.18103ESTs 4.2 106540AA454607Hs.38114ESTs; Weakly similar 4.2 to coded for by C.
elega 119367T78324Hs.90905ESTs 4.2 133633D21262Hs.75337nucleolar phosphoprotein4.2 p130 105520AA258068Hs.33085WD repeat domain 3 4.2 114264240074Hs.27595ESTs 4.1 131046X02530Hs.2248IP10;'small inducible 4.1 cytokine subfamily B ( 105220AA210695Hs.i7212'ESTs 4.1 103111X63187Hs.2719epididymis-specific; 4.1 whey-acidic protein type 125640837700Hs.208261ESTs 4.1 110561H59617Hs.5199ESTs; Weakly similar 4.1 to UBIQUITIN-CONJUGATING

118092N54915Hs.82719Homo sapiens mRNA; 4.1 cDNA DKFZp586F1822 (from c 134891F03517Hs.90787ESTs 4.1 112364859312Hs.197642ESTs; Weakly similar 4.1 to DNA-DIRECTED RNA
POLY

120699AA291716Hs.97258ESTs 4.1 1 106272AA432074Hs.32538ESTs 4.1 ~

112041843300Hs.22929ESTs 4.1 131689AA599653Hs.30696iranscdption factor-like4.1 5 (basic helix-loop 116134AA460246Hs.50441ESTs; Highly similario4.1 CGI-04 protein [H.sap 107638AA009528Hs.42743ESTs; Weakly similar 4.0 to predicted using Genef 15 131941D62657Hs.35086ubiquitin-specific 4.0 protease 1 106154AA425304Hs.6994ESTs 4.0 105546AA262032Hs.26089ESTs; Weakly similar 4.0 to 62D9.a [D.melanogaste 106319AA436606Hs.7392ESTs; Weakly similar 4.0 to Gu protein (H.sapiens 121816AA424814Hs.187509ESTs 4.0 122851AA463627Hs.99598ESTs 4.0 123337AA504153Hs.132797ESTs; Weakly similar 4.0 to ORF YGL050w [S.cerev!

128643N40212Hs.102958ESTs 4.0 129011S72869Hs.107932DNA segment; single d.0 copy; probe pH4 (transfor 130895AA609828Hs.21015ESTs; Highly similar 4.0 to tetracycline transpor 25 132323AA436102Hs.256559ESTs 4.0 134255J05032Hs.80758asparfyl-tRNA synthetase4.0 102827091327Hs.6456chaperonin containing 4.0 TCPt; subunit 2 (beta) 102123014518Hs.1594centromere prole!n 4.0 A (l7kD) 102813090651Hs.151461embryonic ectoderm 3.9 development protein 113970W86748Hs.8109ESTs 3.9 107145AA621108Hs.173001ESTs 3.9 114212239338Hs.21201DKFZP566B0846 protein 3.9 106614AA458934Hs.179912ESTs 3.9 132742AA490862Hs.55901ESTs; Weakly similar 3.9 to C43H8.1 (C.elegans]

35 120948AA397822Hs.104650ESTs; Highly similar 3.9 to similar to mago nosh!

129337863542Hs.110488KIAA0990 prote!n 3.9 103835AA172215Hs.93748ESTs;ModeratelysimilartoTRANSCRIPTiONFAC3.9 133330042360Hs.71119Putative prostate cancertumorsuppressor3.9 133928N34096Hs.7766ubiquiGn-conjugating 3.9 enzyme E2E 1 (homologou 4~ 133640D83004Hs.75355ubiquitin-conjugating 3.9 enzyme E2N (homologous 133350AA135468Hs.71573ESTs 3.9 115623AA401475Hs.39733postsynaptic protein 3.9 CRIPT

101973S82597Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypeptid3.9 102669071207Hs.29279eyes absent (Drosoph!la)3.9 homolog 2 45 134248AA292677Hs.80624ESTs 3.9 102380040434Hs.155981mesothelin 3.9 116157AA461063Hs.44298ESTs; Highly similar 3.8 to HSPC011 [H.sapiens]

106691AA463453Hs.23259ESTs; Weakly similar 3.8 to ACTIN; CYTOPLASMIC

115844AA430124Hs.234607ESTs 3.8 107159AA621340Hs.10600ESTs; Weakly similar 3.8 to ORF YKR081c [S.cerevi 106498AA452141Hs.7171ESTs 3.8 134405J04177Hs.82772collagen; type XI; 3.8 alpha 1 106260AA431448Hs.5250ESTs; Weakly similar 3.8 to BACR37P7.g [D.melanog 109864H02554Hs.30323ESTs 3.8 55 124648N91948Hs.125034ESTs 3.8 134719L07515Hs.89232chromobox homolog 5 3.8 (Drosophila HP1 alpha) 113702T97307Hs.161720ESTs; Moderately similar3.8 to !!!! ALU SUBFAMIL

128639N91246Hs.102897ESTs 3.8 111299N73808Hs.24936ESTs 3.7 60 129351AA167268Hs.62349Human ras inhibitor 3.7 mRNA; 3' end 119741W70205Hs.43670kinesin family member 3.7 105012AA116036Hs.9329chromosome 20 open 3.7 reading frame 1 128734AA343629Hs.104570kallikrein 8 (neuropsinlovasin)3.7 130567L07493Hs.1608replication protein 3.7 A3 (l4kD) 65 114253239909Hs.14831ESTs 3.7 103169X68560Hs.44450Sp3transcriplionfaclor3.7 111269N70711Hs.18885ESTs; Highly similar 3.7 to CGI-116 protein [H.sa 112876T03488Hs.4842ESTs 3.7 118261N62780Hs.94122ESTs 3.7 70 130385AA126474Hs.155223stann!ocalcin 2 3.7 129300C20976Hs.110165ESTs; Highly similar 3.7 to ribosomal protein 134388M15841Hs.82575small nuclear ribonucleoprotein3.7 polypeptide B

106968AA504631Hs.26813ESTs; Weakly similar 3.7 to hypothetical 43.2 kDa 100906HG4716-HT5158 Guanosine 5'-Monophosphate3.7 Synthase 75 100418D86978Hs.84790KIAA0225 protein 3.7 101484M24594Hs.20315interferon-induced 3.7 protein 56 102547057911Hs.46638chromosome 11 open 3.7 reading frame 8 103587229083Hs.821285T4 oncofetal irophoblast3.7 glycoprotein 130600AA478601Hs.258737ESTs 3.7 128733AA328993Hs.104558ESTs 3.7 134375AA412720Hs.82389ESTs; Highly similar 3.7 to CGI-118 prote!n (H.sa 134098X06323Hs.79086ribosomal protein; 3.6 mitochondrial; L3 101188L20320Hs.184298cyclin-dependent kinase3.6 7 (homolog of Xenopus 132149T10822Hs.4095ESTs 3.6 116200AA465358Hs.118793ESTs; Highly similar 3.6 to p621 [H.sapiensj 121920AA428300Hs.161841ESTs 3.6 128609AA234365Hs.102456survival of motor neuron3.6 protein interacfing 101078L04510Hs.792ADP-ribosylafion factor3.6 domain protein 1;
64k 108693AA121289Hs.49597ESTs; Highly similar 3.6 to refinoic acid-induced 109139AA176121Hs.59757zinc finger protein 3.6 111870837778Hs.18685ESTs; Weakly similar 3.6 to hypothetical protein 113848W60080Hs.27099DKFZP564J0863 protein 3.6 127947AI432475Hs.146327ESTs 3.6 128056A1379480Hs.125449ESTs; Weakly similar 3.6 to MaxiK channel beta 129914022377Hs.13321rearranged L-myc fusion3.6 sequence 132148AA283988Hs.4094ESTs 3.6 134644S83308Hs.87224SRY (sex-determining 3.6 region Y)-box 5 115047AA252627Hs.22554homeo box B5 3.6 102398042359 Human N33 protein form3.6 1 (N33) gene, exon 1 a 127479AA513722Hs.179729collagen; type X; alpha3.6 1 (Schmid melaphyseal 105545AA262030Hs.5152ESTs; Weakly similar 3.6 to katanin p80 subunit ( 101483M24486Hs.76768procollagen-proline; 3.6 2-oxoglutarate 4-dioxyge 105709AA291268Hs.26761DKFZP586L0724 protein 3.6 122636AA454103Hs.110031ESTs 3.6 124792844357Hs.132784ESTs; Weakly similar 3.6 to cDNA EST EMBL:T01421 103621247727Hs.150675polymerase (RNA) II 3.5 (DNA directed) polypepfid 105427AA251330Hs.28248ESTs 3.5 121553AA412488Hs.48820ESTs ' 3.5 115167AA258421Hs.43728hypotheticalprotein 3.5 134570066615Hs.172280SWIISNF related; matrix3.5 associated; actin dep 110787N24716Hs.12244ESTs; Weakly similar 3.5 to C44B9.1 [C.elegans]

131621077665Hs.139120ribonuclease P (30kD) 3.5 132813N72116Hs.57435solute carver family 3.5 11 (proton-coupled diva 116370AA521256Hs.236204ESTs; Moderately similario3.5 NUCLEAR PORE COMP

131965W90146Hs.35962ESTs 3.5 115221AA262942Hs.79741ESTs 3.5 116093AA456020Hs.50848ESTs; Weakly similar 3.5 to KIAA0862 protein [H.s 123507AA600176Hs.112345ESTs 3.5 129801F11087Hs.239666ESTs 3.5 115084AA255566Hs.42484Homo sapiens mRNA; 3.5 cDNA DKFZp564C053 (from c7 123442AA598803Hs.111496ESTs 3.5 115061AA253217Hs.41271ESTs 3.5 100146D13645Hs.2471KIAA0020 gene product 3.5 115140AA258030Hs.55356ESTs; Weakly similar 3.5 to supported by GENSCAN

115360AA281950Hs.5057carboxypeptidase D 3.5 130261D83767Hs.153678reproducfion 8 3.4 100824HG4058-HT4328 Oncogene Aml1-Evi-1, 3.4 Fusion Activated 102287031814Hs.3352histone deacetylase 3.4 102788086602Hs.74407nucleolar protein p40 3.4 118836N79820Hs.50854ESTs 3.4 102423044754Hs.179312small nuclear RNA activating3.4 complex; polypep 106300AA435840Hs.19114high-mobility group 3.4 (nonhistone chromosomal) 106156AA425354Hs.4210ESTs 3.4 106483AA451676Hs.30299IGF-II mRNA-binding 3.4 protein 2 107868AA025234Hs.61260ESTs 3.4 108187AA056538Hs.27842ESTs; Weakly similar 3.4 to similar to 1-acyl-gly 116123AA459282Hs,43756ESTs 3.4 119501W37721Hs.151363ESTs 3.4 5 129121AA127459Hs.108788ESTs; Weakly similar 3.4 5 to zeste [D.melanogaster 131638D87120Ns.29882predicted osteoblast 3.4 protein 132962N34893Hs.6153ESTs; Highly similar 3.4 to CGI-48 protein [H.sap 133767D63875Hs.173288KIAA0155 gene product 3.4 111823835253Hs.24944ESTs 3.4 134372D63877Hs.82324KIAA0157 protein 3.4 130938AA013250Hs.21398ESTs; Moderately similar3.4 to PUTATIVE GLUCOSAM

115169AA258427Hs.58427ESTs 3.4 123978C20653Hs.170278ESTs 3.4 108807AA129968Hs.49376ESTs; Weakly similar 3.4 to PROTEIN PHOSPHATASE
P

132581842266Hs.52256ESTs; Weakly similar 3.4 to beta-TrCP protein 134654W23625Hs.8739ESTs; Weakly similar 3.4 to ORF YGR200c [S.cerevi 105730AA292701Hs.5364DKFZP5641052 protein 3.4 111295N73275Hs.21275ESTs; Weakly similar 3.3 to ubiquifin-con]ugafing 102009002680Hs.82643protein tyrosine kinase3.3 114161238904Hs.22385ESTs; Weakly similar 3.3 1o KIAA0970 protein [H.s 130604X03635Hs.1657estrogen receptorl 3.3 100103AF007875Hs.5085dolichyl-phosphate 3.3 mannosyltransferase polyps 121748AA421171Hs.234545ESTs 3.3 106698AA463745Hs.29403ESTs; Weakly similar 3.3 to PROBABLE ATP-DEPENDEN

134353S77154Hs.82120nuclear receptor subfamily3.3 4; group A; member 134154AA211320Hs.79404neuron-specific protein3.3 133142F03321Hs.65874ESTs 3.3 124461N50641Hs.80285Homo sapiens mRNA; 3.3 cDNA DKFZp586C1723 (from c 104903AA055534Hs.124134ESTs 3.3 106772AA478106Hs.12692ESTs; Weakly similar 3.3 to protein phosphatase-1 109704F09687Hs.12876ESTs 3.3 111131N64267Hs.10177ESTs 3.3 115019AA251906Hs.48473ESTs 3.3 116019AA450312Hs.237480Homo sapiens mRNA; 3.3 cDNA DKFZp434E102 (from c7 118528N67889Hs.49397ESTs 3.3 124027F03625Hs.107537ESTs 3.3 131699868657Hs.90421ESTs; Moderately similar3.3 to !!!! ALU SUBFAMIL

111044N55443Hs.23625ESTs 3.3 103768AA089997Hs.180320ESTs; Weakly similar 3.3 to GOLGI 4-TRANSMEMBRANE

131882N49091Hs.3385ESTs; Highly similar 3.3 to CGI-134 protein [H.sa 123673AA609471Hs.112712ESTs 3.3 132936AB002305Hs.6111KIAA0307 gene product 3.3 103023X53793Hs.117950multifunctional polypeptide3.3 similar to SAICAR

1 120572AA280794Hs.258787ESTs 3.3 ~

132384AA479933Hs.46967Human DNA sequence 3.3 from clone 167A19 on chrom 105658AA282914Hs.10176ESTs 3.2 105086AA147719Hs.159441ESTs 3.2 118695N71781Hs.50081Homo sapiens mRNA full3.2 length insert cDNA
clo 1 112092844538Hs.140889ESTs 3.2 125154W38419Hs.24936ESTs 3.2 108040AA041551Hs.48644ESTs 3.2 133453M68941Hs.73826proteintyrosine phosphatase;non-receptoriy3.2 124006D60302Hs.108977ESTs 3,2 116083AA455653Hs.44581ESTs; Weakly similar 3.2 to HEAT SHOCK 70 KD
PROT

106753AA476944Hs.7331ESTs 3.2 102621066075Hs.50924GATA-binding protein 3.2 103330X85373Hs.77496small nuclear ribonucleoprotein3.2 polypeptide G

128926AA481403Hs.107213ESTs; Highly similar 3.2 to NY-REN-6 antigen [H.s 25 101167L15309Hs.193677zinc fingerprotein 3.2 141 (clone pHZ-44) 104055AA393755Hs.117211ESTs; Highly s!milarto3,2 CGI-62 protein [H.sap 112917T10196Hs.4263ESTs; Weakly similar 3.2 to (prediction 120358AA213459Hs.100932franscdptionfactor17 3.2 121857AA426017Hs.62694ESTs; Highly similar 3.2 to DNA-REPAIR PROTEIN
CO

122124AA434257Hs.186679ESTs; Moderately similar3.2 to !!!! ALU SUBFAMIL

132231H99131Hs.42635ESTs 3.2 134272X76040Hs.223014protease; serine;15 3.2 115860AA431719Hs.61809ESTs 3.2 115278AA279757Hs.67466ESTs; Weakly similar 3.2 to BACN32Gi 1.d [D.melano 35 134125838102Hs.50421KIAA0203 gene product 3.2 129160AA131252Hs.109007ESTs 3.2 121710AA419011Hs.96744DKFZP586D0823 protein 3.2 102242027185Hs.32943retinoic acid receptorresponder(tazarotene3.2 ' 104956AA074880Hs.120975ESTs; Weakly similar 3.2 to hypothetical protein 113047T25867Hs.7549ESTs 3.2 115017AA251880Hs.179982tumor protein p53-binding3.2 protein 133780Mi4219Hs.76152decorin 3.1 129453AA421213Hs.111632Lsm3 protein 3.1 130353X86018Hs.172210MUF1 protein 3.1 45 106036AA412505Hs.10653ESTs 3.1 102234026312Hs.8123chromobox homolog 3 3.1 (Drosophila HP1 gamma) 106133AA424346Hs.107573sialyltransferase 3.1 116803H47357 ESTs; Moderately similar3.1 to weak similarity t 106721AA465194Hs.6670ESTs 3.1 107115AA610108Hs.27693ESTs; Highly similar 3.1 to CGI-124 protein (H.sa 133228N90029Hs.6831Homo sapiens clone 3.1 1400 unknown protein mRNA;

104733AA019498Hs.23071ESTs 3.1 103879AA228148Hs.50252ESTs; Weakly s!milar 3.1 to putative (C.elegans]

103038X54941Hs.77550CDC28 protein kinase 3.1 5 135154AA126433Hs.173242sorting nexin 4 3.1 S

114860AA235112Hs.106227ESTs; Moderately similar3.1 to similar to mudne 102437046569Hs.22i986aquaporin 5 3.1 100352Dfi4159 Homo sapiens mRNA for 3.1 3-7 gene product, parti 103631248570 H.sapiens Spl7 gene 3.1 104238AB002364Hs.27916a disintegrin-like 3.1 and melalloprotease (repro 108613AA100967Hs.69165ESTs 3.1 115915AA436884Hs.48926ESTs 3.1 120640AA286945Hs.163933ESTs 3.1 124068H03099Hs.101619ESTs 3.1 65 130375091931Hs.155172adaplor-related protein3.1 complex 3; beta 1 sub 131632AA443671Hs.29826ESTs 3.1 131523H88801Hs.201676M phase phosphoprotein3.1 t0 (U3 small nucleolar 115827AA427890Hs.44426ESTs; Weakly similar 3.1 to PHOSPHOLIPID HYDROPER

108828AA131584Hs.7i435DKFZP56400463 protein 3.1 112198849483Hs.22159ESTs; Weakly similar 3.1 to ZINC FINGER PROTEIN
H

123960AA621785Hs.170008methylmalonate-semialdehyde3.1 dehydrogenase 131538229331Hs.28505ubiquitin~on]ugating 3.1 enzyme E2H (homologous 105616AA280670Hs.24968ESTs 3.1 101228L27706Hs.82916chaperonin containing 3.1 TCP1; subunit 6A (zeta 75 100280D42085Hs.i55314KIAA0095 gene product 3.1 132744X54326Hs.55921glutamyl-prolyl-tRNA 3.1 synthetase 103105X61970Hs.76913proteasome (prosome; 3.1 macropain) subunit;
alph 106984AA521201Hs.7129ESTs 3.1 105127AA15B132Hs.11817ESTs; Weakly similar 3.1 to contains similarity t 102302033052Hs.69171protein kinase C-like 3.1 117708N45114Hs.46476ESTs 3.1 111314N74574Hs.33922H.sapiens novel gene 3.0 from PAC 117P20; chromos 132902AA490969Hs.i6B147ESTs 3.0 130356X84373Hs.155017nuclearreceptorinteracting3.0 protein 1 128420A1088155Hs.14146ESTs; Weakly similar 3.0 to unknown [H.sapiens]

108746AA126974Hs.43388ESTs 3.0 127236A1341818Hs.98658budding uninhibited 3.0 by benzimidazoles 1 (yeas 114208239301Hs.7859ESTs 3.0 107071AA609053Hs.35198ESTs 3.0 104957AA074919Hs.10026ESTs; Weakly similar 3.0 to ORF YJL063c [S.cerevi 124073H05394Hs.127376KIAA0266 gene product 3.0 130869AA128100Hs.2057uddine monophosphate 3.0 synthetase (orotate pho 101232L28997Hs.242894ADP-ribosylafion factor-like3.0 1 104276CD2193Hs.85222ESTs; Weakly similar 3.0 ~ to 827090-2 [H.sapiensj 126160N90960Hs.247277ESTs; Weakly similar 3.0 to transformafion-relate 128584M11433Hs.101850refinol-binding protein3.0 1; cellular 100405D86425Hs.82733nidogen 2 3.0 101335L49054 Homo sapiens t(3;5)(q25.i;p34)3.0 fusion gene NP

I5 108761AA127514Hs.61603ESTs 3.0 111346N89829Hs.13259ESTs 3.0 114988AA251089Hs.94576ESTs; Weakly similar 3.0 to phosducin; retinal [H

f AA449338H~.48589ESTs; Weakly similar 3.0 16008 to finger protein HZF6;

116545D20313Hs.74899ESTs 3.0 117873N49967Hs.46624ESTs 3.0 121463AA411745Hs.239681ESTs; Weakly similar 3.0 to KIAA0554 protein [H.s 128625AA242816Hs.102652ESTs; Weakly similar 3.0 to KIAA0437 [H.sapiensj 131185M25753Hs.23960cyclin B1 3.0 134380D38073Hs.t79565minichromosome maintenance3.0 deficient (S. cere 25 105740AA293206Hs.10852ESTs .s 3.0 130919AA2917i0Hs.2f276collagen; type IV; 3.0 alpha 3 (Goodpasture antig 134423W96151Hs.83006ESTs; Highly similar 3.0 to CGI-139 protein [H.sa 104896AA054228Hs.23165ESTs 3.0 134407X72964Hs.82794caltracfin (20kD calcium-binding3.U
protein) 106378AA445994Hs.21331ESTs 3.0 112283853545Hs.20952Homo sapiens clone 3.0 24411 mRNA sequence f090f8AA156960Hs.i14992ESTs 3.0 114239239742Hs.222478ESTs 3.0 114969AA250775Hs.87747ESTs 3.0 3 116408AA608752Hs.71969Homo sapiens mRNA; 3.0 S cDNA DKFZp564P0823 (from c 115286AA279803Hs.82204ESTs 2.9 105809AA393827Hs.20104ESTs 2.9 113811W44928Hs.4878ESTs 2.9 107248D59894Hs.34782ESTs 2.9 134489U0928dHs.112378LIM and senescent cell2.9 antigen-like domains 134064D87685Hs.78893KIAA0244 protein 2.9 127370A1024352Hs.70337immunog!obulin superfamily;2.9 member 4 113277T65797Hs.11774protein (pepfidyl-prolyl2.9 cisltrans isomerase) 132783N74897Hs.5683DEADIH (Asp-Glu-Ala-AspIHis)2.9 box polypeptide 45 109010AA156460Hs.44229dual specificity phosphatase2.9 130095F01831Hs.14838ESTs 2.9 106618AA459249Hs.8715ESTs; Weakly similar 2.9 to Similarity with snail 103427X97303 H.sapiens mRNA for 2.9 Ptg-12 protein 133980D00760Hs.181309proteasome (prosome; 2.9 macropain) subunit;
alph 111353N90430Hs.6616ESTs 2.9 105344AA235303Hs.8645ESTs 2.9 134498M63180Hs.84131threonyl-tRNA synthetase2.9 117910N50828Hs.12940zinc-fingers and homeoboxes2.9 118903N90774Hs.132207ESTs; Moderately similar2.9 to !!!! ALU SUBFAMIL

55 121713AA419198Hs.105577ESTs 2.9 129080H19307Hs.108507ESTs 2.9 129404AA172056Hs.111128ESTs 2.9 129457X55330Hs.207776asparfylglucosaminidase2.9 130352D87450Hs.154978KIAA0261 protein 2.9 133415X69699Hs.73149paired box gene B 2.9 120649AA287115Hs.99697ESTs 2.9 131257AA256042Hs.24908ESTs 2.9 134480AA024664Hs.83916NADN dehydrogenase 2.9 (ubiquinone) 1 alpha subco 116734F13789Hs.93796DKFZP586D2223 protein 2.9 65 105028AA126719Hs.25282ESTs 2.9 114986AA251010Hs.87807ESTs 2.9 105651AA282481Hs.18439ESTs 2.9 101714M68874' Human phosphafidylcholine2.9 2-acylhydrelase (cP

123398AA521265Hs.105514ESTs 2.9 70 106007AA411462Hs.t ESTs; Weakly similar 2.9 1042 to veli i [H.sapiens]

109450AA232183Hs.173042ESTs; Weakly similar 2.9 to !!!! ALU SUBFAMILY
J

104685AA010530Hs.9599Human BAC clone GS025M022.9 from 7q21-q22 108677AA115629Hs.118531ESTs 2.9 116028AA452112Hs.42644thioredoxin-like 2.9 75 105404AA243303Hs.21187ESTs 2.9 132365AA598694Hs.46541Homo sapiens PAC clone2.9 DJ0894A10 from 7q32-q3 f W52480Hs.56148ESTs; Moderately similar2.9 19638 to NY-REN-58 anfigen 124637N8071 Hs.75798Human DNA sequence 2.9 fi , from clone 1183121 on chro 130588AA287735Hs.16411Human DNA sequence 2.9 from clone 1189824 on chro 105640AA281623Hs.7525ESTs; Weakly similar 2.9 io KIAA0742 protein [H.s 131818239297Hs.3281neuronal pentraxin 2.9 II

119298T23820Hs.155478cyclin T2 2.9 128742D00763Hs.251531proteasome (prosome; 2.9 macropain) subunit;
alph 115089AA255876Hs.86919ESTs; Weakly similar 2.9 to !!!! ALU SUBFAMILY
J

100468D89289Hs.118722fucosyltransferase 8 2.8 (alpha (1;6) fucosyltran 132920L06133Hs.606ATPase; Cu++transporiing;2.8 alpha polypeptide 113490T88700Hs.173374ESTs 2.8 133451Y00764Hs.73818ubiquinol-cytochrome 2.8 c reductase hinge protei 128770H98645Hs.143460protein kinase C; nu 2.8 129122N62515Hs.108790ESTs 2.8 104827AA035630Hs.8551PRP41STKIWD splicing 2.8 factor 111348N90041Hs.9585ESTs 2.8 130987845698Hs.21893ESTs; Weakly similar 2.8 to cAMP inducible 2 prot 1 102139015932Hs.2128dual specificity phosphatase2.B
~ 5 114902AA236359Hs.39504ESTs 2.8 106094AA419461Hs.18127ESTs 2.8 126438N93125Hs.137300ESTs 2.8 107129AA620553Hs.4756flap sUucture-specific 2.8 endonuclease 1 15 104491N71513Hs.39328ESTs 2.8 105043AA132239Hs.11810ESTs; Weakly similar 2.8 to CD4.2 [C.elegans]

106855AA486182Hs.17975ESTs 2.8w 109695F09530Hs.180591ESTs; Weakly similar 2.8 to RO6F6.5b [C.elegans]

120455AA251083Hs.104347ESTs 2.8 130861N23393Hs.20509ESTs 2.8 131649AA481254Hs.30120ESTs 2.8 128517AA280617Hs.100861ESTs; Weakly similar 2.8 to p60 katanin [H.sapien 100486HGi Ras-Like Protein Tc4 2.8 116729F13700Hs.1 ribonuclease P; 40kD 2.8 1 subunit 101851M94250Hs.82045midkine (neurite growth-promoflng2.8 factor 2) 115465AA286941Hs.43691ESTs 2.8 100137D13627Hs.15071chaperonin containing 2.8 TCP1; subunit 8 (theta) 125837H05323Hs.146401endothelial monocyte-activating2.8 polypeptide 131562090551Hs.28777H2A histone family; 2.8 member L

3 129445AA306121Hs.111515ESTs; Weakly similar 2.8 ~ to predicted using Genef 129239D31544Hs.109701ESTs; Moderately similar2.8 to weak similarity t 106507AA452584Hs.91585protein phosphatase 2.8 1; regulatory (inhibitor) 101664M60752Hs.121017H2A histone family; 2.8 member A

129426AA412087Hs.168272EST; Highly similar 2.8 to protein inhibitor of a 35 103437X98260Hs.82254M-phase phosphoprotein 2.8 129821F11019Hs.12696cortacGn SH3 domain-binding2.8 protein 130160239228Hs.151344UDP-Gal:betaGIcNAc beta2.8 1;3-galactosyltransfe 104257AF006265Hs.9222estrogen receptor-binding2.8 fragment-associated 116204AA465701Hs.108646ESTs 2.8 125914AA262925Hs.180034cleavage stimulation 2.8 factor; 3' pre-RNA;
subu 131510AA207114Hs.27842ESTs; Weakly similar 2.8 to similar to i-acyl-gly 106291AA435551Hs.30824ESTs 2.8 122761AA459296Hs.105039ESTs; Weakly similar 2.8 to !!!! ALU SUBFAMILY
J

107056AA600310Hs.18720programmed cell death 2.8 8 (apoptosis-inducing f 45 108535AA084505Hs.226440Homo sapiens clone 248812.8 mRNA sequence 116226AA478729Hs.76450ESTs 2.8 120266AA173939Hs.193902ESTs; Weakly similar 2.8 to inner centromere prot 128654H20689Hs.103180actin-like 6 2.8 116726F13681Hs.42309ESTs 2.7 132640033821 Tax1 (human T-cell leukemia2.7 virus type I) bin 133273AA147725Hs.69469dendriflc cell protein 2.7 108846AA132983Hs.44155DKFZP586G1517 protein 2.7 105621AA280865Hs.6375Homo Sapiens mRNA; cDNA2.7 DKFZp564K0222 (from c 129164AA282183Hs.109045ESTs 2.7 133618078524Hs.75251DEADIH (Asp-Glu-Ala-AspIHis)2.7 box binding prot 120521AA258785Hs.107476ATP synthase; H+transporting;2.7 milochondrial 116429AA609710Hs.82837Human chromosome 3p21.12.7 gene sequence 110984N52006Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypepfld2.7 100372D79997Hs.184339KIAA0175 gene product 2.7 ()~125134W19228Hs.100748ESTs 2.7 129254AA453624Hs.1098deoxynucleotidylUansferase;2.7 terminal ~

102339037022Hs.95577cyclin-dependent kinase2.7 106589AA456646Hs.28661ESTs 2.7 119118844122Hs.42743ESTs; Weakly similar 2.7 to predicted using Genef 65 105973AA406320Hs.21201DKFZP566B0846 protein 2.7 106317AA436568Hs.172140ESTs 2.7 115551AA365527Hs.177861ESTs; Highly similar 2.7 to CGI-110 protein [H.sa 103789AA096178Hs.70337immunoglobulin superfamily;2.7 member 4 105079AA743190Hs.12677ESTs; Highly similar 2.7 to CGI-147 protein (H.sa 109299AA205649Hs.86371zinc finger protein 2.7 122089AA432136Hs.98682ESTs 2.7 129108L20321Hs.1087serinelthreonine kinase2.7 129385D82675Hs.110950Homo Sapiens clone 250072.7 mRNA sequence 131412034044Hs.124027SELENOPHOSPHATE SYNTHETASE2.7 ; Human selenium d 75 104052AA393164Hs.97644mammaglobin 2 2.7 116254AA481146Hs.41086ESTs; Weakly similar 2.7 to OXYSTEROL-BINDING
PRO

106878AA488872Hs.12314Homo Sapiens mRNA; cDNA2.7 DKFZp586C1019 (from c 114652AA101416Hs.107149ESTs; Weakly similar 2.7 to PTB-ASSOCIATED SPLICI

106831AA482014Hs.29463centrin; EF-hand protein;2.7 3 (CDC31 yeast homo 101445M21259Hs.1066small nuclear ribonucleoprotein2.7 polypepflde E

124428N36881Hs.82202ribosomal protein L17 2.7 114471AA028074Hs.103387ESTs 2.7 102051007550Hs.1197heat shock lOkD protein2.7 1 (chaperonin 10) 106916AA490814Hs.24170ESTs; Weakly similar 2.7 to ribosomal S1 protein 116142AA460649Hs.39457ESTs 2.7 109912H05509Hs.24639ESTs 2.7 103193X70476Hs.75724coatomer protein complex;2.7 subunit beta 2 (bet 102046007151Hs.182215ADP-ribosylation factor-like2.7 104567864534Hs.101469ESTs 2.7 112996T23539Hs.7165zincfingerprofein 259 2.7 118138N57773Hs.93560ESTs; Weakly similar 2.7 to Ug [R.norvegicus]

123095AA485724Hs.192119ESTs 2.7 124315H94892Hs.6906v-rat simian leukemia 2.7 viral oncogene homolog 1 124447N48000Hs.140945Homo Sapiens mRNA; 2.7 ~ cDNA DKFZp586L141 (from c7 132834H77546Hs.57898ESTs; Highly similar 2.7 to NY-REN-49 antigen [H.

107529Y12065Hs.5092nucleolar protein (KKEID2.7 repeaf) ' 130648AA075427Hs.17296ESTs; Weakly similar 2.7 to (prediction 106685AA461551Hs.16251ESTs; Highly similar 2.6 to 73 kDA subunit of cle 15 133848AA093287Hs.76728ESTs 2.6 134880AA092376Hs.9060615 kDa selenoprotein 2.6 128871AA400271Hs.106778Homo Sapiens mRNA for 2.6 putative Ca2~-Uansport 106846AA485223Hs.34892ESTs 2.6 119892W84548Hs.94896ESTs 2.6 132309AA460917Hs.2780jun D proto-oncogene 2.6 132923021858Hs.60679TATA box binding protein2.6 (TBP)-associated fac 114365241688Hs.i8653ESTs 2.6 114162238909Hs.22265ESTs 2.6 133370AA156897Hs.72157DKFZP56411922 protein 2.6 25 106818AA480890Hs.3542ESTs 2.6 133501W16684Hs.74284ESTs; Moderately similar2.6 to Similar 1o S.cere 100530HG1869-HT1904 Male Enhanced Antigen 2.6 130553AAd30032Hs.252587pituitary tumor-Uansforming2.6 108917AA137078Hs.173648ESTs 2.6 122249AA436679Hs.258543ESTs; Highly similar 2.6 to CGI-07 protein [H.sap 119598W45531Hs.94642ESTs 2.6 119902W84865Hs.40094Human DNA sequence 2.6 from clone 167A19 on chrom 133272AA465016Hs.69423kallikrein 10 2.6 132575AA045365Hs.5188ESTs; Weakly similar 2.6 to 60S RIBOSOMAL PROTEIN

35 130459AA460264Hs.155983KIAA0677 gene product 2.6 133083N70633Hs.6456chaperonin containing 2.6 TCP1; subunit 2 (beta) 131130T19399Hs.23255nucleoporin 155kD 2.6 112043843317Hs.26312glioma amplified on 2.6 chromosome 1 protein (feu 116146AA460701Hs.193200ESTs 2.6 4~ 122378AA446100Hs.103617ESTs 2.6 103134X65724Hs.2839Norrie disease (pseudoglioma)2.6 133395AA491296Hs.72805ESTs 2.6 115652AA405098Hs.38178ESTs 2.6 104975AA086071Hs.50758chromosomo-associated 2.6 polypeptide C

4S 134691M59979Hs.88474prostaglandin-endoperoxide2.6 synthase 1 (prosta 112869T03313Hs.4747dyskeratosis congenita2.6 1; dyskerin 100092AF000231Hs.75618RAB11A; member RAS 2.6 oncogene family 102635066838Hs.79378cyclin A1 2.6 104490N71503Hs.43087ESTs; Weakly similar 2.6 to dysfedin [H.sapiensJ

106813AA479922Hs.181022ESTs 2.6 106872AA487907Hs.18282ESTs; Highly similar 2.6 to unknown [H.sapiens]

107022AA599041Hs.28866programmed cell death 2.6 107113AA610073Hs.23900ESTs; Weakly similar 2.6 to oligophrenin-1 like p 113281T66300Hs.112356Homo Sapiens mRNA for 2.6 IipoylUansferase;
comp 115586AA399218Hs.92423ESTs 2.6 S

115779AA424183Hs.70945ESTs 2.6 122895AA469946Hs.105325ESTs 2.6 124726815740Hs.104576carbohydrate (keratan 2.6 sulfate Gal-6) sulfolra 129775894659Hs.12420ESTs 2.6 131991AA251909Hs.36708budding uninhibited 2.6 by benzimidazoles 1 (yeas 132518D57975Hs.5064ESTs 2.6 134612AA451712Hs.171581ESTs; Highly similar 2.6 to ubiquitin Gterminal 130313AA620323Hs.154320ubiquitin-activating 2.6 enzyme E1C (homologous t 131971870167Hs.3611ESTs 2.6 65 133175AA134767Hs.66666ESTs 2.6 102083010323Hs.75117intedeukin enhancer 2.6 binding factor 2;
45kD

125670A1432621Hs.82685CD47 antigen (Rh-related2.6 antigen;integ~n-as 121822AA425107Hs.97016ESTs; Moderately similar2.6 to SH3 domain-bindin 106719AA465171Hs.236844ESTs 2.6 70 130029AA236412Hs.236510ESTs; Moderately similar2.6 to PFT27 [M.musculus 124328H97781Hs.14415ESTs; Highly similar 2.6 to CGI-108 protein [H.sa 105387AA236951Hs.108636chromosome 1 open reading2.6 frame 9 103073X59417Hs.74077proteasome (prosome; 2.6 macropain) subunit;
alph 116294AA489000Hs.93748ESTs; Moderately similar2.6 to TRANSCRIPTION FAC

75 135339D59269Hs.127842Homo Sapiens mRNA full2.6 length insert cDNA
clo 125390H95094Hs.75187Uanslocase of outer 2.6 mitochondria) membrane 102504052077Hs.247948Human mariner) transposase2.6 gene; complete con 131076H44386Hs.22666ESTs 2.6 114096238342Hs.27007chromosome condensation)-like2.6 120402AA234339Hs.50282GTP-binding protein 2.6 raga 102125014550Hs.107573sialylUansferase 2.6 134653AA452818Hs.87385ESTs 2.6 101959S80343Hs.180B32arginyl-tRNA synthetase2.6 116766H13260Hs.95097ESTs 2.6 104954AA074514Hs.26213ESTs; Weakly similar 2.5 to protein [H.sapiens]

108771AA127924Hs.71034ESTs 2.5 116439AA610068Hs.43913PIBFt gene product 2.5 133859086782Hs.17876126S proteasome-associated2.5 padl homolog 132792AA401903Hs.242985hemoglobin; gamma G 2.5 129620AA010686Hs.239720ESTs; Weakly similar 2.5 to KIAA0691 protein [H.s 120296AA191353Hs.22385ESTs; Weakly similar 2.5 to KIAA0970 protein [H.s 115615AA401186Hs.48617ESTs 2.5 102983X17620Hs.118638non-metastatic cells 2.5 1; protein (NM23A) expre 1 106288AA435536Hs.24336ESTs 2.5 ~

107444W28391Hs.5181proliferafion-associated2.5 2G4; 38kD

104525816007Hs.75355ubiquifin-conjugafing 2.5 enzyme E2N (homologous 128917AA204876Hs.206097oncogene TC21 2.5 102299032907Hs.15554537 kDa leucine-rich 2.5 repeat (L88) protein I 115363AA282071Hs.152759aclivalor of S phase 2.5 S kinase 130399AA449417Hs.155356Homo Sapiens mRNA for 2.5 putafive glucosyllransf 130752D50927Hs.18895tousled-like kinase 2.5 ~ 1 132724AA417962Hs.55498geranylgeranyl diphosphate2.5 synlhase 1 106743AA476352Hs.21938ESTs; Weakly similar 2.5 to KIAA0704 protein [H.s 128949AA190993Hs.8850a disintegrin and metalloproteinase2.5 domain 12 125685A1040346Hs.4943hepatocellularcaroinoma2.5 associated protein;

105826AA398243Hs.21806ESTs; Moderately similar2.5 to similar to NEDD-4 110841N31610Hs.18645ESTs; Weakly similar 2.5 to partial CDS (C.elegan 111987842036Hs.6763KIAA0942 protein 2.5 132669AA188378Hs.54602ESTs; Weekly similar 2.5 to 60S RIBOSOMAL PROTEIN

100398D84557Hs.155462minichromosome maintenance, deficient (miss; S 2.5 130800AA223386Hs.19574ESTs; Weakly similar 2.5 to katanin p80 subunit [

114481AA033562Hs.15i572ESTs 2.5 113404T82323Hs.70337immunoglobulin superfamily;2.5 member 4 100260D38491Hs.174i35KIAA0117 protein 2.5 103563122534Hs.150402activin A receptor; 2.5 type I

104573868952Hs.29780ESTs 2.5 105025AA126336Hs.22744ESTs; Weakly similar 2.5 to ZINC FINGER PROTEIN

105524AA258158Hs.22153ESTs; Weakly similar 2.5 to KIAA0352 [H.sapiens]

3 106157AA425367Hs.32094ESTs 2.5 S

107243D59489Hs.34727ESTs 2.5 109920H05733Hs.30558ESTs 2.5 109981H09552Hs.26090ESTs; Weakly similar 2.5 to T20B12.1 [C.elegans]

114518AA046407Hs.106469suppressor of varl 2.5 (S.cerevisiae) 3-like 40 114768AA149007Hs.182339Ets homologous factor 2.5 118906N91000Hs.94433ESTs 2.5 119025N98926Hs.55209ESTs; Weakly similar 2.5 to DMR-N9 PROTEIN
[H.sap 131712N29502Hs.30991KIAA0957 protein 2.5 132233X04706Hs.93574homeo box D3 2.5 45 132740AA227751Hs.55896ESTs 2.5 115239AA278650Hs.73291ESTs; Weakly similar 2.5 to similar to the beta t 128820F10338Hs.106309Friend of GATA2 2.5 124049F10523Hs.74519pdmase; polypepfide 2.5 2A (58kD) 128781X85372Hs.105465small nuclear ribonucleoprotein2.5 polypepfide F

121361AA405494Hs.183052ESTs 2.5 134133X93920Hs.180383dual specificity phosphatase2.5 102502051678Hs.78050small acidic protein 2.5 115875AA433943Hs.43946ESTs; Weakly similar 2.5 to Weak similarity to Ye 132874AA425776Hs.58609ESTs 2.5 55 109646F04543Hs.5028DKFZP56400423 protein 2.5 111197N68093Hs.22909ESTs 2.5 102968X16396Hs.154672methylene tetrahydrofolate2.5 dehydrogenase (NAD

124911888992Hs.123645ESTs 2.5 106628AA459657Hs.12311Homo Sapiens clone 2.5 23570 mRNA sequence 60 116988H82527 ys69e12.s1 Soares refina2.5 N2b4HR Homo Sapiens 131075Y00757Hs.2265secretory granule; 2.5 neuroendocdne protein 1 ( 133578X78627Hs.75066franslin 2.5 100420D86983Hs.118893p53-responsive gene 2.5 130743W87710Hs.18724Homo Sapiens mRNA; 2.5 cDNA DKFZp564F093 (from c1 65 122465AA448164Hs.99153ESTs; Highly similar 2.5 to CGI-73 protein [H.sap 115117AA256492Hs.49007poly(A) polymerase 2.5 124582N68477Hs.108408ESTs; Highly similar 2.5 to CGI-78 protein [H.sap 104771AA025911Hs.24994ESTs; Highly similar 2.5 to CGI-53 protein [H.sap 108059AA043944Hs.62663ESTs 2.5 105628AA281251Hs.35696ESTs; Weakly similar 2.5 to putafive zinc finger 109261AA195255Hs.61779ESTs 2.5 119789W73140Hs.50915kallikrein 5 2.5 130512AA045304Hs.181271ESTs; Highly similar 2.5 to CGI-120 protein [H.sa 134402025165Hs.82712fragile X mental rotardafion;2.5 autosomal homol 75 104769AA025887Hs.114774ESTs; Weakly similar 2.5 to !!!! ALU SUBFAMILY
J

125787, Hs.29403ESTs; Weakly similar 2.5 AA744748 to PROBABLE ATP-DEPENDEN

131775AA459555Hs.31921KIAA0648 protein 2.5 TABLE 7B:
Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 101335 d6413-1 L49054 N874d7 AA248791 AA452193 A1015525 AI762070 AA781526 T35999 T19178 AA164313 AI74d010 A1015466 A1014921 AA446421 AW881866 AI469428 BE548103 T96204 894457 N78225 Ai564549 AW004984 AW780d23 AW675448 AW087890 AA971d54 AW673d12 BE063175 AW674408 A1202011800723 AI753769 AI460161 AW079585 AW275744 Roo722 102221 3861_1 NM-006769 U24576 AWi61961 AW160473 AW160465 AW160472 AW161069 AI923255 AI9d9082 AI142826 A1684160 AI701987 AI678954 AI827349 BE463635 AA971281 AA2d8036 A1039197 AI914689 AA973825 AL047305 AA129966 AI798369 AI216121 AI33317d T10972 AI375028 AI186756 AI273778 AA610487 AI7979d6 AA853903 101714 30725_1 M68874 AL022147 M72393 AL049797 BE439441 T27650 AI766240 116803 55078 4 H47357 W33034 H55976 H55975 867830 AA527091 F24d82 AW841585 R6651d ~J~ 132640 179_1 AW162087 AA224538 AA471218 AA088655 AA375275 8E440052 AI142478 AA081824 AI887930 AA070570 BE1852d8 AI459825 BE257794 AA420459 BE5432d2 AI811690 AW852076 AW852270 BE182212 AA081009 T69431 AI186207 AA604124 AA7073d6 AA173953 A1016700 AI125916 AW513002 AW30d292 AA724885 AW474759 AI811621 AW068925 AA666305 AI580161 Ai128023 AW471151 AA5348d9 AA666358 AA807994 AI2888t 2 AA632832 AA157933 AA639802 AW392890 WOd825 AA771848 AA084634 AA041269 Wd4443 AI581770 W46171 AA878485 W46535 AA197336 AA894945 AA394224 AI76683d AI582590 A1033007 AA481889 AW173598 AI499145 AI122566 AW903d08 AI810569 AA854936 BE049510 D62065 D61900 N48922 N487d6 AA481381 822858 H13912 AC004549 AW602500 AW768788 45 103427 43892_1 BE514383 AA071273 AW247987 AW673286 8E312102 AW749824 103631 152_34 864730 AF214731 T19173 BE258318 AF161446 BE542228 8E383856 AW580281 AA302597 AW888908 AW888893 BE312970 AA134402 H52679 AA478191 T3d090 AWd05576 T33102 889545 N46625 H08434 S S AI815980 AW157278 AW607664 AWi 63288 AA133492 AA099328 AA157348 AI816063 AW449556 AAi 57252 AW608980 H66576 AW821127 T32030 AW856058 AA032188 242120 Ri 8582 AW402392 BE408021 AA280989 AW839942 H60108 AW36d002 AW363800 AA872914 W31065 N54216 AI568741 H56262 NM_017425 248570 A1831777 T75007 AW821145 BE081547 AW881571 AW881573 AW055249 AA204724 Aid17415 AI127303 AI220431 N51090 Ai 143003 AA96i480 AA039351 A1094885 A1096520 AA179553 AI265911 AI352444 AA4d3158 AA910603 AI420273 FOd560 AA661955 AI857675 AA369666 AA424207 129097 25953_1 BE243933 AA355449 T29766 F08396 N83324 NM 006963 S50223 N56058 AA393593 W24864 Hi0710 F06925 F07239 AW3861d0 AA325018 AA235950 AA782239 834295 H87165 AW419059 AI653689 240349 H8911 d AW07d506 AA397785 10035237786_1AL133887 10108413883_1AW409934 AA316055 BE621134 AA171883 AW245855 BE27249d L05425 BE250310 AA93d590 AA48361d AI47d094 10050226409_1015979X17544 W52755 NM 003836T49116 AA333753 BE262238 AA701996 11577 AA575957 Al l 49135 AA3198d5 AA2352d5 AA4d9494 AW93538d 102398entrez_042359 Tablests in ovarian cancer compared 8A about to normal adult fissues.
li 54 These were selected genes from 35403 probesels up-regulated on the AffymefrixlEos-Hu01 GeneChiparray e such ratio that of th "average"
ovarian cancer to "average"
normal adult tissues was greater than or equal to 4Ø
The "average"
ovarian cancer level was set to the ous 4th highest amongst various 3rd ovarian non-malignant fissues.
highest cancers. In order to remove amongst The vari "average"
normal adult tissue level was set to the gene-specific malignant tissues was subfracted background from both the numerator levels and the of non-specific hybridization, the 15th percentile value amongst the non-denominator was before evaluated.
the ratio TABLE
8A:
ABOUT

UP-REGULATED
GENES, OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES

Pkey:
Primekey Ex.Accn:ExempIarAccession UG
ID:
UniGene ID

Tifie:
UniGene Title ratio:
ration tumor vs.
normal tissues Pkey Ex. UG Tifie ratio Accn ID

130941D49394Hs.21425-hydroxytryptamine 12.1 (serotonin) receptor 101249L33881Hs.1904protein kinase C; iota11.8 132528AA283006Hs.50758chromosome-associated 11.5 polypepfide C

102610U650T1Hs.30743preferenfially expressed11.0 anfigen in melanoma 115536AA347193Hs.62180ESTs 10.0 129571X51630Hs.1145Wilmstumorl 9.3 105298AA233459Hs.26369ESTs 7.8 121779AA422036Hs.98367ESTs 7.3 104301Dd5332Hs.6783ESTs 6.9 132191AA449431Hs.158688KIAA0741 gene product 6.7 102136015552Hs.85769acidic 82 kDa protein 6.6 mRNA

101804M86699Hs.169840TTK protein kinase 6.5 132572AA448297Hs.237825signal recognition 5.9 particle 72kD

106738AA470145Hs.25130ESTs 5.8 108857AA133250Hs.62180ESTs 5.8 115291AA279943Hs.122579ESTs 5.8 132632N59764Hs.5398guanine-monophosphate 5.8 synthetase 116401AA599963Hs.59698ESTs 5.7 132725L41887Hs.184167splicing factor, argininelsedne-rich5.7 7 (35kD

129097S50223 HKR-T1=Kruppel-like 5.6 zinc finger protein (puma 134520N21407Hs.257325ESTs 5.5 , 108778AA128548Hs.90847general transcription 5.4 factor IIIC; polypepfid 131228AA279157Hs.24485chondroifin sulfate 5.2 proteoglycan 6 (bamacan) 116238AA479362Hs.47144DKFZP586N0819 protein 5.2 108055AA043562Hs.62637ESTs 5.1 132939076189Hs.61152exostoses (mulfiple)-like5.1 115909AA436666Hs.59761ESTs 5.0 120438AA243441Hs.99488ESTs; Weakly similar 5.0 to ORF YKR074w [S.cerevi 123494AA599786Hs.112110ESTs 5.0 109648F04600Hs.7154ESTs 4.9 132624AA164819Hs.53631ESTs 4.9 111234N69287Hs.21943ESTs; Weakly similar 4.9 to ORF YGL221c [S.cerevi 135242M74093Hs.9700cyclin E1 4.9 123005AA479726Hs.105577ESTs 4.8 116296AA489033Hs.62601Homo sapiens mRNA; 4.7 cDNA DKFZp586K1318 (from c 100661HG287d-HT3018 Ribosomal Protein L39 4.6 Homolog 111345N89820Hs.14559ESTs 4.6 102627066561Hs.158174zinc finger protein 4.5 184 (Kruppel-like) 106459AA449741Hs.4029glioma-amplified sequence-414.5 102305033286Hs.90073chromosome segregafion4.5 1 (yeast homology-like 129229AA211941Hs.109643polyadenylate binding 4.5 protein-interacfing pro 130376840873Hs.155174KIAA0432 gene product 4.4 120619AA284372Hs.111471ESTs 4.4 122802AA460530Hs.256579ESTs 4.4 116416AA609219Hs.39982ESTs 4.3 ~f0115094AA255921Hs.88095ESTs 4.2 126802AA947601Hs.97056ESTs 4.2 126892A1160190Hs.76127heot(homologoustothe 4.2 E6-AP (UBE3A)carboxy 105516AA257971Hs.21214ESTs 4.1 131985AA434329Hs.36563ESTs 4.t 114965 AA250737 Hs.72472 ESTs 4.0 120821 AA347dt9 Hs.96870 Homo sapiens mRNAfull length insertcDNAclo 4.0 134621 L025d7 Hs.172865 cleavage stimulation factor, 3' pre-RNA; subu 4.0 134161 097188 Hs.79440 IGF-II mRNA-binding protein 3 4.0 TABLE 8B:
Pkey: Unique Eos probeset identifier number CAT number. Gene cluster number 1 O Accession: Genbank accession numbers Pkey CAT Number Accession 101249 2520 1 L18964 NM X02740 L33881 AA095249 BE080871 AWfi05320 M85571 AW087514 AI480090 AI873147 157875 AI217d04 AA827196 AI279471 AA9fi9093 116401 95855_1 AW893940 AW978851 AA034240 AI686323 AI767653 AA829515 AA053933 116416 373989_1 AW753676 811789 AW001886 AA609219 AW780420 A1860557 AI280331 AI33d300 AI288870 AAfi69343 N29918 BE537790 AA934687 AI189144 A1016691 W45515 AA551452 AA44943t 110046 AA42d059 N62822 AWt97701 AI743979 AI283341 AW340338 AA774643 AW104778 A1078020 N21d87 H97562 AA970063 At0399fi7 AA677529 AI694291885811 N28fi72 130941 2774_1 NM 000869 D49394 8E252349 AW249320 AW249140 AW250535 S82612 1 15909 47548_1 AW872527 AA4538fi3 AA442475 AF086541 AA36580t AI692575 108778 18565_1 AF133123 NM 012086 AA128292 S81493 AL137453 BE614053 AA307628 AA429306 813465 855236 AW99d182 W00838 AW994417 AW994404 AW994426 AW994321 AA4690fi5 170340 AA477fii5 AAd78070 AI0177d3 AI381293 AW298d73 855237 837375 AI768014 AA128548 102136 17647_1 AA300576 015552 NM 014597 AA223318 AA171806 BE269461 AW578439 AW002266 BEO6d947 BE064722 110372 AW838681 AI811119 AW262098 AA588547 AI916666 40 A1953413 A1064798 AI420425 AAt9t324 BE503222 AI632721 AA180035 AA558329 W44843 110610 W38442 8E542869 A1125024 BE2795fi6 AI215522 Ai216389 N87835 812261 R57094 AI660045 AA347193 816712 AW1 1 9006 45 AI351088 AI872789 AI91905fi AI611216 AK001 472 BE568761 AA581004 102305 18424_1 AL043202 033286 NM_001316 AF053641 AL048759 N99830 AA263091 AA207207 AA315560 AA113938 AW386317 AW386316 L44546 AW386335 AA243317 AA7t3588 W95535 AA1fi4768 AI279876 H02142 C18698 o AA365866 AW954410 AI539769 139128 ALt21103 AAt92466 AA213367 A1963800 889384 AA872668 AI3d4110 W95d20 AA164700 55 AI868711 AA582354 AA524392 801549 801641221083 AA5284fi3 139127 AA989472 F09450 AA084485 BE004378 AW97d353 AA137250 AI27840fi AW609291 AA137249 AA142866 AA639198 AW609271 AW149760 At025112 AA236620 AA937248 090736 AW005487 AW67d427 AW609317 AW60925fi AWfi09305 AW582063 F06655 AW605343 AA446d26 BE090595 AW969578 179852 A1082505 N63239 AI973168 AW023353 H77d83 H68082 842337 H58601 197267 65 101804 26687-1 M86699 NM 003318 AL133475 AA122377 121415 857092 AA8065fi9 AA311187 AAd63631 AI421918 AI400518 AI92id04 AA143770 AA587675 BE302192 AASS3080 A1493386 AW327435 AW340871 Ati43616 AA68723i AA21896i AI362249 AI378345 N74716 AW969249 AA468581 AA516399 AI274726 A11312d4 AI572604 AI929236 AW327971 AI873956 199348 A1924643 AW 103910 A1802993 A1080390199098 Dt 9794 AW327972 75 AW769295 W32639 AA363094 N89012 W39751 AI29i329 A129i371 AA829411 AI985219 AF086131 AA373679 AAi 65043 AA355705 AI243507 A1027796 AA573461 AA757260 835393 AA448435 AA334fi59 AW879356 AA436527 AW972044 W25165 AA521219 A1094141 Al 1 31472 N50381 AA736938 A1089112 AA863053 A1359793 AA962268127353 D82590 AAdd8297 A1277168 A1368457 AA872737 AA330346 AA308346 AA3d2341 AA355159T85701 BE162893 199703 131985 113870_1 AA503020 A1858190 A1fi86571 AW615203 AW073686 AW172459 AA434329 AA171844 A1684143 AA953518 AW470i O8 A1870700 AA706376 A1539668 AI683712 AA075579 AI682137 AA291512 AA55443i 132624 42095_1 AA326108 W74020 AW61269B AI750909 AA487800 AJ270695 AA044941 15~

AA988105 A1242138 AW1d8523 A1978761 N50882 AA527448 AW086200 AI750910 N50868 AA709437 N519d6 AI222179 AA732883 H96742 AA446d21 AW881866 AId69428 BE5d8103 T96204 R94d57 N78225 AI564549 AW004984 AW780d23 AW6754d8 AW087890 AA97145d AI873729 D25791 BE537646 TSi 139 800722 102610 9336_1 065011 NM 006115 AW182053 BE383930 BE407839 BE409930 BE408826 1 ~ BE622732 AW939295 AA781195 A1017284 AW375329 AW375366 AW178384 AW178333 AW17&424 AW365726 AF025440 AW172852 AI570998 AW117792 AI885499 BEd65516 BE207d27 AW130942 AW513316 AW770892 A1810101 AI744983 AI861974 BE207d04 AI744982 AI613210 AW591505 AW169285 AI521444 AI7450d4 AI62790d AI690634 AI289305 AA861253 AI612799 BE207425 AI149694 AA902662 A1082d68 A1014752 AA613844 AI859014 AW051225 AA665758 AA49699i AA564738 T19d28 AI567170 AWi66726 AW084200 D20455 BE410282 BE25d766 BE256014 AA357423 102627 25245-1 AL021918 AA160639 066561 AA321623 052098 AL119d53 AA455712 AI275d09 AI139i21 A1927568 AI927562 AI139471 AA160473 N78795 AI719983 AI718928 132725 29101 1 NA~.006276 NM 006276 L41887 L22253 BE379909 BE567870 BE274265 AA494481 BEd40161 AW780428 BE543960 D55986 AA852399 AI630020 W77996 AA278193 810505 A1963201 A113933fi BE174301 AI718952 AI953572 BE464509 AA777315 AI337221 AW070910 AI9538d8 AW674561 H54177 BE50207d AA278769 AI499038 AW469072 AA778071 AW236753 AI933033 AI690458 H16969 F13487 D19858 AA452207 BE085942 AA344396 AW949533 AA279472 AW902d06 AA729303 AA420591 AA385025 AAd20542 869155 AA420592 AA2817d7 N88502 AI458206 AI140387 AW051969 AW299438 AI127170 AW769164 AI422d35 AI307116 BE549519 N503d5 AW338776 BE326601 AI142892 AW470687 A1989568 AA911241 AW294822 AI17d414 AA804366 A1004725 AW27199d AI559313 AI601238 AA513452 AW612802 BE075163 839171 Ai565328 AI375559 F10356 AA284625 8 E241509 AI702889 AWi 93010 AA649847 111234 83711_2 AA902656 AI185915 843705 H15150 H09794 AA832464 AI697438 AA827088 Ai081207 AA992399 AW130757 AI266084 N49879 AW024457 AI2d6246 AI934031 AI369270 A1003836 AA010063 AA494361 Ai284151 AI919536 N34884 N69287 AW510465 AI358609 AW08142i AA706205 A1085317 AI140633 AI347104 AA602547 AI686707 AA872686 AA69d028 A1094546 240832 AI382838 AA610132 AA50i433 H84120 AI140722 AW674839 BE503822 AW663895 BE327472 AW393494 BE089878 BE301950 A1025d75 AA724446 BE275324 H152i0 AW957667 134161 16074_1 AA634543 AI682259 AF117108 BE396917 NM 006547 097188 076705 R64d32 AW044616 A1086619 AW628546 AW043682 AA425750 AI743038 AI368723 AA187143 AW104877 AA195464 W81072 AW197351 AA932674 AI393d20 AI434998 863822 AW085083 132939 11857_1 AB009284 AF000416 AA022636 BE082610 AW367997 AA491di 0 AA337477 AA336421 W38526 AA625283 AA773685 AA490078 T6613d AA847838 AA022647 AW054726 AI9i8001 AA431966 AI263596 AI804298 AW469314 076189 AA410350 AK001450 AV654353 AA058443 D81618 AA853665 W31930 AA3344d5 AW955767 AW263652 BE440048 BE440013 AA577463 A103B77d AW204992 AA846580 AA501952 111345 6692_1 AW263155 AA314512 AW408152 AA360413 BE206274 AK001402 AA307665 104301 145380_1 AA768491 AA476251 AA809748 AI186268 AA621244 AI379029 8E550341 AA651915 AI216376 A1215585 AI471780 AA772159 AWi81980 Ai768535 881435 D45332 N75682 N51177 65 AW207d06 AA425184 820997 AA504168 Zd3298 134520 13358_3 BE091005 BE541579 AW387738 AW386083 H13769 AW377820 AW369180 AW891416 BE091358 N50375 BE091354 BE091365 BE09136t BE091363 BE091350 AA353863 AA526557 AA525443 AW893622 AA630898 AI418983 BE172016 AA550754 AA66d574 C16147 135242 5782_1 A1583187 M73812 AW339829 M74093 BE252510 BE252518 BE536901040788 W95578 BE018493 BE5d4205 N83637 A1671049 AWd39693 134621 ~ 27351_1 AA037145 L02547 NM-001324 AW411516 AA314711 AA143605 BE394455 AW90d214 AA363564 894127 AA352101 828249 AA206337 AW577208 AA385473 AA355463 AA075530 AA620555 AA554034 T2780d AW950014 AI570740 AI268538 AA704423 AW411517 AA992763 AW516454 AA992759 AW270d44 g O AA227188 AI208929 AA167720 A1052527 AA865660 AA569368 AI888464 AI670003 ,. A1341077 AI825719 BE552285 AA738076 AW085903 828242 126802 116467_4 AW805510 AW805503 AW805500 AW805819 AW517040 AW473670 AW516701 T301d1 AA894497 BE349504 AI272007 AI98527d BE501962 126892 38252-1 AF121856 BE242657 083194 AA226732 All fi0190 AA948725 A1079958 AW513369 W394d3 AW408479 W06854 AA094683 AI985095 ' AA165080 834212 AA150886 T82168 N77082 W56864 819848 AA888217 AA314539 W15351 H93997 AA725325.~E180993 W05350 AI510771 W06941 AA48841 d 879863 N91264 876884 AA312948 T71267 AW959659 AA85d381881331 AA7D0449 H06174 AW518427 AA876634 AA150778 N32393 H78585 T85364 AI680306 AA436854 AI537153 AA883723 228659 AA705973 240741 AAd63884 AI216025 AI817119 A1091896 AA738d40 AA1950i3 AA976687 AA459659 AI246250 BE219252 AI703457 AA243291 AA243d01 AA989100 AA931640 105516 9334_1 AK001269 AL354613 AA147472 AA490803 BE207628 AW816113 AA085574 AW880296 AA253485 AW95d441 H98989 AW614348 129097 25953_1 8E243933 AA355449 T29766 F08396 N83324 NM 006963 S50223 R3d173 AW889005 AA74564d AI693852 AA424914 AA744771 W72632 AI291213 AA524318 ' N29739 AI216718 AI383349 A1038618 AI351476 AAB06031 AI914178 H10711 A1095573 AW44951 d AA804785 A1215473 A1357263 A16512D8 A1651753 129229 20927_1 AF013758 NM_006451 AI538709 AA209236 AA300293 AA367274 AA126598 AA324825 AW955225 F11436 AW3747d0 AW37d714 AW374774 AA3d5052 AI446735 AI142106 AA662683 AW002813 AI418280 AW613203 AI613333 AI354d80 AI929755 AI1d6977 W74674 AW799610 AI798529 AI589422 AA043957 AI223043 AA157016 AId46759 D56729 AI587d71 F30716 120821 19274_2 Y19062 NM 014393 AW296801 AK001576 AL079288 W16667 245664 Ai768561 AL079286 812736 AW080147 AW136530 AI202958 AW241579 821013 AA347419 AI929333 AWi96689 A1040867 F13437 AA918240 AI869798 Ai365176 AW440030 AW440072 N80892 AI873524 AW473151 AW004719 AI810504 AI581093 AA493977 Zd0600 F04553 846130 AA448598 AJ245746 AI365301 N4d728 AA255743 AA360783 BE550380 AW083185 T62128 278373 AW673713 AWd68061 BE350755 AW673958 AW675504 AA995709 s 5 115094 190995_1 AA255920 A1817197 AA255921 AI612925 AW874669 AA493440 129571 1726_1 X51630 M80232 X61631 S75264 AA172249 AA134066 AAi 30278 AA130187 AW08988d 106738 174703_1 AW149266 849246 AW237401 AA938113 AW665871 AI969698 AI950812 AW874276 AI571939 AA1d1222 AI869822 AWi 04061 AI569994 A1480343 AA044582 AW956159 AA373451 AAi 27965 AL134913 AW994956 BE62231d BE006298 8E006312 BE006305 BE006317 BE006303 115291 22325_1 BE545072 AI540751 AA301103 AI916675 N85422 BE563965 AA327978 70 130376 24827_ 4 840873 Ai215522 AI216389 N87835 812261 857094 A1660045 AA3d7193 816712 AW119006 75 114965 153955_1 A1133881 AA165164 AI826437 AI972791 AA165165 BE219575 AI73258fi A1821571 AA250737 AW136875 AI984273 AI249271 131228 8262_1 AW207469 AL079814 AA354351 AF020043 AW291396 BE550484 NM 005445 BE536295 AA463d12 BE093222 AA213739 g 0 AA485586 AI825913 AA706307 AI337348 831995 AI819641832095 AW976653 AA742375 AA142957 AI808214 AWd68303 AI205987 122802 287993_1 AI687303 AW571681 AI554465 AI684252 AI581056 AA604098 AI628160 AW130822 AW167419 AI28948frAW150010 123494 21202-1 AW179019 AW179011 AF135160 Ntvi_014050 AF078860 BE018005 AW8608B3 AWi48667 N89861 AA557195 AI191824 1 ~ AW674302 AI925483 AW170412 AI698717 AI375985 BE220535 AI688151 AW514809 BE463534 AI628252 AA836139 AI27729t AA489033 AA741239 AI209064 AI300253 Table 9A lists about 382 genes up-regulated in ovarian cancer compared to normal ovaries. These were selected from 35403 probesets on the AfiymetrixlEos-Hu01 GeneChip array such that the ratio of"average" ovarian cancer to "average" normal adult ovaries was greater than or equal to 10. The "average" ovarian cancer level was set to the 2nd 2o highest amongst various ovarian cancers. The "average" normal adult ovaries level was set to the arithmetic mean amongst various non-malignant ovaries. In order to remove gene-specific background levels of non-specific hybridization, the.l5th percenUle value amongst the non-malignant tissues (see Table 7A) was subfracted from both the numerator and the denominator before the ratio was evaluated.
TABLE
9A:

UP-REGULATED
GENES, OVARIAN
CANCER
VERSUS
NORMAL
OVARY

Pkey:mekey Pri Ex.Accn:ExempIarAccession 3 UG
1D:
UniGene ID

Tifie:
UniGene title ratio:
ratio tumor vs.
normal tissues PkeyEx. UG Title ratio Acon ID

134454L33930Hs.173996CD24 antigen (small 86.2 cell lung carcinoma clust 102927X12876Hs.65114keratin 18 84.7 115909AA436666Hs.59761ESTs 72.3 123169AA488892Hs.104472ESTs; Weakly similar 66.8 to Gag-Pol polyprotein [

35 115674AA406542Hs.71520ESTs 65.4 102193020758Hs.313secreted phosphoprotein63.1 1 (osteoponfin; bone 101839M93036Hs.692membrane component; 56.8 chromosomal 4; surface ma 115221AA262942Hs.79741ESTs 56.1 108059AA043944Hs.62663ESTs 52.3 121853AA425887Hs.98502ESTs 47.8 133504W95070Hs.74316desmoplakin (DPI; DPII)47.0 103546214244Hs.75752cytochrome c oxidase 46.5 subunit Vllb 100147D13666Hs.136348osteoblast specific 45.5 factor 2 (fasciclin I-lik 102979X17042Hs.1908proteoglycan l;secretory44.6 granule 45 130967AA134138Hs.182579Homo sapiens leucine 44.5 aminopepfidase mRNA;
cam 102009002680Hs.82643protein tyrosine kinase40.4 126960AA317900Hs.161756ESTs 39.6 103111X63187Hs.2719epididymis-specific; 39.1 whey-acidic protein type 133829AA453783Hs.76550Homo Sapiens mRNA; 39.0 cDNA DKFZp564B1264 (from c 50 t N68921Hs.34806ESTs; Weakly similar 38.9 t to neogenin [H.sapiens]

102803089916Hs.26126claudin 10 38.8 104943AA065217Hs.169674ESTs 38.7 106605AA457718Hs.21103Homo Sapiens mRNA; 38.4 cDNA DKFZp564B076 (from c1 120655AA287347Hs.238205ESTs 38.1 55 102968X16396Hs.154672methylene tetrahydrofolate36.3 dehydrogenase (NAD

104052AA393164Hs.97644mammaglobin 2 36.0 109166AA179845Hs.73625RAB6 interacting; kinesin-like35.9 (rabkinesin6) 101332L47276 Homo Sapiens (cell 35.0 line HL-6) alpha topoisome 106167AA425906Hs.7956ESTs 34.5 60 101042J05428Hs.10319UDP glycosylUansferase34.3 2 family; polypepfide 125852H09290Hs.76550Homo sapiens mRNA; 33.7 cDNA DKFZp564B1264 (from c 101201L22524Hs.2256matrix metalloproteinase32.3 7 (matrilysin; uteri 126410851912Hs.12409somatostatin 32.1 134326016306Hs.81800chondroitin sulfate 32.0 proteoglycan 2 (versican) 65 125739AA428557Hs.92137v-myc avian myelocytomatosis31.6 viral oncogene h 132254L20826Hs.430plastin 1 (I isofortn)31.4 112610879392Hs.23643ESTs 30.9 101441M21005Hs.100000S100 calcium-binding 30.6 protein AS (calgranulin 116345AA496981Hs.199067HER3 receptor tyrosine30.1 kinase (c~rbB3; ERBB3 108860AAi33334Hs.129911ESTs 29.8 133859086782Hs.17876126S proteasome-associated29.2 pads homolog 107295T34527Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypepfid28.9 106210AA42B239Hs.10338ESTs 28.9 134711X04011Hs.88974cytochrome 1r245; beta28.0 polypepfide (chronic g 75 125769AI382972Hs.821285T4 oncofetal Uophoblast27.5 glycoprotein 107222D51235Hs.82689tumorrejecfion anfigen(gp96)27.4 102260028386Hs.159557karyopherin alpha 2 26.9 (RAG cohort 1; imporGn a 134691M59979Hs.88474prostaglandin-endoperoxide26.8 synthase 1 (prosta 105588AA279215Hs.10867ESTs 26.3 130718N70196Hs.18376ESTs 26.3 111185N67551Hs.12844EGF-like-domain; mulfiple25.6 131965W90146Hs.35962ESTs 25.6 132903AA235404Hs.5985Homo Sapiens clone 25.6 25186 mRNA sequence 114359241589Hs.153483ESTs; Moderately similar25.5 to Hi chloride chann 101185L19872Hs.170087arylhydrocarbon receptor25.2 128742000763Hs.251531proteasome (prosome; 25.1 macropain) subunit;
alph 116724F13665Hs.65641ESTs 24.9 111929840057Hs.112360prominin (mouse)-like24.9 102915X07820Hs.2258mafrix metalloproteinase24.8 10 (sfromelysin 2) 131210AA430047Hs,24248ESTs 24.7 101714M68874 Human phospha6dylcholine24.6 2-acylhydrolase (cP

100154014657Hs.81892KIAA0101 gene product24.6 134656X14787Hs.87409thrombospondin 1 24.3 100294049396Hs.75454antioxidant protein 23.9 104080AA402971Hs.57771kallikrein 11 23.7 107056AA600310Hs.18720programmed cell death23.7 8 (apoptosis-inducing f 115697AA411502Hs.63325ESTs; Weakly similar 23.7 to airway trypsin-like p 130350002020Hs.239138pre-B-cell colony-enhancing23.7 factor 1 105870AA399623Hs.23505ESTs 23.6 S

118528N67889Hs.49397ESTs 23.4 105309AA233790Hs.4104ESTs; Weakly similar 23.2 to cDNA EST yk386g7.5 co 109680F09255Fis.4993ESTs 23.2 131501AA121127Hs.181307H3 histone; family 23.2 100824HG4058-HT4328 Oncogene Aml1-Evi-1, 23.1 Fusion Activated 111890838678Hs.12365ESTs 23.0 101543M31166Hs.2050pentaxin-related gene;22.8 rapidly induced by IL-102095011313Hs.75760sterol carrier protein22.8 114988AA251089Hs.94576ESTs; Weakly similar 22.8 to phosducin; retinal [H

25 120695AA291468 ESTs 22.8 130941049394Hs.21425-hydroxytryptamine 22.8 (serotonin) receptor 106654AA460449Hs.3784ESTs; Highly similar 22.7 to phosphoserine aminofr 109141AA176428Hs.193380ESTs 22.6 102345037283Hs.58882Microfibril-associated22.6 glycoprotein-2 115652AA405098Hs.38178ESTs 22.4 100103AF007875Hs.5085dolichyl-phosphate 22.3 mannosyltransferase polype 105463AA253370Hs.32646ESTs 22.2 132624AA164819Hs.53631ESTs 22.2 119743W70242Hs.58086ESTs 22.0 35 132528AA283006Hs.50758chromosome-associated22.0 polypeplide C

107174AA62i714Hs.25338ESTs 21.8 134495063477Hs.84087KIAA0143 protein 21.6 131985AA434329Hs.36563ESTs 21.5 105832AA398346Hs.21898ESTs 21.2 40 126160N90960Hs.247277ESTs; Weakly similar 21.2 to transformation-relate 114846AA234929Hs.44343ESTs 20.9 109703F09684Hs.24792ESTs; Weakly similar 20,9 to ORF YOR283w (S.cerevi 135154AA126433Hs.173242sorting nexin 4 20.8 131185M25753Hs.23960cyclin B1 20.7 45 105616AA280670Hs.24968ESTs 20.5 131148C00038Hs.23579ESTs 20.2 129337863542Hs.110488KIAA0990 protein 20.2 133640083004Hs.75355ubiquitin-conjugating20.1 enzyme E2N (homologous 127479AA513722Hs.179729collagen; type X; 19.9 alpha 1 (Schmid metaphyseal 133711J04130Hs.75703small inducible cytokine19.8 A4 (homologous 1o mo 131818239297Hs.3281neuronal penfraxin 19.7 II

125303239821Hs.107295ESTs 19.6 109112AA169379Hs.72865ESTs 19.5 105376AA236559Hs.8768ESTs; Weakly similar 19.2 to !!!! ALU SUBFAMILY
SO

55 103605235402Hs.194657cadherin 1; E-cadherin19.1 (epithelial) 100661HG2874-HT3018 Ribosomal Protein 19.1 L39 Homolog 129571X51630Hs.1145Wilms tumor 1 19.0 115239AA278650Hs.73291ESTs; Weakly similar 18.9 to similar to the beta t 131562090551Hs.28777H2A histone family; 18.9 member L

131272AAd23884Hs.139033paternally expressed 18.9 gene 3 130343AA490262Hs.15485ESTs; Weakly similar 18.8 to APICAL-LIKE PROTEIN
[

103245X76648Hs.28988glutaredoxin (thiolfransferase)18.7 101809M86849 Homo Sapiens connexin18.6 26 (GJB2) mRNA, complet 105344AA235303Hs.8645ESTs 18.4 65 135225AA455988Hs.9667butyrobetaine (gamma);18.4 2-oxoglutarate dioxyge 116786H25836Hs.83429tumor necrosis factor18.3 (Iigand) superfamily;
m 131510AA207114Hs.27842ESTs; Weakly similar 18.2 to similar to 1-acyl-g!y 124059F13673H5.99769ESTs 18.0 103352X89398Hs.78853uracil-DNA glycosylase17.9 70 132742AA490862~H5.55901ESTs; Weakly similar 17.9 to C43H8.1 [C.elegans]

135242M74093Hs.9700cyclin E1 17.9 123494AA599786Hs.112110ESTs 17.8 129168T90621Hs.109052chromosome 14 open 17.7 reading frame 2 128517AA2806i7Hs.100861ESTs; Weakly similar 17.6 to p60 katanin [H.sapien 75 130160239228Hs.151344UDP-Gal:betaGIcNAc 17.6 beta 1;3-galactosylfransfe 103448X99133Hs.204238tipocatin 2 (oncogene17.5 24p3) 119708W67810Hs.57904mago-nashi (Drosophila)17.5 homolog; proliferatio 122946AA477445Hs.105341ESTs 17.5 125819AA044840Hs.251871CTP synthase 17.5 131689AA599653Hs.30696franscripGon factor-like17.5 5 (basic helix-loop 115061AA253217Hs.41271ESTs 17.3 113702T97307Hs.161720ESTs; Moderately similar17.3 to !!!! ALU SUBFAMIL

115291AA279943Hs.122579ESTs 17.3 102567059863Hs.146847TRAF family member-associated17.2 NFKB activator 129229AA211941Hs.109643polyadenylate binding 17.2 protein-interacting pro 129351AA167268Hs.62349Human ras inhibitor 17.2 mRNA; 3' end 110769N22222 yw34bO6.s1 Morton Fetal17.1 Cochlea Homo Sapiens 113182T55234Hs.9676Human DNA sequence 17.0 from clone 30M3 on chromos 115892AA435946Hs.50831ESTs 17.0 123114AA486407Hs.105235ESTs; Moderately similar17.0 to KIAA0454 protein 123442AA598803Hs.111496ESTs 17.0 123339AA504253Hs.101515ESTs 16.9 123689AA609556Hs.256562ESTs 16.9 1 131941D62657Hs.35086ubiquitin-specific 16.8 ~ protease 1 120649AA287115Hs.99697ESTs 16.8 102139U15932Hs.2128dual specificity phosphatase16.8 115522AA331393Hs.47378ESTs 16.7 135243AA215333Hs.97101putative G protein-coupled16.6 receptor 15 131257AA25fi042Hs.2d908ESTs 16.5 109508AA233892Hs.55902ESTs; Weakly similar 16.3 to !!!! ALU SUBFAMILY
SX

132701AA279359Hs.55220BCL2-associated athanogene16.3 134449L3d155Hs.83450laminin; alpha 3 (nicein16.3 (150kD); kalinin (16 126180818070Hs.37i2ubiquinol-cytochrome 16.3 c reductase; Rieske iron 20 106124AA423987Hs.7567ESTs 16.2 115363AA282071Hs.152759ac8vatorofS phase kinase16.2 117588N34895Hs.446d8ESTs 16.1 131245AA620599Hs.24766DKFZP564E1962 protein 16.1 101674M61916Hs.82124laminin; beta 1 16.0 25 126819AA305536Hs.161d89ESTs 16.0 134039S78569Hs.78fi72laminin; alpha 4 16.0 130648AA075427Hs.17296ESTs; Weakly similar 15.9 to /prediction 102823U90914Hs.5057carboxypeptidase D 15.8 128470AA447504Hs.100261Homo Sapiens mRNA; 15.8 cDNA OKFZp5648222 (from c7 30 115844AA430124Hs.234607ESTs 15.7 132543AA417152Hs.5101protein regulator of 15.7 cytokinesis 1 130155L33404Hs.151254kallikrein 7 (chymotryptic;15.7 sfratum comeum) 101008J04162Hs.763Fc fragment of IgG; 15.7 low affinity Illa;
recept 120472AA251875Hs.104472ESTs; Weakly similar 15.6 to Gag-Poi polyprotein [

35 116844H64938Hs.38331ESTs 15.6 106753AA476944Hs.7331ESTs 15.6 114767AA148885Hs.1544d3minichromosome maintenance15.5 deficient (S. cere 114768AAt49007Hs.182339Ets homologous factor 15.5 127370A1024352Hs.70337immunoglobulin superfamily;15.5 member 4 101507M27492Hs.82112intedeukin 1 receptor,15.4 type I

102519U52969Hs.80296Purkinje cell protein 15.4 102610U65011Hs.30743preferen8ally expressed15.4 antigen in melanoma 1112d4N69556Hs.24724MFH-amplified sequences15.4 with leucine-rich tan 120404AA234921Hs.96427KIAA1013 protein 15.3 45 130455X17059Hs.155956N-acetylfransferase 15.2 1 (arylamine N-acetylfran 129519AA298786Hs.112242ESTs 15.1 106553AA454967Hs.5887ESTs; Highly similar 15.0 to RNA binding mofif pro 109502AA233837Hs.44755ESTs; Weakly similar 14.9 to membrane glycoprotein 115967AAdd6887Hs.42911ESTs 14.9 104636AA004415Hs.106106ESTs 14.9 134133X93920Hs.180383dual specificity phosphatase14.9 134444X04470Hs.251754secretory leukocyte 1d.8 protease inhibitor (anti) 132998Y00062Hs.170121protein tyrosine phosphatase;1d.8 receptor type;

131997D82399Hs.136644Homo Sapiens clone 14.6 23714 mRNA sequence 134056827358Hs.7886ESTs; Weakly similar 14.6 S to Pelle associated prot"

101249L33881Hs.1904protein kinase C; iota14.5 105298AA233459Hs.26369ESTs 14.5 107119AA620307Hs.27379ESTs 14.5 115839AA429038Hs.40541ESTs 14.5 122802AA460530Hs.256579ESTs 14.5 129896AA043021Hs.13225UDP-Gal:betaGIcNAc 14.3 beta 1;4-galactosyltransf 130269AA284694Hs.168352nucleoporin-like protein14.3 134374D62633Hs.8236ESTs 14.3 106370AA443841Hs.18676sprouty (Drosophila) 14.2 homolog 2 65 130919AA291710Hs.21276collagen; type 1V; 14.1 alpha 3 (Goodpasiure antig 132923U21858Hs.60679TATA box binding protein14.1 (TBP)-associated fac 107968AA034020Hs.61539ESTs 14.1 125390H95094Hs.75187franslocase of outer 14.1 mitochondria) membrane 107148AA621131Hs.5889ESTs; Weakly similar 14.1 to W01A11.2 gene product 110788N24730Hs.15420ESTs 14.0 109481AA233342H5.90fi80ESTs; Weakly similar 13.9 to WD40 protein Ciao 1 [

105646AA282147Hs.5888ESTs 13.9 106030AA412251Hs.12802development and differentiation13.8 enhancing fac 132618AA253330Hs.5344adaptor-related protein13.7 complex 1; gamma 1 su 75 133230S82240Hs.6838ras homolog gene family;13.7 member E

124803845480Hs.164866cyclin K 13.6 121381AA405747Hs.97865ESTs; Weakly similar 13.6 to WASP-family protein [

105200AA195399Hs.24641ESTs 13.5 105627AA281245Hs.23317ESTs 13.5 114986AA251010Hs.87807ESTs 13.5 118036N52844Hs.196008ESTs 13.5 134672N79749Hs.87627ESTs; Weakly similar 13.5 to cDNA EST EM8L:T005d2 110915N46252Hs.29724ESTs 13.3 - N51919Hs.47368ESTs 13.3 132550AA029597Hs.170195bone morphogenetic 13.3 protein 7 (osteogenic prot 124315H94892Hs.6906v-rat simian leukemia13.2 viral oncogene homolog 102547057911Hs.46638chromosome 11 open 13.2 reading frame 9 125134W19228Hs.100748ESTs 13.2 111806833468Hs.24651ESTs 13.1 106983AA521195Hs.10887similar to lysosome-associated13.0 membrane glyco 106498AA452141Hs.7171ESTs 13.0 110787N24716Hs.1224dESTs; Weakly similar 13.0 to C44B9.1 [C.elegans]

122860AA464414Hs.112159ESTs 13.0 131535AA504642Hs.28436ESTs; Weakly similar 13.0 to coded for by C.
elega 116188AA464728Hs.184598ESTs 13.0 107243D59489Hs.34727ESTs 12.9 129300C20976Hs.110165ESTs; Highly similar 12.9 to ribosomal protein 134487838185Hs.83954Homo Sapiens unknown 12.8 mRNA

1 102348037519Ns.87539aldehyde dehydrogenase12.8 131839H80622Hs.33010KIAA0633 protein 12.8 119620W47620Hs.560092'-5'oligoadenylate 12.8 synlhetase 3 120802AA343533Hs.128777ESTs; Weakly similar 12.7 to predicted using Genef 102250028014Hs.74122caspase 4; apoptosis-related12.7 cysteine proteas 105539AA258873Hs.25242ESTs 12.7 114965AA250737Hs.72472ESTs 12.7 118001N52151Hs.d7447ESTs , 12.7 100448D87469Hs.57652EGF-Like-domain; multiple12.6 130920D50975Hs.75525calreticulin ' 12.6 131075Y00757Hs.2265secretory granule; 12.6 neuroendocrine protein 1 ( 105496AA256323Hs.25264DKFZP434N126 protein 12.5 109235AA193592Hs.42300ESTs; Weakly similar 12.5 to !!!! ALU SUBFAMILY
SO

118215N62195Hs.779103-hydroxy-3-methylglutaryl-Coenzyme12.5 A synihas 134388M15841Hs.82575small nuclear ribonucleoprotein12.5 polypeptide 8 3 106897AA489790Hs.167496RAN binding protein 12.4 133050S67325Hs.63788propionyl Coenzyme 12.4 A carboxylase; beta polype 109683F09308Hs.27607ESTs 12.3 121d63AA411745Hs.239681ESTs; Weakly similar 12.3 to KIAA0554 protein [H.s 102876X03663Hs.174142colony stimulating 12.2 factor 1 receptor;
farmed 3 101804M86699Hs.169840TTK protein kinase 12.2 129017H13108Hs.107968ESTs 12.1 105812AA394126Hs.20814ESTs; Highly similar 12.1 to CGI-27 protein (H.sap 106459AA449741Hs.4029glioma-amplified sequence-4112.0 107059AA608545Hs.23044RAD51 (S. cerevisiae)12.0 homolog (E colt RecA
ho 4~ 107080AA609210Hs.19221ESTs 12.0 110799N26101Hs.7838Human ring zinc-finger12.0 protein (ZNF127-Xp) ge 112253851818Hs.104222Homo Sapiens mRNA; 12.0 cDNA DKFZp566L034 (from c1 116760H11054Hs.155342protein kinase C; 12.0 delta 120314AA194166Hs.221040KIAA1038 protein 12.0 45 123005AA479726Hs.105577ESTs 12.0 132572AA448297Hs.237825signal recognition 12.0 particle 72kD

110561H59617Hs.5199ESTs; Weakly similar 12.0 to UBIQUITIN-CONJUGATING

101923S75256 HNL=neuirophil lipocalin11.9 [human, ovarian cane 134992H05625Hs.92414ESTs 11.8 50 105516AA257971Hs.21214ESTs 11.8 105248AA226968Hs.22826ESTs 11.7 109130AA172040Hs.20161ESTs; Weakly similar 11.7 to IgE receptor beta sub 115955AA4d6121Hs.44198Homo Sapiens BAC clone11.7 RG054D04 from 7q31 116135AA460314Hs.94179ESTs 11.7 5 116284AA487252Hs.237809ESTs; Weakly similar 11.7 S to hypothetical protein 132384AA479933Hs.46967Human DNA sequence 11.7 from clone 167A19 on chrom 134753Y09216Hs.173135dual-specificity tyrosine-(Y)-phosphorylation11.7 125136W31479Hs.129051ESTs 11.7 133928N34096Hs.7766ubiquitin-conjugating11.6 enzyme E2E 1 (homologou 117395N26330Hs.93701ESTs 11.5 127007AA299360 ESTi 1857 Uterus tumor11.5 I Homo Sapiens cDNA
5' 130567L07493Hs.1608replication protein 11.5 A3 (l4kD) 135073AA452000Hs.94030Homo Sapiens mRNA; 11.5 cDNA DKFZp586E1624 (from c 115140AA258030Hs.55356ESTs; Weakly similar 11.4 to supported by GENSCAN

65 115536AA347193Hs.62180ESTs 11.4 133240D31161Hs.68613ESTs 11.3 106521AA453431Hs.14732malic enzyme 1; NADP(+)-dependent;11.3 cytosolic 107674AA011027Hs.41143KIAA0581 protein 11.3 114149238814Hs.27196ESTs 11.3 132478H20906Hs.49500KIAA0746 protein 11.2 104252AF0022d6Hs.210863cell adhesion molecule11.2 with homology 1o 102436046499Hs.790microsomal glutathione11.2 S-transferase 1 106726AA465339Hs.7141ESTs 11.2 100116D00654Hs.77443actin; gamma 2; smooth11.2 muscle; enteric 75 110970N51374Hs.96870Homo Sapiens mRNA 11.2 full length insert cDNA clo 130417058522Hs.155485huntingtin-interacting11.2 protein 2 132906AA1d2857Hs.234896ESTs; Highly similar 11.2 to geminin [H.sapiens]

107853AA024427Hs.59d61DKFZP434C245 protein 11.2 103467Y00451Hs.78712aminolevulinate; delta-;11.1 synthase 1 100438D87448Hs.91417topoisomerase (DNA) 11.1 II binding protein 102654068494Hs.24385Human hbc647 mRNA 11.1 sequence 103172X68742Hs.116774integrin; alpha 1 11.1 106856AA486183Hs.15839ESTs; Weakly similar 11.1 to similar 1o oxysterol-.

108255AA063157Hs.172608ESTs 11.1 124308H93575Hs.227146Homo Sapiens mRNA; 11.1 cDNA DKFZp564J142 (from c1 129057X62466Hs.214742CDW52 antigen (CAMPATH-111.1 antigen) 128845AA455658Hs.10649basement membrane-induced11.1 gene 129025AA420992Hs.103441ESTs; Weakly similar 11.0 to tesficular tekfin 107638AA009528Hs.42743ESTs; Weakly similar 11.0 to predicted using Genef 134480AA024664Hs.83916NADH dehydrogenase 11.0 (ubiquinone) 1 alpha subco 115262AA279112Hs.88594ESTs 11.0 102580060808Hs.152981CDP-diacylglycerol 10.9 synthase (phosphatidate cy 106614AA458934Hs.179912ESTs 10.9 107115AA610108Hs.27693ESTs; Highly similar 10.9 to CGI-124 protein [H.sa 115764AA421562Hs.91011anterior gradient 2 10.9 (Xenepus laevis) homolog 121770AA421714Hs.11469KIAA0896 protein 10.9 132191AA449431Hs.158688KIAA0741 gene product 10.9 133214Y10659Hs.250911interleukin 13 receptor;10.9 alpha 1 1 133914N32811Hs.77542ESTs 10.8 ~

101973S82597Hs.80120UDP-N-acetyl-alpha-D-galactosamine:polypeptid10.8 102669071207Hs.29279eyes absent (Drosophila)10.8 homolog 2 104147AA451992Hs.226799ESTs; Highly similar 10.8 to HSPC039 protein [H.sa 106474AA450212Hs.42484Homo Sapiens mRNA; 10.8 cDNA DKFZp564C053 (from c1 115881AA435577Hs.184942G protein-coupled receptor10.8 129950M31516Hs.1369decay accelerafingfactorforcomplement(CD510.8 132783N74897Hs.5683DEADIH (Asp-Glu-Ala-AspIHis)10.8 box polypepttde 133784AA214305Hs.76173ESTs 10.8 134248AA292677Hs.80624ESTs 10.8 25 105565AA278302Hs.18349ESTs; Weakly imilar 10.8 to partial CDS [C.elegan 127999AA837495Hs.69851ESTs; Weakly similar 10.8 to Wiskott-Aldrich syndr 108040AA041551Hs.48644ESTs 10.7 130367238501Hs.8768ESTs; Weakly similar 10.7 to !!!! ALU SUBFAMILY
SO

108539AA084677Hs.54558ESTs; Weakly similar 10.7 to protein B [H.sapiens]

3 111345N89820Hs.14559ESTs 10.7 115583AA398913Hs.45231LDOCt protein 10.7 128965T17440Hs.107418ESTs 10.7 101396M15796Hs.78996proliferating cell 10.6 nuclear anfigen 132164084573Hs.41270proccllagen-lysine; 10.6 2-oxoglutarate 5-dioxygen 35 101275L37936Hs.3273Ts franslafion elongation10.6 factor; mitochondri 104660AA007160Hs.14846Homo Sapiens mRNA; 10.6 cDNA DKFZp564D016 (from c1 108609AA100694Hs.69499Human DNA sequence 10.6 from BAC 15E1 on chromosom 112041843300Hs.22929ESTs 10.6 114208239301Hs.7859ESTs 10.6 118537N67974Hs.75431fibrinogen; gamma polypeptide10.6 106919AA490885Hs.21766ESTs 10.6 115984AA447687Hs.91109ESTs 10.6 105538AA258860Hs.32597ring finger protein 10.6 (C3H2C3 type) 6 102200021551Hs.157205branched chain aminofransferase10.5 1; cytosolic 45 116710F10577Hs.70312ESTs 10.5 119780W72967Hs.191381ESTs; Weakly similar 10.5 to hypothetical protein 112996T23539Hs.7165zinc finger protein 10.5 103029X54489Hs.789GR01 oncogene (melanoma10.5 growth stimulating ac 101255L34600Hs.149894mitochondrial iranslational10.4 inifiafion factor 107032AA599472Hs.247309succinate-CoA ligase; 10.4 GDP-forming; beta subun 125617AI287461Hs.164950ESTs 10.4 131475239053Hs.27263ESTs 10.4 132073N67408Hs.38516ESTs 10.4 101469M22877Hs.169248Human somafic cytochrome10.3 c (HCS) gene; comple 102437046569Hs.221986aquapodn 5 10.3 104301D45332Hs.6783ESTs 10.3 127236AI341818Hs.98658budding uninhibited 10.3 by benzimidazoles 1 (yeas 101465M226t2Hs.241395protease; serine; t 10.3 (trypsin 1) 113805W42957Hs.250617ESTs 10.2 133536Y00264Hs.177486amyloid beta (A4) precursor10.2 protein (protease 109799F10770Hs.180378Homo Sapiens clone 10.2 669 unknown mRNA;
complete 113523T90037Hs.16686ESTs 10.2 116195AA465148Hs.72402ESTs 10.2 134542X57025Hs.85112insulin-like growth 10.2 factor 1 (somatomedin C) 65 125298239255Hs.235350YD019 protein 10.2 119367T78324Hs.90905ESTs 10.2 134470X54942Hs.83758CDC28 protein kinase 10.2 134288AA430008Hs.8117ESTs 10.1 105127AA158132Hs.11817ESTs; Weakly similar 10.1 to contains similarity t 110627H70485Hs.35225ESTs; Weakly similar 10.1 to MBNL protein [H.sapie 115188AA261819Hs.88367ESTs 10.1 132632N59764Hs.5398guanine-monophosphate 10.1 synthetase 124049F10523Hs.74519primase; polypepfide 10.1 2A (58kD) 100079AB002365Hs.23311KIAA0367 protein 10.0 75 113987W87494Hs.9641ESTs; Moderately similar10.0 to COMPLEMENT C10 SU

117280N22107Hs.i72241ESTs 10.0 TABLE 9B:
Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession 101332 25130-1 J04088 NM 001067 AF071747 AJ011741 N85424 AL042d07 AI970337 AA737616 AI827d44 AW003286 AI742333 AI344044 AA7d6288 AA568223 BE090591 H93033 N57027 AA504348 1 ~ AA583483 AW873194 AW575166 AI128799 AI803319 AL042776 AW090687 AA236763 AAd35535 AA236910 AA047124 AA236734 AI686720 AI587374 AA936731 AA702d53 AI859757 AA216786 AA66897d AI688160 BE045915 AW466315 AA731314 AA649568 100824 5_36 A1393237 AI521317 AI761348 AF025841 D43968 AW994987 X90976 AW139668 AW674280 AI365552 AA877d52 AV657554 101714 30725_1 M68874 AL022147 M72393 AL049797 BE439441 T27650 AI766240 AW150345 AW7789d3 AI627464 BE439479 AA587049 AI277900 101809 32963-1 M868d9 AA31528Q NM 004004 AA3i5269 BE142653 AA461d00 d AW26d544 A1018136 AW021810 AA961504 AW086214 AW771d89 AA461087 AI341438 AI970613 AIOd0737 AI418d00 AA947181 AA962716 AI280695 AW769275 AW023591 AI160977 AA055d00 101923 30543_1 X99133 X83006 W38398 AA401137 AA298242 AA366738 AA308126 AW517424 AI939989 AA076188 BE182636 AA169569 AA167d39 AA400973 AA514773 AA514789 AA164458 AA167440 AA07d845 AA515574 AW352267 AI797418 AA772395 AI74919d AI559933 127007 19921_1 AB037771 BE005079 AA394189 AW959650 AA299360 AA398081 110769 229824_1BE000831 AA541787 AW173038 AA327931 AW117510 AW664665 A1066624 AI478955 AI863075 A1073744 AA490170 Rd6651 120695 9683_3 AA976503 AI917802 AA953664 AA404613 AA4287718E280542 AW194691 AI927301 AI7d0458 AI796100 AI935603 AW052210 O

Table 10A lists about 733 genes up-regulated in ovarian cancer compared to normal adult fissues. These were selected from 59680 probesets on the AffymetrixlEos-Hb03 GeneChip array such that the rafio of "average" ovarian cancer to 'average"
normal adult fissues was greater than or equal 1o 3Ø The "average" ovarian cancer level was set to the about the 80th percenfile amongst various ovarian cancers. The 'average"
normal adult tissue level was set to the 90th percentile value amongst various non-malignant 5 5 tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15th percenfile value amongst the non-malignant tissues was subtracted from both the numerator and the denominator before the rafio was evaluated.
TABLE 10A:
ABOUT

GENES, OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES

Pkey: Primekey Ex.Accn:
ExempIarAccession UG ID:
UniGene ID

Title:
UniGene title ratio:
ratio tumor vs normal tissues 65 Pkey Ex. UG Tifie ratio Accn ID

432938 Hs.3132steroidogenic acute 56.1 T27013 regulatory protein 418179 Hs.11d5Wilms tumor 1 33.5 400292 Hs.72472BMPR-Ib; bone morphogenetic30.0 AA250737 protein receptor 452838 Hs.30743Preferenfially expressed29.5 U65011 antigen in melanoma 415511 Hs.182362ESTs 28.1 422956 Hs.122579ESTs 28.1 410929 Hs.30643ESTs 27.4 400289 Hs.2258Matrix Metalloproteinase25.2 X07820 10 (Stromolysin 2) 449034 Hs.277523gbas41a09.x1 NCI CGAP 23.7 AI624049 Ut1 Homo sapiens cDNA

75 427585 Hs.179729collagen; type X; alpha22.7 D31152 1 (Schmid metaphyseal 428392 Hs.2265secretary granule, 21.9 Hf0233 neuroendocrine protein 448243 Hs.77496ESTs 21.3 430691 Hs.103538ESTs 21.2 444783 Hs.62180ESTs 20.8 407638 Hs.288693EST 20.1 423739 Hs.97600ESTs 19.7 436982 Hs.5378spondin 1, (f spondin)19.0 A8018305 extracellular maUix p 451110 Hs.301584ESTs 18.8 426427 Hs.1698d0. TTK protein kinase 18.7 428227AA321649Hs.2248INTERFERON-GAMMA INDUCED18.3 419854AW664873Hs.87836Homo Sapiens PAC clone 18.3 RP5-1087M19 from 7q11.

439706AW872527Hs.59761ESTs 18.3 428579NM Hs.184942G protein-coupled receptor17.4 410247AF181721Hs.61345RU2S 17.0 428153AW513143Hs.98367hypothetical protein 16.9 FLJ22252 similar to SRY-415076NM_000857Hs.77890guanylate cyclase 1, 16.6 soluble, beta 3 416209AA236776Hs.79078MAD2 (mitotic arrest 16.6 deficient, yeast, homolo 424905NM Hs.153704NIMA (never in mitosis 16.2 002497 gene a)-related kinase 1 423685BE350494Hs.49753Homo sapiens mRNA far 15.9 ~ KIAA1561 protein, parti 428187A1687303Hs.285529ESTs 15.9 438817A1023799Hs.i63242ESTs 15.9 424906A1566086Hs.153716Homo Sapiens mRNA for 15.9 Hmob33 protein, 3' untr 407721Y12735Hs.38018dual-specificity tyrosine-(Y)-phosphorylatlon15.7 15 412723AA648459Hs.179912ESTs 15.3 424717H03754Hs.i wingless-type MMTV integrafion15.2 52213site family, m 443646A1085198Hs.298699ESTs 15.1 424345AK001380Hs.i45479Homo Sapiens cDNA FLJ1051814.8 fis, clone NT2RP20 428976AL037824Hs.194695ras homolog gene family,14.6 member I

418738AW388633Hs.6682solute carrier family 14.3 7, member 11 428479Y00272Hs.184572cell division cycle 14.2 2, Gi to S and G2 to M

436209AW850417Hs.254020ESTs, Moderately similar14.1 to unnamed protein p 427356AW023482Hs.97849ESTs 13.9 418601AA279490Hs.86368calmegin 13.8 25 416661AA634543Hs.79440IGF-II mRN9-binding 13.7 protein 3 428532AF157326Hs.184786TBP-interacting protein13.6 402408 0 13.6 447350A1375572Hs.172634ESTs; HER4(c-erb-84) 13.4 451807W52854Hs.27099DKFZP564J0863 protein 13.4 423575C18863Hs.163443ESTs 13.2 443211A1128388Hs.143655ESTs 13.2 d37872AK002015Hs.5887RNA binding motif protein13.0 451659BE379761Hs.14248ESTs, Weakly similar 12.7 to ALU8 HUMAN ALU SUBFAM

452904AL157581Hs.30957Homo Sapiens mRNA; cDNA12.7 DKFZp434E0626 (from c 3 442655AW027457Hs.30323ESTs 12.5 S

452096BE394901Hs.226785ESTs 12.4 414972BE263782Hs.77695KIAA0008 gene product 12.3 d35039AW043921Hs.130526ESTs 12.3 447033A1357412Hs.157601EST-notin UniGene 12.3 433764AW753676Hs.39982ESTs 12.2 442611BE077155Hs.177537ESTs 12.0 408562A1436323Hs.31141Homo sapiens mRNA for 11.9 KIAA1568 protein, parti 427344NM Hs.21425-hydroxytryptamine 11.8 000869 (serotonin) receptor 421478AI683243Hs.97258ESTs 11.8 45 426635BE395109Hs.129327ESTs 11.8 415989A1267700Hs.t11128ESTs 11.7 433159AB035898Hs.150587kinesin-like protein 11.5 452249BE394412Hs.61252ESTs 11.4 418506AA084248Hs.85339G proteincoupled receptor11.3 442353BE379594Hs.49136ESTs 11.3 447700A1420183Hs.171077ESTs, Weakly similar 11.3 to similar to serinelthr 450480X82125Hs.25040zinc finger protein 11.3 425176AW015644Hs.301430ESTs, Moderately similar11.2 to TEF1 HUMAN TRANSC

435496AW840171Hs.265398ESTs, Weakly similar 11.2 to Uansformafion-relate SS 433133AB027249Hs.104741PDZ-binding kinase; 11.1 T-cell originated protein 445258AI635931Hs.147613ESTs 11.1 432677NM Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polypeptid11.0 429782NM_005754Hs.220689Ras-GTPase-activating 10.9 protein SH3-domain-bind 404567 0 10.8 423811AW299598Hs.50895homeo box C4 10.7 452891N75582Hs.212875ESTs, Weakly similar 10.6 to KIAA0357 [H.sapiens]

441627AA947552Hs.58086ESTs 10.3 443555N71710Hs.21398ESTs, Moderately similar10.3 to GNPI_HUMAN GLUCOS

412140AA219691Hs.73625RAB6 interacting, kinesin-like10.2 (rabkinesin6) 6S 427469AA403084Hs.269347ESTs 10.1 415227AW821113Hs.72402ESTs 10.1 445413AA151342Hs.12677CGI-147 protein 10.0 425734AF056209Hs.159396peptidylglycine alpha-amidafing10.0 monooxygenase 421451AA291377Hs.50831ESTs 10.0 410044BE566742Hs.58169highly expressed in 9.8 cancer, rich in leucine h d27878005766Hs.181022CGI-07 protein 9.7 d08460AA054726Hs.285574ESTs 9.7 422972N59319Hs.145404ESTs 9.7 443715AI583187Hs.9700cyclin E1 9.7 75 440901AA909358Hs.128612ESTs 9.6 453160AI263307Hs.146228ESTs 9.6 415211R64730.compHs.155986ESTs; Highly similar 9.5 to SPERM SURFACE PROTEIN

425282AW163518Hs.155485hunfingtin interacting 9.5 protein 2 400250 0 9.5 410568AW162948Hs.64542pre-mRNA cleavage factor9.3 Im (68kD) 442957AI949952Hs.49397ESTs 9.3 453922AF053306Hs.36708budding uninhibited 9.3 by benzimidazoles 1 (yeas 434401AI864131Hs.71119Pulafive prostate cancer9.2 tumor suppressor 453628AW243307Hs.170187. ESTs 9.1 452055AI377431Hs.293772ESTs 9.1 424086A1351010Hs.102267lysyl oxidase 9.1 442875BE623003Hs.23625Homo sapiens clone 9.1 TCCCTA00142 mRNA sequence 416208AW291168Hs.41295ESTs 9.0 407168845175Hs.117183gb:yg40tO1.slSoaresinfantbrainiNIBHomos9.0 445537AJ245671Hs.12844EGF-like-domain; mulfiple8.9 409269AA576953Hs.22972Homo Sapiens cDNA FLJ133528.9 fis, clone OVARC10 433527AW235613Hs.133020ESTs 8.9 409928AL137163Hs.57549hypothetical protein 8.8 dJ47384 1 423020AA383092Hs.1608replication protein 8.7 ~ A3 (l4kD) 425665AK001050Hs.159066ESTs 8.6 443204AW205878Hs.29643Homo Sapiens cDNA FLJ131038.6 fis, clone NT2RP30 449433AL672096Hs.9012ESTs 8.6 453878AW964440Hs.19025ESTs 8.6 15 450505NM-004572Hs.25051plakophilin 2 8.6 407001U12471Hs.247954Human thrombospondin-18.5 gene, partial cds 414315224878 gb:HSB65D052 STRATAGENE8.5 Human skeletal muscle 425492AL021918Hs.158i74zinc finger protein 8.5 184 (Kroppel-like) 435181AA669339Hs.28838KIAA1571 protein 8.5 436396AI683487Hs.299112Homo Sapiens cDNA FLJ11d418.5 fis, clone HEMBA10 418384AW149266Hs.25130ESTs 8.4 453370AI470523Hs.182356ESTs, Moderately similar8.4 to translation iniG

409041A8033025Hs.50081KIAA1199 protein 6.4 447078AW885727Hs.301570ESTs ' 8.4 448674W31178Hs.15d140ESTs _s 8.3 433393AF038564Hs.98074atrophin-1 interacting8.3 protein 4 433496AF064254Hs.49765VERY-LONG-CHAIN ACYL-COA8.3 SYNTHETASE

421155H87879Hs.102267lysyl oxidase 8.2 438394BE379623Hs.27693CGI-124 protein 8.2 400298AA032279Hs.61635STEAP1 8.1 409092A1735283Hs.172608ESTs 8.1 440250AA876179Hs.134650ESTs 8.1 409143AW025980Hs.138965ESTs 8.1 407771AL138272Hs.62713ESTs 8.1 35 419088AI538323Hs.77496ESTs 8.1 431725X65724Hs.2839Norrie disease (pseudoglioma)7.9 431750AA514986Hs.283705ESTs 7.9 435635AF220050Hs.181385uncharacterized hematopoiefic7.9 stemiprogenitor 441826AW503603Hs.129915phosphotriesterase 7.9 related 417728AW138437Hs.24790KIAA1573 protein 7.8 418845AA852985Hs.89232chromobox homolog 5 7.8 (Drosophila HPi alpha) 421039NM_003478Hs.101299cullin 5 7.8 446999AA151520Hs.279525hypothetical protein 7.8 429609AF002246Hs.210863cell adhesion molecule7.8 with homology to L1 CAM

45 415139AW975942Hs.48524ESTs 7.7 450192AA263143Hs.24596RAD51-interacting protein7.7 423992AW898292Hs.137206Homo Sapiens mRNA; 7.7 cDNA DKFZp564N1663 (from c 436211AK001581Hs.80961polymerase (DNA directed),7.7 gamma 450101AV649989Hs.24385Human hbc647 mRNA sequence7.5 426921AA037145Hs.172865cleavage stimulafion 7.5 0 factor, 3' pre-RNA, subu 433330AW207084Hs.132816ESTs 7.5 439759AL359055Hs.67709Homo Sapiens mRNA full7.5 length insert cDNA
clo 427660A1741320Hs.114121Homo sapiens cDNA: 7.5 FLJ23228 fis, clone 422095AI868872Hs.288966ceruloplasmin (feroxidase)7.5 55 436476AA326108Hs.53631ESTs 7.5 412170D16532Ns.73729very low density lipoprotein7.4 receptor 428954AF100781Hs.194678WNT1 inducible signaling7.4 pathway protein 3 450221AA328102Hs.24641cytoskeleton associated7.4 protein 2 439262AA832333Hs.124399ESTs 7.4 435420A1928513Hs.59203ESTs 7.3 422892AA988176Hs.121553hypotheficalprotein 7.3 457030A1301740Hs.173381dihydropyrimidinase-like7.3 411571AA122393Hs.70811hypotheficalprotein 7.2 409916BE313625Hs.57435solute carcierfamily 7.2 11 (proton-coupled diva 65 418007M13509Hs.83169Matrix metalloprotease7.2 1 (intersfitial collag 420900AL045633Hs.44269ESTs 7.2 424001W67883Hs.137476KIAA1051 protein 7.2 400301X03635Hs.1657Estrogenreceptort 7.1 400238 0 7.1 70 413573AI733859Hs.149089ESTs 7.1 428071AF212848Hs.182339transcription factor 7.1 447164AF026941Hs.17518Homo Sapiens cig5 mRNA,7.1 partial sequence 453062AW207538Hs.61603ESTs 7.1 456965AW131888Hs.172792ESTs, Weakly similar 7.1 to hypothetical protein 442500AI819068Hs.209122ESTs 7.1 -046142AI754693Hs.145968ESTs 7.0 417791AW965339Hs.111471ESTs 7.0 418524AA300576Hs.85769acidic 82 kDa protein 7.0 mRNA

451797AW663858Hs.56120ESTs 7.0 8~ 452909NM Hs.30985pannexin 1 7.0 453616NM Hs.33846dynein, axonemal, light7.0 003462 intermediate polypept 436281AW411194Hs.120051ESTs 7.0 449897AW819642Hs.24135transmembrane protein 6.9 vezafin; hypothetical p 414142AW368397Hs.150042. ESTs 6.9 448776BE302464Hs.30057fransporter similar 6.9 to yeast MRS2 419423D26488Hs.90315KIAA0007 protein 6.9 420908AL049974Hs.100261Homo Sapiens mRNA; 6.8 cDNA DKFZp564B222 (from c1 452971AI873878Hs.91789ESTs 6.8 413597AW302885Hs.117183ESTs 6.8 415138C18356Hs.78045fissue factor pathway 6.8 inhibitor 2 TFPI2 437478AL390172Hs.118811ESTs 6.7 425292NM Hs.15554537 kDa leucine-rich 6.7 005824 repeat (L88) protein 421184NM-003616Hs.102456survival of motor neuron6.7 protein interacfing 1 410227AB009284Hs.61152exostoses (multiple)-like6.6 ~ 2 446608N75217Hs.257846ESTs 6.6 438167828363Hs.24286ESTs 6.6 445459A1478629Hs.158465ESTs 6.6 452291AF015592Hs.28853CDC7 (cell division 6.6 cycle 7, 5. cerevisiae, h 15 410011AB020641Hs.57856PFTAIRE protein kinase6.6 410292AA843087Hs.124194ESTs 6.5 415716N59294Hs.301141Homo Sapiens cDNA FLJ116896.5 fis, clone HEMBA10 424770AA425562 gb:zw46e05.r1 Soares 6.5 total-fetus_Nb2HF8-9w Ho 438122AI620270Hs.129837ESTs 6.5 439820AL360204Hs.283853HomosapiensmRNAfuIIlengthinsertcDNAclo6.5 444743AA045648Hs.11817nudix (nucleoside diphosphate6.5 linked moiety X

450638AK001826Hs.25245hypothetical protein 6.5 418203X54942Hs.83758CDC28 protein kinase 6.5 439901N73885Hs.124169ESTs 6.5 428758AA433988Hs.98502Homo Sapiens cDNA FLJ 6.4 14303 fis, clone PLACE20 404552 0 6.4 404599 0 6.4 419503AA243642Hs.137422ESTs 6.4 420149AA255920Hs.88095ESTs 6.4 440411N30256Hs.156971ESTs, Weakly similar 6.4 to Weak similarity with 449108AI1406B3Hs.98328ESTs 6.4 452097AB002364Hs.27916ADAM-TS3 ; a disintegrin-like6.4 and metallopr 453619H87648Hs.33922H.sapiens novel gene 6.4 from PAC 117P20, chromos 410273BE326877Hs.281523ESTs 6.3 35 434486AA678816Hs.117142ESTs 6.3 454036AA374756Hs.93560ESTs, Weakly similar 6.3 to unnamed protein produ 403381 0 6.2 421308AA687322Hs.192843ESTs 6.2 419346A1830417 gb:wh94d12.x1 NCI CGAP_CLL16.2 Homo Sapiens cDNA

446140AA356170Hs.26750Homo sapiens cDNA: 6.2 FLJ21908 fis, clone 453047AW023798Hs.286025ESTs 6.2 442573H93366Hs.7567Branched chain aminotransferase6.1 1, cytosolic, d10102AW248508Hs.279727ESTs; 6.1 410004AI298027Hs.299115ESTs 6.1 45 413335A1613318Hs.48442ESTs 6.1 424945AI221919Hs.173438hypotheficalprotein 6.1 427510247542Hs.179312small nuclear RNA acfivafing6.1 complex, polypep 451229AW967707Hs.48473ESTs 6.1 452641AW952893Hs.237825signal recognifion 6.1 particle 72kD

433172A8037841Hs.102652hypothetical protein 6.1 425465L18964Hs.1904protein kinase C; iota6.1 437117AL049256Hs.122593ESTs 6.0 423440825234Hs.i43434contacfin 1 6.0 430510AW162916Hs.241576hypothetical protein 6.0 55 433252A8040957Hs.151343KIAAi524pratein 6.0 434699AA643687Hs.149425Homo Sapiens cDNA FLJ119806.0 fis, clone HEMBB10 436954AA740151Hs.130425ESTs 5.9 436032AA150797Hs.109276latexin protein 5.9 424590AW966399Hs.46821hypothetical protein 5.9 444078BE246919Hs.10290U5 snRNP-specific 40 5.9 kDa protein (hPrpB-bindi 418379AA218940Hs.137516fidgefin-like 1 5.9 438081H49546Hs.298964ESTs 5.8 443270NM Hs.9192Homer, neuronal immediate5.8 004272 early gene,18 450459AI697193Hs.299254ESTs 5.8 65 433612AF078164Hs.61188Homo Sapiens Ku70-binding5.8 protein (KUB3) mRNA

449048245051Hs.22920similar to S68401 (cattle)5.8 glucose induced ge 417251AW015242Hs.99488ESTs; Weakly similar 5.7 to ORF YKR074w [S.cerevi 429181AW979104Hs.294009ESTs 5.7 454933BE141714 gb:OVO-HT0101-061099-032-c045.7 HT0101 Homo sapi 70 456553AA721325Hs.189058ESTs, Weakly similar 5.7 to cAMP-regulated guanin 430371D87466Hs.240112KIAA0276 protein 5.7 425371D49441Hs.155981mesothelin 5.7 424513BE385864Hs.149894mitochondrial franslational5.6 inifiafion factor 432015AL157504Hs.159115ESTs 5.6 75 438109A1076621Hs.71367ESTs, Moderately similar5.6 to ALU7-HUMAN ALU
SU

407137197307Hs.199067v-erb-b2 avian erythroblastic5.6 leukemia viral 407945X69208Hs.606ATPase, Cu++Uansporfing,5.6 alpha polypeptide 416565AW000960Hs.44970ESTs 5.6 417830AW504786Hs.132808epithelial cell fransforming5.5 sequence 2 oncog 419752AA249573Hs.152618ESTs 5.5 ~

422093AF151852Hs.111449CGI-94 protein 5.5 424583AF017445Hs.150926fucose-1-phosphate 5.5 guanylylUansferase 430388AA356923Hs.240770nuclear cap binding 5.5 protein subunit 2, 20kD

452534AW083022Hs.149425. Homo Sapiens cDNA 5.5 FL,l11980 fis, clone 453279AW893940Hs.59698ESTs 5.5 424188AW954552Hs.142634zinc finger protein 5.5 453884AA355925Hs.36232KIAA0186 gene product 5.5 424641AB001106Hs.151413glia maturation factor,5.5 beta 444478W07318Hs.240M-phase phosphoprotein5.5 427975AI536065Hs.122460ESTs 5.5 424620AA101043Hs.151254kallikrein 7 (chymotryptic;5.5 sfratum comeum) 442914AW188551Hs.99519Homo sapiens cDNA FLJ140075.5 tis, clone Y79AA10 417995AW974175Hs.188751ESTs 5.4 1 418946AI798841Hs.132103ESTs 5.4 419963AA743276Hs.301052ESTs 5.4 420362U79734Hs.97206huntingtin interacting5.4 protein 1 422670AA371612Hs.115351ESTs 5.4 432837AA310693Hs.279512HSPC072 protein 5.4 15 447020T27308Hs.16986hypothetical protein 5.4 458027L49054Hs.85195ESTs, Highly similar 5.4 to t(3;5)(q25.1;p34) fus 425217AU076696Hs.155174CDCS (cell division 5.4 cycle 5, S. pombe, homolo 422938NM Hs.1594cenfromere protein 5.4 001809 A (l7kD) 450434AA166950Hs.i ESTs, Weakly similar 5.4 8645 to partial GDS [C.elegan 20 438279AA805166Hs.165165ESTs, Moderately similar5.4 to ALUB-HUMAN ALU

413384NM_000401Hs.75334exostoses (multiple) 5.3 420328Y19062Hs.96870staufen (Drosophila, 5.3 RNA-binding protein) hom 436586A1308862Hs.167028ESTs 5.3 435793AB037734Hs.4993ESTs ' 5.3 422306BE044325Hs.227280Homo Sapiens mRNA for 5.3 Lsm5 protein 425154NM Hs.154850collagen, type IX, 5.2 001851 alpha 1 453293AA382267Hs.10653ESTs 5.2 429944813949Hs.226440Homo Sapiens clone 5.2 24881 mRNA sequence 434891AA814309Hs.123583ESTs 5.2 30 415263AP,948033Hs.130853ESTs 5.2 409506NM-006153Hs.54589NCK adaptor protein 5.2 412848AA121514Hs.70832ESTs 5.2 421246AW582962Hs.300961ESTs, Highly similar 5.2 to AF1518051 CGI-47 pro 431548AI834273Hs.9711Homo Sapiens cDNA FLJ 5.2 13018 fis, clone NT2RP30 35 412719AW016610Hs.129911ESTs 5.2 411945AL033527Hs.92137v-myc avian myelocytomatosis5.1 viral oncogene h 424078AB006625Hs.139033paternally expressed 5.1 gene 3 433558AA833757Hs.201769ESTs 5.1 434265AA846811Hs.130554Homo Sapiens cDNA: 5.1 FLJ23089 fis, clone 40 453911AW503857Hs.4007Sarcolemmal-associated5.1 protein 415539AI733881Hs.72472BMPR-Ib; bone morphogenetic5.1 protein receptor 442717888362Hs.180591ESTs, Weakly similar 5.1 to R06F6.5b [C.elegans]

432358A1093491Hs.72830ESTs 5.0 409731AA125985Hs.56145thymosin, beta, identified5.0 in neuroblastoma c 45 419699AA248998Hs.31246ESTs 5.0 420313AB023230Hs.96427KIAA1013 protein 5.0 422505AL120862Hs.124165ESTs; (HSA)PAP protein5.0 (programmed cell deat 425733F13287Hs.159388Homo Sapiens clone 5.0 23578 mRNA sequence 434160BE551196Hs.114275ESTs 5.0 50 435094A1560129Hs.277523EST 5.0 436612AW298067 gb:Ul-H-BWO-ajp-g-09-0-ULs15.0 NCI-CGAP-Sub6 Ho 432415T16971Hs.289014ESTs 4.9 406117 0 4.9 438018AK001160Hs.5999hypothetical protein 4.9 447505AL049266Hs.18724Homo Sapiens mRNA; 4.9 S cDNA DKFZp564F093 (from c1 448621A1097144Hs.5250ESTs, Weakly similar 4.9 to BACR37P7.g (D.melanog 453001AW131636Hs.191260ESTs 4.9 410561BE540255Hs.6994Homo sapiens cDNA: 4.9 FW22044 fis, clone 418811AK001407Hs.88663hypothetical protein 4.9 60 436754A1061288Hs.133437ESTs, Moderately similar4.8 to gonadofropin indu d37212AI765021Hs.210775ESTs 4.8 447312AI434345Hs.36908activating Uanscription4.8 factor 1 409732NM-016122Hs.56148NY-REN-58 antigen 4.8 434690AI867679Hs.148410ESTs 4.8 65 444172BE147740Hs.104558ESTs 4.8 424539L02911Hs.150402activin A receptor, 4.8 type I

418677583308Hs.87224SRY (sex determining 4.8 region Y)-box 5 406076AL390179Hs.137011Homo Sapiens mRNA; 4.8 cDNA DKFZp547P134 (from c1 420179N74530Hs.21168ESTs 4.7 70 450375AA009647Hs.8850a disintegrin and metalloproteinase4.7 domain 12 419247S65791Hs.89764fragile X mental retardation4.7 420850BE139590Hs.122406ESTs 4.7 425420BE536911Hs.234545ESTs 4.7 428664AK001666Hs.189095similar to SALL1 (sat 4.7 (Drosophila)-like 75 419131AA406293Hs.301622ESTs 4.7 422278AF072873Hs.114218ESTs 4.7 d51684AF216751Hs.26813CDA14 4.6 400296AA305627Hs.139336ATP-binding cassette; 4.6 sub-family C (CFTRIMRP) 408425AW058674Hs.44787Homo Sapiens mRNA; 4.6 cDNA DKFZp43400227 (from c 417168AL133117Hs.81376Homo Sapiens mRNA; 4.6 cDNA DKFZp586L1121 (from c 429486AF155827Hs.203963hypothetical protein 4.6 442917AA314907Hs.85950ESTs 4.6 443268A1800271Hs.129445hypotheticalprotein 4.6 452795AW392555Hs.18878hypothetical protein 4.6 457300AW297436Hs.158849Homo Sapiens cDNA: FLJ216634.6 its, clone COL088 d59551AI472808 gbaj70e07.x1 Soares 4.6 NSF_F8-9W-OT-PA_P_S1 Ham 421977W94197Hs.110165ribosomal protein L26 4.6 homolog 429441AJ224172Hs.204096lipophilin B (uteroglobin4.6 family member), pro 449722BE280074Hs.23960cyclin 81 4.6 431689AA305688Hs.267695UDP-Gal:betaGIcNAc beta4.5 1,3-galactosyltransfe 425178H16097Hs.161027ESTs 4.5 429597NM Hs.2442a disintegrtn and metalloproteinase4.5 003816 domain 9 436556AI364997Hs.7572ESTs 4.5 10400534 0 4.5 417845AL117461Hs.82719Homo Sapiens mRNA; cDNA4.5 DKFZp586F1822 (from c 423123NM-012247Hs.124027SELENOPHOSPHATE SYNTHETASE4.5 ; Human selenium d 448305AA625207Hs.264915Homo Sapiens cDNA FLJ129084.5 fis, clone NT2RP20 441006AW605267Hs.7627CGI-60 protein 4.5 1 414569AF109298Hs.118258Prostate cancer associated4.5 S protein 1 447924AI817226Hs.170337ESTs 4.5 d25506NM Hs.158205basic leucine zipper 4.5 003666 nuclear factor 1 (JEM-1) 411630042349Hs.71119Putative prostate cancer4.4 tumor suppressor 432842AW674093Hs.279525hypothetical protein 4.4 413472BE242870Hs.75379solute carrier family 4.4 1 (glial high affinity 414699A1815523Hs.76930synuclein, alpha (non 4.4 A4 component of amyloid 412733AA984472Hs.74554KIAA0080 protein 4.4 419790079250Hs.93201glycerol-3-phosphate 4.4 dehydrogenase 2(mitocho 433377A1752713Hs.43845ESTs 4.4 449535W15267Hs.23672low density lipoprotein4.4 receptor-related prot 453900AW003582Hs.226414ESTs, Weakly similar 4.4 to ALUS HUMAN ALU SUBFAM

443861864512Hs.237146Homo Sapiens cDNA FLJ 4.4 14234 fis, clone NT2RP40 423025AA831267Hs.12244Homo sapiens cDNA: FLJ235814.4 fis, clone LNG136 408621AI970672Hs.d6638chromosome 11 open reading4.3 frame 8; fetal br 30416241N52639Hs.32683ESTs 4.3 432005AA524190Hs.120777ESTs, Weakly similar 4.3 to ELL?-HUMAN RNA POLYME

435532AW291488Hs.117305ESTs 4.3 451813NM Hs.27182phospholipase A2-activating4.3 016117 protein 454193BE141183 gb:MRO-HT0071-191199-001-b044.3 HT0071 Homo sapi 35418478038945Hs.1174cyclin-dependent kinase4.3 inhibitor 2A (melanom 406069 0 4.3 419465AW500239Hs.21187Homo Sapiens cDNA: FLJ230684.3 fis, clone LNG055 418413895735Hs.117753ESTs, Weakly similar 4.3 to antigen of the monocl 452028AK001859Ns.27595hypothetical protein 4.3 418693AI750878Ns.87409thrombospondin 1 4.3 410361BE391804Hs.62661guanylate binding protein4.2 1, interferon-induc 409763AL043212 gb:DKFZp434H0623 r1434 4.2 (synonym: htes3) Homo 455601AI368680Hs.81658Y (sex determining 4.2 region Y)-box 2, partial 408908BE296227Hs.48915sedneithreonine kinase 4.2 45413582AW295647Hs.71331Homo Sapiens cDNA: FW219714.2 fis, clone HEP057 423248AA380177Hs.i25845dbulose-5-phosphate-3-epimerase4.2 425024839235Hs.12407ESTs 4.2 447153AA805202Hs.173912eukaryotic translation 4.2 inifiafion factor 4A, 447406BE618060Hs.282882ESTs 4.2 449347AV649748Hs.295901ESTs 4.2 d14279AW021691Hs.3804DKFZP564C1940 protein 4.2 428856AA436735Hs.183171Homo Sapiens cDNA: FLJ220024.2 fis, clone HEPO66 d07872AB039723Hs.40735frizzled (Drosophila) 4.2 homolog 3 421502AF111856Hs.105039solute carrier family 4.2 34 (sodium phosphate), SS436406AW105723Hs.t25346ESTs 4.2 438209AL120659Hs.6111KIAA0307 gene product 4.2 443653AA137043Hs.9663programmed cell death 4.1 6-interacting protein 454556AW807073 gb:MR4-ST0062-031199-018-d064.1 ST0062 Homo sapi 424834AK001432Hs.153408Homo Sapiens cDNA FLJ105704.1 fis, clone NT2RP20 412593Y07558Hs.74088early growth response 4.1 416566NM-003914Hs.79378cyclin A1 4.1 426342AF093419Hs.169378mulUple PDZ domain proteind.t 428417AK001699Hs.184227F-box only protein 21 4.1 429317AA831552Hs.268016solute carrier family 4.1 5 (inositol transporter 6S446880AI811807Hs.108646Homo Sapiens cDNA FLJ125344.1 fis, clone NT2RM40 422988AW673847Ns.97321ESTs 4.0 d34657AA641876Hs.191840ESTs 4.0 412494AL133900Hs.792ADP-rtbosylafion factor4.0 domain protein 1, 64k 443271BE568568Hs.195704ESTs 4.0 421437AW821252Hs.104336ESTs 4.0 401644 0 4.0 405095 0 4.0 418417877182 gb:yi65e02.r1 Soares 4.0 placenta Nb2HP Homo sapi 420807AA280627Hs.57846ESTs 4.0 75429529AA454190Hs.193811ESTs, Moderately similar4.0 to reduced expressio 457726AI217477Hs.194591ESTs 4.0 431130NM_006103Hs.2719epididymis-specific; 4.0 whey-acidic protein type 453403BE466639Hs.61779Homo Sapiens cDNA FLJ1359i4.0 fis, clone PLACE10 442768AL048534Hs.48458ESTs, Weakly similar 4.0 to ALUB HUMAN ALU SUBFAM

413430822479Hs.24650Homo Sapiens cDNA FLJ130474.0 fis, clone NT2RP30 424081NM Hs.139120dbonuclease P (30kD) 4.0 425692D90041Hs.155956NAT1; arylamine N-acetyltransferase4.0 407792A10777t5Hs.39384putative secreted ligand4.0 homologous to fjxl 408353BE439838Hs.44298hypothefical protein 4.0 421175Ai879099Hs.102397GIOT-3 for gonadoUopin 3.9 inducible transcripfi 420324AF163474Hs.96744DKFZP586D0823 protein, 3.9 Prostate androgen-regu 417531NM Hs.1087serinelthreonine kinase3.9 458924BE242158Hs.24427DKFZP56601646 protein 3.9 400195 0 3.9 401480 0 3.9 410360AW663690 gb:hj21g03.x1 NCI_CGAP-U83.9 Homo Sapiens cDNA

410908AA121686Hs.10592ESTs 3.9 420159AI572490Hs.99785ESTs 3.9 422805AA436989Hs.121017H2A histone family; 3.9 member A

' 424639A1917494Hs.131329ESTs 3.9 428555NM-002214Hs.184908integrin, beta 8 3.9 431699NM Hs.267831Homo Sapiens cDNA FLJ129523.9 001173 fis, clone NT2RP20 433703AA210863Hs.3532nemo-like kinase 3.9 1 437144ALOd9466Hs.7859ESTs 3.9 Jr 452728AI915676Hs.239708ESTs 3.9 430447W17064Hs.241451SWIISNF related, matrix3.9 associated, actin dep 440594AW445167Hs.126036ESTs 3.9 408938AA059013Hs.22607ESTs 3.9 427051BE178110Hs.173374ESTs 3.9 447568AF155655Hs.18885CGI-116 protein 3.9 457211AW972565Hs.32399ESTs, Weakly similar 3.9 to Similar to Ena-VASP
I

443475A1066470Hs.134482ESTs 3.9 433447029195Hs.3281neuronal pehtraxin II 3.9 428093AW594506Hs.104830ESTs 3.8 437938AI950087 ESTs; Weakly similar 3.8 to Gag-Pol polyprotein [

408829NM Hs.48384heparan sulfate (glucosamine)3.8 006042 3-0-sulfotransf 429250H56585Hs.198308iryptophan rich basic 3.8 protein 441859AW194364Hs.128022ESTs, Weakly similar 3.8 to FIG1 MOUSE FIG-1 PROT

437700AA766060Hs.122848ESTs 3.8 439560BE565647Hs.74899hypothetical protein 3.8 409564AA045857Hs.54943fracture callus 1 (rat)3.8 homolog 429474AA453441Hs.31511ESTs 3.8 431965BE175190 gb:OV2-HT0577-010500-165-g043.8 HT0577 Homo sapi 454018AW016892Hs.241652ESTs 3.8 426320W47595Hs.169300transforming growth 3.8 factor, beta 2 439635AA477288Hs.94891Homo sapiens cDNA: FLJ227293.8 fis, clone HSI156 417517AF001176Hs.82238POP4 (processing of 3.8 precursor , S. cerevisiae 446402AI681145Hs.160724ESTs 3.8 450236AW162998Hs.24684KIAA1376 protein 3.8 410804064820Hs.66521Machado-Joseph disease 3.8 (spinocerebellar ataxi 400268 0 3.8 418217AI9101i47Hs.13442ESTs 3.8 421928AFOi3758Hs.109643poiyadenylate binding 3.8 protein-interacting pro 45 417300AI765227Hs.55610solute carrier family 3.8 30 (zinc transporter),.

414136AA812d34Hs.178227ESTs 3.8 453945NM-005171Hs.36908acfivating transcription3.7 factor 1 400240 0 3.7 407877AW016811Hs.234478Homo sapiens cDNA: FLJ226483.7 fis, clone HSI073 450581AF081513Hs.25195endometdal bleeding 3.7 associated factor (left-418223NM_014733Hs.83790KIAA0305 gene product 3.7 411704AI499220Hs.71573hypothetical protein 3.7 432712AB016247Hs.288031sterol-C5-desaturase 3.7 (fungal ERG3, delta-5-de 422809AK001379Hs.121028hypothetical protein 3.7 5 402820 0 3.7 408090BE173621Hs.292478ESTs 3.7 416421AA734006Hs.79306eukaryotic translation 3.7 initiation factor 4E

418282AA215535Hs.98133ESTs 3.7 418454AA315308 gb:EST187095 Colon carcinoma3.7 (HCC) cell line 418668AW407987Hs.87150Human clone A9A2BR11 3.7 (CAC)nl(GTG)n repeat-con 422290AA495854Hs.48827hypothetical protein 3.7 432824AK001783Hs.279012hypotheficalprotein 3.7 439907AA853978Hs.124577ESTs 3.7 447479AB037834Hs.18685Homo Sapiens mRNA for 3.7 KIAA1413 protein, parti 65 451073AI758905Hs.206063ESTs 3.7 450377AB033091Hs.24936ESTs 3.7 414343AL036166Hs.75914coated vesicle membrane3.7 protein 448807AI571940Hs.7549ESTs 3.7 442821BE391929Hs.8752Putative type II membrane3.7 protein 426300015979Hs.169228delta-like homolog (Drosophila)3.7 418068AW971155Hs.293902ESTs, Weakly similar 3.7 to prolyl 4-hydroxylase 411263BE297802Hs.69360kinesin-like 6 (mitofic3.7 centromere-associated 443054AI745185Hs.8939yes-associated protein 3.7 65 kDa 421154AA284333Hs.287631Homo Sapiens cDNA FLJ142693.7 fis, clone PLACE10 75 411402BE297855Hs.69855NRAS-related gene 3.7 450447AF212223Hs.25010hypotheficalprotein 3.6 414706AW340125Hs.76989KIAA0097 gene product 3.6 434228242047Hs.283978ESTs; KIAA0738 gene 3.6 product 434164AW207019Hs.148135ESTs 3.6 409533AW969543Hs.21291mitogen-acfivated protein3.6 kinase kinase kings 402222. ~ 0 3.6 404915 0 3.6 404996 0 3.6 411560AW851186 gb:IL3-CT0220-150200-071-H053.6 CT0220 Homo sapi 419750AL079741Hs.183114Homo Sapiens cDNA FLJ142363.6 tis, clone NT2RP40 426010AA136563Hs.1975Homo Sapiens cDNA: FLJ210073.6 tis, clone CAE038 427038NM Hs.173288KIAA0155 gene product 3.6 439255BE164500 gb:RC4-HT0469-230300-014-e103.6 HT0469 Homo sapi 458242BE299588Hs.28465Homo sapiens cDNA: FLJ218693.6 tis, clone HEP024 415115AA214228Hs.121751hypothefical protein 3.6 453468W00712Hs.32990DKFZP566F084 protein 3.6 441205AW137827Hs.176904ESTs 3.6 452693T79153Hs.48589zinc finger protein 3.6 228 .

1 417389BE260964Hs.82045Midkine (neurite growth-promoting3.6 ~ factor 2) 448105AW591433Hs.170675ESTs, Weakly similar 3.6 to TMS2_HUMAN TRANSMEMBR

451522BE565817Hs.26498hypothetical protein 3.6 440048AA897461Hs.158469ESTs, Weakly similar 3.5 to envelope protein [H.s 419359AL043202Hs.90013chromosome segregation 3.5 1 (yeast homology-like 15 452030AL137578Hs.27607Homo Sapiens mRNA; cDNA3.5 DKFZp564N2464 (from c 400666 0 3.5 422646H87863Hs.151380ESTs 3.5 407846AA426202Hs.40403Cbp/p300.interacting 3.5 Uansactivator, with Glu 408730AV660717Hs.47144DKFZP586N0819 protein 3.5 401517 0 3.5 413775AW409934Hs.75528nucleolar GTPase 3.5 417177NM-004458Hs.81452fatty-acid-Coenzyme 3.5 A ligase, long-chain 427943AW959075 gb:EST371145 MAGE resequences,3.5 MAGE Homo sapi 439107AL046134Hs.27895ESTs 3.5 447268A1370413Hs.36563Homo Sapiens cDNA: FLJ224i83.5 tis, clone HRC085 412604AW978324Hs.47144DKFZP586N0819 protein 3.5 427134AA398409Hs.173561EST 3.5 430273A1311127Hs.125522ESTs 3.5 436671AW131159Hs.146151ESTs 3.5 3 433037NM Hs.279938HSPCO61 protein 3.5 ~ 014158 453745AA952989Hs.63908Homo Sapiens HSPC316 3.5 mRNA, partial cds 400531AF151064Hs.36069hypothetical protein 3.5 433345AI681545Hs.152982EST cluster (not in 3.4 UniGene) 406400AA343629Hs.104570kallikrein 8 (neuropsinlovasin)3.4 35 407596886913 gb:yq30f05.r1 Soaresfetal3.4 liver spleen 1NFL5 453779N35187Hs.43388ESTs 3.4 444858AI199738Hs.208275ESTs, Weakly similar 3.4 to unnamed protein produ 447688N87079Hs.19236NADH dehydrogenase (ubiquinone)3.4 1 beta subcom 424856AA347746Hs.9521ESTs, Weakly similar 3.4 to KIAA1015 protein (H.s 407864AF069291Hs.d0539chromosome 8 open reading3.4 frame 1 404108 0 3.4 403729 0 3.4 404232 0 3.4 423687AA329633Hs.133011ESTs, Highly similar 3.4 to 2117 HUMAN ZINC
FINGE

45 428372AK000684Hs.183887hypothetical protein 3.4 439741BE379646Hs.6904Homo Sapiens mRNA full 3.4 length insert cDNA
clo 441447AA934077Hs.126980ESTs 3.4 448358844433Hs.106614Human DNA sequence from3.4 clone RP4-534K7 on ch 450926AI744361Hs.205591ESTs, Weakly similar 3.4 to zinc finger protein P

458477NM Hs.10712phosphatase and lensin 3.4 000314 homolog (mutated in mu d21379Y15221Hs.103982small inducible cytokine3.4 subfamily 8 (Cys-X-C

452822X85689Hs.288617Homo Sapiens cDNA: FLJ226213.4 fis, clone HSI056 441111AI806867Hs.126594ESTs 3.4 447519046258Hs.23448ESTs 3.4 S 446913AA430650Hs.16529Uansmembrane 4 superfamily3.4 member (tetraspan 449581AI989517Hs.181605ESTs 3.4 456132BE219771Hs.237146Homo Sapiens cDNA FLJ142343.4 fis, clone NT2RP40 448186AA262105Hs.4094Homo Sapiens cDNA FLJ 3.4 14208 tis, clone NT2RP30 422611AA158177Hs.118722fucosylUansferase 8 3.4 (alpha (1,6) fucosyltran ' 441433AA933809Hs.42746ESTs 3.4 417837AL079905Hs.1103Uansforming growth factor,3.4 beta 1 450516AA902656Hs.21943NIF3 (Ngg1 interacting 3.4 factor 3, S.pombe homo 407796AA195509Hs.272239lymphocyte activation-associated3.3 protein 419200AW966405Hs.288856prefoldin 5 3.3 65 423161AL049227Hs.124776Homo Sapiens mRNA; cDNA3.3 DKFZp564N1116 (from c 445679AI343868Hs.58800Homo Sapiens cDNA FLJ124883.3 tis, clone NT2RM20 435014BE560898Hs.10026ribosomal protein L17 3.3 isolog 446619AU076643Hs.313secroted phosphoprotein3.3 1 (osteopontin, bone 439110AA332365Hs.165539ESTs 3.3 429830A1537278Hs.225841DKFZP434D193 protein 3.3 428943AW086180Hs.37636ESTs, Weakly similar 3.3 to KIAA1392 protein [H.s 445817NM Hs.13340histone acetylUansferase3.3 408805H69912Hs.48269vaccinia related kinase3.3 441134W29092Hs.7678cellular retinoic acid-binding3.3 protein 1 75 408532AI453137Hs.63176ESTs 3.3 409517X90780Hs.54668troponin I, cardiac 3.3 414304AI621276Hs.165998DKFZP564M2423 protein 3.3 436427A1344378Hs.143399ESTs 3.3 d36662A1582393Hs.126695ESTs 3.3 440304BE159984Hs.125395ESTs 3.3 447385F12863 gb:HSC3FE081 normalized3.3 infant brain cDNA Hom 451177AI969116Hs.13034ESTs 3.3 428949AA442153Hs.104744ESTs, Weakly similar 3.3 to AF2088551 BM-013 [H.

d51743AW074266Hs.23071ESTs 3.3 421515Y11339Hs.105352GaINAc alpha-2, 6-sialylUansferase3.3 I, long f 446351AW444551Hs.258532ESTs 3.3 435102AW899053Hs.76917F-box only protein 8 3.3 418216AA662240Hs.283099AF15q14 protein 3.3 401508 0 3.3 437108AA434054Hs.80624Homo Sapiens cDNA: FLJ234423.3 fis, clone HS1009 416530062801Hs.79361kallikrein 6 (neurosin,3.3 zyme) 443171BE281128Hs.9030TONDU 3.3 458627AW088642Hs.97984ESTs; Weakly similar 3.3 to WASP-family protein [

1 412078X69699Hs.73149paired box gene 8 3.3 ~

414080AA735257Hs.47783ESTs, Weakly similar 3.3 to T12540 hypothetical p 401197 0 3.3 422134AW179019Hs.112110ESTs 3.3 409044A1129586Hs.33033ESTs 3.3 15 416198H27332Hs.99598ESTs 3.2 436481AA379597Hs.5199HSPC150 protein similar3.2 to ubiquifin-conjugal 436525AA721428Hs.26145Homo sapiens cDNA FLJ141273.2 fis, clone MAMMA10 409142AL136877Hs.50758chromosome-associated 3.2 polypepfide C

428819AL135623Hs.193914KIAA0575 gene product 3.2 20 428728NM Hs.i ESTs; Weakly similar 3.2 01662591381 to hypothefical protein 421261AA600853Hs.98133ESTs 3.2 446219A1287344Hs.149827ESTs 3.2 457574H88717Hs.27774ESTs, Highly similar 3.2 to AF1613491 HSPC086 [H

409172299399Hs.118145ESTs 3.2 419388T67012Hs.75323prohibifin _~ 3.2 434187AA627098Hs.99103ESTs, Weakly similar 3.2 to 138428 T-complex prot 445060AA830811Hs.88808ESTs 3.2 448254A1829900Hs.22929ESTs 3.2 452943BE247449Hs.31082hypothefical protein 3.2 411393AW797437Hs.69771B-factor, properdin 3.2 453775NM_002916Hs.35120replicafion factor C 3.2 (activator 1) 4 (37kD) 408418AW963897Hs.44743KIAA1435 protein 3.2 442025AW887434Hs.11810ESTs, Weakly similar 3.2 to CD4.2 [C.elegans]

417006AW673606Hs.80758aspartyl-tRNAsynthetase3.2 35 407881AW072003Hs.40968heparin sulfate (glucosamine)3.2 3-0-sulfotransf 444755AA431791Hs.183001ESTs 3.2 402829 0 3.2 451593AF151879Iis.26706CGI-121 protein 3.2 419926AW900992Hs.93796DKFZP586D2223 protein 3.2 4~ 434551BE387162Hs.280858ESTs,HighlysimilartoXPB3.2 HUMAN DNA-REPAIR

445929A1089660Hs.7838makorin, ring finger 3.2 protein,1 409365AA702376Hs.226440Homo Sapiens clone 248813.2 mRNA sequence 418836AI655499Hs.161712ESTs 3.2 441020W79283Hs.35962ESTs 3.1 45 422363T55979Hs.115474replicafion factor C 3.1 (acfivator 1) 3 (38kD) 413010AA393273Hs.75133Uanscription factor 3.1 6-like 1 (mitochondria) 452092BE245374Hs.27842hypothetical protein 3.1 410486AW235094Hs.193424ESTs, Weakly similar 3.1 to KIAA1064 protein [H.s 434540NM Hs.5184TH1 drosophila homolog 3.1 50 409178BE393948Hs.50915kallikrein 5 3.1 439480AL038511Hs.125316ESTs 3.1 417848AA206581Hs.39457ESTs 3.1 446293A1420213Hs.149722ESTs 3.1 408108A1580492Hs.42743hypothetical protein 3.1 55 415947004045Hs.78934mutS (E. coli) homolog 3.1 2 (colon cancer, nonpo 410519AW612264Hs.131705ESTs 3.1 421987A113316iHs.286131CGI-101 protein 3.1 440046AW402306Hs.6877hypothetical protein 3.1 453931AL121278Hs.25144ESTs 3.1 454423AW603985Hs.i79662nucleosome assembly 3~1 protein 1-like 1 459069F13036Hs.27373Homo Sapiens mRNA; cDNA3.1 DKFZp56401763 (from c 418735N48769Hs.44609ESTs , 3.1 414245BE148072Hs.75850WAS protein family, 3.1 member 1 410909AW898161Hs.53112ESTs, Weakly similar 3.1 to ALUB HUMAN ALU SUBFAM

434926BE543269Hs.50252Homo sapiens HSPC283 3.1 mRNA, partial cds 409239AA740875Hs.44307ESTs 3.1 429017AA463605Hs.238995ESTs 3.1 447072D61594Hs.17279tyrosylprotein sulfotransferase3.1 426514BE616633Hs.301122bone morphogenefic protein3.1 7 (osteogenic prot 448133AA723157Hs.73769folate receptor 1 (adult)3.1 418792AB037805Hs.88442KIAA1384 protein 3.1 427528AU077143Hs.179565minichromosome maintenance3.1 deficient (S. cere 402077 0 3.1 440671AW297920Hs.130054ESTs 3.1 419890X17360Hs.278255homeo box D4 3.1 406687M31126Hs.272620pregnancy specific beta-1-glycoprotein3.1 409151AA306105Hs.50785SEC22, vesicle Uafficking3.1 protein (S. cerevi 431221AA449015Hs.286145SRB7 (suppressor of 3.1 RNA polymerise B; yeast) 443584A1807036Hs.101619ESTs 3.1 g0 445525BE149866Hs.14831ESTs 3.1 410441BE298210 gb:601118016F1 NIH_MGC-173.1 Homo Sapiens cDNA c 422634NM_016010Hs.118821CGI-62 protein 3.0 420022AA256253Hs.120B17ESTs 3.0 453912AL121031Hs.32556_ KIAA0379 protein 3.0 456844AI264155Hs.152981CDP-diacylglycerol synihase (phosphafidate cy 3.0 414941C14865Hs.182159ESTs 3.0 407807AL031427Hs.40094Human DNA sequence from clone 167A19 on chrom 3.0 414725AA769791Hs.120355Homo Sapiens cDNA FLJ13148 fis, clone NT2RP30 3.0 444420AI148157Hs.146766ESTs 3.0 431742NM-016652Hs.268281CGI-201 protein 3.0 412519AA196241Hs.73980froponin T7, skeletal, slow 3.0 418348AI537167Hs.96322Homo Sapiens cDNA: FLJ23560 fis, clone LNG098 3.0 444261AA298958Hs.10724MDS023 protein 3.0 1 457465AW301344Hs.195969ESTs 3.0 ~

443933At091631Hs.135501Homo Sapiens two pore potassium channel KT3.3 3.0 442150AI368158Hs.128864ESTs 3.0 414883AA926960Hs.77550CDC28 protein kinase 1 3.0 442879AF032922Hs.8813syntaxin binding protein 3 3.0 1 437949078519Hs.41654ESTs 3.0 403515 0 3.0 403864 0 3.0 407785AW207285Hs.98279ESTs 3.0 426199AA371865Hs.97090ESTs 3.0 426324AW291787Hs.200933ESTs 3.0 427738NM-000318Hs.180612peroxisomal membrane protein 3 (35kD, Zellweg 3.0 427837087309Hs.180941vacuolar protein sorting 41 (yeast homology 3.0 439430AF124250Hs.6564breast cancer anti-esfrogen resistance 3 3.0 442039AW276240Hs.128352ESTs, Weakly similar to p80 [R.norvegicus] 3.0 446978NM-001938Hs.16697down-regulator offranscripfionl,TBP-bindin 3.0 452431088879Hs.29499 toll-like receptor 3 3.0 452841T17431Hs.65412DEADIH (Asp-Glu-Ala-AspIHis) box polypeplide 3.0 432114AL036021Hs.225597ESTs 3.0 445640AW969626Hs.31704ESTs, Weakly similar to KIAA0227 [H.sapiens] 3.0 30 442607AA507576Hs.288361KIAA0741geneproduct 3.0 453920AI133148Hs.36602I factor (complement) 3.0 430000AW205931Hs.99598ESTs 3.0 429164AI688663Hs.116586ESTs 3.0 453331AI240665Hs.8895ESTs 3.0 35 448663BE614599Hs.106823H.sapiens gene from PAC
42616, similar to syn 3.0 425776025128Hs.159499parathyroid hormone receptor2 3.0 401714 0 3.0 400903 0 3.0 428428AL037544Hs.184298cyclin~dependent kinase 7 (homolog of Xenopus 3.0 443761AI525743Hs.160603ESTs 3.0 451640AA195601Hs.26771Human DNA sequence from clone 747H23 on chrom 3.0 442580AI733682Hs.130239ESTs 3.0 TABLE t08:
45 Pkey: Unique Eos probeset idenfifier number CAT number. Gene cluster number Accession: Genbank accession numbers Pkey CAT Accession Number 409763115392_1AL043212 AA077575 AA077655 819502 BE545457 AI638421 424770243504AA425562 A1880208 AA346fi46 N22655 AW811775 AW811786 6S _ AA251875 AI820501 AI820532 W87891 T85904 071456 T82391 AW235363 AA663345 AW008282 AA488964 AA2831 d4 AI890387 AI9503d4 7o AA908741 AW072629 AW513996 AA293273 AA969759 N75628 447385719912_1F12863 A1377223 T75099 75 _ AW178161 AW178207 AW178210 AW178214 AW178212 BE140918 AW178219 BE141592 AW845901 BE141580 AW178155 BEi41598 4545561223878_1AW807073 AW807055 AW807067 AW807276 AW807030 AW807363 TABLE 10C:
Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank IdenUfier (GI) numbers. "Dunham I. et al." refers to the publication entitled "The DNA
sequence of human chromosome 22" Dunham, et al. (1999) Nature 402:489-095 Strand: Indicates DNA strand from which exons were predicted Nt-position: Indicates nucleotide positions of predicted exons Pkey Ref StrandNt~osition 4005346981826Minus278637-279292 1 4006668118496Plus 17982-18115,20297-20456 ~

4009032911732Plus 59112-59228 4011979719705Plus 176341-176452 4014807321503Plus 166120-166347,166451-166557,169651-169832 4015087534110Minus110779-110983 1 4015177677912Plus 29278-29770 4016448576138Plus 82655-83959 4017146715702Plus 96484-96681 4020778117414Plus 65014-65195 4022229958106Plus 3261-3834,3939-4269 4024089796239Minus110326-110491 4028206456853Minus82274-82443 4028298918414Plus 101532-101852,102006-102263 4033819438267Minus26009-26178 4035157656757Minus173358-179553 25 4037297543752Minus37662-37909.., 4038647709019Minus51753-51890,79290-79445 4041088247074Minus6360&64942 4042328218045Minus71800-71956 4045527243881Plus 19854-20010 4045677249169Minus101320-101501 4045998705107Plus 110443-110733 4049157341766Minus100915-101087 4049966007890Plus 37999-38145,38652-38998,39727-39672,40557-40674,42351-42450 4050958072599Plus 138877-139066 3 4060699117732Plus 68880-69374 S

4061179142932Plus 54304-54584 Table 11A lists about 222 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to encode extracellular or cell-surface proteins. These were selected as for Table 10A, except that the ratio was greater than or equal to 2.0, and the predicted protein contained a structural domain that is indicative of extracellular localization (e.g. ig, fn3, egf, 7tm domains, signal sequences, transmembrane domains). Predicted protein domains are noted.
TABLE 11A: ABOUT 222 UP-REGULATED GENES ENCODING EXTRACELLULAR/CELL SURFACE
PROTEINS, OVARIAN CANCER VERSUS NORMAL ADULT TISSUES
Pkey:
Primekey 45 Ex. Exemplar Accn:Accession UG
ID:
UniGene ID

Title:
UniGene title PFAM protein domains: siroctural predicted domains ratio:
ratio tumor vs normal tissue 5o PkeyEx. UG Title PFAM domainsratio Accn (D

400292AA250737Hs.72472BMPR-Ib; bone pkinase,Activin30.0 morphogenetic recp pro 400289X07820Hs.2258Matrix MetalloproteinaseSS,hemopexin,Peptidas25.2 10 (Strom 427585031152Hs.179729collagen; type C1q Collagen22.7 X; alpha 1 ~
(Schmid m 436982AB018305Hs.5378spondin 1, (f tsp- 19.0 spondin) extracellular1 m 428579NM-005756Hs.184942G protein-coupledTM 17.4 receptor 64 443646A1085198Hs.298699ESTs TSPN,vwc,tsp_1,EGF15.1 436209AW850417Hs.254020ESTs, ModeratelyTM 14.1 similar to unname 418601AA279490Hs.86368calmegin SS,calreticulin13.8 428532AF157326Hs.184786TBP-interactingTM 13.6 protein 427344NM Hs.21425-hydroxytryptamineTM,neur_chan11.8 000869 (serotonin) rec 432677NM-004482Hs.278611UDP-N-acetyl-alpha-D-gataclosaminTM,Glycos-transf_2,Ri11.0 404567NM_015902Hs.278428progestin inducedTM,HECT,zf-UBR110.8 protein (0D5) 445537AJ245671Hs.12844EGF-like-domain;SS,MAM,EGF 8.9 mulUple 6 65 409928AL137163Hs.57549hypothetical TM,MSP_domain8.8 protein 4J47384 407001012471Hs.247954Human thrombospondin-1TSPN,vwc,tsp-1,EGF8.5 gene, par 453370AI470523Hs.182356ESTs, ModeratelyABC_tran,ABC8.4 similar to membr translat 400298AA032279Hs.61635STEAP1 TM 8.1 431725X65724Hs.2839Norrie disease SS,Cys knot 7.9 (pseudoglioma) 70 429609AF002246Hs.210863cell adhesion TM,fn3,ig 7.8 molecule with homolo 412170016532Hs.73729very low densityTM,IdI_recept_a,Idl_rec7.4 lipoprotein recepto 428954AF100781Hs.194678WNT1 inducible SS,IGFBP,Cys7.4 signaling pathwayknot,tsp 418007M13509Hs.83169Matrix metalloproteaseSS,hemopexin,Peptidas7.2 1 (interstitia 424001W67883Hs.137476ItIAA1051 proteinPep-M12B_propep,Rep7.2 75 456965AW131888Hs.172792ESTs, Weakly TM 7.1 similar to hypothelica 446142AI754693Hs.145968ESTs Cadherin_C 7.0 term,cadhe 415138C18356Hs.78045tissue factor Kunitz_BPTI,G-gamma6.8 pathway inhibitor 438167828363Hs.24286ESTs 7tm 1 6.6 452097AB002364Hs.27916ADAM-TS3 ; a Pep-M12B-prapep,Rep6.4 disintegrin-like and go 449048245051Hs.22920similar to 568401SS 5.8 (caUle) glucose in 425371049441Hs.155981mesothelin SS 5.7 407945X69208Hs.606ATPase, Cu++transporUng,alphaTM,E1-E2_ATPase,Hy5.6 p 424620AA101043Ns.151254kallikrein 7 SS,trypsin 5.5 (chymotryptic;
stratum c 420362079734Hs.97206hunting8n interactingTM,ENTH,I_LWEO. 5.4 protein 1 413384NM Hs.75334exostoses (mulfiple)TM 5.3 425154NM Hs.154850collagen, type Coltagen,TSPN5.2 001851 lX, alpha 1 411945AL033527Hs.92137v-myc avian TGF-bela,TGFb,~ropep5.1 myelocytomatosis viral 415539AI733881Hs.72472BMPR-Ib; bone pkinase,Activin5.1 morphogenefic recp pro 436018AK001160Hs.5999hypothefical TM 4.9 protein FLJ10298 424539L02911Hs.150402acfivin A receptor,Acfivin recp,pkinase4.8 type I

450375AA009647Hs.8850a disintegrin disintegrin,Reprolysin,P4.7 and metalloproteinase d 451684AF216751Hs.26813CDA74 TM 4.6 400296AA305627Hs.139336ATP-binding TM,A8C_tran,ABC_m4.6 cassette; sub-family C

1 429597NM-003816Hs.2442a disintegrin TM 4.5 ~ and metalloproleinase d 400534AP000541 predicted exonsTM,KRAB,zf-C2H24.5 425506NM Hs.158205basic leucine TM,Folate 4.5 003666 zipper nuclear carrier factor 1 413472BE242870Hs.75379solute carrier TM,SDF 4.4 family 1 (glial high off 449535W15267Hs.23672towdensilylipoproteinreceptor-velaSS,tdl-recept4.4 b,ldl-rece 15 452028AK001859Hs.27595hypothefical Zn carbOpept,Propep-M4.3 protein FLJ10997 418693AI750878Hs.87409lhrombospondin EGF,TSPN,tsp-l,isp_3,4.3 410361BE391804Hs.62661guanylate bindingTM,GBP 4.2 protein 1, interfer 407872AB039723Hs.40735fizzled (Drosophila)FrizzIed,Fz,7tm4.2 homolog 3 2 421502AF111856Hs.105039solute carrier TM,Na Pi_cotrans4.2 family 34 (sodium pho 412494AL133900Hs.792ADP-ribosylafionarf,zf B 4.0 factor domain box,zf C3HC4 pro 405095NM-014479Hs.145296disintegrin Reprolysin,disintegrin4.0 protease 431130NM Hs.2719epididymis-specific;SS,wap 4.0 006103 whey-acidic pro 407792A1077715Hs.39384putafive secretedSS 4.0 ligand homologous 408829NM Hs.48384heparan sulfateTM 3.8 006042 (glucosamine) 3-0-s 25 450581AF081513Hs.25195endomeUial.bleedingSS,TGF-beta,TGFb-pro3.7 associated fact 432712AB016247Hs.288031sterol-C5-desaturaseTM,Sterol_desat3.7 (fungal ERG3, 450447AF212223Hs.25010hypothetical TM,ANF-receptor,guan3.6 protein Pi5-2 414706AW340125Hs.76989KIAA0097 gene TM 3.6 product 417389BE260964Hs.82045Midkine (neuriteTM,PTN MK 3.6 growth-promofing 400666X07820Hs.2258Matrix MetalloproteinaseSS,hemopexin,Peptidas3.5 10 (Strom 406400AA343629Hs.104570kallikrein 8 SS,trypsin 3.4 (neuropsinlovasin) 407864AF069291Hs.40539chromosome 8 TM,FHA,BRCT 3.4 open reading frame 1 452822X85689Hs.288617Homo sapiens EGF,fn3,pkinase3.4 cDNA: FLJ22621 fis, 446913AA430650Hs.16529transmembrane TM,transmembrane43.4 4 superfamily memb 3 422611AA158fHs.118722fucosyltransferaseSS 3.4 S 77 8 (alpha (1,6) fuc 423161AL049227Hs.124776Homo Sapiens cadherin,Cadherin-C3.3 mRNA; cDNA to DKFZ

435102AW899053Hs.76917F-box only proteinTM,Sec7 3.3 416530062801Hs.79361kallikrein 6 SS,TM,trypsin3.3 (neurosin, zyme) 401197 predicted exonsarf,Ets 3.3 40 436525AA721428Hs.26145Homo Sapiens TM 3.2 cDNA FLJ 14127 fis, 4529438E247449Hs.31082hypothefical TM 3.2 protein FW10525 411393AW797437Hs.69771B-factor, properdinSS,sushi,trypsin,vwa,fib3.2 407881AW072003Hs.40968heparan sulfateSS 3.2 (glucosamine) 3-0-s 418836A1655499Hs.161712ESTs pkinase,Activin3.2 recp 409178BE393948Hs.50915kallikrein 5 SS,Irypsin 3.1 421987AL133161Hs.286131CGI-101 proteinTM 3.1 447072D61594Hs.17279tyrosylprotein 5S 3.1 sulfotransferase 426514BE616633Hs.301122bone morphogeneticSS,TGFb_propeptide,T3.1 protein 7 (osteo 448133AA723157Hs.73769folate receptorTM 3.1 1 (adult) 406687M31126Hs.272620pregnancy specificSS,Pepfidase3.1 beta-1-glycoprotMlO,hem 456844A1264155Hs.152981CDP-diacylglycerolTM,Cytidylyltrans3.0 synthase (phosp' 414725AA769791Hs.120355Homo Sapiens SPRY,7tm_1 3.0 cDNA FLJ13148 fis, 407785AW207285Hs.98279ESTs Sema,ig 3.0 427738NM Hs.180612peroxisomal TM,zf-C3HC4 3.0 000318 membrane protein 3 (35 55 452431088879Hs.29499toll-like receptorTM,TIR,LRRCT3.0 453920AI133148Hs.36602I factor (complement)Idl recept_a,trypsin,SRC3.0 453331AI240665Hs.8895ESTs disintegrin,Reprolysin,P3.0 425776025128Hs.159499parathyroid TM,7Un 2 3.0 hormone receptor 428428AL037544Hs.184298cyclin-dependentTM,pkinase 3.0 kinase 7 (homolog 6fl407910AA650274Hs.41296fibronecfin TM,LRRCT,LRRNT,LR2.9 leucine rich iransmembra 408380AF123050Hs.44532diubiquifin TM,ubiquifin,7tmL3,AN2.9 407783AW996872Hs.172028a disintegrin disintegrin,Reprolysin2.9 and metalloproteinase d 420757X78592Hs.99915androgen receptorTM,Androgen-recep,ho2.9 (dihydrotestostero 424406D54120Hs.146409wingless-type cadherin,Cadherin_C2.9 MMTV integrationto ~
sit 65 428549AA430064Hs.220929ESTs, Moderatelyarf 2.9 similar to ARF-fa 419452033635Hs.90572PTK7 protein TM,pkinase,ig2.9 tyrosine kinase 452281T93500Hs.28792ESTs TGFb-propepfide,TGF-2.9 420440NM Hs.97644mammaglobin SS,Uteroglobin2.9 418848AI820961Hs.193465ESTs pkinase,Acfivin2.9 recp 421991NM Hs.110488KIAA0990 proteinSS 2.9 433190M26901Hs.3210renin SS,asp 2.9 424538NM Hs.150390zinc finger TM 2.8 005095 protein 262 433002AF048730Hs.279906cyclin T1 SS 2.8 444342NM Hs.10887similar to lysosome-associatedTM,Lamp 2.8 014398 mem 75 430598AK001y64Hs.247112hypothefical TM 2.8 protein FLJ10902 428450NM Ns.184339KIAA0175 gene TM,pkinase,KA12.8 014791 product 450171AL133661Hs.24583hypothetical TM 2.8 protein DKFZp434C03 423554M90516Hs.i674glutamine-fructose-6-phosphatetranTM,GATase-2,SIS2.6 430016NM-004736Hs.227656xenotropic and TM 2.8 polytropic retrovirus 417866AW067903Hs.82772collagen, type Collagen,COLFI,TSPN2.8 XI, alpha 1 424894H83520Hs.153678reproducfion SS,UBX 2.8 430651AA961694Hs.105187kinesin proteinSS 2.7 9 gene 414853031116Hs.77501sarcoglycan, TM 2.7 beta (43kD
dystrophin-448595AB014544Hs.21572KIAA0644 gene TM,LRRCT,LRR2.7 product 452835AK001269Hs.30738ESTs TM 2.7 403019AA834626Hs.66718RAD54 (S.cerevisiae)-likeSS,Anfi-proliferat2.7 420281AI623693Hs.191533ESTs Cafion efflux2.7 434815AF155582Hs.46744corel UDP-galactose:N-acetylgalactSS 2.6 432201AI538613Hs.135657TMPRSS3a mRNA Uefoil,trypsin2.6 for serine protea 430450823553Hs.241489hypotheficalproteinSS 2.6 448402BE244226Hs.21094RA818, member ras,arf 2.6 RAS oncogene tam 421802BE261458Hs.108408CGI-78 protein TM 2.6 452355N54926Hs.29202G protein-coupledTM,7tm 1 2.6 receptor 34 1 417742864719 gb:EST22d11 ank,death,RHD,TIG2.6 ~ WATMi Homo sapie 451346NM_006338Hs.26312glioma amplifiedTM,ig,LRR,LRRNT,LR2.6 on chromosome 433147AF091434Hs.43080platelet delvedTM,PDGF,CUB 2.6 growth factor C

420079NM-014051Hs.94896PTDOtt protein SS,TM, 2.6 419918X80700Hs.93728pre-B~cell leukemiahomeobox,ig,Acyltransf2.5 Uanscripfion fac 15 432350NM_005865Hs.274407protease, serine,16SS 2.5 (thymus) 406671AA129547Hs.285754met proto-oncogenepkinase,Sema,Plexin2.5 (hepatocyte re gro 417412X16896Hs.82112interleukin SS,TIR,ig 2.5 1 receptor, type I

422530AW972300Hs.118110bone marrow TM 2.5 sUcmal cell anfigen 2 433929AI375499Hs.27379ESTs EGF,IdI_recept-a,ldl_re2.5 443562AF118838Hs.9599solute carrier TM,mito carr2.5 family 25, member 13 414386X00442Hs.75990haptoglobin sushi,trypsin2.5 417576AA339449Hs.82285phosphoribosylglycinamideAIRS,formyt_Uansf,GA2.5 formylU

449207AL044222Hs.23255nucleoporin TM 2.5 155kD

416107AA173846Hs.79015antigen ide~fifiedTM,ig 2.4 by monoclonal ant 25 421750AK000768Hs.107872hypotheficalproteinTM,PH 2.4 d14812X72755Hs.77367monokine inducedSS,ILB 2.4 by gamma interfe 406137842764Hs.3248mutS (E. colt) TM,MutS C,MutS_N,P2.4 homolog 6 450710AW953381Hs.18627ESTs, Weakly TM 2.4 similar to 430291AV660345Hs.23812fiCGl-49 protein TM 2.4 30 425184BE278288Hs.155048Lutheran blood ig 2.4 group (Auberger b a 451418BE387790Hs.26369ESTs TM 2.4 412277BE277592Hs.73799guanine nucleotideTM,G-alpha 2.4 binding protein ( 4137198E439580Hs.75498small inducibleSS,ILB 2.4 cytokine subfamily A

451806NM Hs.27076RNA 3'-terminalTM,RCT 2.3 003729 phosphate cyclase 35 416224NM_002902Hs.79088reticulocalbin SS,efhand 2.3 2, EF-hand calcium bi 452268NM_003512Hs.28777H2A histone histone,Calc_CGRP_IA42.3 family, member L

451668243948Hs.26789ASPIC (acidic SS,TM, 2.3 secreted protein in ca 400880M84349Hs.119663CD59 anfigen SS,UPAR LY6 2.3 421340F07783Hs.1369decay acceleratingSS,sushi 2.3 factor for comple 443986AI381750Hs.283437HTGN29 protein TM 2.3 443037AW500305Hs.8906syntaxin 7 TM,Syntaxin 2.3.-440516S42303Hs.i61cadherin 2, HNH,cadherin,Cadherin2.3 type 1, N-cadherin (near 404877AI394145Hs.18048melanoma anfigenTM,MAGE 2.3 440704M69241Hs.162insulin-like SS,thyroglobulin-1,IGF2.3 growth factor binding pr 437952D63209Hs.5944solute comer TM 2.3 family 11 (proton~coup 418624AI734080Hs.104211ESTs Sema,ig 2.2 410434AF051152Hs.63668toll-like receptorSS,TIR,LRRCT,LRR2.2 424687J05070Hs.151738matrix metalloproteinaseSS,fn2,hemopexin,Pepti2.2 9 (gelatins 431457NM Hs.256297integrin, alphaTM,FG-GAP,vwa2.2 407907AI752235Hs.41270procollagen-lysine,SS,Lysyl_hydro2.2 2-oxoglutarate 400898AF220030Hs.125300Homo Sapiens SPRY,7tm-1 2.2 tripartite motif protein 400303AA242758Hs.79136Human breast SS,TM, 2.2 cancer, estrogen regal 411789AF245505Hs.72157Homo sapiens ig,LRRCT 2.2 mRNA; cDNA
OKFZ

414809AI434699Hs.77356Uansferrin receptorTM,PA,Ribosomal_S22.2 (p90, CD71) 55 401131NM_001651Hs.298023Homo Sapiens TM,MIP 2.2 aquapodn 5 (AOP5), 400277Y00281Hs.2280Human mRNA for TM 2.1 ribophorin I

409317U20165Hs.53250bone morphogeneticTM,pkinase 2.1 protein recepto 409956AW103364Hs.727H.sapiens activinTGF-beta,TGFb-propep2.1 beta-A subunit (ex 451253H48299Hs.26126claudin 10 TM,PMP22 2.1 Claudin 60 429638AI916662Hs.211577Kinecfin 1 (kinesin_ 2.1 receptor) TM

409267NM-012453Hs.52515Uansducin (beta)-likeTM,WD40 2.1 418414J04977Hs.84981X-ray repair SS 2.1 complementing defectiv 449057AB037784Hs.22941ESTs TM 2.1 417666AI345001Hs.82380menage a trots zf C3HC4 2.1 1 (CAK assembly fac 65 428485NM_002950Hs.2280ri6ophorin I TM 2.1 445798NM Hs.13321rearranged L-mycTM,zf C2H2 2.1 012421 fusion sequence 430057AWd50303Hs.2534bone morphogeneticTM,Acfivin 2.1 protein receptorecp,pkina 425189H16fi22 gb:ym26c07.r1 RasGEF,PH,fibrinogen_2.1 Soares infant brain 1 413063AL035737Hs.75184chifinase 3-likeSS,Glyco-hydro-182.1 1 (cartilage glycopro 421343BE246444Hs.283fi85hypothetical . TM 2.1 protein FLJ20396 425627AF019612Hs.297007ESTs TM,Peptidase2.1 426261AW242243Hs.168670peroxisomal Ei-E2_ATPase,Cafion-2.1 famesylated protein 431638NM-000916Hs.2820oxytocin receptorTM,7tm-1 2.1 456546AI690321Hs.203845ESTs, Weakly TM 2.1 similar to TWIK-vela 421685AF189723Hs.106778calcium UansportATPaseTM,Et-E2_ATPase,Hy2.1 424099AF071202Hs.139336ATP-binding TM,ABC_Uan,ABC-m2.1 cassette; sub-family C

424800AL035588Hs.153203MyoD family TM 2.1 inhibitor 410007AW950887Hs.57813zinc ribbon TFIIS 2.1 domain containing,1 436135D85390Hs.5057carboxypepfidaseSS,Zn carbOpept2.1 D

d20633NM Hs.99526odorant-bindingTM,lipocalin2.1 014581 protein 2B

420162BE378432Hs.95577cyclin-dependentkinase4pkinase,ank,ArfGap,PH2.1 4261568E244537Hs.167382naUiurefic pepfideTM,ANF recepior,guan2.0 receptor A/guany 442711AF151073Hs.8645hypothetical TM 2.0 protein 411872AW327356Hs.90918. chromosome TM 2.0 11 open reading Uame 17g 427801 AW979155Hs.234433hypothefical TM,Aa_Uans 2.0 protein PR01068 430268 AK000737Hs.237480hypotheficalproteinTM 2.0 431183 NM Hs.250696KDEL (Lys-Asp-Glu-Leu)TM,ER_lumen 2.0 006855 endoplas recept,l 431846 HE019924Hs.271580Uroplakin 1B TM,transmembrane42.0 $ 404210 002478Hs.100469Human AF-6 mRNATM,RA,DIL,PDZ,FHA2.0 4356d0 AF220053Hs.54960uncharactedzedhematopoieficstemlTM,SET,zf-CXXC,PHD2.0 447906 AL050062Hs.19999DKFZP566K023 SS 2.0 protein 412666 AL080116Hs.74420origin recognifionTM 2.0 complex, subunit 417181 L10i23~Hs.1071surfactant proteinTM 2.0 A binding protein 1 423945 AA410943Hs.72472BMPR-Ib; bone TM,pkinase,Acfivin_rec2.0 ~ morphogenefic pro 411773 NM Hs.72026protease, serine,SS,trypsin 2.0 006799 21 (tesfisin) 448350 L14561Hs.785d6Homo Sapiens TM,E1-E2 2.0 clone 24411 ATPase,Hy mRNA s 401093 AI955244Hs.121520HYPOTHETICAL TM,LRRCT 2.0 16.4 kDa PROTE

415664 NM_004939Hs.78580DEADIH (Asp-Glu-Ala-AspIHis)DEAD,helicase_C,SPRY2.0 bo 1$ 448165 NM_005591Hs.202379meiotic recombinafionDNA_repair,Glyco_tran2.0 (S. cerevisiae 416391 AI878927Hs.79284mesoderm specificTM,abhydrolase2.0 transcript (mouse 422926 NM_016102Hs.121748ring finger SPRY,zf C3HC4,zf2.0 protein 16 B_ 446849 AU076617Hs.16251cleavage and TM 2.0 polyadenylafion specif 427617 D42063Hs.179825RAN binding TM,Ran BPl,zf2.0 protein 2-like RanBP

411678 AI90711dHs.71d65squalene epoxidaseTM,Monooxygenase2.0 432554 A1479813Hs.278411NCK-associated TM 2.0 protein 1 TABLE 11B:

Pkey: Unique Eos probeset idenUfier number 2$ CAT number. _s Gene cluster number Accession:
Genbank accession numbers Pkey CAT Accession Number 417742 1696262_1864719 425189 247825_1H16622 TABLE 11C:

Pkey: Unique n Eos probeset number corresponding to a Ref: Sequence GI) numbers.
source. "Dunham The 7 digit I. et al."
numbers refers to in this the publication column enfitled are Genbank "The DNA
Identifier sequence ( of 3 human chromosome et al. (1999) $ 22" Dunham, Nature 402:489-495 Strand: exons were predicted Indicates DNA strand from which Nt_position:eotide Indicates positions nucl of predicted exons Pkey Ref StrandNt_position 40 400534 6981826Minus278637-279292 401197 9719705Plus 176341-176452 4$ Table 12A lists about 57 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to encode either enzymes or proteins amenable to modulation by small molecules. These were selected as for Table 10A, except that the ratio was greater than or equal to 2.0, and the predicted protein contained a structural domain that is indicative of enzymatic function or of being modulated by small molecules (e.g., pkinase, peptidase, isomerase, iransporters). Predicted protein domains are noted.
TABLE 12A: ABOUT 57 UP-REGULATED GENES ENCODING EXTRACELLULAR/CELL SURFACE
PROTEINS, OVARIAN CANCER VERSUS NORMAL ADULT TISSUES
Pkey:
Primekey $~ Ex.Accn:ExempIarAccession UG
7D:
UniGene ID

Tifie:Gene Uni fifie PFAM mains: ains do predicted structural dom rafio:
ratio tumor vs.
normal $

Pkey Ex. UG Tifie PFAM domains ratio Accn ID

400292AA250737Hs.72472BMPR-Ib; bone pkinase,Acfivin30.0 morphogenefic recp pro 400289X07820Hs.2258Matrix MetalloproteinaseSS, ,Peptidase_M1025.2 ' 10 (Strom 426427M86699Hs.169840TTK protein pkinase 18.7 kinase 60 424905NM Hs.153704NIMA (never pkinase 16.2 002497 in mitosis gene a)-vela 433159A8035898Hs.150587kinesin-like kinesin 11.5 protein 2 453370AI470523Hs.182356ESTs, ModeratelyABC trap 8.4 similar to translat 418007M13509Hs.83169Matrix metalloproteaseSS, ,Peptidase_M107.2 1 (intersfifia 425465L18964Ns.1904protein kinase Ski Sno,pkinase_C6.1 C; iota 6$ 409506NM_006153Ns.54589NCKadaptorproteiniSH2,SH3 5.2 415539AI733881Hs.72472BMPR-Ib; bone pkinase,Acfivin5.1 morphogenefic recp pro 424539L02911Hs.150402acfivin A receptor,Acfivin recp,pkinase4.8 type I

400296AA305627Hs.139336ATP-binding TM,ABC_tran 4.6 cassette; sub-family C

431699NM_001173Hs.267831Homo Sapiens RhoGAP,FF,ras3.9 cDNA FLJi2952 fis, 439560BE565647Hs.74899hypothetical C2,PI-PLGY,PI-PLGX3.8 protein FLJ12820 450447AF212223Hs.25010hypothetical ANF_receptor,pkinase3.6 protein P15-2 400666X07820Hs.2258Matrix MetalloproteinaseSS, ,Pepfidase_M103.5 10 (Strom 452822X85689Hs.288617Homo Sapiens EGF,fn3,pkinase3.4 cDNA: FW22621 fis, 416530062801Ns.79361kallikrein 6 SS,TM,trypsin3.3 (neurosin, zyme) 7$ 411393AW797437Hs.69771B-factor, properdinSS,sushi,irypsin,vwa,fn3,3.2 444755AA431791Hs.183001ESTs AAA 3.2 418836A1655499Hs.161712ESTs pkinase,Activin3.2 recp d09178BE393948Hs.50915kallikrein 5 SS,trypsin 3.1 406687M31126Hs.272620pregnancy specificSS,Pepfidase 3.1 beta-1-glycoprotMi 0, ,1g 453920AI133148Hs.36602I factor (complement)Idl recept_a,trypsin,SRCR3.0 404653AA923729Hs.263220 pkinase 2.9 419452033635Hs.90572PTK7 protein TM,pkinase,ig2.9 tyrosine kinase 418848AI820961Hs.193465ESTs pkinase,Acfivin2.9 recp 428450NM Hs.184339fUAA0175 gene TM,pkinase,KAi2.8 014791 product 401323AL158037 predicted exon lactamase-B 2.7 444798BE242144Hs.12013ATP-binding 5H3,pkinase 2.7 cassette, sub-family,ABC-Uan E

432201AI538613Hs.135657TMPRSS3a mRNA Uefoil,irypsin2.6 for serine protea 448402BE244226Hs.21094RA818, member ras,arf 2.6 RAS oncogene tam 406671AA1295d7Hs.285754met proto-oncogenepkinase,Sema 2.5 (hepatocyte gro 453448AL036710Hs.209527ESTs CNH,pkinase 2.5 414386X00442Hs.75990haptogtobin sushi,trypsin2.5 421270H56037Hs.108146ESTs RhoGAP 2.4 .

414695BE439915Hs.76913proteasome (prosome,proteasome 2.4 macropain) su 10431341AA307211Hs.251531proteasome (prosome,proteasome 2.4 macropain) su 424085NM_002914Hs.i39226replication AAA,Viral 2.2 factor C (activatorhelicaset 1) 2 (4 424687J05070Hs.151738maUix metalloproteinaseSS,fn2, ,Peptidase-M102.2 9 (gelatins 416517AA775987Hs.79357proteasome (prosome,AAA 2.2 macropain) 417601NM Hs.82292KIAA0215 gene PHD 2.1 014735 product 15400509M97639Hs.155585receptor tyrosinepro-isomerase2.1 kinase-like orphan 430057AW450303Hs.2534bane morphogenelicActivin recp,pkinase2.1 protein recepto 421841AA908197Hs.108850KIAA0936 proteinTPR,pkinase 2.1 453078AF053551Hs.31584metaxin 2 pro-isomerase2.1 424099AF071202Hs.139336ATP-binding TM,ABC-Iran 2.1 cassette; sub-family C

20411190AA306342Hs.69171. pkinase,pkinase-C,HRi2.1 protein kinase Glike 2 407740AA295547Hs.62666ESTs p450 2.1 420162BE378432Hs.95577cyclin-dependentpkinase,ank,ArfGap2.1 kinase 4 ,ras 420490H69894Hs.193041ESTs Pl3Ka,Pl3_P14-kinase2.1 426156BE244537Hs.167382naUiureticpeP6dereceptorAlguanyTM,ANF-receptor,pkinase2.0 25423945AA410943Hs.72472BMPR-Ib; bone TM,pkinase,AcUvin2.0 morphogenetic recp pro 411773NM Hs.72026protease, sedne,SS,irypsin 2.0 006799 21 (testisin) 447298BE617527Hs.180450ribosomal proteinPI3Ka, PI4_kinase2.0 427617D42063Hs.179825RAN binding TPR,pro isomerase2.0 protein 2-like 453546AF042385Hs.33251peptidylprolyl pro-isomerase,rrm2.0 isomerase E
(cycloph TABLE2C:

Pkey: an Eos probeset Unique numt~er corresponding 1o Ref:
Sequence source.
The digit numbers in this column are Genbank Identifier (GI) numbers.
"Dunham I.
et al."
refers to the publication entitled "The DNA
sequence of human chromosome 22"
Dunham, et al.
(1999) Nature 402:489-495 35SUand:Indicates h exons were DNA predicted strand from whic N~position:
Indicates nucleotide positions of predicted exons Pkey Ref StrandN(_.position 4013239212516,Plus213509-214450 Table 13A lists about 1086 genes up-regulated in ovarian cancer compared to normal ovaries. These were selected as far Table 1 OA, except that the ratio was greater than or equal to 10, and the denominator was the median value for various non-malignant ovary specimens.
4S TABLE 13A: About 1086 UP-REGULATED GENES, OVARIAN CANCER VERSUS NORMAL
OVARY
Pkey:
Primekey Ex. Exemplay Accn:Accession UG
ID:
UniGene ID

Title:
UniGeneUUe 50 ratio: al ration ovary tumor vs.
norm PkeyEx. UG Title ratio Accn ID

439706AW872527Hs.59761ESTs 109.2 446619AU076643Hs.313secreted phosphaprotein107.8 1 (osteopontin, bone 55 422095AI868872Hs.288966ceruloplasmin (ferroxidase)104.4 447111A1017574Hs.17409cysteine-rich protein 88.3 1 (intestinal) 431130NM Hs.2719epididymis-specific; 82.8 006103 whey-acidic protein type 431369BE184455Hs.251754secretory leukocyte 81.9 protease inhibitor (antil 413859AW992356Hs.8364ESTs 73.9 60 446291BE397753Hs.14623interferon, gamma-inducible72.7 protein 30 426050AF017307Hs.166096E74-like factor 3 (ets68.1 domain Uanscription f 411469T09997Hs.70327cysteine-rich protein 66.6 429504X99133Hs.204238lipocalin 2 (oncogene 65.7 24p3) 416971834657Hs.80658uncoupling protein 64.9 2 (mitochondrial, proton c 65 450273AW296454Hs.24743hypothetical protein 62.5 446441AK001782Hs.15093hypothetical protein 60.7 428758AA433988Hs.98502Homo Sapiens cDNA FLJ1430359.7 Us, clone PLACE20 441406245957Hs.7837Homo Sapiens cDNA FLJ1045757.8 Us, clone NT2RP10 441859AW194364Hs.128022ESTs, Weakly similar 56.7 to FIG1 MOUSE FIG-1 PROT

70 448406AW772298Hs.21103Homo sapiens mRNA; 55.7 cDNA DKFZp5648076 414602AW630088Hs.76550Homo Sapiens mRNA; 55.2 cDNA DKFZp564B1264 418068AW971155Hs.293902ESTs, Weakly similar 54.8 to prolyl d-hydroxylase 428330L22524Hs.2256maUix metalloproteinase53.4 7 (matrilysin, uteri 412636NM Hs.743i6desmoplakin (DPI, DPII)51.4 75 430634AI860651Hs.26685ESTs 50.7 439318AW837046Hs.6527G protein-coupled receptor50.7 417259AW903838Hs.81800chondroi8n sulfate 50.6 proteoglycan 2 (versican) 407786AA687538Hs.38972teUaspan 1 50.4 426836N41720Hs.172684vesicle-assxiated membrane49.7 protein 8 (endobr 80 417308H60720Hs.81892KIAA0101 gene product 48.9 436876AI124756Hs.5337isociUate dehydrogenase48.4 2 (NADP+), mitochond 439180AI393742Hs.199067v-erb-b2 avian erythroblastic47.1 leukemia viral 428289M26301Hs.2253complement component 46.3 405484 0 46.1 425371D49441Hs.155981mesothelin 45.7 403912 0 45.0 443021AA368546Hs.8904Ig superfamily protein44.6 427697T18997Hs.180372BCL2-like 1 44.3 S 428227AA321649Hs.2248INTERFERON-GAMMA INDUCED44.0 PROTEIN

404678 0 43.9 400289X07820Hs.2258MaUix Metalloproteinase43.8 10 (SUcmolysin 2) 451035AU076785Hs.430plasfin 1 (I isoform) 43.8 440848BE314650Hs.7476ATPase, H+Uansporfing,42.8 lysosomal (vacuolar 1 436278BE396290Hs.5097synaptogyrin 2 42.4 ~

413936AF113676Hs.75621serine (or cysteine) 42.1 proteinase inhibitor, c7 420859AW468397Hs.100000S100 calcium-binding 42.1 protein A8 (calgranulin 428411AW291464Hs.10338ESTs 41.8 422166W72424Hs.112405S100 calcium-binding 41.5 protein A9 (calgranulin 15 412477AA150864Hs.790microsomal glutathione40.7 5-Uansferase 1 417130AW276858Hs.81256S100 calcium-binding 40.1 protein A4 (calcium prot 424673AA345051Hs.294092ESTs 39.8 416530U62801Hs.79361kallikrein 6 (neurosin,39.7 zyme) 443162T49951Hs.9029ESTs; Highly similar 39.5 to KERATIN; TYPE I
CYTO

413719BE439580Hs.75498small inducible cytokine39.3 subfamily A (Cys-Cys 424687J05070Hs.151738matrix metalloproteinase38.9 9 (gelafinase B, 92k 413063AL035737Hs.75184chifinase 3-like 1 38.5 (cartilage glycoprotein-39 429441AJ224172Hs.204096lipophilin B (uteroglobin38.1 family member), pro 418526BE019020Hs.85838solute comer family 37.9 16 (monocarboxylic acid 415511AI732617Hs.182362ESTs , 37.7 409453AI8855i6Hs.95612ESTs 37.7 445537AJ245671Hs.12844EGF-like-domain; mulfiple37.3 442432BE093589Hs.38178Homo Sapiens cDNA: 37.3 FLJ23468 fis, clone HSIi i6 408243Y00787Hs.624interleukin 8 37.3 419092J05581Hs.89603mucin 1, Uansmembrane 36.7 444172BE147740Hs.104558ESTs 36.0 412115AK001763Hs.73239hypothetical protein 35.8 420440NM Hs.97644mammaglobin 2 35.7 414386X00442Hs.75990haptoglobin 35.3 35 423225AA852604Hs.125359Thy-1 cell surface 35.1 anfigen 440596H13032Hs.103378ESTs, Weakly similar 35.0 to DRR1 [H.sapiens]

413278BE563085Hs.833interferon-sfimulated 34.9 protein,15 kDa 418506AA084248Hs.85339G protein-coupled receptor34.8 445919T53519Hs.290357ESTs 34.7 416854H40164Hs.80296Purkinje cell protein 34.4 414186U33446Hs.75799protease, serine, 8 34.2 (prostasin) 434371AA631362 gb:np86b01.s1 NCI-CGAP_Thyi33.9 Homo Sapiens cDNA

421937AI878857Hs.109706HN1 protein 33.9 449722BE280074Hs.23960cyclin 81 33.8 45 400965 0 33.7 452203X57522Hs.158164ATP-binding cassette, 33.5 sub-family B (MDR/TAP), 411945AL033527Hs.92137v-myc avian myelocytomatosis33:5 viral oncogene h 425811AL039104Hs.159557karyopherin alpha 2 33.4 (RAG cohort 1, importin a 408901AK001330Hs.48855hypotheiicai protein 33.3 438461AW075485Hs.286049phosphoserine aminotransferase33.3 422963M79141Hs.13234ESTs 33.3 426158NM Hs.199067v-erb-b2 avian erythroblastic33.2 001982 leukemia viral 431836AF178532Hs.271411beta-site APP-cleaving32.8 enzyme 2 421502AF111856Hs.105039solute comer family 32.5 34 (sodium phosphate), 431211M86849Hs.5566Homo Sapiens connexin 32.5 5 26 (GJB2) mRNA, complet 436552NM Hs.5216HSPC028 protein 32.5 442533AA161224Hs.8372ubiquinol-cytochrome 32.5 c reductase (6.4kD) subu 406400AA343fi29Hs.104570kallikrein 8 (neuropsinlovasin)32.4 450353A1244661Hs.103296ESTs 32.4 422158L10343Hs.112341protease inhibitor 32.4 3, skin-derived (SKALP) 433412AV653729Hs.8185CGI-44 protein; sulfide32.3 dehydrogenase like (y 441020W79283Hs.35962ESTs 32.2 432201A1538613Hs.135657TMPRSS3a mRNA for serine32.0 protease (ECHOS1) (T

424125M31669Hs.1735inhibin, beta B (acfivin31.9 AB beta polypeptide) 65 453309At791809Hs.32949defensin, beta 1 31.8 408380AF123050Hs.44532diubiquitin 31.7 419329AY007220Hs.2889985100-type calcium binding31.6 protein A14 409231AA446644Hs.692GA733-2; epithelial 31.6 glycoprotein (EGP) (KSA) 423961D13666Hs.136348Homo Sapiens mRNA for 31.2 osteoblast specific fac 413840AI301558Hs.290801ESTs 30.8 440943AW082298Hs.146161ESTs, Weakly similar 30.8 to KIAA0859 protein [H.s 419239AA468183Hs.184598Homo Sapiens cDNA: 30.4 FLJ23241 fis, clone 410132NM Hs.58882Microfibril-associated30.2 003480 glycoprotein-2 418203X54942Hs.83758CDC28 protein kinase 30.1 75 412719AW016610Hs.129911ESTs 30.0 407862BE548267Hs.50724Homo Sapiens cDNA FLJ1093430.0 fis, clone OVARC10 431563A1027643Hs.120912ESTs 29.9 431743AW972642Hs.293055ESTs a 29.8 443295A1049783Hs.241284ESTs 29.7 8~ 413745AW247252Hs.75514nucleosidephosphorylase29.7 441028AI333660Hs.17558ESTs 29.6 442315AA173992Hs.7956ESTs 29.6 452838U65011Hs.30743Preferentially expressed29.5 anfigen in melanoma 428479Y00272Hs.184572cell division cycle 29.5 2, Gt to S and G2 to M

432280BE440142Hs.2943signal recognifion 29.4 parficle l9kD

420158AI791905Hs.95549hypotheficalprotein 29.3 445033AV652402Hs.155145ESTs 29.2 452367071207Hs.29279eyes absent (Drosophila)29.1 homolog 2 432706NM-013230Hs.286124CD24 29.0 422163AF027208Hs.297332prominin (mouse)-like 28.7 447035NM Hs.17144shortrohain dehydrogenaselreductase28.6 443958BE241880Hs.10029cathepsin C 28.2 422956BE545072Hs.122579ESTs 28.1 1 450377AB033091Hs.24936ESTs 28.0 ~

447471AF039843Hs.18676sprouty (Drosophila) 28.0 homolog 2 444725AW952022Hs.234174Homo sapiens cDNA FLJi38i927.8 fis, clone THYR010 430250NM Hs.283021chloddeinfracellularchannel527.7 416305AU076628Hs.79187coxsackie virus and 27.6 adenovirus receptor 15 418174L20688Hs.83656Rho GDP dissociafion 27.5 inhibitor (GDI) beta 417233W25005Hs.24395small inducibie cytokine27.4 subfamily B (Cys-X-C

417866AW067903Hs.82772collagen, type XI, 27.3 alpha 1 427344NM-000869Hs.2i425-hydroxytryptamine 27.2 (serotonin) receptor 442993BE0i8682Hs.44343ESTs 27.2 407137T97307Hs.199067v-erb-b2 avian erythroblasfic27.0 leukemia viral 419356AI656166Hs.7331ESTs 27.0 433662W07162Hs.150826CATX-8 protein 26.7 422576BE548555Hs.118554CGI-83 protein 26.4 423271W47225Hs.126256intedeukin 1, beta 26.3 25 443715AI583187Hs.9700cyclin E1 26.1 420186NM Hs.95697liver-specific bHLH-Zip26.0 015925 franscription factor 419551AW582256Hs.91011anterior gradient 2 25.9 (Xenepus laevis) homolog 443672AA323362Hs.9667butyrobetaine (gamma),25.8 2-oxoglutarate dioxyge 416889AW250318Hs.80395mat, T-cell dif(erenfiafion25.3 protein 3 408474AA188823Hs.83196Homo sapiens cDNA: 25.3 0 FLJ23597 fis, clone 411825AK000334Hs.72289hypothetical protein 25.3 400881 0 25.2 440594AW445167Hs.126036ESTs 25.1 414586AA306160Hs.76506lymphocyte cytosolic 25.1 protein 1 (L-plastin) 3 411925AW014588Hs.72925chromosome 11 open 25.1 reading frame 13 417869BE076254Hs.82793proteasome (prosome, 25.0 macropain) subunit, beta 433447029195Hs.3281neuronal penfraxin 25.0 II

450858C18458Hs.25597elongation of very 24.8 long chain fatty acids (FE

410619BE512730Hs.65114keratin 18 24.8 434094AA305599Hs.238205hypothefical protein 24.6 421924BE514514Hs.109606coronin, actin-binding24.6 protein,1A

446859A1494299Hs.i6297COX17 (yeast) homolog,24.5 cytochrome c oxidase a 421451AA291377Hs.50831ESTs 24.3 433929A1375499Hs.27379ESTs 24.3 4S 438930AW843633Hs.81256S100 calcium-binding 24.2 protein A4 (calcium prot 444212AW503976Hs.106d9basement membrane-induced24.2 gene 441633AW958544Hs.t12242ESTs 24.2 441134W29092Hs.7678cellular refinoic acid-binding24.2 protein 1 417715AW969587Hs.86366ESTs 24.1 409361NM Hs.54416sine oculis homeobox 24.1 005982 (Drosophila) homolog 416984H38765Hs.80706diaphorase (NADHINADPH)24.1 (cytochrome b-5 reduc 430125046418Hs.233950serine protease inhibitor,23.9 Kunitz type 1 434078AW880709Hs.283683EST 23.8 ~

408669A1493591Hs.78146plateleUendothelial 23.8 cell adhesion molecule ( 5 439413A1598252Hs.37810ESTs 23.7 S

449034AI624049Hs.277523gbas41a09.x1 NCI_CGAP 23.7 Ut1 Homo~apienscDNA

420344BE463721Hs.97101Putafive G protein-coupled23.6 receptor GPCR150 431243046455Hs.252189syndecan 4(amphiglycan,ryudocan)23.6 417515L24203Hs.82237ataxia-telangiectasia 23.5 group D-associated prat 60 451267A1033894Hs.117865solute carver family 23.4 17 (anionlsugar franspo 450101AV649989Hs.24385Human hbc647 mRNA sequence23.4 419693AA133749Hs.92323FXYD domain-containing23.4 ion fransport regulato 431103M57399Hs.44 pleiotrophin (heparin 23.4 binding growth factor 451110AI955040Hs.301584ESTs 23.3 6$ 426295AW367283Hs.75839zinc finger protein 23.2 6 (CMPX1) 448517AA0B2750Hs.42194hypothetical protein 23.1 FLJ22649 similar to sign 424670W61215Hs.116651epithelial V-like anfigen23.1 417847AI521558Hs.288312Homo Sapiens cDNA: 23.1 FLJ22316 fis, clone 449027AJ271216Hs.22880dipeptidylpepfidaselll23.1 424969AW950928Hs.153998creative kinase, mitochondrial23.1 1 (ubiquitous) 433159A8035898Hs.150587kinesin-like protein 23.0 411393AW797437Hs.69771B-factor, properdin 23.0 434815AF155582Hs.46744corel UDP-galactose:N-acetylgalactosamine-alp22.8 427585D31152Hs.179729ccllagen; type X; alpha22.7 1 (Schmid metaphyseal 75 445721H92136Hs.13144HSPC160 protein 22.6 448258BE386983Hs.85015ESTs,WeaklysimilartoA4P_HUMANINTESTINAL22.6 456844AI264155Hs.152981CDP-diacylglycerol 22.6 synthase (phosphafidate cy 452698NM Hs.301921ESTs 22.5 418693A1750878Hs.87409ihrombospondin 1 22.4 8~ 414880AW247305Hs.119140eukaryofic franslafion22.4 inifiafion factor 401519 0 22.3 402496 0 22.3 420324AF163474Hs.96744DKFZP586D0823 protein,22.3 Prostate androgen-regu 403022 0 22.2 434042AI589941Hs.8254hypothetical protein 22.1 419080AW150835Hs.18878hypothetical protein 22.1 406545A8018249Hs.10458small inducible cytokine22.1 subfamily A (Cys-Cys 447362AW176120Hs.9061ESTs 22.0 429547AW009166Hs.99376ESTs 22.0 427954J03060Hs.247551metaxin 1 22.0 423161AL049227Hs.124776Homo Sapiens mRNA; 22.0 cDNA DKFZp564Ni 1 i6 (from c 428392H10233Hs.2265secretary granule, 21.9 neuroendocrine protein 1 ( 444107T46839Hs.10319UDP glycosylUansferase21.7 2 family, polypeptide l 414421.A1521130Hs.55567ESTs, Weakly similar 21.5 0 to LAK-4p [H.sapiens]

412589828660Hs.24305ESTs 21.5 446525AW967069Hs.211556Homo Sapiens cDNA: 21.5 FLJ23378 fis, clone 416847L43821Hs.80261enhancer of filamentation21.5 1 (cas-like docking 436972AA284679Hs.25640claudin 3 21.5 15 428698AA852773Hs.297939ESTs; Weakly similar 21.5 to neogenin [H.sapiens]

421340F07783Hs.1369decay acceleratingfactorforcomplement(CD521.4 413966AA133935Hs.173704ESTs 21.4 448243AW369771Hs.77496ESTs 21.3 421928AF013758Hs.109643polyadenylate binding 21.3 protein-interacting pro 403399 0 21.3 435793A8037734Hs.4993ESTs 21.3 432629AW860548Hs.280658ESTs 21.2 449057AB037784Hs.22941ESTs 21.2 437575AW954355Hs.36529ESTs 21.2 401131 0 21.0 407207T03651Hs.179661tubulin, beta~polypeplide20.8 444783AK001468Hs.62180ESTs 20.8 426230AA367019Hs.241395protease, serine,1 20.6 (trypsin 1) 447343AA256641Hs.23689dESTs; Nighty similar 20.7 to LOW-DENSITY LIPOPROTE

409041AB033025Hs.50081KIAA1199 protein 20.6 421305BE397354Hs.289721diptheda toxin resistance20.6 protein required f 411704AI499220Hs.71573hypotheticalprotein 20.5 417018M16038Hs.80887v-yes-1 Yamaguchi sarcoma20.5 viral related oncog 432827268128Hs.3109Rho GTPase activating 20.4 protein 4 35 410174AA306007Hs.59461DKFZP434C245protein 20.4 425184BE278288Hs.155048Lutheran blood group 20.4 (Auberger b antigen incl 452322BE566343Hs.28988glutaredoxin (thiolUansferase)20.3 447526AL048753Hs.340small inducible cytokine20.2 A2 (monocyte chemota 447335BE617695Hs.286192protein phosphatase 20.2 1, regulatory (inhibitor) 424867A1024860Hs.153591Not56 (D. melanogaster)-like20.1 protein 410275U85658Hs.61796transcription factor 20.1 AP-2 gamma (activating a 429083Y09397Hs.227817BCL2-related protein 20.0 410173AA706017Hs.119944ESTs 19.8 433047M86135Hs.279946methionine-tRNA synthetase19.8 45 419088AI538323Hs.77496ESTs 19.7 403381 0 19.6 409162H25530Hs.50868solute carrfer family 19.5 22 (organic canon Uan 426150NM Hs.167218Bares-like homeobox 19.4 449292AI990292Hs.225457ESTs 19.4 425207A8014551Hs.155120rhohac guanine nucleotide19.4 0 exchange factor (G

419950AK001645Hs.93871hypothetical protein 19.3 436481AA379597Hs.5199HSPC150 protein similar19.3 to ubiquitin-conjugat 445930AF055009Hs.13456Homo sapiens clone 19.2 24747 mRNA sequence 446608N75217Hs.257846ESTs 19.1 5 425222M85430Hs.155191villin 2 (ezrin) 19.1 428309M97815Hs.183650cellular retinoic acid-binding19.1 protein 2 420005AW271106Hs.133294ESTs 19.1 436982AB018305Hs.5378spondin 1, (f spondin)19.0 extracellular matrix p 407142AA412535Hs.55235sphingomyelin phosphodiesterase19.0 2, neufral me 430122NM Hs.233765TCF3 (E2A) fusion partner18.9 013342 (in childhood Leuke 446293AI420213Hs.149722ESTs 18.9 444825AW167613Hs.248mitogen-activated protein18.9 kinase kinase kings 407634AW016569Hs.301280UDP-GIcNAc:betaGal 18.9 beta-1,3-N-acetylglucosami 445200AA084460Hs.12409somatostatin 18.9 6S 418917X02994Hs.1217adenosine deaminase 18.8 435777AW419202Hs.286192protein phosphatase 18.8 1, regulatory (inhibitor) 431049AA846576Hs.103267hypothetical protein 18.7 FLJ22548 similar to gene 426427M86699Hs.169840TTK protein kinase 18.7 436281AW411194Hs.120051ESTs 18.6 425907AA365752Hs.155965ESTs 18.6 459720 ESTs 18.6 421242AW161386Hs.13561ESTs, Weakly similar 18.5 to dJ37E16.5 [H.sapiens]

457715AA642402Hs.59142ESTs 18.5 451668243948Hs.26789ASPIC (acidic secreted18.4 protein in cartilage)A

75 437142AI791617Hs.145068ESTs 18.4 418588BE387040Hs.182476ESTs, Weakly similar 18.3 to similar to alphalbeta 433068NM Hs.288215sialylUansferase 18.3 419854AW664873Hs.87836Homo Sapiens PAC clone18.3 RP5-1087M19 from 7q11.

444726NM Hs.11801interferon regulatory 18.3 006147 factor 6 423011NM Hs.299847ESTs, Highly similar 18.2 000683 to A2AD HUMAN ALPHA-2G2 451428AW083334Hs.11067ESTs, Weakly similar 18.2 to K02E10.2 [C.elegans]

424865AF011333Hs.153563lymphocyte antigen 18.2 418742AW451197Hs.113418ESTs 18.1 446627A1973016Hs.15725ESTs; hypotheticalprotein18.1 1~3 424885Af333771Hs.82204ESTs 18.1 402926 0 18.0 405452 0 18.0 428641AA431367Hs.234546GMPR2 for guanosine 18.0 monophosphate reductase t 454390AB020713Hs.56966KIAA0906 protein 18.0 441784A1522132Hs.28700ESTs 18.0 418758AW959311Hs.87019ESTs 17.9 406621A1970672Hs.46638chromosome 1 t open 17.9 reading frame 8; fetal 6r 426201AW182614Hs.i28499ESTs 17.8 1 410442X73424Hs.63788propionyl Coenzyme A 17.8 ~ carboxylase, beta polype 456423AW748920 gb:CM2-BT0306-171199-034-g0217.8 BT0306 Homo sapi 422867L32137Hs.i584cartilage oligomertc 17.8 matrix protein 448110AA626937Hs.181551ESTs 17.7 421750AK000768Hs.107872hypotheticalprotein 17.7 1 405224 0 17.7 447630AI660149Hs.44865lymphoid enhancer-binding17.7 factor 1 407663NM Hs.37482COPZ2 for nonclathrin 17.7 016429 coat protein zeta-COP

427490295152Hs.178695mitogen-activated protein17.6 kinase 13 414812X72755Hs.77367monokine induced by 17.6 gamma interferon 427691AW194426Hs.20726ESTs 17.6 420650AA455706Hs.44581heat shock protein hsp70-related17.5 protein 439841AF038961Hs.6710mannose-P-dolichol utilization17.5 defect 1 425810A1923627Hs.31903ESTs 17.5 425397J04088Hs.156346topoisomerase (DNA) 17.5 II alpha (170kD) 456098AW747800Hs.55016hypothetical~rotein 17.4 428579Nt~005756Hs.184942G protein-coupled receptor17.4 410361BE391804Hs.62661guanylate binding protein17.4 1, interferon-induc 442402NM Hs.8272prostaglandin D2synthase17.4 000954 (2lkD, brain) 411734AW374954Hs.71779Homo Sapiens DNA from 17.3 chromosome 19, cosmid F

405295 0 17.3 408340AB037762Hs.44268myelin gene expression 17.3 factor 2 456068AI677897Hs.76640RGC32 protein 17.3 448571AA486794Hs.66915ESTs, Weakly similar 17.2 ~ to 16.7K4 protein [H.sap 441829AL117482Hs.7978DKFZP434C131 protein 17.2 35 418004037519Hs.87539aldehyde dehydrogenase 17.2 412078X69699Hs.73149paired box gene 8 17.2 414658X58528Hs.76781ATP-binding cassette, 17.1 sub-family D (ALD), mem 418478038945Hs.1174cyclin-dependentkinaseinhibitor2A(melanom17.0 426805AB032945Hs.172506myosin VB 17.0 410247AF181721Hs.61345RU2S 17.0 434516AA807814Hs.70582ESTs, Moderately similar16.9 to AF1440561 apoplo 428153AW513143Hs.98367hypothetical protein 16.9 FLJ22252 similar to SRY-417793AW405434Hs.82575small nuclear ribonucleoprotein16.9 polypeptide 8 454163AW175997 gb:OVO-BT0078-190899-D05-E0216.9 8TOD78 Homo sapi 4S 415402AA164687Hs.297889ESTs 16.9 420309AW043637Hs.21766ESTs 16.9 419201M22324Hs.1239alanyl (membrane) aminopeptidase16.9 (aminopeptid 444391AL137597Hs.11114hypotheticalprotein 16.9 dJ1181N3.1 457705AW974668 gb:EST386757 MAGE resequences,16.8 MAGM Homo sapi 412723AA648459Hs.179912ESTs 16.8 435774888066Hs.4992tumor suppressing subtransferable16.8 candidate 1 408753AI337192Hs.47438SH3 domain binding glutamic16.8 acid-rich protein 447783AF054178Hs.19561NADH dehydrogenase (ubiquinone)16.8 1 alpha subco 418085840328Hs.258822ESTs 16.7 ~

5 452472AW957300Hs.294142ESTs, Weakly similar 16.7 5 to SP49 HUMAN SPLICEOSOM

409112BE243971Hs.50649quinone oxidoreductase 16.7 homolog 410250A1082777Hs.61384KIAA1445 protein 16.7 446219A1287344Hs.149827ESTs 16.6 428928BE409838Hs.194657cadhedn 1, type 1, E-cadherin16.6 (epithelial) 425812AA364128Hs.245633ESTs 16.6 411742AW247593Hs.71819eukaryotic Uanslation 16.6 initiation factor 4E
b 415076NM Hs.77890guanylate cyctase 1, 16.6 OOD857 soluble, beta 3 416209AA236776Hs.79078MAD2 (mitotic arrest 16.6 deficient, yeast, homolo ' 440667BE076969Hs.7337hypothetical protein 16.6 65 430375AW371048Hs.93758H4 histone family, member16.6 H

419607852557Hs.91579Homo Sapiens clone 2378316.6 mRNA sequence 410328BE080190Hs.62275CGI-141 protein 16.5 405426 0 16.5 432636AA340864Hs.278562claudin 7 16.5 434725AK000796Hs.4104hypothetical protein 16.5 ~

414683S78296Hs.76888internexin neuronal 16.5 intermediate filament pro 429500X78565Hs.289114hexabrachion (tenascin 16.5 C, cytotactin) 449944AF290512Hs.58215Homo Sapiens rhotekin 16.4 mRNA, partial cds 400666 0 16.4 75 421536BE250690Hs.105509CTL2gene 16.4 436032AA150797Hs.109276latexin protein 16.4 418196AI745649Hs.26549ESTs, Weakly similar 16.4 to T00066 hypothetical p 452323Wd4356Hs.292812ESTs, Weakly similar 16.4 to C43H8.1 (C.elegans]

407699AA825974Hs.32646Homo sapiens cDNA: FLJ2190116.4 tis, clone HEP034 g0 414617AI339520Hs.20524ESTs, Moderately similar16.3 to hexokinase I [H.s 408204AA454501Hs.43666protein tyrosine phosphatase16.3 type IVA, member 452650AW270150Hs.254516ESTs 16.3 432906BE265489Hs.3123lethal giant larvae 16.3 (Drosophila) homolog 402408 0 16.3 1~4 408805H69912Hs.48269vaccinia related kinase16.3 447155AA100605Hs.121557ESTs, Weakly similar 16.3 to AF251041 1 SGG32445 p 405699 0 16.2 406893M22406 gb:Human intestinal 16.2 mucin mRNA, partial cds, 418629BE247550Hs.86859growth factor receptor-bound16.2 protein 7 (GRB7) 424905NM_002497Hs.153704NIMA (never in mitosis 16.2 gene a)-related kinase 424243AI949359Hs.301837ESTs, Highly similar 16.2 to cis Golgi-localized c 418462BE001596Hs.85266integrin, beta 4 16.1 457205AI905780Hs.198272NADH dehydrogenase (ubiquinone)16.1 1 beta subcom 428188M98447Hs.22 transglutaminase 1 (K 16.1 polypepfide epidermal 449845AW971183Hs.60054ESTs 16.1 406429 0 16.1 407375AA091354 gb:110815.seq.F Human 16.1 fetal heart, Lambda ZAP

448377AI494514Hs.171380ESTs 16.1 431156NM_002220Hs.2722inositol 1,4,5-irisphosphate16.0 3-kinase A

450043AA885699Hs.24332CGI-26 protein 16.0 403121 0 16.0 400214 0 15.9 453252802436Hs.215725ESTs 15.9 451734NM_006176Hs.26944neurogranin (protein 15.9 kinase C substrate, RC3) 416855AA188763Hs.36793Homo Sapiens cDNA: FLJ2318815.9 fis, clone LNG120 424474AA308883Hs.148680calcyon; D1 dopamine 15.9 receptor-interacting pro 423685BE350494Hs.49753Homo Sapiens mRNA for 15.9 KIAA1561 protein, parfi 428187AI687303Hs.285529ESTs 15.9 438817A1023799Hs.163242ESTs 15.9 425692D90041Hs.155956NAT1; arylamine N-acetylUansferase15.9 421674T10707Hs.296355neuronal PAS domain 15.9 protein 2 439999AA115811Hs.6838ras homolog gene family,15.9 member E

411351W02919Hs.283476peroxisomal acyl-CoA 15.9 thioesterase 413027NM-002885Hs.75151RAP1, GTPase activating15.9 protein 1 453884AA355925Hs.36232KIAA0186 gene product 15.8 407894AJ278313Hs.41143phosphoinosifide-specific15.8 phospholipase Gbet 422748AA316266Hs.129349ESTs 15.8 414591AI888490Hs.55902ESTs 15.8 3 421877AW250380Hs.109059mitochondria) ribosomal15.8 S protein L12 404780 0 15.8 401192 0 15.8 447519U46258Hs.23448ESTs 15.8 434262AF121858Hs.12169sorting nexin 8 15.7 451253H48299Hs.26126claudin 10 15.7 435499889344Hs.14148ESTs 15.7 422424A1i86431Hs.116577prostate differenfiation15.7 factor; placental bo 424834AK001432Hs.153408Homo Sapiens cDNA FLJ1057015.7 fis, clone NT2RP20 424562AI420859Hs.150557basic transcription 15.7 element binding protein 45 443247BE614387Hs.47378ESTs 15.7 430696AA531276Hs.59509ESTs 15.6 437044AL035864Hs.69517ESTs, highly similar 15.6 to differentially expres 428237AF175206Hs.i83125killer celllectin-IikereceptorFl15.6 440048AA897461Hs.158469ESTs, Weakly similar 15.6 to envelope protein (H.s -414922D00723Hs.77631glycine cleavage system15.6 protein H (aminomethy 422030X51416Hs.110849estrogen-related receptor15.6 alpha 408716AI567839Hs.151714ESTs 15.5 410258X52638Hs.7396-phosphofructo-2-kinaselfructose-2,6-biphosp15.5 410530M25809Hs.64173ESTs, Highly similar 15.5 to VABi HUMAN VACUOLAR
A

5 447072D61594Hs.17279tyrosylprotein sulfotransferase15.5 409015BE389387Hs.49767NADH dehydrogenase (ubiquinone)15.5 Fe-S protein 447549AI871120- Hs.231265ESTs ~ 15.5 449704AK000733Hs.23900GTPase acfivafing protein15.4 427337246223Hs.176663Fc fragment of IgG, 15.4 low affinity illb, recept 421630NM Hs.1407endothelin 2 15.4 433018AI669760Hs.188881ESTs 15.4 422938NM-001809Hs.1594centromere protein A 15.3 (l7kD) 407014U38268 gb:Human cytochrome 15.2 b pseudogene, partial cds 429311AF080157Hs.198998conserved helix-loop-helix15.2 ubiquitous kinase 65 431842NM_005764Hs.271473epithelial protein up-regulated15.2 in carcinoma, 406907225427 gb:H.sapiens protein-serinelthreonine15.2 kinase 458495AI202029Hs.148593ESTs 15.2 420551AL137692Hs.98790Homo Sapiens mRNA; cDNA15.1 DKFZp434P182 (from c) 448443AW167128Hs.231934ESTs 15.1 70 443646A1085198Hs.298699ESTs 15.1 431538AL137547Hs.259619Homo Sapiens mRNA; cDNA15.1 DKFZp434B1120 (from c 436687AA868643Hs.120461ESTs 15.1 420917AW135716Hs.117330ESTs 15.0 428575M19684Hs.184929serine (orcysteine) 15.0 proteinase inhibitor, cI

75 4o34ez o 15.0 421499AI271438Hs.105022Homo Sapiens PAC clone 15.0 RP4-701016 from 7q33-q 401047 0 14.9 417749U09196Hs.82520polymerise (DNA-directed),14.9 delta 4 416693AI373204Hs.79531Homo Sapiens TTF-I interacfing1d.9 pepfide 20 mRN

80 428474A8023182Hs.184523KIAA0965 protein 14.9 428862NM Hs.2316SRY (sex-determining 14.9 000346 region Y)-box 9 (campome 430271T06199Hs.237506heatshockcognate 40 14.9 414328221666Hs.75900aconitase 2, mitochondria)14.9 415314N88802Hs.5422glycoprotein M6B 14.8 453735A1066629Hs.125073ESTs 14.8 424345AK001380Hs.145479Homo Sapiens cDNA FLJ1051814.8 fis, clone NT2RP20 423575C18863Hs.163443ESTs 14.8 438081H49546Hs.298964ESTs 14.8 403485 0 14.8 452114N22687Hs.8236ESTs 14.8 426559AB001914Hs.170414paired basic amino 14.8 acid cleaving system 412869AA290712Hs.82407Homo Sapiens HSPC296 14.8 mRNA, parfial cds 452101T60298 gb:yb87f12.r1 Stratagene14.7 liver (937224) Homo 420505AW967984Hs.291612ESTs 14.7 426125X87241Hs.166994FATiumorsuppressor(Drosophila)14.7 hcmolog 433336AF017986Hs.31386ESTs; Nighty similar 14.7 to FRIZZLED PROTEIN
PRE

428977AK001404Hs.194698cyclin B2 14.7 429785H82114Hs.301769ESTs 14.7 1 402424 0 14.7 ~

424971AA479005Hs.154036tumor suppressing subtransferable14.7 candidate 3 433037NM Ns.279938HSPC067 protein 14.6 421670BE207318Hs.106674BRCA1 associated protein-114.6 (ubiquitin carboxy 438598AI805943Hs.5723Homo Sapiens cDNA: 14.6 FLJ23439 fis, clone 453370A1470523Hs.182356ESTs, Moderately similar14.6 to translafion inifi 410561BE540255Hs.6994Homo Sapiens cDNA: 14.6 FLJ22044 fis, clone 402287 0 14.6 419741NM Hs.93002ubiquifin carrier protein14.6 442047AA974598Hs.150324ESTs 14.5 428582BE336699Hs.185055BENE protein 14.5 440006AK000517Hs.6844hypotheticaI protein 14.5 406851AAfi09784Hs.180255major histocompatibility14.5 complex, class II, D

457316A1123657Hs.127264ESTs 14.5 420453AL157500Hs.97840Homo Sapiens mRNA; 1d.5 cDNA DKFZp43dG015 (from c7 3 436406AW105723Hs.125346ESTs 14.5 420736A1263022Hs.82204ESTs 14.5 419743AW408762Hs.127478ESTs 14.5 429113D28235Hs.196384Prostaglandin-endoperoxide14.5 synthase 2(COX-2) 450256AA286887Hs.24724MFH-amplified sequences14.5 with leucine-rich tan 3 424906AI566086Hs.153716Homo Sapiens mRNA for 14.5 S Hmob33 protein, 3' untr 427414F11750Hs.6647Homo Sapiens cDNA FLJ1308814.4 fis, clone NT2RP30 419839U24577Hs.9330dphospholipaseA2,groupVll(platelet-activat14.4 418738AW3B8633Hs.6682solute carrier family 14.3 7, member 11 429414AI783656Hs.202095empty spiracles (Drosophila)14.3 homolog 2 424669AA417181Hs.120858Homo Sapiens cDNA FLJ1394514.3 fis, clone Y79AA10 408989AW361666Hs.49500KIAA0746 protein 14.3 406788A1911841Hs.518dTHldrosophilahomolog 14.3 417861AA334551Hs.82767sperm specific anfigen14.3 402104 0 14.3 45 416368888849 gb:ym96a06.r1 Soares 14.2 adult brain N2b4HB55Y
Ho 405802 0 14.2 448357N20169Hs.108923ESTs 14.2 444261AA298958Hs.10724MDS023 protein 14.2 407846AA426202Hs.40403CbpIp300-interacfing 14.2 iransactivator, with GIu 50 425163D10040Hs.154890fatty-acid-Coenzyme 14.1 A ligase, long-chain 402520 0 14.1 429597NM Hs.2442a disintegrin and metalloproleinase14.1 003816 domain 9 430044AA464510Hs.152812EST cluster (not in 14.1 UniGene) 429663M68874Hs.211587Human phosphatidylcholine14.1 2-acylhydrolase (cP

5 427036AA397625Hs.163913ESTs 14.1 444381BE387335Hs.283713ESTs 14.1 432090AW972855Hs.292853ESTs 14.0 406778H06273Hs.101651Homo Sapiens mRNA; 14.0 cDNA DKFZp434C107 (from c7 404961AW972195Hs.284236aldo-keto reductase 1d.0 family 7, member A3 (aila 60 452313Y00486Hs.28914adenine phosphoribosyltransferase14.0 452355N54926Hs.29202G protein-coupled receptcr3414.0 429942A1338993Hs.134535ESTs 14.0 403165 0 13.9 442150A1368158Hs.128864ESTs 13.9 65 439709AW401433Hs.6649hypothetical protein 13.9 ' FLJ20128 456799AC004923Hs.135187Homo sapiens clone 13.9 CDABP0025 mRNA sequence 427356AW023482Hs.97849ESTs 13.9 448982A163816dHs.225520ESTs 13.9 432025BE407132Hs.111286hypothetical protein 13.8 427505AA361562Hs.17876126S proteasome-associated13.8 padl homolog 402965 0 13.8 418601AA279490Hs.86368calmegin 13.8 436954AA740151Hs.130425ESTs 13.8 405024 0 13.8 75 453976BE463830Hs.163714ESTs 13.8 431921N46466Hs.58879ESTs 13.8 401735 0 13.8 445496AB007860Hs.12802development and differenfiation13.8 enhancing fac 425007AA456483Hs.1720B1phosphodiesterase 4D, 13.7 cAMP-specific (dunce (D

8~ 409463AI458165Hs.17296ESTs 13.7 430193A1826653Hs.102928Homo Sapiens cDNA FLJ1347913.7 fis, clone PLACE10 458869AI637934Hs.224978ESTs 13.7 426769AA075596Hs.172153glutathione peroxidase13.7 3 (plasma) 416661AA634543Hs.79440tGF-It mRNA-binding 13.7 protein 3 439901N73885Hs.124169ESTs 13.7 431374BE258532Hs.251871CTP synthase 13.7 432861AA339526Hs.279593HSPC171 protein 13.7 441172AI279652Hs.132879ESTs 13.7 410001A8041036Hs.57771kallikrein 11; serine 13.7 protease (TLSP) 430315NM Hs.239147guanine deaminase 13.6 422769AA938905Hs.289112CGI-43 protein 13.6 402389 0 13.6 448977X91809Hs.22698regulator of G-protein13.6 signalling 19 1 459648 gb:IL3-CT0220-150200-070-80213.6 ~ CT0220 Homo sapi 452972M31732Hs.31210B-cell CLLllymphoma 13.6 431441U81961Hs.2794sodium channel, nonvoltage-gated13.6 1 alpha 448585AB020676Hs.21543KIAA0869 protein 13.6 428385AF112213Hs.184062putafive Rab5-interacting13.6 protein I 434699AA643687Hs.149425Homo Sapiens cDNA FLJ1198013.6 S fis, clone HEMBB10 447238AW451676Hs.158564ESTs 13.6 437108AA434054Hs.80624Homo Sapiens cDNA: 13.6 FLJ23442 fis, clone 425749AW328587Hs.1594d8surfeit 2 13.5 425154NM-001851Hs.154850collagen, type IX, 13.5 alpha 1 413753U17760Hs.301103Laminin, beta 3 (nicein13.5 (125kD), kalinin (140 419034NM_002110Hs.89555hemopoieticcellkinase 13.5 448361H82028Hs.238707Homo Sapiens cDNA: 13.5 FLJ22457 fis, clone 412754AW160375Hs.74565amyloid beta (A4) precursor-like13.5 protein 1 419081AI798863Hs.87191ESTs 13.5 407732AW138839Hs.24210ESTs 13.5 423329AF054910Hs.127111tekfin 2 (testicular) 13.5 422627BE336857Hs.118787transforming growth 13.4 factor, beta-induced, 68k 439636AF086467 gb:Homo Sapiens full 13.4 length insert cDNA
clone 417605AF006609Hs.8229dregulator of G-protein13.4 signalling 3 445861BE293423Hs.11809single Ig IL-1R-related13.4 molecule 447350AI375572Hs.172634ESTs; HER4 (c-erb-84) 13.4 451807W52854Hs.27099DKFZP564J0863 protein 13.4 421515Y11339Hs.105352GaINAc alpha-2, 6-sialyltransferase13.4 I, long f 422443NM Hs.116753histone deacetylase 13.4 35 412504244496Hs.26039Homo Sapiens cDNA FLJ1393713.4 fis, clone Y79AA10 453344BE349075Hs.44571ESTs 13.4 402885 0 13.4 438712AW978161Hs.169877ESTs 13.4 421774AL050374Hs.108169DKFZP586C1619 protein 13.3 425638NM-012337Hs.158450nasopharyngeal epitheliumt3.3 specific protein 1 401897 0 13.3 425601AW629485Hs.293352ESTs 13.3 450779AW204f45Hs.1560d4ESTs 13.3 444858AI199738Hs.208275ESTs, Weakly similar 13.3 to unnamed protein produ 45 442619AA447492Hs.20183ESTs, Weakly similar 13.3 to AF1647931 protein x 434263N34895Hs.446d8ESTs 13.3 426059BE292842Hs.166120interferon regulatory 13.3 factor 7 407467D55638 gb:Human B-cell PABL 13.3 (pseudoautosomal boundar 412560824601Hs.108300CCR4-NOT transcription13.2 complex, subunit 3 442986A1025990Hs.285520ESTs 13.2 420317AB006628Hs.96485KIAA0290 protein 13.2 443211A1128388Hs.143655ESTs 13.2 434361AF129755Hs.117772ESTs 13.2 423493AI815965Hs.129683ubiquifin-conjugafing 13.2 enzyme E2D 1 (homologou SS 414183AW957446Hs.301711ESTs 13.2 447778BE620592Hs.71190ESTs 13.2 435106AA100847Hs.193380ESTs, Highly similar 13.1 to AF1746001 F-box prot 439490AW249197Hs.100043ESTs, Weakly similar ~
to PSF_HUMAN PTB-ASSOCIA13.1 409606AW4d4594Hs.2387transglutaminase 4 13.1 (prostate) 421308AA687322Hs.192843ESTs 13.1 414950C15407 gb:C15407 Clontech 13.1 human aorta polyA+mRNA
(6 416783AA206186Hs.79889monocyle to macrophage13.1 differentiation-associ 415927AL120168Hs.78919Kell blood group precursor13.1 (McLeod phenotype) 422605H16646Hs.118666Human clone 23759 mRNA,13.0 partial cds 65 430427AA296701Hs.241413opficin 13.0 424620AA101043Hs.151254kallikrein 7 (chymotrypfic;13.0 stratum comeum) 421693X71490Hs.106876ATPase, H+ Uansporting,13.0 lysosomal (vacuolar 407727AW411148Hs.3804dDKFZP564M082 protein 13.0 427706AW971225Hs.293800ESTs, Weakly similar 13.0 to ALU1 HUMAN ALU
SUBFAM

70 406709AI355761Hs.242463keratin 8 13.0 405353 0 13.0 453060AW294092Hs.21594ESTs 13.0 459299BE094291Hs.155651hepatocyte nuclear 13.0 factor 3, beta 447843AW337186Hs.224891ESTs 13.0 75 446576AI659477Hs.51820ESTs, Moderately similar13.0 to ALU7_HUMAN ALU
SU

449700L02867Hs.78358ESTs 13.0 436476AA326108Hs.53631ESTs 13.0 432532AW058459Hs.162246ESTs 13.0 408405AK001332Hs.44672hypothefical protein 13.0 8~ 432673AB028859Hs.278605ER associated DNAJ; 12.9 ER-associated Hsp40 co-ch 414684AW630023Hs.768933-hydroxybulyrate dehydrogenase12.9 (heart, mitoc 447210AF035269Hs.17752phosphafidylserine-specificphospholipaseAla12.9 427923AW274357Hs.268384Fzr1 protein 12.9 437395AL365408Hs.10632hypoihefical protein 12.9 DKFZp762M136 441627AA947552Hs.58086ESTs 12.9 419084AA496539Hs.179902transporter-like protein12.9 423067AA321355Hs.285401ESTs 12.9 423070855677Hs.155569ESTs 12.8 441344BE250144Hs.41514ESTs 12.8 423527A1206965Hs.105861Homo Sapiens cDNA FLJ1382412.8 fis, clone THYR010 417006AW673606Hs.80758aspartyl-tRNA synthetase12.6 453552AL041941Hs.1547293-phosphoinositide 12.8 dependent protein kinase-1 453657W23237Hs.296162ESTs 12.8 1 434414A1798376 gbar34b07.x1 NCI CGAP 12.7 ~ Ov23 Homo Sapiens cDNA

456051T85626Hs.76239hypothetical protein 12.7 451659BE379761Hs.14248ESTs, Weakly similar 12.7 to ALU8_HUMAN ALU
SUBFAM

418216AA662240Hs.283099AF15q14 protein 12.7 423281AJ271684Hs.126355Gtype (calcium dependent,12.7 carbohydrate-recog I 424275AW673173Hs.144505DKFZP566F0546 protein 12.7 S

440062AI350518Hs.129692ESTs 12.7 444371BE540274Hs.239Forkhead box M1 12.7 412520AAd42324Hs.795H2A histone family, 12.7 member 0 413349BE086692 gb:QV1-BT0678-130400-156-g0712.7 BT0678 Homo sapi 414500W24087Hs.76285DKFZP564B167 protein 12.6 429261AW176254Hs.143475ESTs 12.6 402238 0 12.6 400280 0 12.6 421246AW582962Hs.300961ESTs, Highly similar 12.6 to AF1518051 CGI-47 pro 442029AW956698Hs.14456neural precursor cell 12.6 expressed, developments 435502L13266Hs.105glutamate receptor, 12.6 ionotropic, N-methyl D-as 409964AW368226Hs.67928ESTs 12.6 418793AW382987Hs.88474prostaglandin-endoperoxide12.5 synthase 1 (prosta 452117AI42i760Hs.77870Homo Sapiens cDNA FLJ1275012.5 fis, clone NT2RP20 3 448074BE621355Ns.27160ESTs 12.5 442655AW027457Hs.30323ESTs 12.5 409928AL137163Hs.57549hypothetical protein 12.5 dJ473B4 400240 0 12.5 413048M93221Hs.75182mannose receptor, C 12.5 type 1 3 426215AW963419Hs.155223ESTs 12.5 430024A1808780Hs.227730integrin, alpha 6 12.5 445655AA873830Hs.i67746Bcelllinkerprotein 12.5 419941X98654Hs.93837phosphatidylinositol 12.5 transfer protein, membra 425280U31519Hs.1872phosphoenolpyruvate 12.5 carboxykinase 1 (soluble) 40 427767AI879283Hs.180714cytochrome c oxidase 12.4 subunit Vla polypeptide 450243AW119084Hs.201037ESTs 12.4 408930AA146721Hs.49005hypothetical protein 12.4 418783T41368 gb:phldl 19I1TV Outward12.4 Alu-primed hncDNA
lib 452096BE394901Hs.226785ESTs 12.4 45 424513BE385864Hs.149894mitochondria) translafional12.4 inifiation factor 422306BE044325Hs.227280Homo Sapiens mRNA far 12.4 Lsm5 protein 409031AA376836Hs.76728ESTs 12.4 435515N40080Hs.6879DC13 protein 12.4 429583NM Hs.2091191-acylglycerol-3-phosphate12.3 006412 0-acyltransferase 449643805989Hs.19603ESTs 12.3 440313AL050060Hs.7158DKFZP566H073 protein 12.3 425593AA278921Hs.1908proteoglycan 1, secretary12.3 granule 447357AI375922Hs.159367ESTs 12.3 405089 0 12.3 5 414972BE263782Hs.77695KIAA0008 gene product 12.3 435039AW043921Hs.130526ESTs 12.3 447033A1357412Hs.157601EST-not inUniGene 12.3 427521AW973352Hs.299056ESTs 12.3 409377AA300274Hs.115659Homo Sapiens cDNA: 12.3 FLJ23461 fis, clone 400116 0 12.3 445806AL137516Hs.13323hypothelicalprotein 12.2 457817AA247751Hs.79572cathepsin D (lysosomal12.2 aspartyl protease) 442410AW996503Hs.197680ESTs 12.2 445404AI261687Hs.145541ESTs, Weakly similar 12.2 to JC4974 sodium iodide 65 403372AW249152Hs.44017SIR2 (silent mafing 12.2 type information regulati 427082AB037858Hs.173484hypothetical protein 12.2 433764AW753676Hs.39982ESTs 12.2 400268 0 12.2 433190M26901Hs.3210renin 12.2 444863AW384082Hs.301323ESTs 12.2 434779AF153815Hs.50151potassium inwardly-recfifying12.2 channel, subfam 451346NM_006338Hs.26312glioma amplified on 12.2 chromosome 1 protein (leu 430262AA218780Hs.237323N-acetylglucosamine-phosphate12.2 mutase 421071AI311238Hs.104476ESTs 12.2 75 426773NM-015556Hs.172180KIAA0440 protein 12.1 4091788E393948Hs.50915kallikrein 5 12.1 400250 0 12.1 428450NM Hs.184339KIAA0175 gene product 12.1 414531T693B7Hs.76364allograft inflammatory12.1 factor 1 8~ 448210AW247775Hs.7393hypothetical protein 12.1 from EUROIMAGE 1987170 440061AA863389Hs.135643ESTs 12.1 413179N99692Hs.75227NADH dehydrogenase 12.1 (ubiquinone) 1 alpha subco 447551BE066634Hs.929myosin, heavy polypepfide12.1 7, cardiac muscle, 400517AF242388Hs.149585lengsin 12.1 401610 0 12.0 454381AI935093Hs.193428ESTs 12.0 443997AW081465Hs.299644ESTs 12.0 402944 0 12.0 430637BE160081Hs.256290S100 calcium-binding 12.0 protein A11 (calgizzarin 415099AId92170Hs.77917ubiquifin carboxyl-terminal12.0 esterase L3 (ubiq 445422AV653731Hs.282829ESTs 12.0 416667AK000526Hs.79457hypothetical protein 12.0 442611BE077155Hs.177537ESTs 12.0 1 443271BE568568Hs.195704ESTs 12.0 ~

415120N64464Hs.34950ESTs 12.0 439574AI469788Hs.165190ESTs 12.0 405804 0 12.0 412519AA196241Hs.73980Uoponin T1, skeletal, 12.0 slow .

15 414135NM Hs.2128dual specificity phosphatase12.0 447075AV662037Hs.124740ESTs 12.0 416841N33878Hs.249495heterogeneous nuclear 12.0 ribonucleoprotein A1 402943 0 11.9 416933BE561850Hs.80506small nuclear ribonucleoprotein11.9 polypeptide A

439744AL389994Hs.301272ESTs, Weakly similar 11.9 to homologue of Drosphil 405762 0 11.9 408983NM_000492Hs.663cystic fibrosis Uansmembrane11.9 conductance reg 455102BE005496 gb:CM1-BN0117-110400-183-b0911.9 BN0117 Homo sapi 402840 0 ' 11.9 25 449183AW445022Hs,196985Homo sapiens cDNA: FLJ2113511.9 fis, clone CAS072 439273AW139099 Hs.269701ESTs 11.9 450484BE220675 gb:ht98f11.x1 NCI_CGAP-Lu2411.9 Homo Sapiens cDNA

445431AF137386Hs.12701plasmolipin 11.9 401888 0 , 11.9 30 426037AW160780Hs.166071cyclin-dependent kinase11.9 416742838644Hs.248420ESTs 11.9 418324AW246273Hs.84131threonyl-tRNA synthetase11.8 412870N22788Hs.82407Homo Sapiens HSPC296 11.8 mRNA, partial cds 432680T47364Hs.278613interferon, alpha-inducible11.8 protein 27 3 421478AI683243Hs.97258ESTs 11.8 426635BE395109Hs.129327ESTs 11.8 420523AA262999Hs.42788ESTs 11.8 426227067058Hs.168102Human proteinase acfivated11.8 receptor-2 mRNA; 3 416658003272Hs.79432fibrillin 2 (congenital11.8 contractural arachnod 441816AI401807Hs.i49997ESTs 11.8 424596A8020639Hs.151017estrogen-relaledreceptor11.8 gamma 400640 0 11.8 448133AA723157Hs.73769folate receptor 1 (adult)11.8 401532 0 11.8 4Jr400161 0 11.8 442556AL137761Hs.8379Homo Sapiens mRNA; cDNA11.7 DKFZp586L2424 (from c 451002AA013299Hs.8018ESTs, Weakly similar 11.7 to ALU3-HUMAN ALU SUBFAM

401879 0 11.7 415989A1267700Hs.111128ESTs 11.7 416434AW163045Hs.79334nuclear factor, interleukin11.7 3 regulated 410616AW873d01Hs.273599ESTs 11.7 449239T24653Hs.23360likely orlholog of yeast11.7 447669AL049985Hs.19180Homo Sapiens mRNA; cDNA11.7 DKFZp56dE122 (from c7 436877AA931484Hs.121255ESTs, Weakly similar 11.7 to cDNA EST EMBL:D67419 55 434560813052Hs.3964Homo Sapiens clone 2487711.7 mRNA sequence 448105AW591433Hs.170675ESTs, Weakly similar 11.7 to TMS2_HUMAN TRANSMEMBR

400279 0 11.6 440497AA8B7266Hs.144979ESTs 11.6 451260AW750773 gb:CMO-GN0044-260100-164-h03t CN004d Homo sapi 1.6 429175AI953040Hs.127714ESTs, Moderately similar11.6 to SOX30 protein [H.

408209NM_004454Hs.43697ets variant gene 5 (ets-related11.6 molecule) 428856AA436735Hs.183171Homo Sapiens cDNA: FLJ2200211.6 fis, clone HEPO66 420153N22120Ns.75277hypothefical protein 11.6 428760A1351459Hs.i92398ESTs 11.6 65 421401AW410478Hs.104019Uansforming, acidic 11.6 coiled-coil containing p 404502 0 11.6 430423A1190548Hs.143479ESTs, Weakly similar 11.6 to hypothetical protein 405192 0 11.6 439092AA830149 gb:oc44f08.s1 NCI_CGAP-GCBs11.6 HomosapienscDNA

401714 0 11.5 439335AA742697Hs.62492ESTs, Weakly similar 11.5 to 559856 collagen alpha 406082S47833Hs.82927adenosine monophosphate11.5 deaminase 2 (isoform 401010 0 i1.5 412140AA219691Hs.73625RAB6 interacting, kinesin-like11.5 (rabkinesin6) 75 409339A8020686Hs.54037ectonucleofide pyrophosphataselphosphodiester11.5 459684 gb:ao86a08,x1 Schiller 11.5 meningioma Homo sapien 451051BE254309Hs.125262DKFZP586G1624 protein 11.5 415323BE269352Hs.949neutrophil cytosolic 11.5 factor 2 (65kD, chronic 412153887934 gb:yo47b10.r1 Soares 11.5 adult brain N2b4HB55Y
Ho 8~ 427256AL042436Hs.97723ESTs 11.5 406708AI282759Hs.242463kerafin 8 11.4 457644AA770080Hs.144962ESTs, Moderately similar11.4 to 159365 ubiquitin 422848225884Hs.121483chloride channel 1, 11.4 skeletal muscle (Thomsen 424134AF070637Hs.140950, hypothetical protein 11.4 451931AK000208Hs.27267Homo Sapiens cDNA FLJ2020111.4 fis, clone COLF121 400438AF185611Hs.115352growth hormone 1 11.4 412994D32257Hs.75113general transcription 11.4 factor IIIA

408124089337Hs.42853cAMP rosponsive element11.4 binding protein-like 452249BE394412Hs.61252ESTs 11.4 424627AA344555 gb:EST50715 Gall bladder11.4 I Homo Sapiens cDNA

405626 0 11.4 436690AA373970Hs.183096ESTs 11.4 415862851034Hs.144513ESTs 11.4 406755N80129Hs.94360metallothionein 1L 11.4 433657AI244368Hs.8124PH domain containing 11.4 protein in refina 429612AF062649Hs.252587pituitary tumor-transforming11.4 423334AK000906Hs.127273hypothetical protein 11.4 433053BE301909Hs.279952glutathione S-transferase11.4 subunit 13 homolog I 428423AU076517Hs.184276solute carrier family 11.3 S 9 (sodiumlhydrogen exch ~

442353BE379594Hs.49136ESTs 11.3 447700A1420183Hs.171077ESTs, Weakly similar 11.3 to similar to serinelthr 402077 0 11.3 409203AA780473Hs.687cytochrome P450, subfamily11.3 IVB, polypeptide 1 405145 0 11.3 428248A1126772Hs.40479ESTs 11.3 425508AA99i551Hs.97013ESTs 11.3 428340AF261088Hs.154721aconitase 1, soluble 11.3 431452A1073641Hs.152372ESTs 11.3 446651AA393907Hs.97179ESTs 11.3 443755C18397Hs.9730tachykinin 3 (neuromedin11.3 K, neurokinin beta) 436209AW850417Hs.254020ESTs, Moderately similar11.3 to unnamed protein p 401020 0 11.3 456724AW247388Hs.301423calcium binding protein11.2 1 (calbrain) 30 d07227H94949Hs.171955trophinin associated 11.2 protein (tastin) 402066 0 11.2 442721A1015892Hs.101282Homo Sapiens mRNA; 11.2 cDNA DKFZp434B102 (from c1 401025 0 11.2 452423AA991724Hs.180535Homo sapiens cDNA: 11.2 FLJ22711 fis, clone 3 431685AW296135Hs.267659vav 3 oncogene 11.2 S

425176AW015644Hs.301430ESTs, Moderately similar11.2 to TEFi HUMAN TRANSG

435496AW840i71Hs.265398ESTs, Weakty similar 11.2 to transformation-relate 409079W87707Hs.82065intedeukin 6 signal 11.2 transducer (gp130;
oncos 456995T89832Hs.170278ESTs 11.2 40 419223X60111Hs.1244CD9 antigen (p24) 11.2 407788BE514982Hs.38991S100 calcium-binding 11.2 protein A2 407604AW191962Hs.288061actin, beta 11.2 437929T09353Hs.106642ESTs, Weakly similar 11.1 to hypothetical protein 415789H01581 gb:yj33tO8.r1 Soares 11.1 placenta Nb2HP Homo sapi 45 424447AL137376Hs.147368Homo sapiens mRNA; 11.1 cDNA DKFZp434J0226 (from c 436034AF282693Hs.150185infiammafion-related 11.1 G protein-coupled recept 404931 0 11.1 445979A1695047Hs.202395ESTs 11.1 446733AA863360Hs.26040ESTs; Highly similar 11.1 to CYTOCHROME P45 433133A8027249Hs.104741PDZ-binding kinase; 11.1 T-cell originated protein 445258AI635931Hs.147613ESTs 11.1 417251AW015242Hs.99488ESTs; Weakly similar 11.1 to ORF YKR074w [S.cerevi 421041N36914Hs.14691ESTs 11.1 425537AB007913Hs.158291KIAA0444 protein 11.1 55 435763A1243929Hs.190419ESTs 11.1 444790A8030506Hs.1195589 protein 11.1 ~

453857AL080235Hs.35861DKFZP586E1621 protein 11.1 433882090441Hs.3622procollagen-proline, 11.1 2-oxoglutarate 4-dioxyge 405358 0 11.1 60 435814AW615179Hs.152870ESTs 11.0 422809AK001379Hs.121028hypothetical protein 11.0 446772AW29440dHs.144515Homo Sapiens cDNA FLJ1167211.0 fis, clone HEMBA10 456694AW016382Hs.105642Homo Sapiens cDNA: 11.0 FLJ23271 fis, clone 441128AA570256Hs.54628ESTs 11.0 65 432677NM Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polypeptid11.0 412576AA447718Hs.107057ESTs 11.0 411122F00809Hs.143696coactivator-associated11.0 arginine methyltransfe 427225AA432391Hs.258903Homo Sapiens mRNA for 11.0 KIAA1640 protein, pare 426260NM Hs.168669oxoglutarate dehydrogenase11.0 002541 (lipoamide) 70 444652BE513613Hs.11538acfin related protein 11.0 213 complex, subunit 431947AL359613Hs.49933hypotheticalprotein 11.0 DKFZp762D1011 414432BE378174Hs.26506Homo Sapiens clone 11.0 CDABP0005 mRNA sequence 458627AW088642Hs.97984ESTs; Weakly similar 10.9 to WASP-family protein [

409142AL136877Hs.50758chromosome-associated 10.9 polypepfide C

75 447627AF090922Hs.285902CGI-113 protein 10.9 447656NM_003726Hs.19126sro kinase-associated 10.9 phosphoprolein of 55 kD

454227AW963897Hs.44743KIAA7435 protein 10.9 4o2s27 o io.s 422380AA309881Hs.136246ESTs 10.9 $0 455986BE177736 gb:RC1-HT0598-140300-021-g0610.9 HT0598 Homo sapi 410962BE273749Hs.752FK506-binding protein 10.9 1A (l2kD) 450361BE327108Hs.202512ESTs 10.9 457484H57645 gb:yr21e01.r1 Soaros 10.9 fetal liver spleen 407903AI287341Hs.154029. bHLH factor Hes4 10.9 403398 0 10.9 401405 0 10.9 405570 0 10.9 421240872730Hs.29283ESTs, Weakly similar 10.9 to PLK-HUMAN PROTEOGLYCA

403649 0 10.9 447824BE6208C0 gb:601483379T1 NIH 10.9 MGC-69 Homo Sapiens cDNA o 450935BE514743Hs.25664tumor suppressor deleted10.9 in oral cancer-relat ~

439853AL119566Hs.6721lysophospholipase-like10.9 451852851928 gb:yj71c05.r1 Soares '10.9 breast 2NbHBst Homo sapi 1 431218NM Hs.2733homeo box B2 10.9 ~ 002145 457794AA689292Hs.246850ESTs 10.9 44437dAA009841Hs.11039Homo Sapiens cDNA FLJ1279810.9 fis, clone NT2RP20 456566AW235317Hs.2592i4ESTs 10.8 405552 0 10.8 1 439436BE140845Hs.57868ESTs 10.8 435310AA705075Hs.169536Rhesus blood group-associated10.8 glycoprotein 411125AA151647Hs.68877cytochrome b-245, alpha10.8 polypeptide 415807H03139Hs.24683ESTs 10.8 409430821945Hs.166975splicing factor, argininelserine-rich10.8 417033H83784Hs.40532ESTs, Weakly similar 10.8 to PEBP MOUSE PHOSPHATID

418464887580 gb:ym89hOl.r1 Soares 10.8 adult brain N2b4H855Y
Ho 404567 0 10.8 418384AW149266Hs.25130ESTs 10.8 421971063127Hs.110121SEC7 homolog 10.8 25 428769AW207175Hs.106771ESTs , 10.8 459104819238Hs.282057ESTs 10.8 410896AW809637 gb:MR4-ST0124-261099-015-b0710.8 ST0124 Homo sapi 416969AI815443Hs.283404organic canontransporter10.8 408796AA688292Hs.118553ESTs 10.8 426298AW965058Hs.111583ESTs 10.8 421595AB014520Hs.105958Homo Sapiens cDNA: 10.8 FLJ22735 fis, clone 408007AW135965Hs.246783ESTs 10.8 400167 0 10.7 445243A1217439Hs.109854ESTs, Weakly similar 10.7 to ALU1 HUMAN ALU
SUBFAM

3 421733AL119671Hs.1420fibroblastgrowth factorreceptor310.7 S (achondro 412241AW948343 gb:RCO-MT00i5-130400-031-c0110.7 MT0015 Homo sapi 425827W28316 gb:45b6 Human retina 10.7 cDNA randomly primed sub 420255NM Hs.1298membrane metallo-endopepfidase10.7 007289 (neutral endop 430891022492Hs.248118G protein-coupled receptor10.7 40 402883 0 10.7 423811AW299598Hs.50895homeo box C4 10.7 447078AW885727Hs.301570ESTs 10.7 414343AL036166Hs.75914coated vesicle membrane10.7 protein 446913AA430650Hs.16529Uansmembrane 4 superfamily10.7 member (tetraspan 45 452279AA286844Hs.61260hypothetical protein 10.7 401220 0 10.7 459259AJ003294 gb:AJ003294 Selected 10.7 chromosome 21 cDNA
libra d14171AA360328Hs.865RAP1A, member of RAS 10.7 oncogene family 448449BE314567Hs.211440ESTs 10.7 429670L01087Hs.211593protein kinase C, theta10.7 446759861463Hs.i6165expressed in activated10.7 TILAKIymphocytes 400776 0 10.7 428093AW594506Hs.104830ESTs 10.7 412801AA121055 gb:zm22b01.r1 SUatagene10.6 pancreas (937208) Ho 5 440545AW183201Hs.190559ESTs 10.6 434540NM-016045Hs.5184TH1 drosophila homolog10.6 414273BE269057 gb:601184231F1 NIH_MGC-810.6 Homo Sapiens cDNA
cl 401817 0 10.6 410423AW402432Hs.63489protein tyrosine phosphatase,10.6 non-receptor ly 60 430590AW383947Hs.246381CD68 antigen 10.6 426680AA320160Hs.1718i1adenylate kinase 2 10.6 445413AA151342Hs.12677CGI-147 protein 10.6 402947 0 10.6 457426AW971119 gb:EST383206 MAGE resequences,10.6 MAGL Homo sapi 65 424148BE242274Hs.1741integrin, beta? 10.6 ' 404944 0 10.6 405421 0 10.6 416772A1733872Hs.79769protocadherin 1 (cadherin-like10.6 1) 414191AW250089Hs.75807PDZ and LIM domain 10.6 1 (elfin) 7~ 457588AI571225Hs.284171KIAA1535 protein 10.6 406038Y14443Hs.88219zinc finger protein 10.6 404790 0 10.6 418922AW956580Hs.42699Thrombospondin-1 (Hs.87409)10.6 425940A8023184Hs.163990KIAA0967 protein 10.6 75 448749AW859679Ns.21902Homo Sapiens clone 10.6 25237 mRNA sequence 418870AF147204Hs.89414CXCR4; chemokine CXG 10.5 receptor 4 (fusin) 417933X02308Hs.82962thymidylate synthetase10.5 450538AW297396Hs.227052ESTs 10.5 427928AA417662Hs.119217ESTs 10.5 432721AL121478Hs.3132steroidogenic acute 10.5 regulatory protein 429267AA299290Hs.246857ESTs, Highly similar 10.5 to S71100 protein kinase 439190AW978693Hs.293811ESTs 10.5 d08975AW958693Hs.49391hypothetical protein 10.5 415130W85893Hs.249867ESTs 10.5 425738H29630Hs.159408Homo Sapiens clone 10.5 24420 mRNA sequence 440232A1766925Hs.i12554ESTs 10.5 425065AA371906Hs.294151ESTs, Moderately similar10.5 to KIAA054d protein 420829AW665612Hs.221969ESTs 10.5 430466AF052573Hs.241517polymerase (DNA directed),~
theta 10.5 407771AL138272Hs.62713ESTs 10.5 444611AK002180Hs.114d9DKFZP5640123 protein 10.5 444665BE613126Hs.47783ESTs, Weakly similar 10.5 to T12540 hypothetical p 448030N307idHs.20161HDCME31P protein 10.5 1 438982AW97910iHs.291980ESTs 10.5 ~

446224AW450551Hs.13308ESTs 10.5 405108 0 10.5 438233W52448Hs.56147ESTs 10.5 401799 0 10.5 15 454038X06374Hs.37040platelet-derived growth10.5 factor alpha polypept 414222AL135173Hs.878sorbitoldehydrogenase 10.5 421828AW891965Hs.289109dimethylarginine dimethylaminohydrolase10.5 422626AA344932Hs.118786metallothionein 2A 10.5 449261AI637592Hs.224958ESTs 10.4 2~ 416218821499Hs.23213ESTs 10.4 457848W26524Hs.125682ESTs; Weakly similar 10.4 to D2092.2 [C.elegans]

442577AA292998Hs.163900ESTs 10.4 406505AF016272Hs.115418cadherin 16, KSP-cadherin10.4 412258AA376768Hs.288977Homo Sapiens cDNA: 10.4 FLJ22622 fis, clone 25 429224AI905780Hs.198272NADH dehydrogenase 10.4 (ubiquinone) 1 beta subcom 447774BE018118Hs.19554chromosome 1 open reading10.4 frame 2 403914 0 10.4 406329 0 10.4 ' 402423 0 10.4 431986AA536130Hs.149018ESTs 10.4 423145BE264548Hs.222190ESTs, Weakly similar 10.4 to secretory carrier mem 414402BE294186 gb:601172959F1 NIH 10.4 MGC-17 Homo sapiens cDNA c 417079065590Hs.81134interleukin 1 receptor10.4 antagonist 426095AI278023Hs.89986ESTs 10.4 3 434577837316Hs.179769Homo Sapiens cDNA: 10.4 FLJ22487 fis, clone 442415A1005101Hs.129550ESTs 10.3 421506BE302796Hs.105097ihymidine kinase 1, 10.3 soluble 435084D17516Hs.301607adenylate cyclase activating10.3 polypeptide 1 (p 431724AA514535Hs.283704ESTs 10.3 456798AJ006422Hs.135183centaurin-alpha 10.3 41737(1T28651Ns.82030tryptophanyl-tRNA synthetase10.3 422596AF063611Hs.1186332'-5'oligoadenylate 10.3 synthetase-like 435226AI248938Hs.270106ESTs 10.3 433192AB040880Hs.225594ESTs, Moderately similar10.3 to KIAA1447 protein 45 419879217805Hs.93564Homer, neuronal immediate10.3 early gene, 2 416228AW505190Hs.79089sema domain, immunoglobulin10.3 domain (1g), Uan 453403BE466639Hs.61779Homo Sapiens cDNA FLJ1359110.3 fis, clone PLACE10 447906AL050062Hs.19999DKFZP566K023 protein 10.3 401782NM-012434Hs.117865solute cartierfamily 10.3 17 (anionisugar transpo 453927AA082465Hs.301751ESTs, Weakly similar 10.3 to /prediction 450737AW007152Hs.203330ESTs 10.3 421633AF121860Hs.106260sorting nexin 10 10.3 409881AF139799Hs.202830ESTs 10.3 432883048936Hs.3112sodium channel, nonvoltage-gated10.3 1, gamma 5 440099AL080058Hs.6909DKFZP564G202 protein 10.3 419024X56411Hs.1219alcohol dehydrogenase 10.3 4 (class II), pi polype 401835 0 10.3 408896A1610447Hs.d8778niban protein 10.3 443120AW402677Hs.290801ESTs 10.3 400208 0 10.2 416908AA333990Hs.80424coagulation factor 10.2 X111, A1 polypeptide 400166 0 10.2 434642W25739Hs.135287ESTs 10.2 424837BE276113Hs.153436N-acetylUansferase, 10.2 homolog of S. cerevisiae 65 435075851094Hs.12400ESTs 10.2 425912AL137629Hs.162189serinelthreonine kinase10.2 with Dbl- and pleckst 435080A1831760Hs.155111ESTs 10.2 414998NM-002543Hs.77729oxidised low density 10.2 lipoprotein (lectin-like 410020T86315Hs.728ribonuclease, RNase 10.2 A family, 2 (liver, eosin 411410820693Hs.69954laminin, gamma 3 10.2 450294H42587Hs.238730ESTs 10.2 421154AA284333Hs.287631Nomo Sapiens cDNA FLJ1426910.2 fis, clone PLACE10 414271AK000275Hs.75871protein kinase C binding10.2 protein 1 40D812 0 10.2 75 425843BE3i3280Hs.159627death associated protein10.2 449392241698Hs.26039Homo Sapiens cDNA FLJ7393710.2 fis, clone Y79AA10 409089NM-014781Hs.50421KIAA0203 gene product 10.2 401383 0 10.2 456855AF035528Hs.153863MAD (mothers against 10.2 decapentaplegic, Drosoph 442912A1088060Hs.131450ESTs 10.2 400954D25969Hs.76325Homo Sapiens cDNA: 10.2 FW23125 fis, clone 401029BE382701Hs.25960v-myc avian myelocytomatosis10.2 viral related on 416602NM-OD6159Hs.79389net (chicken)-like 10.2 421905AI660247Hs.32699ESTs, Weakly similar 10.2 to LIV-1 protein [H.sapi 4o5os4 o io.a 450832AW970602Hs.105421ESTs 10.2 440076832052Hs.178617ESTs, Weakly similar 10.2 to AF1518401 CGI-82 pro 447563BE536115Hs.160983ESTs 10.2 421238AB033101Hs.102796KIAA1275 protein 10.2 400882 0 10.2 415738BE539367Hs.295953ESTs, Weakly similar 10.1 to AF2200491 uncharacte 445464AW172389Hs.249999ESTs 10.1 459042AW272058Hs.210338ESTs 10.1 1 414469851952Hs.32587stedod receptor RNA 10.1 ~ activator 1 (complexes w 434732A1078443 gb:oz05g05.x1 Soares 10.1 fetal liver_spleen_1NFL5 441030AW204139Hs.174424ESTs, Weakly similar 10.1 to p140mDia [M.musculus]

446855BE616767Hs.162698-cell CLLIlymphoma 10.1 456785AF151074Hs.132744hypothetical protein 10.1 15 404182 0 10.1 410358AW975168Hs.13337ESTs, Weakly similar 10.1 to unnamed protein produ 430355NM-006219Hs.239818phosphoinosifide-3-kinase,10.1 catalytic, beta po 442152839246Hs.239666Homo Sapiens cDNA FLJ1349510.1 fis, clone PLACE10 436354AI879252Hs.5151Homo Sapiens mRNA; 10.1 cDNA DKFZp564C2163 (from c 20 426711AA383471Hs.180669conserved gene amplified10.1 in osteosarcoma 450599AA460865Hs.48516ESTs 10.1 454393BE153288 gb:PMO-HT0335-180400-008-cOB10.1 HT0335 Homo sapi 403383 0 10.1 415947U04045Hs.78934mutS (E. coli) homolog10.1 2 (colon cancer, nonpo 411773NM Hs.72026protease, sg~ne, 21 10.1 006799 (lestisin) 412116AW402166Hs.784Epstein-Barrvirus induced10.1 gene 2 (lymphocyte 413808J00287Hs.182183caldesmon 1 10.0 458572A1223423Hs.292794ESTs 10.0 403295 0 10.0 3~ 403910 0 10.0 453400A1991901Hs.82590ESTs, Moderately similar10.0 to ALU7-HUMAN ALU
SU

406502 0 10.0 404743 0 10.0 412517BE271584 gb:601141065F1 NIH 10.0 MGC-9 Homo Sapiens cDNA c1 -35 4a2s7s o io.o 455864BE148970 gb:CMO-HT0245-031199-085-h0510.0 NT0245 Homo sapi 425734AF056209Hs.159396peptidylglycine alpha-amidaling10.0 monooxygenase 419280W07506Hs.283725Homo Sapiens cDNA FLJ1262710.0 fis, clone NT2RM40 443503AV645438Hs.282927ESTs 10.0 40 423165A1937547Hs.124915Human DNA sequence 10.0 from clone 380A1 on chromo 450206AI796450Hs.201600ESTs 10.0 459052AA298812Hs.98539ESTs 10.0 456248AL035786Hs.82425actin related protein 10.0 2/3 complex, subunit 428438NM Hs.2271Endothelia i 10.0 45 456525AW468397Hs.100000S100 calcium-binding 10.0 protein A8 (calgranulin 426127L36983Hs.167013dynamin 2 10.0 TABLE 138:
Pkey: Unique Eos probesetidenfifiernumber 50 CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Accession Number _ AW809836 AW809774 AW810023 AW810013 AW809813 AW809660 4121531279701_1887934 AW898205 AW896020 AW896035 4133491363558_1BE086692 BE087077 BE087072 T

414402i443240BE294186 BE298975 43441438585_1A1798376 S46400 AW811617 AW811616 W00557 BE142245 AA173345 AA199942 AA223384 AA227092 AA227080 Ti AA157730 AA157715 AA05352d AW849581 AW854566 C05254 i 455864 1377038_1 BE148970 BE148975 BE148957 BE148937 ' 455986 1397521 1 BE177736 BE177735 BE177734 TABLE 13C:
Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Identifier (GI) numbers. "Dunham I. et al." refers 1o the publication entitled "fhe DNA sequence of 15 human chromosome 22" Dunham, et al. (1999) Nature 402:489-495 Strand: Indicates DNA strand from which exons were predicted N~posiGon: Indicates nucleotide positions of predicted exons Pkey Ref Strand Nt~osition 400640 8117686 Plus 144324-144429 400666 8118496 Plus 17982-18115,20297-20456 400776 8131651 Plus 103576-103720 400812 8568711 Plus 71708-72153 400881 2842777 Minus 91446-91603,92123-92265 25 400882 2842777 Minus 110431-1107Q8 400965 7770576 Minus 173043-173564 401010 8117391 Minus 83967-84180 401020 8117458 Minus 59085-60227 401025 8117518 Minus 179287-179483,181044-181166,181844-182039 3 0 401047 6705887 Minus 4804-5035,5133-5314 401131 8699812 Minus 94802-94987,95804-95887,96323-96487,97596-97826 401192 9719502 Minus 69559-70101 401220 9929324 Minus 48079-48279 401383 6721135 Minus 155543-157381 35 401405 7768126 Minus 69276-69452,69548-69958 401519 6649315 Plus 157315-157950 401532 7798785 Plus 124414-124950,125050-125418 401610 7705041 Minus 18921-19505 ' 401714 6715702 Plus 96484-96681 4~ 401735 3252819 Plus 217235-217356,217621-217873 401799 7331447 Plus 147802-148251 401817 7417850 Minus 4588&46535 401835 7139700 Plus 142257-142742 401879 8099914 Minus 101064-102827 45 401888 8516069 Minus 189498-190514 401897 8569218 Plus 604-767 402066 6649269 Plus 135543-136031 402077 8117414 Plus 65014-65195 402104 8119072 Plus 122409-122600 0 402238 7690126 Plus 24726-24880,26791-27021 402287 4559317 Plus 40811-42447 402389 9885999 Minus 771-972,1571-1683 402408 9796239 Minus 110326-110491 402423 9796344 Minus 62487-62664 5 5 402424 9796344 Minus 64925-65073 402496 9797769 Minus 8615-9103 402520 7596899 Minus 171761-171996 402679 8113438 Plus 132079-132216 402840 9369121 Minus 57118-57306 402883 9926562 Plus 38666-38803,38885-39019,39097-39231,39308-39445 402885 9926751 Plus 71919-72049 402926 8217647 Minus 41261-41443 402927 8217647 Minus 47247-47396 402943 6456831 Plus 38467-39068 65 402944 9368423 Plus 110411-110716,111173-111640 402947 9368458 Minus 101629-101991 402965 9581599 Minus 46865-46941,47032-47148 403022 3132351 Plus 92097-92864 403121 9180223 Plus 4059-4258 403165 9838098 Minus 90595-91848 403295 8096528 Plus 22386-22708 403381 9438267 Minus 26009-26178 403383 9438267 Minus 119837-121197 403398 6862689 Minus 13685-14699 75 403399 6684178 Plus 61841-62145,62367-62756 403482 9966050 Plus 196964-197135 403485 9966528 Plus 2888-3001,3198-3532,3655-4117 403649 8705159 Minus 27141-27247 403910 7710710 Minus 5761-6188 403912 7710730 Minus 72000-72290,72431-72700,72929-73199 403914 7417588 Minus 7431-8472 404182 4775644 Plus 18163-18444 404502 7229863 Minus 56277-56819 404567 7249169 Minus 101320-101501 4046789797204Plus115196-115448 4047438894169Minus120556-120999 4047809887810Minus175708-175871 4047907230958Plus38611-38761 4049317342203Plus44226-44382 4049446899705Plus4256-4581 4050247107727Plus88500-88697 4050898072523Plus103182-103973 d050948072579Plus135587-135758 1 4051087107890Minus135020-135472 ~

4051459438278Plus37883-38052,38138-38332 4051927230070Plus115629-116071 4052246731245Minus14413-15979 4052953818412Plus56933-57099 1 4053532811095Plus118525-118892 4053582341017Minus18016-18315 4054217243869Minus97411-97687 4054267243900Minus37640-37817 4054527656638Minus93876-94275 4054845922025Plus199214-199579,199672-199920,200262-200495 4055521552506Plus45199-45647 4055702808656Plus98208-98331 ' 4056264508116Minus89275-89384,92450-92629,97091-97279,98546-98666 4056994165331Plus100727-100859 4057625931935Plus160502-16111 4058025924004Minus27743-28264 4058047274891Minus122557-123551 4063296982072Minus.607903-608271 4064299256476Minus83206-83365,94051-94193 4065027711350Minus63430-63602 Table 14A lists about 695 genes up-regulated in ovarian cancer compared to normal adult tissues. These were selected from 59680 probesets on the Af<ymetrixlEos Hu03 GeneChip array such that the ratio of "average" ovarian cancer to "average"
normal adult tissues was greater than or equal to 4Ø The "average" ovarian cancer level was set to 3 5 the 90th percentile amongst various ovarian cancers. The "average" normal adult tissue level was set to the 90th percentile amongst various non-malignant tissues. In order to remove gene-specific background levels of non-specific hybridization, the 15th percentile value amongst various non-malignant tissues was subtracted from both the numerator and the denominator before the rafio was evaluated.
TABLE
14A:
ABOUT

UP-REGULATED
GENES, OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES

Pkey:
Primekey Ex.Accn:ExempIarAccession UG niGene ID: ID
U

Title:
UniGene fifie ratio:
ratio of tumor vs.
normal tissues PkeyEx. UG Tifie ratio Accn ID

452838U65011Hs.30743Preferentially expressed70.4 antigen in melanoma 438817A1023799Hs.163242ESTs 62.8 432938T27013Hs.3132steroidogenic acute 57.8 regulatory protein 421478A1683243Hs.97258ESTs 45.7 415989A1267700Hs.111128ESTs 42.7 418179X51630Hs.1145Wilms tumor 1 36.0 449034AI624049 gbas4l a09.x1 NCI CGAP 34.0 Ut1 Homo Sapiens cDNA
clone 428579NM Hs.184942G protein-coupled receptor30.5 55 428153AW513143Hs.98367hypothefical protein 30.1 FLJ22252 similar to SRY-box c 436982AB018305Hs.5378spondin 1, (f-spondin) 29.4 extracellular matrix protei 427585D31152Hs.179729collagen; type X; alpha27.0 1 (Schmid metaphyseal chon 435094AI560129Hs.277523EST 26.2 430691C14187Hs.103538ESTs 26.2 430491AL109791Hs.241559Homo Sapiens mRNA full 26.1 length insert cDNA
clone EU

415511AI732617Hs.182362ESTs 24.8 448243AW369771Hs.77496ESTs 24.7 428187AI687303Hs.285529ESTs 23.9 408081AW451597Hs.167409ESTs 21.9 65 418007M13509Hs.83169Matrix metalloprotease 20.6 1 (interstitial collagenase 400292AA250737Hs.72472BMPR-Ib; bone morphogenetic20.6 protein receptor, iyp 422956BE545072Hs.122579ESTs 20.0 413335AI613318Hs.48442ESTs 19.9 423739AA398155Hs.97600ESTs 18.9 410929H47233Hs.30643ESTs 18.5 424086A13510i0Hs.102267lysyloxidase 17.7 424905NM Hs.153704NIMA (never in mitosis 17.4 002497 gene a)-related kinase 427356AW023482Hs.97849ESTs 17.4 407168845175 gb:yg40f01.s1 Soares 17.1 infant brain 1 NIB
Homo sapien 75 407638AJ404672Hs.288693EST 17.1 427469AA403084Hs.269347ESTs 17.0 438993AA828995 integdn; beta 8 16.7 428664AK001666Hs.189095similar to SALL1 (sat 16.5 (Drosophila)-like d39820AL360204Hs.283853Homo Sapiens mRNA full 16.5 length insert cDNA
clone EU

g0 d21155H87879Hs.102267lysyloxidase 16.1 426635BE395109Hs.129327ESTs 15.9 431989AW972870Hs.291069ESTs 15.9 422805AA436989Hs.121017H2A histone family; 15.9 member A

444783AK001468Hs.62180ESTs 15.8 424581M62062Hs.150917catenin (cadhedn-associated15.7 protein), alpha 2 453197AI916269Hs.109057ESTs,WeaklysimilartoALUS_HUMANALUSUBFAMIL15.7 459325AW088369Hs.282184ESTs 15.6 428976AL037824Hs.194695ras homolog gene family,15.1 member 1 416209AA236776Hs.79078MAD2 (mitotic arrest 15.0 deficient, yeast, homology-li 408660AA525775Ns.292523ESTs 15.0 410247AF181721Hs.61345RU2S 15.0 418738AW388633Hs.6682solute carrier family 15.0 7, member 11 459583AI907673 gb:IL-BT152-080399-004 14.8 BT152 Homo sapiens cDNA, m8 l0 413623AA825721Hs.246973ESTs 14.8 439706AW872527Hs.59761ESTs 14.7 409041A8033025Hs.50081KIAA1199 protein 14.6 451110A1955040Hs.301584ESTs 14.5 436775AA731111Hs.291891ESTs 14.3 15 443211A1128388Hs.143655ESTs 14.3 445258AI635931Hs.1d7613ESTs 14.2 447350A1375572Hs.172634ESTs; HER4 (c-erb-84) 14.2 428227AA321649Hs.2248INTERFERON-GAMMA INDUCED14.1 PROTEIN PRECURS

453392023752Hs.32964SRY (sex determining 13.9 region Y)-box 11 20 447033AI357412Hs.157601EST-not inUniGene 13.7 423811AW299598Hs.50895homeo box C4 13.7 452461N78223Hs.108106iranscdptionfactor 13.7 451106BE382701Hs.25960N-myc 13.6 416208AW291168Hs.41295ESTs 13.5 25 452249BE394412Hs.61252ESTs , 13.4 452055AI377431Hs.293772ESTs 13.2 439243AA593254Hs.191349ESTs 13.1 420149AA255920Hs.88095ESTs 12.9 429125AA446854Hs.271004ESTs 12.9 30 413597AW302885Hs.117183ESTs 12.8 416566NM-003914Ns.79378oyclin A1 12.8 442438AA995998 gb:os26b03.s1 NCI-CGAP-Kid512.7 Homo Sapiens cDNA clon 407710AW022727Hs.23616ESTs 12.6 416661AA6345d3Hs.79440iGF-ll mRNA-binding 12.6 protein 3 35 428392H10233Ns.2265secretory granule, neuroendocrine12.4 protein 1 (782 p 431725X65724Hs.2839Norrie disease (pseudoglioma)12.3 447700AI420183Hs.171077ESTs, Weakly similar 12.2 to similar to serinelthreonin 458027L49054Hs.85195ESTs, Highly similar 12.2 to t(3;5)(q25.1;p34) fusion g 408460AA054726Hs.285574ESTs 12.2 424735031875Hs.152677short-chain alcohol 12.0 dehydrogenase family member 415263AA948033Hs.130853ESTs 11.9 400298AA032279Hs.61635STEAP1 11.8 452096BE394901Hs.226785ESTs 11.7 421451AA291377Ns.50831ESTs 11.6 45 435496AW840171Hs.265398ESTs, Weakly similar 11.6 to transformation-related pro 443715AI583187Hs.9700cyclin E1 11.5 402606#(NOCAT) 11.5 436954AA740151Hs.130425ESTs 11.5 413472BE242870Hs.75379solute camerfamily 1 11.5 (glial high afflnily gluta 50 410102AW248508Hs.279727ESTs; 11.4 408562AI436323Hs.31141Homo Sapiens mRNA for 11.4 KIAA1568 protein, partial c4 452030AL137578Hs.27607Homo sapiens mRNA; cDNA11.4 DKFZp564N2464 (from clon 442353BE379594Hs.49136ESTs 11.3 427344NM Hs.21425-hydroxytryptamine 11.2 000869 (serotonin) receptor 55 453160AI263307Hs.146228ESTs 11.2 426427M86699Hs.169840TTK protein kinase 11.1 449433AI672096Hs.9012ESTs 11.1 412723AA648459Hs.179912ESTs 11.1 400250 0 11.1 419752AA249573Hs.152618ESTs 11.1 438167828363Hs.24286ESTs 11.1 434539AW748078Hs.214410ESTs 10.9 429918AW873986Hs.119383ESTs 10.8 450375AA009647Hs.8850a disintegrin and metalloproteinase10.8 domain 12 (met 65 400289X07820Hs.2258Matrix Metalloproteinase10.8 10 (SUomofysin 2) 420900AL045633Hs.44269ESTs 10.8 428758AA433988Hs.98502Homo sapiens cDNA FLJ1430310.8 fis, clone PLACE2000132 446142AI754693Hs.145968ESTs 10.7 421285NM-000102Hs.1363cytochrome P450, subfamily10.6 XVII (stercid 17-alpha-433496AF064254Hs.49765VERY-LONG-CHAIN ACYL-COA10.6 SYNTHETASE

418506AA084248Hs.85339G protein-coupled receptor10.5 433447029195Hs.3281neuronal pentraxin II 10.4 424188AW954552Hs.142634zinc finger protein 10.4 414245BE148072Hs.75850WAS protein family, 10.3 member 1 75 426462059111Hs.169993dermatan sulphate proteoglycan10.3 418601AA279490Hs.86368calmegin 10.3 444170AW613879Ns.102408ESTs 10.3 453616NM Hs.33846dynein, axonemal, light10.3 003462 intermediate polypeptide 407378AA299264 gb:EST11752 Uterus Homo10.2 Sapiens cDNA 5' end simila 440901AA909358Hs.128612ESTs 10.2 407366AF026942 gb:Homo Sapiens cig33 10.2 mRNA, partial sequence.

415227AW821113Hs.72402ESTs 10.2 409269AA576953Hs.22972Homo Sapiens cDNA FLJ1335210.1 fis, clone OVARC1002165 450480X82125Hs.25040zinc finger protein 10.1 419088AI538323Hs.77496ESTs 10.0 453922AF053306Hs.36708budding uninhibited 9.9 by benzimidazoles 1 (yeast hom 428253AL133640Hs.183357Homo Sapiens mRNA; cDNA9.8 DKFZp586C1021 (from clone 426471M22440Hs.170009transforming growth 9.8 factor, alpha 407881AW072003Hs.40968heparan sulfate (glucosamine)9.7 3-0-sulfotransferase 452291AF015592Hs.28853CDC7 (cell division 9.7 cycle 7, S. cerevisiae, homolo 445537AJ245671Hs.12844EGF-like-domain; mulfiple9.7 442875BE623003Hs.23625Homo Sapiens clone TCCCTA001429.6 mRNA sequence 423992AW898292Hs.137206Homo Sapiens mRNA; cDNA9.6 DKFZp564H1663 (from clon 1 412140AA219691Hs.73625RAB6 interacfing, kinesin-like9.6 ~ (rabkinesin8) 407721Y12735Hs.38018dual-specificity tyrosine-(Y)-phosphorylaficn9.6 regu 438209AL120659Hs.6111KIAA0307 gene product 9.5 429782NM Hs.220689Ras-GTPase-activating 9.5 005754 protein SH3-domain-binding p 424945A1221919Hs.173438hypotheficalprotein 9.5 414972BE263782Hs.77695KIAA0008 gene product 9.4 439262AA832333Hs.124399ESTs 9.4 403381#(NOCAT) 0 9.3 424834AK001432Hs.153408Homo Sapiens cDNA FLJ105709.3 fis, clone NT2RP2003117 435509AI458679Hs.181915ESTs 9.3 ZQ 445413AA151342Hs.12677CG!-147 protein 9,2 414083AL121282Hs.257786ESTs 9.2 421373AA808229Hs.167771ESTs 9.2 430510AW162916Hs.241576hypothefical protein 9.1 446999AA151520Hs.279525hypothefical protein 9.1 459587AA031956 gb:zk15e04.s1 Soares~regnant_uterus-NbHPU9.1 Homo sa 414569AF109298Hs.118258Prostate cancer associated9.1 protein 1 406687M31126Hs.272620pregnancy specific beta-1-glycoprolein9.0 428479Y00272Hs.184572cell division cycle 9.0 2, G1 to S and G2 to M

408908BE296227Hs.48915serine/threonine kinase9.0 431548AI834273Hs.9711Homo Sapiens cDNA FLJ130189.0 fis, clone NT2RP3000685 433764AW753676Hs.39982ESTs 9.0 434636AA083764Hs.241334ESTs 8.9 451807W52854Hs.27099DKFZP564J0863 protein 8.8 437872AK002015Hs.5887RNA binding motif protein8.8 35 443054AI745185Hs.8939yes-associated protein 8.8 65 kDa 420092AA814043Hs.88045ESTs 8.8 420159A1572490Hs.99785ESTs 8.8 447164AF026941Hs.17518Homo Sapiens cig5 mRNA,8.8 partial sequence 451254AI571016Hs.172967ESTs 8.8 432677NM Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polypeptide8.7 004482 N-a 450434AA166950Hs.18645ESTs, Weakly similar 8.7 to partial CDS [C.elegans]

400301X03635Hs.i657Estrogen receptor 1 8.7 408829NM Hs.48384heparan sulfate (glucosamine)8.7 006042 3-0-sulfotransferase 434891AA814309Hs.123583ESTs 8.7 45 436812AW298067 gb:Ul-H-BWO-ajp-g-09-0-ULs18.7 NCI-CGAP_Sub6 Homo s 438885AI886558Hs.184987ESTs 8.7 449765N92293Hs.206832EST, Moderately similar8.7 to ALU8 HUMAN ALU SUBFAM

447342AI199268Hs.19322ESTs; Weakly similar 8.6 to Illl ALU SUBFAMILY
J WARNI

434424AI811202Hs.125365Homo sapiens cDNA: FLJ235238.6 fis, clone LNG05548 438078A1016377Hs.131693ESTs 8.6 437212A1765021Hs.210775ESTs 8.5 417728AW138437Hs.24790KIAA1573 protein 8.5 438081H49546Hs.298964ESTs 8.5 411571AA122393Hs.70811hypothetical protein 8.4 55 435663A1023707Hs.134273ESTs 8.4 424717H03754Hs.152213wingless-type MMTV integration8.4 site family, member 425734AF056209Hs.159396pepfidylglycine alpha-amidafing8.4 monooxygenase COOH

450505NM Hs.25051plakophilin 2 8.4 436211AK001581Hs.80961polymerase (DNA directed),8.3 gamma 436396AI683487Hs.299112Homo Sapiens cDNA FLJ114418.3 fis, clone HEMBA1001323 425695NM-005401Hs.159238protein tyrosine phosphatase,8.3 non-receptor type 14 438180AA808189Hs.272151ESTs 8.2 447268A1370413Hs.36563Homo Sapiens cDNA: FLJ224188.2 fis, clone HRC08590 433159AB035898Hs.150587kinesin-like protein 8.1 65 400195 0 8.1 424906A1566086Hs.153716Homo Sapiens mRNA for 8.1 Hmob33 protein, 3' untransla 438202AW169287Hs.22588ESTs 8.1 438915AA280174Hs.23282ESTs 8.1 448776BE302464Hs.30057transporter similar 8.1 to yeast MRS2 453884AA355925Hs.36232KIAA0186 gene product 8.0 420757X78592Hs.99915androgen receptor(dihydrotestosterone8.0 receptor;t 439759AL359055Hs.67709Homo Sapiens mRNA full 8.0 length insert cDNA
clone EU

453102NM Hs.31664fizzled (Drosophila) 8.0 007197 homolog 10 424001W67883Hs.137476KIAA1051 protein 8.0 75 434415BE177494 gb:RC&HT0596-270300-011-C058.0 HT0596 Homo Sapiens c 417576AA339449Hs.82285phosphoribosylglycinamide7.9 formyltransferase, phosp 438966AW979074 gb:EST391184 MAGE resequences,7.9 MAGP Homo sapiens c 415245N59650Hs.27252ESTs 7.9 422352AA766296Hs.99200ESTs 7.9 425492AL021918Hs.158174zinc finger protein 7.8 184 (Kruppel-like) 442655AW027457Hs.30323ESTs 7.8 445657AW612141Hs.279575ESTs 7.8 450221AA328102Hs.24641cytoskeleton associated7.8 protein 2 426320W47595Hs.169300, transforming growth 7.8 factor, beta 2 414142AW368397Hs.150042ESTs 7.7 412170D16532Hs.73729very low density lipoprotein7.6 receptor 410011AB020641Hs.57856PFTAIRE protein kinase 7.6 436476AA326108Hs.53631ESTs 7.6 414132A1801235Hs.48480ESTs 7.6 437789AI581344Hs.127812ESTs, Weakly similar 7.6 to AF1413261 RNA helicase HD

450192AA263143Hs.24596RAD51-interacting protein7.6 449328AI962493Hs.197647ESTs 7.5 440238AW451970Hs.155644paired box gene 2 7.5 1 403657#(NOCAT) 0 7.5 ~

408826AF216077Hs.48376Homo Sapiens clone HB-27.5 mRNA sequence 418735N48769Hs.44609ESTs 7.5 413627BE182082Hs.246973ESTs 7.4 446293AI420213Hs.i49722ESTs 7.4 15 441627AA947552Hs.58086ESTs 7.4 425465L18964Hs.1904protein kinase C; iota 7.3 409242AL080170Hs.51692DKFZP434C091 protein 7.3 450262AW409872Hs.271166ESTs, Moderately similar7.3 to ALU7-HUMAN ALU SUBFA

440250AA876179Hs.134650ESTs 7.3 451659BE379761Hs.14248ESTs, Weakly similar 7.3 to ALUB HUMAN ALU SUBFAMIL

458861AI630223 gb:adO6g08.r1 Proliferafing7.3 Erythroid Cells (LCB:a 436032AA150797Hs.109276latexin protein 7.2 407771AL138272Hs.62713ESTs 7.2 435039AW043921Hs.130526ESTs 7.2 444342NM_014398Hs.10887similar to lysosome-associated7.2 membrane glycoprote 407829AA045084Hs.29725Homo sapiens cDNA FLJi31977.2 fis, clone NT2RP3004451 409731AA125985Hs.56145thymosin, beta, identified7.2 in neuroblasioma cells 404253#(NOCAT) 0 7.1 424120T80579Hs.290270ESTs 7.1 30 429126AW172356Hs.99083ESTs 7.1 413573AI733859Hs.149089ESTs 7.1 421464AA291553Hs.190086ESTs 7.0 430388AA356923Hs.240770nuclear cap binding 7.0 protein subunit 2, 20kD

437938A1950087 ESTs; Weakly similar 7.0 to Gag-Pol polyprotein [M.mus 35 4203112079734Hs.97206hunfingtin interacting 7.0 protein 1 444743AA045648Hs.11817nudix (nucleoside diphosphate7.0 linked moiety X)-typ 415138C18356Hs.78045fissue factor pathway 6.9 inhibitor 2 TFPI2 410568AW162948Hs.64542pre-mRNA cleavage factor6.9 Im (68kD) 429418AI381028Hs.99283ESTs 6.9 409178BE393948Hs.50915kallikrein 5 6.9 446608N75217Hs.257846ESTs 6.9 425905AB032959Hs.161700KIAA1133 protein 6.9 428532AF157326Hs.184786TBP-interacting protein6.9 433426H69125Hs.133525ESTs 6.9 45 431322AW970622 gb:EST382704 MADE resequences,6.8 MAGK Homo Sapiens 437960AI669586Hs.222194ESTs 6.8 423244AL039379Hs.209602ESTs, Weakly similar 6.8 to ubiquitous TPR motif, Y is 424085NtuL002914Hs.139226replication factor C 6.8 (activator 1) 2 (40kD) 448674W31178Hs.154140ESTs 6.8 438122AI620270Hs.129837ESTs 6.8 440048AA897461Hs.158469ESTs, Weakly similar 6.7 to envelope protein [H.sapien 418478038945Hs.i cyclin-dependent kinase6.7 174 inhibitor 2A (melanoma, p1 407162N63855Hs.142634zinc finger protein 6.7 410804064820Hs.66521Machado-Joseph disease 6.7 (spinocerebellar ataxia 3, 55 424639AI917494Hs.131329ESTs 6.7 432415T16971Hs.289014ESTs 6.7 421470827496Hs.1378annexin A3 6.7 445459AI478629Hs.158465ESTs 6.7 418203X54942Hs.83758CDC28 protein kinase 6.6 432809AA565509Hs.131703ESTs 6.6 409234A1879419Hs.27206ESTs 6.6 438394BE379623Hs.27693CGI-124 protein 6.6 452097AB002364Hs.27916ADAM-TS3 ; a disintegrin-like6.6 and metalloproteas 453745AA952989Hs.63908Homo Sapiens HSPC316 6.6 mRNA, partial cds 65 414136AA812434Hs.178227ESTs 6.6 423248AA380177Hs.125845ribulose-5-phosphate-3-epimerase6.6 454018AW016892Hs.241652ESTs 6.6 452281T93500Hs.28792ESTs 6.5 424620AA101043Hs.151254kallikrein 7 (chymotryptic;6.5 stratum comeum) 452594AU076405Hs.29981solute canter family 6.5 26 (sulfate transporter), me ~

434149243829Hs.19574ESTs, Weakly similar 6.5 to katanin p80 subunit [H.sap 425776025128Hs.159499parathyroid hormone 6.4 receptor2 418677583308Hs.87224SRY (sex determining 6.4 region Y)-box 5 409517X90780Hs.54668iroponin I, cardiac 6.4 75 432666AW204069Hs.129250ESTs, Weakly similar 6.4 to unnamed protein product [H

448706AW291095Hs.21814class II cytokine receptorZCYTOR76.4 429163AA884766 gb:am20a10.s1 Soares 6.4 NFL-T-GBC_S1 Homo Sapiens cDN

413582AW295647Hs.71331Homo Sapiens cDNA: FLJ219716.4 fis, clone HEP05790 419917AA320068Hs.93701Homo Sapiens mRNA; cDNA6.4 DKFZp434E232 (from clone 8~ 424153AA451737Hs.141496MAGE-like2 6.4 434265AA846811Hs.130554Homo Sapiens cDNA: FLJ23089G.4 fis, clone LNG07061 435082AA664273Hs.186104Homo Sapiens cDNA FLJ138036.4 fis, clone THYR01000187 441081AI584019Hs.169006ESTs, Moderately similar6.4 to plakophilin 2b [H.sapi 443539A1076182Hs.134074ESTs 6.4 443830A1142095Hs.143273ESTs 6.4 452606N45202Hs.90012Homo Sapiens cDNA: FLJ234416.4 fis, clone HS100612 418384AW1d9266Hs.25130ESTs 6.3 425371D49441Hs.155981mesothelin 6.3 429441AJ224172Hs.204096lipophilin B (uteroglobin6.3 family member), prostate 449048245051Hs.22920similar to S68401 (cattle)6.3 glucose induced gene 437117AL049256Hs.122593ESTs 6.3 449579AW207260Hs.134014prostate cancer associated6.3 protein 6 453370AI470523Hs.182356ESTs, Moderately similar6.3 to Uanslafion initiation 1 426514BE616633Hs.301122bone morphogenefic protein' ~ 7 (osteogenic protein 6.3 415076NM Hs.77890guanylale cyclase 1, 6.3 000857 soluble, beta 3 408155AB014528Hs.43133KIAA0628 gene product 6.2 452904AL157581Hs.30957Homo Sapiens mRNA; cDNA6.2 DKFZp434E0626 (from clone 439138AI742605Hs.193696ESTs 6.2 15 457030A1301740Hs.173381dihydropyrimidinase-like6.2 436281AW411194Hs.120051ESTs 6.1 407385AA610150Hs.272072ESTs, Moderately similar6.1 to ALU7_HUMAN ALU SUBFA

406815AA833930Hs.288036iRNA isopentenylpyrophosphate6.1 transferase 430437AI768801Hs.169943Homo Sapiens cDNA FLJ135696.1 fis, clone PLACE1008369 428743AL080060Hs.301549Homo Sapiens mRNA; cDNA6.1 DKFZp564H172 (from clone 415139AW975942Hs.4852dESTs 6.1 417404NM Hs.82101-plecksUin homology-like6.1 007350 domain, family A, memt~er 433527AW235613Hs.133020ESTs 6.1 449448D60730Hs.57471ESTs 6.1 457733AW974812Hs.291971ESTs 6.1 457979AA776655Hs.270942ESTs ~ 6.1 422867L32137Hs.1584cartilage oligomeric 6.0 matrix protein 423554M90516Hs.1674glutamine-fructose-6-phosphate6.0 Uansaminase 1 421502AF111856Hs.105039solute carrier family 6.0 34 (sodium phosphate), membe 412733AA984472Hs.74554KIAA0080 protein 6.0 422095AI868872Hs.288966ceruloplasmin (ferroxidase)6.0 449347AV649748Ns.295901ESTs 6.0 440870AI687284Hs.150539Homo Sapiens cDNA FLJ137936.0 fis, clone THYR01000085 437478AL390172Hs.118811ESTs 6.0 35 411598BE336654Hs.70937H3 histone family, member6.0 K

418134AA397769Hs.86617ESTs 6.0 418845AA852985Hs.89232chromobox homolog 5 6.0 (Drosophila NP1 alpha) 452039A1922988Hs.172510ESTs 6.0 410555092649Hs.64311a disintegrin and metalloproteinase5.9 domain 17 (tum 40 412719AW016610Hs.129911ESTs 5.9 410566AA373210Hs.43047Homo Sapiens cDNA FLJ 5,9 13585 fis, clone PLACE1009150 437099N77793Hs.48659ESTs, Highly similar 5.9 to LMA1 HUMAN LAMININ
ALPH

453431AF094754Hs.32973glycine receptor, beta 5.9 40B920AL120071Hs.48998fibroneciin leucine 5,9 rich Uansmembrane protein 45 417866AW067903Hs.82772"collagen, type XI, 5.9 alpha 1"

420440NM_002407Hs.97644mammagiobin 2 5.9 430291AV660345Hs.238126CGI-49 protein 5.9 405547#(NOCAT) 0 5.9 427510247542Ns.179312small nuclear RNA activafing5.9 complex, polypepiide 5O 435793A8037734Hs.4993ESTs 5.8 427975AI536065Hs.122460ESTs 5.8 428949AA442153Hs.104744ESTs, Weakly similar 5.8 to AF2088551 BM-013 [H.sapie 452693179153Hs.48589zinc finger protein 5,8 440138A8033023Hs.6982hypothetical protein 5.8 421246AW582962Hs.300961ESTs, Highly similar 5.8 5 to AF1518051 CGI-47 protein 445424AB028945Hs.12696cortactin SH3 domain-binding5.8 protein 448186AA262105Ns.4094Homo Sapiens cDNA FLJ142085.8 fis, clone NT2RP3003264 425154NM_001851Hs.154850collagen, type IX, alpha5.7 419335AW960146Hs.284137Homo Sapiens cDNA FLJ128885.7 fis, clone NT2RP2004081 60 420637AW976153 gb:EST388262 MAGE resequences,5.7 MAGN Homo Sapiens 431924AK000850Hs.272203Homo Sapiens cDNA FLJ208435.7 fis, clone ADKA01954 446868AV660737Hs.135100ESTs 5.7 452971A1873878Hs.91789ESTs 5.7 428927AA441837Hs.90250ESTs 5.7 65 425282AW163518Hs.155485hunfingtin interacting 5.7 protein 2 419247S65791Hs.89764fragile X mental retardafion5.7 445640AW969626Hs.31704ESTs, Weakly similar 5.7 to KIAA0227 [H.sapiens]

422938NM-001809Hs.1594centromere protein A 5.6 (l7kD) 447078AW885727Hs.301570ESTs 5.6 421247BE391727Hs.102910general Uanscription 5,6 factor IIH, polypeptide 4 (5 407896D76435Hs.41154Zic family member 1 5.6 (odd-paired Drosophila homolog 436556A1364997Hs.7572ESTs 5.6 417830AW504786Hs.132808epithelial cell transforming5.6 sequence 2 oncogene 429826N93266Hs.40747ESTs 5.6 75 432030AI908400Hs.143789ESTs 5.6 443270NM_004272Hs.9192Homer, neuronal immediate5.5 early gene,18 453900AW003582Hs.226414ESTs, Weakly similar 5.5 to ALUS-HUMAN ALU SUBFAMIL

411096080034Hs.68583mitochondrial intermediate5.5 pepfidase 419558AW953679Hs.278394ESTs 5.5 427386AW836261Hs.177486amyloid beta (A4) precursor5.5 protein (protease next 427961AW293165Hs.143134ESTs 5.5 404561#(NOCAT) 0 5.5 429682NM-006306Hs.211602SMC1 (sUuctural maintenance5.5 of chromosomes 1, yea 407216N91773Hs.102267_ lysyloxidase 5.5 410658AW105231Hs.192035ESTs 5.5 413930M86153Hs.75618RA811A, member RAS oncogene5.5 family 414315224878 gb:HSB65D052 STRATAGENE5.5 Human skeletal muscle cD

427878005766Hs.181022CGI-07 protein 5.5 431041AA490967Hs.105276ESTs 5.5 441645A1222279Hs.201555ESTs 5.5 428071AF212848Hs.182339transcdptionfactorESE-385.4 436406AW105723Hs.125346ESTs 5.4 429181AW979104Hs.294009ESTs 5.4 410909AW898161Hs.53112ESTs, Weakly similar 5.4 to ALUB HUMAN ALU SUBFAMIL

424345AKOOi380Hs.145479Homo Sapiens cDNA FLJ105185.4 tis, clone NT2RP2000814 451996AW514021Hs.245510ESTs 5.4 449318AW236021Hs.108788ESTs, Weakly similar 5.4 to zeste [D.melanogaster) 441433AA933809Hs.42746ESTs 5.4 4454958E622641Hs.38489ESTs 5.4 410153BE311926Hs.15830Homo Sapiens cDNA FLJ126915.4 fis, clone NT2RM4002571 442611BE077155Hs.177537ESTs 5.4 452401NM Hs.29352tumor necrosis factor, 5.4 007115 alpha-induced protein 453161AA628608Hs.61656ESTs 5.4 419948AB041035Hs.93847NADPH oxidase 4 5.3 427718AI798680Hs.25933ESTs 5.3 453867A1929383Hs.108196HSPC037 protein 5.3 422634NM Hs.118821CGI-62 protein 5.3 444478W07318Hs.240M-phase ptiosphoprotein5.3 428002AA418703 gb:zv98c03.;1 Soares 5.3 NhHMPu-S1 Homo Sapiens cDNA c 443486NM Hs.9d50zinc finger protein 5.3 003428 84 (HPF2) 451177AI969716Hs.19034ESTs 5.3 408298AI745325Hs.271923ESTs; Moderately similar5.3 to 1!!! ALU SUBFAMILY

435867AA954229Hs.114052ESTs 5.3 423698AA329796Hs.1098DKFZp434J1813prolein 5.3 448543AW897741Hs.21380Homo Sapiens mRNA; cDNA5.3 DKFZp586P1124 (from clone 427660AI741320Hs.114121Homo Sapiens cDNA: FLJ232285.3 tis, clone CAE06654 430345AK000282Hs.239681hypothetical protein 5.3 433222AW514472Hs.238415ESTs, Moderately similar5.3 to ALUB_HUMAN ALU SUBFA

3 449532W74653Hs.271593ESTs 5.3 S

452822X85689Hs.288617Homo Sapiens cDNA: FLJ226215.3 tis, clone HSI05658 437641AA811452Hs.291911ESTs 5.2 418379AA218940Hs.137516tidgetin-like 1 5.2 416530062801Ns.79361kallikrein 6 (neurosin,5.2 zyme) 433589AA886530Hs.188912ESTs 5.2 409143AW025980Hs.138965ESTs 5.2 410303AA32d597Hs.21851Homo Sapiens cDNA FLJ129005.2 fis, clone NT2RP2004321 413384Ntv1,000401Hs.75334exostoses (multiple) 5.2 424698AA16d366Hs.151973hypothetical protein 5.2 45 431229AA496479 gb:zv37h05.r1 Soares 5.2 ovary tumor NbHOT Homo sapien 433377AI752713Hs.43B45ESTs 5.2 445236AK001676Hs.12457hypothetical protein 5.2 406367#(NOCAT) 0 5.2 442500AI819068Hs.209122ESTs 5.2 5 450101AV649989Hs.2d385Numan hbc647 mRNA sequence5.2 419140AI982647Hs.215725ESTs 5.2 411078A1222020Hs.182364ESTs, Weakly similar 5.2 to 25 kDa irypsin inhibitor [

423020AA383092Hs.1608replication protein 5.2 A3 (l4kD) 427061A8032971Hs.173392KIAAi145 protein 5.2 S 439042AW979172 gb:EST391282 MADE resequences,5.2 5 MAGP Homo Sapiens c 452930AW195285Hs.194097ESTs 5.2 417791AW965339Hs.111471ESTs 5.1 433277W27266Hs.151010ESTs 5.1 447835AW591623Hs.t64129ESTs 5.1 60 434401A1864131Hs.71119Putative prostate cancer5.1 tumor suppresser 437496AA452378Hs.170144Homo sapiens mRNA; cDNA5.1 DKFZp547J125 (from clone D

418849AW474547Hs.53565ESTs, Weakly similar 5.1 to 80491.1 [C.elegans]

428093AW594506Hs.104830ESTs 5.1 408621A1970672Hs.46638chromosome 11 open reading5.1 frame 8; fetal brain ( 453096AW294631Hs.11325ESTs ~ 5.1 418852BE537037Hs.273294hypothetical protein 5.1 436787AA908554Hs.192756ESTs 5.1 446577A8040933Hs.15420KIAA1500 protein 5.1 437267AW511443Hs.258110ESTs 5.0 70 419423D26488Hs.90315KIAA0007 protein 5.0 404939 0 5.0 439052AF085917Hs.37921ESTs 5.0 447020T27308Hs.16986hypotheticalprotein 5.0 453878AW964440Hs.19025ESTs 5.0 75 410824AW994813Hs.33264ESTs 5.0 427701AA411101Hs.221750ESTs 5.0 424602AK002055Hs.301129Homo Sapiens clone 238595.0 mRNA sequence 430044AA464510Hs.152812EST cluster (not in 5.0 UniGene) 417423AA197341Hs.111164ESTs 5.0 g0 421477A1904743Hs.104650hypothetical protein 5.0 433384A1021992Hs.124244ESTs 5.0 434160BE551196Hs.114275ESTs 5.0 443555N71710Hs.21398ESTs, Moderately similar5.0 to GNPI_HUMAN GLUCOSAM

416198H27332Hs.99598ESTs 4.9 424539L02911Hs.150402acfivin A receptor, 4.9 type I

436645AW023424Hs.156520ESTs 4.9 417251AW015242Hs.99488ESTs; Weakly similar 4.9 to ORF YKR074w [S.cerevisiae]

447207AA442233Hs.17731hypothefical protein 4.9 416565AW000960Hs.44970ESTs 4.9 425292NM Hs.15554537 kDa leucine-rich 4.9 005824 repeat (L88) protein 435420AI928513Hs.59203ESTs 4.9 435532AW291488Hs.117305ESTs 4.9 443268AI800271Hs.129445hypotheficalprotein 4.9 446140AA356170Hs.26750Homo Sapiens cDNA: FLJ219084.9 fis, clone HEP03830 452891N75582Hs.212875ESTs, Weakly similar 4.9 to KIAA0357 [H.sapiens]

431130NM-006103Hs.2719epididymis-specific; 4.9 whey-acidic protein type; fou 408938AA0590i3Hs.22607ESTs 4.9 432842AW674093Hs.279525hypothetical protein 4.9 436754A1061288Hs.133437ESTs, Moderately similar4.9 to gonadotropin inducible 442573H93366Hs:7567Branched chain aminotransferase4.9 1, cytosolic, 0215 409049AI423132Hs.146343ESTs 4.9 422475AL359938Hs.117313Meis (mouse) homolog 4.9 447112H17800Hs.7154ESTs 4.9 458627AW088642Hs.97984ESTs; Weakly similar 4.8 to WASP-family protein [H.sap 431689AA305688Hs.267695UDP-Gal:betaGIcNAc beta4.8 1,3-galactosylUansferase, 410530M25809Hs.64173ESTs,HighlysimilartoVAB14.8 FIUMANVACUOLARAT

429414AI783656Hs.202095empty spiracles (Drosophila)4.8 homolog 2 418882NM Hs.89433ATP-binding cassette, 4.8 004996 sub-family C (CFTRIMRP), mem 422505AL120862Hs,124165ESTs; (HSA)PAP protein 4.8 (programmed cell death 9;

425977815138Hs.165570Homo Sapiens clone 250524.8 mRNA sequence 428555NM Hs.184908integrin, beta 8 4.8 452909NM Hs.30985pannexin 1 4.8 449535W15267Hs.23672low density lipoproteind.8 receptor-related protein 452232AW020603Hs.271698ESTs 4.8 409732NM Hs.56148NY-REN-58 antigen 4.8 415115AA214228Hs.127751hypothetical protein 4.7 423161AL049227Hs.124776Homo Sapiens mRNA; cDNA4.7 DKFZp564N1116 (from clop 441085AW136551Hs.181245Homo Sapiens cDNA FLJi25324.7 fis, clone NT2RM4000200 423575C18863Hs.i63443ESTs 4.7 415211R64730.compHs.155986ESTs; Highly similar 4.7 to SPERM SURFACE PROTEIN

418804AA809632 gb:nz17h04.s1 NC1 CGAP-GCBt4.7 Homo Sapiens cDNA clo 428405Y00762Hs.2266cholinergic receptor, 4.7 nicotinic, alpha polypeptide 432865AI753709Hs.152484ESTs 4.7 433330AW207084Hs.132816ESTs 4.7 453047AW023798Hs.286025ESTs 4.7 421308AA687322Hs.192843ESTs 4.7 456273AF154846Hs.1148zinc finger protein 4.7 443933A1091631Hs.135501Homo Sapiens two pore 4.7 potassium channel KT3.3 4S 434551BE387162Hs.280858ESTs, Highly similar 4.7 to XPB_HUMAN DNA-REPAIR
PRO

440351AF030933Hs.7179RAD1 (S. pombe) homolog4.7 426300U15979Hs.169228delta-like homolog (Drosophila)4.7 453775NM Hs.35120replication factor C 4.7 002916 (activator 1) 4 (37kD) 446102AW168067Hs.252956ESTs 4.7 420547AF155140Hs.98738gonadotropin-regulated 4.7 testicular RNA helicase 429486AF155827Hs.203963hypothetical protein 4.7 429944813949Hs.226440Homo Sapiens clone 248814.7 mRNA sequence 433042AW193534Hs.281895Homo Sapiens cDNA FLJ116604.7 fis, clone HEMBA1004610 434988AI418055Hs.161160ESTs 4.6 452571W31518Hs.34665ESTs 4.6 434361AF129755Hs.117772ESTs 4.6 406400#(NOCAT) 0 4.6 410227AB009284Hs.61152exosioses (multiple)-like4.6 2 ~

419945AW290975Hs.118923ESTs 4.6 428301AW628666Hs.98440ESTs 4.6 430153AW968128 gb:EST380338 MAGE resequences,4.6 MAGJ Homo Sapiens c 431349AA503653Hs.156942ESTs, Moderately similar4.6 to ALU2 HUMAN ALU SUBFA

446254BE179829Hs.179852Homo Sapiens cDNA FLJ128324.6 fis, clone NT2RP2003137 447505AL049266Hs.18724Homo Sapiens mRNA; cDNA4.6 DKFZp564F093 (from clone 448027AI458437Hs.177224ESTs 4.6 449611A1970394Hs.197075ESTs 4.6 459574A1741122Hs.101810Homo Sapiens cDNA FLJ 4.6 14232 fis, clone NT2RPd000035 409928AL137163Hs.57549hypothetical protein 4.6 dJ473B4 409387AW384900Hs.123526ESTs 4.6 424078A8006625Hs.139033paternally expressed 4.6 gene 3 435244N77221Hs.187824ESTs 4.6 404996#(NOCAT) 0 4.6 407905AW103655Hs.252905ESTs 4.6 411560AW851186 gb:IL3-CT0220-150200-071-H054.6 CT0220 Homo Sapiens c 424341AA385074 gb:EST98673 Thyroid 4.6 Homo Sapiens cDNA 5' end simil 441675AI914329Hs.5461ESTs 4.6 452172H00797Hs.133207Homo Sapiens mRNA for 4.6 KIAA1230 protein, parfial c4 420276AA290938Hs.190561ESTs, Highly similar 4.5 to mosaic protein LR11 [H.sap 402820#(NOCAT) 0 4.5 419699AA248998Hs.31246ESTs 4.5 422529AW015128Hs.256703ESTs 4.5 438018AK001160Hs.5999hypotheficalprotein 4.5 441826AW503603Hs.129915phosphotriesterase related4.5 453931AL121278Hs.25144ESTs 4.5 435538AB0115d0Hs.4930low density lipoprotein4.5 receptor-related protein 457465AW301344Hs.195969ESTs 4.5 418848A1820961Hs.193465ESTs 4.5 408321AW405882Hs.44205cortislafin d.5 447499AW262580Hs.14767dKIAAi621 protein 4.5 424513BE385864Hs.149894mitochondria) translalional4.5 initiation factor 2 432731831178Hs.287820fibronecfin 1 4.5 448275BE514434Ns.20830synapfic Ras GTPase 4.5 acfivating protein 1 (homolog 430371D87466Hs.2d0112KIAA0276 protein d.5 448693AW004854Hs.228320Homo sapiens cDNA: FLJ235374.5 fis, clone LNG07690 407289AA135159Hs.203349Homo Sapiens cDNA FW121494.d fis, clone MAMMA100042 448141AI471598Hs.197531ESTs 4.4 434699AA643687Hs.149425Homo Sapiens cDNA FLJ119804.4 fis, clone HEM8B1001304 417718T86540Hs.193981ESTs 4.d 1 436464A1016176Hs.269783ESTs, Weakly similar 4.4 S to ALU1 FIUMAN ALU
SUBFAMIL

427528AU077143Hs.179565minichromosome maintenance4.4 deficient (S. cerevisia 409092AI735283Hs.172608ESTs 4.d 416241N52639Hs.32683ESTs 4.4 432005AA524190Hs.120777ESTs, Weakly similar 4.4 to ELL2_HUMAN RNA POLYMER

440234AW117264Hs.126252ESTs 4.4 448743A8032962Hs.21896KIAAii36 protein 4.4 451389N73222Hs.21738KIAA1008 protein 4.4 453331A12d0665Hs.8895ESTs 4.4 454036AA374756Hs.93560ESTs, Weakly similar 4.4 to unnamed protein product [H

448133AA723157Hs.73769tolate receptor 1 (adult)4.4 429597NM_003816Hs.2442a disintegdn and meialloproteinase4.4 domain 9 (melt 453279AW893940Hs.59698ESTs 4.4 409459D86407Hs.54481low density lipoproteind.4 receptor-related protein 431708AI698136Hs.108873ESTs 4.4 3 433906A1167816Hs.43355ESTs 4.4 437958BE139550Hs.121668ESTs 4.4 441423A1793299Hs.126877ESTs 4.4 429876AB028977Hs.225974KIAA1054 protein 4.3 446770AV660309Hs.154986ESTs, Weakly similar 4.3 to AF1373861 plasmolipin [H.

3 412078X69699Hs.731d9paired box gene 8 4.3 422093AF151852Hs.111449CGI-94 protein 4.3 423123NM-012247Hs.124027SELENOPHOSPHATE SYNTHETASE4.3 ; Human selenium 448390AL035414Hs.21068hypoiheficalprotein 4.3 453628AW243307Ns.170187ESTs 4.3 40 449722BE280074Hs.23960cyclin B1 4.3 436679AI127483Hs.120451ESTs, Weakly similar 4.3 to unnamed protein product (H

431592869016Hs.293871ESTs, Weakly similar 4.3 to ALU1 HUMAN ALU SUBFAMIL

432383AK000144Hs.274449Homo Sapiens cDNA FLJ201374.3 fis, clone COL07137 419926AW900992Hs.93796DKFZP586D2223 protein 4.3 45 452367U71207Hs.29279eyes absent (Drosophila)4.3 homolog 2 401644#(NOCAT) 0 4.3 410044BE566742Hs.58169highly expressed in 4.3 cancer, rich in leucine heptad 413775AW409934Hs.75528nucleolar GTPase 4.3 424296AI631874Hs.169391ESTs 4.3 50 431118BE264901Hs.250502carbonic anhydrase VIII4.3 432201A1538613Hs.135657TMPRSS3a mRNA for serine4.3 protease (ECHOS1) (TADG-1 451073AI758905Hs.206063ESTs 4.3 451592A1805416Hs.213897ESTs 4.3 452453A1902519 gb:OV-BT009-10119&051 4.3 BT009 Homo Sapiens cDNA, m 5 441020W79283Hs.35962ESTs d.2 S

439024896696Hs.35598ESTs 4.2 453619H87648Hs.33922H.sapiens novel gene 4.2 from PAC 117P20, chromosome 453459BE047032Hs.257789ESTs 4.2 408427AW194270Hs.177236ESTs 4.2 60 419311AA689591 gb:nv66a12.s1 NCI-CGAP_GC814.2 Homo Sapiens cDNA clo 426460D79721Hs.183702Homo Sapiens cDNA FLJ117524.2 fis, clone HEMBA1005582 444540AI693927Hs.265165ESTs 4.2 452943BE247449Hs.31082hypothetical protein 4.2 453913AW004683Ns.233502ESTs 4.2 65 417847A1521558Hs.288312Homo Sapiens cDNA: FLJ223164.2 fis, clone HRC05262 428856AA436735Hs.183171Homo Sapiens cDNA: FLJ220024.2 fis, clone HEP06638 428679AA431765 gb:zw80c03.s1 Soares 4.2 tesfis NHT Homo Sapiens cDNA

441006AW605267Hs.7627CGI-60 protein ' 4.2 436209AW850417Hs.254020ESTs, Moderately similar4.2 to unnamed protein produc 70 446936H10207Hs.47314ESTs 4.2 406076AL390179Hs.137011Homo Sapiens mRNA; cDNA4.2 DKFZp547P134 (from clone 428819AL135623Hs.193914KIAA0575 gene product 4.2 406671AA129547Hs.285754met proto-oncogene (hepatocyte4.2 growth factor recep 418432M14156Hs.85112insulin-like growth 4.2 factor 1 (somatomedia C) 75 417048A1088775Hs.55498geranylgeranyldiphosphate4.2 synthase 1 431750AA514986Hs.283705ESTs 4.2 439314AA382413Hs.178144ESTs 4.2 448582A1538880Hs.94812ESTs 4.2 449554AA682382Hs.59982ESTs 4.2 g 455700BE068115 gb:CM1-BT0368-061299-060-g074.2 0 BT0368 Homo Sapiens c 409073AA063458 gb:zt71 a07.s1 Soares~ineal~land-N3HPG4.1 Homo sapie 433929AI375499Hs.27379ESTs 4.1 415457AW081710Hs.7369ESTs, Weakly similar 4.1 to ALU1 HUMAN ALU SUBFAMIL

444381HE387335Hs.283713. ESTs 4.1 451024AA442176 gb:zw63b08.r1 Soares 4.1 total fetus Nb2HF8_9w Homo so 415539AI733881Hs.72472BMPR-Ib; bone morphogenetic4.1 protein receptor, typ 421515Y11339 Hs.105352GaINAc alpha-2, 6-sialyltransferase4.1 I, long form 420736AI263022Hs.82204ESTs 4.1 453293AA382267Hs.10653ESTs 4.1 409564AA045857Hs.54943fracture callus 1 (rat)4.1 homolog 418378AW962081 gb:EST374154 MAGE resequences,4.1 MAGG Homo Sapiens 429628H09604 Hs.13268ESTs 4.1 439635AA477288Hs.94891Homo Sapiens cDNA: FLJ227294.1 fis, clone HSI15685 1 440452AI925136Hs.55150ESTs, Weakly similar 4.1 ~ to CAYP_HUMAN GALCYPHOStN

443695AW204099Hs.112759ESTs, Weakly similar 4.1 to AF1267801 retinal short-c 448816AB033052Hs.22151KIAA1226 protein 4.1 452795AW392555Hs.18878hypotheficalprotein 4.1 443171BE281128Hs.9030TONDU 4.1 1$ 425322U63630 Hs.155637protein kinase; DNA-acfivated;4.1 catalytic polypep6 442717888362 Hs.180591ESTs, Weakly similar 4.1 to RO6F6.5b [C.elegans]

414747U30872 Hs.77204centramere protein F 4.1 (3501400kD, mitosin) 417300AI765227Hs.55610solute carrier family 4.1 30 (zinc transporter), membe 417389BE260964Hs.82045Midkine (neurite growth-promoting4.1 factor 2) 20 448105AW591433Hs.170675ESTs, Weakly similar 4.1 to TMS2_HUMAN TRANSMEMBR

419131PA4D6293Hs.301622ESTs 4.1 406348#(NOCAT) 0 4.1 419750AL079741Hs.183114Homo Sapiens cDNA FLJ142364.1 fis, clone NT2RP4000515 419790U79250 Hs.93201glycerol-3-phosphate 4.1 dehydrogenase 2 (mitochondria 25 420908AL049974Hs.100261Homo Sapiens mRNA; cDNA4.1 DKFZp564B222 (from clone 421039NM-003478Hs.101299cullin 5 4.t 426890AA393167Hs.41294ESTs d.1 428571NM_006531Hs.2291Probe hTg737 (polycystic4.1 kidney disease, autosomal 452834Ai638627Hs.105685ESTs 4.1 30 428771A8028992Hs.193143KIAA1069 protein 4.0 437949U78519 Hs.41654ESTs 4:0 450568AL050078Hs.25159Homo Sapiens cDNA FLJ107844.0 fis, clone NT2RP4000448 424081NM_006413Hs.139120ribonuclease P (30kD) 4.0 418375NM 003081Hs.84389synaptosomal-associated4.0 protein, 25kD

35 447204AI366881Hs.157897ESTs,ModeratelysimilartoALUC_HUMANiIIIALUCL4.0 407910AA650274Ns.41296fibronectin leucine d.0 dch transmembrane protein 412314AA825247Hs.250899heat shock factor binding4.0 protein 1 436291BE568452Hs.5101ESTs; Highly similar 4.0 to protein regulating cytokin 450654AJ245587Hs.25275Kruppel-type zinc finger4.0 protein 40 426991AK001536Hs.285803Homo Sapiens cDNA FLJ128524.0 fis, clone NT2RP2DD3445 409365AA702376Hs.226440Homo Sapiens clone 248814.0 mRNA sequence 410784AW803201 gb:IL2-UM0077-070500-080-E064.0 UM0077 Homo Sapiens c 413374NM-001034Hs.75319ribonucleotide reductase4.0 M2 polypepfide 413425F20956 gb:HSPD05390 HM3 Homo 4.0 Sapiens cDNA done 032-X4-1 45 417655AA780791Hs.14014ESTs, Weakly similar 4.0 to KIAA0973 protein [H.sapien 424783AA913909Hs.153088TATA box binding protein4.0 (TBP)-associated factor, 425024839235 Hs.12407ESTs 4.0 445941A1267371Hs.172636ESTs 4.0 448595A8014544Hs.21572KIAA0644 gene product 4.0 50 453448AL036710Hs.209527ESTs 4.0 458944N93227 Hs.98403ESTs 4.0 400284 Estrogen receptorl 4.0 441134W29092 Hs.7678cellular refinoic acid-binding4.0 protein 1 408796AA688292Hs.118553ESTs 4.0 55 408296AL117d52Hs.44155DKFZP586G1517protein 4.0 438913AI380429Hs.172445ESTs 4.0 402408 0 4.0 411630U42349 Hs.71119Putafive prostate cancerd.0 tumor suppressor 450701H39960 Hs.288467Homo Sapiens cDNA FLJ122804.0 fis, clone MAMMA10017d 60 439780AL109688 gb:Homo Sapiens mRNA 4.0 full length insert cDNA clone 418301AW976201Hs.187618ESTs 4.0 420077AW512260Hs.87767ESTs 4.0 426572AB037783Hs.170623hypothe6calprotein FLJ111834.0 403721 0 4.0 65 411945AL033527Hs.92137v-myc avian myelocytomatosis4.0 viral oncogene homolo 408684861377 Hs.12727hypotheticalprotein 4.0 FLJ21610 ' 414869AA157291Hs.72163ESTs 4.0 437980850393 Hs.278436KIAA1474 protein 4.0 451050AW937420Hs.69662ESTs 4.0 TABLE
14B:

Pkey: ber Unique Eos probeset idenfifier num CAT
number:
Gene cluster number Accession:
Genbank accession numbers PkeyCAT Accession Number 419311183793_1AA689591AW974261 AA236240 A1077451 424341238294_1AA385074 AA339054 AA339115 AW956359 431322331543_1AW970622 AA503009 AA502998 AA502989 AA502805T92188 AW150329 AI653832 AI762688 AA988777 AA488892 AI35639d 438993_ AA828995 AA834879 AI926361 449034794817_1A1624049 AW117770 A1858360 45102485565 AA442176 AA259181 -.

4557001351264BE068115 BE068104 BE068102 BE068096 BE068i03 BE068154 TABLE4C:

Pkey:
Unique number corresponding to an Eos probeset Ref: The 7 digit numbers in this column are Genbank Identifier Sequence (GI) numbers. "Dunham 1. et al." refers to the publication source. entitled "The DNA sequence of human chromosome 22"
Dunham, et al.
(1999) Nature 402:489-495 SUand:Indicates DNA
strand from which exons were predicted Nt~osition:
Indicates nucleotide positions of predicted exons PkeyRef Strand Nt_position 4016448576138Plus 82655-83959 4024089796239Minus 110326-110491 4026069909429Minus 81747-82094 4028206456853Minus 82274-82443 4033819438267Minus 26009-26178 4036578843996Minus 156223-156370 4037217528046Minus 156647-157366 4042539367202Minus 55675-56055 4045619795980Minus 69039-70100 4049396862697Plus 175318-175476 4049966007890Plus 37999-38145,311652-38998,39727-39872,40557-40674,42351-42450 4055471054740Plus 124361-124520,124914-125050 5 4063489255985Minus 71754-71944 4063679256126Minus 58313-58489 4064009256298Plus 1553-1712,1878-2140,4252-4385,5922-6077 S 5 Table 15A lists about 499 genes up-regulated in ovarian cancer compared to normal adult tissues that are likely to be extracellular or cell-surface proteins. These were selected as for Table 14A, except that the ratio was greater than or equal to 3.0, and the predicted protein contained a structural domain that is indicative of exUacellular localization (e.g., 1g, fn3, egf, 7tm domains). Predicted protein domains are noted.
TABLE 15A:

UP-REGULATED
GENES ENCODING
EXTRACELLULAR/CELL
SURFACE
PROTEINS, OVARIAN
CANCER
VERSUS
NORMAL
ADULT TISSUES

Pkey: Primekey UG ID: UniGene ID

Title: UniGene title Prot. Dom.:
Predicted protein structural domains ratio: ration tumor vs normal tissues Pkey Ex. UG Titie Prot. Dom. ratio Accn ID

415989 AI267700Hs.111128ESTs TM 42.7 428579 NM Hs.184942G protein-coupled TM 30.5 005756 receptor 64 428153 AW513143Hs.98367similar to SRY-boxTM 30.1 containing gene 70 436982 AB018305Hs.5378spondin 1, (f-spondin)SS 29.4 exUacellular matrix 427585 D31152Hs.179729collagen; type Ciq,Collagen27.0 X; alpha 1 (Schmid metaphy 430691 C14187Hs.103538ESTs TM 26.2 418007 M13509Hs.83169Matrix metalloproteaseSS"Peptidase-M1020.6 1 (interstitial collag 400292 AA250737Hs.72472BMPR-Ib; bone morphogeneticTM 20.6 protein rec ' 75 424086 AI351010Hs.102267lysyl oxidase Lysyl-oxidase17.7 424905 NM_002497Hs.153704NIMA (never in pkise,pkinase17.4 mitosis gene a)-related kin 427356 AW023482Hs.97849ESTs TM 17.4 407638 AJ404672Hs.288693EST TM 17.1 427469 AA403084Hs.269347ESTs TM 17.0 g0 438993 AA828995 integdn; beta 8 SS,integrin_816.7 421155 H87879Hs.102267lysyl oxidase SS 16.1 431989 AW972870Hs.291069ESTs SS 15.9 428976 AL037824Hs.194695ras homolog gene ras 15.1 family, member I

416209 AA236776Hs.79078blAD2 (mitotic TM 15.0 . arrest deficient, yeast, hom 413623AA825721Hs.246973ESTs TM 14.8 447350A1375572Hs.172634ESTs; HERO (c-erb-Bd)SS,TM,Furin-like,pkinase14.2 428227AA321649Hs.2248INTERFERON-GAMMA ILS 14.1 INDUCED PRO

452461N78223Hs.108106Uanscdptionfactor G9a,PHD 13.7 451106BE382701Hs.25960N-myc Myc_N term 13.6 416208AW291168Hs.41295ESTs TM 13.5 452249BE394412Hs.61252ESTs homeotwx 13.4 416566NM_003914Hs.79378cyclin A1 cyclin 12.8 416661AA634543Hs.79440IGF-II mRNA-bindingTM 12.6 protein 3 1 431725X65724Hs.2839Nome disease (pseudoglioma)SS,Cys knot12.3 ~ .

458027L49054Hs.85195ESTs, Highly similarTM 12.2 to i(3;5)(q25.1;p34) f 408460AA054726Hs.285574ESTs TM 12.2 415263AA948033Hs.130853ESTs histane 11.9 400298AA032279Hs.61635STEAP1 TM 11.8 15 421451AA291377Hs.50831ESTs TM 11.6 443715AI583187Hs.9700cyclin E1 cyclin 11.5 413472BE242870Hs.75379solute carrier TM,SDF 11.5 family 1 (glial high affinity g7 410102AW248508Hs.279727ESTs; SS 11.4 408562AI436323Hs.31141Homo Sapiens mRNA TM 11.4 for KIAAi 568 prote 20 442353BE379594Hs.49136ESTs TM 11.3 427344NM Hs.21425-hydroxytryptamineTM,neur-chan11.2 000869 (serotonin) receptor 453160AI263307Hs.146228ESTs histone 11.2 412723AA648459Hs.179912ESTs TM 11.1 400250 0 Hist_deacetyl+F10511.1 25 438167828363Hs.24286ESTs 7tm_1 11.1 434539AW748078Hs.214410ESTs ~ TM 10.9 450375AA009647Hs.8850a disintegrin and TM 10.8 metalloproteinase domain 400289X07820Hs.2258Matrix MetalloproteinaseSS,hemopexin10.8 10 (Stromolysin 446142AI754693lis.145968ESTs Cadherin-C 10.7 term 3 421285NM-000102Hs.1363cylochrome P450, TM,p450 10.6 0 subfamily XVII
(steroid 433496AF064254Hs.49765VERY-LONG-CHAIN SS,TM 10.6 ACYL-COA SYNT

418506AA084248Ns.85339G protein-coupled TM 10.5 receptor 39 433447029195Hs.3281neuronal pentraxinSS 10.4 II

414245BE148072Hs.75850WAS protein family,TM 10.3 member t 35 426462059111Hs.i69993dermatan sulphate SS,LRRNT 10.3 proteoglycan 3 418601AA279490Hs.86368calmegin SS 10.3 415227AW821113Hs.72402ESTs TM 10.2 409269AA576953Hs.22972Homo Sapiens cDNA TM 10.1 FLJ13352 fis, clone 0 426471M224d0Hs.170009transforming growthSS,EGF 9.8 factor, alpha 40 407881AW072003Hs.40968heparan sulfate SS 9.7 (glucosamine) 3-0-sulfotran 445537AJ2d5671Hs.12844EGF-like-domain; SS,EGF 9.7 multiple 6 414972BE263782Hs.77695KIAA0008 gene productTM 9.4 435509AI458679Hs.181915ESTs TM 9.3 445413AA151342Hs.12677CGI-147 protein UPF0099 9.2 4S 446999AA151520Hs.279525hypothetical proteinTM 9.1 414569AF109298Hs.118258Prostate cancer TM 9.1 associated protein 406687M31126Hs.272620pregnancy specifichemopexin 9.0 beta-1-glycoprolein 408908BE296227Hs.48915serinelthreonine pkise,TM 9.0 kinase 15 451807W52854Hs.27099DKFZP564J0863 proteinTM 8.8 50 420159AI572490Hs.99785ESTs TM 8.8 432677NM-004482Hs.278611UDP-N-acetyl-alpha-D-galactosamine:polyTM,Ricin-B 8.7 lectin 408829NM-006042Hs.48384heparan sulfate TM 8.7 (glucosamine) 3-0-sulfoUan 438885AI886558Hs.184987ESTs TM 8.7 447342AI199268Hs.19322ESTs; Weakly similarTM 8.6 to !!1! ALU SUBFAM

437212AI765021Hs.210775ESTs UDPGT 8.5 424717H03754Hs.152213wingless-type MMTVwnt 8.4 integration site fami 450505NM-004572Hs.25051plakophilin 2 TM 8.4 436396AI683487Hs.299112Homo sapiens cDNA wnt 8.3 FLJ11d41 fis, clone H

425695NM Hs.i59238protein tyrosine Y~hosphatase8.3 005401 phosphatase, non-receptor 447268AI370413Hs.36563Homo sapiens cDNA:Ribosomal-588.2 FLJ22418 fis, clone 400195 0 TM 8.1 424906A1566086Hs.153716Homo Sapiens mRNA TM 8.1 for Hmob33 protein, 438202AW169287Hs.22588ESTs TM 8.1 439759AL359055Hs.67709Homc Sapiens mRNA TM 8.0 full length insert cDN

65 453102NM-007197Hs.31664frizzled (Drosophila)TM,Fz,Frizzled8.0 homolog 10 424001W67883Hs.t37476KIAA1051 protein TM 8.0 442655AW027457Hs.30323ESTs TM 7.8 445657AW612141Hs.279575ESTs 7tnL1 7.8 426320W47595Hs.169300transforming growthSS,TGF-beta7.8 factor, beta 2 412170D16532Hs.73729very low density TM,IdI_recept_b,EGF7.6 lipoprotein receptor 436476AA326108Hs.53631ESTs TM 7.6 414132AI801235Hs.d8480ESTs TM 7.6 437789A1581344Hs.127812ESTs, Weakly similarTM 7.6 to AF1413261 RNA

450192AA263143Hs.24596RAD51-interacting TM 7.6 protein 75 408826AF216077Hs.d8376Homo Sapiens cloneTM 7.5 HB-2 mRNA sequence 413627BE182082Hs.246973ESTs TM 7.4 446293A1420213Hs.149722ESTs LIM,homeobox7.4 409242AL080170Hs.51692DKFZP434C091 proteinTM,7tm_7 7.3 450262AW409872Hs.271166ESTs, Moderately TM 7.3 similar to ALU7-HUMA

go 451659BE379761Hs.142d8ESTs, Weakly similarTM 7.3 to ALUB-HUMAN
A

444342NM Hs.10887similar to lysosome-associatedTM 7.2 014398 membrane g 429126AW172356Hs.99083ESTs 7trn_i 7.1 421464AA291553Hs.190086ESTs TM 7.0 420362079734Hs.97206hunfingtin interactingTM 7.0 . protein 1 444743AA045648Hs.11817nudix (nucleoside TM 7.0 diphosphaie linked moiet 415138C1835fiHs.78045tissue factor pathwayKuni~ BPTI,G-gamma6.9 inhibitor 2 TFPI2 429418AI381028Hs.99283ESTs AAA 6.9 409178BE393948Hs.50915kallikrein 5 SS,trypsin 6.9 425905AB032959Hs.161700KIAA1133 protein TM 6.9 428532AF157326Hs.184786TBP-interacting TM 6.9 protein 433426H69125Hs.133525ESTs TM 6.9 448674W31178Hs.154140ESTs TM 6.8 432415T16971Hs.289014ESTs TM 6.7 418203X54942Hs.83758_ TM 6.6 CDC28 protein kinase 438394BE379623Hs.27693CGI-124 protein pro-isomerase6.6 452097AB002364Hs.27916ADAM-TS3 ; a disintegrin-likeReprolysin 6.6 and metal 453745AA952989Hs.63908Homo Sapiens HSPC316TGFb~propep6de6.6 mRNA, partial c4 423248AA380177Hs.125845ribulose-5-phosphate-3-epimerasefilament 6.6 I 452281T93500Hs.28792ESTs TGF-beta 6.5 S

424620AA10i043Hs.151254kallikrein l (chymotryptic;SS,irypsin 6.5 stratum comeum 452594AU076405Hs.29981solute carver familyTM,Sulfate-Uansp6.5 26 (sulfate Uansporter) 434149243829Hs.19574ESTs, Weakly similarpkinase,fn36.5 to katanin p80 subun 425776025128Hs.159499parathyroid hormoneTM,7tm 2 6.4 receptor 2 409517X90780Hs.54668Uoponin I, cardiacY~hosphatase6.4 432666AW204069Hs.129250ESTs, Weakly similarTM 6.d to unnamed protein p 448706AW291095Hs.21814class II cytokine SS 6.4 receptor ZCYTOR7 413582AW295647Hs.71331Homo Sapiens cDNA:TM 6.4 FLJ21971 fis, clone 424153AA451737Hs.141496MADE-like 2 TM 6.4 441081AI584019Hs.169006ESTs, Moderately PAX 6.4 similar to plakophilin 2b 443539A1076182Hs.134074ESTs TM 6.4 418384AW149266Hs.25130ESTs TM 6.3 425371D49441Hs.155981mesothelin SS 6.3 449048245051Hs.22920similar to S68401 SS 6.3 (cattle) glucose induced g 437117AL049256Hs.122593ESTs TM 6.3 453370AI470523Hs.182356ESTs, Moderately ABC-tran 6.3 similar to UansIaGon init 426514BE616633Hs.301122bone morphogeneticSS,TGF-beta6.3 protein 7 (osteogenic p 452904AL157581Hs.30957Homo Sapiens mRNA;TM 6.2 cDNA DKFZp434E

457030AI301740Hs.173381dihydropyrimidinase-likeTM 6.2 436281AW411194Hs.120051ESTs TM 6.1 415139AW975942Hs.48524ESTs TM 6.1 449448D60730Hs.57471ESTs TM 6.1 457979AA776655Hs.270942ESTs TM 6.1 422867L32137Hs.1584cartilage oligomericSS,EGF,tsp_36.0 matrix protein 421502AF111856Hs.105039solute cartier TM 6.0 family 34 (sodium phosphate) 412733AA984472Hs.74554KIAA0080 protein C2 6.0 422095A1868872Hs.288966ceruloplasmin (ferroxidase)SS 6.0 418845AA852985Hs.89232chromobox homolog Chromo shadow6.0 5 (Drosophila HP1 alp 410555092649Hs.64311a disintegrin and TM,disintegrin,Reprolysin5.9 melalloproteinase domain 437099N77793Hs.d8659ESTs, Highly similarlaminin_EGF5.9 to LMA1 HUMAN
L

453431AF094754Hs.32973glycine receptor, TM,neur-chan5.9 beta 417866AW067903Hs.82772~collagen, type TSPN,CoIlagen,COLFI5.9 XI, alpha 1~

430291AV660345Hs.238126CGI-49 protein TM 5.9 405547#(NOCAT) 0 TM,ABC-membrane5.9 435793AB037734Hs.4993ESTs TM 5.8 440138AB033023Hs.6982hypothetical proteinTM 5.8 425154NM Hs.154850collagen, type SS,CoIlagen,TSPN5.7 001851 IX, alpha 1 419335AW960146Hs.284137Homo Sapiens cDNA TM 5.7 FLJ12888 fis, clone N

452971AI873878Hs.91789ESTs TM 5.7 428927AA441837Hs.90250ESTs TM 5.7 419247S65791Hs.89764fragile X mental TM 5.7 retardation 1 445640AW969626Hs.31704ESTs, Weakly similarTM 5.7 to KIAA0227 [H.sap 447078AW885727Hs.301570ESTs kazal 5.6 421247BE391727Hs.102910general UanscriptionTM 5.6 factor IIH, polypeptid 432030AI908400Hs.143789ESTs SS 5.6 443270NM-004272Hs.9192Homer, neuronal TM 5.5 immediate early gene,18 411096080034Hs.68583mitochondrialintermediatePeptidase-M35.5 peptidase 419558AW953679Hs.278394ESTs SS 5.5 427386AW836261Hs.177486amyloid beta (A4) TM 5.5 precursor protein (protea 427961AW293165Hs.i43134ESTs TM 5.5 407216N91773Hs.102267lysyl oxidase TM 5.5 413930M86153Hs.75618RAB11A, member ras,TM 5.5 RAS oncogene family 414315224878 gb:HSB65D052 STRATAGENETM 5.5 Human sk 441645AI222279Hs.201555ESTs SS 5.5 449318AW236021Hs.108788ESTs, Weakly similarTM 5.4 to zesie [D.melanoga 441433AA933809Hs.42746ESTs TM 5.4 445495BE622641Hs.38489ESTs I LWEO,ENTH5.4 410153BE311926Hs.15830Homo Sapiens cDNA Glycos transf_25.4 FLJ12691 fis, clone N

442611BE077155Hs.177537ESTs TM 5.4 452401NM_007115Hs.29352tumor necrosis Xlink,CUB 5.4 factor, alpha-induced protein 419948A8041035Hs.93847NADPH oxidase 4 TM 5.3 427718AI798680Hs.25933ESTs histone 5.3 453867A1929383Hs.108196HSPC037 protein TM 5.3 408298AI745325Hs.271923ESTs; Moderately Glycos Uansf_2,DSPc5.3 similar to !!!!

g 448543AW897741Hs.21380Homo Sapiens mRNA;TM 5.3 0 cDNA DKFZp586P

433222AW514472Hs.238415ESTs, Moderately TM 5.3 similar to ALU8_HUMA

449532W74653Hs.271593ESTs TM 5.3 452822X85689Hs.288617Homo Sapiens cDNA:TM,EGF,fn3 5.3 FW22621 fis, clone 418379AA218940Hs.137516fidgeGn-like 1 AAA 5.2 416530062801Hs.79361kallikrein 6 (neurosin,TM,Uypsin 5.2 zyme) 413384NM_000401Hs.75334 exostoses (multiple)TM 5.2 445236AK001676Hs.12457hypothetical proteinTM 5.2 406367#(NDCAT) 0 proteasome,trypsin5.2 442500AI819068Hs.209122ESTs SS 5.2 450101AV649989Hs.24385Human hbc647 mRNA TM 5.2 sequence 419140AI982647Hs.215725ESTs TM 5.2 417791AW965339Hs.111471ESTs Ald Xan 5.1 dh C

437496AA452378Hs.1701d4Homo Sapiens mRNA~TSPN,Folate-carrier5.1 cDNA DKFZp547J1 418849AW474547Hs.53565ESTs, Weakly similarTM 5.1 to 80491.1 [C.elegan 428093AW594506Hs.104830ESTs TM 5.1 408621AI970672Hs.46638chromosome 11 openTM 5.1 reading frame 8; feta 418852BE537037Hs.273294hypothetical proteinTM 5.1 404939 0 TM 5.0 I 447020T27308Hs.16986hypothetical proteinTM 5.0 410824AW994813Hs.33264ESTs TM 5.0 417423AA197341Hs.111164ESTs TM 5.0 421477A1904743Hs.104650hypothetical proteinTM 5.0 443555N717i0Hs.21398ESTs,ModeratelysimilartoGNPIGlucosamine5.0 HUMA iso 424539L02911Hs.150402activin A receptor,SS,Activin 4.9 ~ type I recp,pkinase 416565AW000960Hs.44970ESTs TM 4.9 431130NM Hs.2719epididymis-specific;SS 4.9 006103 whey-acidic protein ty 408938AA059013Hs.22607ESTs TM 4.9 436754A1061288Hs.133437ESTs, Moderately TM 4.9 similar to gonadotropin 409049AI423i32Hs.146343ESTs TM 4.9 458627AW088642Hs.97984ESTs; Weakly similarTM 4.8 to WASP-family pro 418882NM_004996Hs.89433ATP-binding cassette,TM,ABC-membrane4.8 sub-family C (CFTR

422505AL120862Hs.124165ESTs; (HSA)PAP TM 4.8 protein (programmed ce 428555NM Hs.184908integrin, beta SS,inlegrin-B4.8 452909NM Hs.30985pannexin 1 TM 4.8 449535W15267Hs.23672low density lipoproteinSS,IdI_recepLa,EGF4.8 receptor-related pro 452232AW020603Hs.271698ESTs TM 4.8 d23161AL049227Hs.124776Homo Sapiens mRNA;Cadherin 4.7 cDNA DKFZp564N C term 428405Y00762Hs.2266cholinergic receptor,TM,neur_chan4.7 nicotinic, alpha polype 433330AW207084Hs.132816ESTs TM 4.7 443933A1091631Hs.135501Homo Sapiens two TM 4.7 pore potassium channel 440351AF030933Hs.7179RAD1 (S. pombej TM 4.7 hamolog 426300015979Hs.169228delta-like homologTM,EGF 4.7 (Drosophila) 453775NM Hs.35120replicafion factorAAA,DEAD,helicase_C4.7 002916 C (activator 1) 4 (37kD) 429944813949Hs.226440Homo Sapiens cloneTM 4.7 24881 mRNA sequenc 434988AI418055Hs.161160ESTs TM 4.6 406400#(NOCAT) 0 trypsin,TM 4.6 428301AW628666Hs.98440ESTs TM 4.6 446254BE179829Hs.179852Homo Sapiens cDNA TM 4.6 FLJ12832 tis, clone N

459574AI741122Hs.101810Homo Sapiens cDNA TM 4.6 FLJ14232 tis, clone N

409928AL137163Hs.57549hypothetical proteinTM 4.6 dJ473B4 435244N77221Hs.187824ESTs pkinase,fn3d.6 404996#(NOCAT) 0 Peptidase 4.6 407905AW103655Hs.252905ESTs SS,Ephrin 4.6 441675A1914329Hs.5461ESTs TM 4.6 420276AA290938Hs.190561ESTs, Highly similarTM,fn3,ldl_recepL4.5 to mosaic protein a LRt 422529AW015128Hs.256703ESTs TM 4.5 438018AK001160Hs.5999hypothetical proteinTM 4.5 457465AW301344Hs.195969ESTs PribosylUan4.5 418848AI820961Hs.193465ESTs TM,pkise 4.5 447499AW262580Hs.147674KIAA1621 protein TM 4.5 432731831178Hs.287820fibronectin 1 SS d.5 434699AA643687Hs.149425Homo sapiens cDNA Nucleoside-Ua24.4 FLJ11980 fis, clone H

427528AU077143Hs.179565minichromosome TM 4.4 maintenance deficient (S.

409092AI735283Hs.172608ESTs TM 4.d 451389N73222Hs.21738KIAA1008 protein TM 4.4 453331AI240665Ns.8895ESTs TM 4.4 448133AA723157Hs.73769folate receptor TM 4.d 1 (adult) 429597NM-003816Hs.2442a disintegrin and TM 4.4 metalloproteinase domain 453279AW893940Hs.59698ESTs TM 4.4 409459D86407Hs.54481low density lipoproteinTM,EGF,IdI_recept4.4 receptor-related a pro 431708AI698136Hs.108873ESTs TM d.4 433906AI167816Hs.43355ESTs TM 4.4 441423A1793299Hs.126877ESTs TM 4.4 446770AV660309Hs.154986ESTs, Weakly similarTM 4.3 to AF1373861 plasm 412078X69699Hs.73149paired box gene TM 4.3 ti 423123NM Hs.124027SELENOPHOSPHATE AIRS 4.3 012247 SYNTHETASE; H

d48390AL035414Hs.21068hypothetical proteinTM d.3 453628AW243307Hs.170187ESTs TM 4.3 452367071207Hs.29279eyes absent (Drosophila)TM 4.3 homolog 2 413775AW409934Hs.75528nucleolar GTPase MMR-HSR1 4.3 451592AI805416Hs.213897ESTs TM 4.3 419311AA689591 gb:nv66a12.s1 NCI_CGAPTM 4.2 GCB1 Homo s 452943BE247449Hs.31082hypothetical proteinTM 4.2 g0 428679AA431765 gb:zw80c03.s1 SoaresTM 4.2 testis-NHT Homc s 436209AW850417Hs.254020ESTs, Moderately TM 4.2 similar to unnamed prate 406076AL390179Hs.137011Homo Sapiens mRNA;TM 4.2 cDNA DKFZp547P

428819AL135623Hs.193914KIAA0575 gene productTM 4.2 406671AA129547Hs.285754met prolo-oncogeneF-actin 4.2 . (hepatocyte growthcap-A
fac 431750AA514986Hs.283T05ESTs TM 4.2 449554AA682382Hs.59982ESTs TM 4.2 409073AA063d58 gb:zf71a07.s1 Soares~ineal~land-N3HPSEA 4.1 433929AI375499Hs.27379ESTs TM 4.1 415457AW081710Hs.7369ESTs, Weakly similarTM 4.1 to ALUt_HUMAN
A

44-0381BE387335Hs.283713ESTs TM 4.1 415539A1733881Hs.72472BMPR-Ib; bone morphogenetlcTM 4.1 protein rec 421515Y11339Hs.105352GaINAc alpha-2, TM d.1 6-siatyltransferase I, long 453293AA382267Hs.10653ESTs TM 4.1 409564AA045857Hs.54943fracture callus TM 4.1 1 (rat) homolog 429628H09604Hs.13268ESTs TM 4.1 440452A1925136Hs.55150ESTs, Weakly similarTM 4.1 to CAYP-HUMAN

443695AW204099Hs.112759ESTs, Weakly similarTM 4.1 1o AF1267801 retina 425322063630Hs.155637protein kinase; TM 4.1 DNA-activated;
catalytic po 417300AI765227Hs.55610solute carrier TM 4.1 family 30 (zinc transporter), m 417389BE260964Hs.820d5Midkine (neurite SS,TM 4.1 growth-promoting factor 2 452834AI638627Hs.105685ESTs kinesin 4.1 -028771AB028992Hs.193143KIAA1069 protein PI-PLGX,PI-PLGY4.0 412314AA825247Hs.250B99heat shock factor TM 4.D
binding protein 4362918E568452Hs.5101ESTs; Highly similarTM 4.0 to protein regulating c 450654AJ245587Hs.25275Kruppel-type zinc KRAB 4.0 finger protein 409365AA702376Hs.226440Homo Sapiens cloneTM 4.0 24881 mRNA sequenc 413374NM Hs.75319ribonucleotide ribonuc_red4.0 001034 reductase M2 polypeptide 417655AA780791Hs.14014ESTs, Weakly similarTM 4.0 to KIAA0973 protein -045941AI267371Hs.172636ESTs TM,lectin 4.0 c 441134W29092Hs.7678cellular re6noic lipocalin 4.0 acid-binding protein 411630042349Hs.71119Putative prostate TM 4.0 cancer tumor suppressor 418301AW976201Hs.187618ESTs TM 4.0 d1 AL033527Hs.92137v-myc avian myelocytomatosisTGF-beta,Myc_N4.0 1945 viral oncog term 408684861377Hs.12727hypothetical proteinTM 4.0 414869AA157291Hs.72163ESTs TM 4.0 420281AI623693Hs.191533ESTs Cation_etflux3.9 416658~U03272Hs.79432fibdllin 2 (congenitalEGF,TB 3.9 contractural arachnod 411274NM Hs.69423kallikrein 10 trypsin,TM 3.9 3 437222AL117588Hs.299963ESTs TM 3.9 S

431958X63629Hs.2877Cadherin 3, P-cadhednTM,cadherin,3.9 (placental) 430634AI860651Hs.26685ESTs TM 3.9 415716N59294Hs.301141Homo Sapiens cDNA NAP family 3.9 FLJ 11689 fis, clone H

420179N74530Hs.21168ESTs TM 3.8 451250AA491275Hs.236940Homo sapiens cDNA TM 3.8 FLJ12542 fis, clone N

429496AA453800Hs.192793ESTs TM 3.8 421764AI681535Hs.99342ESTs, Weakly similarTM 3.8 to KCC1 HUMAN
C

447197836075 gb:yh88b01.s1 SoaresTM,SDF 3.8 placenta Nb2HP
Hom 422939AW394055Hs.98427ESTs TM 3.8 414737AI160386Hs.125087ESTs TM 3.8 411773NM Hs.72026protease, swine, SS,trypsin 3.8 006799 21 (tesGsin) 425247NM Hs.155324matrix metalloproteinaseSS,Peplidase-M103.7 005940 11 (stromelysin 3) 424433H04607Hs.9218ESTs TM 3.7 431846BE019924Hs.271580Uroplakin 18 TM,transmembrane43.7 S 407792A1077715Hs.39384putative secreted SS 3.7 0 ligand homologous to fjxl 417531NM Hs.1087serinelihreonine pkise,pkinase3.7 003157 kinase 2 434836AA651629Hs.118088ESTs TM 3.7 439810AL109710Hs.85568EST TM 3.7 418693AI750878Hs.87d09thromtwspondin SS,EGF,TSPN3.7 5 407864AF069291Hs.40539chromosome 8 open TM 3.7 5 reading frame 436304AA339622Hs.108887ESTs TM 3.7 452259AA317439Hs.28707signal sequence TM 3.7 receptor, gamma (Uansloco 453468W00712Hs.32990DKFZP566F084 proteinTM 3.6 428943AW086180Hs.37636ESTs, Weakly similarTM 3.6 to KIAAi 392 protein 60 411402BE297855Hs.69855NRAS-related gene CSD,ras,CSD3.6 -025176AW0156d4Hs.301430ESTs,ModeratelysimilartoTEFiTM 3.6 HUMA

400296AA305627Hs.139336ATP-binding cassette;ABC_tran 3.6 sub-family C (CFTR

407340AA810168Hs.232119ESTs TM 3.6 418524AA300576Hs.85769acidic 82 kDa proteinTM 3.6 mRNA

65 438279AA805166Hs.165165ESTs,ModeratelysimilartoALUBTM 3.6 HUMA

439453BE264974Hs.6566thyroid hormone AAA,AAA 3.6 receptor interactor 441111AI806867Hs.126594ESTs TM 3.6 451806NM_003729Hs.27076RNA 3'-terminal TM 3.6 phosphate cyclase 409542AA503020Hs.36563ESTs Ribosomal_S83.6 70 425441AAd49644Hs.193063Homo Sapiens cDNA Aa traps 3.6 FLJ14201 fis, clone N

428137AA421792Hs.170999ESTs AAA 3.6 433692A1805860Hs.208675ESTs, Weakly similarTM 3.6 to neuronal thread pr 438689AW129261Hs.250565ESTs TM 3.6 443341AW631480Hs.8688ESTs TM 3.6 75 446261AA313893Hs.13399hypothetical proteinATP-synt-D,PH3.6 FLJ12615 similar to m 41-0343AL036166Hs.75914coated vesicle TM 3.5 membrane protein 414812X72755Hs.77367monokine induced SS,ILS 3.5 by gamma interferon 410361BE391804Hs.62661guanylate binding TM 3.5 protein 1, interferon-indu 415786AW419196Hs.257924ESTs TM 3.5 g0 427177A8006537Hs.173880interleukin 1 receptorTM,ig 3.5 accessory protein 427687AW003867Hs.112403ESTs 7trrL1 3.5 444619BE538082Hs.8172ESTs TM 3.5 447336AW139383Hs.245437ESTs AhpGTSA 3.5 412519AA196241Hs.73980troponin T1, skeletal,TM 3.5 . slow 418792A8037805Hs.884d2KIAA1384 protein TM 3.5 408031AA081395Hs.42173Homo Sapiens cDNA TM 3.5 FLJ10366 fis, clone N

416892L24498Hs.80409growth arrest and TM 3.5 DNA-damage-inducible, 418793AW382987Hs.88474prostaglandin-endoperoxideEGF 3.5 synthase 1 (pro 448089AI467945Hs.173696ESTs SS 3.5 422278AF072873Hs.i14218ESTs TM,Fz,Frizzled3.5 442133AW874138Hs.129017ESTs TM 3.5 410908AA121686Hs.10592ESTs GTP_EFTU 3.5 452198A1097560Hs.61210ESTs TM 3.5 1 408730AV660717Hs.47144DKFZP586N0819 proteinpkinase 3.4 436488BE620909Hs.261023hypotheficalproteinTM 3.4 409745AA077391 gb:7B14E12 ChromosomeTM 3.4 7 Fetal Brain cD

445870AW410053Hs.13406syntaxin 18 TM 3.4 451743AW074266Hs.23071ESTs TM 3.4 1 407846AA426202Hs.40403CbpIp300-interacfingTM 3.4 S Uansactivator, with G

432350NM Hs.274407protease, serine,16SS 3.4 005865 (thymus) 412848AA121514Hs.70832ESTs TM 3.4 413625AW451i03Hs.71371ESTs filament 3.4 417801AA417383Hs.82582integrin, beta-likeSS 3.4 1 (with EGF-like repeat d 20 422972N59319Hs.145404ESTs TM 3.4 429170NM-001394Hs.2359dual specificity DSPc,Rhodanese3.4 phosphatase 4;
MAP kinas 450377AB033091Hs.24936ESTs TM 3.4 443475A1066470Hs.134482. ESTs TM 3.4 419452033635Hs.90572PTK7 protein tyrosineTM,pkise,ig,SRF-TF3.4 kinase 7 25 409744AW675258Hs.56265Homo sapjens mRNA;TM 3.4 cDNA DKFZp586P

422789AK001113Hs.120842hypothetical proteinTM 3.4 404440#(NOCAT) 0 TM,neur_chan3.4 417412X16896Hs.82112intedeukin 1 receptor,SS,TIR,ig 3.4 type I

411828AW161449Hs.72290wingless-type MMTVwnt 3.4 integration site fami 30 417177NM_004458Hs.81452fatty-acid-CoenzymeSS 3.4 A ligase, long-chain 421013M62397Hs.1345mutated in colorectalTM 3.4 cancers 427072H38046 gb:yp58c10.r1 SoaresfetalliverspleenRibosomal-L22e3.4 433703AA210863Hs.3532nemo-like kinase pkinase 3.4 434294AJ271379Hs.21175ESTs TM 3.4 35 444188A1393i65Hs.19175ESTs TM 3.4 446109N67953Hs.145920ESTs TM 3.4 400881 0 Asparaginase-23.3 450236AW162998Hs.24684KIAA1376 protein TM 3.3 d18836AI655499Hs.i61712ESTs TM 3.3 40 437951T34530Hs.4210Homo Sapiens cDNA TM 3.3 FLJ 13069 fis, clone N

446896T15767Hs.22452Homo Sapiens cDNA:TM 3.3 FLJ21084 fis, clone 430687BE274217Hs.249247heterogeneous nuclearrrm 3.3 protein similar to rat 410060NM Hs.58367glypican-4 SS 3.3 419546AA244199 gb:ncO6c05.s1 NCI-CGAP_Pr1TM 3.3 Homo sapi 45 429609AF002246Hs.210863cell adhesion moleculeTM,fi3,ig 3.3 with homology to L

413289AA128061Hs.i14992ESTs TM 3.3 440006AK000517Hs.6844hypothetical proteinTM 3.3 401435#(NOCAT)- 0 TM 3.3 420072AW961196Hs.207725ESTs TM 3.3 421426AA291 Hs.33020Homo Sapiens cDNA TM 3.3 1 FLJ20434 fis, 01 clone K

425851NM-001490Hs.159642glucosaminyl (N-acetyl)SS 3.3 Uansferase 1, core 443295A1049783Hs.241284ESTs TM 3.2 453116A1276680Hs.146086ESTs Ribosomal-L5-C3.2 456546A1690321Hs.203845ESTs, Weakly similarTM 3.2 to TWIK-related acid 55 430016NM Hs.227656xenotropic and TM 3.2 004736 polytropic reUovirus recepto 418281009550Hs.1154oviductal glycoproteinasp,Glyco-hydro-183.2 1,120kD (mucin 9, 433800A1034361Hs.135150lung type-I cell TM 3.2 membrane-associated glyco 425159NtvL004341Hs.154868carbamoyl-phosphateTM 3.2 synihetase 2, aspartat 428882AA436915Hs.131748ESTs, Modgralely carb_anhydrase3.2 similar to ALU7 HUMA

60 409533AW969543Hs.21291mitogen-acfivated TM 3.2 protein kinase kinase kin 411248AA551538Hs.69321KIAA1359 protein TM 3.2 421379Y15221Hs.103982small inducible SS,ILB 3.2 cytokine subfamily B (Cys-430259BE550182Hs.127826RaIGEF-like proteinTM 3.2 3, mouse homolog 414945BE076358Hs.77667lymphocyte antigenSS 3.2 6 complex, locus E

65 444471A8020684Hs.11217KIAA0877 protein TM 3.2 421674T10707Hs.296355neuronal PAS domainRibosomal_L3le3.2 protein 2 434163AW974720Hs.25206ESTs TM 3.2 421991NM Hs.110488KIAA0990 protein SS 3.2 409589AW439900Hs.256914ESTs ' TM 3.2 70 414147BE091634 gb:IL2-8T0731-240400-069-C03TM 3.2 414661T97401Hs.21929ESTs TM 3.2 437537AA758974Hs.121417ESTs, Weakly similarTM 3.2 to unnamed protein p 439702AW085525Hs.i34182ESTs A2M 3.1 420552AK000492Hs.98806hypoiheficalproteinTM 3.1 441028A1333660Hs.17558ESTs ICE~20,CARD3.1 425264AA353953Hs.20369ESTs, Weakly similarTM 3.1 to gonadoiropin indu 422109S73265Hs.1473gasUin-releasing SS,Bombesin3.1 pepfide 441859AW194364Hs.128022ESTs, Weakly similarTM 3.1 to FIGi MOUSE
FIG

415451H19415Hs.268720ESTs,ModeratelysimilartoALU1_HUMASS,Ephrin 3.1 g0 447866AWd44754Hs.211517ESTs homeobox 3.1 419978NM-001454Hs.93974forkhead box J1 Fork-head 3.1 446219A1287344Hs.149827ESTs MIP 3.1 448428AF282874Hs.21201necfin 3; DKFZP566B0846TM,ig 3.1 protein 407615AW753085 gb:PM1-CT0247-151299-005-a03TM 3.1 410518AW976443Hs.285655ESTs RasGEF,PH,RhoGEF3.1 418396AI765805Hs.26691ESTs TM 3.1 427855861253Hs.98265ESTs TM 3.1 429272W25140Hs.110667ESTs TM 3.1 450171AL133661Hs.24583hypotheficalproteinTM 3.1 DKFZp434C0328 414774X02419Hs.77274plasminogen acfivator,SS,kdngle,trypsin3.1 urokinase 422363T55979Hs.115474replicafion factorTM 3.1 C (acfivator 1) 3 (38kD) 420062AW411096Hs.94785hypothetical proteinTM 3.1 428698AA852773Hs.297939ESTs; Weakly similarTM 3.1 to neogenin [H.sapie d27051BE178110Hs.173374ESTs TM 3.1 428242H55709Hs.2250leukemia inhibitorySS 3.1 factor (cholinergic diffe 452906BE207039Hs.75621sedne (orcysteine)TM 3.1 proteinase inhibitor, cla 429419AB023226Hs.202276KIAA1009 protein TM 3.1 417517AF001176Hs.82238POP4 (processing TM 3.1 of precursor, S. cerevisia 1 406137#(NOCAT) 0 TM 3.1 S

424800AL035588Hs.153203MyoD family inhibitorTM 3.1 410252AW821182Hs.61418microfibdllar-associatedTM 3.1 protein 1 420392AI242930Hs.97393KIAA0328 protein SS 3.1 423629AW021173Hs.18612Homo Sapiens cDNA:voltage_CLC,CBS3.1 FLJ21909 fis, clone 429334D63078Hs.186180Homo sapiens cDNA:Glyco-hydro-23.1 FLJ23038 fis, clone 449802AW901804Hs.23984hypothetical proteinTM 3.1 450506NM Hs.418fibroblast activafionSS,Peptidase-S93.0 004460 protein; alpha 433849BE465884Hs.280728ESTs TM 3.0 411984NM_005419Hs.72988signal Uarisducer SH2,STAT 3.0 and acfivator of transcript 422530AW972300Hs.118110bone marrgw stromalTM 3.0 cell antigen 2 422128AW881145 gb:OVO-0T0033-010400-182-a07TM 3.0 409757NM_001898Hs.123114cystatin SN SS,cystatin3.0 418727AA227609Hs.94834ESTs TM 3.0 422244Y08890Hs.113503karyophedn (imporfin)TM 3.0 beta 3 456844AI264155Hs.152981CDP-diacylglycerolTM 3.0 synthase (phosphatidat 432358A109349iHs.72830ESTs SS 3.0 416896A1752862Hs.5638KIAA1572 protein BTB 3.0 447312A1434345Hs.36908activating transcriptionTM 3.0 factor 1 445021AK002025Hs.12251Homo Sapiens cDNA TM 3.0 FLJ11163 fis, clone P

3 422611AA158177Hs.118722fucosyltransferaseSS 3.0 S B (alpha (1,6) fucosyltran 453597BE281130Hs.33713myo-inositol 1-phosphateTM 3.0 synthase A1 401197#(NOCAT) 0 arf,Ets 3.0 d03000BE247275Hs.15i787USsnRNP-specific TM 3.0 protein,ti6kD

410008AA079552 gb:zm20h12.s1 SUatageneTM,FG-GAP 3.0 pancreas (93720 413268AL039079Hs.75256regulator of GproteinRGS 3.0 signalling 1 414080AA135257Hs.47783ESTs, Weakly similarTM 3.0 to T12540 hypotheti 426682AA393108Hs.97365ESTs TM 3.0 427651AW405731Hs.18498Homo Sapiens cDNA TM 3.0 FLJ12277 fis, clone M

439444AI277652Hs.54578ESTs TM 3.9 433001AF217513Hs.279905clone H00310 PR00310p1TM 3.0 444895AI674383Hs.301192EST cluster (not TM,ASC 3.0 in UniGene) 441962AW972542Hs.289008Homo Sapiens cDNA:TM 3.0 FLJ21814 fis, clone 414725AA769791Hs.120355Homo Sapiens cDNA TM,7lm_1 3.0 FLJ13148 fis, clone N

434241AF119913Hs.283607hypothefical proteinSS 3.0 424962NM Hs.153954TRAM-like protein TM 3.0 411987AA375975Hs.183380ESTs, Moderately TM 3.0 similar to ALU7-HUMA

421977W94197Hs.110165ribosomal protein TM 3.0 L26 homolog 436481AA379597Hs.5199HSPC150 protein TM 3.0 similar to ubiquitin-conju 407872AB039723Hs.40735frizzled (Drosophila)TM,7tm_2,Fz,Frizzled3.0 homolog 3 442577AA292998Hs.163900ESTs TM 3.0 416120H46739 gb:yo14h02.s1 SoaresTM 3.0 adult brain N2b5HB5 443775AF291664Hs.204732matrix metalloproteinaseTM,Peptidase-M10,7tnL13.0 414664AA587775Hs.66295Homo Sapiens HSPC311TM 3.0 mRNA, partial cd 457590AI612809Hs.5378spondin 1, (f spondin)SS 3.0 extracellular matrix 418946AI798841Hs.132103ESTs TM 3.0 457940AL360159Hs.30445Homo Sapiens mRNA TM,SPRY,7tm-13.0 full length insert cDN

TABLE 158:
Pkey: Unique Eos probeset identifier number CAT number. Gene cluster number Accession: Genbank accession numbers Pkey CAT Accession Number 409745115237_1AA077391 A1347618 A1361453 A1088754 AW207491 414147142127=BE091fi34 414315143512224878 AA494098 F13654 AA494040 AA1d3127 419311183793AAfi89591 AW974261 AA236240 A1077451 AA631399 g 428679294049_1AA431765 AA432015 447197711623_1836075 AI366546 836167 TABLE 15C:
Pkey: Unique number corresponding to an Eos probeset Ref: Sequence source. The 7 digit numbers in this column are Genbank Idenfifier (GI) numbers. °Dunham I. et al." refers to the publication entitled °The DNA sequence of human chromosome 22" Dunham, et at. (1999) Nature 402:489-095 SUand: Indicates DNA strand from which exons were predicted N~position: Indicates nucleofide posifions of predicted exons Pkey Ref SfrandNt_posilion 400881 2842777Minus91446-91603,92123-92265 1 ~ 4011979719705Plus 176341-176452 401435 8217934Minus'54508-55233 404440 7528051Plus 80430-81581 404939 6862697Plus 175318-175476 404996 6007890Plus 37999-38145,38652-38998,39727-39872,40557-40674,42351-1 5 4055471054740Plus 124361-124520,124914-125050 406137 9166422Minus30487-31058 406367 9256126Minus58313-58489 406400 9256298Plus 1553-1712,1878-2140,4252-4385,5922-6077 Table 16A lists about 92 genes up-regulated in mucinous-type ovarian cancer compared to normal adult tissues. These were selected as for Table 14A, except that the "average" ovarian cancer level was set to the 75th percentile amongst various mucinous-type ovarian cancers, and the tumor/normal tissue ratio was greater than or equal to 2.5.
TABLE
16A:
ABOUT

UP-REGULATED
GENES, MUCINOUS
OVARIAN
CANCER
VERSUS
NORMAL
ADULT
TISSUES

Pkey: s Primekey Ex.Accn:
ExempIarAccession UG
ID:
UniGene ID

Title:
UniGene title Prot.Predicted Dom.:protein domain structure 30 ratio:tumor ratiovs.
normal tissues Pkey Ex. UG Title Prot. Dom. ratio Accn iD

430691Ci4187Hs.103538ESTs 34.9 432938T27013Hs.3132steroidogenic acuteSTART 28.0 regulatory protein 35 418007M13509Hs.83169Matrix metalloproteaseSS,Peptidase-M1022.3 1 (interstitial collag 451181AI796330Hs.207461ESTs 10.8 452838065011Hs.30743Preferentially 10.0 expressed antigen in melanom 407638AJ404672Hs.288693EST 9.3 450159A1702416Hs.200771ESTs, Weakly similar 9.2 to CAN2_HUMAN

40 426890AA393167Hs.41294ESTs 9.1 421155H87879Hs.102267.lysyl oxidase SS,Lysyl_oxidase8.9 437099N77793Hs.48659ESTs, Nighty similarlaminin EGF 1.6 to LMAi HUMAN
L

453866AW291498Hs.250557ESTs 7.6 435496AW840171Hs.265398ESTs, Weakly similar 7.4 to transformation-rel 4$ 418738AW388633Hs.6682solute comer family 7.2 7, member 11 431956AK002032Hs.272245Homo Sapiens cDNA RA 7.0 FLJ11170 fis, clone P

449579AW207260Hs.134014prostate cancer 6.7 associated protein 424586NM Hs.150930X-ray repair complementing 6.7 003401 defecfive repa 445891AW391342Hs.199460ESTs 6.2 424717H03754Hs.152213wingless-type MMTVwnt 6.1 integration site fami 452705H49805Hs.246005ESTs 6.1 421285NM Hs.1363cytochrome P450, TM,p450 5.5 000102 subfamily XVII
(steroid 408562AI436323Hs.31141Homo Sapiens mRNA 5.3 for KIAA1568 prote 420159AI572490Hs.99785ESTs 5.3 55 451105A1761324 gb:wi60b11.x1 NCI-CGAP-Co16 5.2 Homo s 409049AI423132Hs.146343ESTs 5.0 448674W31178Hs.154140ESTs TM 5.0 423811AW299598Hs.50895homeo box C4 4.9 427469AA403084Hs.269347ESTs 4.9 go 447033A1357412Hs.157601EST-notin UniGene PH 4.9 424433H04601Hs.9218ESTs 4.9 448811AI590371Hs.174759ESTs TM 4.8 444330A1597655Hs.49265ESTs 4.8 409041A8033025Hs.50081KIAA1199 protein 4.7 418735N48769Hs.44609ESTs 4.5 416661AA634543Hs.79440IGF-II mRNA-bindingKH-domain 4.5 protein 3 430073086136Hs.232070telomerase-associatedWD40 4.4 protein 1 407881AW072003Hs.40968heparan sulfate SS 4.4 (glucosamine) 3-0-sulfotran 422260AA315993Hs.105484ESTs; Weakly similar 4.4 to LITHOSTATHIN

70 421110AJ250717Hs.1355cathepsin E SS,asp 4.3 445676A1247763Hs.i6928ESTs 4.2 430704AW813091 gb:RC3-ST0i86-240400-111-407Epimerase 3.8 414569AF109298Hs.118258Prostate cancer TM 3.8 associated protein 438078A10163T7Hs.131693ESTs 3.7 434032AW009951Hs.206892ESTs 3.7 445657AW612141Hs.279575ESTs 7tm-1 3.6 439759AL359055Hs.67709Homo Sapiens mRNA 3.5 full length insert cDN

455666BE065813 gb:RC2-BT0318-110100-012-a08 3.5 448844A1581519Hs.177164ESTs 3.5 449048245051Hs.22920similar to 568401 SS 3.5 (cattle) glucose induced g 438018AK0011fi0Hs.5999hypothetical proteinTM - 3.4 458123AW892676 gb:CM3-NN0004-280300-131-c12 NN0004 3.4 407385AA610150Hs.272072ESTs,ModeratelysimilartoALU7_HUMA 3.4 424894H83520Hs.153678reproduction 8 SS,UBX 3.3 424639 AI917494 ESTs 3.3 Hs.131329 414083 AL121282 ESTs 3.2 Hs.257786 426471 M22440 transforming growth SS,EGF 3.2 Hs.170009 factor, alpha 428927 AA441837 ESTs 3.1 Hs.90250 406129 #(NOCAT) 0 TM,cNMP_binding3.1 452699 AW295390 ESTs 3.1 Hs.213062 425842 A1587490 NK-2 (Drosophila) homeobox 3.1 Hs.159623 homolog B

428976 AL037824 ras homolog gene ras 3.1 Hs.194695 family, member I

436396 AI683487 Homo Sapiens cDNA wnt 3.0 Hs.299112 FLJ11d41 fis, clone H

1 454077 AC005952 insulin-like 3 (LeydigSS,Insulin,pkinase3.0 o Hs.37062 cell) 404253 #(NOCAT) 0 hisione 2.9 452461 N78223 transcdptionfactor G9a,PHD 2.9 Hs.108106 429597 NM-003816a disintegrin and TM 2.9 Hs.2442 metalloproteinase domain 413289 AA128061 ESTs 2.9 Hs.114992 1 429703 T93154 ESTs 2.9 Hs.28705 407829 AA045084 Homo Sapiens cDNA 2.8 Hs.29725 FLJ13197 fis, clone N

424796 AW2982d4 ESTs 2.8 Hs.293507 424086 A1351010 lysyl oxidase Lysyl-oxidase2.8 Hs.102267 408427 AW194270 ESTs 2.7 Hs.177236 450375 AA009647 a disintegrin and 2.7 Hs.8850 metalloproteinase domain 446999 AA151520 hypothetical protein 2.7 Hs.279525 PR02605 428819 AL135623 KIAA0575 gene product 2.7 Hs.193914 422956 BE545072 ESTs 2.7 Hs.122579 428949 AA442153 ESTs, Weakly similar 2.7 Hs.104744 to AF2088551 BM-0 25 426300 015979 delta-like homolog TM,EGF 2.6 Hs.169228 (Drosophila) 420380 AA640891 ESTs 2.6 Hs.102406 428651 AF196478 annexin A10 TM,annexin 2.6 Hs.188401 417849 AW291587 Nidogen 2 EGF,IdI_recept_b2.6 Hs.82733 453700 AB009426 apolipoprotein B TM 2.6 Hs.560 mRNA editing enzyme, ca 417975 AA641836 Homo Sapiens cDNA: 2.6 Hs.30085 FLJ23186 fis, clone 448756 A1739241 ESTs 2.6 Hs.171480 425087 R62d2d ESTs 2.5 Hs.i26059 444153 AK001610 hypothetical proteinKetch 2.5 Hs.1041d FLJ10748 443211 A1128388 ESTs 2.5 Hs.143655 35 415263 AA948033 ESTs histone 2.5 Hs.130853 432867 AW016936 ESTs GSHPx 2.5 Hs.233364 438639 AI278360 ESTs 2.5 Hs.31409 455386 AW935875 gb:OV3-DTOOi9-120100-055-406 2.5 419092 J05581 mucin 1, transmembraneTM,SEA 2.5 Hs.89603 452055 AI377431 ESTs 2.5 Hs.293772 TABLE 168:

Pkey: Unique Eos probeset identifier number CAT number: Gene cluster number Accession: Genbank accession numbers Pkey CAT Number Accession TABLE 16C:

5 Pkey: Unique 5 number corresponding to an Eos probeset Ref: Sequence . "Dunham source. The I. et a1."
7 digit numbers refers to in this column the publication are Genbank entitled Identifier (GI) "The DNA
numbers sequence of human chromosome, et al. (1999) Nature 22" Dunham 402:489-495 Strand: Indicates DNA strand from which exons were predicted Nk.position:
Indicates nucleotide posiUons of predicted exons 6o Pkey Ref Strand Nt~osiUon Minus Plus Table 17A lists normal adult about 183 genes tissues.
up-regulated These were in endometrioid-type selected ovarian cancer as for Table compared to 14A, except that the "average" ovarian cancer level was set to the 75th percentile amongst various endometrioid-type ovarian cancers, and the tumodnormal tissue ratio was greater than or equal to 2.5.

7O TABLE 17A: ABOUT

GENES, ENDOMETRIOID
OVARIAN CANCER
VERSUS NORMAL
ADULT TISSUES

Pkey: Primekey Ex.Accn: ExempIarAccession UG ID: UniGene ID

Titre: UniGene title 75 Prot. Dom.: Predicted protein domains ratio: ratio tumor vs. normal tissue Pkey Ex. Accn Title Prot. Dom. ratio UG ID

452838 065011 Preferentially expressed 38.9 Hs.30743 antigen in melanom 435094 AI560129 EST 28.8 Hs.277523 428153 AW513143 hypothetical protein 24.1 Hs.98367 FLJ22252 similar to SR

428187 AI687303 ESTs 23.9 Hs.285529 449034 A1624049 gbas41a09.xi NCI-CGAP-Utt 19.9 Homosapi 453102 NM-007197frizzled (Drosophila)TM,Fz,Frizzled15.7 Hs.31664 homolog 10 412925A1089319Hs.179243ESTs 15.7 438817A1023799Hs.i63242ESTs 13.6 447033A1357412Hs.157601EST- not in UniGenePH 13.5 433222AW514472Hs.238415ESTs,ModeratelysimilartoALUB_HUMA 13.1 S 422956BE545072Hs.122579ESTs 12.9 450451AW591528Hs.202072ESTs 11.9 453964A1961486Hs.12744ESTs homeobox 11.5 442438AA995998 gb:os26b03.s1 NCI-CGAP-Kid5 11.d Homo sa 431989AW972870Hs.291069ESTs SS 10.3 1 413623AA825721Hs.246973ESTs 9.7 ~

440901AA909358Hs.128612ESTs 9.6 416661AA634543Hs.79440IGF-II mRNA-bindingKH-domain 9.6 protein 3 421478AI683243Hs.97258ESTs 9.3 448706AW291095Hs.21814class II cytokine SS,Tissue 9.2 receptor ZCYTOR7 fac 1 410566AA373210Hs.43047Homo Sapiens cDNA 8.7 S FLJ13585 fis, clone P

438993AA828995 integrin; beta SS,integrin-B8.7 427121AI272815Hs.173656KIAA0941 protein C2, 8.4 420610AI683183Hs.99348distal-less homeo homeobox 8.1 box 5 427356AW023482Hs.97849ESTs 8.0 20 446577AB040933Hs.15420KIAA1500 protein 8.0 431118BE264901Hs.250502carbonic anhydrasecart-anhydrase7.5 VIII

448112AW245919Hs.301018ESTs, Weakly similar 6.9 to ALUB_HUMAN

451106BE382701Hs.25960N-myc HLH,Myc_N-term6.6 449433A1672096Hs.9012ESTs 6.3 2S 453922AF053306Hs.36708budding uninhibited 6.3 by benzimidazoles 1 (y 434636AA083764Hs.241334ESTs 6.1 453688AW381270Hs.194110Homo Sapiens mRNA; 5.9 cDNA DKFZp434C

422805AA436989Hs.121017H2Ahistonefamily;memberAhistone 5.8 400292AA250737Hs.72472BMPR-Ib; bone morphogenetic 5.7 protein rec 443179AI928402Hs.6933Homo Sapiens cDNA 5.6 FLJ12684 fis, clone N

418134AA397769Hs.86617ESTs 5.5 452249BE3944i2Hs.61252ESTs homeobox 5.5 409269AA576953Hs.22972Homo Sapiens cDNA TM,UPF0016 5.5 FLJ13352 fis, clone 0 413335AI613318Hs.48442ESTs 5.4 3 441081AI584019Hs.169006ESTs, Moderately PAX 5.4 S similar to plakophilin 2b 428029H05840Hs.293071ESTs 5.3 419183060669Hs.89663cytochrome P450, p450 5.3 subfamily XXIV
(vitami 409094AW337237 gb:xw82t01.x1 NCI 5.2 CGAP_Pan1 Homo sa 432938T27013Hs.3132steroidogenic acuteSTART 5.1 regulatory protein 410102AW248508Hs.279727ESTs; SS 5.1 447835AW591623Hs.164129ESTs 5.1 438202AWi69287Hs.22588ESTs 5.0 423992AW898292Hs.137206Homo Sapiens mRNA; 5.0 cDNA DKFZp564H

425905AB032959Hs.161700KIAA1133 protein TM 5.0 4S 452461N78223Hs.108106transcriplionfactorG9a,PHD 4.9 430691C14187Hs.103538ESTs 4.8 441675AI914329Hs.5461ESTs 4.7 425695NM Hs.159238proteintyrosine Band 41,Y_phosphatase4.6 405401 phosphatase,non-receptor 440340AW895503Hs.125276ESTs 4.5 S 428579NM Hs.184942G protein-coupled TM 4.5 ~ 005756 receptor 64 444783AK001468Hs.62180ESTs PH 4.4 451459AI797515Hs.270560ESTs, Moderately 4.4 similar to ALU7-HUMA

413395AI266507Hs.145689ESTs 4.3 415263AA948033Hs.130853ESTs histone 4.2 S 413988M81883Hs.75668glutamate decarboxylasepyridoxal_deC4.2 S t (brain, 67kD) 452030AL137578Hs.27607Homo Sapiens mRNA; 4.1 cDNA DKFZp564N

418852BE537037Hs.273294hypothefical protein 4.1 446431845652Hs.153486ESTs 4.1 434891AA814309Hs.123583ESTs 4.0 415139AW975942Hs.48524ESTs G-patch 4.0 453197Ai916269Hs.109057ESTs, Weakly similar 4.0 to ALUS-HUMAN
A

447112H17800Hs.7154ESTs 3.9 420633NM_014581Hs.99526odorant-binding TM,lipocalin 3.9 protein 2B

459574A1741122Hs.101810Homc Sapiens cDNA 3.9 FLJ14232 fis, clone N

6S d15138C18356Hs.78045fissue factor pathwayKunitz_BPTI,G-gamma3.9 inhibitor 2 TFPI2 414083AL121282Hs.257786ESTs 3.7 442006AW975183Hs.292663ESTs 3.7 409731AA125985Hs.56145thymosin, beta, Thymosin 3.7 identified in neuroblastoma 424906AI566086Hs.153716Homo Sapiens mRNA 3.7 for Hmob33 protein, 456662NM-002448Hs.1494msh (Drosophila) homeobox 3.7 homeo box homolog t (fo 429125AA446854Hs.271004ESTs 3.6 435538A80115d0Hs.4930low density lipoprotein 3.6 receptor-related pro 458861AI630223 gb:adO6gO8.r1 ProliferafingPHD 3.5 Erythroid Cells 418506AA084248Hs.85339G protein-coupled 3.5 receptor 39 7S 423123NM-012247Hs.124027SELENOPHOSPHATE AIRS,AIRS 3.4 SYNTHETASE; H

437960AI669586Hs.222194ESTs 3.4 400298AA032279Hs.61635STEAP1 TM 3.4 407162N63855Hs.142634zinc finger protein 3.4 d08621AI970672Hs.46638chromosome 11 open 3.3 reading frame 8; feta go 445829AI452457Hs.145526ESTs 3.3 450262AW409872Hs.271166ESTs, Moderately 3.3 similar to ALU7_HUMA

457979AA776655Hs.270942ESTs TM 3.3 402606#(NOCAT) 3.2 426471M22440Hs.170009transforming growthSS,EGF 3.2 factor, alpha DEMANDE OU BREVET VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter 1e Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS
THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME
NOTE POUR LE TOME / VOLUME NOTE:

Claims (24)

WHAT IS CLAIMED IS:

1. A method of detecting an ovarian cancer-associated transcript in a cell from a patient, the method comprising contacting a biological sample from the patient with a polynucleotide that selectively hybridizes to a sequence at least 80%
identical to a sequence as shown in Tables 1-26.

2. The method of claim l, wherein the biological sample comprises isolated nucleic acids.

3. The method of claim 2, wherein the nucleic acids are mRNA.

4. The method of claim 2, further comprising the step of amplifying nucleic acids before the step of contacting the biological sample with the polynucleotide.

5. The method of claim l, wherein the polynucleotide comprises a sequence as shown in Tables 1-26.

6. The method of claim l, wherein the polynucleotide is immobilized on a solid surface.

7. The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat ovarian cancer.

8. The method of claim 1, wherein the patient is suspected of having ovarian cancer.

9. An isolated nucleic acid molecule consisting of a polynucleotide sequence as shown in Tables 1-26.

10. The nucleic acid molecule of claim 9, which is labeled.

11. An expression vector comprising the nucleic acid of claim 9.

12. A host cell comprising the expression vector of claim 11.

13. An isolated polypeptide which is encoded by a nucleic acid molecule having polynucleotide sequence as shown in Tables 1-26.

14. An antibody that specifically binds a polypeptide of claim 13.

15. The antibody of claim 14, further conjugated to an effector component.

16. The antibody of claim 15, wherein the effector component is a fluorescent label.

17. The antibody of claim 15, wherein the effector component is a radioisotope or a cytotoxic chemical.

18. The antibody of claim 15, which is an antibody fragment.

19. The antibody of claim 15, which is a humanized antibody

20. A method of detecting an ovarian cancer cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 14.

21. The method of claim 20, wherein the antibody is further conjugated to an effector component.

22. The method of claim 21, wherein the effector component is a fluorescent label.

23. A method for identifying a compound that modulates an ovarian cancer-associated polypeptide, the method comprising the steps of:
(i) contacting the compound with an ovarian cancer-associated polypeptide, the polypeptide encoded by a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26; and (ii) determining the functional effect of the compound upon the polypeptide.

24. A drug screening assay comprising the steps of (i) administering a test compound to a mammal having ovarian cancer or a cell isolated therefrom;
(ii) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence at least 80% identical to a sequence as shown in Tables 1-26 in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of ovarian cancer.